<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005049.pub4" GROUP_ID="VASC" ID="063004010223071218" MERGED_FROM="" MODIFIED="2015-04-21 18:28:46 +0100" MODIFIED_BY="Nicole Martin" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2015-04-21 18:27:58 +0100" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="0331" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.2">
<COVER_SHEET MODIFIED="2015-04-21 18:27:58 +0100" MODIFIED_BY="[Empty name]">
<TITLE>Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation</TITLE>
<CONTACT>
<PERSON ID="17025" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Carmelo</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Lafuente-Lafuente</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>c.lafuente@nodo3.net</EMAIL_1>
<EMAIL_2>carmelo.lafuente@cfx.ap-hop.paris.fr</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Service de Gériatrie à Orientation Cardiologique et Neurologique</DEPARTMENT>
<ORGANISATION>Groupe Hospitalier Pitié-Salpêtrière-Charles Foix, AP-HP, Université Pierre et Marie Curie</ORGANISATION>
<ADDRESS_1>7 Avenue de la République</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ivry-sur-Seine</CITY>
<ZIP>94205</ZIP>
<REGION>Ile-de-France</REGION>
<COUNTRY CODE="FR">France</COUNTRY>
<PHONE_1>+33 1 49 59 43 51</PHONE_1>
<PHONE_2>+33 1 49 59 43 56</PHONE_2>
<FAX_1>+33 1 49 59 43 79</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2015-04-21 18:27:07 +0100" MODIFIED_BY="Nicole Martin">
<PERSON ID="17025" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Carmelo</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Lafuente-Lafuente</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>c.lafuente@nodo3.net</EMAIL_1>
<EMAIL_2>carmelo.lafuente@cfx.ap-hop.paris.fr</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Service de Gériatrie à Orientation Cardiologique et Neurologique</DEPARTMENT>
<ORGANISATION>Groupe Hospitalier Pitié-Salpêtrière-Charles Foix, AP-HP, Université Pierre et Marie Curie</ORGANISATION>
<ADDRESS_1>7 Avenue de la République</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ivry-sur-Seine</CITY>
<ZIP>94205</ZIP>
<REGION>Ile-de-France</REGION>
<COUNTRY CODE="FR">France</COUNTRY>
<PHONE_1>+33 1 49 59 43 51</PHONE_1>
<PHONE_2>+33 1 49 59 43 56</PHONE_2>
<FAX_1>+33 1 49 59 43 79</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1408011126268757423389116102992" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Lucie</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Valembois</LAST_NAME>
<SUFFIX>MD</SUFFIX>
<POSITION>Clinical Assistant</POSITION>
<EMAIL_1>lucie.valembois@cfx.aphp.fr</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Service de Gériatrie à Orientation Cardiologique et Neurologique</DEPARTMENT>
<ORGANISATION>Groupe Hospitalier Pitié-Salpêtrière-Charles Foix, AP-HP, Université Pierre et Marie Curie</ORGANISATION>
<ADDRESS_1>7 avenue de la République</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ivry-sur-Seine</CITY>
<ZIP>94200</ZIP>
<REGION/>
<COUNTRY CODE="FR">France</COUNTRY>
<PHONE_1>+33 149 594 350</PHONE_1>
<PHONE_2/>
<FAX_1>+33 149 594 383</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="E4F6ACE582E26AA2014D8C017CD08607" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Jean-François</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Bergmann</LAST_NAME>
<SUFFIX/>
<POSITION>Chef de Service</POSITION>
<EMAIL_1>jf.bergmann@lrb.ap-hop-paris.fr</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Service de Médecine Interne A</DEPARTMENT>
<ORGANISATION>Hôpital Lariboisière, AP-HP, Université Paris 7 Diderot</ORGANISATION>
<ADDRESS_1>2, rue Ambroise Paré</ADDRESS_1>
<ADDRESS_2/>
<CITY>Paris</CITY>
<ZIP>75010</ZIP>
<REGION/>
<COUNTRY CODE="FR">France</COUNTRY>
<PHONE_1>+33 1 49 95 63 37</PHONE_1>
<PHONE_2>+33 1 49 95 63 41</PHONE_2>
<FAX_1>+33 1 49 95 84 46</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="20908063795870049882110228154915" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Joël</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Belmin</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>j.belmin@cfx.aphp.fr</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>La Triade - Service Hospitalo-Universitaire de Gérontologie</DEPARTMENT>
<ORGANISATION>Université Pierre et Marie Curie (Paris 6)</ORGANISATION>
<ADDRESS_1>Group Hospitalier Pitié-Salpêtrière-Charles Foix</ADDRESS_1>
<ADDRESS_2>7, Avenue de la République, 94 Ivry-sur-Seine</ADDRESS_2>
<CITY>Paris</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="FR">France</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2015-04-21 18:27:07 +0100" MODIFIED_BY="Nicole Martin">
<UP_TO_DATE>
<DATE DAY="10" MONTH="1" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="10" MONTH="1" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="10" MONTH="1" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2004"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2015-04-21 18:27:58 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-04-21 18:27:50 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="21" MONTH="4" YEAR="2015"/>
<DESCRIPTION>
<P>Minor corrections in Figures 6 and 7</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-04-21 18:27:58 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-04-21 18:27:55 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="25" MONTH="7" YEAR="2014"/>
<DESCRIPTION>
<P>The inclusion of three new trials did not change the conclusions of this review</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-04-21 18:27:58 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="25" MONTH="7" YEAR="2014"/>
<DESCRIPTION>
<P>Searches re-run to January 2014. Three new trials were included, studying flecainide, amiodarone and sotalol. Conclusions of the review did not change</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2014-07-30 10:35:22 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="15" MONTH="3" YEAR="2011"/>
<DESCRIPTION>
<P>Searches were re-run for this update to February 2010. Eleven new publications were included. This new trials studied several drugs (amiodarone, azimilide, dofetilide, dronedarone, metoprolol and sotalol) and added 8 212 more patients. Some of the conclusions have changed in light of this new evidence: a) Beta-blockers (metoprolol) showed a significant effect in preventing AF recurrence; b) In addition to Class IA drugs, sotalol was also associated with increased all-cause mortality.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-07-30 10:34:46 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="25" MONTH="2" YEAR="2011"/>
<DESCRIPTION>
<P>Eleven new studies added and results changed</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-02-25 20:45:33 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="8" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="23" MONTH="6" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2011-02-22 10:42:50 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2011-02-22 10:42:50 +0000" MODIFIED_BY="[Empty name]">
<SOURCE>
<NAME>Unité de Recherches Thérapeutiques, Hôpital Lariboisière, Paris</NAME>
<COUNTRY CODE="FR">France</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2011-02-22 10:42:50 +0000" MODIFIED_BY="[Empty name]">
<NAME>Assistance Publique - Hôpitaux de Paris</NAME>
<COUNTRY CODE="FR">France</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-03-18 14:16:26 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2015-03-17 09:37:01 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2015-03-16 06:04:37 +0000" MODIFIED_BY="[Empty name]">Antiarrhythmics for maintaining sinus rhythm after reversing atrial fibrillation</TITLE>
<SUMMARY_BODY MODIFIED="2015-03-17 09:37:01 +0000" MODIFIED_BY="[Empty name]">
<P>Atrial fibrillation is a disease where the heart rhythm is irregular (this is called arrhythmia) and too fast (this is called tachycardia, from the Greek tachy meaning fast). Atrial fibrillation may produce complications, either in the heart (heart failure, syncope) or in other organs (mainly causing embolism, the formation of blood clots in the cavities of the heart that may then travel to other places, for example the brain).</P>
<P>Atrial fibrillation can be reverted, restoring normal heart rhythm, by using drugs or a controlled electrical shock. However, a major problem is that atrial fibrillation frequently recurs. A variety of drugs have been employed to avoid recurrences and keep the normal heart rhythm. This systematic review looked at the effectiveness and safety of antiarrhythmic drugs used to prevent recurrences of atrial fibrillation. This is an update of a review previously published in 2008 and 2012, with results of a search in January 2014 incorporated.</P>
<P>We found 59 studies testing various antiarrhythmic drugs and involving 21,305 patients. The risk of bias of the studies was low to moderate. The cumulative data from these studies showed that several drugs are effective at preventing recurrences of atrial fibrillation (quinidine, disopyramide, flecainide, propafenone, amiodarone, azimilide, dofetilide, dronedarone and sotalol) but all of them increased adverse effects. The data also showed that some of these drugs, one specific group called class IA drugs comprising quinidine, disopyramide and sotalol, may cause a small increase in the number of deaths in treated patients. Less data were available on the risk of embolic stroke (only 11 studies) and no consistent evidence of an effect on this outcome was apparent; one single study showed a reduction with dronedarone but that was not confirmed in other trials on the same drug. Finally, too few studies reported data on heart failure and the use of anticoagulants to be able to analyse the findings.</P>
<P>Thus, it is unclear if the long-term benefits obtained with antiarrhythmic drugs outweigh their risks.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-03-17 09:36:47 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2015-03-16 05:27:27 +0000" MODIFIED_BY="[Empty name]">
<P>Atrial fibrillation is the most frequent sustained arrhythmia. Atrial fibrillation frequently recurs after restoration of normal sinus rhythm. Antiarrhythmic drugs have been widely used to prevent recurrence, but the effect of these drugs on mortality and other clinical outcomes is unclear. This is an update of a review previously published in 2008 and 2012.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-03-16 07:14:47 +0000" MODIFIED_BY="[Empty name]">
<P>To determine in patients who have recovered sinus rhythm after having atrial fibrillation, the effects of long-term treatment with antiarrhythmic drugs on death, stroke, embolism, drug adverse effects and recurrence of atrial fibrillation.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-03-16 05:31:15 +0000" MODIFIED_BY="[Empty name]">
<P>We updated the searches of CENTRAL in <I>The Cochrane Library</I> (2013, Issue 12 of 12)<I>,</I> MEDLINE (to January 2014) and EMBASE (to January 2014). The reference lists of retrieved articles, recent reviews and meta-analyses were checked.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2015-03-16 05:40:51 +0000" MODIFIED_BY="[Empty name]">
<P>Two independent authors selected randomised controlled trials comparing any antiarrhythmic drug with a control (no treatment, placebo, drugs for rate control) or with another antiarrhythmic drug in adults who had atrial fibrillation and in whom sinus rhythm was restored. Post-operative atrial fibrillation was excluded.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-07-30 10:54:00 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors independently assessed quality and extracted data. Studies were pooled, if appropriate, using Peto odds ratio (OR). All results were calculated at one year of follow-up.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-03-16 07:49:17 +0000" MODIFIED_BY="[Empty name]">
<P>In this update three new studies, with 534 patients, were included making a total of 59 included studies comprising 21,305 patients. All included studies were randomised controlled trials. Allocation concealment was adequate in 17 trials, it was unclear in the remaining 42 trials. Risk of bias was assessed in all domains only in the trials included in this update.</P>
<P>Compared with controls, class IA drugs quinidine and disopyramide (OR 2.39, 95% confidence interval (95% CI) 1.03 to 5.59, number needed to treat to harm (NNTH) 109, 95% CI 34 to 4985) and sotalol (OR 2.23, 95% CI 1.1 to 4.50, NNTH 169, 95% CI 60 to 2068) were associated with increased all-cause mortality. Other antiarrhythmics did not seem to modify mortality, but our data could be underpowered to detect mild increases in mortality for several of the drugs studied.</P>
<P>Several class IA (disopyramide, quinidine), IC (flecainide, propafenone) and III (amiodarone, dofetilide, dronedarone, sotalol) drugs significantly reduced recurrence of atrial fibrillation (OR 0.19 to 0.70, number needed to treat to beneft (NNTB) 3 to 16). Beta-blockers (metoprolol) also significantly reduced atrial fibrillation recurrences (OR 0.62, 95% CI 0.44 to 0.88, NNTB 9).</P>
<P>All analysed drugs increased withdrawals due to adverse affects and all but amiodarone, dronedarone and propafenone increased pro-arrhythmia. Only 11 trials reported data on stroke. None of them found any significant difference with the exception of a single trial than found less strokes in the group treated with dronedarone compared to placebo. This finding was not confirmed in others studies on dronedarone.</P>
<P>We could not analyse heart failure and use of anticoagulation because few original studies reported on these measures.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-03-17 09:36:47 +0000" MODIFIED_BY="[Empty name]">
<P>Several class IA, IC and III drugs, as well as class II drugs (beta-blockers), are moderately effective in maintaining sinus rhythm after conversion of atrial fibrillation. However, they increase adverse events, including pro-arrhythmia, and some of them (disopyramide, quinidine and sotalol) may increase mortality. Possible benefits on clinically relevant outcomes (stroke, embolism, heart failure) remain to be established.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-03-18 14:16:26 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2015-03-16 07:13:40 +0000" MODIFIED_BY="[Empty name]">
<P>Atrial fibrillation is the most common sustained arrhythmia and its incidence increases substantially with age (<LINK REF="REF-Go-2001" TYPE="REFERENCE">Go 2001</LINK>; <LINK REF="REF-Knuiman-2014" TYPE="REFERENCE">Knuiman 2014</LINK>; <LINK REF="REF-Ruigomez-2002" TYPE="REFERENCE">Ruigomez 2002</LINK>). Atrial fibrillation is associated with increased morbidity and mortality, due to stroke, other embolic complications and heart failure (<LINK REF="REF-Benjamin-1998" TYPE="REFERENCE">Benjamin 1998</LINK>; <LINK REF="REF-Heeringa-2006" TYPE="REFERENCE">Heeringa 2006</LINK>; <LINK REF="REF-Krahn-1995" TYPE="REFERENCE">Krahn 1995</LINK>; <LINK REF="REF-Stewart-2002" TYPE="REFERENCE">Stewart 2002</LINK>). In developed countries, atrial fibrillation has grown progressively in the last few decades as a contributing cause of hospitalisation and death (<LINK REF="REF-Chugh-2014" TYPE="REFERENCE">Chugh 2014</LINK>; <LINK REF="REF-MMWR-2003" TYPE="REFERENCE">MMWR 2003</LINK>; <LINK REF="REF-Wattigney-2003" TYPE="REFERENCE">Wattigney 2003</LINK>).</P>
<P>In people who have atrial fibrillation, normal sinus rhythm is interrupted by periods of atrial fibrillation that may be either symptomatic or asymptomatic. Symptoms can be mild (for example palpitations, breathlessness or reduced effort capacity) or severe, causing syncope, heart failure or acute coronary syndrome. Many of the symptoms caused by atrial fibrillation are related to the degree of tachycardia and can be improved by either controlling heart rate (rate control strategy) or converting atrial fibrillation to normal sinus rhythm by electrical or pharmacological means (rhythm control strategy).</P>
<P>Most patients alternate between atrial fibrillation and sinus rhythm. The frequency and duration of atrial fibrillation are highly variable, both within patients and between patients, and are employed to classify this arrhythmia (<LINK REF="REF-ACC_x002f_AHA_x002f_ESC-2011" TYPE="REFERENCE">ACC/AHA/ESC 2011</LINK>; <LINK REF="REF-NICE-2014" TYPE="REFERENCE">NICE 2014</LINK>). If the arrhythmia terminates spontaneously atrial fibrillation is designated as 'paroxysmal', and it may recur afterwards or not. When atrial fibrillation is sustained beyond seven days it is designated as 'persistent'. Termination with pharmacological or electrical intervention does not change the designation. When atrial fibrillation is first detected, and it is not known if it will resolve or persist, it is designated 'recent onset' or simply 'first detected' atrial fibrillation. Finally, 'permanent' atrial fibrillation refers to persistent atrial fibrillation where cardioversion has failed or has not been attempted because it is considered that there is no possibility to restore sinus rhythm. An individual patient can show different classes of atrial fibrillation over time.</P>
<P>Many patients recover sinus rhythm spontaneously after an episode of recent onset atrial fibrillation, as many as 70% in some studies (<LINK REF="REF-Geleris-2001" TYPE="REFERENCE">Geleris 2001</LINK>). Electrical and pharmacological cardioversion are very effective in restoring sinus rhythm, even in long-standing persistent atrial fibrillation. However, a major problem is that recurrence of atrial fibrillation occurs frequently. The risk of recurrence of atrial fibrillation is dependent on age, duration of the atrial fibrillation and the existence and severity of underlying heart disease (<LINK REF="REF-Flaker-1995" TYPE="REFERENCE">Flaker 1995</LINK>; <LINK REF="REF-Frick-2001" TYPE="REFERENCE">Frick 2001</LINK>). The overall rate of recurrence of atrial fibrillation without treatment is high; of patients who have converted to sinus rhythm, only 20% to 30% will remain in sinus rhythm one year later (<LINK REF="REF-Gelder-1996" TYPE="REFERENCE">Gelder 1996</LINK>; <LINK REF="REF-Golzari-1996" TYPE="REFERENCE">Golzari 1996</LINK>).</P>
<P>Long-term antiarrhythmic therapy has been widely used to prevent the recurrence of atrial fibrillation. Antiarrhythmic drugs are usually grouped into four classes following the classification by Vaughan Williams (<LINK REF="REF-Vaughan-Williams-1984" TYPE="REFERENCE">Vaughan Williams 1984</LINK>). Class I drugs are those with a direct membrane action (sodium (Na) channel blockade), subdivided to IA, IB and IC depending on specific effects on conduction and repolarization; class II drugs are beta-blockers; class III drugs are those that prolong repolarization; and class IV drugs are calcium channel blockers. There is evidence that several class I, class III and maybe class II antiarrhythmic drugs are more effective than placebo for maintaining sinus rhythm (<LINK REF="REF-Miller-2000" TYPE="REFERENCE">Miller 2000</LINK>; <LINK REF="REF-Nichol-2002" TYPE="REFERENCE">Nichol 2002</LINK>). However, some questions remain.</P>
<P>It has been assumed that keeping patients in sinus rhythm would reduce the risks of embolism, stroke, heart failure or increased mortality that are associated with atrial fibrillation (<LINK REF="REF-Anter-2009" TYPE="REFERENCE">Anter 2009</LINK>). However, this has not been proven and, unfortunately, many of the trials with antiarrhythmic drugs have focused only on maintenance of sinus rhythm and have not assessed other relevant outcomes (<LINK REF="REF-Connolly-2000" TYPE="REFERENCE">Connolly 2000</LINK>). Overall the rhythm control strategy, using antiarrhythmics to maintain sinus rhythm, has not shown any clear benefit on clinical outcomes (for example mortality or stroke) in randomised controlled trials using a rate control strategy (<LINK REF="REF-Caldeira-2012" TYPE="REFERENCE">Caldeira 2012</LINK>; <LINK REF="REF-Chatterjee-2013" TYPE="REFERENCE">Chatterjee 2013</LINK>; <LINK REF="REF-Cordina-2005" TYPE="REFERENCE">Cordina 2005</LINK>; <LINK REF="REF-Denus-2005" TYPE="REFERENCE">Denus 2005</LINK>; <LINK REF="REF-Testa-2005" TYPE="REFERENCE">Testa 2005</LINK>).</P>
<P>Chronic treatment with antiarrhythmic drugs can be associated with severe adverse effects, including the potential induction of life-threatening arrhythmias. Adverse effects could compromise any benefits of maintaining sinus rhythm, or even outweigh them, leading to worse outcomes overall. In fact, the results of some trials show a significantly increased mortality associated with the long-term use of some antiarrhythmics, as in the case with quinidine (<LINK REF="REF-Coplen-1990" TYPE="REFERENCE">Coplen 1990</LINK>; <LINK REF="REF-SPAF-1992" TYPE="REFERENCE">SPAF 1992</LINK>) or flecainide (<LINK REF="REF-CAST-1991" TYPE="REFERENCE">CAST 1991</LINK>). Finally, it is not known if all antiarrhythmic drugs are equivalent in their effectiveness and safety.</P>
<IMPORTANCE MODIFIED="2015-03-16 07:13:40 +0000" MODIFIED_BY="[Empty name]">
<P>Many trials have studied long-term treatment with diverse antiarrhythmic drugs for maintaining sinus rhythm, sometimes compared to placebo and sometimes compared to other antiarrhythmic drugs. Attempts to summarise this evidence in systematic reviews of trials or meta-analyses have been incomplete. They were combined in a narrative review (<LINK REF="REF-Golzari-1996" TYPE="REFERENCE">Golzari 1996</LINK>); trials using different antiarrhythmics and with very dissimilar lengths of treatment were pooled together (<LINK REF="REF-Nichol-2002" TYPE="REFERENCE">Nichol 2002</LINK>); and outcomes other than sinus rhythm maintenance were not evaluated (<LINK REF="REF-Miller-2000" TYPE="REFERENCE">Miller 2000</LINK>). Consequently, we planned to conduct a more exhaustive systematic review of randomised controlled trials studying the long-term use of antiarrhythmic drugs to maintain sinus rhythm and aimed to determine their effects not only on the recurrence of atrial fibrillation but also on other important clinical outcomes. After the first publication of this review, another meta-analysis on the same subject was published by Freementle et al (<LINK REF="REF-Freemantle-2011" TYPE="REFERENCE">Freemantle 2011</LINK>). This meta-analysis employed non-classical statistical methods (a mixed treatment comparison method, combining the estimates obtained from direct and indirect comparisons in a network of trials); and it is not known if these methods are better or worse than the classical meta-analytical approach.</P>
<P>After the first publication of this review in 2007, several new randomised controlled trials have been published. They have been systematically searched, assessed and, when found adequate, included in the successive updates of this review.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-03-16 07:14:19 +0000" MODIFIED_BY="[Empty name]">
<P>To determine in patients who have recovered sinus rhythm after having atrial fibrillation, the effects of long-term treatment with antiarrhythmic drugs on death, stroke, embolism, drug adverse effects and recurrence of atrial fibrillation.</P>
<P>The primary aim was to assess the effects of any antiarrhythmic drug compared with no antiarrhythmic treatment, that is no treatment, placebo, or treatment for rate control. If several antiarrhythmic drugs appeared to be effective the secondary aim was to compare them.</P>
</OBJECTIVES>
<METHODS MODIFIED="2015-03-18 14:00:48 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2015-03-16 07:29:25 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2014-07-30 11:55:51 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials with concealed allocation of participants to intervention or placebo. We excluded studies that were not randomised or where allocation to treatment was not concealed. We also excluded cross-over studies and studies where duration of follow up was less than six months.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2015-03-16 07:25:43 +0000" MODIFIED_BY="[Empty name]">
<P>Adults (&gt; 16 years) who had atrial fibrillation of any type and duration and in whom sinus rhythm had been restored, spontaneously or by any therapeutic intervention.</P>
<P>We excluded patients with atrial fibrillation following cardiac surgery as well as patients with any condition causing a life expectancy of less than 12 months.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-03-16 07:28:43 +0000" MODIFIED_BY="[Empty name]">
<P>To be included, studies must have randomly allocated patients to an intervention group and a control group. The intervention group must have received oral long-term treatment with any available antiarrhythmic drug, at an appropriate dosing regime, aimed at preventing new episodes of atrial fibrillation and maintaining sinus rhythm.</P>
<P>The control group, for the primary objective of the review, could use placebo, drugs for rate control (digoxin, calcium channel blockers, beta-blockers) or no treatment. For the secondary objective of evaluating differences between antiarrhythmic drugs, the control group could be any of the other antiarrhythmic drugs that have shown effectiveness compared to no antiarrhythmic treatment.</P>
<P>Both groups, intervention and control, had to be similar with regard to cardiac disease (frequency, type and severity) and type of atrial fibrillation (especially duration). Also, both groups must have been treated similarly apart from the experimental therapy, that is:</P>
<OL>
<LI>the guidelines used to manage initiation, discontinuation, dose and surveillance of anticoagulation had to be the same in both the intervention and control groups;</LI>
<LI>management and drugs used for hypertension and heart failure had to be similar.</LI>
</OL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-03-16 07:29:25 +0000" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2015-03-16 07:29:25 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Mortality (total mortality and mortality due to cardiovascular causes)</LI>
<LI>Embolic complications (stroke and peripheral embolism combined)</LI>
<LI>Adverse effects (withdrawals caused by adverse events and pro-arrhythmia, including any of the following: sudden death, any new symptomatic arrhythmia (including symptomatic bradycardia), aggravation of existing arrhythmias (i.e. rapid atrial fibrillation) and new appearance on electrocardiogram of QRS or QT widening that leads to stopping treatment (<LINK REF="REF-Friedman-1998" TYPE="REFERENCE">Friedman 1998</LINK>))</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2015-03-16 07:21:12 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Use of anticoagulation (number of patients started on long-term treatment with anticoagulants at the end of follow up)</LI>
<LI>Recurrence of atrial fibrillation (number of patients who had a recurrence of atrial fibrillation during follow up)</LI>
</OL>
<P>It was planned to analyse all outcomes at 6, 12 and 24 months, when data were available. If a trial did not measure outcomes at these exact time points then the nearest measure point, if close enough, was used (e.g. at 9 or 15 months instead of 12 months).</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-03-16 07:31:41 +0000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2015-03-16 06:19:54 +0000" MODIFIED_BY="[Empty name]">
<P>The searches from 2005 (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>) and 2010 (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>) (<LINK REF="REF-Lafuente_x002d_Lafuente-2012" TYPE="REFERENCE">Lafuente-Lafuente 2012</LINK>) have been updated and were re-run on 10 January 2014 (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>). We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in <I>The Cochrane Library </I>(2013, Issue 12 of 12), MEDLINE (1950 to January 2014) and EMBASE (1966 to January 2014).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2015-03-16 07:31:41 +0000" MODIFIED_BY="[Empty name]">
<P>In addition, we checked the reference lists of retrieved studies as well as the reference lists of recent guidelines, meta-analyses and general reviews on atrial fibrillation.</P>
<P>We applied no language restrictions.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-03-18 14:00:48 +0000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2015-03-18 14:00:48 +0000" MODIFIED_BY="[Empty name]">
<P>The titles (and abstracts where available) were read by the any of the authors and any publication that seemed to possibly meet the above criteria was retrieved. Two independent authors read the full texts of the studies that were retrieved and selected the trials that met the criteria for inclusion. A predefined form was developed and used for this task. The selected trials were compared and any discrepancy resolved by discussion and consensus between the authors. The articles that were finally selected for the review were checked to avoid duplication of data. Records of the selection process were kept and a PRISMA flowchart was prepared (<LINK REF="REF-PRISMA-2009" TYPE="REFERENCE">PRISMA 2009</LINK>).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2015-03-16 07:42:09 +0000" MODIFIED_BY="[Empty name]">
<P>Two authors (CL-L, LV, JB, JFB) extracted data independently using a data collection form specifically developed for this task. When necessary, we contacted the authors of primary studies for additional information. We checked the completed data forms for agreement and resolved any differences by discussion and consensus.</P>
<P>In addition to data relating to the outcomes of the review, we collected information on the following.</P>
<OL>
<LI>Study methods and design (randomisation, allocation concealment and blinding).</LI>
<LI>Baseline characteristics of patients (age, gender, frequency and type of heart disease, echocardiographic measures, duration and type of atrial fibrillation, as defined in each study and knowing that definitions employed have not been always consistent).</LI>
<LI>Details of treatments (method of cardioversion employed, time interval between conversion to sinus rhythm and initiation of intervention, antiarrhythmic drugs used and dose, treatment used in control group, concomitant treatments (beta-blockers, angiotensin converting enzyme inhibitors, antiplatelets and warfarin)).</LI>
<LI>Follow-up duration, patients lost to follow up and withdrawals.</LI>
</OL>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-03-16 07:45:08 +0000" MODIFIED_BY="[Empty name]">
<P>Two authors (CL-L, LV, JB, JFB) independently assessed the risk of bias of the selected studies. In the first versions of this review, this was done mainly by attending to the adequacy of allocation concealment, which was ranked as high (adequate), low (inadequate) or unclear in accordance with the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). In this update, new included studies were evaluated in all the main domains of risk of bias, as recommended in the more recent <I>Cochrane Handbook for Systematic Reviews of Interventions</I>: random sequence generation, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data and selective reporting. In future updates, the assessment of risk of bias will be extended to all six domains for all included studies.</P>
<P>Any differences of opinion were resolved by discussion and consensus.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-03-17 04:46:19 +0000" MODIFIED_BY="[Empty name]">
<P>Odds ratio (OR) was determined for all outcomes as they are all dichotomous variables. If results for any outcome were significant and the control group levels of the outcomes were broadly similar, we calculated the number needed to treat to benefit (NNTB) or number needed to treat to harm (NNTH) to prevent or produce, respectively, one adverse outcome for the specified duration of treatment. We used the pooled OR and the pooled rate from the control groups.</P>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2015-03-17 04:47:58 +0000" MODIFIED_BY="[Empty name]">
<P>We analysed the data on the basis of intention to treat. By default, available case analysis was used (missing patients were considered not to have experienced an event). Nevertheless, the worst-case scenario intention-to-treat-analysis (all missing patients considered as having events) was also carried out for all outcomes to test if any potential difference might have arisen due to losses to follow up.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-03-16 06:21:57 +0000" MODIFIED_BY="[Empty name]">
<P>Heterogeneity was tested using the Mantel-Haenszel Chi<SUP>2</SUP> test and the I<SUP>2</SUP> statistic (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). If significant heterogeneity was found, we searched for an explanation based on the differences in clinical characteristics of the included studies. If the studies were found to be clinically very dissimilar they were not statistically combined.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2011-01-27 13:56:39 +0000" MODIFIED_BY="[Empty name]">
<P>A funnel plot was used to test for the presence of publication bias, based on the data for the primary outcome of total mortality.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2015-03-17 04:51:09 +0000" MODIFIED_BY="[Empty name]">
<P>Data were pooled using RevMan software (Version 5.0). If no heterogeneity was found, Peto ORs were calculated for all outcomes using a fixed-effect model. If heterogeneity between studies was observed, ORs were calculated using a random-effects model.</P>
<P>Data for all antiarrhythmic drugs were pooled and analysed individually (for each specific drug), and also grouped by pharmacological class following the classification of Vaughan Williams (<LINK REF="REF-Vaughan-Williams-1984" TYPE="REFERENCE">Vaughan Williams 1984</LINK>).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2015-03-17 04:52:23 +0000" MODIFIED_BY="[Empty name]">
<P>Predefined subgroup analyses were:</P>
<OL>
<LI>paroxysmal atrial fibrillation and persistent atrial fibrillation;</LI>
<LI>patients with heart failure opposed to patients who had never developed heart failure;</LI>
<LI>studies where warfarin was mandatory versus those where warfarin was discretionary; and</LI>
<LI>patients with a structurally normal heart ('lone' atrial fibrillation).</LI>
</OL>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2015-03-17 04:52:54 +0000" MODIFIED_BY="[Empty name]">
<P>Sensitivity analyses were performed by selectively pooling:</P>
<OL>
<LI>studies having the best methodological quality; and</LI>
<LI>studies including the greatest number of patients (i.e. &gt; 200 patients).</LI>
</OL>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-03-18 14:16:26 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2015-03-17 05:20:05 +0000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2015-03-17 04:59:59 +0000" MODIFIED_BY="[Empty name]">
<P>We found a total of 5343 references,and assessed 189 articles in more detail. We retrieved, translated, when needed, and assessed articles in Chinese, English, French, Italian, German, Spanish and Swedish. Finally, 59 studies fulfilled the inclusion criteria and had useable data. They comprised 21,305 patients in total.</P>
<P>Compared with the previous publication of this review in 2012, which searched the medical literature until February 2010, we read 1767 additional references (LV, CLL), assessed in detail 17 new articles (LV, CLL, JB, JFB) and included three new randomised controlled trials (<LINK REF="STD-Flec_x002d_SL-2012" TYPE="STUDY">Flec-SL 2012</LINK>; <LINK REF="STD-Santas-2012" TYPE="STUDY">Santas 2012</LINK>; <LINK REF="STD-Vijayalaskshmi-2006" TYPE="STUDY">Vijayalaskshmi 2006</LINK>). The three new included trials studied several drugs (flecainide, amiodarone and sotalol) and added 534 more patients. The three new studies compared one or two antiarrhythmic drugs with no treatment.</P>
<P>Agreement between authors was good for both selecting studies and extracting the data.</P>
<P>
<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> illustrates the selection of articles, following the PRISMA model. Details of each included study are shown in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table, and the reasons for exclusion are shown in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-03-17 05:20:05 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Patients</HEADING>
<P>Entry criteria differed between studies in several aspects. In some trials atrial fibrillation was documented in the past history but patients were in sinus rhythm at the time of inclusion, while in other trials patients were in atrial fibrillation and needed to be converted to sinus rhythm (only those converted were included in the review). The duration of atrial fibrillation when persistent, or the time from the last documented episode of atrial fibrillation when paroxysmal, were highly variable (from one month to one year, or no time limit in some studies). Some of the studies required atrial fibrillation to be symptomatic while others did not. A few studies (six in total) enrolled both patients with atrial fibrillation or atrial flutter. When available, only data from patients with atrial fibrillation were used.</P>
<P>Regarding the type of atrial fibrillation, 8 studies included exclusively paroxysmal or recent onset atrial fibrillation, 26 studies included only persistent atrial fibrillation, and the remaining 25 studies included both types. Overall, 44% of the pooled population had persistent or permanent atrial fibrillation.</P>
<P>The mean age of patients varied from 46 to 72 years in the included studies and was 64.5 years in the pooled population. The proportion of patients having underlying heart disease varied widely, from 29% to 100%, with only one study selectively including patients without structural heart disease (<LINK REF="STD-FAPIS-1996" TYPE="STUDY">FAPIS 1996</LINK>). The most frequent diseases were coronary artery disease (5% to 50% of patients), hypertension, and valvular abnormalities (less frequent in recent studies). The mean left ventricle ejection fraction was greater than 50% in almost all trials but with five exceptions (<LINK REF="STD-DIAMOND-2001" TYPE="STUDY">DIAMOND 2001</LINK>; <LINK REF="STD-Kalusche-1994" TYPE="STUDY">Kalusche 1994</LINK>; <LINK REF="STD-Nergardh-2007" TYPE="STUDY">Nergardh 2007</LINK>; <LINK REF="STD-Plewan-2001" TYPE="STUDY">Plewan 2001</LINK>; <LINK REF="STD-Vijayalaskshmi-2006" TYPE="STUDY">Vijayalaskshmi 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>Thirty trials (accumulating 13,865 patients) compared an antiarrhythmic with a control, 12 trials (4536 patients) compared two different antiarrhythmics and a control, and 17 trials (2904 patients) compared two or more antiarrhythmics with each other. The comparator used in the 42 trials with control groups was a placebo in 33 trials, a beta-blocker in 2 trials (<LINK REF="STD-DAPHNE-2008" TYPE="STUDY">DAPHNE 2008</LINK>; <LINK REF="STD-Plewan-2001" TYPE="STUDY">Plewan 2001</LINK>), digoxin in 1 trial (<LINK REF="STD-Steinbeck-1988" TYPE="STUDY">Steinbeck 1988</LINK>) and no treatment in 6 trials (<LINK REF="STD-Flec_x002d_SL-2012" TYPE="STUDY">Flec-SL 2012</LINK>; <LINK REF="STD-Hillestad-1971" TYPE="STUDY">Hillestad 1971</LINK>; <LINK REF="STD-Santas-2012" TYPE="STUDY">Santas 2012</LINK>; <LINK REF="STD-Sodermark-1975" TYPE="STUDY">Sodermark 1975</LINK>; <LINK REF="STD-Van-Gelder-1989" TYPE="STUDY">Van Gelder 1989</LINK>; <LINK REF="STD-Vijayalaskshmi-2006" TYPE="STUDY">Vijayalaskshmi 2006</LINK>).</P>
<P>Drugs included in this review, for which at least one well designed randomised controlled trial was found, were (a) class IA: quinidine, disopyramide; (b) class IB: aprindine, bidisomide; (c) class IC: flecainide, propafenone; (d) class II (beta-blockers): metoprolol; (e) class III: amiodarone, azimilide, dofetilide, dronedarone and sotalol.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>All studies but two (<LINK REF="STD-DAPHNE-2008" TYPE="STUDY">DAPHNE 2008</LINK>; <LINK REF="STD-Santas-2012" TYPE="STUDY">Santas 2012</LINK>) had data on mortality, all but two (<LINK REF="STD-ASAP-2003" TYPE="STUDY">ASAP 2003</LINK>; <LINK REF="STD-PITAGORA-2008" TYPE="STUDY">PITAGORA 2008</LINK>) on atrial fibrillation recurrence rates, and all but two (<LINK REF="STD-AFIB-1997" TYPE="STUDY">AFIB 1997</LINK>; <LINK REF="STD-Santas-2012" TYPE="STUDY">Santas 2012</LINK>) presented data for adverse effects, either withdrawals or pro-arrhythmia (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). All-cause mortality and cardiovascular mortality were virtually identical in all studies, so we reported only all-cause mortality. Other outcomes were less well reported: in studies with a placebo or no treatment arm, stroke was reported in 11 trials, heart failure in 2 trials and actual frequency of anticoagulation in none.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Follow up</HEADING>
<P>The most frequent length of follow up was one year. It was shorter in 17 trials (6 to 9 months). Five trials followed patients for two years or more (<LINK REF="STD-AFFIRM-Substudy-2003" TYPE="STUDY">AFFIRM Substudy 2003</LINK>; <LINK REF="STD-ATHENA-2009" TYPE="STUDY">ATHENA 2009</LINK>; <LINK REF="STD-Kochiadakis-2000" TYPE="STUDY">Kochiadakis 2000</LINK>; <LINK REF="STD-Kochiadakis-2004a" TYPE="STUDY">Kochiadakis 2004a</LINK>; <LINK REF="STD-Kochiadakis-2004b" TYPE="STUDY">Kochiadakis 2004b</LINK>). Therefore, we decided to extract and pool all outcomes at one year of follow up. For studies with shorter duration of follow up the last observation available was employed.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-03-17 05:26:49 +0000" MODIFIED_BY="[Empty name]">
<P>The funnel plot (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>) showed asymmetry with fewer small studies on the left side (for example more small studies showing a trend to more deaths on active treatment). This is, however, the contrary to what is expected when publication bias is present (usually small studies with negative results are under-reported). We do not have a satisfactory explanation for the asymmetry observed in the funnel plot.</P>
<P>All included studies were randomised controlled trials. Allocation concealment was adequate in 17 trials, in the remaining 42 trials it was unclear or the procedure was not well reported. The majority of trials comparing an antiarrhythmic versus a control were blinded (of 42 trials: 26 were double-blind and 5 single-blind, the remaining 11 were open-label). In contrast, most trials comparing two or more different antiarrhythmics were open-label (14 out of 17). More details are provided in <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK> and <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>.</P>
<P>The percentage of patients lost to follow up was reported in 43 out of the 59 included trials and was small (5% to 10%). However, virtually all studies followed patients until atrial fibrillation recurred or until treatment was stopped for any reason, and no longer. Data for some outcomes, like mortality, were therefore not extensive.</P>
<P>Conflict of interest could exist as almost all the studies included in the review were funded by the company manufacturing the antiarrhythmic drug tested.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-03-18 14:16:26 +0000" MODIFIED_BY="[Empty name]">
<P>All outcomes were calculated at one year of follow up.</P>
<P>Imputing missing patients as events (the worst-case intention-to-treat scenario) generally did not modify the results, so the best-case intention-to-treat analysis (missing patients counted as being free of events) was reported as the default; where differences existed details are given.</P>
<SUBSECTION>
<HEADING LEVEL="3">Mortality</HEADING>
<P>Results for mortality are summarised in <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> and <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>. The all-cause mortality rate was low (0% to 5.1% at 1 year). The only exception to this generally low mortality rate was the DIAMOND study (<LINK REF="STD-DIAMOND-2001" TYPE="STUDY">DIAMOND 2001</LINK>). It recruited patients with advanced heart failure and had a mortality of 31% at 1 year.</P>
<P>Quinidine, compared with controls, showed a non-significant but clear trend to increase mortality (OR 2.26, 95% CI 0.93 to 5.45, P = 0.07). This trend became significant if missing patients were counted as deaths (OR 2.29, 95% CI 1.05 to 5.01, P = 0.04) and when all class IA drugs (quinidine and disopyramide) were combined (OR 2.39, 95% CI 1.03 to 5.59, P = 0.04) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). The corresponding NNTH for combined class IA drugs was 109 patients treated for 1 year to have one excess death, with a wide 95% CI of 34 to 4895 patients.</P>
<P>However, a sensitivity analysis of studies on quinidine and class IA drugs, selectively pooling trials with adequate allocation concealment or those including more than 200 patients, left only 2 studies (<LINK REF="STD-PAFAC-2004" TYPE="STUDY">PAFAC 2004</LINK>; <LINK REF="STD-SOPAT-2004" TYPE="STUDY">SOPAT 2004</LINK>) in which no difference in mortality was apparent compared with controls. These 2 trials employed a lower dose of quinidine (320 to 480 mg/day) than other studies (800 to 1800 mg/day) and combined quinidine with verapamil.</P>
<P>Sotalol also showed a significant increase in associated mortality compared with controls (OR 2.23, 95% CI 1.10 to 4.50, P = 0.03). This increase in mortality was confirmed In the sensitivity analyses, either counting missing patients as deaths (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>), pooling high-quality trials only (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>) or pooling trials with more than 200 patients (<LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>). The corresponding NNTH for sotalol was 169 patients treated for 1 year to have 1 excess death, with a wide 95% CI of 60 to 2067 patients.</P>
<P>A strong but non-significant trend to increased mortality was also apparent with azimilide compared with controls (OR 2.18, 95% CI 0.98 to 4.89, P = 0.06). This trend persisted in the sensitivity analysis.</P>
<P>Very little data on mortality was found for class IC drugs. We had previously retrieved only three small randomised trials (146 patients in total) on flecainide that fulfilled the inclusion criteria, in which no deaths were reported in any treatment group. In this update we retrieved one recent randomised trial (<LINK REF="STD-Flec_x002d_SL-2012" TYPE="STUDY">Flec-SL 2012</LINK>) including more patients (362 patients followed at 6 months) but still no deaths were reported in any treatment group. We found more studies on propafenone that fulfilled the inclusion criteria (5 trials, 998 patients) but only two deaths in patients taking placebo and no deaths in patients taking propafenone were reported. As the data obtained on mortality with flecainide and propafenone seemed incomplete, we chose not to analyse this outcome for these drugs.</P>
<P>No other significant difference in mortality was apparent with respect to the remaining drugs analysed, beta-blockers, amiodarone, dofetilide and dronedarone. In direct comparisons between antiarrhythmics, no significant differences were found (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>). No heterogeneity between studies was detected for this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse effects (withdrawals and pro-arrhythmia)</HEADING>
<P>Results for adverse effects are summarised in <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK> and <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>. Compared to controls, withdrawals due to adverse effects were more frequent with all drugs except aprindine, pilsicainide (both with results from one study only) and dofetilide (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). Substantial heterogeneity between studies was detected for quinidine (I<SUP>2</SUP> = 76%, P = 0.0003) and sotalol (I<SUP>2</SUP> = 63%, P = 0.002). In both cases the heterogeneity was due to the effects of the PAFAC and SOPAT trials (<LINK REF="STD-PAFAC-2004" TYPE="STUDY">PAFAC 2004</LINK>; <LINK REF="STD-SOPAT-2004" TYPE="STUDY">SOPAT 2004</LINK>), in which neither quinidine nor sotalol showed significant differences in withdrawals compared with placebo. The PAFAC and SOPAT trials employed lower doses of quinidine but usual doses of sotalol (320 mg/day). The remaining studies of quinidine or sotalol did show a significant increase in withdrawals from treatment because of adverse effects.</P>
<P>All studied antiarrhythmics showed increased pro-arrhythmic effects (counting both bradyarrhythmias and tachyarrhythmias attributable to treatment) with the exceptions of amiodarone, dronedarone and propafenone (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>). Pooled event rates varied depending on the antiarrhythmic used: from 4% to 23% for withdrawals due to adverse effects, and from 1% to 12% for pro-arrhythmia. The NNTH, the mean number of patients needed to treat for 1 year to have 1 excess withdrawal due to adverse effects from treatment were 9 with quinidine, 15 with sotalol, 22 with dronedarone and 26 with amiodarone or propafenone. The NNTH for pro-arrhythmia was 38 with flecainide and sotalol, 85 with quinidine and 156 with dofetilide.</P>
<P>Ventricular arrhythmias (torsades, ventricular tachycardia (VT), ventricular fibrillation (VF), widening QRS or QT leading to stopping treatment, sudden death or unexplained syncope) were the most frequent pro-arrhythmic events reported with dofetilide (100% of all pro-arrhythmic events), quinidine (94%) and flecainide (69%), while symptomatic bradyarrhythmias (sinus bradycardia leading to stopping treatment, atrio-ventricular (AV) block) were more frequent with metoprolol (94% of all events) and amiodarone (69%). Others drugs demonstrated both types of pro-arrhythmic events: propafenone (63% ventricular events, 39% bradycardia), sotalol (61% ventricular events, 39% bradycardia) and dronedarone (41% ventricular events, 59% bradycardia).</P>
<P>In direct comparisons between antiarrhythmics (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK> and <LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK>), quinidine caused more withdrawals than the other class I drugs (OR 2.25, 95% CI 1.45 to 3.51, P = 0.0003) but not more pro-arrhythmia. Amiodarone produced significantly fewer withdrawals (OR 0.55, 95% CI 0.36 to 0.84, P = 0.006) and fewer pro-arrhythmic events (OR 0.28, 95% CI 0.13 to 0.59, P = 0.0007) than class I drugs combined. However, compared to placebo, amiodarone had a high OR for increasing withdrawals (OR 5.55, 95% CI 2.24 to 13.7). Significant heterogeneity between the studies comparing two antiarrhythmic drugs was found in the analysis of withdrawals. This heterogeneity was probably explained by the differences in criteria for stopping treatment and withdrawal of patients when adverse effects appeared.</P>
<P>Sensitivity analysis did not modify the results for withdrawals and pro-arrhythmia.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Stroke</HEADING>
<P>Results for stroke are summarised in <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>. Only 11 of the 42 studies with a control group (placebo or no treatment arm) reported stroke outcomes (<LINK REF="STD-ATHENA-2009" TYPE="STUDY">ATHENA 2009</LINK>; <LINK REF="STD-Benditt-1999" TYPE="STUDY">Benditt 1999</LINK>; <LINK REF="STD-Carunchio-1995" TYPE="STUDY">Carunchio 1995</LINK>; <LINK REF="STD-EURIDIS-ADONIS-2007" TYPE="STUDY">EURIDIS ADONIS 2007</LINK>; <LINK REF="STD-Flec_x002d_SL-2012" TYPE="STUDY">Flec-SL 2012</LINK>; <LINK REF="STD-Hillestad-1971" TYPE="STUDY">Hillestad 1971</LINK>; <LINK REF="STD-Karlson-1998" TYPE="STUDY">Karlson 1998</LINK>; <LINK REF="STD-Lloyd-1984" TYPE="STUDY">Lloyd 1984</LINK>; <LINK REF="STD-SAFE_x002d_T-2005" TYPE="STUDY">SAFE-T 2005</LINK>; <LINK REF="STD-Sodermark-1975" TYPE="STUDY">Sodermark 1975</LINK>; <LINK REF="STD-SOPAT-2004" TYPE="STUDY">SOPAT 2004</LINK>) and we were uncertain that reporting of stroke was complete. The reported stroke rate was very low (1% to 2% at 1 year). No significant difference appeared between antiarrhythmic drugs and controls except for dronedarone, which showed a significant association with reduced risk of stroke (OR 0.66, 95% CI 0.46 to 0.95, P = 0.02). This result, however, was due to a single large study, the ATHENA trial, where stroke was significantly less frequent in the group treated with dronedarone (1.2% per year) than in the placebo group (1.8% per year). The other studies on dronedarone either did not show any difference compared with the control group or did not report stroke.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Atrial fibrillation recurrence</HEADING>
<P>Results for atrial fibrillation recurrence are summarised in <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK> and <LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>. All class IA, class IC and class III drugs included in this review significantly reduced the recurrence of atrial fibrillation. Metoprolol, based on two studies (562 patients), also showed a significant effect in reducing the number of recurrences of atrial fibrillation (OR 0.62, 95% CI 0.44 to 0.88, P = 0.008). In contrast, class IB drugs did not show any difference compared with control.</P>
<P>Substantial heterogeneity (I<SUP>2</SUP> = 76%, P = 0.02) between studies was detected for dofetilide. Moderate, non-significant inconsistency (I<SUP>2</SUP> = 52%, P = 0.15) was apparent between the two studies on metoprolol. In both cases, dofetilide and metoprolol, all studies showed the same direction of effect (that is a reduction of atrial fibrillation recurrences) and the heterogeneity was probably caused by the differences in the characteristics of recruited patients.</P>
<P>Pooled recurrence rates of atrial fibrillation at 1 year were high: 69% to 84% in controls not receiving antiarrhythmic treatment, reduced to 43% to 67% in patients treated with antiarrhythmics. The corresponding average NNTBs for 1 year, to avoid 1 recurrence of atrial fibrillation, were 3 with amiodarone, 4 with flecainide, 5 with dofetilide and propafenone, 8 with quinidine and sotalol, 9 with dronedarone and metoprolol, and 17 with azimilide (the 95% CI varied between 2 and 60).</P>
<P>In direct comparisons between antiarrhythmics (<LINK REF="CMP-005.05" TYPE="ANALYSIS">Analysis 5.5</LINK>), amiodarone reduced the recurrence of atrial fibrillation significantly more than the combined class I drugs (OR 0.36, 95% CI 0.26 to 0.50, P &lt; 0.00001) and dronedarone (OR 0.45, 95% CI 0.31 to 0.63, P &lt; 0.00001, 1 trial, 504 patients), and more than sotalol (OR 0.43, 95% CI 0.33 to 0.56, P &lt; 0.00001). No other significant differences were apparent in comparisons between antiarrhythmics.</P>
<P>Results for atrial fibrillation recurrence were unchanged in sensitivity analyses.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Other outcomes</HEADING>
<P>Chronic anticoagulation with warfarin was mandatory (that is every patient received anticoagulation therapy throughout the whole follow-up period) in only three studies (<LINK REF="STD-Channer-2004" TYPE="STUDY">Channer 2004</LINK>; <LINK REF="STD-Hillestad-1971" TYPE="STUDY">Hillestad 1971</LINK>; <LINK REF="STD-Van-Gelder-1989" TYPE="STUDY">Van Gelder 1989</LINK>). In the rest of the studies the decision on anticoagulation use was left to the judgement of the attending physician. Unfortunately, no trial reported the actual frequency of anticoagulation in the different treatment groups during follow up.</P>
<P>Seven trials reported some data on the incidence of heart failure (<LINK REF="STD-ATHENA-2009" TYPE="STUDY">ATHENA 2009</LINK>; <LINK REF="STD-DYONISOS-2010" TYPE="STUDY">DYONISOS 2010</LINK>; <LINK REF="STD-FAPIS-1996" TYPE="STUDY">FAPIS 1996</LINK>; <LINK REF="STD-Hohnloser-1995" TYPE="STUDY">Hohnloser 1995</LINK>; <LINK REF="STD-Kuhlkamp-2000" TYPE="STUDY">Kuhlkamp 2000</LINK>; <LINK REF="STD-PRODIS-1996" TYPE="STUDY">PRODIS 1996</LINK>; <LINK REF="STD-Reimold-1993" TYPE="STUDY">Reimold 1993</LINK>), which was low. There were no differences between groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analysis</HEADING>
<P>Twenty-three of the studies with a control group (placebo or no treatment) included only patients with persistent atrial fibrillation. The mean duration of atrial fibrillation in those studies varied greatly, from 3 to 36 months. Only four of the studies with a control group exclusively included patients with paroxysmal atrial fibrillation. The remaining studies included patients with both paroxysmal and persistent atrial fibrillation; none reported outcomes separately by type of atrial fibrillation.</P>
<P>Selectively pooling studies with only persistent atrial fibrillation provided results almost identical to those obtained in the entire population (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>, <LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>, <LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>, <LINK REF="CMP-005.06" TYPE="ANALYSIS">Analysis 5.6</LINK>). The only difference was that the increase in mortality associated with class IA antiarrhythmics did not reach statistical significance, by a small margin (OR 2.27, 95% CI 0.94 to 5.49, P = 0.07). This was probably explained by the subgroup analysis having less statistical power to detect this difference, as the analysis included fewer studies and patients.</P>
<P>Other planned subgroup analyses (patients with heart failure, studies where warfarin was mandatory versus those where it was discretionary, patients with a structurally normal heart) were not possible as separate data for each group of patients were seldom available. A more detailed analysis by left ventricular function or by the New York Heart Association (NYHA) class was not possible either, for the same reason.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-03-17 09:23:00 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2015-03-17 08:58:33 +0000" MODIFIED_BY="[Empty name]">
<P>In the second update of this systematic review we have found and included three new randomised controlled trials. They comprised 534 more patients and added more data on amiodarone, flecainide and sotalol. The main results and the conclusions of the review did not change.</P>
<P>Our results show that antiarrhythmic drugs belonging to class IA, class IC and class III are effective in reducing the recurrence of atrial fibrillation, by 20% to 50% compared to patients not receiving antiarrhythmics. Of all these drugs, amiodarone seemed to be the most effective in preventing recurrence of atrial fibrillation as it had the lowest OR and in direct comparisons it was better than combined class I drugs and other class III antiarrhythmics. Less information is available about the relative effectiveness of the other antiarrhythmics. In any case, the overall effectiveness of antiarrhythmics is limited as atrial fibrillation still recurred in 44% to 67% of treated patients at one year.</P>
<P>Another interesting result of this review is that metoprolol, a beta-blocker, also showed a significant reduction in atrial fibrillation recurrence, based on the pooled data from two high-quality randomised controlled trials (<LINK REF="STD-Kuhlkamp-2000" TYPE="STUDY">Kuhlkamp 2000</LINK>; <LINK REF="STD-Nergardh-2007" TYPE="STUDY">Nergardh 2007</LINK>). The estimated OR and NNTB for metoprolol were greater (that is it was less effective in reducing recurrences) than for amiodarone and class IC drugs or dofetilide, but not very different from class IA drugs and some class III antiarrhythmics. Besides, no significant difference in preventing recurrences was found between beta-blockers and sotalol in two other trials (<LINK REF="STD-DAPHNE-2008" TYPE="STUDY">DAPHNE 2008</LINK> comparing sotalol against metoprolol or atenolol, and <LINK REF="STD-Plewan-2001" TYPE="STUDY">Plewan 2001</LINK> against bisoprolol). The effect of beta-blockers in reducing the recurrence of atrial fibrillation could be due to the ability of beta-blockers to suppress atrial extrasystoles, known to be a frequent cause of paroxysmal atrial fibrillation (<LINK REF="REF-Ha_x00ef_ssaguerre-1998" TYPE="REFERENCE">Haïssaguerre 1998</LINK>). Beta-blocker effects might also relate to antihypertensive and anti-ischaemic actions or to their effect in reducing cardiac remodelling associated with coronary artery disease or heart failure.</P>
<P>The primary aim of this review was, however, to determine if long-term treatment with antiarrhythmics carried other clinical benefits to patients in addition to maintenance of sinus rhythm. Consequently, we focused on mortality, stroke, embolism and also potential adverse effects of treatment as the main outcomes.</P>
<P>Concerning mortality, we found that no antiarrhythmic produced a benefit on mortality and that two different antiarrhythmics, class IA drugs and sotalol, appeared to be associated with a small but significant increase in mortality. Class IA drugs (quinidine and disopyramide together) showed a significant increase in mortality. These results were not replicated when only the PAFAC and SOPAT studies were analysed. These two trials are recent, high-quality, large (848 and 1033 patients, respectively) studies that compared quinidine, sotalol and placebo and showed no increase in mortality in the active treatment groups. They also differed from other trials studying quinidine and sotalol in that they showed no increase in adverse effects or withdrawals with these drugs. A possible explanation is that both studies used a lower dose of quinidine than earlier trials and that quinidine was combined with verapamil, which has been shown to reduce some of the pro-arrhythmic effects of quinidine, such as accelerated atrio-ventricular (AV) conduction. Finally, the proportion of patients having structural heart disease was lower in the PAFAC and SOPAT studies than in earlier trials.</P>
<P>The overall accumulated evidence on class IA antiarrhythmics suggests that long-term use of these drugs may slightly increase mortality (NNTH 109, 95% CI 34 to 4985), with the possible exception of low dose quinidine combined with verapamil, although this exception requires confirmation. A previous meta-analysis by Coplen et al also found that quinidine increased mortality (<LINK REF="REF-Coplen-1990" TYPE="REFERENCE">Coplen 1990</LINK>). A meta-analysis by Nichol et al found no difference in mortality with any antiarrhythmic, but most of the trials that they pooled had very short follow-up periods (<LINK REF="REF-Nichol-2002" TYPE="REFERENCE">Nichol 2002</LINK>).</P>
<P>Sotalol showed a significant increase in mortality associated with its long-term use. This result remained significant in all sensitivity analysis, which suggests the effect is real. Again, the absolute increase in deaths seems small, with an estimate average NNTH of 166. A recent meta-analysis, using a mixed treatment comparison method (where the estimates obtained from direct and indirect comparisons are combined in a network of trials), also found a significant increase in mortality associated with sotalol (<LINK REF="REF-Freemantle-2011" TYPE="REFERENCE">Freemantle 2011</LINK>). Quinidine was not studied in the meta-analysis by Freemantle et al.</P>
<P>It is important to note that our data does not allow us to exclude a small increase in mortality with other antiarrhythmics, similar to those observed with class IA drugs and sotalol. Pooled data for other drugs included fewer studies and patients than for class IA drugs and sotalol and could be underpowered to detect effects that are of small size. For instance, the combined flecainide data had a fifth of the patients included for sotalol but this drug show a risk of pro-arrhythmia similar to sotalol and it has been shown to induce a significant excess of mortality in other trials (<LINK REF="REF-CAST-1991" TYPE="REFERENCE">CAST 1991</LINK>). Also, it is important to note the clear trend toward increased mortality observed with the use of azimilide, even if not significant.</P>
<P>With respect to adverse effects, virtually all the antiarrhythmics showed more withdrawals due to adverse effects than the controls. Concerning pro-arrhythmia, only amiodarone, dronedarone and propafenone showed no significant difference compared with the controls. It is important to note that we employed an extended definition of pro-arrhythmia that included severe, symptomatic bradycardia and AV blocks. Metoprolol was associated with a significant increase in pro-arrhythmia, precisely because an increased incidence of severe bradycardias. Of all antiarrhythmics, quinidine at higher doses appeared to be the drug with more withdrawals because of adverse events both compared to controls and to other antiarrhythmics, and flecainide and sotalol seemed to be the most pro-arrhythmic. Amiodarone compared favourably with class I drugs combined, but had a high OR for increasing withdrawals compared to placebo. Moreover, these were the results at one year follow up, and the adverse effects of amiodarone are known to increase in frequency over time (<LINK REF="REF-Harris-1983" TYPE="REFERENCE">Harris 1983</LINK>; <LINK REF="REF-Lafuente_x002d_Lafuente-2009" TYPE="REFERENCE">Lafuente-Lafuente 2009</LINK>).</P>
<P>Finally, much fewer data were reported for stroke rates. The available data showed no difference in strokes between the different antiarrhythmic drugs and the controls, with the only exception being a single study (<LINK REF="STD-ATHENA-2009" TYPE="STUDY">ATHENA 2009</LINK>) in which the stroke rate was significantly lower in the dronedarone arm than in the placebo arm. This finding was not confirmed by other studies of dronedarone.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2015-03-17 09:23:00 +0000" MODIFIED_BY="[Empty name]">
<P>Finally, we intended to analyse other clinically relevant outcomes such as the frequency of systemic embolism and use of long-term anticoagulation, or the influence of heart failure and structural heart disease in the response to treatment. Unfortunately data on those outcomes were sparse, if reported at all. In the few trials where they were reported, the frequencies of stroke and heart failure were very low, perhaps because the populations that were included were low risk. No differences from the controls were apparent with the only exception being the ATHENA trial, where the incidence of stroke were lower in the group treated with dronedarone than in the placebo group (<LINK REF="STD-ATHENA-2009" TYPE="STUDY">ATHENA 2009</LINK>). The frequency of use of anticoagulants during the follow up was not reported in any study.</P>
<P>Similarly, we wanted to analyse the influence of structural heart disease on effectiveness, specially with respect to left ventricular ejection fraction and left atrial size, and the influence of duration of atrial fibrillation before cardioversion. These are factors well known to influence the risk of recurrence of atrial fibrillation. Unfortunately this analysis was not possible either as separate data were not available for patients having and not having structural heart disease, by left ventricular function, or by left atrial size.</P>
<P>This lack of data for some clinical outcomes is the main limitation of our review. Another limitation could be that in many studies patients were followed up until atrial fibrillation recurred, and not thereafter, hence events between that point and the complete one year of follow up might have been missed. Also, the populations included in most studies were at low risk of events, the mean age of included patients was 64 years old and most of them had a normal left ventricular ejection fraction. We do not know if our results can be extrapolated to other patient populations, especially older patients and those with a reduced left ventricular ejection fraction.</P>
<P>Finally, it is important to remember that maintaining sinus rhythm by using long-term antiarrhythmic drugs is only one possible step in the more general 'rhythm control' strategy, and antiarrhythmic drugs should be put within the perspective of the global strategy chosen for the patient (<LINK REF="REF-ACC_x002f_AHA_x002f_ESC-2011" TYPE="REFERENCE">ACC/AHA/ESC 2011</LINK>; <LINK REF="REF-NICE-2014" TYPE="REFERENCE">NICE 2014</LINK>). Other therapies have proven to be useful to prevent or reduce recurrence of atrial fibrillation in selected patients, especially catheter ablation (<LINK REF="REF-Oral-2006" TYPE="REFERENCE">Oral 2006</LINK>; <LINK REF="REF-Terasawa-2009" TYPE="REFERENCE">Terasawa 2009</LINK>; <LINK REF="REF-Wazni-2005" TYPE="REFERENCE">Wazni 2005</LINK>); and antiarrhythmics have been occasionally used for terminating recurrences (<LINK REF="REF-Alboni-2004" TYPE="REFERENCE">Alboni 2004</LINK>). However, the effects of these therapies on the important clinical endpoints of mortality, stroke, incidence of heart failure are still not known. A different Cochrane review has studied the effectiveness of catheter ablation for paroxysmal and persistent atrial fibrillation (<LINK REF="REF-Chen-2012" TYPE="REFERENCE">Chen 2012</LINK>).</P>
</APPLICABILITY_OF_FINDINGS>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-03-17 09:32:18 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2015-03-17 09:28:35 +0000" MODIFIED_BY="[Empty name]">
<P>Various antiarrhythmic drugs are moderately effective in maintaining sinus rhythm after conversion of atrial fibrillation. These are disopyramide and quinidine in class IA; flecainide and propafenone in class IC; metoprolol and probably other beta-blockers in class II; and amiodarone, dofetilide, dronedarone and sotalol in class III. However, all antiarrhythmics show evidence of increased adverse effects; and the majority show increased pro-arrhythmia. Moreover, there is good evidence of a small but significant increase in the risk of death with the use of class IA drugs, except possibly quinidine at low doses combined with verapamil, and with the use of sotalol. Class IA drugs and sotalol should be used most carefully for this indication.</P>
<P>On the basis of results at one year, amiodarone showed some advantages with respect to class I and other class III drugs. It was more effective in preventing recurrences of atrial fibrillation, produced no significant pro-arrhythmia, and was not associated with increases in mortality. However, amiodarone clearly had more adverse effects that placebo and it is known that the frequency of its adverse effects increases over time, so we do not know if the advantages of amiodarone persist with longer treatment.</P>
<P>Currently available evidence does not allow an accurate assessment of several important clinical outcomes, that is stroke, peripheral embolism or the development of heart failure. Overall, it remains unclear whether it is worthwhile maintaining sinus rhythm with antiarrhythmics, or which specific groups of patients might benefit.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-03-17 09:32:18 +0000" MODIFIED_BY="[Empty name]">
<P>Adequate evidence exists for some outcomes (mortality, withdrawals, pro-arrhythmia and atrial fibrillation recurrences) for all drugs included in this review.</P>
<P>Available evidence is limited by the lack of systematic assessment of other important clinical outcomes: stroke, heart failure, and functional measures (exercise capacity, quality of life). Trials studying antiarrhythmic drugs should measure their effects on these outcomes in addition to the prevention of arrhythmia recurrences. Pending questions include the effects of antiarrhythmics on these clinical outcomes, and the effects in specific subgroups of patients, specifically patients with heart failure or reduced left ventricular ejection fraction, and older patients.</P>
<P>Finally, new antiarrhythmic drugs or other procedures that are more effective in preventing atrial fibrillation recurrence or are associated with fewer adverse effects, or both, would be desirable.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-03-17 09:34:09 +0000" MODIFIED_BY="[Empty name]">
<P>We thank all the trial authors who answered our request for additional data; Professor Charles Caulin for his most valuable suggestions; Dr Barbara Stadler for translating articles from German, Lone Gale for helping with articles in Swedish, Dr Qian Zhang for translating from Chinese; Dr Miguel Angel Longas-Tejero and Professor Stéphane Mouly for their help in previous versions of this review; and all the staff of Cochrane Heart Group for their most important help and support.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-03-17 09:35:08 +0000" MODIFIED_BY="[Empty name]">
<P>Carmelo Lafuente-Lafuente has received consultant fees (less than EUR 5000 total) from Sanofi-Aventis, in 2009 and 2010, for helping to conduct a study (a mixed treatment comparison meta-analysis) on several antiarrhythmic drugs for the management of atrial fibrillation. Sanofi-Aventis is the manufacturer of amiodarone and dronedarone, two of the antiarrhythmics studied in this review.</P>
<P>Lucie Valembois: none known.</P>
<P>Jean-François Bergmann: received honoraria for being on scientific boards for Sanofi, Takeda, Novartis, Takeda, Celgene, Lilly, Prioritis, BMS, MSD, GSK.</P>
<P>Joël Belmin: none known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-03-17 09:34:47 +0000" MODIFIED_BY="[Empty name]">
<P>CL-L: prepared and designed the protocol, searched for primary studies, performed analysis and interpreted data, and contacted authors of primary studies when needed.</P>
<P>MAL-T, LV: screened search results, and retrieved papers.</P>
<P>JFB: designed the review.</P>
<P>CL-L, MAL-T, LV, JB and JFB: assessed papers for inclusion and risk of bias.</P>
<P>CL-L, MAL-T, LV, JB and JFB: extracted data.</P>
<P>JB, LV and JFB: interpreted data and reviewed the manuscript.</P>
<P>CL-L and MAL-T: wrote the review.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-03-17 09:36:09 +0000" MODIFIED_BY="[Empty name]">
<P>None of the methods or the outcomes stated in the original protocol were modified. Some of the outcomes and planned subgroup analyses could not be performed because the data needed were not recorded or not reported in the original studies.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-03-17 15:54:02 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2015-03-17 15:54:02 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2015-03-17 15:54:02 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-A_x002d_COMET_x002d_I-2006" MODIFIED="2014-07-30 12:56:37 +0100" MODIFIED_BY="[Empty name]" NAME="A-COMET-I 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-07-30 12:56:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>A-COMET-I Investigators, Pritchett EL, Kowey P, Connolly S, Page RL, Kerr C, et al</AU>
<TI>Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm</TI>
<SO>American Heart Journal</SO>
<YR>2006 May</YR>
<VL>151</VL>
<NO>5</NO>
<PG>1043-9</PG>
<IDENTIFIERS MODIFIED="2010-08-20 11:07:48 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-08-20 11:07:48 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="PMID: 16644334"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-08-20 11:07:59 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-A_x002d_COMET_x002d_II-2006" MODIFIED="2010-08-27 16:05:40 +0100" MODIFIED_BY="[Empty name]" NAME="A-COMET-II 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-08-27 16:05:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>A-COMET-II Investigators; Lombardi F, Borggrefe M, Ruzyllo W, Lüderitz B</AU>
<TI>Azimilide vs. placebo and sotalol for persistent atrial fibrillation: the A-COMET-II (Azimilide-CardiOversion MaintEnance Trial-II) trial</TI>
<SO>European Heart Journal</SO>
<YR>2006 Sep</YR>
<VL>27</VL>
<NO>18</NO>
<PG>2224-31</PG>
<IDENTIFIERS MODIFIED="2010-08-27 16:05:40 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-08-27 16:05:40 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="PMID: 16935870"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-AFFIRM-Substudy-2003" NAME="AFFIRM Substudy 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>AFFIRM First Antiarrhythmic Drug Substudy Investigators</AU>
<TI>Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2003</YR>
<VL>42</VL>
<NO>1</NO>
<PG>20-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 12849654"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0735-1097"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-AFIB-1997" NAME="AFIB 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The Atrial Fibrillation Investigation with Bidisomide (AFIB) Investigators</AU>
<TI>Treatment of atrial fibrillation and paroxysmal supraventricular tachycardia with bidisomide</TI>
<SO>Circulation</SO>
<YR>1997</YR>
<VL>96</VL>
<NO>8</NO>
<PG>2625-32</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 9355903"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0009-7322"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aliot-1996" NAME="Aliot 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Erratum in: Am J Cardiol 1996 Jul 1;78(1):130&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aliot E, Denjoy I. The Flecainide AF French Study Group</AU>
<TI>Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter</TI>
<SO>American Journal of Cardiology</SO>
<YR>1996</YR>
<VL>77</VL>
<NO>3</NO>
<PG>66A-71A</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 8607394"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0002-9149"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ASAP-2003" NAME="ASAP 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Connolly SJ, Schnell DJ, Page RL, Wilkinson WE, Marcello SR, Pritchett EL, Azimilide Supraventricular Arrhythmia Program Investigators</AU>
<TI>Symptoms at the time of arrhythmia recurrence in patients receiving azimilide for control of atrial fibrillation or flutter: results from randomized trials</TI>
<SO>American Heart Journal</SO>
<YR>2003</YR>
<VL>146</VL>
<NO>3</NO>
<PG>489-93</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 12947368"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0002-8703"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Connolly SJ, Schnell DJ, Page RL, Wilkinson WE, Marcello SR, Pritchett EL</AU>
<TI>Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation</TI>
<SO>American Journal of Cardiology</SO>
<YR>2001</YR>
<VL>88</VL>
<NO>9</NO>
<PG>974-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 11703992"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0002-9149"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Page RL, Connolly SJ, Wilkinson WE, Marcello SR, Schnell DJ, Pritchett EL; Azimilide Supraventricular Arrhythmia Program (ASAP) Investigators</AU>
<TI>Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: efficacy and dose-response</TI>
<SO>American Heart Journal</SO>
<YR>2002</YR>
<VL>143</VL>
<NO>4</NO>
<PG>643-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 11923801"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0002-8703"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Page RL, Tilsch TW, Connolly SJ, Schnell DJ, Marcello SR, Wilkinson WE et al. Azimilide Supraventricular Arrhythmia Program (ASAP) Investigators</AU>
<TI>Asymptomatic or "silent" atrial fibrillation: frequency in untreated patients and patients receiving azimilide</TI>
<SO>Circulation</SO>
<YR>2003</YR>
<VL>107</VL>
<NO>8</NO>
<PG>1141-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 12615792"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0009-7322"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pritchett EL, Page RL, Connolly SJ, Marcello SR, Schnell DJ, Wilkinson WE</AU>
<TI>Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2000</YR>
<VL>36</VL>
<NO>3</NO>
<PG>794-802</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 10987602"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0735-1097"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-A_x002d_STAR-2006" MODIFIED="2014-07-30 12:58:16 +0100" MODIFIED_BY="[Empty name]" NAME="A-STAR 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-07-30 12:58:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>A-STAR Investigators, Kerr CR, Connolly SJ, Kowey P, Page RL, Pritchett EL, et al</AU>
<TI>Efficacy of azimilide for the maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation in the presence and absence of structural heart disease</TI>
<SO>American Journal of Cardiology</SO>
<YR>2006</YR>
<VL>98</VL>
<NO>2</NO>
<PG>215-8</PG>
<IDENTIFIERS MODIFIED="2010-09-24 15:40:38 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-24 15:40:38 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="PMID: 16828595"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-ATHENA-2009" MODIFIED="2014-07-30 12:58:32 +0100" MODIFIED_BY="[Empty name]" NAME="ATHENA 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-07-30 12:58:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>ATHENA Investigators, Connolly SJ, Crijns HJ, Torp-Pedersen C, van Eickels M, Gaudin C, et al</AU>
<TI>Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death in patients with atrial fibrillation/atrial flutter</TI>
<SO>Circulation</SO>
<YR>2009</YR>
<VL>120</VL>
<NO>13</NO>
<PG>1174-80</PG>
<IDENTIFIERS MODIFIED="2010-09-24 15:45:46 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-24 15:45:46 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="PMID: 19752319"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-30 12:58:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>ATHENA Investigators, Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, et al</AU>
<TI>Effect of dronedarone on cardiovascular events in atrial fibrillation</TI>
<SO>New England Journal of Medicine</SO>
<YR>2009</YR>
<VL>360</VL>
<NO>2</NO>
<PG>668-78</PG>
<IDENTIFIERS MODIFIED="2010-09-24 15:43:40 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-24 15:43:40 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="PMID: 19213680"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bellandi-2001" NAME="Bellandi 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bellandi F, Dabizzi RP, Niccoli L, Cantini F, Palchetti R</AU>
<TI>Propafenone and sotalol: long-term efficacy and tolerability in the prevention of paroxysmal atrial fibrillation. A placebo-controlled double-blind study</TI>
<TO>Propafenone e sotalolo: efficacia e tollerabilita a lungo termine nella prevenzione della fibrillazione atriale parossistica. Studio in doppio cieco controllato con placebo</TO>
<SO>Giornale Italiano di Cardiologia</SO>
<YR>1996</YR>
<VL>26</VL>
<NO>4</NO>
<PG>379-90</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 8707022"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0046-5968"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bellandi F, Dabizzi RP, Niccoli L, Cantini F</AU>
<TI>Propafenone and sotalol in the prevention of paroxysmal atrial fibrillation - Long-term safety and efficacy study</TI>
<TO>Propafenon und sotalol bei der pravention von paroxysmalem vorhofflimmern. Langzeitstudie zur beurteilung von sicherheit und wirksamkeit</TO>
<SO>Munchener Medizinische Wochenschrift</SO>
<YR>1996</YR>
<VL>138</VL>
<NO>12</NO>
<PG>39-46</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="not indexed"/>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 1996098252; ISSN: 0027-2973"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bellandi F, Dabizzi RP, Niccoli L, Cantini F</AU>
<TI>Propafenone and sotalol in the prevention of paroxysmal atrial fibrillation: Long-term safety and efficacy study</TI>
<SO>Current Therapeutic Research, Clinical &amp; Experimental</SO>
<YR>1995</YR>
<VL>56</VL>
<NO>11</NO>
<PG>1154-68</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="not indexed"/>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 1996000327; ISSN: 0011-393X"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bellandi F, Leoncini M, Maioli M, Gallopin M, Dabizzi RP</AU>
<TI>Comparing agents for prevention of atrial fibrillation recurrence</TI>
<SO>Cardiology Review</SO>
<YR>2002</YR>
<VL>19</VL>
<NO>9</NO>
<PG>18-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 2002284566; ISSN 1061-5377"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bellandi F, Simonetti I, Leoncini M, Frascarelli F, Giovannini T, Maioli M, et al</AU>
<TI>Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation</TI>
<SO>American Journal of Cardiology</SO>
<YR>2001</YR>
<VL>88</VL>
<NO>6</NO>
<PG>640-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 11564387"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0002-9149"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Benditt-1999" NAME="Benditt 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Benditt DG, Williams JH, Jin J, Deering TF, Zucker R, Browne K, et al</AU>
<TI>Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. d,l-Sotalol Atrial Fibrillation/Flutter Study Group</TI>
<SO>American Journal of Cardiology</SO>
<YR>1999</YR>
<VL>84</VL>
<NO>3</NO>
<PG>270-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 10496434"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0002-9149"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Byrne_x002d_Quinn-1970" MODIFIED="2014-07-30 12:59:14 +0100" MODIFIED_BY="[Empty name]" NAME="Byrne-Quinn 1970" YEAR="1970">
<REFERENCE MODIFIED="2014-07-30 12:59:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Byrne-Quinn E, Wing AJ</AU>
<TI>Maintenance of sinus rhythm after DC reversion of atrial fibrilllation. A double-blind controlled trial of long-acting quinidine bisulphate</TI>
<SO>British Heart Journal</SO>
<YR>1970</YR>
<VL>32</VL>
<NO>3</NO>
<PG>370-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 4911757"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0007-0769"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carunchio-1995" NAME="Carunchio 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carunchio A, Fera MS, Mazza A, Burattini M, Greco G, Galati A, et al</AU>
<TI>A comparison between flecainide and sotalol in the prevention of recurrences of paroxysmal atrial fibrillation</TI>
<TO>Confronto tra flecainide e sotalolo nella profilassi delle recidive di fibrillazione atriale parossistica</TO>
<SO>Giornale Italiano di Cardiologia</SO>
<YR>1995</YR>
<VL>25</VL>
<NO>1</NO>
<PG>51-68</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 7642012"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0046-5968"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Channer-2004" NAME="Channer 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Channer KS, Birchall A, Steeds RP, Walters SJ, Yeo WW, West JN, et al</AU>
<TI>A randomized placebo-controlled trial of pre-treatment and short- or long-term maintenance therapy with amiodarone supporting DC cardioversion for persistent atrial fibrillation</TI>
<SO>European Heart Journal</SO>
<YR>2004</YR>
<VL>25</VL>
<NO>2</NO>
<PG>144-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 14720531"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0195-668X"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DAFNE-2003" NAME="DAFNE 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Touboul P, Brugada J, Capucci A, Crijns HJ, Edvardsson N, Hohnloser SH</AU>
<TI>Dronedarone for prevention of atrial fibrillation: a dose-ranging study</TI>
<SO>European Heart Journal</SO>
<YR>2003</YR>
<VL>24</VL>
<NO>16</NO>
<PG>1481-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 12919771"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0195-668X"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DAPHNE-2008" MODIFIED="2014-07-30 12:59:45 +0100" MODIFIED_BY="[Empty name]" NAME="DAPHNE 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-07-30 12:59:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>DAPHNE Study Investigators, Capucci A, Botto G, Molon G, Spampinato A, Favale S, et al</AU>
<TI>The Drug And Pace Health cliNical Evaluation (DAPHNE) study: a randomized trial comparing sotalol versus beta-blockers to treat symptomatic atrial fibrillation in patients with brady-tachycardia syndrome implanted with an antitachycardia pacemaker</TI>
<SO>American Heart Journal</SO>
<YR>2008</YR>
<VL>156</VL>
<NO>2</NO>
<PG>373.e1-8</PG>
<IDENTIFIERS MODIFIED="2010-09-27 10:01:14 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-27 10:01:14 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="PMID: 18657671"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DIAMOND-2001" MODIFIED="2015-03-17 09:44:24 +0000" MODIFIED_BY="[Empty name]" NAME="DIAMOND 2001" YEAR="2001">
<REFERENCE MODIFIED="2015-03-17 09:44:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moller M, Torp-Pedersen CT, Kober L</AU>
<TI>Dofetilide in patients with congestive heart failure and left ventricular dysfunction: safety aspects and effect on atrial fibrillation. The Danish Investigators of Arrhythmia and Mortality on Dofetilide (DIAMOND) Study Group</TI>
<SO>Congestive Heart Failure</SO>
<YR>2001</YR>
<VL>7</VL>
<NO>3</NO>
<PG>146-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 11828153"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 1527-5299"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pedersen OD, Bagger H, Keller N, Marchant B, Kober L, Torp-Pedersen C</AU>
<TI>Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (DIAMOND) substudy</TI>
<SO>Circulation</SO>
<YR>2001</YR>
<VL>104</VL>
<NO>3</NO>
<PG>292-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 11457747"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0009-7322"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Torp-Pedersen C, Moller M, Bloch-Thomsen PE, Kober L, Sandoe E, Egstrup K, et al</AU>
<TI>Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group</TI>
<SO>New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>341</VL>
<NO>12</NO>
<PG>857-65</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 10486417"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0028-4793"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Torp-Pedersen CT, Moller M, Bloch-Thomsen PE, Kober L, Sandoe E, Egstrup K, et al</AU>
<TI>Dofetilide to patients with heart failure and left ventricular dysfunction</TI>
<TO>Dofetilid til patienter med hjerteinsufficiens og darligt fungerende venstre ventrikel</TO>
<SO>Ugeskrift for Laeger</SO>
<YR>2000</YR>
<VL>10</VL>
<NO>44</NO>
<PG>5948-53</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 11094565"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0041-5782"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dogan-2004" NAME="Dogan 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dogan A, Ergene O, Nazli C, Kinay O, Altinbas A, Ucarci Y, et al</AU>
<TI>Efficacy of propafenone for maintaining sinus rhythm in patients with recent onset or persistent atrial fibrillation after conversion: a randomized, placebo-controlled study</TI>
<SO>Acta Cardiologica</SO>
<YR>2004</YR>
<VL>59</VL>
<NO>3</NO>
<PG>255-61</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 15255456"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0001-5385"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-DYONISOS-2010" MODIFIED="2015-03-02 14:36:50 +0000" MODIFIED_BY="[Empty name]" NAME="DYONISOS 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-03-02 14:36:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM</AU>
<TI>A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study</TI>
<SO>Journal of Cardiovascular Electrophysiology</SO>
<YR>2010</YR>
<VL>21</VL>
<NO>6</NO>
<PG>597-605</PG>
<IDENTIFIERS MODIFIED="2010-09-27 10:37:10 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-27 10:37:10 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="PMID: 20384650 "/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-EMERALD-2000" MODIFIED="2015-03-17 15:54:02 +0000" MODIFIED_BY="[Empty name]" NAME="EMERALD 2000" YEAR="2000">
<REFERENCE MODIFIED="2015-03-17 09:46:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cambell TJ, Greenbaum RA, Channer KS, Dalrymple HW, Kingma JH, Santini M, et al</AU>
<TI>Mortality in patients with atrial fibrillation - 1 year follow up of EMERALD (European and Australian multicenter evaluative research on atrial fibrillation dofetilide)</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2000</YR>
<VL>35</VL>
<NO>2 Suppl A</NO>
<PG>154A-5A</PG>
<IDENTIFIERS MODIFIED="2010-09-27 10:30:52 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2015-03-17 15:53:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dalrymple HW, Cambell TJ, Channer KS, Greenbaum R, Kingma JH, Santini M, et al</AU>
<TI>Maintenance of sinus rhythm by dofetilide improves quality of life. The EMERALD (European and Australian multicenter evaluative research on atrial fibrillation dofetilide) study</TI>
<SO>Circulation</SO>
<YR>1998</YR>
<VL>98</VL>
<NO>Suppl 13-14</NO>
<PG>66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-03-17 15:54:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greenbaum R, Campbell TJ, Channer KS, Dalrymple HW, Kingma JH, Santini M, et al</AU>
<TI>Conversion of atrial fibrillation and maintenace of sinus rhythm by dofetilide. The EMERALD (European and Australian multicenter evaluative research on atrial fibrillation dofetilide) study</TI>
<SO>Circulation</SO>
<YR>1998</YR>
<VL>98</VL>
<NO>Suppl I-633</NO>
<PG>3326</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-03-17 09:53:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>US Food and Drug Administration</AU>
<TI>Drug Approval Package: Tikosyn (Dofetilide). Medical Review: Parts 1 and 2 (Study number 345)</TI>
<SO>http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20-931_Tikosyn.cfm.</SO>
<YR>Accessed 10 August 2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-EURIDIS-ADONIS-2007" MODIFIED="2015-03-17 09:59:18 +0000" MODIFIED_BY="[Empty name]" NAME="EURIDIS ADONIS 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Brookes, L</AU>
<TI>Dronedarone on Trial: EURIDIS and ADONIS</TI>
<SO>http://www.medscape.com/viewarticle/489226 (accessed January 2007)</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-30 13:04:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>EURIDIS and ADONIS Investigators; Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, et al</AU>
<TI>Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter</TI>
<SO>New England Journal of Medicine</SO>
<YR>2007</YR>
<VL>357</VL>
<NO>10</NO>
<PG>987-99</PG>
<IDENTIFIERS MODIFIED="2010-08-18 11:06:21 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-08-18 11:06:21 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="PMID: 17804843"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-03-17 09:59:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hohnloser SH</AU>
<TI>EURIDIS and ADONIS: maintenance of sinus rhythm with dronedarone in patients with atrial fibrillation or flutter</TI>
<SO>Program and abstracts from the European Society of Cardiology Congress 2004 Aug 28 - Sept 1</SO>
<YR>2004</YR>
<CY>Munich, Germany</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="none"/>
<IDENTIFIER TYPE="OTHER" VALUE="none"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-FAPIS-1996" NAME="FAPIS 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chimienti M, Cullen MT Jr, Casadei G</AU>
<TI>Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group</TI>
<SO>European Heart Journal</SO>
<YR>1995</YR>
<VL>16</VL>
<NO>12</NO>
<PG>1943-51</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 8682031"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0195-668X"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chimienti M, Cullen MT Jr, Casadei G</AU>
<TI>Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the Flecainide and Propafenone Italian Study Investigators</TI>
<SO>American Journal of Cardiology</SO>
<YR>1996</YR>
<VL>77</VL>
<NO>3</NO>
<PG>60A-75A</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 8607393"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0002-9149"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Flec_x002d_SL-2012" MODIFIED="2014-10-06 12:58:45 +0100" MODIFIED_BY="[Empty name]" NAME="Flec-SL 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-10-06 12:58:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kirchhof P, Andresen D, Bosch R, Borggrefe M, Meinertz T, Parade U, et al</AU>
<TI>Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial</TI>
<SO>Lancet</SO>
<YR>2012</YR>
<VL>380</VL>
<NO>9838</NO>
<PG>238-46</PG>
<IDENTIFIERS MODIFIED="2014-06-23 14:55:06 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-06-23 14:55:06 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="22713626"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-06-23 14:52:49 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-GEFACA-2001" MODIFIED="2015-03-17 10:01:21 +0000" MODIFIED_BY="[Empty name]" NAME="GEFACA 2001" YEAR="2001">
<REFERENCE MODIFIED="2015-03-17 10:01:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galperin J, Elizari MV, Chiale PA, Molina RT, Ledesma R, Scapin AO, et al</AU>
<TI>Efficacy of amiodarone for the termination of chronic atrial fibrillation and maintenance of normal sinus rhythm: a prospective, multicenter, randomized, controlled, double blind trial</TI>
<SO>Journal of Cardiovascular Pharmacology and Therapeutics</SO>
<YR>2001</YR>
<VL>6</VL>
<NO>4</NO>
<PG>341-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 11907636"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 1074-2484"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hillestad-1971" NAME="Hillestad 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hillestad L, Bjerkelund C, Dale J, Maltau J, Storstein O</AU>
<TI>Quinidine in maintenance of sinus rhythm after electroconversion of chronic atrial fibrillation. A controlled clinical study</TI>
<SO>British Heart Journal</SO>
<YR>1971</YR>
<VL>33</VL>
<NO>4</NO>
<PG>518-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 4934041"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0007-0769"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hohnloser-1995" NAME="Hohnloser 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hohnloser SH, van de Loo A, Baedeker F</AU>
<TI>Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1995</YR>
<VL>26</VL>
<NO>4</NO>
<PG>852-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 7560608"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0735-1097"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Juul_x002d_Moller-1990" NAME="Juul-Moller 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Juul-Moller S, Edvardsson N, Rehnqvist-Ahlberg N</AU>
<TI>Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation</TI>
<SO>Circulation</SO>
<YR>1990</YR>
<VL>82</VL>
<NO>6</NO>
<PG>1932-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 2242519"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0009-7322"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kalusche-1994" MODIFIED="2015-03-17 10:02:28 +0000" MODIFIED_BY="[Empty name]" NAME="Kalusche 1994" YEAR="1994">
<REFERENCE MODIFIED="2015-03-17 10:02:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kalusche D, Stockinger J, Betz P, Roskamm H</AU>
<TI>Sotalol and quinidine/verapamil (Cordichin) in chronic atrial fibrillation - conversion and 12-month follow-up - a randomized comparison</TI>
<TO>Sotalol und Chinidin/Verapamil (Cordichin) bei chronischem Vorhoflimmern - Konversion und 12-Monats-Follow-up - ein randomisierter Vergleich</TO>
<SO>Zeitschrift fur Kardiologie</SO>
<YR>1994</YR>
<VL>83 Suppl 5</VL>
<PG>109-16</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 7846939"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0300-5860"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karlson-1998" NAME="Karlson 1998" YEAR="1988">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Karlson BW, Torstensson I, Abjorn C, Jansson SO, Peterson LE</AU>
<TI>Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation. A placebo-controlled one-year follow-up study</TI>
<SO>European Heart Journal</SO>
<YR>1988</YR>
<VL>9</VL>
<NO>3</NO>
<PG>284-90</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 3289932"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0195-668X"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karlson BW, Torstensson I, Abjorn C, Kallryd A, Jonsson J, Jansson SO, Peterson LE</AU>
<TI>Preventive disopyramide after electroconversion of atrial fibrillation--a good alternative</TI>
<TO>Disopyramid som profylax efter elregularisering av formaksflimmer--ett bra alternativ</TO>
<SO>Lakartidningen</SO>
<YR>1991</YR>
<VL>88</VL>
<NO>24</NO>
<PG>2242-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 2056838"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0023-7205"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kochiadakis-2000" MODIFIED="2015-03-17 10:04:07 +0000" MODIFIED_BY="[Empty name]" NAME="Kochiadakis 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kochiadakis GE, Igoumenidis NE, Marketou ME, Kaleboubas MD, Simantirakis EN, Vardas PE</AU>
<TI>Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study</TI>
<SO>Heart</SO>
<YR>2000</YR>
<VL>84</VL>
<NO>3</NO>
<PG>251-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 10956284"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 1355-6037"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kochiadakis GE, Igoumenidis NE, Marketou ME, Solomou MC, Kanoupakis EM, Vardas PE</AU>
<TI>Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation</TI>
<SO>American Journal of Cardiology</SO>
<YR>1998</YR>
<VL>81</VL>
<NO>8</NO>
<PG>995-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 9576159"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0002-9149"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-03-17 10:04:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kochiadakis GE, Marketou ME, Igoumenidis NE, Chrysostomakis SI, Mavrakis HE, Kaleboubas MD, et al</AU>
<TI>Amiodarone, sotalol, or propafenone in atrial fibrillation: which is preferred to maintain normal sinus rhythm?</TI>
<SO>Pacing and Clinical Electrophysiology</SO>
<YR>2000</YR>
<VL>23</VL>
<NO>11 Pt 2</NO>
<PG>1883-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 11139949"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0147-8389"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kochiadakis-2004a" NAME="Kochiadakis 2004a" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kochiadakis GE, Igoumenidis NE, Hamilos MI, Tzerakis PG, Klapsinos NC, Zacharis EA, et al</AU>
<TI>Long-term maintenance of normal sinus rhythm in patients with current symptomatic atrial fibrillation: amiodarone vs propafenone, both in low doses</TI>
<SO>Chest</SO>
<YR>2004</YR>
<VL>125</VL>
<NO>2</NO>
<PG>377-83</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 14769712"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0012-3692"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kochiadakis-2004b" NAME="Kochiadakis 2004b" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kochiadakis GE, Igoumenidis NE, Hamilos ME, Tzerakis PG, Klapsinos NC, Chlouverakis GI, et al</AU>
<TI>Sotalol versus propafenone for long-term maintenance of normal sinus rhythm in patients with recurrent symptomatic atrial fibrillation</TI>
<SO>American Journal of Cardiology</SO>
<YR>2004</YR>
<VL>94</VL>
<NO>12</NO>
<PG>1563-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 15589019"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0002-9149"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuhlkamp-2000" NAME="Kuhlkamp 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuhlkamp V, Schirdewan A, Stangl K, Homberg M, Ploch M, Beck OA</AU>
<TI>Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2000</YR>
<VL>36</VL>
<NO>1</NO>
<PG>139-46</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 10898425"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0735-1097"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lloyd-1984" NAME="Lloyd 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lloyd EA, Gersh BJ, Forman R</AU>
<TI>The efficacy of quinidine and disopyramide in the maintenance of sinus rhythm after electroconversion from atrial fibrillation. A double-blind study comparing quinidine, disopyramide and placebo</TI>
<SO>South African Medical Journal</SO>
<YR>1984</YR>
<VL>65</VL>
<NO>10</NO>
<PG>367-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 6367096"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0038-2469"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Naccarelli-1996" MODIFIED="2015-03-17 10:05:12 +0000" MODIFIED_BY="[Empty name]" NAME="Naccarelli 1996" YEAR="1996">
<REFERENCE MODIFIED="2015-03-17 10:05:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Naccarelli GV, Dorian P, Hohnloser SH, Coumel P</AU>
<TI>Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter</TI>
<SO>American Journal of Cardiology</SO>
<YR>1996</YR>
<VL>77</VL>
<NO>3</NO>
<PG>53A-9A</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 8607392"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0002-9149"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nergardh-2007" MODIFIED="2012-03-14 15:03:00 +0000" MODIFIED_BY="[Empty name]" NAME="Nergardh 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-09-27 10:18:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nergårdh AK, Rosenqvist M, Nordlander R, Frick M</AU>
<TI>Maintenance of sinus rhythm with metoprolol CR initiated before cardioversion and repeated cardioversion of atrial fibrillation: a randomized double-blind placebo-controlled study</TI>
<SO>European Heart Journal</SO>
<YR>2007 Jun</YR>
<VL>28</VL>
<NO>11</NO>
<PG>1351-7</PG>
<IDENTIFIERS MODIFIED="2010-09-27 10:18:14 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-27 10:18:14 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="PMID: 17329409"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Niu-2006" MODIFIED="2015-03-17 10:05:36 +0000" MODIFIED_BY="[Empty name]" NAME="Niu 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-03-17 10:05:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Niu F, Huang CX, Jiang H, Yang B, Guo WL, Chen YX, et al</AU>
<TI>Effects of amiodarone versus sotalol in treatment of atrial fibrillation: a random controlled clinical study</TI>
<TO>Original in Chinese</TO>
<SO>Zhonghua Yi Xue Za Zhi</SO>
<YR>2006</YR>
<VL>86</VL>
<NO>2</NO>
<PG>121-3</PG>
<IDENTIFIERS MODIFIED="2010-09-27 10:41:30 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-27 10:41:30 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="PMID: 16620720"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Okishige-2000" MODIFIED="2010-09-16 13:43:55 +0100" MODIFIED_BY="[Empty name]" NAME="Okishige 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-09-16 13:43:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Okishige K, Nishizaki M, Azegami K, Igawa M, Yamawaki N, Aonuma K</AU>
<TI>Pilsicainide for conversion and maintenance of sinus rhythm in chronic atrial fibrillation: A placebo-controlled, multicenter study</TI>
<SO>American Heart Journal</SO>
<YR>2000</YR>
<VL>140</VL>
<NO>3</NO>
<PG>e13</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 10966544"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0002-8703"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PAFAC-2004" NAME="PAFAC 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fetsch T, Bauer P, Engberding R, Koch HP, Lukl J, Meinertz T, et al</AU>
<TI>Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial</TI>
<SO>European Heart Journal</SO>
<YR>2004</YR>
<VL>25</VL>
<NO>16</NO>
<PG>1385-94</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 15302102"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0195-668X"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fetsch T, Burschel G, Breithardt G, Engberding R, Koch HP, Lukl J, et al</AU>
<TI>Medicamentous prevention after electric cardioversion of chronic atrial fibrillation. Goals and design of the PAFAC Study</TI>
<TO>Die medikamentöse Prophylaxe nach elektronischer Kardioversion von chronischem Vorhofflimmern. Ziele und Design der PAFAC-Studie</TO>
<SO>Zeitschrift fur Kardiologie</SO>
<YR>1999</YR>
<VL>88</VL>
<NO>3</NO>
<PG>195-207</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 10355070"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0300-5860"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PITAGORA-2008" MODIFIED="2014-07-30 13:07:51 +0100" MODIFIED_BY="[Empty name]" NAME="PITAGORA 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-07-30 13:07:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>PITAGORA Study Investigators, Gulizia M, Mangiameli S, Orazi S, Chiarandà G, Piccione G, et al</AU>
<TI>A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the PITAGORA trial</TI>
<SO>American Heart Journal</SO>
<YR>2008</YR>
<VL>155</VL>
<NO>1</NO>
<PG>107.e1</PG>
<IDENTIFIERS MODIFIED="2010-09-27 14:48:24 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-27 14:48:24 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="PMID: 18082498"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Plewan-2001" NAME="Plewan 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Plewan A, Lehmann G, Ndrepepa G, Schreieck J, Alt EU, Schomig A, et al</AU>
<TI>Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs bisoprolol</TI>
<SO>European Heart Journal</SO>
<YR>2001</YR>
<VL>22</VL>
<NO>16</NO>
<PG>1504-10</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 11482924"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0195-668X"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PRODIS-1996" NAME="PRODIS 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Crijns HJ, Gosselink AT, Lie KI</AU>
<TI>Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study</TI>
<SO>Cardiovascular Drugs and Therapy</SO>
<YR>1996</YR>
<VL>10</VL>
<NO>2</NO>
<PG>145-52</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 8842506"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0920-3206"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-RAFT-2003" NAME="RAFT 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pritchett EL, Page RL, Carlson M, Undesser K, Fava G</AU>
<TI>Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation</TI>
<SO>American Journal of Cardiology</SO>
<YR>2003</YR>
<VL>92</VL>
<NO>8</NO>
<PG>941-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 14556870"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0002-9149"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reimold-1993" NAME="Reimold 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reimold SC, Cantillon CO, Friedman PL, Antman EM</AU>
<TI>Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation</TI>
<SO>American Journal of Cardiology</SO>
<YR>1993</YR>
<VL>71</VL>
<NO>7</NO>
<PG>558-63</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 8438741"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0002-9149"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Richiardi-1992" NAME="Richiardi 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Richiardi E, Gaita F, Greco C, Gaschino G, Comba Costa G, Rosettani E, et al</AU>
<TI>Propafenone versus hydroquinidine in long-term pharmacological prophylaxis of atrial fibrillation</TI>
<TO>Propafenone versus idrochinidina nella profilassi farmacologica a lungo termine della fibrillazione atriale</TO>
<SO>Cardiologia</SO>
<YR>1992</YR>
<VL>37</VL>
<NO>2</NO>
<PG>123-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 1600529"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0393-1978"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SAFE_x002d_T-2005" MODIFIED="2015-03-17 10:07:22 +0000" MODIFIED_BY="[Empty name]" NAME="SAFE-T 2005" YEAR="2005">
<REFERENCE MODIFIED="2015-03-17 10:07:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL, et al</AU>
<TI>Amiodarone versus sotalol for atrial fibrillation</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>352</VL>
<NO>18</NO>
<PG>1861-72</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 15872201"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0028-4793"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Singh SN, Singh BN, Reda DJ, Fye CL, Ezekowitz MD, Fletcher RD, et al</AU>
<TI>Comparison of sotalol versus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation (Sotalol-Amiodarone Fibrillation Efficacy Trial [Safe-T])</TI>
<SO>American Journal of Cardiology</SO>
<YR>2003</YR>
<VL>92</VL>
<NO>4</NO>
<PG>468-72</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 12914883"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0002-9149"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SAFIRE_x002d_D-2000" NAME="SAFIRE-D 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Singh S, Zoble RG, Yellen L, Brodsky MA, Feld GK, Berk M, et al</AU>
<TI>Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study</TI>
<SO>Circulation</SO>
<YR>2000</YR>
<VL>102</VL>
<NO>19</NO>
<PG>2385-90</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 11067793"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0009-7322"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Santas-2012" MODIFIED="2015-03-17 10:36:06 +0000" MODIFIED_BY="[Empty name]" NAME="Santas 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-03-17 10:36:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Santas E, Dominguez E, Martinez-Brotons A, Ruiz-Granell R, Ruiz V, Ferrero A, et al</AU>
<TI>Early withdrawal of amiodarone after cardioversion in atrial fibrillation patients treated with irbesartan. A prospective randomized study. Abstract from the ESC Congress 25-29 August 2012; Munchen, Germany</TI>
<SO>European Heart Journal</SO>
<YR>2012</YR>
<VL>33 Suppl 1</VL>
<PG>380</PG>
<IDENTIFIERS MODIFIED="2014-06-23 15:01:36 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-06-23 15:01:31 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1093/eurheartj/ehs282"/>
<IDENTIFIER MODIFIED="2014-06-23 15:01:36 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="23805432"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Singh-1991" NAME="Singh 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Singh S, Saini RK, DiMarco J, Kluger J, Gold R, Chen YW</AU>
<TI>Efficacy and safety of sotalol in digitalized patients with chronic atrial fibrillation. The Sotalol Study Group</TI>
<SO>American Journal of Cardiology</SO>
<YR>1991</YR>
<VL>68</VL>
<NO>11</NO>
<PG>1227-30</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 1951086"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0002-9149"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SMART-2002" NAME="SMART 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Atarashi H, Inoue H, Fukunami M, Sugi K, Hamada C, Origasa H</AU>
<TI>Double-blind placebo-controlled trial of aprindine and digoxin for the prevention of symptomatic atrial fibrillation</TI>
<SO>Circulation Journal</SO>
<YR>2002</YR>
<VL>66</VL>
<NO>6</NO>
<PG>553-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 12074271"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 1346-9843"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SOCESP-1999" NAME="SOCESP 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Veloso HH, de Paola AA</AU>
<TI>Analysis of atrial fibrillation recurrence during therapy with sotalol or quinidine. Researchers of +SOCESP</TI>
<TO>Analise da recorrencia de fibrilacao atrial durante terapia com sotalol ou quinidina. Investigadores da SOCESP</TO>
<SO>Arquivos Brasileiros de Cardiologia</SO>
<YR>1998</YR>
<VL>70</VL>
<NO>1</NO>
<PG>43-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 9629687"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0066-782X"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>de Paola AA, Veloso HH</AU>
<TI>Efficacy and safety of sotalol versus quinidine for the maintenance of sinus rhythm after conversion of atrial fibrillation. SOCESP Investigators</TI>
<SO>American Journal of Cardiology</SO>
<YR>1999</YR>
<VL>84</VL>
<NO>9</NO>
<PG>1033-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 10569659"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0002-9149"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sodermark-1975" NAME="Sodermark 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sodermark T, Jonsson B, Olsson A, Oro L, Wallin H, Edhag O, et al</AU>
<TI>Effect of quinidine on maintaining sinus rhythm after conversion of atrial fibrillation or flutter. A multicentre study from Stockholm</TI>
<SO>British Heart Journal</SO>
<YR>1975</YR>
<VL>37</VL>
<NO>5</NO>
<PG>486-92</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 1093559"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0007-0769"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SOPAT-2004" NAME="SOPAT 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patten M, Koch HP, Sonntag F, Luderitz B, Meinertz T</AU>
<TI>Medicamentous prevention of symptomatic paroxysmal atrial fibrillation/flutter onset. Goals and design of the SOPAT study. Executive committee of the investigators representing trial physicians</TI>
<TO>Die medikamentose Anfallsprophylaxe bei symptomatischem paroxysmalem Vorhofflimmern/-flattern. Ziele und Design der SOPAT-Studie. Investigators in Vertretung der Prufarzte</TO>
<SO>Zeitschrift fur Kardiologie</SO>
<YR>1999</YR>
<VL>88</VL>
<NO>3</NO>
<PG>185-94</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 10355069"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0300-5860"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Patten M, Maas R, Bauer P, Luderitz B, Sonntag F, Dluzniewski M, et al</AU>
<TI>Suppression of paroxysmal atrial tachyarrhythmias--results of the SOPAT trial</TI>
<SO>European Heart Journal</SO>
<YR>2004</YR>
<VL>25</VL>
<NO>16</NO>
<PG>1395-404</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 15321697"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0195-668X"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steinbeck-1988" MODIFIED="2015-03-17 10:11:36 +0000" MODIFIED_BY="[Empty name]" NAME="Steinbeck 1988" YEAR="1988">
<REFERENCE MODIFIED="2015-03-17 10:11:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steinbeck G, Doliwa R, Bach P</AU>
<TI>Therapy of paroxysmal atrial fibrillation. Cardiac glycosides alone or combined with anti-arrhythmia agents?</TI>
<TO>Therapie des paroxysmalen Vorhofflimmerns. Herzglykoside allein oder in Kombination mit Antiarrhythmika?</TO>
<SO>Deutsche Medizinische Wochenschrift</SO>
<YR>1988</YR>
<VL>113</VL>
<NO>48</NO>
<PG>1867-71</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 3143539"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0012-0472"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stroobandt-1997" NAME="Stroobandt 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stroobandt R, Stiels B, Hoebrechts R</AU>
<TI>Propafenone for conversion and prophylaxis of atrial fibrillation. Propafenone Atrial Fibrillation Trial Investigators</TI>
<SO>American Journal of Cardiology</SO>
<YR>1997</YR>
<VL>79</VL>
<NO>4</NO>
<PG>418-23</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 9052343"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0002-9149"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SVA_x002d_4-2008" MODIFIED="2014-07-30 13:09:13 +0100" MODIFIED_BY="[Empty name]" NAME="SVA-4 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-07-30 13:09:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>SVA-4 Investigators, Page RL, Pritchett EL, Connolly S, Wilkinson WE</AU>
<TI>Azimilide for the treatment of atrial fibrillation, atrial flutter, and paroxysmal supraventricular tachycardia: results of a randomized trial and insights on the concordance of symptoms and recurrent arrhythmias</TI>
<SO>Journal of Cardiovascular Electrophysiology</SO>
<YR>2008</YR>
<VL>19</VL>
<NO>2</NO>
<PG>172-7</PG>
<IDENTIFIERS MODIFIED="2010-09-27 10:20:50 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-27 10:20:50 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="PMID: 17916138"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Gelder-1989" MODIFIED="2015-03-17 10:12:04 +0000" MODIFIED_BY="[Empty name]" NAME="Van Gelder 1989" YEAR="1989">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Van Gelder IC, Crijns HJ, Van Gilst WH, Van Wijk LM, Hamer HP, Lie KI</AU>
<TI>Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter</TI>
<SO>American Journal of Cardiology</SO>
<YR>1989</YR>
<VL>64</VL>
<NO>19</NO>
<PG>1317-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 2511744"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0002-9149"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-03-17 10:12:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Gelder IC, et al</AU>
<TI>Efficacy of flecainide to maintain sinus rhythm after cardioversion of chronic atrial fibrillation and flutter. Abstracts from the 61st scientific sessions. American Heart Association. Washington, DC, November 1988</TI>
<SO>Circulation</SO>
<YR>1988</YR>
<VL>78</VL>
<NO>4 Pt 2</NO>
<PG>III626</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 3168202"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0009-7322"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vijayalaskshmi-2006" MODIFIED="2015-03-17 10:14:11 +0000" MODIFIED_BY="[Empty name]" NAME="Vijayalaskshmi 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-03-17 10:14:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Vijayalakshmi K, Whittaker VJ, Sutton A, Campbell P, Wright RA, Hall JA, et al</AU>
<TI>A randomized trial of prophylactic antiarrhythmic agents (amiodarone and sotalol) in patients with atrial fibrillation for whom direct current cardioversion is planned</TI>
<SO>American Heart Journal</SO>
<YR>2006</YR>
<VL>151</VL>
<NO>4</NO>
<PG>863.e1-6</PG>
<IDENTIFIERS MODIFIED="2014-06-23 15:05:47 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-06-23 15:05:47 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16569550"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-06-23 15:03:45 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Villani-1992" MODIFIED="2015-03-17 10:14:28 +0000" MODIFIED_BY="[Empty name]" NAME="Villani 1992" YEAR="1992">
<REFERENCE MODIFIED="2015-03-17 10:14:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Villani R, Zoletti F, Veniani M, Locati F, Nava S</AU>
<TI>A comparison between amiodarone and disopyramide in a delayed-release formulation in the prevention of recurrences of symptomatic atrial fibrillation</TI>
<TO>Confronto fra amiodarone e disopiramide in formulazione retard nella prevenzione delle recidive di fibrillazione atriale sintomatica</TO>
<SO>La Clinica Terapeutica</SO>
<YR>1992</YR>
<VL>140</VL>
<NO>1 Pt 2</NO>
<PG>35-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 1559321"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0009-9074"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vitolo-1981" NAME="Vitolo 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vitolo E, Tronci M, Larovere MT, Rumolo R, Morabito A</AU>
<TI>Amiodarone versus quinidine in the prophylaxis of atrial fibrillation</TI>
<SO>Acta Cardiologica</SO>
<YR>1981</YR>
<VL>36</VL>
<NO>6</NO>
<PG>431-44</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 7039195"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0001-5385"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-03-17 10:52:06 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Aberg-1968" NAME="Aberg 1968" YEAR="1968">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aberg H, Cullhed I</AU>
<TI>Procaine amide quinidine as prophylactic drugs against relapse of atrial fibrillation</TI>
<TO>Prokainamid och kinidin som profylaktikum mot recidiv av formaksflimmer</TO>
<SO>Nordisk Medicin</SO>
<YR>1968</YR>
<VL>79</VL>
<NO>24</NO>
<PG>781-2</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 4880307"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0029-1420"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Aberg H</AU>
<TI>Procaine amide as a prophylactic drug against atrial fibrillation. A controlled study</TI>
<TO>Prokainamid som profylax mot formaksflimmer. En kontrollerad studie</TO>
<SO>Nordisk Medicin</SO>
<YR>1969</YR>
<VL>82</VL>
<NO>33</NO>
<PG>1011-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID:&amp;#160;5808590"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0029-1420"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-AF_x002d_CHF-2002" MODIFIED="2010-09-27 15:19:48 +0100" MODIFIED_BY="[Empty name]" NAME="AF-CHF 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-09-27 15:19:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Atrial Fibrillation and Congestive Heart Failure (AF-CHF) investigators</AU>
<TI>Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial</TI>
<SO>American Heart Journal</SO>
<YR>2002 Oct</YR>
<VL>144</VL>
<NO>4</NO>
<PG>597-607</PG>
<IDENTIFIERS MODIFIED="2010-09-27 15:19:48 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-27 15:19:48 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="PMID: 12360154"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 15:18:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Atrial Fibrillation and Congestive Heart Failure (AF-CHF) investigators</AU>
<TI>Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial</TI>
<SO>American Heart Journal</SO>
<YR>2002</YR>
<VL>144</VL>
<NO>4</NO>
<PG>597-607</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID 12360154"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0002-8703, EMBASE 2002364426"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-AFFIRM-2002" MODIFIED="2015-03-17 10:16:31 +0000" MODIFIED_BY="[Empty name]" NAME="AFFIRM 2002" YEAR="2002">
<REFERENCE MODIFIED="2015-03-17 10:15:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>AFFIRM Investigators; Chung MK, Shemanski L, Sherman DG, Greene HL, Hogan DB, Kellen JC, et al</AU>
<TI>Functional status in rate- versus rhythm-control strategies for atrial fibrillation: results of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Functional Status Substudy</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2005 Nov 15</YR>
<VL>46</VL>
<NO>10</NO>
<PG>1891-9</PG>
<IDENTIFIERS MODIFIED="2010-09-27 15:15:01 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-27 15:15:01 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="PMID: 16286177"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-03-17 10:16:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>AFFIRM Investigators; Corley SD, Epstein AE, DiMarco JP, Domanski MJ, Geller N, Greene HL, et al</AU>
<TI>Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study</TI>
<SO>Circulation</SO>
<YR>2004 Mar 30</YR>
<VL>109</VL>
<NO>12</NO>
<PG>1509-13</PG>
<IDENTIFIERS MODIFIED="2010-09-27 15:16:30 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-27 15:16:30 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="PMID: 15007003"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-03-17 10:16:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al</AU>
<TI>A comparison of rate control and rhythm control in patients with atrial fibrillation</TI>
<SO>New England Journal of Medicine</SO>
<YR>2002</YR>
<VL>347</VL>
<NO>23</NO>
<PG>1825-33</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 12466506"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0028-4793"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anderson-1994" MODIFIED="2015-03-17 10:17:21 +0000" MODIFIED_BY="[Empty name]" NAME="Anderson 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson JL, Gilbert EM, Alpert BL, Henthorn RW, Waldo AL, Bhandari AK, et al</AU>
<TI>Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group</TI>
<SO>Circulation</SO>
<YR>1989</YR>
<VL>80</VL>
<NO>6</NO>
<PG>1557-70</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 2513143"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0009-7322"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Anderson JL, Platt ML, Guarnieri T, Fox TL, Maser MJ, Pritchett EL</AU>
<TI>Flecainide acetate for paroxysmal supraventricular tachyarrhythmias. The Flecainide Supraventricular Tachycardia Study Group</TI>
<SO>American Journal of Cardiology</SO>
<YR>1994</YR>
<VL>74</VL>
<NO>6</NO>
<PG>578-84</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 8074041"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0002-9149"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-03-17 10:17:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson JL</AU>
<TI>Long-term safety and efficacy of flecainide in the treatment of supraventricular tachyarrhythmias: the United States experience. The Flecainide Supraventricular Tachyarrhythmia Investigators</TI>
<SO>American Journal of Cardiology</SO>
<YR>1992</YR>
<VL>70</VL>
<NO>5</NO>
<PG>11A-7A</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 1509993"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0002-9149"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Andromeda-2008" MODIFIED="2015-03-17 10:17:44 +0000" MODIFIED_BY="[Empty name]" NAME="Andromeda 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-03-17 10:17:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dronedarone Study Group; Køber L, Torp-Pedersen C, McMurray JJ, Gøtzsche O, Lévy S, Crijns H, et al</AU>
<TI>Increased mortality after dronedarone therapy for severe heart failure</TI>
<SO>New England Journal of Medicine</SO>
<YR>2008 Jun 19</YR>
<VL>358</VL>
<NO>25</NO>
<PG>2678-87</PG>
<IDENTIFIERS MODIFIED="2014-06-23 15:08:11 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-06-23 15:08:11 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18565860"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Antman-1990" NAME="Antman 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Antman EM, Beamer AD, Cantillon C, McGowan N, Friedman PL</AU>
<TI>Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1990</YR>
<VL>15</VL>
<NO>3</NO>
<PG>698-707</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 2303641"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0735-1097"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Antman EM, Beamer AD, Cantillon C, McGowan N, Goldman L, Friedman PL</AU>
<TI>Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1988</YR>
<VL>12</VL>
<NO>4</NO>
<PG>1005-11</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 3417972"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0735-1097"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aros-1978" NAME="Aros 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aros F, Valles V, Alegria E, Loma-Osorio A, Malpartida F</AU>
<TI>Maintaining sinus rhythm with quinidine and amiodarone after electric cardioversion</TI>
<TO>Mantenimiento del ritmo sinusal con quinidina y amiodarona tras cardioversion electrica</TO>
<SO>Revista Espanola de Cardiologia</SO>
<YR>1978</YR>
<VL>31</VL>
<NO>1 Pt 2</NO>
<PG>185-91</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 663366"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0300-8932"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Babuty-1999" NAME="Babuty 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Babuty D, D'Hautefeuille B, Scheck F, Mycinsky C, Pruvost P, Peraudeau P</AU>
<TI>Cibenzoline versus flecainide in the prevention of paroxysmal atrial arrhythmias: a double-blind randomized study</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1995</YR>
<VL>35</VL>
<NO>5</NO>
<PG>471-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 7657846"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0091-2700"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Babuty D, Maison-Blanche P, Fauchier L, Brembilla-Perrot B, Medvedowsky JL, Bine-Scheck F</AU>
<TI>Double-blind comparison of cibenzoline versus flecainide in the prevention of recurrence of atrial tachyarrhythmias in 139 patients</TI>
<SO>Annals of Noninvasive Electrocardiology</SO>
<YR>1999</YR>
<VL>4</VL>
<NO>1</NO>
<PG>53-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="not indexed"/>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 1999048462; ISSN: 1082-720X"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maison-Blanche P, Brembilla-Perrot B, Fauchier JP, Babuty D, Garnier LF, Rouesnel P, et al</AU>
<TI>Comparative study of cibenzoline and flecainide by oral route for preventing recurrence of paroxysmal atrial tachyarrhythmias</TI>
<TO>Étude comparative de la cibenzoline et du flecaïnide administrés par voie orale dans la prévention de récidive des tachycardies auriculaires</TO>
<SO>Annales de Cardiologie et d Angeiologie</SO>
<YR>1997</YR>
<VL>46</VL>
<NO>2</NO>
<PG>109-16</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 9137677"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0003-3928"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beck-1978" NAME="Beck 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beck OA, Lehmann HU, Hochrein H</AU>
<TI>Propafenone and lidoflazine in chronic atrial fibrillation and flutter (author's transl)</TI>
<TO>Original title: Propafenon und Lidoflazin bei chronischem Vorhofflimmern und -flattern. Vergleichende Untersuchungen</TO>
<SO>Deutsche Medizinische Wochenschrift</SO>
<YR>1978</YR>
<VL>103</VL>
<NO>26</NO>
<PG>1068-72</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID:&amp;#160;668524"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0012-0472"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berns-1987" NAME="Berns 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berns E, Rinkenberger RL, Jeang MK, Dougherty AH, Jenkins M, Naccarelli GV</AU>
<TI>Efficacy and safety of flecainide acetate for atrial tachycardia or fibrillation</TI>
<SO>American Journal of Cardiology</SO>
<YR>1987</YR>
<VL>59</VL>
<NO>15</NO>
<PG>1337-41</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 3109229"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0002-9149"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blevins-1987" NAME="Blevins 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blevins RD, Kerin NZ, Benaderet D, Frumin H, Faitel K, Jarandilla R, et al</AU>
<TI>Amiodarone in the management of refractory atrial fibrillation</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1987</YR>
<VL>147</VL>
<NO>8</NO>
<PG>1401-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 3307669"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0003-9926"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blomstrom-1984" NAME="Blomstrom 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blomstrom P, Edvardsson N, Olsson SB</AU>
<TI>Amiodarone in atrial fibrillation</TI>
<SO>Acta Medica Scandinavica</SO>
<YR>1984</YR>
<VL>216</VL>
<NO>5</NO>
<PG>517-24</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 6524456"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0001-6101"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boissel-1981" NAME="Boissel 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boissel JP, Wolf E, Gillet J, Soubrane A, Cavallaro A, Mazoyer G, Delahaye JP</AU>
<TI>Controlled trial of a long-acting quinidine for maintenance of sinus rhythm after conversion of sustained atrial fibrillation</TI>
<SO>European Heart Journal</SO>
<YR>1981</YR>
<VL>2</VL>
<NO>1</NO>
<PG>49-55</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 7274266"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0195-668X"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brodsky-1987" NAME="Brodsky 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brodsky MA, Allen BJ, Walker CJ 3rd, Casey TP, Luckett CR, Henry WL</AU>
<TI>Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium</TI>
<SO>American Journal of Cardiology</SO>
<YR>1987</YR>
<VL>60</VL>
<NO>7</NO>
<PG>572-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 3630939"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0002-9149"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CHF_x002d_STAF-1998" NAME="CHF-STAF 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SN</AU>
<TI>Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT)</TI>
<SO>Circulation</SO>
<YR>1998</YR>
<VL>98</VL>
<NO>23</NO>
<PG>2574-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 9843465"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0009-7322"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chun-1995" NAME="Chun 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chun SH, Sager PT, Stevenson WG, Nademanee K, Middlekauff HR, Singh BN</AU>
<TI>Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter</TI>
<SO>American Journal of Cardiology</SO>
<YR>1995</YR>
<VL>76</VL>
<NO>1</NO>
<PG>47-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 7793402"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0002-9149"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clementy-1992" MODIFIED="2015-03-17 10:20:06 +0000" MODIFIED_BY="[Empty name]" NAME="Clementy 1992" YEAR="1992">
<REFERENCE MODIFIED="2015-03-17 10:20:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clementy J, Dulhoste MN, Laiter C, Denjoy I, Dos Santos P</AU>
<TI>Flecainide acetate in the prevention of paroxysmal atrial fibrillation: a nine-month follow-up of more than 500 patients</TI>
<SO>American Journal of Cardiology</SO>
<YR>1992</YR>
<VL>70</VL>
<NO>5</NO>
<PG>44A-9A</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 1509998"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0002-9149"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Connolly-1989" NAME="Connolly 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Connolly SJ, Hoffert DL</AU>
<TI>Usefulness of propafenone for recurrent paroxysmal atrial fibrillation</TI>
<SO>American Journal of Cardiology</SO>
<YR>1989</YR>
<VL>63</VL>
<NO>12</NO>
<PG>817-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 2648787"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0002-9149"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CTAF-2000" NAME="CTAF 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dorian P, Paquette M, Newman D, Green M, Connolly SJ, Talajic M, et al</AU>
<TI>Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation</TI>
<SO>American Heart Journal</SO>
<YR>2002</YR>
<VL>143</VL>
<NO>6</NO>
<PG>984-90</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 12075253"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0002-8703"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lumer GB, Roy D, Talajic M, Couturier A, Lambert J, Frasure-Smith N, Thibault B, et al</AU>
<TI>Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial</TI>
<SO>European Heart Journal</SO>
<YR>2002</YR>
<VL>23</VL>
<NO>13</NO>
<PG>1050-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 12093058"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0195-668X"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, Kus T, et al</AU>
<TI>Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators</TI>
<SO>New England Journal of Medicine</SO>
<YR>2000</YR>
<VL>342</VL>
<NO>13</NO>
<PG>913-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 10738049"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0028-4793"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roy D, Talajic M, Thibault B, Dubuc M, Nattel S, Eisenberg MJ, et al</AU>
<TI>Pilot study and protocol of the Canadian Trial of Atrial Fibrillation (CTAF)</TI>
<SO>American Journal of Cardiology</SO>
<YR>1997</YR>
<VL>80</VL>
<NO>4</NO>
<PG>464-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 9285659"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0002-9149"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cuan_x002d_Perez-1971" NAME="Cuan-Perez 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cuan Perez M, Ortiz A</AU>
<TI>Comparative study of quinidine, propranolol and diphenylhydantoin for preventing recurrence in post-cardioversion auricular fibrillation</TI>
<TO>Estudio comparativo entre quinidina, propranolol y difenil-hidantoinato para prevenir la recaida en fibrilacion auricular post-cardioversion</TO>
<SO>Archivos del Instituto de Cardiologia de Mexico</SO>
<YR>1971</YR>
<VL>41</VL>
<NO>3</NO>
<PG>278-84</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 5566599"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0020-3785"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ERAFT-2002" NAME="ERAFT 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meinertz T, Lip GY, Lombardi F, Sadowski ZP, Kalsch B, Camez A, et al</AU>
<TI>Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation. The European Rythmol/Rytmonorm Atrial Fibrillation Trial (ERAFT) Study</TI>
<SO>American Journal of Cardiology</SO>
<YR>2002</YR>
<VL>90</VL>
<NO>12</NO>
<PG>1300-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 12480038"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0002-9149"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Faivre-1970" NAME="Faivre 1970" YEAR="1970">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Faivre G, Polu JM</AU>
<TI>Disopyramide in the preparation for electric shock in atrial fibrillation and in the maintenance of subsequent sinus rhythm</TI>
<TO>La disopiramide nella preparazione allo shock elettrico della fibrillazione atriale e nel mantenimento dell'ulteriore ritmo sinusale</TO>
<SO>Minerva Medica</SO>
<YR>1970</YR>
<VL>61</VL>
<NO>71 Suppl</NO>
<PG>3745-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 5454439"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0026-4806"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fernandez-1998" MODIFIED="2015-03-17 10:21:39 +0000" MODIFIED_BY="[Empty name]" NAME="Fernandez 1998" YEAR="1998">
<REFERENCE MODIFIED="2015-03-17 10:21:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fernández JM, Martínez-Marcos FJ, Ortega A, García JL, Camacho C, et al</AU>
<TI>Comparative study of propafenone, amiodarone and flecainide in the treatment of paroxystic atrial fibrillation</TI>
<TO>Estudio comparativo de propafenona, amiodarona y flecainida en el tratamiento de la fibrilación auricular paroxística</TO>
<SO>Revista Espanola de Cardiologia</SO>
<YR>1998</YR>
<VL>51 Suppl 5</VL>
<PG>84</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="Not indexed"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0300-8932"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fragakis-2012" MODIFIED="2015-03-17 10:33:21 +0000" MODIFIED_BY="[Empty name]" NAME="Fragakis 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-06-23 15:24:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fragakis N, Koskinas KC, Katritsis DG, Pagourelias ED, Zografos T, Geleris P</AU>
<TI>Comparison of effectiveness of ranolazine plus amiodarone versus amiodarone alone for conversion of recent-onset atrial fibrillation</TI>
<SO>American Journal of Cardiology</SO>
<YR>2012 Sep 1</YR>
<VL>110</VL>
<NO>5</NO>
<PG>673-7</PG>
<IDENTIFIERS MODIFIED="2014-06-23 15:11:01 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-06-23 15:11:01 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/j.amjcard.2012.04.044"/>
<IDENTIFIER MODIFIED="2014-06-23 15:10:46 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="22621799"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-03-17 10:33:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koskinas KC, Fragakis N, Pagourelias ED, Rossios K, Abramidou A, Sotiriou P, et al</AU>
<TI>Ranolazine added to amiodarone vs. amiodarone alone for the conversion of recent-onset atrial fibrillation. Abstract from the ESC Congress 25-29 August 2012; Munchen, Germany</TI>
<SO>European Heart Journal</SO>
<YR>2012</YR>
<VL>33 Suppl 1</VL>
<PG>383</PG>
<IDENTIFIERS MODIFIED="2014-06-23 15:23:51 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-06-23 15:23:51 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1093/eurheartj/ehs282"/>
<IDENTIFIER MODIFIED="2014-06-23 15:23:34 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="23805432"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frances-1985" NAME="Frances 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frances Y, Luccioni R, Delaage M, Donnarel G, Medvedowsky JL, Quiret JC</AU>
<TI>Long-term prevention of the recurrence of auricular fibrillation using cibenzoline. Multicenter study apropos of 89 case reports</TI>
<TO>Prevention au long cours des recidives de fibrillation auriculaire par la cibenzoline. Etude multicentrique a propos de 89 observations</TO>
<SO>Archives des Maladies du Coeur et des Vaisseaux</SO>
<YR>1985</YR>
<VL>78</VL>
<NO>Spec No</NO>
<PG>99-103</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 3938266"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0003-9683"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Galperin-2014" MODIFIED="2015-03-17 10:27:37 +0000" MODIFIED_BY="[Empty name]" NAME="Galperin 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-03-17 10:27:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galperin J, Elizari MV, Bonato R, Ledesma R, Vazquez Blanco M, Lago M, et al</AU>
<TI>Short-term amiodarone therapy after reversion of persistent atrial fibrillation reduces recurrences at 18 months</TI>
<SO>Cardiology Journal</SO>
<YR>2014</YR>
<VL>21</VL>
<NO>4</NO>
<PG>397-404</PG>
<IDENTIFIERS MODIFIED="2014-06-23 15:19:48 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-06-23 15:19:48 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.5603/CJ.a2013.0152"/>
<IDENTIFIER MODIFIED="2014-06-23 15:19:34 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="24293165"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gold-1986" NAME="Gold 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gold RL, Haffajee CI, Charos G, Sloan K, Baker S, Alpert JS</AU>
<TI>Amiodarone for refractory atrial fibrillation</TI>
<SO>American Journal of Cardiology</SO>
<YR>1986</YR>
<VL>57</VL>
<NO>1</NO>
<PG>124-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 3942054"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0002-9149"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gosselink-1992" NAME="Gosselink 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gosselink AT, Crijns HJ, Van Gelder IC, Hillige H, Wiesfeld AC, Lie KI</AU>
<TI>Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter</TI>
<SO>JAMA</SO>
<YR>1992</YR>
<VL>267</VL>
<NO>24</NO>
<PG>3289-93</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 1597910"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0098-7484"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Graboys-1983" NAME="Graboys 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Graboys TB, Podrid PJ, Lown B</AU>
<TI>Efficacy of amiodarone for refractory supraventricular tachyarrhythmias</TI>
<SO>American Heart Journal</SO>
<YR>1983</YR>
<VL>106</VL>
<NO>4 Pt 2</NO>
<PG>870-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 6613832"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0002-8703"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gramley-2011" MODIFIED="2015-03-17 10:31:19 +0000" MODIFIED_BY="[Empty name]" NAME="Gramley 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-03-17 10:31:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gramley F, Koellensperger E, Munzel T, Kettering KC</AU>
<TI>Dronedarone therapy after catheter ablation of atrial fibrillation: a new hybrid therapy option. Abstract from EHRA Europace 26-29 June 2011 Madrid, Spain</TI>
<SO>Europace</SO>
<YR>2011</YR>
<VL>13 Suppl 3</VL>
<PG>NP</PG>
<IDENTIFIERS MODIFIED="2014-06-23 15:15:29 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-06-23 15:15:29 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="doi:10.1093/europace/eur214"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grigoriyan-2011" MODIFIED="2015-03-17 10:32:51 +0000" MODIFIED_BY="[Empty name]" NAME="Grigoriyan 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-03-17 10:32:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grigoryan S, Hazarapetyan LGC</AU>
<TI>Procoralan as a preventive treatment for paroxysmal atrial fibrillation. Abstract from the ESC Congress 27-31 August 2011; Paris, France</TI>
<SO>European Heart Journal</SO>
<YR>2011</YR>
<VL>32 Suppl 1</VL>
<PG>624</PG>
<IDENTIFIERS MODIFIED="2014-06-23 15:32:56 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-06-23 15:32:56 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1093/eurheartj/ehr323"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gu-2012" MODIFIED="2015-03-17 10:37:50 +0000" MODIFIED_BY="[Empty name]" NAME="Gu 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-03-17 10:37:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gu J, Liu X, Tan H, Zhou L, Gu J, Jiang W, et al</AU>
<TI>Extensive antiarrhythmic drugs after catheter ablation of persistent atrial fibrillation</TI>
<SO>Acta Cardiologica</SO>
<YR>2012 Aug</YR>
<VL>67</VL>
<NO>4</NO>
<PG>407-14</PG>
<IDENTIFIERS MODIFIED="2014-06-23 15:35:40 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-06-23 15:35:40 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="22997994"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-GUSTO-2002" NAME="GUSTO 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wong CK, White HD, Wilcox RG, Criger DA, Califf RM, Topol EJ, Ohman EM</AU>
<TI>Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience. Global use of strategies to open occluded coronary arteries</TI>
<SO>Heart</SO>
<YR>2002</YR>
<VL>88</VL>
<NO>4</NO>
<PG>357-62</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 12231591"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 1355-6037"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hammill-1988" NAME="Hammill 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hammill SC, Wood DL, Gersh BJ, Osborn MJ, Holmes DR Jr</AU>
<TI>Propafenone for paroxysmal atrial fibrillation</TI>
<SO>American Journal of Cardiology</SO>
<YR>1988</YR>
<VL>61</VL>
<NO>6</NO>
<PG>473-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 3341233"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0002-9149"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hartel-1970" NAME="Hartel 1970" YEAR="1970">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Härtel G, Louhija A, Halonen PI</AU>
<TI>Investigations on the value of quinidine therapy after electrical rhythmization of atrial fibrillation</TI>
<TO>Untersuchungen über den Wert der Chinidinbehandlung nach elektrischer Rhythmisierung von Vorhofflimmern</TO>
<SO>Die Medizinische Welt</SO>
<YR>1969</YR>
<VL>20</VL>
<NO>25</NO>
<PG>1464</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="not indexed"/>
<IDENTIFIER TYPE="OTHER" VALUE="CENTRAL: CN-00247601"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Härtel G, Louhija A, Halonen PI</AU>
<TI>The value of quinidine therapy in order to maintain sinus rhythm after electrical rhythmization of atrial fibrillation</TI>
<TO>Der Wert der Chinidinbehandlung für die Erhaltung des Sinusrhythmus nach elektrischer Rhythmisierung von Vorhofflimmern</TO>
<SO>Klinische Wochenschrift</SO>
<YR>1969</YR>
<VL>47</VL>
<NO>17</NO>
<PG>942</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="not indexed"/>
<IDENTIFIER TYPE="OTHER" VALUE="CENTRAL: CN-00247602; ISSN: 0023-2173"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hartel G, Louhija A, Konttinen A, Halonen PI</AU>
<TI>Value of quinidine in maintenance of sinus rhythm after electric conversion of atrial fibrillation</TI>
<SO>British Heart Journal</SO>
<YR>1970</YR>
<VL>32</VL>
<NO>1</NO>
<PG>57-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 5417847"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0007-0769"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hartel-1974" MODIFIED="2015-03-17 10:38:41 +0000" MODIFIED_BY="[Empty name]" NAME="Hartel 1974" YEAR="1974">
<REFERENCE MODIFIED="2015-03-17 10:38:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hartel G, Louhija A, Konttinen A</AU>
<TI>Disopyramide in the prevention of recurrence of atrial fibrillation after electroconversion</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1974</YR>
<VL>15</VL>
<NO>6</NO>
<PG>551-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 4601741"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0009-9236"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hopson-1996" NAME="Hopson 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hopson JR, Buxton AE, Rinkenberger RL, Nademanee K, Heilman JM, Kienzle MG</AU>
<TI>Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: results of a multicenter trial. The Flecainide Supraventricular Tachycardia Study Group</TI>
<SO>American Journal of Cardiology</SO>
<YR>1996</YR>
<VL>77</VL>
<NO>3</NO>
<PG>72A-82A</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 8607395"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0002-9149"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Horowitz-1985" NAME="Horowitz 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horowitz LN, Spielman SR, Greenspan AM, Mintz GS, Morganroth J, Brown R, et al</AU>
<TI>Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1985</YR>
<VL>6</VL>
<NO>6</NO>
<PG>1402-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 4067122"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0735-1097"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-HOT_x002d_CAFE-2003" NAME="HOT-CAFE 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Opolski G, Torbicki A, Kosior D, Stolarz P, Dawidowska R, Zawadzka M, et al</AU>
<TI>Should sinus rhythm be restored in patients with chronic atrial fibrillation? Preliminary results from the Polish "Hot Cafe" study</TI>
<TO>Czy przywracac rytm zatokowy u chorych z przewleklym migotaniem przedsionkow? Wstepne wyniki polskiego badania "Hot Cafe"</TO>
<SO>Polskie Archiwum Medycyny Wewnetrznej</SO>
<YR>1999</YR>
<VL>101</VL>
<NO>5</NO>
<PG>413-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 10740421"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0032-3772"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Opolski G, Torbicki A, Kosior D, Szulc M, Zawadzka M, Pierscinska M, et al</AU>
<TI>Rhythm control versus rate control in patients with persistent atrial fibrillation. Results of the HOT CAFE Polish Study</TI>
<SO>Kardiologia Polska</SO>
<YR>2003</YR>
<VL>59</VL>
<NO>7</NO>
<PG>1-16</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 14560344"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0022-9032"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Opolski G, Torbicki A, Kosior DA, Szulc M, Wozakowska-Kaplon B, Kolodziej P, et al</AU>
<TI>Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study</TI>
<SO>Chest</SO>
<YR>2004</YR>
<VL>126</VL>
<NO>2</NO>
<PG>476-86</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 15302734"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0012-3692"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ishiguro-2008" MODIFIED="2014-06-23 15:37:29 +0100" MODIFIED_BY="[Empty name]" NAME="Ishiguro 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-06-23 15:37:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ishiguro H, Ikeda T, Abe A, Tsukada T, Mera H, Nakamura K, Yusu S, Yoshino H</AU>
<TI>Antiarrhythmic effect of bisoprolol, a highly selective beta1-blocker, in patients with paroxysmal atrial fibrillation</TI>
<SO>International Heart Journal</SO>
<YR>2008 May</YR>
<VL>49</VL>
<NO>3</NO>
<PG>281-93</PG>
<IDENTIFIERS MODIFIED="2014-06-23 15:37:29 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-06-23 15:37:29 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18612186"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-J_x002d_BAF-2009" MODIFIED="2015-03-17 10:40:24 +0000" MODIFIED_BY="[Empty name]" NAME="J-BAF 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-03-17 10:40:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>J-BAF Investigators, Yamashita T, Ogawa S, Sato T, Aizawa Y, Atarashi H, Fujiki A, et al</AU>
<TI>Dose-response effects of bepridil in patients with persistent atrial fibrillation monitored with transtelephonic electrocardiograms: a multicenter, randomized, placebo-controlled,double-blind study (J-BAF Study)</TI>
<SO>Circulation Journal</SO>
<YR>2009 Jun</YR>
<VL>73</VL>
<NO>6</NO>
<PG>1020-7</PG>
<IDENTIFIERS MODIFIED="2010-09-27 14:51:41 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-27 14:51:41 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="PMID: 19359813"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jong-2006" MODIFIED="2015-03-17 10:41:13 +0000" MODIFIED_BY="[Empty name]" NAME="Jong 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-03-17 10:41:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jong GP, Chang MH, Chang TC, Chou P, Fu CY, Tien LY, et al</AU>
<TI>Long-term efficacy and safety of very-low-dose amiodarone treatment for the maintenance of sinus rhythm in patients with chronic atrial fibrillation after successful direct-current cardioversion</TI>
<SO>Chinese Medical Journal (English)</SO>
<YR>2006 Dec 20</YR>
<VL>119</VL>
<NO>24</NO>
<PG>2030-5</PG>
<IDENTIFIERS MODIFIED="2010-09-27 14:57:23 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-27 14:57:23 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="PMID: 17199952"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-J_x002d_RHYTHM-2009" MODIFIED="2015-03-17 10:41:42 +0000" MODIFIED_BY="[Empty name]" NAME="J-RHYTHM 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-03-17 10:41:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>J-RHYTHM Investigators, Ogawa S, Yamashita T, Yamazaki T, Aizawa Y, Atarashi H, Inoue H, et al</AU>
<TI>Optimal treatment strategy for patients with paroxysmal atrial fibrillation: J-RHYTHM Study</TI>
<SO>Circulation Journal</SO>
<YR>2009 Feb</YR>
<VL>73</VL>
<NO>2</NO>
<PG>242-8</PG>
<IDENTIFIERS MODIFIED="2010-09-27 14:54:33 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-27 14:54:33 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="PMID: 19060419"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kanoupakis-2004" NAME="Kanoupakis 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kanoupakis EM, Manios EG, Mavrakis HE, Tzerakis PG, Mouloudi HK, Vardas PE</AU>
<TI>Comparative effects of carvedilol and amiodarone on conversion and recurrence rates of persistent atrial fibrillation</TI>
<SO>American Journal of Cardiology</SO>
<YR>2004</YR>
<VL>94</VL>
<NO>5</NO>
<PG>659-62</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 15342304"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0002-9149"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kennelly-1977" NAME="Kennelly 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kennelly BM</AU>
<TI>Comparison of lidoflazine and quindine in prophylactic treatment of arrhythmias</TI>
<SO>British Heart Journal</SO>
<YR>1977</YR>
<VL>39</VL>
<NO>5</NO>
<PG>540-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="not indexed"/>
<IDENTIFIER TYPE="OTHER" VALUE="CENTRAL: CN-00345795; ISSN: 0007-0769"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kerr-1988" NAME="Kerr 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kerr CR, Klein GJ, Axelson JE, Cooper JC</AU>
<TI>Propafenone for prevention of recurrent atrial fibrillation</TI>
<SO>American Journal of Cardiology</SO>
<YR>1988</YR>
<VL>61</VL>
<NO>11</NO>
<PG>914-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 3354467"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0002-9149"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khitri-2012" MODIFIED="2015-03-02 14:39:39 +0000" MODIFIED_BY="[Empty name]" NAME="Khitri 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-03-02 14:39:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khitri AR, Aliot EM, Capucci A, Connolly SJ, Crijns H, Hohnloser SH, et al</AU>
<TI>Celivarone for maintenance of sinus rhythm and conversion of atrial fibrillation/flutter</TI>
<SO>Journal of Cardiovascular Electrophysiology</SO>
<YR>2012 May</YR>
<VL>23</VL>
<NO>5</NO>
<PG>462-72</PG>
<IDENTIFIERS MODIFIED="2014-06-23 15:40:09 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-06-23 15:39:57 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1111/j.1540-8167.2011.02234.x"/>
<IDENTIFIER MODIFIED="2014-06-23 15:40:09 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="22171925"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Komatsu-2006" MODIFIED="2014-07-28 15:04:54 +0100" MODIFIED_BY="[Empty name]" NAME="Komatsu 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-07-28 15:04:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Komatsu T, Sato Y, Tachibana H, Nakamura M, Horiuchi D, Okumura K</AU>
<TI>Randomized crossover study of the long-term effects of pilsicainide and cibenzoline in preventing recurrence of symptomatic paroxysmal atrial fibrillation: influence of the duration of arrhythmia before therapy</TI>
<SO>Circulation Journal</SO>
<YR>2006 Jun</YR>
<VL>70</VL>
<NO>6</NO>
<PG>667-72</PG>
<IDENTIFIERS MODIFIED="2014-06-23 15:42:27 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-06-23 15:42:27 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16723785"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kosior-2001" NAME="Kosior 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kosior D, Karpinski G, Wretowski D, Stolarz P, Stawicki S, Rabczenko D, et al</AU>
<TI>Sequential prophylactic antiarrhythmic therapy for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation - One year follow-up</TI>
<SO>Kardiologia Polska</SO>
<YR>2002</YR>
<VL>56</VL>
<NO>4</NO>
<PG>361-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="not indexed"/>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE: 2002162110; ISSN: 0022-9032"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kosior D, Opolski G, Torbicki A</AU>
<TI>Efficacy of sequential antiarrhythmic treatment in sinus rhythm maintenance after successful electrocardioversion in patients with chronic non-valvular atrial fibrillation</TI>
<SO>Medical Science Monitor</SO>
<YR>2001</YR>
<VL>7</VL>
<NO>1</NO>
<PG>68-73</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 11208496"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 1234-1010"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kosior D, Szulc M, Zawadzka M, PierScinska M, Stawicki S, Rabczenko D, et al</AU>
<TI>Role of amiodarone in sinus rhythm maintenance after successful cardioversion in patients with chronic non-valvular atrial fibrillation</TI>
<TO>Rola amiodaronu w utrzymaniu rytmu zatokowego po skutecznej kardiowersji elektrycznej u chorych z przetrwalym migotaniem</TO>
<SO>Polskie Archiwum Medycyny Wewnetrznej</SO>
<YR>2002</YR>
<VL>108</VL>
<NO>6</NO>
<PG>1151-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID 12687927, MEDLINE 22574733"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0032-3772"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kosior-2009" MODIFIED="2014-06-23 15:44:23 +0100" MODIFIED_BY="[Empty name]" NAME="Kosior 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-06-23 15:44:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kosior DA, Kochanowski J, Scis&#322;o P, Piatkowski R, Postu&#322;a M, Rabczenko D, Opolski G</AU>
<TI>Efficacy and tolerability of oral propafenone versus quinidine in the treatment of recent onset atrial fibrillation: A randomized, prospective study</TI>
<SO>Cardiology Journal</SO>
<YR>2009</YR>
<VL>16</VL>
<NO>6</NO>
<PG>521-7</PG>
<IDENTIFIERS MODIFIED="2014-06-23 15:44:23 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-06-23 15:44:23 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19950088"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kyles-1991" NAME="Kyles 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kyles AE, Murdock CJ, Yeung-Lai-Wah JA, Vorderbrugge S, Kerr CR</AU>
<TI>Long term efficacy of propafenone for prevention of atrial fibrillation</TI>
<SO>Canadian Journal of Cardiology</SO>
<YR>1991</YR>
<VL>7</VL>
<NO>9</NO>
<PG>407-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 1756420"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0828-282X"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lardoux-1996" NAME="Lardoux 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lardoux H, Maison Blanche P, Marchand X, Canler A, Rouesnel P, Bleinc D, et al</AU>
<TI>Cibenzoline versus propafenone by the oral route for preventing recurrence of atrial arrhythmia: multicenter, randomized, double-blind study</TI>
<TO>Cibenzoline versus propafénone par voie orale dans la prévention de la récidive des arythmies auriculaires: étude multicentrique randomisée realisée en double aveugle</TO>
<SO>Annales de Cardiologie et d Angeiologie</SO>
<YR>1996</YR>
<VL>45</VL>
<NO>8</NO>
<PG>469-79</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 8952741"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0003-3928"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lau-1992" NAME="Lau 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lau CP, Leung WH, Wong CK</AU>
<TI>A randomized double-blind crossover study comparing the efficacy and tolerability of flecainide and quinidine in the control of patients with symptomatic paroxysmal atrial fibrillation</TI>
<SO>American Heart Journal</SO>
<YR>1992</YR>
<VL>124</VL>
<NO>3</NO>
<PG>645-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 1514492"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0002-8703"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levi-1973" NAME="Levi 1973" YEAR="1973">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Levi G, Proto C, Rovetta A</AU>
<TI>Double-blind evaluation of practolol and quinidine in the treatment of chronic atrial fibrillation</TI>
<SO>Cardiology</SO>
<YR>1973</YR>
<VL>58</VL>
<NO>6</NO>
<PG>364-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 4608474"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0008-6312"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Quadri A, Levi GP, Proto C</AU>
<TI>Treatment of chronic artrial fibrillation with practolol-quinidine</TI>
<TO>Trattamento della fibrillazione atriale cronica con practololo-chinidina</TO>
<SO>Minerva Cardioangiologica</SO>
<YR>1973</YR>
<VL>21</VL>
<NO>10</NO>
<PG>668-71</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 4589190"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0026-4725"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2004" NAME="Li 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li H, Riedel R, Oldemeyer JB, Rovang K, Hee T</AU>
<TI>Comparison of recurrence rates after direct-current cardioversion for new-onset atrial fibrillation in patients receiving versus those not receiving rhythm-control drug therapy</TI>
<SO>American Heart Journal</SO>
<YR>2004</YR>
<VL>93</VL>
<NO>1</NO>
<PG>45-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 14697464"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0002-9149"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lobe-2013" MODIFIED="2015-03-02 14:40:09 +0000" MODIFIED_BY="[Empty name]" NAME="Lobe 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-03-02 14:40:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Löbe S, Salmá&#353; J, John S, Kornej J, Husser D, Hindricks G, et al</AU>
<TI>Usefulness of dronedarone in patients with atrial arrhythmias</TI>
<SO>American Journal of Cardiology</SO>
<YR>2013</YR>
<VL>111</VL>
<NO>9</NO>
<PG>1311-4</PG>
<IDENTIFIERS MODIFIED="2014-06-23 15:47:46 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-06-23 15:47:33 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/j.amjcard.2012.12.057"/>
<IDENTIFIER MODIFIED="2014-06-23 15:47:46 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="23465099"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Manios-2003" MODIFIED="2015-03-17 10:44:46 +0000" MODIFIED_BY="[Empty name]" NAME="Manios 2003" YEAR="2003">
<REFERENCE MODIFIED="2015-03-17 10:44:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Manios EG, Mavrakis HE, Kanoupakis EM, Kallergis EM, Dermitzaki DN, Kambouraki DC, et al</AU>
<TI>Effects of amiodarone and diltiazem on persistent atrial fibrillation conversion and recurrence rates: a randomized controlled study</TI>
<SO>Cardiovascular Drugs and Therapy</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>1</NO>
<PG>31-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 12843685"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0920-3206"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martin-1986" NAME="Martin 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martin A, Benbow LJ, Leach C, Bailey RJ</AU>
<TI>Comparison of amiodarone and disopyramide in the control of paroxysmal atrial fibrillation and atrial flutter</TI>
<SO>British Journal of Clinical Practice. Supplement</SO>
<YR>1986</YR>
<VL>44</VL>
<PG>52-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 3089263"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0260-8767"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mary_x002d_Rabine-1990" NAME="Mary-Rabine 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mary-Rabine L, Kulbertus HE</AU>
<TI>Clinical efficacy of flecainide acetate in atrial fibrillation</TI>
<SO>Cardiology</SO>
<YR>1990</YR>
<VL>77</VL>
<NO>6</NO>
<PG>443-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 2127378"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0008-6312"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Massacci-1991" NAME="Massacci 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Massacci E, Morellini C, De PG, Chioffi M, Longobardi M, Cellino F, et al</AU>
<TI>Flecainide versus amiodarone in preventing paroxysmal idiopathic atrial fibrillation</TI>
<SO>New Trends in Arrhythmias</SO>
<YR>1991</YR>
<VL>7</VL>
<NO>4</NO>
<PG>693-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="not indexed"/>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 1992241383"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mizutani-1995" NAME="Mizutani 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mizutani N, Oki Y, Wakida Y, Iwa T, Haga M, Mizutani K, et al</AU>
<TI>Pilsicainide in the acute conversion and the prevention of paroxysmal atrial fibrillation</TI>
<SO>Japanese Pharmacology &amp; Therapeutics</SO>
<YR>1995</YR>
<VL>23</VL>
<NO>7</NO>
<PG>113-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="not indexed"/>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 1995251738"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nedostup-1990" NAME="Nedostup 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nedostup AV, Alekseevskaia MA, Novikov ID, Maevskaia IV</AU>
<TI>A comparison of the efficacy of quinidine and kordaron as agents to stabilize the recovered sinus rhythm in patients with the permanent form of atrial fibrillation</TI>
<TO>Sravnenie effektivnosti khinidina i kordarona kak sredstv stabilizatsii vosstanovlennogo sinusovogo ritma u bol'nykh s postoianno formo mertsatel'no aritmii</TO>
<SO>Terapevticheskii Arkhiv</SO>
<YR>1990</YR>
<VL>62</VL>
<NO>9</NO>
<PG>47-51</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 2281406"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0040-3660"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Opolski-1997" NAME="Opolski 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Opolski G, Stanislawska J, Gorecki A, Swiecicka G, Torbicki A, Kraska T</AU>
<TI>Amiodarone in restoration and maintenance of sinus rhythm in patients with chronic atrial fibrillation after unsuccessful direct-current cardioversion</TI>
<SO>Clinical Cardiology</SO>
<YR>1997</YR>
<VL>20</VL>
<NO>4</NO>
<PG>337-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 9098591"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0160-9289"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PEPS-2002" MODIFIED="2015-03-17 10:48:17 +0000" MODIFIED_BY="[Empty name]" NAME="PEPS 2002" YEAR="2002">
<REFERENCE MODIFIED="2015-03-17 10:48:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simon T, Mary-Krause M, Funck-Brentano C, Davy JM, Weingrod M, Jaillon P</AU>
<TI>Efficacy and tolerance of propafenone after correction of atrial fibrillation: PEPS pharmaco-epidemiologic study</TI>
<TO>Efficacité et tolérance de la propafénone après régularisation de la fibrillation auriculaire: étude pharmaco-épidémiologique PEPS</TO>
<SO>Archives des Maladies du Coeur et des Vaisseaux</SO>
<YR>2002</YR>
<VL>95</VL>
<NO>6</NO>
<PG>567-72</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 12138815"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0003-9683"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PIAF-2000" NAME="PIAF 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gronefeld GC, Lilienthal J, Kuck KH, Hohnloser SH</AU>
<TI>Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation. Results from a prospective randomized study</TI>
<SO>European Heart Journal</SO>
<YR>2003</YR>
<VL>24</VL>
<NO>15</NO>
<PG>1430-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 12909072"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0195-668X"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hohnloser SH, Kuck KH, Lilienthal J</AU>
<TI>Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial</TI>
<SO>Lancet</SO>
<YR>2000</YR>
<VL>356</VL>
<NO>9244</NO>
<PG>1789-94</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 11117910"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0140-6736"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pietersen-1991" MODIFIED="2015-03-17 10:49:03 +0000" MODIFIED_BY="[Empty name]" NAME="Pietersen 1991" YEAR="1991">
<REFERENCE MODIFIED="2015-03-17 10:49:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pietersen AH, Hellemann H</AU>
<TI>Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter. Danish-Norwegian Flecainide Multicenter Study Group</TI>
<SO>American Journal of Cardiology</SO>
<YR>1991</YR>
<VL>67</VL>
<NO>8</NO>
<PG>713-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 1900978"/>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 1991186337; ISSN: 0002-9149"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Piot-1998" NAME="Piot 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Piot O, Flammang D, Dambrine P, Cheikel J, Jouannon C, Graux P, et al</AU>
<TI>A randomized double-blind trial comparing cibenzoline and disopyramide in the prevention of recurrences of atrial tachyarrhythmia</TI>
<TO>Etude randomisee en double aveugle comparant la cibenzoline et le disopyramide dans la prevention de recidives de tachyarythmies atriales</TO>
<SO>Archives des Maladies du Coeur et des Vaisseaux</SO>
<YR>1998</YR>
<VL>91</VL>
<NO>12</NO>
<PG>1481-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 9891831"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0003-9683"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Porterfield-1989" NAME="Porterfield 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Porterfield JG, Porterfield LM</AU>
<TI>Therapeutic efficacy and safety of oral propafenone for atrial fibrillation</TI>
<SO>American Journal of Cardiology</SO>
<YR>1989</YR>
<VL>63</VL>
<NO>1</NO>
<PG>114-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 2909141"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0002-9149"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PSVT-1995" NAME="PSVT 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cobbe SM, Rae AP, Poloniecki JD, Chong E, Balnave K, Moriarty A, et al</AU>
<TI>A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. UK Propafenone PSVT Study Group</TI>
<SO>Circulation</SO>
<YR>1995</YR>
<VL>92</VL>
<NO>9</NO>
<PG>2550-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 7586356"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0009-7322"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-RACE-2002" NAME="RACE 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, et al</AU>
<TI>A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation</TI>
<SO>New England Journal of Medicine</SO>
<YR>2002</YR>
<VL>347</VL>
<NO>23</NO>
<PG>1834-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 12466507"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0028-4793"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rasmussen-1981" NAME="Rasmussen 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rasmussen K, Wang H, Fausa D</AU>
<TI>Comparative efficiency of quinidine and verapamil in the maintenance of sinus rhythm after DC conversion of atrial fibrillation. A controlled clinical trial</TI>
<SO>Acta Medica Scandinavica - Supplementum</SO>
<YR>1981</YR>
<VL>645</VL>
<PG>23-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 7015799"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0365-463X"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Resnekov-1971" NAME="Resnekov 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Resnekov L, Gibson D, Waich S, Muir J, McDonald L</AU>
<TI>Sustained-release quinidine (Kinidin Durules) in maintaining sinus rhythm after electroversion of atrial dysrhythmias</TI>
<SO>British Heart Journal</SO>
<YR>1971</YR>
<VL>33</VL>
<NO>2</NO>
<PG>220-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 5572656"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0007-0769"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-STAF-2003" NAME="STAF 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, et al</AU>
<TI>Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2003</YR>
<VL>41</VL>
<NO>10</NO>
<PG>1690-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 12767648"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0735-1097"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steeds-1999" NAME="Steeds 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steeds RP, Birchall AS, Smith M, Channer KS</AU>
<TI>An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation</TI>
<SO>Heart</SO>
<YR>1999</YR>
<VL>82</VL>
<NO>2</NO>
<PG>170-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID 10409530, MEDLINE 99340341"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 1355-6037"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tonet-1986" MODIFIED="2015-03-17 10:50:30 +0000" MODIFIED_BY="[Empty name]" NAME="Tonet 1986" YEAR="1986">
<REFERENCE MODIFIED="2015-03-17 10:50:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tonet JL, Bernardeau C, Lechat P, Frank R, Touzet I, Fontaine G, et al</AU>
<TI>Comparison between the efficacy of amiodarone and quinidine in the treatment of atrial cardiac arrhythmias</TI>
<SO>British Journal of Clinical Practice. Supplement</SO>
<YR>1986</YR>
<VL>44</VL>
<PG>42-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 3089261"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0262-8767"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Torp_x002d_Pedersen-2011" MODIFIED="2015-03-02 14:40:30 +0000" MODIFIED_BY="[Empty name]" NAME="Torp-Pedersen 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-03-02 14:40:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Torp-Pedersen C, Raev DH, Dickinson G, Butterfield NN, Mangal B, Beatch GN</AU>
<TI>A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion</TI>
<SO>Circulation. Arrhythmia and Electrophysiology</SO>
<YR>2011</YR>
<VL>4</VL>
<NO>5</NO>
<PG>637-43</PG>
<IDENTIFIERS MODIFIED="2014-06-23 15:49:41 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-06-23 15:49:26 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1161/CIRCEP.111.962340"/>
<IDENTIFIER MODIFIED="2014-06-23 15:49:41 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21841207"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Touboul-1995" NAME="Touboul 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Touboul P, Brembilla-Perrot B, Scheck F, Gabriel A, Lardoux H, Marchand X</AU>
<TI>Comparative effects of cibenzoline and hydroquinidine in the prevention of auricular fibrillation. A randomized double-blind study</TI>
<TO>Effets comparés de la cibenzoline et de l'hydroquinidine dans la prévention de la fibrillation auriculaire. Une étude randomisée en double aveugle</TO>
<SO>Annales de Cardiologie et d Angeiologie</SO>
<YR>1995</YR>
<VL>44</VL>
<NO>9</NO>
<PG>525-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 8745663"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0003-3928"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Wijk-1989" NAME="Van Wijk 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Wijk LM, den Heijer P, Crijns HJ, van Gilst WH, Lie KI</AU>
<TI>Flecainide versus quinidine in the prevention of paroxysms of atrial fibrillation</TI>
<SO>Journal of Cardiovascular Pharmacology</SO>
<YR>1989</YR>
<VL>13</VL>
<NO>1</NO>
<PG>32-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID:&amp;#160;2468933"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0160-2446"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-VEPARAF-2003" NAME="VEPARAF 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Simone A, De Pasquale M, De Matteis C, Canciello M, Manzo M, Sabino L et al</AU>
<TI>VErapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF Study)</TI>
<SO>European Heart Journal</SO>
<YR>2003</YR>
<VL>25</VL>
<NO>15</NO>
<PG>1425-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 12909071"/>
<IDENTIFIER TYPE="OTHER" VALUE="0195-668X"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wanless-1997" NAME="Wanless 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wanless RS, Anderson K, Joy M, Joseph SP</AU>
<TI>Multicenter comparative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachyarrhythmias</TI>
<SO>American Heart Journal</SO>
<YR>1997</YR>
<VL>133</VL>
<NO>4</NO>
<PG>441-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 9124166"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0002-8703"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zehender-1992" MODIFIED="2015-03-17 10:52:06 +0000" MODIFIED_BY="[Empty name]" NAME="Zehender 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zehender M, Hohnloser S, Muller B, Meinertz T, Just H</AU>
<TI>Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: results of a comparative study and a 2-year follow-up</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1992</YR>
<VL>19</VL>
<NO>5</NO>
<PG>1054-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 1552095"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0735-1097"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-03-17 10:52:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zehender M, Meinertz T, Just H</AU>
<TI>Amiodarone and verapamil/chinidin in the treatment of patients with chronic atrial fibrillation</TI>
<TO>Amiodaron und Verapamil/Chinidin in der Behandlung von Patienten mit chronischem Vorhofflimmern</TO>
<SO>Zeitschrift fur Kardiologie</SO>
<YR>1994</YR>
<VL>83 Suppl 5</VL>
<PG>101-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="not indexed"/>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 1994379000; ISSN: 0300-5860"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2011-02-22 10:49:22 +0000" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2011-02-22 10:49:30 +0000" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-03-17 11:02:46 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2015-03-17 11:02:46 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-ACC_x002f_AHA_x002f_ESC-2011" MODIFIED="2015-03-02 14:40:57 +0000" MODIFIED_BY="[Empty name]" NAME="ACC/AHA/ESC 2011" TYPE="JOURNAL_ARTICLE">
<AU>Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, et al</AU>
<TI>2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines</TI>
<SO>Circulation</SO>
<YR>2011</YR>
<VL>123</VL>
<NO>10</NO>
<PG>e269-367</PG>
<IDENTIFIERS MODIFIED="2014-07-15 15:35:33 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-07-15 15:35:33 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1161/CIR.0b013e318214876d"/>
<IDENTIFIER MODIFIED="2014-07-15 15:35:03 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="PMID: 21382897"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Alboni-2004" MODIFIED="2015-03-17 10:52:54 +0000" MODIFIED_BY="[Empty name]" NAME="Alboni 2004" TYPE="JOURNAL_ARTICLE">
<AU>Alboni P, Botto GL, Baldi N, Luzi M, Russo V, Gianfranchi L, et al</AU>
<TI>Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach</TI>
<SO>New England Journal of Medicine</SO>
<YR>2004</YR>
<VL>351</VL>
<NO>23</NO>
<PG>2384-91</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 15575054"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0028-4793"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Anter-2009" MODIFIED="2015-03-02 14:41:06 +0000" MODIFIED_BY="[Empty name]" NAME="Anter 2009" TYPE="JOURNAL_ARTICLE">
<AU>Anter E, Callans DJ, Wyse DG</AU>
<TI>Pharmacological and electrical conversion of atrial fibrillation to sinus rhythm is worth the effort</TI>
<SO>Circulation</SO>
<YR>2009 Oct 6</YR>
<VL>120</VL>
<NO>14</NO>
<PG>1436-43</PG>
<IDENTIFIERS MODIFIED="2012-03-16 15:24:56 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-16 15:24:56 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19805660"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Benjamin-1998" MODIFIED="2008-09-08 15:29:04 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Benjamin 1998" TYPE="JOURNAL_ARTICLE">
<AU>Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D</AU>
<TI>Impact of atrial fibrillation on the risk of death: the Framingham Heart Study</TI>
<SO>Circulation</SO>
<YR>1998</YR>
<VL>98</VL>
<NO>10</NO>
<PG>946-52</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 9737513"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0009-7322"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Caldeira-2012" MODIFIED="2015-03-17 10:53:34 +0000" MODIFIED_BY="[Empty name]" NAME="Caldeira 2012" TYPE="JOURNAL_ARTICLE">
<AU>Caldeira D, David C, Sampaio C</AU>
<TI>Rate versus rhythm control in atrial fibrillation and clinical outcomes: updated systematic review and meta-analysis of randomized controlled trials</TI>
<SO>Archives of Cardiovascular Diseases</SO>
<YR>2012</YR>
<VL>105</VL>
<NO>4</NO>
<PG>226-38</PG>
<IDENTIFIERS MODIFIED="2014-07-22 09:38:50 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-07-22 09:38:50 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/j.acvd.2011.11.005"/>
<IDENTIFIER MODIFIED="2014-07-22 09:38:18 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="22633297"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-CAST-1991" MODIFIED="2008-09-08 15:29:04 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="CAST 1991" TYPE="JOURNAL_ARTICLE">
<AU>Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al</AU>
<TI>Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial</TI>
<SO>New England Journal of Medicine</SO>
<YR>1991</YR>
<VL>324</VL>
<PG>781-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PMID: 1900101"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chatterjee-2013" MODIFIED="2015-03-17 10:54:04 +0000" MODIFIED_BY="[Empty name]" NAME="Chatterjee 2013" TYPE="JOURNAL_ARTICLE">
<AU>Chatterjee S, Sardar P, Lichstein E, Mukherjee D, Aikat S</AU>
<TI>Pharmacologic rate versus rhythm-control strategies in atrial fibrillation: an updated comprehensive review and meta-analysis</TI>
<SO>Pacing and Clinical Electrophysiology: PACE</SO>
<YR>2013</YR>
<VL>36</VL>
<NO>1</NO>
<PG>122-33</PG>
<IDENTIFIERS MODIFIED="2014-07-22 09:45:41 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-07-22 09:45:41 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1111/j.1540-8159.2012.03513.x"/>
<IDENTIFIER MODIFIED="2014-07-22 09:45:22 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="22978656"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chen-2012" MODIFIED="2014-11-27 11:07:56 +0000" MODIFIED_BY="[Empty name]" NAME="Chen 2012" TYPE="COCHRANE_REVIEW">
<AU>Chen HS, Wen JM, Wu SN, Liu JP</AU>
<TI>Catheter ablation for paroxysmal and persistent atrial fibrillation</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2014-09-25 15:47:28 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-09-25 15:47:28 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD007101.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chugh-2014" MODIFIED="2015-03-02 14:41:53 +0000" MODIFIED_BY="[Empty name]" NAME="Chugh 2014" TYPE="JOURNAL_ARTICLE">
<AU>Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al</AU>
<TI>Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study</TI>
<SO>Circulation</SO>
<YR>2014</YR>
<VL>129</VL>
<NO>8</NO>
<PG>837-47</PG>
<IDENTIFIERS MODIFIED="2014-09-24 10:27:34 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-09-24 10:27:34 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1161/CIRCULATIONAHA.113.005119"/>
<IDENTIFIER MODIFIED="2014-09-24 10:27:21 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="24345399"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Connolly-2000" MODIFIED="2008-09-08 15:29:04 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Connolly 2000" TYPE="JOURNAL_ARTICLE">
<AU>Connolly SJ</AU>
<TI>Appropriate outcome measures in trials evaluating treatment of atrial fibrillation</TI>
<SO>American Heart Journal</SO>
<YR>2000</YR>
<VL>139</VL>
<PG>752-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PMID: 10783204"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Coplen-1990" MODIFIED="2008-09-08 15:29:04 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Coplen 1990" TYPE="JOURNAL_ARTICLE">
<AU>Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC</AU>
<TI>Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials</TI>
<SO>Circulation</SO>
<YR>1990</YR>
<VL>82</VL>
<PG>1106-16</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PMID: 2144796"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cordina-2005" MODIFIED="2008-09-08 15:29:04 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Cordina 2005" TYPE="COCHRANE_REVIEW">
<AU>Cordina J, Mead G</AU>
<TI>Pharmacological cardioversion for atrial fibrillation and flutter</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>2</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD003713.pub2"/>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID 15846675"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Denus-2005" MODIFIED="2015-03-17 10:55:32 +0000" MODIFIED_BY="[Empty name]" NAME="Denus 2005" TYPE="JOURNAL_ARTICLE">
<AU>de Denus S, Sanoski CA, Carlsson J, Opolski G, Spinler SA</AU>
<TI>Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2005</YR>
<VL>165</VL>
<NO>3</NO>
<PG>258-62</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 15710787"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0003-9926"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Flaker-1995" MODIFIED="2008-09-08 15:29:04 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Flaker 1995" TYPE="JOURNAL_ARTICLE">
<AU>Flaker GC, Fletcher KA, Rothbart RM, Halperin JL, Hart RG: Stroke Prevention in Atrial Fibrillation (SPAF) Investigators</AU>
<TI>Clinical and echocardiographic features of intermittent atrial fibrillation that predict recurrent atrial fibrillation</TI>
<SO>American Journal of Cardiology</SO>
<YR>1995</YR>
<VL>76</VL>
<PG>355-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PMID: 7639159"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Freemantle-2011" MODIFIED="2015-03-02 14:42:05 +0000" MODIFIED_BY="[Empty name]" NAME="Freemantle 2011" TYPE="JOURNAL_ARTICLE">
<AU>Freemantle N, Lafuente-Lafuente C, Mitchell S, Eckert L, Reynolds M</AU>
<TI>Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide and propafenone, for the management of atrial fibrillation</TI>
<SO>Europace</SO>
<YR>2011</YR>
<VL>13</VL>
<NO>3</NO>
<PG>329-45</PG>
<IDENTIFIERS MODIFIED="2011-02-21 14:28:14 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-02-21 14:28:14 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21227948"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Frick-2001" MODIFIED="2008-09-08 15:29:04 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Frick 2001" TYPE="JOURNAL_ARTICLE">
<AU>Frick M, Frykman V, Jensen-Urstad M, Ostergren J, Rosenqvist M</AU>
<TI>Factors predicting success rate and recurrence of atrial fibrillation after first electrical cardioversion in patients with persistent atrial fibrillation</TI>
<SO>Clinical Cardiology</SO>
<YR>2001</YR>
<VL>24</VL>
<PG>238-44</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PMID: 11288971"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Friedman-1998" MODIFIED="2015-03-17 10:56:43 +0000" MODIFIED_BY="[Empty name]" NAME="Friedman 1998" TYPE="JOURNAL_ARTICLE">
<AU>Friedman PL, Stevenson WG</AU>
<TI>Proarrhythmia</TI>
<SO>American Journal of Cardiology</SO>
<YR>1998</YR>
<VL>82</VL>
<NO>8A</NO>
<PG>50N-8N</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 9809901"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0002-9149"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gelder-1996" MODIFIED="2015-03-17 10:57:01 +0000" MODIFIED_BY="[Empty name]" NAME="Gelder 1996" TYPE="JOURNAL_ARTICLE">
<AU>Van Gelder IC, Crijns HJ, Tieleman RG, Brugemann J, De Kam PJ, Gosselink AT, et al</AU>
<TI>Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1996</YR>
<VL>156</VL>
<PG>2585-92</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PMID: 8951302"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Geleris-2001" MODIFIED="2008-09-08 15:29:04 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Geleris 2001" TYPE="JOURNAL_ARTICLE">
<AU>Geleris P, Stavrati A, Afthonidis D, Kirpizidis H, Boudoulas H</AU>
<TI>Spontaneous conversion to sinus rhythm of recent (within 24 hours) atrial fibrillation</TI>
<SO>Journal of Cardiology</SO>
<YR>2001</YR>
<VL>37</VL>
<PG>103-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PMID: 11255692"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Go-2001" MODIFIED="2015-03-17 10:57:26 +0000" MODIFIED_BY="[Empty name]" NAME="Go 2001" TYPE="JOURNAL_ARTICLE">
<AU>Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al</AU>
<TI>Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>285</VL>
<PG>2370-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PMID: 11343485"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Golzari-1996" MODIFIED="2008-09-08 15:29:04 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Golzari 1996" TYPE="JOURNAL_ARTICLE">
<AU>Golzari H, Cebul RD, Bahler RC</AU>
<TI>Atrial fibrillation: restoration and maintenance of sinus rhythm and indications for anticoagulation therapy</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1996</YR>
<VL>125</VL>
<PG>311-23</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PMID: 8678396"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Harris-1983" MODIFIED="2008-09-08 15:29:04 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Harris 1983" TYPE="JOURNAL_ARTICLE">
<AU>Harris L, McKenna WJ, Roxland E, Holt DW, Storey GC, Krikler DM</AU>
<TI>Side effects of long-term amiodarone therapy</TI>
<SO>Circulation</SO>
<YR>1983</YR>
<VL>67</VL>
<NO>1</NO>
<PG>45-51</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 6291807"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0009-7322"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ha_x00ef_ssaguerre-1998" MODIFIED="2015-03-17 10:58:03 +0000" MODIFIED_BY="[Empty name]" NAME="Haïssaguerre 1998" TYPE="JOURNAL_ARTICLE">
<AU>Garrigue S, Bordier P, Jaïs P, Shah DC, Hocini M, Raherison C, et al</AU>
<TI>Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998 Sep 3</YR>
<VL>339</VL>
<NO>10</NO>
<PG>659-66</PG>
<IDENTIFIERS MODIFIED="2011-02-21 10:48:20 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-02-21 10:48:20 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="9725923"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Heeringa-2006" MODIFIED="2015-03-17 10:58:31 +0000" MODIFIED_BY="[Empty name]" NAME="Heeringa 2006" TYPE="JOURNAL_ARTICLE">
<AU>Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, et al</AU>
<TI>Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study</TI>
<SO>European Heart Journal</SO>
<YR>2006 Apr 27</YR>
<VL>27</VL>
<NO>8</NO>
<PG>949&#8211;53</PG>
<IDENTIFIERS MODIFIED="2011-01-26 10:53:24 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-01-26 10:53:24 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16527828"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-03-29 16:55:16 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<TI>Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</TI>
<SO>The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Knuiman-2014" MODIFIED="2015-03-02 14:42:22 +0000" MODIFIED_BY="[Empty name]" NAME="Knuiman 2014" TYPE="JOURNAL_ARTICLE">
<AU>Knuiman M, Briffa T, Divitini M, Chew D, Eikelboom J, McQuillan B, et al</AU>
<TI>A cohort study examination of established and emerging risk factors for atrial fibrillation: the Busselton Health Study</TI>
<SO>European Journal of Epidemiology</SO>
<YR>2014 Mar</YR>
<VL>29</VL>
<NO>3</NO>
<PG>181-90</PG>
<IDENTIFIERS MODIFIED="2014-09-24 10:31:10 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-09-24 10:31:10 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1007/s10654-013-9875-y"/>
<IDENTIFIER MODIFIED="2014-09-24 10:30:58 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="24389686"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Krahn-1995" MODIFIED="2008-09-08 15:29:04 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Krahn 1995" TYPE="JOURNAL_ARTICLE">
<AU>Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE</AU>
<TI>The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study</TI>
<SO>American Journal of Medicine</SO>
<YR>1995</YR>
<VL>98</VL>
<PG>476-84</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PMID: 7733127"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lafuente_x002d_Lafuente-2009" MODIFIED="2015-03-17 10:59:44 +0000" MODIFIED_BY="[Empty name]" NAME="Lafuente-Lafuente 2009" TYPE="JOURNAL_ARTICLE">
<AU>Lafuente-Lafuente C, Alvarez JC, Leenhardt A, Mouly S, Extramiana F, Caulin C, et al</AU>
<TI>Amiodarone concentrations in plasma and fat tissue during chronic treatment and related toxicity</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>2009 May</YR>
<VL>67</VL>
<NO>5</NO>
<PG>511-9</PG>
<IDENTIFIERS MODIFIED="2011-02-21 14:34:32 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-02-21 14:34:32 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19552745"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Miller-2000" MODIFIED="2008-09-08 15:29:04 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Miller 2000" TYPE="JOURNAL_ARTICLE">
<AU>Miller MR, McNamara RL, Segal JB, Kim N, Robinson KA, Goodman SN, et al</AU>
<TI>Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials</TI>
<SO>Journal of Family Practice</SO>
<YR>2000</YR>
<VL>49</VL>
<PG>1033-46</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PMID: 11093570"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-MMWR-2003" MODIFIED="2008-09-08 15:29:04 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="MMWR 2003" TYPE="JOURNAL_ARTICLE">
<AU>Ayala C, Wattigney WA, Croft JB, Hyduk A, Mensah GA, Davis H</AU>
<TI>Atrial fibrillation as a contributing cause of death and Medicare hospitalization -- United States, 1999</TI>
<SO>MMWR Morbidity and Mortality Weekly Report MMWR: Morbidity and Mortality Weekly Report</SO>
<YR>2003</YR>
<VL>52</VL>
<NO>7</NO>
<PG>128-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PMID: 12617537"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-NICE-2014" MODIFIED="2015-03-02 14:42:35 +0000" MODIFIED_BY="[Empty name]" NAME="NICE 2014" TYPE="OTHER">
<AU>UK National Institute for Health and Clinical Excellence</AU>
<TI>Atrial fibrillation: the management of atrial fibrillation. (Clinical guideline 180)</TI>
<SO>http://guidance.nice.org.uk/CG180 (Accessed 17 June 2014)</SO>
<YR>2014</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nichol-2002" MODIFIED="2008-09-08 15:29:04 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Nichol 2002" TYPE="JOURNAL_ARTICLE">
<AU>Nichol G, McAlister F, Pham B, Laupacis A, Shea B, Green M, et al</AU>
<TI>Meta-analysis of randomised controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation</TI>
<SO>Heart</SO>
<YR>2002</YR>
<VL>87</VL>
<PG>535-43</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PMID: 12010934"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Oral-2006" MODIFIED="2008-09-08 15:29:04 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Oral 2006" TYPE="JOURNAL_ARTICLE">
<AU>Oral H, Pappone C, Chugh A, Good E, Bogun F, et al</AU>
<TI>Circumferential pulmonary-vein ablation for chronic atrial fibrillation</TI>
<SO>New England Journal of Medicine</SO>
<YR>2006</YR>
<VL>354</VL>
<NO>9</NO>
<PG>934-41</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 16510747"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0028-4793"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-PRISMA-2009" MODIFIED="2011-01-27 14:36:04 +0000" MODIFIED_BY="[Empty name]" NAME="PRISMA 2009" TYPE="JOURNAL_ARTICLE">
<AU>PRISMA Group; Moher D, Liberati A, Tetzlaff J, Altman DG</AU>
<TI>Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement</TI>
<SO>PLoS Medicine</SO>
<YR>2009 Jul 21</YR>
<VL>6</VL>
<NO>7</NO>
<PG>e1000097</PG>
<IDENTIFIERS MODIFIED="2011-01-27 14:36:04 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-01-27 14:35:41 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19621072"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ruigomez-2002" MODIFIED="2008-09-08 15:29:04 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Ruigomez 2002" TYPE="JOURNAL_ARTICLE">
<AU>Ruigomez A, Johansson S, Wallander MA, Rodriguez LA</AU>
<TI>Incidence of chronic atrial fibrillation in general practice and its treatment pattern</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2002</YR>
<VL>55</VL>
<PG>358-63</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PMID: 11927203"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-SPAF-1992" MODIFIED="2008-09-08 15:29:04 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="SPAF 1992" TYPE="JOURNAL_ARTICLE">
<AU>Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG</AU>
<TI>Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1992</YR>
<VL>20</VL>
<PG>527-32</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PMID: 1512329"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Stewart-2002" MODIFIED="2008-09-08 15:29:04 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Stewart 2002" TYPE="JOURNAL_ARTICLE">
<AU>Stewart S, Hart CL, Hole DJ, McMurray JJ</AU>
<TI>A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study</TI>
<SO>American Journal of Medicine</SO>
<YR>2002</YR>
<VL>113</VL>
<PG>359-64</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PMID: 12401529"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Terasawa-2009" MODIFIED="2015-03-17 11:01:40 +0000" MODIFIED_BY="[Empty name]" NAME="Terasawa 2009" TYPE="JOURNAL_ARTICLE">
<AU>Terasawa T, Balk EM, Chung M, Garlitski AC, Alsheikh-Ali AA, Lau J, Ip S</AU>
<TI>Systematic review: Comparative effectiveness of radiofrequency catheter ablation for atrial fibrillation</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2009 Aug 4</YR>
<VL>15</VL>
<NO>3</NO>
<PG>191-202</PG>
<IDENTIFIERS MODIFIED="2011-02-22 10:20:24 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-02-22 10:20:24 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19581635"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Testa-2005" MODIFIED="2008-09-08 15:29:04 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Testa 2005" TYPE="JOURNAL_ARTICLE">
<AU>Testa L, Biondi-Zoccai GG, Russo AD, Bellocci F, Andreotti F, Crea F</AU>
<TI>Rate-control vs rhythm-control in patients with atrial fibrillation: a meta-analysis</TI>
<SO>European Heart Journal</SO>
<YR>2005</YR>
<VL>26</VL>
<NO>19</NO>
<PG>2000-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID 15872032"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0195-668X"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vaughan-Williams-1984" MODIFIED="2015-03-17 11:02:07 +0000" MODIFIED_BY="[Empty name]" NAME="Vaughan Williams 1984" TYPE="JOURNAL_ARTICLE">
<AU>Vaughan Williams EM</AU>
<TI>A classification of antiarrhythmic actions reassessed after a decade of new drugs</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1984</YR>
<VL>24</VL>
<NO>4</NO>
<PG>129-47</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 6144698"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0091-2700"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wattigney-2003" MODIFIED="2008-09-08 15:29:04 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Wattigney 2003" TYPE="JOURNAL_ARTICLE">
<AU>Wattigney WA, Mensah GA, Croft JB</AU>
<TI>Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention</TI>
<SO>Circulation</SO>
<YR>2003</YR>
<VL>108</VL>
<PG>711-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PMID: 12885749"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wazni-2005" MODIFIED="2015-03-17 11:02:46 +0000" MODIFIED_BY="[Empty name]" NAME="Wazni 2005" TYPE="JOURNAL_ARTICLE">
<AU>Wazni OM, Marrouche NF, Martin DO, Verma A, Bhargava M, et al</AU>
<TI>Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial</TI>
<SO>JAMA</SO>
<YR>2005</YR>
<VL>293</VL>
<NO>21</NO>
<PG>2634 -40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 15928285"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0098-7484"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2015-03-02 14:50:53 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Lafuente_x002d_Lafuente" NAME="Lafuente-Lafuente" TYPE="JOURNAL_ARTICLE">
<AU>Lafuente-Lafuente C, Mouly S, Longás-Tejero MA, Mahé I, Bergmann JF</AU>
<TI>Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomised controlled trials</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2006</YR>
<VL>166</VL>
<NO>7</NO>
<PG>719-28</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 16606807"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 0003-9926"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lafuente_x002d_Lafuente-2012" MODIFIED="2015-03-02 14:50:53 +0000" MODIFIED_BY="[Empty name]" NAME="Lafuente-Lafuente 2012" TYPE="COCHRANE_REVIEW">
<AU>Lafuente-Lafuente C, Longas-Tejero MA, Bergmann JF, Belmin J</AU>
<TI>Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>5</NO>
<IDENTIFIERS MODIFIED="2015-03-02 14:50:53 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-03-02 14:50:53 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005049.pub3"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-03-17 12:34:01 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-03-17 12:34:01 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2015-03-17 11:26:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-A_x002d_COMET_x002d_I-2006">
<CHAR_METHODS MODIFIED="2015-03-17 11:25:51 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Double-blind<BR/>Loss to follow up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 11:26:37 +0000" MODIFIED_BY="[Empty name]">
<P>Symptomatic AF in the previous 6 months. Type: recent onset 28%, persistent 72% (mean duration: NS). N = 446<BR/>Male: 78%. Age (mean, SD): 65 ± 10<BR/>Structural heart disease: 70%. LAD: NS. LVEF: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 11:26:58 +0000" MODIFIED_BY="[Empty name]">
<P>Azimilide 250 mg/d versus placebo<BR/>Method of AF cardioversion: both pharmacological and electrical, % NS<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-29 13:46:48 +0100" MODIFIED_BY="[Empty name]">
<P>At 6 months:<BR/>Mortality<BR/>Pro-arrhythmia<BR/>Adverse effects<BR/>AF recurrence<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 11:28:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006">
<CHAR_METHODS MODIFIED="2015-03-17 11:28:52 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Double-blind<BR/>Loss to follow up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 11:27:45 +0000" MODIFIED_BY="[Empty name]">
<P>Symptomatic AF, persistent for more than 48 hours, less than 6 months duration. N = 658<BR/>Male: 66%. Age (mean, SD): 62 ± 9<BR/>Structural heart disease: 73%. LAD: enlarged in 72%. LVEF: reduced (&lt; 40%) in 10% of patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 11:28:23 +0000" MODIFIED_BY="[Empty name]">
<P>Azimilide 125 mg/d versus sotalol 320 mg/d versus placebo<BR/>Method of AF cardioversion: 6% pharmacological, 94% electrical<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-27 16:22:49 +0100" MODIFIED_BY="[Empty name]">
<P>At 6 months:<BR/>Mortality<BR/>Pro-arrhythmia<BR/>Adverse effects<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 11:30:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-A_x002d_STAR-2006">
<CHAR_METHODS MODIFIED="2015-03-17 11:28:42 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Double-blind<BR/>Loss to follow up reported: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 11:29:59 +0000" MODIFIED_BY="[Empty name]">
<P>Symptomatic AF in the previous 6 months<BR/>Type: paroxysmal or recent onset 95%, persistent 5% (mean duration: NS). N = 431<BR/>Male: 62%. Age (mean, SD): 62 ± 10<BR/>Structural heart disease: 69%. LAD: NS. LVEF: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 11:30:27 +0000" MODIFIED_BY="[Empty name]">
<P>Azimilide 125 mg/d versus placebo<BR/>Method of AF cardioversion: 100% spontaneous or pharmacological<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-29 13:57:51 +0100" MODIFIED_BY="[Empty name]">
<P>At 6 months:<BR/>Mortality<BR/>Adverse effects<BR/>Pro-arrhythmia<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 11:32:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-AFFIRM-Substudy-2003">
<CHAR_METHODS MODIFIED="2015-03-17 11:30:46 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Open-label<BR/>Loss to follow up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 11:31:37 +0000" MODIFIED_BY="[Empty name]">
<P>AF likely to be recurrent and to cause illness or death. Type: paroxysmal or recent onset 29%, persistent 71% (mean duration: NS). N = 410<BR/>Male: 63%. Age (mean, SD): 69 ± 8<BR/>Structural heart disease: 85%. LAD: enlarged in 71%. LVEF: 55%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 11:32:08 +0000" MODIFIED_BY="[Empty name]">
<P>Amiodarone 200 mg/d versus class I drugs versus sotalol 240 mg/d<BR/>Method of AF cardioversion: both pharmacological and electrical, % NS<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>At 3.8 years: <BR/>Mortality<BR/>At 12 months: <BR/>Pro-arrhythmia<BR/>Adverse effects<BR/>AF recurrence<BR/>Symptomatic recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 11:33:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-AFIB-1997">
<CHAR_METHODS MODIFIED="2015-03-17 11:32:39 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Open-label<BR/>Loss to follow up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 11:33:22 +0000" MODIFIED_BY="[Empty name]">
<P>Previous AF documented in the last 2 years. Type: NS. N = 1227<BR/>Male: 62%. Age (mean, SD): 63 ± 13<BR/>Structural heart disease: 67%. LAD: NS. LVEF: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 11:33:34 +0000" MODIFIED_BY="[Empty name]">
<P>Bidisomide various doses (400, 800, 1200 mg/d) versus placebo<BR/>Method of AF cardioversion: pharmacological 70%, electrical 30%<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-12-15 15:31:27 +0000" MODIFIED_BY="[Empty name]">
<P>At 6 months: </P>
<P>Mortality<BR/>AF recurrence<BR/>Symptomatic recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 11:35:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aliot-1996">
<CHAR_METHODS MODIFIED="2015-03-17 11:33:55 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Open-label<BR/>Loss to follow up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 11:34:28 +0000" MODIFIED_BY="[Empty name]">
<P>Paroxysmal AF documented any time before (70% in last 1 year). N = 97<BR/>Male: 53%. Age (mean, SD): 63 ± 12<BR/>Structural heart disease: 45%. LAD: NS. LVEF: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 11:35:04 +0000" MODIFIED_BY="[Empty name]">
<P>Flecainide 100 to 200 mg/d versus propafenone 600 mg/d<BR/>Method of AF cardioversion: pharmacological<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>At 12 months: <BR/>Mortality<BR/>Stroke<BR/>Pro-arrhythmia<BR/>Adverse effects<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 11:36:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ASAP-2003">
<CHAR_METHODS>
<P>RCT<BR/>Double-blind<BR/>Loss to follow-up reported: no<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 11:36:31 +0000" MODIFIED_BY="[Empty name]">
<P>Previous AF documented in the last 2 years. Type: NS. N = 1380 (4 sub-studies)<BR/>Male: 66%. Age (mean, SD): 63 ± 13<BR/>Structural heart disease: 73%. LAD: NS. LVEF: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 11:36:48 +0000" MODIFIED_BY="[Empty name]">
<P>Azimilide various doses (35 to 125 mg/d) versus placebo<BR/>Method of AF cardioversion: pharmacological 65%, electrical 35%<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-02-04 15:09:59 +0000" MODIFIED_BY="[Empty name]">
<P>At 6 months:<BR/>Mortality<BR/>Pro-arrhythmia<BR/>Adverse effects<BR/>Time to AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 11:38:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ATHENA-2009">
<CHAR_METHODS MODIFIED="2015-03-17 11:37:11 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Double-blind<BR/>Loss to follow up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 11:37:59 +0000" MODIFIED_BY="[Empty name]">
<P>Non-permanent AF with high risk of recurrence<BR/>Type: all types, % NS. N = 4628<BR/>Male: 53%. Age (mean, SD): 72 ± 9<BR/>Structural heart disease: 57%. LAD: NS. LVEF: reduced (&lt; 45%) in 12%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 11:38:09 +0000" MODIFIED_BY="[Empty name]">
<P>Dronedarone 800 mg/d versus placebo<BR/>Method of AF cardioversion: both pharmacological and electrical, % NS<BR/>Warfarin discretionary, 60% patients in both groups</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-24 15:10:58 +0100" MODIFIED_BY="[Empty name]">
<P>At 22 months:<BR/>Mortality<BR/>Pro-arrhythmia<BR/>Adverse effects<BR/>Stroke<BR/>Hospitalizations due to cardiovascular events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 11:39:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bellandi-2001">
<CHAR_METHODS>
<P>RCT<BR/>Double-blind<BR/>Loss to follow-up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 11:39:04 +0000" MODIFIED_BY="[Empty name]">
<P>Paroxysmal recurrent AF (47%), or persistent AF (53%, mean duration: NS). N = 194<BR/>Male: 56%. Age (mean, range): 52, 20 to 75<BR/>Structural heart disease: 72%. LAD: 42 mm. LVEF: 55%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 11:39:18 +0000" MODIFIED_BY="[Empty name]">
<P>Propafenone 900 mg/d versus sotalol 240 mg/d versus placebo<BR/>Method of AF cardioversion: pharmacological 89%, electrical 11%<BR/>Warfarin discretionary.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>At 12 months: <BR/>Mortality<BR/>Pro-arrhythmia<BR/>Adverse effects<BR/>AF recurrence<BR/>Symptomatic recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 12:27:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Benditt-1999">
<CHAR_METHODS MODIFIED="2015-03-17 12:27:03 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Double-blind<BR/>Loss to follow up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 11:40:05 +0000" MODIFIED_BY="[Empty name]">
<P>AF or AFl documented in the last 3 months. Type: paroxysmal or recent onset 77%, persistent 23% (mean duration: NS). N = 253<BR/>Male: 64%. Age (mean, range): 62, 24 to 86<BR/>Structural heart disease: 57%. LAD: NS (enlarged in 28%). LVEF: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 11:40:13 +0000" MODIFIED_BY="[Empty name]">
<P>Sotalol various doses (80, 120, 160 mg/d) versus placebo<BR/>Method of AF cardioversion: NS<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>At 12 months: <BR/>Mortality<BR/>Stroke<BR/>Pro-arrhythmia<BR/>Adverse effects<BR/>AF recurrence<BR/>Symptomatic recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 11:40:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Byrne_x002d_Quinn-1970">
<CHAR_METHODS MODIFIED="2015-03-17 11:40:36 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Double-blind<BR/>Loss to follow up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 11:40:45 +0000" MODIFIED_BY="[Empty name]">
<P>Persistent AF (mean duration: 12 months). N = 74<BR/>Male: 53%. Age (mean, range): 54, 30 to 70<BR/>Structural heart disease: 80%. LAD: NS. LVEF: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 11:40:55 +0000" MODIFIED_BY="[Empty name]">
<P>Quinidine 1.2 g/d versus placebo<BR/>Method of AF cardioversion: electrical<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>At 12 months: <BR/>Mortality<BR/>Pro-arrhythmia<BR/>Adverse effects<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 11:41:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carunchio-1995">
<CHAR_METHODS MODIFIED="2015-03-17 11:41:13 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Open-label<BR/>Loss to follow up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 11:41:23 +0000" MODIFIED_BY="[Empty name]">
<P>Recurrent AF (type: NS) with &gt; 3 episodes in previous 1 year. NS. N = 66<BR/>Male: 50%. Age (mean, range): 48, 30 to 69<BR/>Structural heart disease: 65%. LAD: 36 mm. LVEF: NS, all &gt; 40%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 11:41:41 +0000" MODIFIED_BY="[Empty name]">
<P>Flecainide 200 mg/d versus sotalol 240 mg/d versus placebo<BR/>Method of AF cardioversion: pharmacological 67%, electrical 33%<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>At 12 months: <BR/>Mortality<BR/>Stroke<BR/>Pro-arrhythmia<BR/>Adverse effects<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 11:42:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Channer-2004">
<CHAR_METHODS MODIFIED="2015-03-17 11:42:01 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Double-blind<BR/>Loss to follow up reported: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 11:42:22 +0000" MODIFIED_BY="[Empty name]">
<P>Persistent AF (mean duration: 6 months)<BR/>N = 99<BR/>Male: 78%. Age (mean, SD): 67 ± 10<BR/>Structural heart disease: NS. LAD: 44 mm. LVEF: 58%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 11:42:32 +0000" MODIFIED_BY="[Empty name]">
<P>Amiodarone 200 mg/d versus placebo<BR/>Method of AF cardioversion: pharmacological 20%, electrical 80%<BR/>Warfarin mandatory</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>At 12 months: <BR/>Mortality<BR/>Pro-arrhythmia<BR/>Adverse effects<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 11:43:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-DAFNE-2003">
<CHAR_METHODS MODIFIED="2015-03-17 11:42:53 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Double-blind<BR/>Loss to follow up reported: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Persistent AF (mean duration: 3 months)<BR/>N = 199<BR/>Male: 70%. Age (mean): 63<BR/>Structural heart disease: NS. LAD: 45 mm. LVEF: 55%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 11:43:06 +0000" MODIFIED_BY="[Empty name]">
<P>Dronedarone various doses (800, 1200, 1600 mg/d) versus placebo<BR/>Method of AF cardioversion: pharmacological 15%, electrical 85%<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>At 6 months: <BR/>Mortality<BR/>Pro-arrhythmia<BR/>Adverse effects<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 12:28:07 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-DAPHNE-2008">
<CHAR_METHODS MODIFIED="2015-03-17 11:43:23 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Single-blind<BR/>Loss to follow up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 12:28:07 +0000" MODIFIED_BY="[Empty name]">
<P>Bradycardia-tachycardia sinus node disease with history of several episodes of AF or AFl and needing a pacemaker<BR/>AF type: 100% paroxysmal. N = 135<BR/>Male: 49,6%. Age (mean, SD): 73 ± 7<BR/>Structural heart disease: 71%. LAD: 43 mm. LVEF: 56%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 11:44:21 +0000" MODIFIED_BY="[Empty name]">
<P>Sotalol 167 mg/d (mean) versus beta-blockers (atenolol or metoprolol)<BR/>Method of AF cardioversion: 100% spontaneous<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-29 14:49:05 +0100" MODIFIED_BY="[Empty name]">
<P>At 19 months:<BR/>Adverse effects<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 11:45:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-DIAMOND-2001">
<CHAR_METHODS MODIFIED="2015-03-17 11:44:44 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Double-blind<BR/>Loss to follow up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 11:44:53 +0000" MODIFIED_BY="[Empty name]">
<P>Persistent AF (mean duration: NS) in patients with heart failure or recent myocardial infarction and reduced LVEF. N = 506<BR/>Male: 77%. Age (mean, range): 72, 36 to 92<BR/>Structural heart disease: 100%. LAD: NS. LVEF: NS, all &lt; 35%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 11:45:17 +0000" MODIFIED_BY="[Empty name]">
<P>Dofetilide 500 µg/d versus placebo<BR/>Method of AF cardioversion: pharmacological 44%, electrical 15%<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-24 14:52:39 +0100" MODIFIED_BY="[Empty name]">
<P>At 12 and 24 months:<BR/>Mortality<BR/>Pro-arrhythmia<BR/>Heart failure<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 11:46:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dogan-2004">
<CHAR_METHODS MODIFIED="2015-03-17 11:45:36 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Single-blind<BR/>Loss to follow up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 11:46:02 +0000" MODIFIED_BY="[Empty name]">
<P>AF of duration 3 hours to 3 months: recent onset 71%, persistent 29% (mean duration: 0.5 months). N = 110<BR/>Male: 45%. Age (mean, SD): 61 ± 12<BR/>Structural heart disease: 79%. LAD: 44 mm. LVEF: 64%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 11:46:11 +0000" MODIFIED_BY="[Empty name]">
<P>Propafenone 450 mg/d versus placebo<BR/>Method of AF cardioversion: spontaneous 42%, pharmacological 31%, electrical 27%<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>At 15 months: <BR/>Mortality<BR/>Pro-arrhythmia<BR/>Adverse effects<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 11:47:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-DYONISOS-2010">
<CHAR_METHODS MODIFIED="2015-03-17 11:46:29 +0000" MODIFIED_BY="[Empty name]">
<P>RCT.<BR/>Double-blind.<BR/>Loss to follow up reported: yes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 11:47:03 +0000" MODIFIED_BY="[Empty name]">
<P>Documented AF for more than 72 hours<BR/>Type: 5% paroxysmal, 22% recent onset, 63% persistent (mean duration: 1.5 months). N = 504<BR/>Male: 71%. Age (mean, SD): 64 ± 10<BR/>Structural heart disease: 29%. LAD: NS. LVEF: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 11:47:15 +0000" MODIFIED_BY="[Empty name]">
<P>Amiodarone 200 mg/d versus dronedarone 800 mg/d<BR/>Method of AF cardioversion: both pharmacological and electrical, % NS<BR/>Warfarin required</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-07 16:39:17 +0100" MODIFIED_BY="[Empty name]">
<P>At 12 months:<BR/>Mortality<BR/>Adverse effects<BR/>Pro-arrhythmia<BR/>AF recurrence<BR/>Heart failure</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 11:48:36 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-EMERALD-2000">
<CHAR_METHODS MODIFIED="2015-03-17 11:47:41 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Double-blind<BR/>Loss to follow up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 11:47:46 +0000" MODIFIED_BY="[Empty name]">
<P>Persistent AF (1 week to 1 year, mean duration &lt; 6 months). N = 535<BR/>Male: 70%. Age (mean, SD): 64, NS<BR/>Structural heart disease: NS. LAD: NS. LVEF: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 11:48:36 +0000" MODIFIED_BY="[Empty name]">
<P>Dofetilide 250, 500 or 1000 µg/d (3 different groups) versus sotalol 160 mg/d versus placebo<BR/>Method of AF cardioversion: 10% pharmacological, 90% electrical<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-29 17:27:46 +0100" MODIFIED_BY="[Empty name]">
<P>At 12 months:<BR/>Mortality<BR/>Adverse effects<BR/>Pro-arrhythmia<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 11:49:59 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-EURIDIS-ADONIS-2007">
<CHAR_METHODS MODIFIED="2015-03-17 11:48:57 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Double-blind<BR/>Loss to follow up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 11:49:51 +0000" MODIFIED_BY="[Empty name]">
<P>AF or AFl documented in the previous 3 months. Proportions of paroxysmal and persistent AF not reported. N = 1244</P>
<P>Male: 69%. Age (mean, SD): 63 ± 11</P>
<P>Structural heart disease: 41%. LAD: 42.5 mm. LVEF: 58%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 11:49:59 +0000" MODIFIED_BY="[Empty name]">
<P>Dronedarone 800 mg/d versus placebo<BR/>Method of AF cardioversion: any (frequencies of use not reported)<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-02-04 14:48:33 +0000" MODIFIED_BY="[Empty name]">
<P>At 12 months:<BR/>Mortality<BR/>Stroke<BR/>Pro-arrhythmia<BR/>Adverse effects<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 11:51:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-FAPIS-1996">
<CHAR_METHODS MODIFIED="2015-03-17 11:50:34 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Open-label<BR/>Loss to follow up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 11:50:54 +0000" MODIFIED_BY="[Empty name]">
<P>Paroxysmal recurrent AF with &gt; 2 episodes in the last 4 months. N = 200<BR/>Male: 54%. Age (mean, SD): 57 ± 10<BR/>Structural heart disease: 0%. LAD: 35 mm. LVEF: 61%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 11:51:05 +0000" MODIFIED_BY="[Empty name]">
<P>Flecainide 200 mg/d versus propafenone 520 mg/d<BR/>Method of AF cardioversion: pharmacological<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>At 12 months: <BR/>Mortality<BR/>Pro-arrhythmia<BR/>Adverse effects<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 11:51:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Flec_x002d_SL-2012">
<CHAR_METHODS MODIFIED="2015-03-17 11:51:24 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Open-label<BR/>Loss to follow up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 11:51:49 +0000" MODIFIED_BY="[Empty name]">
<P>Persistent AF with indication for cardioversion (mean duration: 20 months). N = 362<BR/>Male: 66%. Age (mean, SD): 64 ± 10<BR/>Structural heart disease: NS<BR/>LAD: 46 mm. LVEF: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 11:51:58 +0000" MODIFIED_BY="[Empty name]">
<P>Flecainide 200 to 300 mg/d versus no treatment<BR/>Method of AF cardioversion: pharmacological 20%, electrical 80%<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-24 09:29:28 +0100" MODIFIED_BY="[Empty name]">
<P>At 6 months:<BR/>Mortality<BR/>Pro-arrhythmia<BR/>Stroke, embolism<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-24 09:30:19 +0100" MODIFIED_BY="[Empty name]">
<P>A third group of patients randomised to flecainide for only 3 months was not included in the review</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 11:54:07 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-GEFACA-2001">
<CHAR_METHODS MODIFIED="2015-03-17 11:53:18 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Double-blind<BR/>Loss to follow up reported: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 11:54:02 +0000" MODIFIED_BY="[Empty name]">
<P>Persistent AF lasting &gt; 2 months (mean duration: 36 months). N = 50<BR/>Male: 73%. Age (mean, SD): 62 ± 7<BR/>Structural heart disease: 94%<BR/>LAD: 48 mm. LVEF: 60%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 11:54:07 +0000" MODIFIED_BY="[Empty name]">
<P>Amiodarone 200 mg/d versus placebo<BR/>Method of AF cardioversion: pharmacological 32%, electrical 68%<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>At 16 months: <BR/>Mortality <BR/>Pro-arrhythmia <BR/>Adverse effects <BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 11:54:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hillestad-1971">
<CHAR_METHODS MODIFIED="2015-03-17 11:54:28 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Open-label<BR/>Loss to follow up reported: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 11:54:36 +0000" MODIFIED_BY="[Empty name]">
<P>Persistent AF lasting 1 month to 2 years (mean duration: NS). N = 100<BR/>Male: 46%. Age (mean, range): 54, 22 to 77<BR/>Structural heart disease: 92%. LAD: NS. LVEF: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 11:54:55 +0000" MODIFIED_BY="[Empty name]">
<P>Quinidine 0.8 to 1.2 g/d versus no treatment<BR/>Method of AF cardioversion: electrical<BR/>Warfarin mandatory</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>At 12 months:<BR/>Mortality<BR/>Stroke<BR/>Pro-arrhythmia<BR/>Adverse effects<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 11:56:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hohnloser-1995">
<CHAR_METHODS MODIFIED="2015-03-17 11:55:12 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Open-label<BR/>Loss to follow up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 11:56:04 +0000" MODIFIED_BY="[Empty name]">
<P>Persistent AF between 2 days and 6 months (mean duration: 1.5 months). N = 50<BR/>Male: 36%. Age (mean, SD): 62 ± 11<BR/>Structural heart disease: 86%. LAD: 50 mm. LVEF: 51%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 11:56:15 +0000" MODIFIED_BY="[Empty name]">
<P>Quinidine 1 g/d versus sotalol 240 to 320 mg/d<BR/>Method of AF cardioversion: pharmacological 40%, electrical 60%<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>At 6 months: <BR/>Mortality<BR/>Pro-arrhythmia<BR/>Adverse effects<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 11:57:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Juul_x002d_Moller-1990">
<CHAR_METHODS MODIFIED="2015-03-17 11:56:35 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Open-label<BR/>Loss to follow up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 11:56:49 +0000" MODIFIED_BY="[Empty name]">
<P>Persistent AF between 2 months and 1 year (mean duration: 5 months). N = 183<BR/>Male: 81%. Age (mean, SD): 59 ± 9<BR/>Structural heart disease: NS. LAD: 42 mm. LVEF: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 11:57:18 +0000" MODIFIED_BY="[Empty name]">
<P>Quinidine 1.2 g/d versus sotalol 160 to 320 mg/d<BR/>Method of AF cardioversion: electrical<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>At 6 months: <BR/>Mortality<BR/>Stroke<BR/>Pro-arrhythmia<BR/>Adverse effects<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 11:58:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kalusche-1994">
<CHAR_METHODS MODIFIED="2015-03-17 11:57:36 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Open-label<BR/>Loss to follow up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 11:57:51 +0000" MODIFIED_BY="[Empty name]">
<P>AF lasting from 2 weeks to 2 years. Type: paroxysmal 32%, persistent 68% (mean duration: NS). N = 82<BR/>Male: 68%. Age (mean, SD): 61 ± 5<BR/>Structural heart disease: 68%. LAD: 45 mm. LVEF: 30%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 11:58:06 +0000" MODIFIED_BY="[Empty name]">
<P>Quinidine 1 g/d versus sotalol 240 to 400 mg/d<BR/>Method of AF cardioversion: pharmacological 47%, electrical 53%<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>At 12 months: <BR/>Mortality<BR/>Pro-arrhythmia<BR/>Adverse effects<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 11:58:42 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Karlson-1998">
<CHAR_METHODS MODIFIED="2015-03-17 11:58:27 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Double-blind<BR/>Loss to follow up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 11:58:35 +0000" MODIFIED_BY="[Empty name]">
<P>Persistent AF between 6 weeks and 1 year (mean duration: 5 months). N = 92<BR/>Male: 71%. Age (mean, range): 60, 31 to 72<BR/>Structural heart disease: 60%. LAD: NS. LVEF: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 11:58:42 +0000" MODIFIED_BY="[Empty name]">
<P>Disopyramide 500 mg/d versus placebo<BR/>Method of AF cardioversion: electrical<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>At 12 months: <BR/>Mortality<BR/>Stroke<BR/>Pro-arrhythmia<BR/>Adverse effects<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 11:59:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kochiadakis-2000">
<CHAR_METHODS MODIFIED="2015-03-17 11:58:56 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Single-blind<BR/>Loss to follow up reported: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 11:59:16 +0000" MODIFIED_BY="[Empty name]">
<P>Any documented symptomatic previous or persistent AF. Type: paroxysmal or recent onset 64%, persistent 34% (mean duration: 10 months). N = 186<BR/>Male: 52%. Age (mean, SD): 63 ± 9<BR/>Structural heart disease: 35%. LAD: 44 mm. LVEF: 53%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 11:59:27 +0000" MODIFIED_BY="[Empty name]">
<P>Amiodarone 200 mg/d versus sotalol 320 mg/d versus placebo<BR/>Method of AF cardioversion: both pharmacological and electrical, % NS<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>At 12 and 24 months: <BR/>Mortality<BR/>Pro-arrhythmia<BR/>Adverse effects<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 12:00:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kochiadakis-2004a">
<CHAR_METHODS MODIFIED="2015-03-17 11:59:43 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Single-blind<BR/>Loss to follow up reported: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 12:00:03 +0000" MODIFIED_BY="[Empty name]">
<P>Any documented symptomatic previous or persistent AF. Type: paroxysmal or recent onset 63%, persistent 37% (mean duration: 8 months). N = 146<BR/>Male: 49%. Age (mean, SD): 63 ± 9<BR/>Structural heart disease: 38%. LAD: 43 mm. LVEF: 53%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 12:00:10 +0000" MODIFIED_BY="[Empty name]">
<P>Amiodarone 200 mg/d versus propafenone 450 mg/d<BR/>Method of AF cardioversion: both pharmacological and electrical, % NS<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>At 12 and 24 months: <BR/>Mortality<BR/>Pro-arrhythmia<BR/>Adverse effects<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 12:00:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kochiadakis-2004b">
<CHAR_METHODS MODIFIED="2015-03-17 12:00:30 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Single-blind<BR/>Loss to follow up reported: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 12:00:48 +0000" MODIFIED_BY="[Empty name]">
<P>Any documented symptomatic previous or persistent AF. Type: paroxysmal or recent onset 59%, persistent 41% (mean duration: 8 months). N = 254<BR/>Male: 50%. Age (mean, SD): 63 ± 10<BR/>Structural heart disease: 41%. LAD: 44 mm. LVEF: 53%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 12:00:57 +0000" MODIFIED_BY="[Empty name]">
<P>Propafenone 450 mg/d versus sotalol 300 mg/d versus placebo<BR/>Method of AF cardioversion: both pharmacological and electrical, % NS<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>At 12 and 24 months: <BR/>Mortality<BR/>Pro-arrhythmia<BR/>Adverse effects<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 12:01:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kuhlkamp-2000">
<CHAR_METHODS MODIFIED="2015-03-17 12:01:14 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Double-blind<BR/>Loss to follow up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 12:01:20 +0000" MODIFIED_BY="[Empty name]">
<P>Persistent AF lasting 2 days to 1 year (mean duration: 3 months). N = 394<BR/>Male: 70%. Age (mean, range): 60, 24 to 86<BR/>Structural heart disease: 36%. LAD: 42 mm. LVEF: 64%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 12:01:27 +0000" MODIFIED_BY="[Empty name]">
<P>Metoprolol 100 mg/d versus placebo<BR/>Method of AF cardioversion: pharmacological 18%, electrical 82%<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>At 6 months: <BR/>Mortality<BR/>Pro-arrhythmia<BR/>Adverse effects<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 12:02:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lloyd-1984">
<CHAR_METHODS MODIFIED="2015-03-17 12:01:49 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Double-blind<BR/>Loss to follow up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 12:01:56 +0000" MODIFIED_BY="[Empty name]">
<P>Persistent AF lasting 1 month to 3 years (mean duration: NS). N = 82<BR/>Male: 38. Age (mean, range): 46, 15 to 79<BR/>Structural heart disease: 94%. LAD: NS. LVEF: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 12:02:06 +0000" MODIFIED_BY="[Empty name]">
<P>Disopyramide 450 mg/d versus quinidine 1.4 g/d versus placebo<BR/>Method of AF cardioversion: electrical<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>At 6 months: <BR/>Mortality<BR/>Stroke<BR/>Pro-arrhythmia<BR/>Adverse effects<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 12:02:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Naccarelli-1996">
<CHAR_METHODS MODIFIED="2015-03-17 12:02:24 +0000" MODIFIED_BY="[Empty name]">
<P>RCT.<BR/>Open-label.<BR/>Loss to follow up reported: no.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Any documented symptomatic AF. Type: paroxysmal 74%, persistent 26% (mean duration: 36 months). N = 239<BR/>Male: 38. Age (mean): 58<BR/>Structural heart disease: 83%. LAD: NS. LVEF: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 12:02:50 +0000" MODIFIED_BY="[Empty name]">
<P>Flecainide 200 to 300 mg/d versus quinidine 1 to 1.5 g/d<BR/>Method of AF cardioversion: pharmacological<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>At 12 months: <BR/>Mortality<BR/>Pro-arrhythmia<BR/>Adverse effects<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 12:03:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nergardh-2007">
<CHAR_METHODS MODIFIED="2015-03-17 12:03:07 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Double-blind<BR/>Loss to follow up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 12:03:29 +0000" MODIFIED_BY="[Empty name]">
<P>Persistent AF of less than 1 year (mean duration: 5 months). N = 168<BR/>Male: 71%. Age (mean, SD): 67 ± 11<BR/>Structural heart disease: NS. LAD: 45 mm. LVEF: 49%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 12:03:45 +0000" MODIFIED_BY="[Empty name]">
<P>Metoprolol 170 mg/d (mean) versus placebo<BR/>Method of AF cardioversion: 100% electrical<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-29 14:56:52 +0100" MODIFIED_BY="[Empty name]">
<P>At 6 months:<BR/>Mortality<BR/>Adverse effects<BR/>Pro-arrhythmia<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 12:04:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Niu-2006">
<CHAR_METHODS MODIFIED="2015-03-17 12:04:09 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Open-label<BR/>Loss to follow up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 12:04:44 +0000" MODIFIED_BY="[Empty name]">
<P>Any type of AF. Type: 41% paroxysmal, 59% persistent (mean duration: NS). N = 102<BR/>Male: 56%. Age (mean, SD): 56 ± 11<BR/>Structural heart disease: NS (coronary artery disease 33%, hypertension 25%). LAD: NS. LVEF: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 12:04:58 +0000" MODIFIED_BY="[Empty name]">
<P>Amiodarone 200 mg/d versus sotalol 40 to 80 mg/d<BR/>Method of AF cardioversion: pharmacological<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-22 16:05:28 +0100" MODIFIED_BY="[Empty name]">
<P>At 12 months:<BR/>Mortality<BR/>Adverse effects<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 12:05:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Okishige-2000">
<CHAR_METHODS MODIFIED="2015-03-17 12:05:19 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Single-blind<BR/>Loss to follow up reported: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 12:05:33 +0000" MODIFIED_BY="[Empty name]">
<P>Persistent AF lasting &gt; 6 months (mean duration: 22 months). N = 62<BR/>Male: 92%. Age (mean, SD): 51 ± 17<BR/>Structural heart disease: 61%. LAD: 41 mm. LVEF: 61%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 12:05:40 +0000" MODIFIED_BY="[Empty name]">
<P>Pilsicainide 150 mg/d versus placebo<BR/>Method of AF cardioversion: pharmacological 21%, electrical 79%<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>At 12 months: <BR/>Mortality<BR/>Pro-arrhythmia<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 12:06:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-PAFAC-2004">
<CHAR_METHODS MODIFIED="2015-03-17 12:05:57 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Double-blind<BR/>Loss to follow up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 12:06:08 +0000" MODIFIED_BY="[Empty name]">
<P>Persistent AF lasting &gt; 7 days (mean duration: 15 months). N = 848<BR/>Male: 66%. Age (mean, SD): 63 ± 9<BR/>Structural heart disease: NS. LAD: 45 mm. LVEF: 60%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 12:06:24 +0000" MODIFIED_BY="[Empty name]">
<P>Quinidine 0.480 g/d (+ verapamil) versus sotalol 320 mg/d versus placebo<BR/>Method of AF cardioversion: both pharmacological and electrical, % NS<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>At 12 months: <BR/>Mortality<BR/>Pro-arrhythmia<BR/>Adverse effects<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 12:07:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-PITAGORA-2008">
<CHAR_METHODS MODIFIED="2015-03-17 12:06:50 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Open-label<BR/>Loss to follow up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 12:07:15 +0000" MODIFIED_BY="[Empty name]">
<P>Recurrent symptomatic AF in patients with sinus node disease and an indication for pacemaker. Excluded those with underlying coronary disease or reduced LVEF<BR/>Type of AF: 53% paroxysmal, 47% persistent (mean duration: NS). N = 176<BR/>Male: 81%. Age (mean, SD): 72 ± 8<BR/>Structural heart disease: NS%. LAD: 47 mm. LVEF: 56%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 12:07:50 +0000" MODIFIED_BY="[Empty name]">
<P>Amiodarone 190 mg/d versus class IC (flecainide 170 mg/d or propafenone 530 mg/d) versus sotalol 140 mg/d<BR/>Method of AF cardioversion: NS<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-22 16:21:43 +0100" MODIFIED_BY="[Empty name]">
<P>At 21 months:<BR/>Mortality<BR/>Adverse effects<BR/>Pro-arrhythmia<BR/>Stroke</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 12:08:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Plewan-2001">
<CHAR_METHODS MODIFIED="2015-03-17 12:08:14 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Open-label<BR/>Loss to follow up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 12:08:27 +0000" MODIFIED_BY="[Empty name]">
<P>Persistent AF (mean duration: 9 months). N = 128<BR/>Male: 62%. Age (mean, SD): 59 ± 10<BR/>Structural heart disease: 72%. LAD: 48 mm. LVEF: 41%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 12:08:34 +0000" MODIFIED_BY="[Empty name]">
<P>Sotalol 160 mg/d versus bisoprolol 5 mg/d<BR/>Method of AF cardioversion: electrical<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>At 8 months: <BR/>Mortality<BR/>Pro-arrhythmia<BR/>Adverse effects<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 12:09:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-PRODIS-1996">
<CHAR_METHODS MODIFIED="2015-03-17 12:08:53 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Double-blind<BR/>Loss to follow up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 12:09:04 +0000" MODIFIED_BY="[Empty name]">
<P>Persistent AF (mean duration: 5 months). N = 56<BR/>Male: 68%. Age (mean, SD): 60 ± 11<BR/>Structural heart disease: 65%. LAD: 46 mm. LVEF: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 12:09:11 +0000" MODIFIED_BY="[Empty name]">
<P>Disopyramide 750 mg/d versus propafenone 900 mg/d<BR/>Method of AF cardioversion: electrical<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>At 6 months: <BR/>Mortality<BR/>Pro-arrhythmia<BR/>Adverse effects<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 12:09:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-RAFT-2003">
<CHAR_METHODS MODIFIED="2015-03-17 12:09:28 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Double-blind<BR/>Loss to follow up reported: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 12:09:36 +0000" MODIFIED_BY="[Empty name]">
<P>Previous symptomatic AF documented in the last year. Type: NS. N = 523<BR/>Male: 59%. Age (mean, range): 63, 22 to 89<BR/>Structural heart disease: 48%. LAD: NS. LVEF: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 12:09:47 +0000" MODIFIED_BY="[Empty name]">
<P>Propafenone at various doses (450, 650, 850 mg/d) versus placebo<BR/>Method of AF cardioversion: pharmacological 79%, electrical 21%<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>At 9 months: <BR/>Mortality<BR/>Pro-arrhythmia<BR/>Adverse effects<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 12:10:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reimold-1993">
<CHAR_METHODS MODIFIED="2015-03-17 12:10:04 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Open-label<BR/>Loss to follow up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 12:10:20 +0000" MODIFIED_BY="[Empty name]">
<P>Any symptomatic AF or AFl. Type: paroxysmal 47%, persistent 53% (mean duration: 36 months). N = 100<BR/>Male: 64%. Age (mean, SD): 61 ± 12<BR/>Structural heart disease: 81%. LAD: 46 mm. LVEF: 59%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 12:10:31 +0000" MODIFIED_BY="[Empty name]">
<P>Propafenone 675 mg/d versus sotalol 320 mg/d<BR/>Method of AF cardioversion: both pharmacological and electrical, % NS<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>At 12 months: <BR/>Mortality<BR/>Pro-arrhythmia<BR/>Adverse effects<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 12:11:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Richiardi-1992">
<CHAR_METHODS MODIFIED="2015-03-17 12:10:46 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Open-label<BR/>Loss to follow up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 12:10:52 +0000" MODIFIED_BY="[Empty name]">
<P>Paroxysmal AF having &gt; 3 episodes in the last 3 months. N = 200<BR/>Male: 54%. Age (mean, range): 57, 29 to 75<BR/>Structural heart disease: 48%. LAD: 45 mm. LVEF: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 12:11:00 +0000" MODIFIED_BY="[Empty name]">
<P>Propafenone 900 mg/d versus quinidine 1 g/d<BR/>Method of AF cardioversion: pharmacological 88%, electrical 12%<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>At 12 months: <BR/>Mortality<BR/>Pro-arrhythmia<BR/>Adverse effects<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 12:12:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-SAFE_x002d_T-2005">
<CHAR_METHODS MODIFIED="2015-03-17 12:11:27 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Double-blind<BR/>Loss to follow up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 12:11:48 +0000" MODIFIED_BY="[Empty name]">
<P>Persistent AF lasting 3 days to 1 year (mean duration: NS). N = 655</P>
<P>Male: 99%. Age (mean, SD): 67 ± 9<BR/>Structural heart disease: 33%. LAD: 48 mm. LVEF: 51%<BR/>Type of AF: persistent, mean duration: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 12:12:18 +0000" MODIFIED_BY="[Empty name]">
<P>Amiodarone 300 mg/d versus sotalol 320 mg/d versus placebo<BR/>Method of AF cardioversion: pharmacological 20%, electrical 80%</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-24 14:49:49 +0100" MODIFIED_BY="[Empty name]">
<P>At 12 months:<BR/>Mortality<BR/>Stroke<BR/>Pro-arrhythmia<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 12:13:02 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-SAFIRE_x002d_D-2000">
<CHAR_METHODS MODIFIED="2015-03-17 12:12:35 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Double-blind<BR/>Loss to follow up reported: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 12:12:44 +0000" MODIFIED_BY="[Empty name]">
<P>Persistent AF or AFl lasting 2 weeks to 6 months (mean duration: NS). N = 250<BR/>Male: 84%. Age (mean, range): 67, 30 to 88<BR/>Structural heart disease: 67%. LAD: NS. LVEF: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 12:13:02 +0000" MODIFIED_BY="[Empty name]">
<P>Dofetilide various doses (250, 500, 1000 µg/d) versus placebo<BR/>Method of AF cardioversion: pharmacological 15%, electrical 85%<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>At 12 months: <BR/>Mortality<BR/>Pro-arrhythmia<BR/>Adverse effects<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 12:13:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Santas-2012">
<CHAR_METHODS MODIFIED="2015-03-17 12:13:21 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Open-label<BR/>Loss to follow up reported: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-24 09:36:41 +0100" MODIFIED_BY="[Empty name]">
<P>First episode of persistent AF submitted for cardioversion (mean duration: NS). N = 94<BR/>Male: NS. Age (mean, SD): NS<BR/>Structural heart disease: NS. LAD: NS. LVEF: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 12:13:35 +0000" MODIFIED_BY="[Empty name]">
<P>Amiodarone (dose: NS) versus no antiarrhythmic<BR/>Method of AF cardioversion: pharmacological 19%, electrical 81%<BR/>Warfarin: NS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-24 09:40:18 +0100" MODIFIED_BY="[Empty name]">
<P>At 15 months:<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-17 12:13:54 +0000" MODIFIED_BY="[Empty name]">
<P>Only data from a congress poster presentation available. Authors have been contacted. All patients received ibesartan. The study compared ibesartan alone with ibesartan plus amiodarone</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 12:15:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Singh-1991">
<CHAR_METHODS MODIFIED="2015-03-17 12:15:07 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Double-blind<BR/>Loss to follow up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 12:15:23 +0000" MODIFIED_BY="[Empty name]">
<P>Persistent AF or AFl lasting 2 weeks to 1 year (mean duration: 3 months). N = 34<BR/>Male: 71%. Age (mean, SD): 60 ± 14<BR/>Structural heart disease: NS. LAD: 44 mm. LVEF: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 12:15:38 +0000" MODIFIED_BY="[Empty name]">
<P>Sotalol 80 to 320 mg/d versus placebo<BR/>Method of AF cardioversion: pharmacological 17%, electrical 83%<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>At 6 months: <BR/>Mortality<BR/>Pro-arrhythmia<BR/>Adverse effects<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 12:16:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-SMART-2002">
<CHAR_METHODS MODIFIED="2015-03-17 12:15:56 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Double-blind<BR/>Loss to follow up reported: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 12:16:11 +0000" MODIFIED_BY="[Empty name]">
<P>Symptomatic paroxysmal AF having &gt; 1 episode monthly (59%) or persistent AF lasting &lt; 1 month (41%). N = 94<BR/>Male: 72%. Age (mean, SD): 60 ± 12<BR/>Structural heart disease: NS. LAD: NS. LVEF: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 12:16:18 +0000" MODIFIED_BY="[Empty name]">
<P>Aprindine 40 mg/d versus placebo<BR/>Method of AF cardioversion: pharmacological 50%, electrical 50%<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>At 6 months: <BR/>Mortality<BR/>Pro-arrhythmia<BR/>Adverse effects<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 12:17:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-SOCESP-1999">
<CHAR_METHODS MODIFIED="2015-03-17 12:16:35 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Open-label<BR/>Loss to follow up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 12:17:00 +0000" MODIFIED_BY="[Empty name]">
<P>AF lasting &lt; 6 months. Type: recent onset 61%, persistent 39% (mean duration: NS). N = 121</P>
<P>Male: 59%. Age (mean, SD): 54 ± 13<BR/>Structural heart disease: 54%. LAD: 39 mm. LVEF: 68%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 12:17:08 +0000" MODIFIED_BY="[Empty name]">
<P>Quinidine 700 mg/d versus sotalol 240 mg/d<BR/>Method of AF cardioversion: both pharmacological and electrical, % NS<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>At 6 months: <BR/>Mortality<BR/>Pro-arrhythmia<BR/>Adverse effects<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 12:17:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sodermark-1975">
<CHAR_METHODS MODIFIED="2015-03-17 12:17:25 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Open-label<BR/>Loss to follow up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 12:17:38 +0000" MODIFIED_BY="[Empty name]">
<P>Persistent AF or AFl lasting &lt; 3 years (mean duration: 3 to 6 months). N = 185<BR/>Male: 78%. Age (mean, range): 58, 24 to 78<BR/>Structural heart disease: 94%. LAD: NS. LVEF: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 12:17:48 +0000" MODIFIED_BY="[Empty name]">
<P>Quinidine 1.2 to 1.8 g/d versus no treatment<BR/>Method of AF cardioversion: pharmacological 49%, electrical 51%<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>At 12 months: <BR/>Mortality<BR/>Stroke<BR/>Pro-arrhythmia<BR/>Adverse effects<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 12:18:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-SOPAT-2004">
<CHAR_METHODS MODIFIED="2015-03-17 12:18:05 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Double-blind<BR/>Loss to follow up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 12:18:17 +0000" MODIFIED_BY="[Empty name]">
<P>Paroxysmal AF documented in the last 1 month (mean duration: NS). N = 1033<BR/>Male: 63%. Age (mean, SD): 60 ± 11<BR/>Structural heart disease: NS. LAD: 39 mm. LVEF: 61%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 12:18:37 +0000" MODIFIED_BY="[Empty name]">
<P>Quinidine 0.320 or 0.480 g/d (+ verapamil) versus sotalol 320 mg/d versus placebo<BR/>Method of AF cardioversion: both pharmacological and electrical, % NS<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>At 12 months: <BR/>Mortality<BR/>Stroke<BR/>Pro-arrhythmia<BR/>Adverse effects<BR/>AF recurrence<BR/>Symptomatic recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 12:19:43 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Steinbeck-1988">
<CHAR_METHODS MODIFIED="2015-03-17 12:18:57 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Open-label<BR/>Loss to follow up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Paroxysmal symptomatic AF of any duration (mean duration: 6 years). N = 45<BR/>Male: 58%. Age (mean): 59<BR/>Structural heart disease: 73%. LAD: NS. LVEF: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 12:19:43 +0000" MODIFIED_BY="[Empty name]">
<P>Quinidine 1 g/d (+ digoxin) versus flecainide 200 to 300 mg/d (+ digoxin) versus digoxin alone<BR/>Method of AF cardioversion: pharmacological<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>At 12 months: <BR/>Mortality<BR/>Pro-arrhythmia<BR/>Adverse effects<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 12:20:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stroobandt-1997">
<CHAR_METHODS MODIFIED="2015-03-17 12:20:02 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Double-blind<BR/>Loss to follow up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 12:20:17 +0000" MODIFIED_BY="[Empty name]">
<P>Recent onset AF (46%) or persistent AF lasting &gt; 2 weeks (54%, mean duration: NS). N = 102<BR/>Male: 73%. Age (mean, range): 62, 27 to 84<BR/>Structural heart disease: 71%. LAD: 39 mm. LVEF: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 12:20:23 +0000" MODIFIED_BY="[Empty name]">
<P>Propafenone 450 mg/d versus placebo<BR/>Method of AF cardioversion: pharmacological 34%, electrical 66%<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>At 6 months: <BR/>Mortality<BR/>Pro-arrhythmia<BR/>Adverse effects<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 12:21:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-SVA_x002d_4-2008">
<CHAR_METHODS MODIFIED="2015-03-17 12:20:42 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Not blinded, open-label.<BR/>Loss to follow up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 12:21:40 +0000" MODIFIED_BY="[Empty name]">
<P>Symptomatic AF and AFl. All types, % NS. N = 422<BR/>Male: 63%. Age (mean, SD): 61, NS<BR/>Structural heart disease: 48%. LAD: NS. LVEF: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 12:21:16 +0000" MODIFIED_BY="[Empty name]">
<P>Azimilide 125 mg/d versus placebo<BR/>Method of AF cardioversion: spontaneous or electrical, % NS<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-29 15:05:52 +0100" MODIFIED_BY="[Empty name]">
<P>At 6 months:<BR/>Mortality<BR/>Adverse effects<BR/>Pro-arrhythmia<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 12:22:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Gelder-1989">
<CHAR_METHODS MODIFIED="2015-03-17 12:22:14 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Open-label<BR/>Loss to follow up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 12:22:35 +0000" MODIFIED_BY="[Empty name]">
<P>Any persistent AF or AFl (mean duration: 12 months). N = 73</P>
<P>Male: 55%. Age (mean, SD): 60 ± 11<BR/>Structural heart disease: 82%. LAD: 44 mm. LVEF: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 12:22:45 +0000" MODIFIED_BY="[Empty name]">
<P>Flecainide 200 to 300 mg/d versus no treatment<BR/>Method of AF cardioversion: electrical<BR/>Warfarin mandatory?</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-24 15:51:24 +0100" MODIFIED_BY="[Empty name]">
<P>At 6 months:<BR/>Mortality<BR/>Adverse effects<BR/>Pro-arrhythmia<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 12:23:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vijayalaskshmi-2006">
<CHAR_METHODS MODIFIED="2015-03-17 12:23:08 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Open-label<BR/>Loss to follow up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 12:23:27 +0000" MODIFIED_BY="[Empty name]">
<P>Persistent AF in whom cardioversion was planned (mean duration: 7 months). N = 78<BR/>Male: 71%. Age (mean, SD): 64 ± 9<BR/>Structural heart disease: NS<BR/>LAD: 43 mm. LVEF: 43%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 12:23:47 +0000" MODIFIED_BY="[Empty name]">
<P>Amiodarone 200 mg/d versus sotalol 160 to 320 mg/d versus no treatment<BR/>Method of AF cardioversion: pharmacological 22%, electrical 78%<BR/>Warfarin required for 6 weeks, discretionary afterwards</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-24 16:01:36 +0100" MODIFIED_BY="[Empty name]">
<P>At 6 months:<BR/>Mortality<BR/>Adverse effects<BR/>Pro-arrhythmia<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 12:34:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Villani-1992">
<CHAR_METHODS MODIFIED="2015-03-17 12:24:44 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Open-label<BR/>Loss to follow up reported: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 12:34:01 +0000" MODIFIED_BY="[Empty name]">
<P>Symptomatic recent onset AF lasting &gt; 1 hour, being at least the second episode. N = 76<BR/>Male: 49%. Age (mean, range): 65, 37 to 85<BR/>Structural heart disease: 86%. LAD: 38 mm. LVEF: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 12:24:57 +0000" MODIFIED_BY="[Empty name]">
<P>Amiodarone 200 mg/d versus disopyramide 500 mg/d<BR/>Method of AF cardioversion: pharmacological 74%, electrical 26%<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>At 14 months: <BR/>Mortality<BR/>Adverse effects<BR/>AF recurrence<BR/>Symptomatic recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-17 12:25:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vitolo-1981">
<CHAR_METHODS MODIFIED="2015-03-17 12:25:20 +0000" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Open-label<BR/>Loss to follow up reported: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-17 12:25:29 +0000" MODIFIED_BY="[Empty name]">
<P>Any persistent AF (mean duration: NS). N = 54<BR/>Male: 37%. Age (mean, SD): 53 ± 11<BR/>Structural heart disease: 100%. LAD: NS. LVEF: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-17 12:25:44 +0000" MODIFIED_BY="[Empty name]">
<P>Amiodarone 400 mg/d versus quinidine 1.2 g/d<BR/>Method of AF cardioversion: electrical<BR/>Warfarin discretionary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>At 6 months: <BR/>Mortality<BR/>Pro-arrhythmia<BR/>Adverse effects<BR/>AF recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AF = atrial fibrillation; AFl = atrial flutter; LAD = mean left atrium diameter; LVEF = mean left ventricule ejection fraction; mg/d = milligrams per day; N = number of patients included in the study; NS = not stated; RCT = randomised controlled trial; SD = standard deviation.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-03-17 11:25:25 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:04:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aberg-1968">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:04:24 +0000" MODIFIED_BY="[Empty name]">
<P>Non-controlled study: all patients were initially treated with quinidine for 1 year, then allocated to procainamide alone or procainamide plus quinidine and followed for only 3 months</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:04:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-AF_x002d_CHF-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:04:48 +0000" MODIFIED_BY="[Empty name]">
<P>Rate versus rhythm control comparison. Patients in control group (rate control) were in persistent atrial fibrillation not reverted to sinus rhythm.<BR/>Use of long-term oral anticoagulants was significantly different between rate and rhythm control groups</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:05:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-AFFIRM-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:05:21 +0000" MODIFIED_BY="[Empty name]">
<P>Rate versus rhythm control comparison. Patients in persistent atrial fibrillation at inclusion, not reverted to sinus rhythm. Multiple different antiarrhythmics used in intervention group (rhythm control), not analysed separately. Warfarin mandatory in control group (rate control) but discretionary in antiarrhythmics group and actual use was very different</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:05:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anderson-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:05:32 +0000" MODIFIED_BY="[Empty name]">
<P>Crossover study. Follow-up &lt; 6 months (4 months)<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:06:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Andromeda-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:06:12 +0000" MODIFIED_BY="[Empty name]">
<P>Patients with heart failure were randomised to dronedarone or placebo. About 25% of patients had AF but it was not possible to obtain separate data for those patients. Mean follow-up was only 2 months as the trial was terminated early because increased deaths in the dronedarone group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:06:20 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Antman-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:06:20 +0000" MODIFIED_BY="[Empty name]">
<P>Non-controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:06:43 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aros-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:06:43 +0000" MODIFIED_BY="[Empty name]">
<P>Inadequate comparison: quinidine was compared to a combination of quinidine and amiodarone. Probably not truly randomised. All patients underwent cardiac surgery</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:07:07 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Babuty-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:07:07 +0000" MODIFIED_BY="[Empty name]">
<P>Comparison of drugs not relevant: flecainide versus cibenzoline, but the effectiveness of cibenzoline is not known. Included patients having atrial tachyarrhythmias of various types, not only atrial fibrillation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:07:19 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Beck-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:07:19 +0000" MODIFIED_BY="[Empty name]">
<P>Acute pharmacological conversion of atrial fibrillation only, no long-term therapy with antiarrhythmics<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:07:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Berns-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:07:24 +0000" MODIFIED_BY="[Empty name]">
<P>Non-controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:07:29 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Blevins-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:07:29 +0000" MODIFIED_BY="[Empty name]">
<P>Non-controlled trial<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:07:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Blomstrom-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:07:35 +0000" MODIFIED_BY="[Empty name]">
<P>Non-controlled trial<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:07:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boissel-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:07:56 +0000" MODIFIED_BY="[Empty name]">
<P>Follow up &lt; 6 months (3 months). Some patients followed for 1 year but they had not been randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:08:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brodsky-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:08:14 +0000" MODIFIED_BY="[Empty name]">
<P>Non-controlled trial<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:08:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-CHF_x002d_STAF-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:08:23 +0000" MODIFIED_BY="[Empty name]">
<P>Recruited patients with heart failure, only 15% had atrial fibrillation, not reverted to sinus rhythm, not analysed separately</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:08:30 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chun-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:08:30 +0000" MODIFIED_BY="[Empty name]">
<P>Non-controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:08:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Clementy-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:08:35 +0000" MODIFIED_BY="[Empty name]">
<P>Non-controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:08:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Connolly-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:08:50 +0000" MODIFIED_BY="[Empty name]">
<P>Crossover study. Follow up &lt; 6 months (4 months)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:09:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-CTAF-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:09:21 +0000" MODIFIED_BY="[Empty name]">
<P>Initially included, but useable data could not be extracted: amiodarone was compared against the sequential use of propafenone and sotalol, and separate data on each drug were not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:09:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cuan_x002d_Perez-1971">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:09:27 +0000" MODIFIED_BY="[Empty name]">
<P>Non-randomised, retrospective study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:09:42 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ERAFT-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:09:42 +0000" MODIFIED_BY="[Empty name]">
<P>Follow up &lt; 6 months (3 months)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:09:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Faivre-1970">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:09:48 +0000" MODIFIED_BY="[Empty name]">
<P>Non-randomised trial, retrospective control series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:09:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fernandez-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:09:56 +0000" MODIFIED_BY="[Empty name]">
<P>Acute pharmacological conversion of atrial fibrillation only, no long-term therapy with antiarrhythmics</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:10:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fragakis-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:10:25 +0000" MODIFIED_BY="[Empty name]">
<P>Very short-term study (24 hours follow up) on the efficacy for converting recent onset AF. All groups received amiodarone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:10:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Frances-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:10:44 +0000" MODIFIED_BY="[Empty name]">
<P>Comparison of drugs not relevant: quinidine versus cibenzoline, but the effectiveness of cibenzoline is not known</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-24 08:51:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Galperin-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-24 08:51:27 +0100" MODIFIED_BY="[Empty name]">
<P>All randomised patients received amiodarone, treatment for 3 months was compared with treatment for 18 months. A control group existed but included only 9 patients and they were not randomly allocated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:11:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gold-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:11:23 +0000" MODIFIED_BY="[Empty name]">
<P>Non-controlled trial<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:11:28 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gosselink-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:11:28 +0000" MODIFIED_BY="[Empty name]">
<P>Non-controlled trial<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:11:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Graboys-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:11:33 +0000" MODIFIED_BY="[Empty name]">
<P>Non-controlled trial<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:12:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gramley-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:12:25 +0000" MODIFIED_BY="[Empty name]">
<P>Data unuseable: compared a group receiving dronedarone with other group receiving flecainide or amiodarone. Separate data for amiodarone and flecainide not available. Only global outcomes (all groups pooled) were available at 6 months</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:12:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grigoriyan-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:12:47 +0000" MODIFIED_BY="[Empty name]">
<P>Non-randomised study with only 16 weeks follow up. Compared ivabradine with placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:13:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gu-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:13:11 +0000" MODIFIED_BY="[Empty name]">
<P>One antiarrhythmic drug (amiodarone or propafenone) was compared with a combination of both, but separate data for amiodarone and propafenone were not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:13:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-GUSTO-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:13:45 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised trial but allocation to antiarrhythmics was not randomised. Multiple different antiarrhythmics used, mainly for acute cardioversion, only 19% of patients received long-term treatment with an antiarrhythmic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:14:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hammill-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:14:01 +0000" MODIFIED_BY="[Empty name]">
<P>Non-controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:14:30 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hartel-1970">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:14:30 +0000" MODIFIED_BY="[Empty name]">
<P>Quasi-randomised: allocation by year of birth. Follow up &lt; 6 months (3 months)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:14:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hartel-1974">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:14:55 +0000" MODIFIED_BY="[Empty name]">
<P>Follow up &lt; 6 months (3 months)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:15:26 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hopson-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:15:26 +0000" MODIFIED_BY="[Empty name]">
<P>Non-controlled trial<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:15:30 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Horowitz-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:15:30 +0000" MODIFIED_BY="[Empty name]">
<P>Non-controlled trial<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:16:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-HOT_x002d_CAFE-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:16:17 +0000" MODIFIED_BY="[Empty name]">
<P>Rate versus rhythm control comparison. Patients in control group in persistent atrial fibrillation not reverted to sinus rhythm. Various antiarrhythmics used sequentially in intervention group (rhythm control), not analysed separately. Warfarin mandatory in control group (rate control) but discretionary in antiarrhythmics group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:16:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ishiguro-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:16:24 +0000" MODIFIED_BY="[Empty name]">
<P>Non-controlled trial: all patients received bisoprolol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:16:46 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-J_x002d_BAF-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:16:46 +0000" MODIFIED_BY="[Empty name]">
<P>Follow up &lt; 6 months (3 months only). The main endpoint of the study was the rate of cardioversion achieved rather than the maintaining of sinus rhythm. Rate of patients reverted to sinus rhythm were largely different between study groups</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:17:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-J_x002d_RHYTHM-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:17:14 +0000" MODIFIED_BY="[Empty name]">
<P>Rate versus rhythm control comparison. Patients in control group (rate control) in persistent atrial fibrillation not reverted to sinus rhythm.<BR/>Multiple different antiarrhythmics used in intervention group (rhythm control), not analysed separately<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:17:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jong-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:17:22 +0000" MODIFIED_BY="[Empty name]">
<P>Inadequate comparison: two different doses of amiodarone were studied, without any control (placebo or a different drug) group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:17:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kanoupakis-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:17:33 +0000" MODIFIED_BY="[Empty name]">
<P>Follow up &lt; 6 months (4 weeks)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:17:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kennelly-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:17:51 +0000" MODIFIED_BY="[Empty name]">
<P>Non-randomised trial. Comparison of drugs not relevant: quinidine versus lidoflazine, but the effectiveness of lidoflazine is not known.<BR/>Stopped prematurely due to mortality excess with lidoflazine<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:18:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kerr-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:18:04 +0000" MODIFIED_BY="[Empty name]">
<P>Non-controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:18:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Khitri-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:18:10 +0000" MODIFIED_BY="[Empty name]">
<P>Follow up &lt; 6 months (3 months only). It compared celivarone (new drug related to amiodarone) with amiodarone and placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-24 09:16:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Komatsu-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-24 09:16:34 +0100" MODIFIED_BY="[Empty name]">
<P>Comparison of drug not relevant: cibenzoline was compared with pilsicainide, but the effectiveness of both drugs in AF is unknown (no studies comparing them with placebo or no treatment)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:18:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kosior-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:18:35 +0000" MODIFIED_BY="[Empty name]">
<P>Non-controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:18:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kosior-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:18:48 +0000" MODIFIED_BY="[Empty name]">
<P>Very short-term study (24 hours follow up only) comparing quinidine and propafenone for the conversion of paroxysmal AF</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:18:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kyles-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:18:54 +0000" MODIFIED_BY="[Empty name]">
<P>Non-controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:19:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lardoux-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:19:14 +0000" MODIFIED_BY="[Empty name]">
<P>Comparison of drugs not relevant: propafenone versus cibenzoline, but the effectiveness of cibenzoline is not known. Included patients having atrial tachyarrhythmias of various types, not only atrial fibrillation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:19:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lau-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:19:27 +0000" MODIFIED_BY="[Empty name]">
<P>Cross-over study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:19:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Levi-1973">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:19:35 +0000" MODIFIED_BY="[Empty name]">
<P>Acute pharmacological conversion of atrial fibrillation only, no long-term therapy with antiarrhythmics<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:19:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:19:41 +0000" MODIFIED_BY="[Empty name]">
<P>Non-randomised, retrospective study<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:19:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lobe-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:19:56 +0000" MODIFIED_BY="[Empty name]">
<P>Non-controlled, non-randomised trial. All patients received dronedarone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:20:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Manios-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:20:10 +0000" MODIFIED_BY="[Empty name]">
<P>Follow up &lt; 6 months (6 weeks)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:20:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Martin-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:20:21 +0000" MODIFIED_BY="[Empty name]">
<P>Not truly randomised. It is not known if atrial fibrillation was reverted in all patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:20:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mary_x002d_Rabine-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:20:37 +0000" MODIFIED_BY="[Empty name]">
<P>Non-controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:20:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Massacci-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:20:45 +0000" MODIFIED_BY="[Empty name]">
<P>Cross-over study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:20:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mizutani-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:20:55 +0000" MODIFIED_BY="[Empty name]">
<P>Non-controlled trial for long-term use of antiarrhythmics after conversion</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:21:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nedostup-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:21:41 +0000" MODIFIED_BY="[Empty name]">
<P>Non-randomised, retrospective study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:21:43 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Opolski-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:21:43 +0000" MODIFIED_BY="[Empty name]">
<P>Non-controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:21:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-PEPS-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:21:53 +0000" MODIFIED_BY="[Empty name]">
<P>Non-controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:22:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-PIAF-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:22:04 +0000" MODIFIED_BY="[Empty name]">
<P>Rate versus rhythm control comparison. Patients in control group in persistent atrial fibrillation not reverted to sinus rhythm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:22:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pietersen-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:22:12 +0000" MODIFIED_BY="[Empty name]">
<P>Follow up &lt; 6 months (3 months)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:22:19 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Piot-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:22:19 +0000" MODIFIED_BY="[Empty name]">
<P>Comparison of drugs not relevant: disopyramide versus cibenzoline, but the effectiveness of cibenzoline is not known</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:22:29 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Porterfield-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:22:29 +0000" MODIFIED_BY="[Empty name]">
<P>Non-controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:22:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-PSVT-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:22:40 +0000" MODIFIED_BY="[Empty name]">
<P>Crossover study. Follow up &lt; 6 months (3 months)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:23:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-RACE-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:23:06 +0000" MODIFIED_BY="[Empty name]">
<P>Rate versus rhythm control comparison. Patients in control group in persistent atrial fibrillation not reverted to sinus rhythm. Various antiarrhythmics used sequentially in intervention group (rhythm control), not analysed separately. Warfarin mandatory in control group (rate control) but discretionary in antiarrhythmics group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:23:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rasmussen-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:23:18 +0000" MODIFIED_BY="[Empty name]">
<P>Crossover study. Follow up &lt; 6 months (3 months)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:23:29 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Resnekov-1971">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:23:29 +0000" MODIFIED_BY="[Empty name]">
<P>Non-controlled trial<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:23:46 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-STAF-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:23:46 +0000" MODIFIED_BY="[Empty name]">
<P>Rate versus rhythm control comparison. Patients in persistent atrial fibrillation at inclusion, not reverted to sinus rhythm. Multiple different antiarrhythmics used in intervention group (rhythm control), not analysed separately</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:23:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Steeds-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:23:57 +0000" MODIFIED_BY="[Empty name]">
<P>Crossover study. Follow up &lt; 6 months (2 months)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:24:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tonet-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:24:05 +0000" MODIFIED_BY="[Empty name]">
<P>Cross-over study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:24:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Torp_x002d_Pedersen-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:24:22 +0000" MODIFIED_BY="[Empty name]">
<P>Follow up &lt; 6 months (3 months). Multicentre randomised controlled trial comparing several doses of vernakalant with placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:24:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Touboul-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:24:31 +0000" MODIFIED_BY="[Empty name]">
<P>Comparison of drugs not relevant: quinidine versus cibenzoline, but the effectiveness of cibenzoline is not known<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:24:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Wijk-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:24:49 +0000" MODIFIED_BY="[Empty name]">
<P>Cross-over study. Follow up &lt; 6 months (3 months)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:24:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-VEPARAF-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:24:56 +0000" MODIFIED_BY="[Empty name]">
<P>Follow up &lt; 6 months (3 months)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:25:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wanless-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:25:08 +0000" MODIFIED_BY="[Empty name]">
<P>Follow up &lt; 6 months (4 to 8 weeks)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-17 11:25:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zehender-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-17 11:25:25 +0000" MODIFIED_BY="[Empty name]">
<P>Follow up &lt; 6 months (3 months). Some patients followed longer but all were on quinidine, and there was no control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2011-02-22 10:49:22 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2011-02-22 10:49:30 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-03-17 12:24:30 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2015-03-17 12:14:10 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-A_x002d_COMET_x002d_I-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-A_x002d_STAR-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-AFFIRM-Substudy-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-AFIB-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-ASAP-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-ATHENA-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Aliot-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bellandi-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Benditt-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Byrne_x002d_Quinn-1970">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Carunchio-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Channer-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-DAFNE-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-DAPHNE-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-DIAMOND-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-DYONISOS-2010">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Dogan-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-EMERALD-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-EURIDIS-ADONIS-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-FAPIS-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-25 10:56:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Flec_x002d_SL-2012">
<DESCRIPTION>
<P>Random numbers table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-GEFACA-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hillestad-1971">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hohnloser-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Juul_x002d_Moller-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kalusche-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Karlson-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kochiadakis-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kochiadakis-2004a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kochiadakis-2004b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kuhlkamp-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lloyd-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Naccarelli-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Nergardh-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Niu-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Okishige-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-PAFAC-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-PITAGORA-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-PRODIS-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Plewan-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-RAFT-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Reimold-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Richiardi-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-SAFE_x002d_T-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-SAFIRE_x002d_D-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-SMART-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-SOCESP-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-SOPAT-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-SVA_x002d_4-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-17 12:14:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Santas-2012">
<DESCRIPTION>
<P>The study states that is randomised but the procedure is not well described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Singh-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sodermark-1975">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Steinbeck-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Stroobandt-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Van-Gelder-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-25 11:10:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vijayalaskshmi-2006">
<DESCRIPTION>
<P>Computer generated random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Villani-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Vitolo-1981">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-12-15 15:17:43 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-20 11:11:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-A_x002d_COMET_x002d_I-2006">
<DESCRIPTION>
<P>Method of concealment not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-27 16:15:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006">
<DESCRIPTION>
<P>Sequentially numbered drug containers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-29 13:42:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-A_x002d_STAR-2006">
<DESCRIPTION>
<P>Method of concealment not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:20:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-AFFIRM-Substudy-2003">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:22:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-AFIB-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:23:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-ASAP-2003">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-29 14:17:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ATHENA-2009">
<DESCRIPTION>
<P>Central allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:22:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Aliot-1996">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:23:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bellandi-2001">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:23:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Benditt-1999">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:23:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Byrne_x002d_Quinn-1970">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:23:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carunchio-1995">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:23:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Channer-2004">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:23:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-DAFNE-2003">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-29 14:24:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-DAPHNE-2008">
<DESCRIPTION>
<P>Method of concealment not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:23:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DIAMOND-2001">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-07 16:30:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DYONISOS-2010">
<DESCRIPTION>
<P>Central allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:23:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dogan-2004">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-29 17:15:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-EMERALD-2000">
<DESCRIPTION>
<P>Method of concealment not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:23:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-EURIDIS-ADONIS-2007">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:23:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-FAPIS-1996">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-24 09:20:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Flec_x002d_SL-2012">
<DESCRIPTION>
<P>Allocation by a distant central office</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:24:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-GEFACA-2001">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:24:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hillestad-1971">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:24:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hohnloser-1995">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:24:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Juul_x002d_Moller-1990">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:24:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kalusche-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:24:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Karlson-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:24:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kochiadakis-2000">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:45:35 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kochiadakis-2004a">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:24:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kochiadakis-2004b">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:24:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kuhlkamp-2000">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:24:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lloyd-1984">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:24:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Naccarelli-1996">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-29 14:59:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nergardh-2007">
<DESCRIPTION>
<P>Sequentially numbered drug containers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-22 15:53:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Niu-2006">
<DESCRIPTION>
<P>Method of concealment not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:24:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Okishige-2000">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:24:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-PAFAC-2004">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-22 16:10:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-PITAGORA-2008">
<DESCRIPTION>
<P>Method of concealment not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:25:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-PRODIS-1996">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:24:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Plewan-2001">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:25:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-RAFT-2003">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:25:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Reimold-1993">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:25:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Richiardi-1992">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-15 15:17:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-SAFE_x002d_T-2005">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:25:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-SAFIRE_x002d_D-2000">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:25:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SMART-2002">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-15 15:17:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-SOCESP-1999">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:25:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SOPAT-2004">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-29 15:00:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-SVA_x002d_4-2008">
<DESCRIPTION>
<P>Method of concealment not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-24 09:44:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Santas-2012">
<DESCRIPTION>
<P>No description of allocation procedures given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:25:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Singh-1991">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:25:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sodermark-1975">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:25:51 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Steinbeck-1988">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:25:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stroobandt-1997">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:26:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Gelder-1989">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-24 15:43:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vijayalaskshmi-2006">
<DESCRIPTION>
<P>No description of allocation procedures given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:26:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Villani-1992">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-25 11:26:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vitolo-1981">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-12-15 15:38:15 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-A_x002d_COMET_x002d_I-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-A_x002d_STAR-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-AFFIRM-Substudy-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-AFIB-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-ASAP-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-ATHENA-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Aliot-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Bellandi-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Benditt-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Byrne_x002d_Quinn-1970">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Carunchio-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Channer-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-DAFNE-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-DAPHNE-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-DIAMOND-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-DYONISOS-2010">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-12-15 15:38:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dogan-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-EMERALD-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-EURIDIS-ADONIS-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-FAPIS-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-25 10:56:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Flec_x002d_SL-2012">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-GEFACA-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Hillestad-1971">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Hohnloser-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Juul_x002d_Moller-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Kalusche-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Karlson-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Kochiadakis-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Kochiadakis-2004a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Kochiadakis-2004b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Kuhlkamp-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Lloyd-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Naccarelli-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Nergardh-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Niu-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Okishige-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-PAFAC-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-PITAGORA-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-PRODIS-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Plewan-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-RAFT-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Reimold-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Richiardi-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-SAFE_x002d_T-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-SAFIRE_x002d_D-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-SMART-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-SOCESP-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-SOPAT-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-SVA_x002d_4-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-25 11:06:49 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Santas-2012">
<DESCRIPTION>
<P>Open-label study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Singh-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Sodermark-1975">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Steinbeck-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Stroobandt-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Van-Gelder-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-25 11:11:12 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vijayalaskshmi-2006">
<DESCRIPTION>
<P>Open-label study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Villani-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Vitolo-1981">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2015-03-17 12:24:12 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-A_x002d_COMET_x002d_I-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-A_x002d_STAR-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-AFFIRM-Substudy-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-AFIB-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-ASAP-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-ATHENA-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Aliot-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Bellandi-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Benditt-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Byrne_x002d_Quinn-1970">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Carunchio-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Channer-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-DAFNE-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-DAPHNE-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-DIAMOND-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-DYONISOS-2010">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Dogan-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-EMERALD-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-EURIDIS-ADONIS-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-FAPIS-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-03-17 11:52:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Flec_x002d_SL-2012">
<DESCRIPTION>
<P>All withdrawals and dropouts of patients are well described. Missing outcome data are balanced across intervention groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-GEFACA-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Hillestad-1971">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Hohnloser-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Juul_x002d_Moller-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Kalusche-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Karlson-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Kochiadakis-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Kochiadakis-2004a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Kochiadakis-2004b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Kuhlkamp-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Lloyd-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Naccarelli-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Nergardh-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Niu-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Okishige-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-PAFAC-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-PITAGORA-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-PRODIS-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Plewan-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-RAFT-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Reimold-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Richiardi-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-SAFE_x002d_T-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-SAFIRE_x002d_D-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-SMART-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-SOCESP-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-SOPAT-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-SVA_x002d_4-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-03-17 12:14:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Santas-2012">
<DESCRIPTION>
<P>Withdrawals and dropouts of patients after randomisation are not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Singh-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Sodermark-1975">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Steinbeck-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Stroobandt-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Van-Gelder-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-03-17 12:24:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vijayalaskshmi-2006">
<DESCRIPTION>
<P>All withdrawals and dropouts of patients are well described. Missing outcome data are balanced across intervention groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Villani-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Vitolo-1981">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2015-03-17 12:24:30 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-A_x002d_COMET_x002d_I-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-A_x002d_STAR-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-AFFIRM-Substudy-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-AFIB-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-ASAP-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-ATHENA-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Aliot-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bellandi-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Benditt-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Byrne_x002d_Quinn-1970">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Carunchio-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Channer-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-DAFNE-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-DAPHNE-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-DIAMOND-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-DYONISOS-2010">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Dogan-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-EMERALD-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-EURIDIS-ADONIS-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-FAPIS-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-25 11:04:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Flec_x002d_SL-2012">
<DESCRIPTION>
<P>All of the study&#8217;s pre-specified outcomes have been reported in the pre-specified way</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-GEFACA-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hillestad-1971">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hohnloser-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Juul_x002d_Moller-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kalusche-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Karlson-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kochiadakis-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kochiadakis-2004a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kochiadakis-2004b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kuhlkamp-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lloyd-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Naccarelli-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Nergardh-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Niu-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Okishige-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-PAFAC-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-PITAGORA-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-PRODIS-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Plewan-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-RAFT-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Reimold-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Richiardi-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-SAFE_x002d_T-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-SAFIRE_x002d_D-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-SMART-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-SOCESP-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-SOPAT-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-SVA_x002d_4-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-25 11:08:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Santas-2012">
<DESCRIPTION>
<P>There is insufficient information to permit a judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Singh-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sodermark-1975">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Steinbeck-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Stroobandt-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Van-Gelder-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-17 12:24:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vijayalaskshmi-2006">
<DESCRIPTION>
<P>All pre-specified outcomes have been reported in the pre-specified way. All main outcomes expected in this kind of study are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Villani-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Vitolo-1981">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2014-09-25 11:12:23 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-A_x002d_COMET_x002d_I-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-A_x002d_STAR-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-AFFIRM-Substudy-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-AFIB-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-ASAP-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-ATHENA-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Aliot-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bellandi-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Benditt-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Byrne_x002d_Quinn-1970">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Carunchio-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Channer-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-DAFNE-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-DAPHNE-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-DIAMOND-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-DYONISOS-2010">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Dogan-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-EMERALD-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-EURIDIS-ADONIS-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-FAPIS-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-25 11:05:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Flec_x002d_SL-2012">
<DESCRIPTION>
<P>No other problem was apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-GEFACA-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hillestad-1971">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hohnloser-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Juul_x002d_Moller-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kalusche-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Karlson-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kochiadakis-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kochiadakis-2004a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kochiadakis-2004b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kuhlkamp-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lloyd-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Naccarelli-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Nergardh-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Niu-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Okishige-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-PAFAC-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-PITAGORA-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-PRODIS-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Plewan-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-RAFT-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Reimold-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Richiardi-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-SAFE_x002d_T-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-SAFIRE_x002d_D-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-SMART-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-SOCESP-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-SOPAT-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-SVA_x002d_4-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-25 11:09:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Santas-2012">
<DESCRIPTION>
<P>There is insufficient information to permit a judgement. Only data from a congress abstract is available. Authors had been contacted for further details but this has been unsuccessful</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Singh-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sodermark-1975">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Steinbeck-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Stroobandt-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Van-Gelder-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-25 11:12:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vijayalaskshmi-2006">
<DESCRIPTION>
<P>No other problem apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Villani-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Vitolo-1981">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2014-06-27 15:19:23 +0100" MODIFIED_BY="[Empty name]"/>
<ADDITIONAL_TABLES MODIFIED="2010-02-18 15:33:57 +0000" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2015-04-14 15:47:03 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2014-09-25 16:09:24 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>All-cause mortality</NAME>
<DICH_OUTCOME CHI2="38.78449339944258" CI_END="1.2899660152342778" CI_START="0.9007099998753705" CI_STUDY="95" CI_TOTAL="95" DF="29" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.0779078297428304" ESTIMABLE="YES" EVENTS_1="311" EVENTS_2="251" I2="25.22784892062869" I2_Q="58.715215017140764" ID="CMP-001.01" LOG_CI_END="0.11057826875611573" LOG_CI_START="-0.04541501559910356" LOG_EFFECT_SIZE="0.032581626578506113" METHOD="PETO" MODIFIED="2014-07-01 14:46:43 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.10586048481808918" P_Q="0.009535602319361014" P_Z="0.4129359200826611" Q="21.799798651577454" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="41" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11453" TOTAL_2="8067" WEIGHT="100.0" Z="0.8187379977998178">
<NAME>Individual antiarrhythmics</NAME>
<GROUP_LABEL_1>Antiarrhythmic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.764215783965429" CI_END="5.452067743293515" CI_START="0.9328111446664865" DF="5" EFFECT_SIZE="2.255160648916359" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="4" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.7365612434127791" LOG_CI_START="-0.030206273864816145" LOG_EFFECT_SIZE="0.3531774847739815" NO="1" P_CHI2="0.7362808387627097" P_Z="0.07099004314331923" STUDIES="7" TAU2="0.0" TOTAL_1="1128" TOTAL_2="548" WEIGHT="4.138894829806273" Z="1.8055411443749052">
<NAME>Class Ia: Quinidine</NAME>
<DICH_DATA CI_END="527.8001204153296" CI_START="0.19326023079046073" EFFECT_SIZE="10.099642225480048" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.7224694849664623" LOG_CI_START="-0.713857506163923" LOG_EFFECT_SIZE="1.0043059894012696" ORDER="72" O_E="0.5675675675675675" SE="2.0185154846829296" STUDY_ID="STD-Byrne_x002d_Quinn-1970" TOTAL_1="32" TOTAL_2="42" VAR="0.2454346238130022" WEIGHT="0.20607382739853813"/>
<DICH_DATA CI_END="406.0194289218663" CI_START="0.15885962215189478" EFFECT_SIZE="8.031194996067258" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.6085468160197243" LOG_CI_START="-0.7989864747561749" LOG_EFFECT_SIZE="0.9047801706317746" ORDER="73" O_E="0.52" SE="2.001601922563589" STUDY_ID="STD-Hillestad-1971" TOTAL_1="48" TOTAL_2="52" VAR="0.2496" WEIGHT="0.20957119464067328"/>
<DICH_DATA CI_END="113.67197031843577" CI_START="0.4175408606629363" EFFECT_SIZE="6.8893172608039634" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0556533878472827" LOG_CI_START="-0.3793010179238064" LOG_EFFECT_SIZE="0.8381761849617383" ORDER="74" O_E="0.9433962264150944" SE="1.4303042711686382" STUDY_ID="STD-Lloyd-1984" TOTAL_1="28" TOTAL_2="25" VAR="0.4888134293616671" WEIGHT="0.41042153184186275"/>
<DICH_DATA CI_END="4.829173192322102" CI_START="0.22861787023996857" EFFECT_SIZE="1.050730836250954" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="0.6838727811139533" LOG_CI_START="-0.640889825369967" LOG_EFFECT_SIZE="0.021491477871993174" ORDER="75" O_E="0.08172043010752716" SE="0.7781721127293179" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="88" VAR="1.6513862874320733" WEIGHT="1.3865504690319146"/>
<DICH_DATA CI_END="8.24184638422739" CI_START="0.4635516457913856" EFFECT_SIZE="1.9546154240075941" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="0.9160245156600444" LOG_CI_START="-0.33390187266793026" LOG_EFFECT_SIZE="0.29106132149605707" ORDER="77" O_E="1.243243243243243" SE="0.7342129477392609" STUDY_ID="STD-Sodermark-1975" TOTAL_1="110" TOTAL_2="75" VAR="1.8550512910089878" WEIGHT="1.557553346059603"/>
<DICH_DATA CI_END="85.12319633156255" CI_START="0.22966890860097597" EFFECT_SIZE="4.421555336993599" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9300479227881144" LOG_CI_START="-0.6388977933855617" LOG_EFFECT_SIZE="0.6455750647012765" ORDER="76" O_E="0.6527958387516255" SE="1.5090114301668014" STUDY_ID="STD-SOPAT-2004" TOTAL_1="518" TOTAL_2="251" VAR="0.43915207708714865" WEIGHT="0.3687244608336811"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="78" O_E="0.0" SE="0.0" STUDY_ID="STD-Steinbeck-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="122.6563157532565" CI_START="0.46536100533222263" DF="0" EFFECT_SIZE="7.555095393791001" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="2.0886899155768055" LOG_CI_START="-0.33221001099032044" LOG_EFFECT_SIZE="0.8782399522932426" NO="2" P_CHI2="1.0" P_Z="0.15501214260293905" STUDIES="2" TAU2="0.0" TOTAL_1="75" TOTAL_2="71" WEIGHT="0.4152007501598293" Z="1.422048600513436">
<NAME>Class Ia: Disopyramide</NAME>
<DICH_DATA CI_END="122.6563157532565" CI_START="0.46536100533222263" EFFECT_SIZE="7.555095393791001" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0886899155768055" LOG_CI_START="-0.33221001099032044" LOG_EFFECT_SIZE="0.8782399522932426" ORDER="79" O_E="1.0" SE="1.422048600513436" STUDY_ID="STD-Karlson-1998" TOTAL_1="46" TOTAL_2="46" VAR="0.4945054945054945" WEIGHT="0.4152007501598293"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="80" O_E="0.0" SE="0.0" STUDY_ID="STD-Lloyd-1984" TOTAL_1="29" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-06-26 15:37:03 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="4" TAU2="0.0" TOTAL_1="352" TOTAL_2="159" WEIGHT="0.0" Z="0.0">
<NAME>Class Ic: Flecainide</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="81" O_E="0.0" SE="0.0" STUDY_ID="STD-Carunchio-1995" TOTAL_1="20" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-06-26 15:37:03 +0100" MODIFIED_BY="[Empty name]" ORDER="1023" O_E="0.0" SE="0.0" STUDY_ID="STD-Flec_x002d_SL-2012" TOTAL_1="281" TOTAL_2="81" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="82" O_E="0.0" SE="0.0" STUDY_ID="STD-Steinbeck-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="83" O_E="0.0" SE="0.0" STUDY_ID="STD-Van-Gelder-1989" TOTAL_1="36" TOTAL_2="37" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.4098834853880773" CI_END="1.0219794131785696" CI_START="0.0026676569652129317" DF="1" EFFECT_SIZE="0.05221389182842086" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-001.01.04" LOG_CI_END="0.009442147429811316" LOG_CI_START="-2.5738700172192384" LOG_EFFECT_SIZE="-1.2822139348947135" NO="4" P_CHI2="0.5220286645010228" P_Z="0.051698427356744694" STUDIES="5" TAU2="0.0" TOTAL_1="720" TOTAL_2="378" WEIGHT="0.36463472569412503" Z="1.9456364331489417">
<NAME>Class Ic: Propafenone</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="84" O_E="0.0" SE="0.0" STUDY_ID="STD-Bellandi-2001" TOTAL_1="102" TOTAL_2="92" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.112816886521402" CI_START="0.002378805217974163" EFFECT_SIZE="0.12058690105553621" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7862413864057757" LOG_CI_START="-2.6236411175349175" LOG_EFFECT_SIZE="-0.918699865564571" ORDER="85" O_E="-0.5272727272727272" SE="2.002981862005382" STUDY_ID="STD-Dogan-2004" TOTAL_1="58" TOTAL_2="52" VAR="0.24925619834710744" WEIGHT="0.20928252908331701"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="86" O_E="0.0" SE="0.0" STUDY_ID="STD-Kochiadakis-2004b" TOTAL_1="86" TOTAL_2="83" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="87" O_E="0.0" SE="0.0" STUDY_ID="STD-RAFT-2003" TOTAL_1="397" TOTAL_2="126" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.610453732263025" CI_START="1.7750425800542054E-4" EFFECT_SIZE="0.01690746565270528" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.20694825221594015" LOG_CI_START="-3.7507912245464756" LOG_EFFECT_SIZE="-1.7719214861652675" ORDER="88" O_E="-0.7549019607843137" SE="2.3247957597766145" STUDY_ID="STD-Stroobandt-1997" TOTAL_1="77" TOTAL_2="25" VAR="0.18502499038831216" WEIGHT="0.15535219661080799"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.03979323833063356" CI_END="6.020183113641461" CI_START="0.6247221647524531" DF="1" EFFECT_SIZE="1.9393147828447697" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" I2="0.0" ID="CMP-001.01.05" LOG_CI_END="0.7796097012303479" LOG_CI_START="-0.20431308528349904" LOG_EFFECT_SIZE="0.2876483079734244" NO="5" P_CHI2="0.841885483075447" P_Z="0.25180142288897445" STUDIES="3" TAU2="0.0" TOTAL_1="833" TOTAL_2="550" WEIGHT="2.5135629551826804" Z="1.1459848914351032">
<NAME>Class I others: aprindine, bidisomide, pilsicainide</NAME>
<DICH_DATA CI_END="6.028699779604874" CI_START="0.5933179405154558" EFFECT_SIZE="1.8912788628917594" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.7802236571764537" LOG_CI_START="-0.22671251943759063" LOG_EFFECT_SIZE="0.27675556886943153" ORDER="89" O_E="1.8215158924205381" SE="0.5914792945575514" STUDY_ID="STD-AFIB-1997" TOTAL_1="734" TOTAL_2="493" VAR="2.8583862070379222" WEIGHT="2.399981619204168"/>
<DICH_DATA CI_END="679.4028807857774" CI_START="0.01597709873247045" EFFECT_SIZE="3.2946755387198934" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.8321273840216663" LOG_CI_START="-1.7965020810216048" LOG_EFFECT_SIZE="0.5178126515000308" ORDER="90" O_E="0.16129032258064513" SE="2.7188798598517905" STUDY_ID="STD-Okishige-2000" TOTAL_1="52" TOTAL_2="10" VAR="0.1352757544224766" WEIGHT="0.11358133597851269"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="91" O_E="0.0" SE="0.0" STUDY_ID="STD-SMART-2002" TOTAL_1="47" TOTAL_2="47" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.975962368100425" CI_END="19.562071399301516" CI_START="0.3852327753179633" DF="1" EFFECT_SIZE="2.7451686753496727" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="66.39742455351322" ID="CMP-001.01.06" LOG_CI_END="1.2914148396978127" LOG_CI_START="-0.4142767705241337" LOG_EFFECT_SIZE="0.43856903458683955" MODIFIED="2010-12-27 14:22:39 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.08451003232536636" P_Z="0.3135046102084412" STUDIES="2" TAU2="0.0" TOTAL_1="280" TOTAL_2="282" WEIGHT="0.8363937472016669" Z="1.0078955742918352">
<NAME>Class II: Beta-blockers</NAME>
<DICH_DATA CI_END="72.18140228453399" CI_START="0.7720375667293863" EFFECT_SIZE="7.465035444180193" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.85842531494321" LOG_CI_START="-0.11236156672860168" LOG_EFFECT_SIZE="0.8730318741073041" ORDER="92" O_E="1.5" SE="1.157649969846422" STUDY_ID="STD-Kuhlkamp-2000" TOTAL_1="197" TOTAL_2="197" VAR="0.7461832061068703" WEIGHT="0.6265164500185278"/>
<DICH_DATA CI_END="6.984791782614944" CI_START="0.0027485648960008198" EFFECT_SIZE="0.13855740146080406" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8441534642785211" LOG_CI_START="-2.560894004507846" LOG_EFFECT_SIZE="-0.8583702701146625" MODIFIED="2010-12-27 14:22:39 +0000" MODIFIED_BY="[Empty name]" ORDER="932" O_E="-0.49404761904761907" SE="2.0001417384219207" STUDY_ID="STD-Nergardh-2007" TOTAL_1="83" TOTAL_2="85" VAR="0.24996456916099774" WEIGHT="0.20987729718313902"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.6094669642408883" CI_END="4.5626355919694" CI_START="0.5877183722820766" DF="1" EFFECT_SIZE="1.637542293630465" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" I2="37.86762808942437" ID="CMP-001.01.07" LOG_CI_END="0.6592157839783054" LOG_CI_START="-0.23083073287584852" LOG_EFFECT_SIZE="0.21419252555122845" MODIFIED="2014-06-26 16:04:46 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.2045668009142394" P_Z="0.3455054305224422" STUDIES="5" TAU2="0.0" TOTAL_1="450" TOTAL_2="268" WEIGHT="3.071753728741527" Z="0.9433431351922802">
<NAME>Class III: Amiodarone</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="93" O_E="0.0" SE="0.0" STUDY_ID="STD-Channer-2004" TOTAL_1="61" TOTAL_2="38" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="94" O_E="0.0" SE="0.0" STUDY_ID="STD-GEFACA-2001" TOTAL_1="35" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="95" O_E="0.0" SE="0.0" STUDY_ID="STD-Kochiadakis-2000" TOTAL_1="65" TOTAL_2="60" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.665409500607165" CI_START="0.6778569146090587" EFFECT_SIZE="1.9596777806768189" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="3" LOG_CI_END="0.7532313065077162" LOG_CI_START="-0.1688619694866252" LOG_EFFECT_SIZE="0.2921846685105456" ORDER="96" O_E="2.2932330827067666" SE="0.5416421547544066" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="267" TOTAL_2="132" VAR="3.408592513133819" WEIGHT="2.861950340627842"/>
<DICH_DATA CI_END="7.13045089831306" CI_START="0.002802010873979792" EFFECT_SIZE="0.14134921631707822" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8531169935906664" LOG_CI_START="-2.5525301836468692" LOG_EFFECT_SIZE="-0.8497065950281014" MODIFIED="2014-06-26 16:04:46 +0100" MODIFIED_BY="[Empty name]" ORDER="1044" O_E="-0.4888888888888889" SE="2.0004940101347417" STUDY_ID="STD-Vijayalaskshmi-2006" TOTAL_1="22" TOTAL_2="23" VAR="0.24987654320987654" WEIGHT="0.20980338811368449"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.7262258234220083" CI_END="4.886307969906062" CI_START="0.9764994633534685" DF="3" EFFECT_SIZE="2.1843711018032272" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="6" I2="0.0" ID="CMP-001.01.08" LOG_CI_END="0.6889808358293499" LOG_CI_START="-0.010327991047597787" LOG_EFFECT_SIZE="0.339326422390876" MODIFIED="2010-12-28 10:18:21 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.4357889467341345" P_Z="0.05716185554204312" STUDIES="5" TAU2="0.0" TOTAL_1="1756" TOTAL_2="1358" WEIGHT="4.975924519794553" Z="1.9020711346060846">
<NAME>Class III: Azimilide</NAME>
<DICH_DATA CI_END="18.87621100210338" CI_START="0.3693764966788743" EFFECT_SIZE="2.640535682494779" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.2759148233295785" LOG_CI_START="-0.4325307420506507" LOG_EFFECT_SIZE="0.42169204063946397" MODIFIED="2010-08-20 11:20:46 +0100" MODIFIED_BY="[Empty name]" ORDER="832" O_E="0.9641255605381165" SE="1.003549382046287" STUDY_ID="STD-A_x002d_COMET_x002d_I-2006" TOTAL_1="227" TOTAL_2="219" VAR="0.9929388521742903" WEIGHT="0.8336994449331128"/>
<DICH_DATA CI_END="57.03206089278504" CI_START="1.114392143672338" EFFECT_SIZE="7.972206758254706" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.7561190653987615" LOG_CI_START="0.04703804170397372" LOG_EFFECT_SIZE="0.9015785535513675" MODIFIED="2010-08-27 16:23:55 +0100" MODIFIED_BY="[Empty name]" ORDER="838" O_E="2.0597701149425287" SE="1.003922653405828" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="211" TOTAL_2="224" VAR="0.9922006145610918" WEIGHT="0.8330795998268359"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-11-20 10:05:08 +0000" MODIFIED_BY="[Empty name]" ORDER="884" O_E="0.0" SE="0.0" STUDY_ID="STD-A_x002d_STAR-2006" TOTAL_1="216" TOTAL_2="215" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.846545652652908" CI_START="0.3922949397872779" EFFECT_SIZE="1.2284056313760892" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.5850708912200382" LOG_CI_START="-0.4063872937991818" LOG_EFFECT_SIZE="0.08934179871042822" ORDER="108" O_E="0.6065217391304341" SE="0.5823874456774577" STUDY_ID="STD-ASAP-2003" TOTAL_1="891" TOTAL_2="489" VAR="2.948329317976507" WEIGHT="2.4755003900739507"/>
<DICH_DATA CI_END="19.573210244619457" CI_START="0.3829665080229595" EFFECT_SIZE="2.7378612050615585" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.2916620610788163" LOG_CI_START="-0.416839205187577" LOG_EFFECT_SIZE="0.4374114279456196" MODIFIED="2010-12-28 10:18:21 +0000" MODIFIED_BY="[Empty name]" ORDER="940" O_E="1.0" SE="1.0035821010225436" STUDY_ID="STD-SVA_x002d_4-2008" TOTAL_1="211" TOTAL_2="211" VAR="0.992874109263658" WEIGHT="0.8336450849606539"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.498436197269239" CI_END="1.4111240122658892" CI_START="0.6817106863123817" DF="2" EFFECT_SIZE="0.9808049341605399" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="83" I2="0.0" ID="CMP-001.01.09" LOG_CI_END="0.14956518205777078" LOG_CI_START="-0.16639989806532032" LOG_EFFECT_SIZE="-0.008417358003774791" MODIFIED="2010-12-28 10:29:51 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.7794099761266122" P_Z="0.9168301160726223" STUDIES="3" TAU2="0.0" TOTAL_1="752" TOTAL_2="431" WEIGHT="24.374382848846437" Z="0.10442747993513395">
<NAME>Class III: Dofetilide</NAME>
<DICH_DATA CI_END="1.4431434722617116" CI_START="0.6798268094585525" EFFECT_SIZE="0.9904986735673179" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="80" LOG_CI_END="0.1593095092738014" LOG_CI_START="-0.16760171270039934" LOG_EFFECT_SIZE="-0.004146101713299011" ORDER="97" O_E="-0.2588932806324067" SE="0.19202927002429282" STUDY_ID="STD-DIAMOND-2001" TOTAL_1="249" TOTAL_2="257" VAR="27.11846716635919" WEIGHT="22.76942933043978"/>
<DICH_DATA CI_END="353.27126735483773" CI_START="0.040485957738138234" EFFECT_SIZE="3.7818680040723907" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5481083163573324" LOG_CI_START="-1.3926955825711107" LOG_EFFECT_SIZE="0.5777063668931108" MODIFIED="2010-12-28 10:29:51 +0000" MODIFIED_BY="[Empty name]" ORDER="954" O_E="0.2482435597189696" SE="2.3148477175244766" STUDY_ID="STD-EMERALD-2000" TOTAL_1="321" TOTAL_2="106" VAR="0.18661869477702395" WEIGHT="0.15669031573198752"/>
<DICH_DATA CI_END="3.2294735891450452" CI_START="0.16326815408962927" EFFECT_SIZE="0.7261337284418906" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.5091317372038408" LOG_CI_START="-0.7870985173570041" LOG_EFFECT_SIZE="-0.13898339007658164" ORDER="98" O_E="-0.5519999999999996" SE="0.7614120679722834" STUDY_ID="STD-SAFIRE_x002d_D-2000" TOTAL_1="182" TOTAL_2="68" VAR="1.724886361445783" WEIGHT="1.4482632026746673"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8672350800125168" CI_END="1.094020692356054" CI_START="0.6672515308820154" DF="2" EFFECT_SIZE="0.8543927561673141" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="142" I2="0.0" ID="CMP-001.01.10" LOG_CI_END="0.03902553634025023" LOG_CI_START="-0.17571042113303767" LOG_EFFECT_SIZE="-0.0683424423963937" MODIFIED="2010-11-20 10:16:50 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.6481601244988575" P_Z="0.21218976699748793" STUDIES="3" TAU2="0.0" TOTAL_1="3283" TOTAL_2="2788" WEIGHT="52.77184254838541" Z="1.2475668005354672">
<NAME>Class III: Dronedarone</NAME>
<DICH_DATA CI_END="1.0762908893354253" CI_START="0.6495373719681742" EFFECT_SIZE="0.8361167117886241" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="139" LOG_CI_END="0.03192966404398068" LOG_CI_START="-0.1873958561804416" LOG_EFFECT_SIZE="-0.07773309606823046" MODIFIED="2010-11-20 10:16:50 +0000" MODIFIED_BY="[Empty name]" ORDER="898" O_E="-10.783707865168537" SE="0.1288328962586604" STUDY_ID="STD-ATHENA-2009" TOTAL_1="2301" TOTAL_2="2327" VAR="60.24853064116481" WEIGHT="50.586364350216826"/>
<DICH_DATA CI_END="364.75141324228076" CI_START="0.03825601513883153" EFFECT_SIZE="3.7354966988215743" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5619969832581146" LOG_CI_START="-1.417300269367424" LOG_EFFECT_SIZE="0.5723483569453452" ORDER="818" O_E="0.24120603015075381" SE="2.3374589040313243" STUDY_ID="STD-DAFNE-2003" TOTAL_1="151" TOTAL_2="48" VAR="0.18302568116966741" WEIGHT="0.15367352024298953"/>
<DICH_DATA CI_END="4.615162631249554" CI_START="0.37137711023519626" EFFECT_SIZE="1.309185151633994" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.6641870095027342" LOG_CI_START="-0.43018486743762996" LOG_EFFECT_SIZE="0.11700107103255217" MODIFIED="2010-08-18 11:12:42 +0100" MODIFIED_BY="[Empty name]" ORDER="819" O_E="0.651929260450161" SE="0.6428394577429287" STUDY_ID="STD-EURIDIS-ADONIS-2007" TOTAL_1="831" TOTAL_2="413" VAR="2.4198862275884667" WEIGHT="2.0318046779255896"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.093475807135911" CI_END="4.497935483936708" CI_START="1.1038507573182492" DF="4" EFFECT_SIZE="2.2282391007951015" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="6" I2="21.46816532639581" ID="CMP-001.01.11" LOG_CI_END="0.6530132218485627" LOG_CI_START="0.04291035993799506" LOG_EFFECT_SIZE="0.34796179089327894" MODIFIED="2014-06-26 16:10:17 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.2778401562244872" P_Z="0.025373772584076637" STUDIES="13" TAU2="0.0" TOTAL_1="1824" TOTAL_2="1234" WEIGHT="6.537409346187501" Z="2.235664248520947">
<NAME>Class III: Sotalol</NAME>
<DICH_DATA CI_END="53.766620926152854" CI_START="1.0528118484471085" EFFECT_SIZE="7.523704909286246" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.7305127432050487" LOG_CI_START="0.022350763889791982" LOG_EFFECT_SIZE="0.8764317535474203" MODIFIED="2010-08-27 18:08:04 +0100" MODIFIED_BY="[Empty name]" ORDER="861" O_E="2.004474272930649" SE="1.0033828021879485" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="223" TOTAL_2="224" VAR="0.9932685714857689" WEIGHT="0.8339762865597259"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="99" O_E="0.0" SE="0.0" STUDY_ID="STD-Bellandi-2001" TOTAL_1="106" TOTAL_2="92" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="100" O_E="0.0" SE="0.0" STUDY_ID="STD-Benditt-1999" TOTAL_1="184" TOTAL_2="69" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="101" O_E="0.0" SE="0.0" STUDY_ID="STD-Carunchio-1995" TOTAL_1="20" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-27 13:05:43 +0000" MODIFIED_BY="[Empty name]" ORDER="912" O_E="0.0" SE="0.0" STUDY_ID="STD-DAPHNE-2008" TOTAL_1="69" TOTAL_2="66" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-28 10:37:36 +0000" MODIFIED_BY="[Empty name]" ORDER="972" O_E="0.0" SE="0.0" STUDY_ID="STD-EMERALD-2000" TOTAL_1="108" TOTAL_2="106" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="102" O_E="0.0" SE="0.0" STUDY_ID="STD-Kochiadakis-2004b" TOTAL_1="85" TOTAL_2="83" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.371323379499582" CI_START="0.3847619309837751" EFFECT_SIZE="1.4375954769804182" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="2" LOG_CI_END="0.7300812997790568" LOG_CI_START="-0.41480790436177406" LOG_EFFECT_SIZE="0.1576366977086414" ORDER="103" O_E="0.8025477707006363" SE="0.6725135858052854" STUDY_ID="STD-PAFAC-2004" TOTAL_1="383" TOTAL_2="88" VAR="2.2110464970742414" WEIGHT="1.8564569543186087"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="104" O_E="0.0" SE="0.0" STUDY_ID="STD-Plewan-2001" TOTAL_1="64" TOTAL_2="64" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.007583308640837" CI_START="0.8129459997107931" EFFECT_SIZE="2.2099413609163703" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="3" LOG_CI_END="0.7786998019864907" LOG_CI_START="-0.08993830164641405" LOG_EFFECT_SIZE="0.34438075017003833" ORDER="105" O_E="3.0458015267175576" SE="0.510242321901928" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="261" TOTAL_2="132" VAR="3.841024201767415" WEIGHT="3.2250321739108005"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="107" O_E="0.0" SE="0.0" STUDY_ID="STD-Singh-1991" TOTAL_1="24" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="113.29018050149466" CI_START="0.4400653449064914" EFFECT_SIZE="7.060813151253114" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0541922687440057" LOG_CI_START="-0.3564828307292117" LOG_EFFECT_SIZE="0.8488547190073971" ORDER="106" O_E="0.974757281553398" SE="1.4160424864647638" STUDY_ID="STD-SOPAT-2004" TOTAL_1="264" TOTAL_2="251" VAR="0.4987092597761316" WEIGHT="0.4187303499585328"/>
<DICH_DATA CI_END="4.707607339689307" CI_START="0.0016307014806284633" EFFECT_SIZE="0.08761679210658638" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.672800231291631" LOG_CI_START="-2.7876255344726837" LOG_EFFECT_SIZE="-1.0574126515905262" MODIFIED="2014-06-26 16:10:17 +0100" MODIFIED_BY="[Empty name]" ORDER="1049" O_E="-0.5892857142857143" SE="2.032671224193758" STUDY_ID="STD-Vijayalaskshmi-2006" TOTAL_1="33" TOTAL_2="23" VAR="0.24202806122448978" WEIGHT="0.2032135814398331"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="43.32525630536738" CI_END="1.347513006988973" CI_START="0.9913476648544028" CI_STUDY="95" CI_TOTAL="95" DF="37" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.155791448678979" ESTIMABLE="YES" EVENTS_1="450" EVENTS_2="319" I2="14.599466557763384" I2_Q="61.42894300410029" ID="CMP-001.02" LOG_CI_END="0.12953296594506494" LOG_CI_START="-0.0037740120648018047" LOG_EFFECT_SIZE="0.06287947694013162" METHOD="PETO" MODIFIED="2014-06-26 16:10:47 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2195579176435547" P_Q="0.0038407585983356585" P_Z="0.06445952634423158" Q="25.9261756841744" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="41" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11453" TOTAL_2="8067" WEIGHT="100.0" Z="1.8489881326430333">
<NAME>Individual antiarrhythmics - ITT Worst case: missing patients counted as events</NAME>
<GROUP_LABEL_1>Antiarrhythmic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.953289035605016" CI_END="5.007326561145707" CI_START="1.0496659924779606" DF="5" EFFECT_SIZE="2.292601231018221" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="6" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.6996059155608523" LOG_CI_START="0.021051126974491314" LOG_EFFECT_SIZE="0.36032852126767184" NO="1" P_CHI2="0.7071874750526199" P_Z="0.037381419475920004" STUDIES="7" TAU2="0.0" TOTAL_1="1128" TOTAL_2="548" WEIGHT="3.8595433862442365" Z="2.0815737687402036">
<NAME>Class Ia: Quinidine</NAME>
<DICH_DATA CI_END="12.706990895055712" CI_START="0.3336982706163355" EFFECT_SIZE="2.0591990885821634" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="1.1040427187369553" LOG_CI_START="-0.4766460440606066" LOG_EFFECT_SIZE="0.31369833733817437" ORDER="111" O_E="0.8378378378378377" SE="0.9285044038028561" STUDY_ID="STD-Byrne_x002d_Quinn-1970" TOTAL_1="32" TOTAL_2="42" VAR="1.1599307563765173" WEIGHT="0.7112348603318007"/>
<DICH_DATA CI_END="406.0194289218663" CI_START="0.15885962215189478" EFFECT_SIZE="8.031194996067258" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.6085468160197243" LOG_CI_START="-0.7989864747561749" LOG_EFFECT_SIZE="0.9047801706317746" ORDER="112" O_E="0.52" SE="2.001601922563589" STUDY_ID="STD-Hillestad-1971" TOTAL_1="48" TOTAL_2="52" VAR="0.2496" WEIGHT="0.15304725748749134"/>
<DICH_DATA CI_END="56.32059641298373" CI_START="0.9865240347640378" EFFECT_SIZE="7.453966864271246" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.7506672451663057" LOG_CI_START="-0.005892329531666832" LOG_EFFECT_SIZE="0.8723874578173194" ORDER="113" O_E="1.8867924528301887" SE="1.0318117892877168" STUDY_ID="STD-Lloyd-1984" TOTAL_1="28" TOTAL_2="25" VAR="0.9392885505381054" WEIGHT="0.5759436564473476"/>
<DICH_DATA CI_END="4.829173192322102" CI_START="0.22861787023996857" EFFECT_SIZE="1.050730836250954" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="0.6838727811139533" LOG_CI_START="-0.640889825369967" LOG_EFFECT_SIZE="0.021491477871993174" ORDER="114" O_E="0.08172043010752716" SE="0.7781721127293179" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="88" VAR="1.6513862874320733" WEIGHT="1.012580698493305"/>
<DICH_DATA CI_END="8.24184638422739" CI_START="0.4635516457913856" EFFECT_SIZE="1.9546154240075941" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="0.9160245156600444" LOG_CI_START="-0.33390187266793026" LOG_EFFECT_SIZE="0.29106132149605707" ORDER="116" O_E="1.243243243243243" SE="0.7342129477392609" STUDY_ID="STD-Sodermark-1975" TOTAL_1="110" TOTAL_2="75" VAR="1.8550512910089878" WEIGHT="1.1374619895334768"/>
<DICH_DATA CI_END="85.12319633156255" CI_START="0.22966890860097597" EFFECT_SIZE="4.421555336993599" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9300479227881144" LOG_CI_START="-0.6388977933855617" LOG_EFFECT_SIZE="0.6455750647012765" ORDER="115" O_E="0.6527958387516255" SE="1.5090114301668014" STUDY_ID="STD-SOPAT-2004" TOTAL_1="518" TOTAL_2="251" VAR="0.43915207708714865" WEIGHT="0.26927492395081526"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="117" O_E="0.0" SE="0.0" STUDY_ID="STD-Steinbeck-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0022227575059230453" CI_END="42.5538364341832" CI_START="1.20985251737705" DF="1" EFFECT_SIZE="7.175225859437999" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="1.6289387199338452" LOG_CI_START="0.08273243247090524" LOG_EFFECT_SIZE="0.8558355762023753" NO="2" P_CHI2="0.9623967747232025" P_Z="0.03002908832107573" STUDIES="2" TAU2="0.0" TOTAL_1="75" TOTAL_2="71" WEIGHT="0.7433115767201173" Z="2.169706486961812">
<NAME>Class Ia: Disopyramide</NAME>
<DICH_DATA CI_END="122.6563157532565" CI_START="0.46536100533222263" EFFECT_SIZE="7.555095393791001" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0886899155768055" LOG_CI_START="-0.33221001099032044" LOG_EFFECT_SIZE="0.8782399522932426" ORDER="118" O_E="1.0" SE="1.422048600513436" STUDY_ID="STD-Karlson-1998" TOTAL_1="46" TOTAL_2="46" VAR="0.4945054945054945" WEIGHT="0.30321598456154514"/>
<DICH_DATA CI_END="70.0050682206034" CI_START="0.6849666782463701" EFFECT_SIZE="6.9246760963583895" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.845129483165138" LOG_CI_START="-0.16433055523125528" LOG_EFFECT_SIZE="0.8403994639669414" ORDER="119" O_E="1.3888888888888888" SE="1.1803667735416545" STUDY_ID="STD-Lloyd-1984" TOTAL_1="29" TOTAL_2="25" VAR="0.7177381784300025" WEIGHT="0.44009559215857214"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.631051313638759" CI_START="0.4598845744795137" DF="0" EFFECT_SIZE="1.2922323662120678" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="4" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="0.5600323863606181" LOG_CI_START="-0.3373511573552504" LOG_EFFECT_SIZE="0.11134061450268384" MODIFIED="2014-06-26 15:42:05 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.6267153215439617" STUDIES="4" TAU2="0.0" TOTAL_1="352" TOTAL_2="159" WEIGHT="2.20673185561387" Z="0.4863552401199655">
<NAME>Class Ic: Flecainide</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="120" O_E="0.0" SE="0.0" STUDY_ID="STD-Carunchio-1995" TOTAL_1="20" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.631051313638759" CI_START="0.4598845744795137" EFFECT_SIZE="1.2922323662120678" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="4" LOG_CI_END="0.5600323863606181" LOG_CI_START="-0.3373511573552504" LOG_EFFECT_SIZE="0.11134061450268384" MODIFIED="2014-06-26 15:42:05 +0100" MODIFIED_BY="[Empty name]" ORDER="1024" O_E="0.9226519337016583" SE="0.5271275356988842" STUDY_ID="STD-Flec_x002d_SL-2012" TOTAL_1="281" TOTAL_2="81" VAR="3.5988901742080497" WEIGHT="2.20673185561387"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="122" O_E="0.0" SE="0.0" STUDY_ID="STD-Steinbeck-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="123" O_E="0.0" SE="0.0" STUDY_ID="STD-Van-Gelder-1989" TOTAL_1="36" TOTAL_2="37" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.7221073352676255" CI_END="3.3707093243040305" CI_START="0.47761906819835337" DF="2" EFFECT_SIZE="1.2688242772904341" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" I2="26.527511458200127" ID="CMP-001.02.04" LOG_CI_END="0.5277213024189907" LOG_CI_START="-0.3209183430009335" LOG_EFFECT_SIZE="0.10340147970902866" NO="4" P_CHI2="0.2563906990717746" P_Z="0.6329214625481724" STUDIES="5" TAU2="0.0" TOTAL_1="720" TOTAL_2="378" WEIGHT="2.4675112049978507" Z="0.47761892169806286">
<NAME>Class Ic: Propafenone</NAME>
<DICH_DATA CI_END="7.987322203229074" CI_START="0.22995810053987137" EFFECT_SIZE="1.3552672955009644" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9024012039344168" LOG_CI_START="-0.6383512872954114" LOG_EFFECT_SIZE="0.1320249583195027" ORDER="124" O_E="0.3711340206185567" SE="0.9050456401962368" STUDY_ID="STD-Bellandi-2001" TOTAL_1="102" TOTAL_2="92" VAR="1.2208408111074338" WEIGHT="0.7485830848108863"/>
<DICH_DATA CI_END="2.3316717085613807" CI_START="0.04352792422750824" EFFECT_SIZE="0.318579392700916" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.3676674032066909" LOG_CI_START="-1.3612320431121614" LOG_EFFECT_SIZE="-0.49678231995273525" ORDER="125" O_E="-1.109090909090909" SE="1.015564092957978" STUDY_ID="STD-Dogan-2004" TOTAL_1="58" TOTAL_2="52" VAR="0.9695837440291152" WEIGHT="0.5945197633337737"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="126" O_E="0.0" SE="0.0" STUDY_ID="STD-Kochiadakis-2004b" TOTAL_1="86" TOTAL_2="83" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="127" O_E="0.0" SE="0.0" STUDY_ID="STD-RAFT-2003" TOTAL_1="397" TOTAL_2="126" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="10.721778934539554" CI_START="0.5930700458842966" EFFECT_SIZE="2.5216593593641186" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="1.0302668485431432" LOG_CI_START="-0.22689401027061804" LOG_EFFECT_SIZE="0.4016864191362626" ORDER="128" O_E="1.6960784313725483" SE="0.7384625115138185" STUDY_ID="STD-Stroobandt-1997" TOTAL_1="77" TOTAL_2="25" VAR="1.833762528501985" WEIGHT="1.124408356853191"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.03979323833063356" CI_END="6.020183113641461" CI_START="0.6247221647524531" DF="1" EFFECT_SIZE="1.9393147828447697" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" I2="0.0" ID="CMP-001.02.05" LOG_CI_END="0.7796097012303479" LOG_CI_START="-0.20431308528349904" LOG_EFFECT_SIZE="0.2876483079734244" NO="5" P_CHI2="0.841885483075447" P_Z="0.25180142288897445" STUDIES="3" TAU2="0.0" TOTAL_1="833" TOTAL_2="550" WEIGHT="1.8356240106015147" Z="1.1459848914351032">
<NAME>Class I others: aprindine, bidisomide, pilsicainide</NAME>
<DICH_DATA CI_END="6.028699779604874" CI_START="0.5933179405154558" EFFECT_SIZE="1.8912788628917594" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.7802236571764537" LOG_CI_START="-0.22671251943759063" LOG_EFFECT_SIZE="0.27675556886943153" ORDER="129" O_E="1.8215158924205381" SE="0.5914792945575514" STUDY_ID="STD-AFIB-1997" TOTAL_1="734" TOTAL_2="493" VAR="2.8583862070379222" WEIGHT="1.7526769624488248"/>
<DICH_DATA CI_END="679.4028807857774" CI_START="0.01597709873247045" EFFECT_SIZE="3.2946755387198934" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.8321273840216663" LOG_CI_START="-1.7965020810216048" LOG_EFFECT_SIZE="0.5178126515000308" ORDER="130" O_E="0.16129032258064513" SE="2.7188798598517905" STUDY_ID="STD-Okishige-2000" TOTAL_1="52" TOTAL_2="10" VAR="0.1352757544224766" WEIGHT="0.08294704815269001"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="131" O_E="0.0" SE="0.0" STUDY_ID="STD-SMART-2002" TOTAL_1="47" TOTAL_2="47" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.704703893647685" CI_END="1.4656531588285624" CI_START="0.3860488905247743" DF="1" EFFECT_SIZE="0.752205939793018" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="21" I2="0.0" ID="CMP-001.02.06" LOG_CI_END="0.16603120834836035" LOG_CI_START="-0.4133576913371356" LOG_EFFECT_SIZE="-0.12366324149438764" MODIFIED="2010-12-27 14:23:32 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.4012080651452137" P_Z="0.40278421977342005" STUDIES="2" TAU2="0.0" TOTAL_1="280" TOTAL_2="282" WEIGHT="5.293774355551582" Z="0.8366591064207314">
<NAME>Class II: Beta-blockers</NAME>
<DICH_DATA CI_END="1.821543958981695" CI_START="0.4116439268710235" EFFECT_SIZE="0.8659258098956375" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" LOG_CI_END="0.26043965645238815" LOG_CI_START="-0.3854782875058519" LOG_EFFECT_SIZE="-0.06251931552673183" ORDER="132" O_E="-1.0" SE="0.37941539762645893" STUDY_ID="STD-Kuhlkamp-2000" TOTAL_1="197" TOTAL_2="197" VAR="6.9465648854961835" WEIGHT="4.259425900176684"/>
<DICH_DATA CI_END="1.905117138724941" CI_START="0.09314787379899366" EFFECT_SIZE="0.42125717894209314" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.27992168402100204" LOG_CI_START="-1.0308270538960602" LOG_EFFECT_SIZE="-0.37545268493752915" MODIFIED="2010-12-27 14:23:32 +0000" MODIFIED_BY="[Empty name]" ORDER="933" O_E="-1.4583333333333335" SE="0.7699402969633772" STUDY_ID="STD-Nergardh-2007" TOTAL_1="83" TOTAL_2="85" VAR="1.686886643379907" WEIGHT="1.0343484553748983"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3318937733743528" CI_END="2.891765552034319" CI_START="0.6419017532684367" DF="1" EFFECT_SIZE="1.3624350912583316" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="9" I2="24.91893723127032" ID="CMP-001.02.07" LOG_CI_END="0.4611630799139353" LOG_CI_START="-0.1925314380970471" LOG_EFFECT_SIZE="0.13431582090844413" MODIFIED="2014-06-26 16:05:47 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.2484687389401179" P_Z="0.42056879786283885" STUDIES="5" TAU2="0.0" TOTAL_1="450" TOTAL_2="268" WEIGHT="4.158685525767253" Z="0.8054348454244178">
<NAME>Class III: Amiodarone</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="133" O_E="0.0" SE="0.0" STUDY_ID="STD-Channer-2004" TOTAL_1="61" TOTAL_2="38" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="134" O_E="0.0" SE="0.0" STUDY_ID="STD-GEFACA-2001" TOTAL_1="35" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="135" O_E="0.0" SE="0.0" STUDY_ID="STD-Kochiadakis-2000" TOTAL_1="65" TOTAL_2="60" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.1988687259284116" CI_START="0.6901074188910759" EFFECT_SIZE="1.4857870102480506" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="8" LOG_CI_END="0.5049964180226181" LOG_CI_START="-0.16108330375450375" LOG_EFFECT_SIZE="0.17195655713405722" ORDER="136" O_E="2.5864661654135332" SE="0.3912585257196799" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="267" TOTAL_2="132" VAR="6.532394006893534" WEIGHT="4.005468700251523"/>
<DICH_DATA CI_END="7.13045089831306" CI_START="0.002802010873979792" EFFECT_SIZE="0.14134921631707822" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8531169935906664" LOG_CI_START="-2.5525301836468692" LOG_EFFECT_SIZE="-0.8497065950281014" MODIFIED="2014-06-26 16:05:47 +0100" MODIFIED_BY="[Empty name]" ORDER="1045" O_E="-0.4888888888888889" SE="2.0004940101347417" STUDY_ID="STD-Vijayalaskshmi-2006" TOTAL_1="22" TOTAL_2="23" VAR="0.24987654320987654" WEIGHT="0.1532168255157301"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.8027605211996143" CI_END="3.0589891462055414" CI_START="0.9923759981296565" DF="3" EFFECT_SIZE="1.7423166782285906" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="17" I2="0.0" ID="CMP-001.02.08" LOG_CI_END="0.48557793603946664" LOG_CI_START="-0.003323748234876764" LOG_EFFECT_SIZE="0.24112709390229495" MODIFIED="2010-12-28 10:19:15 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.6143345457745629" P_Z="0.053197435372494224" STUDIES="5" TAU2="0.0" TOTAL_1="1756" TOTAL_2="1358" WEIGHT="7.434687177567103" Z="1.933314754056399">
<NAME>Class III: Azimilide</NAME>
<DICH_DATA CI_END="3.3829732237787216" CI_START="0.4605093029827673" EFFECT_SIZE="1.2481548947513301" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.5292985603622732" LOG_CI_START="-0.33676159197468625" LOG_EFFECT_SIZE="0.09626848419379341" MODIFIED="2010-08-20 11:21:37 +0100" MODIFIED_BY="[Empty name]" ORDER="833" O_E="0.856502242152466" SE="0.508728020549625" STUDY_ID="STD-A_x002d_COMET_x002d_I-2006" TOTAL_1="227" TOTAL_2="219" VAR="3.863924945112623" WEIGHT="2.369243253153015"/>
<DICH_DATA CI_END="6.89790761897822" CI_START="1.0462514886625305" EFFECT_SIZE="2.686437439251577" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" LOG_CI_END="0.8387173737314806" LOG_CI_START="0.019636088939153876" LOG_EFFECT_SIZE="0.42917673133531714" MODIFIED="2010-08-27 16:25:03 +0100" MODIFIED_BY="[Empty name]" ORDER="839" O_E="4.26896551724138" SE="0.48113240120476286" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="211" TOTAL_2="224" VAR="4.319871121169115" WEIGHT="2.648815816483764"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-11-20 10:06:29 +0000" MODIFIED_BY="[Empty name]" ORDER="885" O_E="0.0" SE="0.0" STUDY_ID="STD-A_x002d_STAR-2006" TOTAL_1="216" TOTAL_2="215" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.846545652652908" CI_START="0.3922949397872779" EFFECT_SIZE="1.2284056313760892" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.5850708912200382" LOG_CI_START="-0.4063872937991818" LOG_EFFECT_SIZE="0.08934179871042822" ORDER="148" O_E="0.6065217391304341" SE="0.5823874456774577" STUDY_ID="STD-ASAP-2003" TOTAL_1="891" TOTAL_2="489" VAR="2.948329317976507" WEIGHT="1.807827388967429"/>
<DICH_DATA CI_END="19.573210244619457" CI_START="0.3829665080229595" EFFECT_SIZE="2.7378612050615585" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.2916620610788163" LOG_CI_START="-0.416839205187577" LOG_EFFECT_SIZE="0.4374114279456196" MODIFIED="2010-12-28 10:19:15 +0000" MODIFIED_BY="[Empty name]" ORDER="941" O_E="1.0" SE="1.0035821010225436" STUDY_ID="STD-SVA_x002d_4-2008" TOTAL_1="211" TOTAL_2="211" VAR="0.992874109263658" WEIGHT="0.6088007189628954"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0244620622418867" CI_END="1.4493014266105295" CI_START="0.7198418233606765" DF="2" EFFECT_SIZE="1.0214048078653992" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="85" I2="0.0" ID="CMP-001.02.09" LOG_CI_END="0.16115871970137013" LOG_CI_START="-0.1427629241083853" LOG_EFFECT_SIZE="0.009197897796492393" MODIFIED="2010-12-28 10:30:25 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.5991574225125289" P_Z="0.905566222840359" STUDIES="3" TAU2="0.0" TOTAL_1="752" TOTAL_2="431" WEIGHT="19.239000576985294" Z="0.118632869897809">
<NAME>Class III: Dofetilide</NAME>
<DICH_DATA CI_END="1.4431434722617116" CI_START="0.6798268094585525" EFFECT_SIZE="0.9904986735673179" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="80" LOG_CI_END="0.1593095092738014" LOG_CI_START="-0.16760171270039934" LOG_EFFECT_SIZE="-0.004146101713299011" ORDER="137" O_E="-0.2588932806324067" SE="0.19202927002429282" STUDY_ID="STD-DIAMOND-2001" TOTAL_1="249" TOTAL_2="257" VAR="27.11846716635919" WEIGHT="16.628233281553904"/>
<DICH_DATA CI_END="6.134913771390169" CI_START="0.5225605021612942" EFFECT_SIZE="1.790492563819768" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="2" LOG_CI_END="0.7878084629273086" LOG_CI_START="-0.28186341960230843" LOG_EFFECT_SIZE="0.25297252166250006" MODIFIED="2010-12-28 10:30:25 +0000" MODIFIED_BY="[Empty name]" ORDER="955" O_E="1.4754098360655732" SE="0.6283305587591116" STUDY_ID="STD-EMERALD-2000" TOTAL_1="321" TOTAL_2="106" VAR="2.532932613147306" WEIGHT="1.5531185490497599"/>
<DICH_DATA CI_END="3.2294735891450452" CI_START="0.16326815408962927" EFFECT_SIZE="0.7261337284418906" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.5091317372038408" LOG_CI_START="-0.7870985173570041" LOG_EFFECT_SIZE="-0.13898339007658164" ORDER="138" O_E="-0.5519999999999996" SE="0.7614120679722834" STUDY_ID="STD-SAFIRE_x002d_D-2000" TOTAL_1="182" TOTAL_2="68" VAR="1.724886361445783" WEIGHT="1.05764874638163"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8860213479458087" CI_END="1.0776869492846166" CI_START="0.660095655482277" DF="2" EFFECT_SIZE="0.8434313683950369" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="145" I2="0.0" ID="CMP-001.02.10" LOG_CI_END="0.03249262361242774" LOG_CI_START="-0.18039312561272738" LOG_EFFECT_SIZE="-0.07395025100014983" MODIFIED="2010-11-20 10:19:54 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.6421003781323968" P_Z="0.17330276629485677" STUDIES="3" TAU2="0.0" TOTAL_1="3283" TOTAL_2="2788" WEIGHT="39.211421437685985" Z="1.3616677408941784">
<NAME>Class III: Dronedarone</NAME>
<DICH_DATA CI_END="1.0592083404752914" CI_START="0.6404142236308373" EFFECT_SIZE="0.8236091834291257" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="141" LOG_CI_END="0.0249813918540597" LOG_CI_START="-0.19353903094420208" LOG_EFFECT_SIZE="-0.08427881954507124" MODIFIED="2010-11-20 10:19:54 +0000" MODIFIED_BY="[Empty name]" ORDER="899" O_E="-11.778089887640448" SE="0.12835997804523713" STUDY_ID="STD-ATHENA-2009" TOTAL_1="2301" TOTAL_2="2327" VAR="60.69329723854541" WEIGHT="37.2153152653546"/>
<DICH_DATA CI_END="364.75141324228076" CI_START="0.03825601513883153" EFFECT_SIZE="3.7354966988215743" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5619969832581146" LOG_CI_START="-1.417300269367424" LOG_EFFECT_SIZE="0.5723483569453452" ORDER="818" O_E="0.24120603015075381" SE="2.3374589040313243" STUDY_ID="STD-DAFNE-2003" TOTAL_1="151" TOTAL_2="48" VAR="0.18302568116966741" WEIGHT="0.11222587561216982"/>
<DICH_DATA CI_END="3.7775055849313035" CI_START="0.4036136548600519" EFFECT_SIZE="1.234768332679609" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.5772051151032017" LOG_CI_START="-0.39403414934777264" LOG_EFFECT_SIZE="0.09158548287771451" MODIFIED="2010-08-20 09:44:31 +0100" MODIFIED_BY="[Empty name]" ORDER="819" O_E="0.6479099678456599" SE="0.5705107516503991" STUDY_ID="STD-EURIDIS-ADONIS-2007" TOTAL_1="831" TOTAL_2="413" VAR="3.0723616337884976" WEIGHT="1.883880296719222"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.9318266560744455" CI_END="3.128597494320208" CI_START="1.3589396926673964" DF="9" EFFECT_SIZE="2.0619348480035664" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="23" I2="0.0" ID="CMP-001.02.11" LOG_CI_END="0.49534969314302735" LOG_CI_START="0.1332001839415321" LOG_EFFECT_SIZE="0.3142749385422798" MODIFIED="2014-06-26 16:10:47 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.7467215705045946" P_Z="6.69605731861808E-4" STUDIES="13" TAU2="0.0" TOTAL_1="1824" TOTAL_2="1234" WEIGHT="13.549708892265192" Z="3.401730750068149">
<NAME>Class III: Sotalol</NAME>
<DICH_DATA CI_END="5.915805557728367" CI_START="0.8056098539857611" EFFECT_SIZE="2.1830783887826164" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.772013891052815" LOG_CI_START="-0.09387523025797899" LOG_EFFECT_SIZE="0.33906933039741805" MODIFIED="2010-08-27 18:11:48 +0100" MODIFIED_BY="[Empty name]" ORDER="869" O_E="3.0178970917225953" SE="0.5086275560782382" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="223" TOTAL_2="224" VAR="3.8654515061884096" WEIGHT="2.3701792947637372"/>
<DICH_DATA CI_END="10.068730387843296" CI_START="0.5944892264996772" EFFECT_SIZE="2.44657960019754" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.0029747118330903" LOG_CI_START="-0.22585601138025455" LOG_EFFECT_SIZE="0.3885593502264179" ORDER="139" O_E="1.7171717171717171" SE="0.7218212496257009" STUDY_ID="STD-Bellandi-2001" TOTAL_1="106" TOTAL_2="92" VAR="1.919290324151115" WEIGHT="1.1768514440448976"/>
<DICH_DATA CI_END="4.7467917862073605" CI_START="0.45794857254749255" EFFECT_SIZE="1.4743766556324145" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" LOG_CI_END="0.6764001821956298" LOG_CI_START="-0.33918329036486944" LOG_EFFECT_SIZE="0.16860844591538018" ORDER="140" O_E="1.0909090909090917" SE="0.5965587590013044" STUDY_ID="STD-Benditt-1999" TOTAL_1="184" TOTAL_2="69" VAR="2.8099173553719012" WEIGHT="1.722957311723454"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="141" O_E="0.0" SE="0.0" STUDY_ID="STD-Carunchio-1995" TOTAL_1="20" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.88044138748738" CI_START="0.18681891909731724" EFFECT_SIZE="0.9548606101040107" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6884591014046701" LOG_CI_START="-0.7285791450036011" LOG_EFFECT_SIZE="-0.020060021799465446" MODIFIED="2010-12-27 13:06:29 +0000" MODIFIED_BY="[Empty name]" ORDER="913" O_E="-0.06666666666666687" SE="0.832375280392666" STUDY_ID="STD-DAPHNE-2008" TOTAL_1="69" TOTAL_2="66" VAR="1.4433167495854062" WEIGHT="0.8849986787251873"/>
<DICH_DATA CI_END="10.652639510573582" CI_START="0.5272140901747715" EFFECT_SIZE="2.3698568833427207" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0274572305773044" LOG_CI_START="-0.27801299142736136" LOG_EFFECT_SIZE="0.37472211957497154" MODIFIED="2010-12-28 10:42:11 +0000" MODIFIED_BY="[Empty name]" ORDER="978" O_E="1.467289719626168" SE="0.7668396705873604" STUDY_ID="STD-EMERALD-2000" TOTAL_1="108" TOTAL_2="106" VAR="1.7005556792585366" WEIGHT="1.0427298995003886"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="142" O_E="0.0" SE="0.0" STUDY_ID="STD-Kochiadakis-2004b" TOTAL_1="85" TOTAL_2="83" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.371323379499582" CI_START="0.3847619309837751" EFFECT_SIZE="1.4375954769804182" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="2" LOG_CI_END="0.7300812997790568" LOG_CI_START="-0.41480790436177406" LOG_EFFECT_SIZE="0.1576366977086414" ORDER="143" O_E="0.8025477707006363" SE="0.6725135858052854" STUDY_ID="STD-PAFAC-2004" TOTAL_1="383" TOTAL_2="88" VAR="2.2110464970742414" WEIGHT="1.3557476063883702"/>
<DICH_DATA CI_END="8.973986079248892" CI_START="0.25453582258990537" EFFECT_SIZE="1.5113573133418767" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9529853915052704" LOG_CI_START="-0.5942510877542916" LOG_EFFECT_SIZE="0.17936715187548932" ORDER="144" O_E="0.5" SE="0.9088543668611608" STUDY_ID="STD-Plewan-2001" TOTAL_1="64" TOTAL_2="64" VAR="1.2106299212598426" WEIGHT="0.7423220724403706"/>
<DICH_DATA CI_END="6.884445501914499" CI_START="1.4255872970929997" EFFECT_SIZE="3.1327907774152983" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="3" LOG_CI_END="0.8378689663566938" LOG_CI_START="0.15399381686466165" LOG_EFFECT_SIZE="0.49593139161067773" ORDER="145" O_E="7.076335877862597" SE="0.4017116480482061" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="261" TOTAL_2="132" VAR="6.196852378851431" WEIGHT="3.799724605921668"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="147" O_E="0.0" SE="0.0" STUDY_ID="STD-Singh-1991" TOTAL_1="24" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="113.29018050149466" CI_START="0.4400653449064914" EFFECT_SIZE="7.060813151253114" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0541922687440057" LOG_CI_START="-0.3564828307292117" LOG_EFFECT_SIZE="0.8488547190073971" ORDER="146" O_E="0.974757281553398" SE="1.4160424864647638" STUDY_ID="STD-SOPAT-2004" TOTAL_1="264" TOTAL_2="251" VAR="0.4987092597761316" WEIGHT="0.3057936077418022"/>
<DICH_DATA CI_END="4.707607339689307" CI_START="0.0016307014806284633" EFFECT_SIZE="0.08761679210658638" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.672800231291631" LOG_CI_START="-2.7876255344726837" LOG_EFFECT_SIZE="-1.0574126515905262" MODIFIED="2014-06-26 16:10:47 +0100" MODIFIED_BY="[Empty name]" ORDER="1050" O_E="-0.5892857142857143" SE="2.032671224193758" STUDY_ID="STD-Vijayalaskshmi-2006" TOTAL_1="33" TOTAL_2="23" VAR="0.24202806122448978" WEIGHT="0.14840437101531573"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.7642157839654313" CI_END="5.452067743293513" CI_START="0.9328111446664864" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.255160648916358" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.7365612434127788" LOG_CI_START="-0.030206273864816197" LOG_EFFECT_SIZE="0.3531774847739813" METHOD="PETO" MODIFIED="2010-12-28 12:20:01 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7362808387627093" P_Q="0.37887201655372316" P_Z="0.07099004314331925" Q="0.7743588512847168" RANDOM="NO" SCALE="150.13411227935356" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1128" TOTAL_2="548" WEIGHT="100.0" Z="1.805541144374905">
<NAME>Quinidine: older and recent studies</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.2735117039032717" CI_END="10.141002613711747" CI_START="0.9901356707072551" DF="3" EFFECT_SIZE="3.168748715908459" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="1.0060808946498718" LOG_CI_START="-0.004305293278628854" LOG_EFFECT_SIZE="0.5008878006856216" NO="1" P_CHI2="0.7354324890683877" P_Z="0.051984628079411864" STUDIES="5" TAU2="0.0" TOTAL_1="233" TOTAL_2="209" WEIGHT="57.5907337092749" Z="1.9432610250779996">
<NAME>Older studies, higher dose</NAME>
<DICH_DATA CI_END="527.8001204153296" CI_START="0.19326023079046073" EFFECT_SIZE="10.099642225480048" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.7224694849664623" LOG_CI_START="-0.713857506163923" LOG_EFFECT_SIZE="1.0043059894012696" ORDER="151" O_E="0.5675675675675675" SE="2.0185154846829296" STUDY_ID="STD-Byrne_x002d_Quinn-1970" TOTAL_1="32" TOTAL_2="42" VAR="0.2454346238130022" WEIGHT="4.978957810536677"/>
<DICH_DATA CI_END="406.0194289218663" CI_START="0.15885962215189478" EFFECT_SIZE="8.031194996067258" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.6085468160197243" LOG_CI_START="-0.7989864747561749" LOG_EFFECT_SIZE="0.9047801706317746" ORDER="152" O_E="0.52" SE="2.001601922563589" STUDY_ID="STD-Hillestad-1971" TOTAL_1="48" TOTAL_2="52" VAR="0.2496" WEIGHT="5.063457837378356"/>
<DICH_DATA CI_END="113.67197031843577" CI_START="0.4175408606629363" EFFECT_SIZE="6.8893172608039634" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0556533878472827" LOG_CI_START="-0.3793010179238064" LOG_EFFECT_SIZE="0.8381761849617383" ORDER="153" O_E="0.9433962264150944" SE="1.4303042711686382" STUDY_ID="STD-Lloyd-1984" TOTAL_1="28" TOTAL_2="25" VAR="0.4888134293616671" WEIGHT="9.916210696783352"/>
<DICH_DATA CI_END="8.24184638422739" CI_START="0.4635516457913856" EFFECT_SIZE="1.9546154240075941" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="0.9160245156600444" LOG_CI_START="-0.33390187266793026" LOG_EFFECT_SIZE="0.29106132149605707" ORDER="154" O_E="1.243243243243243" SE="0.7342129477392609" STUDY_ID="STD-Sodermark-1975" TOTAL_1="110" TOTAL_2="75" VAR="1.8550512910089878" WEIGHT="37.63210736457651"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="155" O_E="0.0" SE="0.0" STUDY_ID="STD-Steinbeck-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7163452287774423" CI_END="5.511922887864247" CI_START="0.366334593825393" DF="1" EFFECT_SIZE="1.4209883997846837" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.7413031331359077" LOG_CI_START="-0.4361220679636763" LOG_EFFECT_SIZE="0.15259053258611568" NO="2" P_CHI2="0.3973458588515213" P_Z="0.6114462606827231" STUDIES="2" TAU2="0.0" TOTAL_1="895" TOTAL_2="339" WEIGHT="42.4092662907251" Z="0.5080101019942029">
<NAME>More recent studies, lower dose</NAME>
<DICH_DATA CI_END="4.829173192322102" CI_START="0.22861787023996857" EFFECT_SIZE="1.050730836250954" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="0.6838727811139533" LOG_CI_START="-0.640889825369967" LOG_EFFECT_SIZE="0.021491477871993174" ORDER="156" O_E="0.08172043010752716" SE="0.7781721127293179" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="88" VAR="1.6513862874320733" WEIGHT="33.500500158802396"/>
<DICH_DATA CI_END="85.12319633156255" CI_START="0.22966890860097597" EFFECT_SIZE="4.421555336993599" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9300479227881144" LOG_CI_START="-0.6388977933855617" LOG_EFFECT_SIZE="0.6455750647012765" ORDER="157" O_E="0.6527958387516255" SE="1.5090114301668014" STUDY_ID="STD-SOPAT-2004" TOTAL_1="518" TOTAL_2="251" VAR="0.43915207708714865" WEIGHT="8.908766131922704"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.9532890356050157" CI_END="5.007326561145707" CI_START="1.0496659924779606" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.292601231018221" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.6996059155608523" LOG_CI_START="0.021051126974491314" LOG_EFFECT_SIZE="0.36032852126767184" METHOD="PETO" NO="4" P_CHI2="0.70718747505262" P_Q="0.39739769462303354" P_Z="0.037381419475920004" Q="0.7161879037594135" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1128" TOTAL_2="548" WEIGHT="100.0" Z="2.0815737687402036">
<NAME>Quinidine: older and recent studies - ITT Worst case: missing patients counted as events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.5207559030681614" CI_END="7.564616189196433" CI_START="1.118102849189527" DF="3" EFFECT_SIZE="2.908267338840388" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="4" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.8787868978393558" LOG_CI_START="0.04848175415958825" LOG_EFFECT_SIZE="0.46363432599947196" NO="1" P_CHI2="0.6774882635606367" P_Z="0.028607766266234312" STUDIES="5" TAU2="0.0" TOTAL_1="233" TOTAL_2="209" WEIGHT="66.78737627324594" Z="2.1888496966988273">
<NAME>Older studies, higher dose</NAME>
<DICH_DATA CI_END="12.706990895055712" CI_START="0.3336982706163355" EFFECT_SIZE="2.0591990885821634" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="1.1040427187369553" LOG_CI_START="-0.4766460440606066" LOG_EFFECT_SIZE="0.31369833733817437" ORDER="158" O_E="0.8378378378378377" SE="0.9285044038028561" STUDY_ID="STD-Byrne_x002d_Quinn-1970" TOTAL_1="32" TOTAL_2="42" VAR="1.1599307563765173" WEIGHT="18.427953494879898"/>
<DICH_DATA CI_END="406.0194289218663" CI_START="0.15885962215189478" EFFECT_SIZE="8.031194996067258" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.6085468160197243" LOG_CI_START="-0.7989864747561749" LOG_EFFECT_SIZE="0.9047801706317746" ORDER="159" O_E="0.52" SE="2.001601922563589" STUDY_ID="STD-Hillestad-1971" TOTAL_1="48" TOTAL_2="52" VAR="0.2496" WEIGHT="3.965423941934833"/>
<DICH_DATA CI_END="56.32059641298373" CI_START="0.9865240347640378" EFFECT_SIZE="7.453966864271246" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.7506672451663057" LOG_CI_START="-0.005892329531666832" LOG_EFFECT_SIZE="0.8723874578173194" ORDER="160" O_E="1.8867924528301887" SE="1.0318117892877168" STUDY_ID="STD-Lloyd-1984" TOTAL_1="28" TOTAL_2="25" VAR="0.9392885505381054" WEIGHT="14.922585363337621"/>
<DICH_DATA CI_END="8.24184638422739" CI_START="0.4635516457913856" EFFECT_SIZE="1.9546154240075941" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="0.9160245156600444" LOG_CI_START="-0.33390187266793026" LOG_EFFECT_SIZE="0.29106132149605707" ORDER="161" O_E="1.243243243243243" SE="0.7342129477392609" STUDY_ID="STD-Sodermark-1975" TOTAL_1="110" TOTAL_2="75" VAR="1.8550512910089878" WEIGHT="29.471413473093598"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="162" O_E="0.0" SE="0.0" STUDY_ID="STD-Steinbeck-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7163452287774423" CI_END="5.511922887864247" CI_START="0.366334593825393" DF="1" EFFECT_SIZE="1.4209883997846837" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.7413031331359077" LOG_CI_START="-0.4361220679636763" LOG_EFFECT_SIZE="0.15259053258611568" NO="2" P_CHI2="0.3973458588515213" P_Z="0.6114462606827231" STUDIES="2" TAU2="0.0" TOTAL_1="895" TOTAL_2="339" WEIGHT="33.21262372675406" Z="0.5080101019942029">
<NAME>More recent studies, lower dose</NAME>
<DICH_DATA CI_END="4.829173192322102" CI_START="0.22861787023996857" EFFECT_SIZE="1.050730836250954" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="0.6838727811139533" LOG_CI_START="-0.640889825369967" LOG_EFFECT_SIZE="0.021491477871993174" ORDER="163" O_E="0.08172043010752716" SE="0.7781721127293179" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="88" VAR="1.6513862874320733" WEIGHT="26.23576410883823"/>
<DICH_DATA CI_END="85.12319633156255" CI_START="0.22966890860097597" EFFECT_SIZE="4.421555336993599" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9300479227881144" LOG_CI_START="-0.6388977933855617" LOG_EFFECT_SIZE="0.6455750647012765" ORDER="164" O_E="0.6527958387516255" SE="1.5090114301668014" STUDY_ID="STD-SOPAT-2004" TOTAL_1="518" TOTAL_2="251" VAR="0.43915207708714865" WEIGHT="6.976859617915829"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.371561833966728" CI_END="3.573487396089185" CI_START="0.9519507724955407" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.8443926065808705" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="9" I2="0.0" I2_Q="51.90414180438521" ID="CMP-001.05" LOG_CI_END="0.553092254656419" LOG_CI_START="-0.021385509374264106" LOG_EFFECT_SIZE="0.2658533726410774" METHOD="PETO" MODIFIED="2014-06-26 15:42:46 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.49724114980926515" P_Q="0.1250326046628114" P_Z="0.06967145305586356" Q="4.158362227087473" RANDOM="NO" SCALE="144.16731028426037" SORT_BY="STUDY" STUDIES="19" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3108" TOTAL_2="1681" WEIGHT="100.0" Z="1.8140407450729035">
<NAME>Class I antiarrhythmics</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.031400451508892" CI_END="5.586228095842532" CI_START="1.0265109058168922" DF="6" EFFECT_SIZE="2.3946448719513906" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="4" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.7471186647597793" LOG_CI_START="0.011363567745516709" LOG_EFFECT_SIZE="0.37924111625264806" NO="1" P_CHI2="0.8048956266791818" P_Z="0.04333089030684303" STUDIES="8" TAU2="0.0" TOTAL_1="1203" TOTAL_2="594" WEIGHT="60.96490311284275" Z="2.020506367752826">
<NAME>Class Ia</NAME>
<DICH_DATA CI_END="527.8001204153296" CI_START="0.19326023079046073" EFFECT_SIZE="10.099642225480048" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.7224694849664623" LOG_CI_START="-0.713857506163923" LOG_EFFECT_SIZE="1.0043059894012696" ORDER="165" O_E="0.5675675675675675" SE="2.0185154846829296" STUDY_ID="STD-Byrne_x002d_Quinn-1970" TOTAL_1="32" TOTAL_2="42" VAR="0.2454346238130022" WEIGHT="2.794843409073529"/>
<DICH_DATA CI_END="406.0194289218663" CI_START="0.15885962215189478" EFFECT_SIZE="8.031194996067258" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.6085468160197243" LOG_CI_START="-0.7989864747561749" LOG_EFFECT_SIZE="0.9047801706317746" ORDER="166" O_E="0.52" SE="2.001601922563589" STUDY_ID="STD-Hillestad-1971" TOTAL_1="48" TOTAL_2="52" VAR="0.2496" WEIGHT="2.8422758943589477"/>
<DICH_DATA CI_END="122.6563157532565" CI_START="0.46536100533222263" EFFECT_SIZE="7.555095393791001" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0886899155768055" LOG_CI_START="-0.33221001099032044" LOG_EFFECT_SIZE="0.8782399522932426" ORDER="167" O_E="1.0" SE="1.422048600513436" STUDY_ID="STD-Karlson-1998" TOTAL_1="46" TOTAL_2="46" VAR="0.4945054945054945" WEIGHT="5.6310939369431825"/>
<DICH_DATA CI_END="88.7516739201402" CI_START="0.20748745592488377" EFFECT_SIZE="4.291253783076077" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9481765529093782" LOG_CI_START="-0.6830081543122732" LOG_EFFECT_SIZE="0.6325841992985524" ORDER="168" O_E="0.6097560975609757" SE="1.5455709215963562" STUDY_ID="STD-Lloyd-1984" TOTAL_1="57" TOTAL_2="25" VAR="0.4186220723995858" WEIGHT="4.766984876714459"/>
<DICH_DATA CI_END="4.829173192322102" CI_START="0.22861787023996857" EFFECT_SIZE="1.050730836250954" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="0.6838727811139533" LOG_CI_START="-0.640889825369967" LOG_EFFECT_SIZE="0.021491477871993174" ORDER="169" O_E="0.08172043010752716" SE="0.7781721127293179" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="88" VAR="1.6513862874320733" WEIGHT="18.804869539435494"/>
<DICH_DATA CI_END="8.24184638422739" CI_START="0.4635516457913856" EFFECT_SIZE="1.9546154240075941" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="0.9160245156600444" LOG_CI_START="-0.33390187266793026" LOG_EFFECT_SIZE="0.29106132149605707" ORDER="171" O_E="1.243243243243243" SE="0.7342129477392609" STUDY_ID="STD-Sodermark-1975" TOTAL_1="110" TOTAL_2="75" VAR="1.8550512910089878" WEIGHT="21.124068778983542"/>
<DICH_DATA CI_END="85.12319633156255" CI_START="0.22966890860097597" EFFECT_SIZE="4.421555336993599" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9300479227881144" LOG_CI_START="-0.6388977933855617" LOG_EFFECT_SIZE="0.6455750647012765" ORDER="170" O_E="0.6527958387516255" SE="1.5090114301668014" STUDY_ID="STD-SOPAT-2004" TOTAL_1="518" TOTAL_2="251" VAR="0.43915207708714865" WEIGHT="5.000766677333594"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="172" O_E="0.0" SE="0.0" STUDY_ID="STD-Steinbeck-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.028699779604876" CI_START="0.5933179405154557" DF="0" EFFECT_SIZE="1.8912788628917594" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="0.7802236571764538" LOG_CI_START="-0.22671251943759071" LOG_EFFECT_SIZE="0.27675556886943153" NO="2" P_CHI2="1.0" P_Z="0.2813065616849689" STUDIES="2" TAU2="0.0" TOTAL_1="781" TOTAL_2="540" WEIGHT="32.54936784067304" Z="1.0773889350742685">
<NAME>Class Ib</NAME>
<DICH_DATA CI_END="6.028699779604874" CI_START="0.5933179405154558" EFFECT_SIZE="1.8912788628917594" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.7802236571764537" LOG_CI_START="-0.22671251943759063" LOG_EFFECT_SIZE="0.27675556886943153" ORDER="173" O_E="1.8215158924205381" SE="0.5914792945575514" STUDY_ID="STD-AFIB-1997" TOTAL_1="734" TOTAL_2="493" VAR="2.8583862070379222" WEIGHT="32.54936784067304"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="174" O_E="0.0" SE="0.0" STUDY_ID="STD-SMART-2002" TOTAL_1="47" TOTAL_2="47" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.1817991553703617" CI_END="1.8758309573514713" CI_START="0.010409475824900353" DF="2" EFFECT_SIZE="0.1397369564651736" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="8.332533951297695" ID="CMP-001.05.03" LOG_CI_END="0.2731936988632646" LOG_CI_START="-1.982571139085512" LOG_EFFECT_SIZE="-0.8546887201111238" MODIFIED="2014-06-26 15:42:46 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.3359144218968866" P_Z="0.1374842448391619" STUDIES="10" TAU2="0.0" TOTAL_1="1124" TOTAL_2="547" WEIGHT="6.485729046484206" Z="1.485224950073875">
<NAME>Class Ic</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="175" O_E="0.0" SE="0.0" STUDY_ID="STD-Bellandi-2001" TOTAL_1="102" TOTAL_2="92" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="176" O_E="0.0" SE="0.0" STUDY_ID="STD-Carunchio-1995" TOTAL_1="20" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.112816886521402" CI_START="0.002378805217974163" EFFECT_SIZE="0.12058690105553621" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7862413864057757" LOG_CI_START="-2.6236411175349175" LOG_EFFECT_SIZE="-0.918699865564571" ORDER="177" O_E="-0.5272727272727272" SE="2.002981862005382" STUDY_ID="STD-Dogan-2004" TOTAL_1="58" TOTAL_2="52" VAR="0.24925619834710744" WEIGHT="2.8383609137882058"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-06-26 15:42:46 +0100" MODIFIED_BY="[Empty name]" ORDER="1025" O_E="0.0" SE="0.0" STUDY_ID="STD-Flec_x002d_SL-2012" TOTAL_1="281" TOTAL_2="81" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="178" O_E="0.0" SE="0.0" STUDY_ID="STD-Kochiadakis-2004b" TOTAL_1="86" TOTAL_2="83" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="679.4028807857774" CI_START="0.01597709873247045" EFFECT_SIZE="3.2946755387198934" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.8321273840216663" LOG_CI_START="-1.7965020810216048" LOG_EFFECT_SIZE="0.5178126515000308" ORDER="179" O_E="0.16129032258064513" SE="2.7188798598517905" STUDY_ID="STD-Okishige-2000" TOTAL_1="52" TOTAL_2="10" VAR="0.1352757544224766" WEIGHT="1.540428749544175"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="180" O_E="0.0" SE="0.0" STUDY_ID="STD-RAFT-2003" TOTAL_1="397" TOTAL_2="126" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="181" O_E="0.0" SE="0.0" STUDY_ID="STD-Steinbeck-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.610453732263025" CI_START="1.7750425800542054E-4" EFFECT_SIZE="0.01690746565270528" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.20694825221594015" LOG_CI_START="-3.7507912245464756" LOG_EFFECT_SIZE="-1.7719214861652675" ORDER="182" O_E="-0.7549019607843137" SE="2.3247957597766145" STUDY_ID="STD-Stroobandt-1997" TOTAL_1="77" TOTAL_2="25" VAR="0.18502499038831216" WEIGHT="2.106939383151826"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="183" O_E="0.0" SE="0.0" STUDY_ID="STD-Van-Gelder-1989" TOTAL_1="36" TOTAL_2="37" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.388705436271573" CI_END="2.838451065390388" CI_START="1.1220841984904486" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.7846515314377014" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.4530814114329768" LOG_CI_START="0.050025446552767056" LOG_EFFECT_SIZE="0.2515534289928719" METHOD="PETO" MODIFIED="2014-06-26 15:43:08 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.8308943937134666" P_Q="0.47052518935820775" P_Z="0.01442558569273705" Q="1.5078120366449241" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="19" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3108" TOTAL_2="1681" WEIGHT="100.0" Z="2.4464873564648295">
<NAME>Class I antiarrhythmics - ITT Worst case: missing patients counted as events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.039305493957562" CI_END="5.0781433633737" CI_START="1.181075841729265" DF="6" EFFECT_SIZE="2.449014586995854" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="6" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.7057049574757153" LOG_CI_START="0.07227778634083443" LOG_EFFECT_SIZE="0.3889913719082749" NO="1" P_CHI2="0.8038977360224002" P_Z="0.016073120977584107" STUDIES="8" TAU2="0.0" TOTAL_1="1203" TOTAL_2="594" WEIGHT="40.48902586172807" Z="2.40725094842734">
<NAME>Class Ia</NAME>
<DICH_DATA CI_END="12.706990895055712" CI_START="0.3336982706163355" EFFECT_SIZE="2.0591990885821634" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="1.1040427187369553" LOG_CI_START="-0.4766460440606066" LOG_EFFECT_SIZE="0.31369833733817437" ORDER="184" O_E="0.8378378378378377" SE="0.9285044038028561" STUDY_ID="STD-Byrne_x002d_Quinn-1970" TOTAL_1="32" TOTAL_2="42" VAR="1.1599307563765173" WEIGHT="6.501865386255106"/>
<DICH_DATA CI_END="406.0194289218663" CI_START="0.15885962215189478" EFFECT_SIZE="8.031194996067258" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.6085468160197243" LOG_CI_START="-0.7989864747561749" LOG_EFFECT_SIZE="0.9047801706317746" ORDER="185" O_E="0.52" SE="2.001601922563589" STUDY_ID="STD-Hillestad-1971" TOTAL_1="48" TOTAL_2="52" VAR="0.2496" WEIGHT="1.399105585818682"/>
<DICH_DATA CI_END="122.6563157532565" CI_START="0.46536100533222263" EFFECT_SIZE="7.555095393791001" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0886899155768055" LOG_CI_START="-0.33221001099032044" LOG_EFFECT_SIZE="0.8782399522932426" ORDER="186" O_E="1.0" SE="1.422048600513436" STUDY_ID="STD-Karlson-1998" TOTAL_1="46" TOTAL_2="46" VAR="0.4945054945054945" WEIGHT="2.771896632935365"/>
<DICH_DATA CI_END="25.178650988392874" CI_START="0.8881380988112139" EFFECT_SIZE="4.728860245287689" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="1.401032457940572" LOG_CI_START="-0.051519499436993896" LOG_EFFECT_SIZE="0.674756479251789" ORDER="187" O_E="2.1341463414634143" SE="0.8532362100117341" STUDY_ID="STD-Lloyd-1984" TOTAL_1="57" TOTAL_2="25" VAR="1.373603675061141" WEIGHT="7.699585634932341"/>
<DICH_DATA CI_END="4.829173192322102" CI_START="0.22861787023996857" EFFECT_SIZE="1.050730836250954" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="0.6838727811139533" LOG_CI_START="-0.640889825369967" LOG_EFFECT_SIZE="0.021491477871993174" ORDER="188" O_E="0.08172043010752716" SE="0.7781721127293179" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="88" VAR="1.6513862874320733" WEIGHT="9.25666578161294"/>
<DICH_DATA CI_END="8.24184638422739" CI_START="0.4635516457913856" EFFECT_SIZE="1.9546154240075941" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="0.9160245156600444" LOG_CI_START="-0.33390187266793026" LOG_EFFECT_SIZE="0.29106132149605707" ORDER="190" O_E="1.243243243243243" SE="0.7342129477392609" STUDY_ID="STD-Sodermark-1975" TOTAL_1="110" TOTAL_2="75" VAR="1.8550512910089878" WEIGHT="10.398287753328656"/>
<DICH_DATA CI_END="85.12319633156255" CI_START="0.22966890860097597" EFFECT_SIZE="4.421555336993599" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9300479227881144" LOG_CI_START="-0.6388977933855617" LOG_EFFECT_SIZE="0.6455750647012765" ORDER="189" O_E="0.6527958387516255" SE="1.5090114301668014" STUDY_ID="STD-SOPAT-2004" TOTAL_1="518" TOTAL_2="251" VAR="0.43915207708714865" WEIGHT="2.4616190868449768"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="191" O_E="0.0" SE="0.0" STUDY_ID="STD-Steinbeck-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.028699779604876" CI_START="0.5933179405154557" DF="0" EFFECT_SIZE="1.8912788628917594" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="0.7802236571764538" LOG_CI_START="-0.22671251943759071" LOG_EFFECT_SIZE="0.27675556886943153" NO="2" P_CHI2="1.0" P_Z="0.2813065616849689" STUDIES="2" TAU2="0.0" TOTAL_1="781" TOTAL_2="540" WEIGHT="16.022372230343883" Z="1.0773889350742685">
<NAME>Class Ib</NAME>
<DICH_DATA CI_END="6.028699779604874" CI_START="0.5933179405154558" EFFECT_SIZE="1.8912788628917594" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.7802236571764537" LOG_CI_START="-0.22671251943759063" LOG_EFFECT_SIZE="0.27675556886943153" ORDER="192" O_E="1.8215158924205381" SE="0.5914792945575514" STUDY_ID="STD-AFIB-1997" TOTAL_1="734" TOTAL_2="493" VAR="2.8583862070379222" WEIGHT="16.022372230343883"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="193" O_E="0.0" SE="0.0" STUDY_ID="STD-SMART-2002" TOTAL_1="47" TOTAL_2="47" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.841587905669086" CI_END="2.6296983881643454" CI_START="0.6437451710233844" DF="4" EFFECT_SIZE="1.301097858974787" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="10" I2="0.0" ID="CMP-001.06.03" LOG_CI_END="0.4199059401751443" LOG_CI_START="-0.1912860157461131" LOG_EFFECT_SIZE="0.11430996221451561" MODIFIED="2014-06-26 15:43:08 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5846754796340319" P_Z="0.4634754984845403" STUDIES="10" TAU2="0.0" TOTAL_1="1124" TOTAL_2="547" WEIGHT="43.48860190792806" Z="0.7331359872918537">
<NAME>Class Ic</NAME>
<DICH_DATA CI_END="7.987322203229074" CI_START="0.22995810053987137" EFFECT_SIZE="1.3552672955009644" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9024012039344168" LOG_CI_START="-0.6383512872954114" LOG_EFFECT_SIZE="0.1320249583195027" ORDER="194" O_E="0.3711340206185567" SE="0.9050456401962368" STUDY_ID="STD-Bellandi-2001" TOTAL_1="102" TOTAL_2="92" VAR="1.2208408111074338" WEIGHT="6.843290056954412"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="195" O_E="0.0" SE="0.0" STUDY_ID="STD-Carunchio-1995" TOTAL_1="20" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.3316717085613807" CI_START="0.04352792422750824" EFFECT_SIZE="0.318579392700916" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.3676674032066909" LOG_CI_START="-1.3612320431121614" LOG_EFFECT_SIZE="-0.49678231995273525" ORDER="196" O_E="-1.109090909090909" SE="1.015564092957978" STUDY_ID="STD-Dogan-2004" TOTAL_1="58" TOTAL_2="52" VAR="0.9695837440291152" WEIGHT="5.434895962300186"/>
<DICH_DATA CI_END="3.631051313638759" CI_START="0.4598845744795137" EFFECT_SIZE="1.2922323662120678" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="4" LOG_CI_END="0.5600323863606181" LOG_CI_START="-0.3373511573552504" LOG_EFFECT_SIZE="0.11134061450268384" MODIFIED="2014-06-26 15:43:08 +0100" MODIFIED_BY="[Empty name]" ORDER="1026" O_E="0.9226519337016583" SE="0.5271275356988842" STUDY_ID="STD-Flec_x002d_SL-2012" TOTAL_1="281" TOTAL_2="81" VAR="3.5988901742080497" WEIGHT="20.173186480298288"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="197" O_E="0.0" SE="0.0" STUDY_ID="STD-Kochiadakis-2004b" TOTAL_1="86" TOTAL_2="83" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="679.4028807857774" CI_START="0.01597709873247045" EFFECT_SIZE="3.2946755387198934" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.8321273840216663" LOG_CI_START="-1.7965020810216048" LOG_EFFECT_SIZE="0.5178126515000308" ORDER="198" O_E="0.16129032258064513" SE="2.7188798598517905" STUDY_ID="STD-Okishige-2000" TOTAL_1="52" TOTAL_2="10" VAR="0.1352757544224766" WEIGHT="0.7582734921407185"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="199" O_E="0.0" SE="0.0" STUDY_ID="STD-RAFT-2003" TOTAL_1="397" TOTAL_2="126" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="200" O_E="0.0" SE="0.0" STUDY_ID="STD-Steinbeck-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="10.721778934539554" CI_START="0.5930700458842966" EFFECT_SIZE="2.5216593593641186" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="1.0302668485431432" LOG_CI_START="-0.22689401027061804" LOG_EFFECT_SIZE="0.4016864191362626" ORDER="201" O_E="1.6960784313725483" SE="0.7384625115138185" STUDY_ID="STD-Stroobandt-1997" TOTAL_1="77" TOTAL_2="25" VAR="1.833762528501985" WEIGHT="10.278955916234446"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="202" O_E="0.0" SE="0.0" STUDY_ID="STD-Van-Gelder-1989" TOTAL_1="36" TOTAL_2="37" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="21.823029862276382" CI_END="1.2310063805010856" CI_START="0.8460344615547463" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.0205262467461056" ESTIMABLE="YES" EVENTS_1="275" EVENTS_2="241" I2="26.68295786160362" I2_Q="63.72931547646492" ID="CMP-001.07" LOG_CI_END="0.09026030395425044" LOG_CI_START="-0.07261194646659679" LOG_EFFECT_SIZE="0.008824178743826861" METHOD="PETO" MODIFIED="2014-07-01 14:37:54 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.14899818413784138" P_Q="0.026249040703355986" P_Z="0.8318137655272664" Q="11.028189990195818" RANDOM="NO" SCALE="131.85" SORT_BY="STUDY" STUDIES="25" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="8065" TOTAL_2="6079" WEIGHT="99.99999999999999" Z="0.21237592636382943">
<NAME>Class III antiarrhythmics</NAME>
<GROUP_LABEL_1>Antiarrhythmic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.6094669642408883" CI_END="4.5626355919694" CI_START="0.5877183722820766" DF="1" EFFECT_SIZE="1.637542293630465" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" I2="37.86762808942437" ID="CMP-001.07.01" LOG_CI_END="0.6592157839783054" LOG_CI_START="-0.23083073287584852" LOG_EFFECT_SIZE="0.21419252555122845" MODIFIED="2014-06-26 16:06:19 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2045668009142394" P_Z="0.3455054305224422" STUDIES="5" TAU2="0.0" TOTAL_1="450" TOTAL_2="268" WEIGHT="3.3486424957319754" Z="0.9433431351922802">
<NAME>Amiodarone</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="203" O_E="0.0" SE="0.0" STUDY_ID="STD-Channer-2004" TOTAL_1="61" TOTAL_2="38" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="204" O_E="0.0" SE="0.0" STUDY_ID="STD-GEFACA-2001" TOTAL_1="35" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="205" O_E="0.0" SE="0.0" STUDY_ID="STD-Kochiadakis-2000" TOTAL_1="65" TOTAL_2="60" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.665409500607165" CI_START="0.6778569146090587" EFFECT_SIZE="1.9596777806768189" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="3" LOG_CI_END="0.7532313065077162" LOG_CI_START="-0.1688619694866252" LOG_EFFECT_SIZE="0.2921846685105456" ORDER="206" O_E="2.2932330827067666" SE="0.5416421547544066" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="267" TOTAL_2="132" VAR="3.408592513133819" WEIGHT="3.119927369707252"/>
<DICH_DATA CI_END="7.13045089831306" CI_START="0.002802010873979792" EFFECT_SIZE="0.14134921631707822" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8531169935906664" LOG_CI_START="-2.5525301836468692" LOG_EFFECT_SIZE="-0.8497065950281014" MODIFIED="2014-06-26 16:06:19 +0100" MODIFIED_BY="[Empty name]" ORDER="1046" O_E="-0.4888888888888889" SE="2.0004940101347417" STUDY_ID="STD-Vijayalaskshmi-2006" TOTAL_1="22" TOTAL_2="23" VAR="0.24987654320987654" WEIGHT="0.22871512602472355"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.7262258234220083" CI_END="4.886307969906062" CI_START="0.9764994633534685" DF="3" EFFECT_SIZE="2.1843711018032272" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="6" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="0.6889808358293499" LOG_CI_START="-0.010327991047597787" LOG_EFFECT_SIZE="0.339326422390876" MODIFIED="2010-12-28 10:20:02 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4357889467341345" P_Z="0.05716185554204312" STUDIES="5" TAU2="0.0" TOTAL_1="1756" TOTAL_2="1358" WEIGHT="5.424455791045885" Z="1.9020711346060846">
<NAME>Azimilide</NAME>
<DICH_DATA CI_END="18.87621100210338" CI_START="0.3693764966788743" EFFECT_SIZE="2.640535682494779" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.2759148233295785" LOG_CI_START="-0.4325307420506507" LOG_EFFECT_SIZE="0.42169204063946397" ORDER="834" O_E="0.9641255605381165" SE="1.003549382046287" STUDY_ID="STD-A_x002d_COMET_x002d_I-2006" TOTAL_1="227" TOTAL_2="219" VAR="0.9929388521742903" WEIGHT="0.9088493533350228"/>
<DICH_DATA CI_END="57.03206089278504" CI_START="1.114392143672338" EFFECT_SIZE="7.972206758254706" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.7561190653987615" LOG_CI_START="0.04703804170397372" LOG_EFFECT_SIZE="0.9015785535513675" ORDER="841" O_E="2.0597701149425287" SE="1.003922653405828" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="211" TOTAL_2="224" VAR="0.9922006145610918" WEIGHT="0.9081736352121053"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-11-20 10:07:45 +0000" MODIFIED_BY="[Empty name]" ORDER="886" O_E="0.0" SE="0.0" STUDY_ID="STD-A_x002d_STAR-2006" TOTAL_1="216" TOTAL_2="215" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.846545652652908" CI_START="0.3922949397872779" EFFECT_SIZE="1.2284056313760892" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.5850708912200382" LOG_CI_START="-0.4063872937991818" LOG_EFFECT_SIZE="0.08934179871042822" ORDER="207" O_E="0.6065217391304341" SE="0.5823874456774577" STUDY_ID="STD-ASAP-2003" TOTAL_1="891" TOTAL_2="489" VAR="2.948329317976507" WEIGHT="2.698642709159788"/>
<DICH_DATA CI_END="19.573210244619457" CI_START="0.3829665080229595" EFFECT_SIZE="2.7378612050615585" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.2916620610788163" LOG_CI_START="-0.416839205187577" LOG_EFFECT_SIZE="0.4374114279456196" MODIFIED="2010-12-28 10:20:02 +0000" MODIFIED_BY="[Empty name]" ORDER="942" O_E="1.0" SE="1.0035821010225436" STUDY_ID="STD-SVA_x002d_4-2008" TOTAL_1="211" TOTAL_2="211" VAR="0.992874109263658" WEIGHT="0.9087900933389693"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.49843619726923905" CI_END="1.4111240122658892" CI_START="0.6817106863123817" DF="2" EFFECT_SIZE="0.9808049341605399" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="83" I2="0.0" ID="CMP-001.07.03" LOG_CI_END="0.14956518205777078" LOG_CI_START="-0.16639989806532032" LOG_EFFECT_SIZE="-0.008417358003774791" MODIFIED="2010-12-28 10:31:17 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7794099761266121" P_Z="0.9168301160726223" STUDIES="3" TAU2="0.0" TOTAL_1="752" TOTAL_2="431" WEIGHT="26.571496748317553" Z="0.10442747993513395">
<NAME>Dofetilide</NAME>
<DICH_DATA CI_END="1.4431434722617116" CI_START="0.6798268094585525" EFFECT_SIZE="0.9904986735673179" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="80" LOG_CI_END="0.1593095092738014" LOG_CI_START="-0.16760171270039934" LOG_EFFECT_SIZE="-0.004146101713299011" ORDER="208" O_E="-0.2588932806324067" SE="0.19202927002429282" STUDY_ID="STD-DIAMOND-2001" TOTAL_1="249" TOTAL_2="257" VAR="27.11846716635919" WEIGHT="24.821872256899443"/>
<DICH_DATA CI_END="353.27126735483773" CI_START="0.040485957738138234" EFFECT_SIZE="3.7818680040723907" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5481083163573324" LOG_CI_START="-1.3926955825711107" LOG_EFFECT_SIZE="0.5777063668931108" MODIFIED="2010-12-28 10:31:17 +0000" MODIFIED_BY="[Empty name]" ORDER="957" O_E="0.2482435597189696" SE="2.3148477175244766" STUDY_ID="STD-EMERALD-2000" TOTAL_1="321" TOTAL_2="106" VAR="0.18661869477702395" WEIGHT="0.17081442598093935"/>
<DICH_DATA CI_END="3.2294735891450452" CI_START="0.16326815408962927" EFFECT_SIZE="0.7261337284418906" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.5091317372038408" LOG_CI_START="-0.7870985173570041" LOG_EFFECT_SIZE="-0.13898339007658164" ORDER="209" O_E="-0.5519999999999996" SE="0.7614120679722834" STUDY_ID="STD-SAFIRE_x002d_D-2000" TOTAL_1="182" TOTAL_2="68" VAR="1.724886361445783" WEIGHT="1.5788100654371704"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8672350800125164" CI_END="1.094020692356054" CI_START="0.6672515308820154" DF="2" EFFECT_SIZE="0.8543927561673141" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="142" I2="0.0" ID="CMP-001.07.04" LOG_CI_END="0.03902553634025023" LOG_CI_START="-0.17571042113303767" LOG_EFFECT_SIZE="-0.0683424423963937" MODIFIED="2010-11-20 10:20:22 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.6481601244988575" P_Z="0.21218976699748782" STUDIES="3" TAU2="0.0" TOTAL_1="3283" TOTAL_2="2788" WEIGHT="57.5287116548886" Z="1.2475668005354674">
<NAME>Dronedarone</NAME>
<DICH_DATA CI_END="1.0762908893354253" CI_START="0.6495373719681742" EFFECT_SIZE="0.8361167117886241" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="139" LOG_CI_END="0.03192966404398068" LOG_CI_START="-0.1873958561804416" LOG_EFFECT_SIZE="-0.07773309606823046" MODIFIED="2010-11-20 10:20:22 +0000" MODIFIED_BY="[Empty name]" ORDER="900" O_E="-10.783707865168537" SE="0.1288328962586604" STUDY_ID="STD-ATHENA-2009" TOTAL_1="2301" TOTAL_2="2327" VAR="60.24853064116481" WEIGHT="55.146233821653794"/>
<DICH_DATA CI_END="364.75141324228076" CI_START="0.03825601513883153" EFFECT_SIZE="3.7354966988215743" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5619969832581146" LOG_CI_START="-1.417300269367424" LOG_EFFECT_SIZE="0.5723483569453452" ORDER="210" O_E="0.24120603015075381" SE="2.3374589040313243" STUDY_ID="STD-DAFNE-2003" TOTAL_1="151" TOTAL_2="48" VAR="0.18302568116966741" WEIGHT="0.1675256956765311"/>
<DICH_DATA CI_END="4.615162631249554" CI_START="0.37137711023519626" EFFECT_SIZE="1.309185151633994" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.6641870095027342" LOG_CI_START="-0.43018486743762996" LOG_EFFECT_SIZE="0.11700107103255217" ORDER="820" O_E="0.651929260450161" SE="0.6428394577429287" STUDY_ID="STD-EURIDIS-ADONIS-2007" TOTAL_1="831" TOTAL_2="413" VAR="2.4198862275884667" WEIGHT="2.214952137558276"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.093475807135911" CI_END="4.497935483936708" CI_START="1.1038507573182492" DF="4" EFFECT_SIZE="2.2282391007951015" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="6" I2="21.46816532639581" ID="CMP-001.07.05" LOG_CI_END="0.6530132218485627" LOG_CI_START="0.04291035993799506" LOG_EFFECT_SIZE="0.34796179089327894" MODIFIED="2014-06-26 16:10:54 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.2778401562244872" P_Z="0.025373772584076637" STUDIES="13" TAU2="0.0" TOTAL_1="1824" TOTAL_2="1234" WEIGHT="7.126693310015972" Z="2.235664248520947">
<NAME>Sotalol</NAME>
<DICH_DATA CI_END="53.766620926152854" CI_START="1.0528118484471085" EFFECT_SIZE="7.523704909286246" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.7305127432050487" LOG_CI_START="0.022350763889791982" LOG_EFFECT_SIZE="0.8764317535474203" ORDER="862" O_E="2.004474272930649" SE="1.0033828021879485" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="223" TOTAL_2="224" VAR="0.9932685714857689" WEIGHT="0.9091511495456989"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="212" O_E="0.0" SE="0.0" STUDY_ID="STD-Bellandi-2001" TOTAL_1="106" TOTAL_2="92" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="213" O_E="0.0" SE="0.0" STUDY_ID="STD-Benditt-1999" TOTAL_1="184" TOTAL_2="69" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="214" O_E="0.0" SE="0.0" STUDY_ID="STD-Carunchio-1995" TOTAL_1="20" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-27 13:13:10 +0000" MODIFIED_BY="[Empty name]" ORDER="914" O_E="0.0" SE="0.0" STUDY_ID="STD-DAPHNE-2008" TOTAL_1="69" TOTAL_2="66" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-28 10:39:18 +0000" MODIFIED_BY="[Empty name]" ORDER="973" O_E="0.0" SE="0.0" STUDY_ID="STD-EMERALD-2000" TOTAL_1="108" TOTAL_2="106" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="215" O_E="0.0" SE="0.0" STUDY_ID="STD-Kochiadakis-2004b" TOTAL_1="85" TOTAL_2="83" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.371323379499582" CI_START="0.3847619309837751" EFFECT_SIZE="1.4375954769804182" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="2" LOG_CI_END="0.7300812997790568" LOG_CI_START="-0.41480790436177406" LOG_EFFECT_SIZE="0.1576366977086414" ORDER="216" O_E="0.8025477707006363" SE="0.6725135858052854" STUDY_ID="STD-PAFAC-2004" TOTAL_1="383" TOTAL_2="88" VAR="2.2110464970742414" WEIGHT="2.0237985195757684"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="217" O_E="0.0" SE="0.0" STUDY_ID="STD-Plewan-2001" TOTAL_1="64" TOTAL_2="64" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.007583308640837" CI_START="0.8129459997107931" EFFECT_SIZE="2.2099413609163703" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="3" LOG_CI_END="0.7786998019864907" LOG_CI_START="-0.08993830164641405" LOG_EFFECT_SIZE="0.34438075017003833" ORDER="218" O_E="3.0458015267175576" SE="0.510242321901928" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="261" TOTAL_2="132" VAR="3.841024201767415" WEIGHT="3.5157375041537082"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="220" O_E="0.0" SE="0.0" STUDY_ID="STD-Singh-1991" TOTAL_1="24" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="113.29018050149466" CI_START="0.4400653449064914" EFFECT_SIZE="7.060813151253114" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0541922687440057" LOG_CI_START="-0.3564828307292117" LOG_EFFECT_SIZE="0.8488547190073971" MODIFIED="2010-12-28 12:22:48 +0000" MODIFIED_BY="[Empty name]" ORDER="219" O_E="0.974757281553398" SE="1.4160424864647638" STUDY_ID="STD-SOPAT-2004" TOTAL_1="264" TOTAL_2="251" VAR="0.4987092597761316" WEIGHT="0.45647482446398013"/>
<DICH_DATA CI_END="4.707607339689307" CI_START="0.0016307014806284633" EFFECT_SIZE="0.08761679210658638" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.672800231291631" LOG_CI_START="-2.7876255344726837" LOG_EFFECT_SIZE="-1.0574126515905262" MODIFIED="2014-06-26 16:10:54 +0100" MODIFIED_BY="[Empty name]" ORDER="1051" O_E="-0.5892857142857143" SE="2.032671224193758" STUDY_ID="STD-Vijayalaskshmi-2006" TOTAL_1="33" TOTAL_2="23" VAR="0.24202806122448978" WEIGHT="0.22153131227681688"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="28.53933510401845" CI_END="1.3225120208277037" CI_START="0.9414338779486698" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.1158215002416636" ESTIMABLE="YES" EVENTS_1="355" EVENTS_2="272" I2="26.417346713017434" I2_Q="75.01996047807256" ID="CMP-001.08" LOG_CI_END="0.12139962819713915" LOG_CI_START="-0.026210177453431745" LOG_EFFECT_SIZE="0.04759472537185366" METHOD="PETO" MODIFIED="2014-06-26 16:11:12 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.12550766838182847" P_Q="0.0030020642100270223" P_Z="0.20625655544806032" Q="16.012784913686012" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="25" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="8065" TOTAL_2="6079" WEIGHT="100.00000000000001" Z="1.263926162246081">
<NAME>Class III antiarrhythmics - ITT Worst case: missing patients counted as events</NAME>
<GROUP_LABEL_1>Antiarrhythmic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.3318937733743528" CI_END="2.891765552034319" CI_START="0.6419017532684367" DF="1" EFFECT_SIZE="1.3624350912583316" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="9" I2="24.91893723127032" ID="CMP-001.08.01" LOG_CI_END="0.4611630799139353" LOG_CI_START="-0.1925314380970471" LOG_EFFECT_SIZE="0.13431582090844413" MODIFIED="2014-06-26 16:06:52 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2484687389401179" P_Z="0.42056879786283885" STUDIES="5" TAU2="0.0" TOTAL_1="450" TOTAL_2="268" WEIGHT="5.0989497381171685" Z="0.8054348454244178">
<NAME>Amiodarone</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="221" O_E="0.0" SE="0.0" STUDY_ID="STD-Channer-2004" TOTAL_1="61" TOTAL_2="38" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="222" O_E="0.0" SE="0.0" STUDY_ID="STD-GEFACA-2001" TOTAL_1="35" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="223" O_E="0.0" SE="0.0" STUDY_ID="STD-Kochiadakis-2000" TOTAL_1="65" TOTAL_2="60" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.1988687259284116" CI_START="0.6901074188910759" EFFECT_SIZE="1.4857870102480506" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="8" LOG_CI_END="0.5049964180226181" LOG_CI_START="-0.16108330375450375" LOG_EFFECT_SIZE="0.17195655713405722" ORDER="224" O_E="2.5864661654135332" SE="0.3912585257196799" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="267" TOTAL_2="132" VAR="6.532394006893534" WEIGHT="4.911091125702747"/>
<DICH_DATA CI_END="7.13045089831306" CI_START="0.002802010873979792" EFFECT_SIZE="0.14134921631707822" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8531169935906664" LOG_CI_START="-2.5525301836468692" LOG_EFFECT_SIZE="-0.8497065950281014" MODIFIED="2014-06-26 16:06:52 +0100" MODIFIED_BY="[Empty name]" ORDER="1047" O_E="-0.4888888888888889" SE="2.0004940101347417" STUDY_ID="STD-Vijayalaskshmi-2006" TOTAL_1="22" TOTAL_2="23" VAR="0.24987654320987654" WEIGHT="0.18785861241442173"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.8027605211996143" CI_END="3.0589891462055414" CI_START="0.9923759981296565" DF="3" EFFECT_SIZE="1.7423166782285906" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="17" I2="0.0" ID="CMP-001.08.02" LOG_CI_END="0.48557793603946664" LOG_CI_START="-0.003323748234876764" LOG_EFFECT_SIZE="0.24112709390229495" MODIFIED="2010-12-28 10:20:17 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6143345457745629" P_Z="0.053197435372494224" STUDIES="5" TAU2="0.0" TOTAL_1="1756" TOTAL_2="1358" WEIGHT="9.115643874044757" Z="1.933314754056399">
<NAME>Azimilide</NAME>
<DICH_DATA CI_END="3.3829732237787216" CI_START="0.4605093029827673" EFFECT_SIZE="1.2481548947513301" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.5292985603622732" LOG_CI_START="-0.33676159197468625" LOG_EFFECT_SIZE="0.09626848419379341" ORDER="835" O_E="0.856502242152466" SE="0.508728020549625" STUDY_ID="STD-A_x002d_COMET_x002d_I-2006" TOTAL_1="227" TOTAL_2="219" VAR="3.863924945112623" WEIGHT="2.9049208434608977"/>
<DICH_DATA CI_END="6.89790761897822" CI_START="1.0462514886625305" EFFECT_SIZE="2.686437439251577" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" LOG_CI_END="0.8387173737314806" LOG_CI_START="0.019636088939153876" LOG_EFFECT_SIZE="0.42917673133531714" ORDER="842" O_E="4.26896551724138" SE="0.48113240120476286" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="211" TOTAL_2="224" VAR="4.319871121169115" WEIGHT="3.2477037828650657"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-11-20 10:07:51 +0000" MODIFIED_BY="[Empty name]" ORDER="887" O_E="0.0" SE="0.0" STUDY_ID="STD-A_x002d_STAR-2006" TOTAL_1="216" TOTAL_2="215" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.846545652652908" CI_START="0.3922949397872779" EFFECT_SIZE="1.2284056313760892" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.5850708912200382" LOG_CI_START="-0.4063872937991818" LOG_EFFECT_SIZE="0.08934179871042822" ORDER="225" O_E="0.6065217391304341" SE="0.5823874456774577" STUDY_ID="STD-ASAP-2003" TOTAL_1="891" TOTAL_2="489" VAR="2.948329317976507" WEIGHT="2.216570821338035"/>
<DICH_DATA CI_END="19.573210244619457" CI_START="0.3829665080229595" EFFECT_SIZE="2.7378612050615585" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.2916620610788163" LOG_CI_START="-0.416839205187577" LOG_EFFECT_SIZE="0.4374114279456196" MODIFIED="2010-12-28 10:20:17 +0000" MODIFIED_BY="[Empty name]" ORDER="943" O_E="1.0" SE="1.0035821010225436" STUDY_ID="STD-SVA_x002d_4-2008" TOTAL_1="211" TOTAL_2="211" VAR="0.992874109263658" WEIGHT="0.7464484263807577"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0244620622418867" CI_END="1.4493014266105295" CI_START="0.7198418233606765" DF="2" EFFECT_SIZE="1.0214048078653992" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="85" I2="0.0" ID="CMP-001.08.03" LOG_CI_END="0.16115871970137013" LOG_CI_START="-0.1427629241083853" LOG_EFFECT_SIZE="0.009197897796492393" MODIFIED="2010-12-28 10:30:59 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5991574225125289" P_Z="0.905566222840359" STUDIES="3" TAU2="0.0" TOTAL_1="752" TOTAL_2="431" WEIGHT="23.58887113387988" Z="0.118632869897809">
<NAME>Dofetilide</NAME>
<DICH_DATA CI_END="1.4431434722617116" CI_START="0.6798268094585525" EFFECT_SIZE="0.9904986735673179" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="80" LOG_CI_END="0.1593095092738014" LOG_CI_START="-0.16760171270039934" LOG_EFFECT_SIZE="-0.004146101713299011" ORDER="226" O_E="-0.2588932806324067" SE="0.19202927002429282" STUDY_ID="STD-DIAMOND-2001" TOTAL_1="249" TOTAL_2="257" VAR="27.11846716635919" WEIGHT="20.387818509236247"/>
<DICH_DATA CI_END="6.134913771390169" CI_START="0.5225605021612942" EFFECT_SIZE="1.790492563819768" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="2" LOG_CI_END="0.7878084629273086" LOG_CI_START="-0.28186341960230843" LOG_EFFECT_SIZE="0.25297252166250006" MODIFIED="2010-12-28 10:30:59 +0000" MODIFIED_BY="[Empty name]" ORDER="956" O_E="1.4754098360655732" SE="0.6283305587591116" STUDY_ID="STD-EMERALD-2000" TOTAL_1="321" TOTAL_2="106" VAR="2.532932613147306" WEIGHT="1.9042732060104812"/>
<DICH_DATA CI_END="3.2294735891450452" CI_START="0.16326815408962927" EFFECT_SIZE="0.7261337284418906" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.5091317372038408" LOG_CI_START="-0.7870985173570041" LOG_EFFECT_SIZE="-0.13898339007658164" ORDER="227" O_E="-0.5519999999999996" SE="0.7614120679722834" STUDY_ID="STD-SAFIRE_x002d_D-2000" TOTAL_1="182" TOTAL_2="68" VAR="1.724886361445783" WEIGHT="1.2967794186331523"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8429748960939206" CI_END="1.0943273012131076" CI_START="0.6691404508891476" DF="2" EFFECT_SIZE="0.8557211366759868" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="143" I2="0.0" ID="CMP-001.08.04" LOG_CI_END="0.03914723411042543" LOG_CI_START="-0.17448271535007764" LOG_EFFECT_SIZE="-0.06766774061982611" MODIFIED="2010-11-20 10:21:20 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.656070240303944" P_Z="0.21436740389035136" STUDIES="3" TAU2="0.0" TOTAL_1="3283" TOTAL_2="2788" WEIGHT="47.74260823712648" Z="1.2416455170727625">
<NAME>Dronedarone</NAME>
<DICH_DATA CI_END="1.0762908893354253" CI_START="0.6495373719681742" EFFECT_SIZE="0.8361167117886241" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="139" LOG_CI_END="0.03192966404398068" LOG_CI_START="-0.1873958561804416" LOG_EFFECT_SIZE="-0.07773309606823046" MODIFIED="2010-11-20 10:21:20 +0000" MODIFIED_BY="[Empty name]" ORDER="903" O_E="-10.783707865168537" SE="0.1288328962586604" STUDY_ID="STD-ATHENA-2009" TOTAL_1="2301" TOTAL_2="2327" VAR="60.24853064116481" WEIGHT="45.29518945982294"/>
<DICH_DATA CI_END="364.75141324228076" CI_START="0.03825601513883153" EFFECT_SIZE="3.7354966988215743" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5619969832581146" LOG_CI_START="-1.417300269367424" LOG_EFFECT_SIZE="0.5723483569453452" ORDER="228" O_E="0.24120603015075381" SE="2.3374589040313243" STUDY_ID="STD-DAFNE-2003" TOTAL_1="151" TOTAL_2="48" VAR="0.18302568116966741" WEIGHT="0.13759975249801304"/>
<DICH_DATA CI_END="3.7775055849313035" CI_START="0.4036136548600519" EFFECT_SIZE="1.234768332679609" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.5772051151032017" LOG_CI_START="-0.39403414934777264" LOG_EFFECT_SIZE="0.09158548287771451" ORDER="821" O_E="0.6479099678456599" SE="0.5705107516503991" STUDY_ID="STD-EURIDIS-ADONIS-2007" TOTAL_1="831" TOTAL_2="413" VAR="3.0723616337884976" WEIGHT="2.3098190248055257"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.524458937422658" CI_END="3.407711676973592" CI_START="1.3938087085598718" DF="9" EFFECT_SIZE="2.1793802356695253" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="18" I2="0.0" ID="CMP-001.08.05" LOG_CI_END="0.5324628424337261" LOG_CI_START="0.14420317367769625" LOG_EFFECT_SIZE="0.33833300805571115" MODIFIED="2014-06-26 16:11:12 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.5826848186745015" P_Z="6.35807161007163E-4" STUDIES="13" TAU2="0.0" TOTAL_1="1824" TOTAL_2="1234" WEIGHT="14.453927016831722" Z="3.4158608989437838">
<NAME>Sotalol</NAME>
<DICH_DATA CI_END="53.766620926152854" CI_START="1.0528118484471085" EFFECT_SIZE="7.523704909286246" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.7305127432050487" LOG_CI_START="0.022350763889791982" LOG_EFFECT_SIZE="0.8764317535474203" ORDER="870" O_E="2.004474272930649" SE="1.0033828021879485" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="223" TOTAL_2="224" VAR="0.9932685714857689" WEIGHT="0.7467449853324053"/>
<DICH_DATA CI_END="10.068730387843296" CI_START="0.5944892264996772" EFFECT_SIZE="2.44657960019754" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.0029747118330903" LOG_CI_START="-0.22585601138025455" LOG_EFFECT_SIZE="0.3885593502264179" ORDER="230" O_E="1.7171717171717171" SE="0.7218212496257009" STUDY_ID="STD-Bellandi-2001" TOTAL_1="106" TOTAL_2="92" VAR="1.919290324151115" WEIGHT="1.442933428179436"/>
<DICH_DATA CI_END="4.7467917862073605" CI_START="0.45794857254749255" EFFECT_SIZE="1.4743766556324145" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" LOG_CI_END="0.6764001821956298" LOG_CI_START="-0.33918329036486944" LOG_EFFECT_SIZE="0.16860844591538018" ORDER="231" O_E="1.0909090909090917" SE="0.5965587590013044" STUDY_ID="STD-Benditt-1999" TOTAL_1="184" TOTAL_2="69" VAR="2.8099173553719012" WEIGHT="2.112511917279087"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="232" O_E="0.0" SE="0.0" STUDY_ID="STD-Carunchio-1995" TOTAL_1="20" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.88044138748738" CI_START="0.18681891909731724" EFFECT_SIZE="0.9548606101040107" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6884591014046701" LOG_CI_START="-0.7285791450036011" LOG_EFFECT_SIZE="-0.020060021799465446" MODIFIED="2010-12-27 13:14:20 +0000" MODIFIED_BY="[Empty name]" ORDER="915" O_E="-0.06666666666666687" SE="0.832375280392666" STUDY_ID="STD-DAPHNE-2008" TOTAL_1="69" TOTAL_2="66" VAR="1.4433167495854062" WEIGHT="1.085093776184794"/>
<DICH_DATA CI_END="10.652639510573582" CI_START="0.5272140901747715" EFFECT_SIZE="2.3698568833427207" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0274572305773044" LOG_CI_START="-0.27801299142736136" LOG_EFFECT_SIZE="0.37472211957497154" MODIFIED="2010-12-28 10:42:39 +0000" MODIFIED_BY="[Empty name]" ORDER="979" O_E="1.467289719626168" SE="0.7668396705873604" STUDY_ID="STD-EMERALD-2000" TOTAL_1="108" TOTAL_2="106" VAR="1.7005556792585366" WEIGHT="1.2784874727943092"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="233" O_E="0.0" SE="0.0" STUDY_ID="STD-Kochiadakis-2004b" TOTAL_1="85" TOTAL_2="83" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.371323379499582" CI_START="0.3847619309837751" EFFECT_SIZE="1.4375954769804182" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="2" LOG_CI_END="0.7300812997790568" LOG_CI_START="-0.41480790436177406" LOG_EFFECT_SIZE="0.1576366977086414" ORDER="234" O_E="0.8025477707006363" SE="0.6725135858052854" STUDY_ID="STD-PAFAC-2004" TOTAL_1="383" TOTAL_2="88" VAR="2.2110464970742414" WEIGHT="1.6622773854177328"/>
<DICH_DATA CI_END="8.973986079248892" CI_START="0.25453582258990537" EFFECT_SIZE="1.5113573133418767" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9529853915052704" LOG_CI_START="-0.5942510877542916" LOG_EFFECT_SIZE="0.17936715187548932" ORDER="235" O_E="0.5" SE="0.9088543668611608" STUDY_ID="STD-Plewan-2001" TOTAL_1="64" TOTAL_2="64" VAR="1.2106299212598426" WEIGHT="0.9101584896035388"/>
<DICH_DATA CI_END="6.884445501914499" CI_START="1.4255872970929997" EFFECT_SIZE="3.1327907774152983" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="3" LOG_CI_END="0.8378689663566938" LOG_CI_START="0.15399381686466165" LOG_EFFECT_SIZE="0.49593139161067773" ORDER="236" O_E="7.076335877862597" SE="0.4017116480482061" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="261" TOTAL_2="132" VAR="6.196852378851431" WEIGHT="4.658829013214975"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="238" O_E="0.0" SE="0.0" STUDY_ID="STD-Singh-1991" TOTAL_1="24" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="113.29018050149466" CI_START="0.4400653449064914" EFFECT_SIZE="7.060813151253114" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0541922687440057" LOG_CI_START="-0.3564828307292117" LOG_EFFECT_SIZE="0.8488547190073971" ORDER="237" O_E="0.974757281553398" SE="1.4160424864647638" STUDY_ID="STD-SOPAT-2004" TOTAL_1="264" TOTAL_2="251" VAR="0.4987092597761316" WEIGHT="0.37493246999610497"/>
<DICH_DATA CI_END="4.707607339689307" CI_START="0.0016307014806284633" EFFECT_SIZE="0.08761679210658638" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.672800231291631" LOG_CI_START="-2.7876255344726837" LOG_EFFECT_SIZE="-1.0574126515905262" MODIFIED="2014-06-26 16:11:12 +0100" MODIFIED_BY="[Empty name]" ORDER="1052" O_E="-0.5892857142857143" SE="2.032671224193758" STUDY_ID="STD-Vijayalaskshmi-2006" TOTAL_1="33" TOTAL_2="23" VAR="0.24202806122448978" WEIGHT="0.18195807882933862"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="37.31396605479083" CI_END="0.9847291649711635" CI_START="0.5959956753424929" CI_STUDY="95" CI_TOTAL="95" DF="25" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.766090284304949" ESTIMABLE="YES" EVENTS_1="128" EVENTS_2="148" I2="33.000957434300425" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="-0.0066831992812256885" LOG_CI_START="-0.22475689157135023" LOG_EFFECT_SIZE="-0.115720045426288" METHOD="PETO" MODIFIED="2014-09-25 16:09:24 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.053893089331780275" P_Q="0.8846136106114717" P_Z="0.037516716812144454" Q="4.380773263809407" RANDOM="NO" SCALE="199.30288363873797" SORT_BY="STUDY" STUDIES="29" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="4713" TOTAL_2="4846" WEIGHT="1000.0" Z="2.0800961266168687">
<NAME>Comparing antiarrhythmic drugs</NAME>
<GROUP_LABEL_1>Antiarrhythmic 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiarrhythmic 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Drug 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Drug 2</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.473604303441881" CI_END="4.515893398354296" CI_START="0.04711163465402293" DF="1" EFFECT_SIZE="0.46124952023799626" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="59.57316218246562" ID="CMP-001.09.01" LOG_CI_END="0.6547436814697324" LOG_CI_START="-1.3268718265852517" LOG_EFFECT_SIZE="-0.33606407255775955" NO="1" P_CHI2="0.11577242499912399" P_Z="0.5061884445949469" STUDIES="2" TAU2="0.0" TOTAL_1="60" TOTAL_2="53" WEIGHT="100.00000000000001" Z="0.6647843398819304">
<NAME>Disopyramide vs other Class I drugs</NAME>
<DICH_DATA CI_END="2.0638963789126037" CI_START="0.007672980188249206" EFFECT_SIZE="0.12584210752365713" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.3146878890810725" LOG_CI_START="-2.1150359231527345" LOG_EFFECT_SIZE="-0.9001740170358311" ORDER="239" O_E="-1.0175438596491229" SE="1.427231794632983" STUDY_ID="STD-Lloyd-1984" TOTAL_1="29" TOTAL_2="28" VAR="0.49092028316405045" WEIGHT="66.51582236188139"/>
<DICH_DATA CI_END="313.90009140467816" CI_START="0.11810614449503411" EFFECT_SIZE="6.088803622424139" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.496791442162424" LOG_CI_START="-0.927727507544224" LOG_EFFECT_SIZE="0.7845319673090999" ORDER="240" O_E="0.4464285714285714" SE="2.0115793826998787" STUDY_ID="STD-PRODIS-1996" TOTAL_1="31" TOTAL_2="25" VAR="0.24713010204081634" WEIGHT="33.484177638118624"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="132" TOTAL_2="137" WEIGHT="0.0" Z="0.0">
<NAME>Quinidine vs Flecainide</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="241" O_E="0.0" SE="0.0" STUDY_ID="STD-Naccarelli-1996" TOTAL_1="117" TOTAL_2="122" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="242" O_E="0.0" SE="0.0" STUDY_ID="STD-Steinbeck-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.038938068599898" CI_END="7.460438971999288" CI_START="0.14462217999826676" DF="1" EFFECT_SIZE="1.0387227483186094" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="75.24101674709136" ID="CMP-001.09.03" LOG_CI_END="0.8727643820984293" LOG_CI_START="-0.8397650963073124" LOG_EFFECT_SIZE="0.016499642895558404" NO="3" P_CHI2="0.04446187927529888" P_Z="0.9698733110468707" STUDIES="4" TAU2="0.0" TOTAL_1="258" TOTAL_2="268" WEIGHT="100.0" Z="0.03776718151815061">
<NAME>Quinidine vs other Class I drugs</NAME>
<DICH_DATA CI_END="130.32745758049148" CI_START="0.4845204489029947" EFFECT_SIZE="7.946465771101373" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.1150359231527345" LOG_CI_START="-0.3146878890810724" LOG_EFFECT_SIZE="0.9001740170358311" ORDER="243" O_E="1.0175438596491229" SE="1.427231794632983" STUDY_ID="STD-Lloyd-1984" TOTAL_1="28" TOTAL_2="29" VAR="0.49092028316405045" WEIGHT="49.677792814236305"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="244" O_E="0.0" SE="0.0" STUDY_ID="STD-Naccarelli-1996" TOTAL_1="117" TOTAL_2="122" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.244913541987938" CI_START="0.008651335830425964" EFFECT_SIZE="0.13936104535345845" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.35119961974442426" LOG_CI_START="-2.062916829067995" LOG_EFFECT_SIZE="-0.8558586046617856" ORDER="245" O_E="-0.98" SE="1.4180639521015652" STUDY_ID="STD-Richiardi-1992" TOTAL_1="98" TOTAL_2="102" VAR="0.4972884422110553" WEIGHT="50.322207185763695"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="246" O_E="0.0" SE="0.0" STUDY_ID="STD-Steinbeck-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.3817636141224243" CI_END="1.4643559864614164" CI_START="0.34091169599777493" DF="4" EFFECT_SIZE="0.7065522506432601" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="17" I2="0.0" ID="CMP-001.09.04" LOG_CI_END="0.16564666699712227" LOG_CI_START="-0.4673580987413079" LOG_EFFECT_SIZE="-0.1508557158720928" NO="4" P_CHI2="0.6659254138050105" P_Z="0.3502084969448097" STUDIES="6" TAU2="0.0" TOTAL_1="1109" TOTAL_2="869" WEIGHT="100.00000000000001" Z="0.9341849729247903">
<NAME>Quinidine vs Sotalol</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="247" O_E="0.0" SE="0.0" STUDY_ID="STD-Hohnloser-1995" TOTAL_1="25" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="18.729126942179235" CI_START="0.07115406692873341" EFFECT_SIZE="1.1544061468827016" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2725175332198093" LOG_CI_START="-1.147800272048707" LOG_EFFECT_SIZE="0.06235863058555117" ORDER="248" O_E="0.07103825136612019" SE="1.4217066595810859" STUDY_ID="STD-Juul_x002d_Moller-1990" TOTAL_1="85" TOTAL_2="98" VAR="0.49474339450152405" WEIGHT="6.840205792509323"/>
<DICH_DATA CI_END="372.3848896839504" CI_START="0.1466175227450357" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" ORDER="249" O_E="0.5" SE="2.0" STUDY_ID="STD-Kalusche-1994" TOTAL_1="41" TOTAL_2="41" VAR="0.25" WEIGHT="3.4564411918026385"/>
<DICH_DATA CI_END="1.631985999260366" CI_START="0.2995924526668997" EFFECT_SIZE="0.6992357887268459" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.21271642863962698" LOG_CI_START="-0.5234691315813993" LOG_EFFECT_SIZE="-0.15537635147088616" ORDER="250" O_E="-1.9131578947368428" SE="0.4324390422511265" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="383" VAR="5.347492773696254" WEIGHT="73.9331771834827"/>
<DICH_DATA CI_END="6.278129394729894" CI_START="0.002455350244490709" EFFECT_SIZE="0.12415718482751754" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7978302624373067" LOG_CI_START="-2.6098865489991505" LOG_EFFECT_SIZE="-0.906028143280922" ORDER="251" O_E="-0.5206611570247934" SE="2.0017097235080428" STUDY_ID="STD-SOCESP-1999" TOTAL_1="63" TOTAL_2="58" VAR="0.24957311659039685" WEIGHT="3.4505392021984407"/>
<DICH_DATA CI_END="3.846957453534936" CI_START="0.06048547377977517" EFFECT_SIZE="0.4823743817696976" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.585117383136246" LOG_CI_START="-1.2183489131949854" LOG_EFFECT_SIZE="-0.31661576502936983" ORDER="252" O_E="-0.6496163682864449" SE="1.0593650297671098" STUDY_ID="STD-SOPAT-2004" TOTAL_1="518" TOTAL_2="264" VAR="0.8910636653694842" WEIGHT="12.31963663000691"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.962540738134865" CI_START="0.0027401896934722146" DF="0" EFFECT_SIZE="0.1381256036041746" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.09.05" LOG_CI_END="0.8427677492655075" LOG_CI_START="-2.562219371494708" LOG_EFFECT_SIZE="-0.8597258111146004" NO="5" P_CHI2="1.0" P_Z="0.32229960889906384" STUDIES="2" TAU2="0.0" TOTAL_1="145" TOTAL_2="152" WEIGHT="100.0" Z="0.989743318610787">
<NAME>Flecainide vs Propafenone</NAME>
<DICH_DATA CI_END="6.962540738134865" CI_START="0.0027401896934722146" EFFECT_SIZE="0.1381256036041746" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8427677492655075" LOG_CI_START="-2.562219371494708" LOG_EFFECT_SIZE="-0.8597258111146004" ORDER="253" O_E="-0.4948453608247423" SE="2.000106289692632" STUDY_ID="STD-Aliot-1996" TOTAL_1="48" TOTAL_2="49" VAR="0.24997342969497294" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="254" O_E="0.0" SE="0.0" STUDY_ID="STD-FAPIS-1996" TOTAL_1="97" TOTAL_2="103" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.544989382789011" CI_END="1.1087965259966017" CI_START="0.3099896608255605" DF="1" EFFECT_SIZE="0.5862725125897055" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="28" I2="84.72113640658236" ID="CMP-001.09.06" LOG_CI_END="0.04485185656889538" LOG_CI_START="-0.5086527910731077" LOG_EFFECT_SIZE="-0.23190046725210614" MODIFIED="2010-12-28 12:07:28 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0105180269828139" P_Z="0.10052318996897026" STUDIES="5" TAU2="0.0" TOTAL_1="311" TOTAL_2="332" WEIGHT="100.0" Z="1.6423224836446595">
<NAME>Amiodarone vs Class I drugs</NAME>
<DICH_DATA CI_END="0.7880650140514919" CI_START="0.18939783265339966" EFFECT_SIZE="0.38633897764958103" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="26" LOG_CI_END="-0.1034379524608295" LOG_CI_START="-0.722624995090161" LOG_EFFECT_SIZE="-0.41303147377549526" ORDER="255" O_E="-7.1891891891891895" SE="0.3637135338657624" STUDY_ID="STD-AFFIRM-Substudy-2003" TOTAL_1="106" TOTAL_2="116" VAR="7.559291222248295" WEIGHT="79.90957570584554"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="256" O_E="0.0" SE="0.0" STUDY_ID="STD-Kochiadakis-2004a" TOTAL_1="72" TOTAL_2="74" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="12.764097557867114" CI_START="0.7431980133998494" EFFECT_SIZE="3.0799759654660788" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1059901149104918" LOG_CI_START="-0.1288954599006314" LOG_EFFECT_SIZE="0.4885473275049301" MODIFIED="2010-12-28 12:07:28 +0000" MODIFIED_BY="[Empty name]" ORDER="1011" O_E="2.1379310344827585" SE="0.7253778994262347" STUDY_ID="STD-PITAGORA-2008" TOTAL_1="70" TOTAL_2="75" VAR="1.9005152596115735" WEIGHT="20.090424294154463"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="257" O_E="0.0" SE="0.0" STUDY_ID="STD-Villani-1992" TOTAL_1="35" TOTAL_2="41" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="258" O_E="0.0" SE="0.0" STUDY_ID="STD-Vitolo-1981" TOTAL_1="28" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.320464532048778" CI_START="0.5235607080055783" DF="0" EFFECT_SIZE="2.32451924434837" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" ID="CMP-001.09.07" LOG_CI_END="1.0136992456599003" LOG_CI_START="-0.281032953673348" LOG_EFFECT_SIZE="0.3663331459932761" MODIFIED="2010-12-28 11:01:46 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.2673830438951944" STUDIES="1" TAU2="0.0" TOTAL_1="255" TOTAL_2="249" WEIGHT="100.0" Z="1.1091093167526462">
<NAME>Amiodarone vs Dronedarone</NAME>
<DICH_DATA CI_END="10.320464532048778" CI_START="0.5235607080055783" EFFECT_SIZE="2.32451924434837" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0136992456599003" LOG_CI_START="-0.281032953673348" LOG_EFFECT_SIZE="0.3663331459932761" MODIFIED="2010-12-28 11:01:46 +0000" MODIFIED_BY="[Empty name]" ORDER="1004" O_E="1.4583333333333335" SE="0.7605321029161002" STUDY_ID="STD-DYONISOS-2010" TOTAL_1="255" TOTAL_2="249" VAR="1.7288801910757676" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.830802565439355" CI_END="1.2498545105752332" CI_START="0.4711739180786896" DF="2" EFFECT_SIZE="0.7673974503320008" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="39" I2="58.59901180171492" ID="CMP-001.09.08" LOG_CI_END="0.09685946186265533" LOG_CI_START="-0.3268187580087463" LOG_EFFECT_SIZE="-0.11497964807304548" MODIFIED="2014-06-26 16:14:21 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.08933152917894438" P_Z="0.2874160674180056" STUDIES="6" TAU2="0.0" TOTAL_1="606" TOTAL_2="562" WEIGHT="100.0" Z="1.0638071942742835">
<NAME>Amiodarone vs Sotalol</NAME>
<DICH_DATA CI_END="1.086376891959221" CI_START="0.2784842649069672" EFFECT_SIZE="0.5500353353823547" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="24" LOG_CI_END="0.03598051926951693" LOG_CI_START="-0.5551993385769048" LOG_EFFECT_SIZE="-0.2596094096536939" ORDER="259" O_E="-4.95703125" SE="0.34726197488648064" STUDY_ID="STD-AFFIRM-Substudy-2003" TOTAL_1="131" TOTAL_2="125" VAR="8.292501112994026" WEIGHT="51.36094666703902"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="260" O_E="0.0" SE="0.0" STUDY_ID="STD-Kochiadakis-2000" TOTAL_1="65" TOTAL_2="61" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-28 12:02:15 +0000" MODIFIED_BY="[Empty name]" ORDER="1008" O_E="0.0" SE="0.0" STUDY_ID="STD-Niu-2006" TOTAL_1="51" TOTAL_2="51" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="27.078062727739017" CI_START="0.7701808499361227" EFFECT_SIZE="4.566728081052525" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="1.4326175899706837" LOG_CI_START="-0.11340728403900148" LOG_EFFECT_SIZE="0.6596051529658411" MODIFIED="2010-12-28 12:09:30 +0000" MODIFIED_BY="[Empty name]" ORDER="1012" O_E="1.8415841584158414" SE="0.9081426639398406" STUDY_ID="STD-PITAGORA-2008" TOTAL_1="70" TOTAL_2="31" VAR="1.2125281835114203" WEIGHT="7.509989388849977"/>
<DICH_DATA CI_END="1.7968513723660982" CI_START="0.39253368516908793" EFFECT_SIZE="0.8398361095451883" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" LOG_CI_END="0.2545121556672609" LOG_CI_START="-0.4061230684592765" LOG_EFFECT_SIZE="-0.07580545639600782" ORDER="261" O_E="-1.1590909090909083" SE="0.38806040084902854" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="267" TOTAL_2="261" VAR="6.640508609468848" WEIGHT="41.129063944111"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-06-26 16:14:21 +0100" MODIFIED_BY="[Empty name]" ORDER="1054" O_E="0.0" SE="0.0" STUDY_ID="STD-Vijayalaskshmi-2006" TOTAL_1="22" TOTAL_2="33" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.3167524255634175" CI_END="1.9924422275589377" CI_START="0.4426858033906517" DF="1" EFFECT_SIZE="0.9391623332610759" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" I2="56.836130224108544" ID="CMP-001.09.09" LOG_CI_END="0.2993857375381064" LOG_CI_START="-0.3539044053036511" LOG_EFFECT_SIZE="-0.02725933388277231" MODIFIED="2010-12-28 10:58:05 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.1279871246984151" P_Z="0.8700745358297529" STUDIES="4" TAU2="0.0" TOTAL_1="243" TOTAL_2="251" WEIGHT="100.0" Z="0.16356381077596496">
<NAME>Sotalol vs Class I drugs other than quinidine</NAME>
<DICH_DATA CI_END="1.7412342298624695" CI_START="0.3650674027519457" EFFECT_SIZE="0.7972878137026027" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="17" LOG_CI_END="0.2408571960998028" LOG_CI_START="-0.43762694392503104" LOG_EFFECT_SIZE="-0.09838487391261413" ORDER="262" O_E="-1.4262295081967213" SE="0.3985449424012465" STUDY_ID="STD-AFFIRM-Substudy-2003" TOTAL_1="88" TOTAL_2="95" VAR="6.2957198673404" WEIGHT="92.71132978881198"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="263" O_E="0.0" SE="0.0" STUDY_ID="STD-Carunchio-1995" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="264" O_E="0.0" SE="0.0" STUDY_ID="STD-Kochiadakis-2004b" TOTAL_1="85" TOTAL_2="86" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="122.28101460830001" CI_START="0.46509877905655417" EFFECT_SIZE="7.54140242899933" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0873590335620484" LOG_CI_START="-0.33245480056523524" LOG_EFFECT_SIZE="0.8774521164984066" ORDER="265" O_E="1.0" SE="1.4214106244380285" STUDY_ID="STD-Reimold-1993" TOTAL_1="50" TOTAL_2="50" VAR="0.494949494949495" WEIGHT="7.288670211188019"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="24.03273372029046" CI_START="0.0028732427690940573" DF="0" EFFECT_SIZE="0.2627772409920377" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.09.10" LOG_CI_END="1.3808031745538158" LOG_CI_START="-2.5416276775849376" LOG_EFFECT_SIZE="-0.5804122515155609" MODIFIED="2010-12-28 10:58:02 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Z="0.561886369762403" STUDIES="1" TAU2="0.0" TOTAL_1="108" TOTAL_2="321" WEIGHT="100.0" Z="0.5800418934273982">
<NAME>Sotalol vs Dofetilide</NAME>
<DICH_DATA CI_END="24.03273372029046" CI_START="0.0028732427690940573" EFFECT_SIZE="0.2627772409920377" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.3808031745538158" LOG_CI_START="-2.5416276775849376" LOG_EFFECT_SIZE="-0.5804122515155609" MODIFIED="2010-12-28 10:54:00 +0000" MODIFIED_BY="[Empty name]" ORDER="1000" O_E="-0.2517482517482518" SE="2.3040552988921648" STUDY_ID="STD-EMERALD-2000" TOTAL_1="108" TOTAL_2="321" VAR="0.1883710694899506" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.09.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-12-28 10:58:00 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="133" TOTAL_2="130" WEIGHT="0.0" Z="0.0">
<NAME>Sotalol vs Other Beta-blockers</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-27 13:15:40 +0000" MODIFIED_BY="[Empty name]" ORDER="916" O_E="0.0" SE="0.0" STUDY_ID="STD-DAPHNE-2008" TOTAL_1="69" TOTAL_2="66" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-27 13:16:37 +0000" MODIFIED_BY="[Empty name]" ORDER="917" O_E="0.0" SE="0.0" STUDY_ID="STD-Plewan-2001" TOTAL_1="64" TOTAL_2="64" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="10.346342431025432" CI_END="1.2601641723639792" CI_START="0.49265145186207804" DF="6" EFFECT_SIZE="0.7879224004301999" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="39" I2="42.008491986425234" ID="CMP-001.09.12" LOG_CI_END="0.1004271280597695" LOG_CI_START="-0.30746023299044195" LOG_EFFECT_SIZE="-0.10351655246533623" MODIFIED="2010-12-28 10:57:59 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.11080437943363042" P_Z="0.31982034234642365" STUDIES="13" TAU2="0.0" TOTAL_1="1353" TOTAL_2="1522" WEIGHT="100.0" Z="0.9948271704885414">
<NAME>Class III vs Class I drugs</NAME>
<DICH_DATA CI_END="0.8510867606753325" CI_START="0.24162410134415274" EFFECT_SIZE="0.4534788569647798" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="26" LOG_CI_END="-0.07002616522454878" LOG_CI_START="-0.6168597482018856" LOG_EFFECT_SIZE="-0.34344295671321723" ORDER="266" O_E="-7.664516129032258" SE="0.32121275351077927" STUDY_ID="STD-AFFIRM-Substudy-2003" TOTAL_1="194" TOTAL_2="116" VAR="9.69202307466939" WEIGHT="55.63782447821452"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="267" O_E="0.0" SE="0.0" STUDY_ID="STD-Carunchio-1995" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="268" O_E="0.0" SE="0.0" STUDY_ID="STD-Hohnloser-1995" TOTAL_1="25" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="14.054010447520609" CI_START="0.053392771755309834" EFFECT_SIZE="0.8662462537126538" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.147800272048707" LOG_CI_START="-1.2725175332198093" LOG_EFFECT_SIZE="-0.062358630585551224" ORDER="269" O_E="-0.0710382513661203" SE="1.4217066595810859" STUDY_ID="STD-Juul_x002d_Moller-1990" TOTAL_1="98" TOTAL_2="85" VAR="0.4947433945015241" WEIGHT="2.8401135586411934"/>
<DICH_DATA CI_END="6.820467167072353" CI_START="0.0026853936013588454" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8338141226232082" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" ORDER="270" O_E="-0.5" SE="2.0" STUDY_ID="STD-Kalusche-1994" TOTAL_1="41" TOTAL_2="41" VAR="0.25" WEIGHT="1.435144758982954"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="271" O_E="0.0" SE="0.0" STUDY_ID="STD-Kochiadakis-2004a" TOTAL_1="72" TOTAL_2="74" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="272" O_E="0.0" SE="0.0" STUDY_ID="STD-Kochiadakis-2004b" TOTAL_1="85" TOTAL_2="86" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.3378677970631148" CI_START="0.6127503547537853" EFFECT_SIZE="1.4301327479544197" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="0.5234691315813993" LOG_CI_START="-0.21271642863962698" LOG_EFFECT_SIZE="0.15537635147088621" ORDER="273" O_E="1.9131578947368428" SE="0.4324390422511265" STUDY_ID="STD-PAFAC-2004" TOTAL_1="383" TOTAL_2="377" VAR="5.347492773696254" WEIGHT="30.697704911477594"/>
<DICH_DATA CI_END="122.28101460830001" CI_START="0.46509877905655417" EFFECT_SIZE="7.54140242899933" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0873590335620484" LOG_CI_START="-0.33245480056523524" LOG_EFFECT_SIZE="0.8774521164984066" ORDER="274" O_E="1.0" SE="1.4214106244380285" STUDY_ID="STD-Reimold-1993" TOTAL_1="50" TOTAL_2="50" VAR="0.494949494949495" WEIGHT="2.841296694552111"/>
<DICH_DATA CI_END="407.2738715153939" CI_START="0.1592831139860607" EFFECT_SIZE="8.054306332647817" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.6098865489991505" LOG_CI_START="-0.7978302624373067" LOG_EFFECT_SIZE="0.906028143280922" ORDER="275" O_E="0.5206611570247934" SE="2.0017097235080428" STUDY_ID="STD-SOCESP-1999" TOTAL_1="58" TOTAL_2="63" VAR="0.24957311659039685" WEIGHT="1.432694201030999"/>
<DICH_DATA CI_END="16.532895214493227" CI_START="0.25994568748898145" EFFECT_SIZE="2.0730785833428342" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="1.2183489131949856" LOG_CI_START="-0.5851173831362458" LOG_EFFECT_SIZE="0.3166157650293699" ORDER="276" O_E="0.6496163682864451" SE="1.0593650297671098" STUDY_ID="STD-SOPAT-2004" TOTAL_1="264" TOTAL_2="518" VAR="0.8910636653694842" WEIGHT="5.115221397100624"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="277" O_E="0.0" SE="0.0" STUDY_ID="STD-Villani-1992" TOTAL_1="35" TOTAL_2="41" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="278" O_E="0.0" SE="0.0" STUDY_ID="STD-Vitolo-1981" TOTAL_1="28" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="30.491215068781663" CI_END="1.9017549636584743" CI_START="1.162898544943292" CI_STUDY="95" CI_TOTAL="95" DF="32" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.487127459257317" ESTIMABLE="YES" EVENTS_1="240" EVENTS_2="111" I2="0.0" I2_Q="10.383777955605582" ID="CMP-001.10" LOG_CI_END="0.27915455845495074" LOG_CI_START="0.06554182711601304" LOG_EFFECT_SIZE="0.17234819278548186" METHOD="PETO" MODIFIED="2014-09-24 16:45:55 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.5429473693421747" P_Q="0.3499552162618501" P_Z="0.0015631453978454093" Q="6.6952164051589875" RANDOM="NO" SCALE="662.600470427028" SORT_BY="STUDY" STUDIES="22" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="6416" TOTAL_2="3359" WEIGHT="700.0" Z="3.162697733817483">
<NAME>Subgroup analysis: Persistent atrial fibrillation</NAME>
<GROUP_LABEL_1>Antiarrhythmic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.545682656333148" CI_END="5.324452169185739" CI_START="0.8373109945820354" DF="4" EFFECT_SIZE="2.111450293373109" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="4" I2="0.0" ID="CMP-001.10.01" LOG_CI_END="0.7262749300189494" LOG_CI_START="-0.07711320611051749" LOG_EFFECT_SIZE="0.324580861954216" NO="1" P_CHI2="0.6364748224805777" P_Z="0.11325979216729898" STUDIES="5" TAU2="0.0" TOTAL_1="595" TOTAL_2="282" WEIGHT="100.0" Z="1.5837097186078224">
<NAME>Class Ia: Quinidine</NAME>
<DICH_DATA CI_END="527.8001204153296" CI_START="0.19326023079046073" EFFECT_SIZE="10.099642225480048" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.7224694849664623" LOG_CI_START="-0.713857506163923" LOG_EFFECT_SIZE="1.0043059894012696" ORDER="279" O_E="0.5675675675675675" SE="2.0185154846829296" STUDY_ID="STD-Byrne_x002d_Quinn-1970" TOTAL_1="32" TOTAL_2="42" VAR="0.2454346238130022" WEIGHT="5.465902259867775"/>
<DICH_DATA CI_END="406.0194289218663" CI_START="0.15885962215189478" EFFECT_SIZE="8.031194996067258" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.6085468160197243" LOG_CI_START="-0.7989864747561749" LOG_EFFECT_SIZE="0.9047801706317746" ORDER="280" O_E="0.52" SE="2.001601922563589" STUDY_ID="STD-Hillestad-1971" TOTAL_1="48" TOTAL_2="52" VAR="0.2496" WEIGHT="5.55866642964953"/>
<DICH_DATA CI_END="113.67197031843577" CI_START="0.4175408606629363" EFFECT_SIZE="6.8893172608039634" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0556533878472827" LOG_CI_START="-0.3793010179238064" LOG_EFFECT_SIZE="0.8381761849617383" ORDER="281" O_E="0.9433962264150944" SE="1.4303042711686382" STUDY_ID="STD-Lloyd-1984" TOTAL_1="28" TOTAL_2="25" VAR="0.4888134293616671" WEIGHT="10.886020833952568"/>
<DICH_DATA CI_END="4.829173192322102" CI_START="0.22861787023996857" EFFECT_SIZE="1.050730836250954" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="0.6838727811139533" LOG_CI_START="-0.640889825369967" LOG_EFFECT_SIZE="0.021491477871993174" ORDER="282" O_E="0.08172043010752716" SE="0.7781721127293179" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="88" VAR="1.6513862874320733" WEIGHT="36.776865057420814"/>
<DICH_DATA CI_END="8.24184638422739" CI_START="0.4635516457913856" EFFECT_SIZE="1.9546154240075941" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="0.9160245156600444" LOG_CI_START="-0.33390187266793026" LOG_EFFECT_SIZE="0.29106132149605707" ORDER="283" O_E="1.243243243243243" SE="0.7342129477392609" STUDY_ID="STD-Sodermark-1975" TOTAL_1="110" TOTAL_2="75" VAR="1.8550512910089878" WEIGHT="41.312545419109306"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.8514845890180034" CI_END="5.487878427984698" CI_START="0.9364408315647781" DF="5" EFFECT_SIZE="2.2669524561905563" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="4" I2="0.0" ID="CMP-001.10.02" LOG_CI_END="0.739404481955217" LOG_CI_START="-0.028519658050315796" LOG_EFFECT_SIZE="0.3554424119524506" NO="2" P_CHI2="0.7228697286946532" P_Z="0.06961875168368306" STUDIES="6" TAU2="0.0" TOTAL_1="670" TOTAL_2="328" WEIGHT="99.99999999999997" Z="1.8143831915476265">
<NAME>All class Ia antiarrhythmics</NAME>
<DICH_DATA CI_END="527.8001204153296" CI_START="0.19326023079046073" EFFECT_SIZE="10.099642225480048" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.7224694849664623" LOG_CI_START="-0.713857506163923" LOG_EFFECT_SIZE="1.0043059894012696" ORDER="284" O_E="0.5675675675675675" SE="2.0185154846829296" STUDY_ID="STD-Byrne_x002d_Quinn-1970" TOTAL_1="32" TOTAL_2="42" VAR="0.2454346238130022" WEIGHT="4.993990056996939"/>
<DICH_DATA CI_END="406.0194289218663" CI_START="0.15885962215189478" EFFECT_SIZE="8.031194996067258" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.6085468160197243" LOG_CI_START="-0.7989864747561749" LOG_EFFECT_SIZE="0.9047801706317746" ORDER="285" O_E="0.52" SE="2.001601922563589" STUDY_ID="STD-Hillestad-1971" TOTAL_1="48" TOTAL_2="52" VAR="0.2496" WEIGHT="5.0787452025356865"/>
<DICH_DATA CI_END="122.6563157532565" CI_START="0.46536100533222263" EFFECT_SIZE="7.555095393791001" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0886899155768055" LOG_CI_START="-0.33221001099032044" LOG_EFFECT_SIZE="0.8782399522932426" ORDER="286" O_E="1.0" SE="1.422048600513436" STUDY_ID="STD-Karlson-1998" TOTAL_1="46" TOTAL_2="46" VAR="0.4945054945054945" WEIGHT="10.061968781439575"/>
<DICH_DATA CI_END="88.7516739201402" CI_START="0.20748745592488377" EFFECT_SIZE="4.291253783076077" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9481765529093782" LOG_CI_START="-0.6830081543122732" LOG_EFFECT_SIZE="0.6325841992985524" ORDER="287" O_E="0.6097560975609757" SE="1.5455709215963562" STUDY_ID="STD-Lloyd-1984" TOTAL_1="57" TOTAL_2="25" VAR="0.4186220723995858" WEIGHT="8.517928052383587"/>
<DICH_DATA CI_END="4.829173192322102" CI_START="0.22861787023996857" EFFECT_SIZE="1.050730836250954" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="0.6838727811139533" LOG_CI_START="-0.640889825369967" LOG_EFFECT_SIZE="0.021491477871993174" ORDER="288" O_E="0.08172043010752716" SE="0.7781721127293179" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="88" VAR="1.6513862874320733" WEIGHT="33.601643368705375"/>
<DICH_DATA CI_END="8.24184638422739" CI_START="0.4635516457913856" EFFECT_SIZE="1.9546154240075941" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="0.9160245156600444" LOG_CI_START="-0.33390187266793026" LOG_EFFECT_SIZE="0.29106132149605707" ORDER="289" O_E="1.243243243243243" SE="0.7342129477392609" STUDY_ID="STD-Sodermark-1975" TOTAL_1="110" TOTAL_2="75" VAR="1.8550512910089878" WEIGHT="37.74572453793882"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.869886871271563" CI_END="5.477423989208443" CI_START="0.957210805091629" DF="6" EFFECT_SIZE="2.2897706056586573" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="4" I2="0.0" ID="CMP-001.10.03" LOG_CI_END="0.7385763595241375" LOG_CI_START="-0.018992407671235417" LOG_EFFECT_SIZE="0.35979197592645096" MODIFIED="2014-06-26 15:44:01 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8249913766860755" P_Z="0.06264671865879172" STUDIES="9" TAU2="0.0" TOTAL_1="1039" TOTAL_2="456" WEIGHT="100.0" Z="1.861690569301108">
<NAME>All class I antiarrhythmics</NAME>
<DICH_DATA CI_END="527.8001204153296" CI_START="0.19326023079046073" EFFECT_SIZE="10.099642225480048" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.7224694849664623" LOG_CI_START="-0.713857506163923" LOG_EFFECT_SIZE="1.0043059894012696" ORDER="290" O_E="0.5675675675675675" SE="2.0185154846829296" STUDY_ID="STD-Byrne_x002d_Quinn-1970" TOTAL_1="32" TOTAL_2="42" VAR="0.2454346238130022" WEIGHT="4.860211359010448"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-06-26 15:44:01 +0100" MODIFIED_BY="[Empty name]" ORDER="1027" O_E="0.0" SE="0.0" STUDY_ID="STD-Flec_x002d_SL-2012" TOTAL_1="281" TOTAL_2="81" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="406.0194289218663" CI_START="0.15885962215189478" EFFECT_SIZE="8.031194996067258" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.6085468160197243" LOG_CI_START="-0.7989864747561749" LOG_EFFECT_SIZE="0.9047801706317746" ORDER="291" O_E="0.52" SE="2.001601922563589" STUDY_ID="STD-Hillestad-1971" TOTAL_1="48" TOTAL_2="52" VAR="0.2496" WEIGHT="4.942696088931938"/>
<DICH_DATA CI_END="122.6563157532565" CI_START="0.46536100533222263" EFFECT_SIZE="7.555095393791001" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0886899155768055" LOG_CI_START="-0.33221001099032044" LOG_EFFECT_SIZE="0.8782399522932426" ORDER="292" O_E="1.0" SE="1.422048600513436" STUDY_ID="STD-Karlson-1998" TOTAL_1="46" TOTAL_2="46" VAR="0.4945054945054945" WEIGHT="9.79242938160121"/>
<DICH_DATA CI_END="88.7516739201402" CI_START="0.20748745592488377" EFFECT_SIZE="4.291253783076077" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9481765529093782" LOG_CI_START="-0.6830081543122732" LOG_EFFECT_SIZE="0.6325841992985524" ORDER="293" O_E="0.6097560975609757" SE="1.5455709215963562" STUDY_ID="STD-Lloyd-1984" TOTAL_1="57" TOTAL_2="25" VAR="0.4186220723995858" WEIGHT="8.28975032047282"/>
<DICH_DATA CI_END="679.4028807857774" CI_START="0.01597709873247045" EFFECT_SIZE="3.2946755387198934" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.8321273840216663" LOG_CI_START="-1.7965020810216048" LOG_EFFECT_SIZE="0.5178126515000308" ORDER="294" O_E="0.16129032258064513" SE="2.7188798598517905" STUDY_ID="STD-Okishige-2000" TOTAL_1="52" TOTAL_2="10" VAR="0.1352757544224766" WEIGHT="2.678793839388191"/>
<DICH_DATA CI_END="4.829173192322102" CI_START="0.22861787023996857" EFFECT_SIZE="1.050730836250954" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="0.6838727811139533" LOG_CI_START="-0.640889825369967" LOG_EFFECT_SIZE="0.021491477871993174" ORDER="295" O_E="0.08172043010752716" SE="0.7781721127293179" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="88" VAR="1.6513862874320733" WEIGHT="32.70152461621131"/>
<DICH_DATA CI_END="8.24184638422739" CI_START="0.4635516457913856" EFFECT_SIZE="1.9546154240075941" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="0.9160245156600444" LOG_CI_START="-0.33390187266793026" LOG_EFFECT_SIZE="0.29106132149605707" ORDER="296" O_E="1.243243243243243" SE="0.7342129477392609" STUDY_ID="STD-Sodermark-1975" TOTAL_1="110" TOTAL_2="75" VAR="1.8550512910089878" WEIGHT="36.73459439438408"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="297" O_E="0.0" SE="0.0" STUDY_ID="STD-Van-Gelder-1989" TOTAL_1="36" TOTAL_2="37" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.975962368100425" CI_END="19.562071399301516" CI_START="0.3852327753179633" DF="1" EFFECT_SIZE="2.7451686753496727" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="66.39742455351322" ID="CMP-001.10.04" LOG_CI_END="1.2914148396978127" LOG_CI_START="-0.4142767705241337" LOG_EFFECT_SIZE="0.43856903458683955" MODIFIED="2010-12-27 14:24:44 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.08451003232536636" P_Z="0.3135046102084412" STUDIES="2" TAU2="0.0" TOTAL_1="280" TOTAL_2="282" WEIGHT="100.0" Z="1.0078955742918352">
<NAME>Class II antiarrhythmics</NAME>
<DICH_DATA CI_END="72.18140228453399" CI_START="0.7720375667293863" EFFECT_SIZE="7.465035444180193" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.85842531494321" LOG_CI_START="-0.11236156672860168" LOG_EFFECT_SIZE="0.8730318741073041" ORDER="298" O_E="1.5" SE="1.157649969846422" STUDY_ID="STD-Kuhlkamp-2000" TOTAL_1="197" TOTAL_2="197" VAR="0.7461832061068703" WEIGHT="74.90687874158216"/>
<DICH_DATA CI_END="6.984791782614944" CI_START="0.0027485648960008198" EFFECT_SIZE="0.13855740146080406" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8441534642785211" LOG_CI_START="-2.560894004507846" LOG_EFFECT_SIZE="-0.8583702701146625" MODIFIED="2010-12-27 14:24:44 +0000" MODIFIED_BY="[Empty name]" ORDER="934" O_E="-0.49404761904761907" SE="2.0001417384219207" STUDY_ID="STD-Nergardh-2007" TOTAL_1="83" TOTAL_2="85" VAR="0.24996456916099774" WEIGHT="25.09312125841784"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.8895092922111596" CI_END="4.802546025616187" CI_START="1.0967241334592803" DF="2" EFFECT_SIZE="2.295009396133755" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="5" I2="0.0" ID="CMP-001.10.05" LOG_CI_END="0.6814715356524932" LOG_CI_START="0.040097400242814205" LOG_EFFECT_SIZE="0.3607844679476537" MODIFIED="2010-12-28 10:39:32 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.38877501299419037" P_Z="0.027451998527781216" STUDIES="6" TAU2="0.0" TOTAL_1="1063" TOTAL_2="624" WEIGHT="100.0" Z="2.2050298704582767">
<NAME>Class III: Sotalol</NAME>
<DICH_DATA CI_END="53.766620926152854" CI_START="1.0528118484471085" EFFECT_SIZE="7.523704909286246" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.7305127432050487" LOG_CI_START="0.022350763889791982" LOG_EFFECT_SIZE="0.8764317535474203" ORDER="863" O_E="2.004474272930649" SE="1.0033828021879485" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="223" TOTAL_2="224" VAR="0.9932685714857689" WEIGHT="14.098236200903461"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-28 10:39:32 +0000" MODIFIED_BY="[Empty name]" ORDER="974" O_E="0.0" SE="0.0" STUDY_ID="STD-EMERALD-2000" TOTAL_1="108" TOTAL_2="106" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.371323379499582" CI_START="0.3847619309837751" EFFECT_SIZE="1.4375954769804182" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="2" LOG_CI_END="0.7300812997790568" LOG_CI_START="-0.41480790436177406" LOG_EFFECT_SIZE="0.1576366977086414" ORDER="299" O_E="0.8025477707006363" SE="0.6725135858052854" STUDY_ID="STD-PAFAC-2004" TOTAL_1="383" TOTAL_2="88" VAR="2.2110464970742414" WEIGHT="31.38310892119018"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="300" O_E="0.0" SE="0.0" STUDY_ID="STD-Plewan-2001" TOTAL_1="64" TOTAL_2="64" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.007583308640837" CI_START="0.8129459997107931" EFFECT_SIZE="2.2099413609163703" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="3" LOG_CI_END="0.7786998019864907" LOG_CI_START="-0.08993830164641405" LOG_EFFECT_SIZE="0.34438075017003833" ORDER="301" O_E="3.0458015267175576" SE="0.510242321901928" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="261" TOTAL_2="132" VAR="3.841024201767415" WEIGHT="54.51865487790636"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="302" O_E="0.0" SE="0.0" STUDY_ID="STD-Singh-1991" TOTAL_1="24" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.6094669642408883" CI_END="4.5626355919694" CI_START="0.5877183722820766" DF="1" EFFECT_SIZE="1.637542293630465" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" I2="37.86762808942437" ID="CMP-001.10.06" LOG_CI_END="0.6592157839783054" LOG_CI_START="-0.23083073287584852" LOG_EFFECT_SIZE="0.21419252555122845" MODIFIED="2014-09-24 16:37:54 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.2045668009142394" P_Z="0.3455054305224422" STUDIES="4" TAU2="0.0" TOTAL_1="385" TOTAL_2="208" WEIGHT="100.0" Z="0.9433431351922802">
<NAME>Class III: Amiodarone</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-09-24 16:34:24 +0100" MODIFIED_BY="[Empty name]" ORDER="1081" O_E="0.0" SE="0.0" STUDY_ID="STD-Channer-2004" TOTAL_1="61" TOTAL_2="38" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-09-24 16:34:29 +0100" MODIFIED_BY="[Empty name]" ORDER="1082" O_E="0.0" SE="0.0" STUDY_ID="STD-GEFACA-2001" TOTAL_1="35" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.665409500607165" CI_START="0.6778569146090587" EFFECT_SIZE="1.9596777806768189" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="3" LOG_CI_END="0.7532313065077162" LOG_CI_START="-0.1688619694866252" LOG_EFFECT_SIZE="0.2921846685105456" MODIFIED="2014-09-24 16:37:54 +0100" MODIFIED_BY="[Empty name]" ORDER="1080" O_E="2.2932330827067666" SE="0.5416421547544066" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="267" TOTAL_2="132" VAR="3.408592513133819" WEIGHT="93.16991508301548"/>
<DICH_DATA CI_END="7.13045089831306" CI_START="0.002802010873979792" EFFECT_SIZE="0.14134921631707822" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8531169935906664" LOG_CI_START="-2.5525301836468692" LOG_EFFECT_SIZE="-0.8497065950281014" MODIFIED="2014-09-24 16:34:44 +0100" MODIFIED_BY="[Empty name]" ORDER="1083" O_E="-0.4888888888888889" SE="2.0004940101347417" STUDY_ID="STD-Vijayalaskshmi-2006" TOTAL_1="22" TOTAL_2="23" VAR="0.24987654320987654" WEIGHT="6.830084916984517"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.054005922447494" CI_END="1.5745570714228578" CI_START="0.8291529713235856" DF="7" EFFECT_SIZE="1.1426060888551337" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="89" I2="22.686156161606" ID="CMP-001.10.07" LOG_CI_END="0.1971584067031583" LOG_CI_START="-0.08136533860165628" LOG_EFFECT_SIZE="0.05789653405075101" MODIFIED="2014-09-24 16:45:55 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.24880202907372473" P_Z="0.41516811321512304" STUDIES="12" TAU2="0.0" TOTAL_1="2384" TOTAL_2="1179" WEIGHT="99.99999999999997" Z="0.8148326559732452">
<NAME>All class III antiarrhythmics</NAME>
<DICH_DATA CI_END="53.766620926152854" CI_START="1.0528118484471085" EFFECT_SIZE="7.523704909286246" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.7305127432050487" LOG_CI_START="0.022350763889791982" LOG_EFFECT_SIZE="0.8764317535474203" ORDER="864" O_E="2.004474272930649" SE="1.0033828021879485" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="223" TOTAL_2="224" VAR="0.9932685714857689" WEIGHT="2.658681728758956"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="303" O_E="0.0" SE="0.0" STUDY_ID="STD-Channer-2004" TOTAL_1="61" TOTAL_2="38" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="364.75141324228076" CI_START="0.03825601513883153" EFFECT_SIZE="3.7354966988215743" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5619969832581146" LOG_CI_START="-1.417300269367424" LOG_EFFECT_SIZE="0.5723483569453452" ORDER="304" O_E="0.24120603015075381" SE="2.3374589040313243" STUDY_ID="STD-DAFNE-2003" TOTAL_1="151" TOTAL_2="48" VAR="0.18302568116966741" WEIGHT="0.48990479351578753"/>
<DICH_DATA CI_END="1.4431434722617116" CI_START="0.6798268094585525" EFFECT_SIZE="0.9904986735673179" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="80" LOG_CI_END="0.1593095092738014" LOG_CI_START="-0.16760171270039934" LOG_EFFECT_SIZE="-0.004146101713299011" ORDER="305" O_E="-0.2588932806324067" SE="0.19202927002429282" STUDY_ID="STD-DIAMOND-2001" TOTAL_1="249" TOTAL_2="257" VAR="27.11846716635919" WEIGHT="72.5879940601562"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-28 10:39:40 +0000" MODIFIED_BY="[Empty name]" ORDER="975" O_E="0.0" SE="0.0" STUDY_ID="STD-EMERALD-2000" TOTAL_1="108" TOTAL_2="106" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="353.27126735483773" CI_START="0.040485957738138234" EFFECT_SIZE="3.7818680040723907" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5481083163573324" LOG_CI_START="-1.3926955825711107" LOG_EFFECT_SIZE="0.5777063668931108" MODIFIED="2010-12-28 10:33:10 +0000" MODIFIED_BY="[Empty name]" ORDER="959" O_E="0.2482435597189696" SE="2.3148477175244766" STUDY_ID="STD-EMERALD-2000" TOTAL_1="321" TOTAL_2="106" VAR="0.18661869477702395" WEIGHT="0.49952221211061115"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="306" O_E="0.0" SE="0.0" STUDY_ID="STD-GEFACA-2001" TOTAL_1="35" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.371323379499582" CI_START="0.3847619309837751" EFFECT_SIZE="1.4375954769804182" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="2" LOG_CI_END="0.7300812997790568" LOG_CI_START="-0.41480790436177406" LOG_EFFECT_SIZE="0.1576366977086414" ORDER="307" O_E="0.8025477707006363" SE="0.6725135858052854" STUDY_ID="STD-PAFAC-2004" TOTAL_1="383" TOTAL_2="88" VAR="2.2110464970742414" WEIGHT="5.9183075876593385"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="308" O_E="0.0" SE="0.0" STUDY_ID="STD-Plewan-2001" TOTAL_1="64" TOTAL_2="64" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.8390786517420095" CI_START="0.7986279044657819" EFFECT_SIZE="1.965864502753387" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="3" LOG_CI_END="0.6847626809513502" LOG_CI_START="-0.09765551940615741" LOG_EFFECT_SIZE="0.29355358077259636" ORDER="309" O_E="3.1999999999999993" SE="0.45959632392255517" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="528" TOTAL_2="132" VAR="4.734203338391503" WEIGHT="12.672040853143494"/>
<DICH_DATA CI_END="3.2294735891450452" CI_START="0.16326815408962927" EFFECT_SIZE="0.7261337284418906" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.5091317372038408" LOG_CI_START="-0.7870985173570041" LOG_EFFECT_SIZE="-0.13898339007658164" ORDER="310" O_E="-0.5519999999999996" SE="0.7614120679722834" STUDY_ID="STD-SAFIRE_x002d_D-2000" TOTAL_1="182" TOTAL_2="68" VAR="1.724886361445783" WEIGHT="4.617002878185928"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="311" O_E="0.0" SE="0.0" STUDY_ID="STD-Singh-1991" TOTAL_1="24" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.4768873000713434" CI_START="4.5755596788039796E-4" EFFECT_SIZE="0.033664737722352886" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.39390624636354277" LOG_CI_START="-3.3395557757942944" LOG_EFFECT_SIZE="-1.4728247647153758" MODIFIED="2014-09-24 16:45:52 +0100" MODIFIED_BY="[Empty name]" ORDER="1053" O_E="-0.7051282051282052" SE="2.19305407275058" STUDY_ID="STD-Vijayalaskshmi-2006" TOTAL_1="55" TOTAL_2="23" VAR="0.20792241946088102" WEIGHT="0.5565458864696599"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="27.481163032048055" CI_END="1.2181428541109434" CI_START="0.8249174560481514" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.0024306980118045" ESTIMABLE="YES" EVENTS_1="260" EVENTS_2="229" I2="45.4171572632961" I2_Q="48.76923419705369" ID="CMP-001.11" LOG_CI_END="0.08569822188810003" LOG_CI_START="-0.08358950620922162" LOG_EFFECT_SIZE="0.0010543578394391709" METHOD="PETO" MODIFIED="2014-06-26 15:44:43 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.025051927888851355" P_Q="0.08233575902500867" P_Z="0.9805223049816648" Q="9.759760412780023" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="7453" TOTAL_2="5260" WEIGHT="600.0" Z="0.024414095638760996">
<NAME>Sensitivity analysis: Best quality studies</NAME>
<GROUP_LABEL_1>Antiarrhythmic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7163452287774423" CI_END="5.511922887864247" CI_START="0.366334593825393" DF="1" EFFECT_SIZE="1.4209883997846837" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" I2="0.0" ID="CMP-001.11.01" LOG_CI_END="0.7413031331359077" LOG_CI_START="-0.4361220679636763" LOG_EFFECT_SIZE="0.15259053258611568" NO="1" P_CHI2="0.3973458588515213" P_Z="0.6114462606827231" STUDIES="2" TAU2="0.0" TOTAL_1="895" TOTAL_2="339" WEIGHT="100.00000000000001" Z="0.5080101019942029">
<NAME>Class Ia: Quinidine</NAME>
<DICH_DATA CI_END="4.829173192322102" CI_START="0.22861787023996857" EFFECT_SIZE="1.050730836250954" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="0.6838727811139533" LOG_CI_START="-0.640889825369967" LOG_EFFECT_SIZE="0.021491477871993174" ORDER="312" O_E="0.08172043010752716" SE="0.7781721127293179" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="88" VAR="1.6513862874320733" WEIGHT="78.99335001258665"/>
<DICH_DATA CI_END="85.12319633156255" CI_START="0.22966890860097597" EFFECT_SIZE="4.421555336993599" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9300479227881144" LOG_CI_START="-0.6388977933855617" LOG_EFFECT_SIZE="0.6455750647012765" ORDER="313" O_E="0.6527958387516255" SE="1.5090114301668014" STUDY_ID="STD-SOPAT-2004" TOTAL_1="518" TOTAL_2="251" VAR="0.43915207708714865" WEIGHT="21.006649987413365"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.054236866768389" CI_END="3.6339640723677484" CI_START="0.27029505130260156" DF="2" EFFECT_SIZE="0.9910814827109079" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" I2="50.668891193962494" ID="CMP-001.11.02" LOG_CI_END="0.56038062928749" LOG_CI_START="-0.5681619055097351" LOG_EFFECT_SIZE="-0.00389063811112252" MODIFIED="2014-06-26 15:44:43 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.1317147599379741" P_Z="0.9892177888153176" STUDIES="6" TAU2="0.0" TOTAL_1="1336" TOTAL_2="529" WEIGHT="100.00000000000001" Z="0.013513909027893617">
<NAME>All class I antiarrhythmics</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-06-26 15:44:43 +0100" MODIFIED_BY="[Empty name]" ORDER="1029" O_E="0.0" SE="0.0" STUDY_ID="STD-Flec_x002d_SL-2012" TOTAL_1="281" TOTAL_2="81" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.829173192322102" CI_START="0.22861787023996857" EFFECT_SIZE="1.050730836250954" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="0.6838727811139533" LOG_CI_START="-0.640889825369967" LOG_EFFECT_SIZE="0.021491477871993174" ORDER="314" O_E="0.08172043010752716" SE="0.7781721127293179" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="88" VAR="1.6513862874320733" WEIGHT="72.57043772789953"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="315" O_E="0.0" SE="0.0" STUDY_ID="STD-SMART-2002" TOTAL_1="47" TOTAL_2="47" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="85.12319633156255" CI_START="0.22966890860097597" EFFECT_SIZE="4.421555336993599" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9300479227881144" LOG_CI_START="-0.6388977933855617" LOG_EFFECT_SIZE="0.6455750647012765" ORDER="316" O_E="0.6527958387516255" SE="1.5090114301668014" STUDY_ID="STD-SOPAT-2004" TOTAL_1="518" TOTAL_2="251" VAR="0.43915207708714865" WEIGHT="19.29860911760874"/>
<DICH_DATA CI_END="1.610453732263025" CI_START="1.7750425800542054E-4" EFFECT_SIZE="0.01690746565270528" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.20694825221594015" LOG_CI_START="-3.7507912245464756" LOG_EFFECT_SIZE="-1.7719214861652675" ORDER="317" O_E="-0.7549019607843137" SE="2.3247957597766145" STUDY_ID="STD-Stroobandt-1997" TOTAL_1="77" TOTAL_2="25" VAR="0.18502499038831216" WEIGHT="8.130953154491738"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="318" O_E="0.0" SE="0.0" STUDY_ID="STD-Van-Gelder-1989" TOTAL_1="36" TOTAL_2="37" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.975962368100425" CI_END="19.562071399301516" CI_START="0.3852327753179633" DF="1" EFFECT_SIZE="2.7451686753496727" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="66.39742455351322" ID="CMP-001.11.03" LOG_CI_END="1.2914148396978127" LOG_CI_START="-0.4142767705241337" LOG_EFFECT_SIZE="0.43856903458683955" MODIFIED="2010-12-27 14:25:10 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.08451003232536636" P_Z="0.3135046102084412" STUDIES="2" TAU2="0.0" TOTAL_1="280" TOTAL_2="282" WEIGHT="100.0" Z="1.0078955742918352">
<NAME>Class II antiarrhythmics</NAME>
<DICH_DATA CI_END="72.18140228453399" CI_START="0.7720375667293863" EFFECT_SIZE="7.465035444180193" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.85842531494321" LOG_CI_START="-0.11236156672860168" LOG_EFFECT_SIZE="0.8730318741073041" ORDER="319" O_E="1.5" SE="1.157649969846422" STUDY_ID="STD-Kuhlkamp-2000" TOTAL_1="197" TOTAL_2="197" VAR="0.7461832061068703" WEIGHT="74.90687874158216"/>
<DICH_DATA CI_END="6.984791782614944" CI_START="0.0027485648960008198" EFFECT_SIZE="0.13855740146080406" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8441534642785211" LOG_CI_START="-2.560894004507846" LOG_EFFECT_SIZE="-0.8583702701146625" MODIFIED="2010-12-27 14:25:10 +0000" MODIFIED_BY="[Empty name]" ORDER="935" O_E="-0.49404761904761907" SE="2.0001417384219207" STUDY_ID="STD-Nergardh-2007" TOTAL_1="83" TOTAL_2="85" VAR="0.24996456916099774" WEIGHT="25.09312125841784"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.3794615693504113" CI_END="7.688981496643416" CI_START="1.0027509479987446" DF="2" EFFECT_SIZE="2.776712711985882" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="2" I2="15.947371213648289" ID="CMP-001.11.04" LOG_CI_END="0.8858688157855126" LOG_CI_START="0.0011930812350147925" LOG_EFFECT_SIZE="0.4435309485102637" MODIFIED="2010-08-27 18:10:21 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.3043032332716712" P_Z="0.04938525943622911" STUDIES="4" TAU2="0.0" TOTAL_1="1054" TOTAL_2="632" WEIGHT="100.00000000000001" Z="1.9652504328056386">
<NAME>Class III: Sotalol</NAME>
<DICH_DATA CI_END="53.766620926152854" CI_START="1.0528118484471085" EFFECT_SIZE="7.523704909286246" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.7305127432050487" LOG_CI_START="0.022350763889791982" LOG_EFFECT_SIZE="0.8764317535474203" ORDER="865" O_E="2.004474272930649" SE="1.0033828021879485" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="223" TOTAL_2="224" VAR="0.9932685714857689" WEIGHT="26.82317164068075"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="320" O_E="0.0" SE="0.0" STUDY_ID="STD-Benditt-1999" TOTAL_1="184" TOTAL_2="69" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.371323379499582" CI_START="0.3847619309837751" EFFECT_SIZE="1.4375954769804182" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="2" LOG_CI_END="0.7300812997790568" LOG_CI_START="-0.41480790436177406" LOG_EFFECT_SIZE="0.1576366977086414" ORDER="321" O_E="0.8025477707006363" SE="0.6725135858052854" STUDY_ID="STD-PAFAC-2004" TOTAL_1="383" TOTAL_2="88" VAR="2.2110464970742414" WEIGHT="59.70920796158307"/>
<DICH_DATA CI_END="113.29018050149466" CI_START="0.4400653449064914" EFFECT_SIZE="7.060813151253114" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0541922687440057" LOG_CI_START="-0.3564828307292117" LOG_EFFECT_SIZE="0.8488547190073971" ORDER="322" O_E="0.974757281553398" SE="1.4160424864647638" STUDY_ID="STD-SOPAT-2004" TOTAL_1="264" TOTAL_2="251" VAR="0.4987092597761316" WEIGHT="13.467620397736185"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="53.766620926152854" CI_START="1.0528118484471085" DF="0" EFFECT_SIZE="7.523704909286246" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-001.11.05" LOG_CI_END="1.7305127432050487" LOG_CI_START="0.022350763889791982" LOG_EFFECT_SIZE="0.8764317535474203" MODIFIED="2012-03-22 14:07:08 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.0442985276641486" STUDIES="1" TAU2="0.0" TOTAL_1="223" TOTAL_2="224" WEIGHT="100.0" Z="2.011255012886805">
<NAME>Class III: Azimilide</NAME>
<DICH_DATA CI_END="53.766620926152854" CI_START="1.0528118484471085" EFFECT_SIZE="7.523704909286246" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.7305127432050487" LOG_CI_START="0.022350763889791982" LOG_EFFECT_SIZE="0.8764317535474203" MODIFIED="2012-03-22 14:06:46 +0000" MODIFIED_BY="[Empty name]" ORDER="1025" O_E="2.004474272930649" SE="1.0033828021879485" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="223" TOTAL_2="224" VAR="0.9932685714857689" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.595396586271362" CI_END="1.1338888082726037" CI_START="0.751932325113928" DF="4" EFFECT_SIZE="0.9233675584647101" ESTIMABLE="YES" EVENTS_1="212" EVENTS_2="221" I2="47.33652213460481" ID="CMP-001.11.06" LOG_CI_END="0.054570468735657005" LOG_CI_START="-0.12382124471706948" LOG_EFFECT_SIZE="-0.03462538799070627" MODIFIED="2012-03-22 14:06:51 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.10757565439271288" P_Z="0.44674770473318803" STUDIES="7" TAU2="0.0" TOTAL_1="3665" TOTAL_2="3254" WEIGHT="99.99999999999999" Z="0.7608482714696717">
<NAME>All class III antiarrhythmics</NAME>
<DICH_DATA CI_END="53.766620926152854" CI_START="1.0528118484471085" EFFECT_SIZE="7.523704909286246" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.7305127432050487" LOG_CI_START="0.022350763889791982" LOG_EFFECT_SIZE="0.8764317535474203" ORDER="866" O_E="2.004474272930649" SE="1.0033828021879485" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="223" TOTAL_2="224" VAR="0.9932685714857689" WEIGHT="1.0906646865683092"/>
<DICH_DATA CI_END="1.0762908893354253" CI_START="0.6495373719681742" EFFECT_SIZE="0.8361167117886241" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="139" LOG_CI_END="0.03192966404398068" LOG_CI_START="-0.1873958561804416" LOG_EFFECT_SIZE="-0.07773309606823046" MODIFIED="2010-11-20 10:20:47 +0000" MODIFIED_BY="[Empty name]" ORDER="901" O_E="-10.783707865168537" SE="0.1288328962586604" STUDY_ID="STD-ATHENA-2009" TOTAL_1="2301" TOTAL_2="2327" VAR="60.24853064116481" WEIGHT="66.15627099693113"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="323" O_E="0.0" SE="0.0" STUDY_ID="STD-Benditt-1999" TOTAL_1="184" TOTAL_2="69" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="324" O_E="0.0" SE="0.0" STUDY_ID="STD-Channer-2004" TOTAL_1="61" TOTAL_2="38" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.4431434722617116" CI_START="0.6798268094585525" EFFECT_SIZE="0.9904986735673179" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="80" LOG_CI_END="0.1593095092738014" LOG_CI_START="-0.16760171270039934" LOG_EFFECT_SIZE="-0.004146101713299011" ORDER="325" O_E="-0.2588932806324067" SE="0.19202927002429282" STUDY_ID="STD-DIAMOND-2001" TOTAL_1="249" TOTAL_2="257" VAR="27.11846716635919" WEIGHT="29.77760027981908"/>
<DICH_DATA CI_END="5.371323379499582" CI_START="0.3847619309837751" EFFECT_SIZE="1.4375954769804182" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="2" LOG_CI_END="0.7300812997790568" LOG_CI_START="-0.41480790436177406" LOG_EFFECT_SIZE="0.1576366977086414" ORDER="326" O_E="0.8025477707006363" SE="0.6725135858052854" STUDY_ID="STD-PAFAC-2004" TOTAL_1="383" TOTAL_2="88" VAR="2.2110464970742414" WEIGHT="2.427853255350873"/>
<DICH_DATA CI_END="113.29018050149466" CI_START="0.4400653449064914" EFFECT_SIZE="7.060813151253114" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0541922687440057" LOG_CI_START="-0.3564828307292117" LOG_EFFECT_SIZE="0.8488547190073971" ORDER="327" O_E="0.974757281553398" SE="1.4160424864647638" STUDY_ID="STD-SOPAT-2004" TOTAL_1="264" TOTAL_2="251" VAR="0.4987092597761316" WEIGHT="0.5476107813305973"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="31.718212140311994" CI_END="1.323291807645023" CI_START="0.9346021634211465" CI_STUDY="95" CI_TOTAL="95" DF="25" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.1120932453092762" ESTIMABLE="YES" EVENTS_1="360" EVENTS_2="256" I2="21.180929462835454" I2_Q="50.05438576431148" ID="CMP-001.12" LOG_CI_END="0.12165562383671294" LOG_CI_START="-0.029373218003789243" LOG_EFFECT_SIZE="0.0461412029164618" METHOD="PETO" MODIFIED="2014-06-26 15:44:15 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.16632805431632802" P_Q="0.07492733788897266" P_Z="0.23107782456033676" Q="10.010888996990776" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="18" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="13680" TOTAL_2="8835" WEIGHT="600.0" Z="1.1975870941939155">
<NAME>Sensitivity analysis: Studies &gt; 200 patients</NAME>
<GROUP_LABEL_1>Antiarrhythmic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7163452287774423" CI_END="5.511922887864247" CI_START="0.366334593825393" DF="1" EFFECT_SIZE="1.4209883997846837" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" I2="0.0" ID="CMP-001.12.01" LOG_CI_END="0.7413031331359077" LOG_CI_START="-0.4361220679636763" LOG_EFFECT_SIZE="0.15259053258611568" NO="1" P_CHI2="0.3973458588515213" P_Z="0.6114462606827231" STUDIES="2" TAU2="0.0" TOTAL_1="895" TOTAL_2="339" WEIGHT="100.00000000000001" Z="0.5080101019942029">
<NAME>Class Ia: Quinidine</NAME>
<DICH_DATA CI_END="4.829173192322102" CI_START="0.22861787023996857" EFFECT_SIZE="1.050730836250954" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="0.6838727811139533" LOG_CI_START="-0.640889825369967" LOG_EFFECT_SIZE="0.021491477871993174" ORDER="328" O_E="0.08172043010752716" SE="0.7781721127293179" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="88" VAR="1.6513862874320733" WEIGHT="78.99335001258665"/>
<DICH_DATA CI_END="85.12319633156255" CI_START="0.22966890860097597" EFFECT_SIZE="4.421555336993599" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9300479227881144" LOG_CI_START="-0.6388977933855617" LOG_EFFECT_SIZE="0.6455750647012765" ORDER="329" O_E="0.6527958387516255" SE="1.5090114301668014" STUDY_ID="STD-SOPAT-2004" TOTAL_1="518" TOTAL_2="251" VAR="0.43915207708714865" WEIGHT="21.006649987413365"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8150409288159244" CI_END="4.045140782651378" CI_START="0.6945079521207899" DF="2" EFFECT_SIZE="1.6761212488956454" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="5" I2="0.0" ID="CMP-001.12.02" LOG_CI_END="0.6069336409210191" LOG_CI_START="-0.1583227772231162" LOG_EFFECT_SIZE="0.22430543184895144" MODIFIED="2014-06-26 15:44:15 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6652980958709147" P_Z="0.2505659625127036" STUDIES="5" TAU2="0.0" TOTAL_1="2307" TOTAL_2="1039" WEIGHT="100.0" Z="1.1489758400898364">
<NAME>All class I antiarrhythmics</NAME>
<DICH_DATA CI_END="6.028699779604874" CI_START="0.5933179405154558" EFFECT_SIZE="1.8912788628917594" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.7802236571764537" LOG_CI_START="-0.22671251943759063" LOG_EFFECT_SIZE="0.27675556886943153" ORDER="330" O_E="1.8215158924205381" SE="0.5914792945575514" STUDY_ID="STD-AFIB-1997" TOTAL_1="734" TOTAL_2="493" VAR="2.8583862070379222" WEIGHT="57.75772424307835"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-06-26 15:44:15 +0100" MODIFIED_BY="[Empty name]" ORDER="1028" O_E="0.0" SE="0.0" STUDY_ID="STD-Flec_x002d_SL-2012" TOTAL_1="281" TOTAL_2="81" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.829173192322102" CI_START="0.22861787023996857" EFFECT_SIZE="1.050730836250954" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="0.6838727811139533" LOG_CI_START="-0.640889825369967" LOG_EFFECT_SIZE="0.021491477871993174" ORDER="331" O_E="0.08172043010752716" SE="0.7781721127293179" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="88" VAR="1.6513862874320733" WEIGHT="33.36858874194714"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="332" O_E="0.0" SE="0.0" STUDY_ID="STD-RAFT-2003" TOTAL_1="397" TOTAL_2="126" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="85.12319633156255" CI_START="0.22966890860097597" EFFECT_SIZE="4.421555336993599" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9300479227881144" LOG_CI_START="-0.6388977933855617" LOG_EFFECT_SIZE="0.6455750647012765" ORDER="333" O_E="0.6527958387516255" SE="1.5090114301668014" STUDY_ID="STD-SOPAT-2004" TOTAL_1="518" TOTAL_2="251" VAR="0.43915207708714865" WEIGHT="8.873687014974498"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="72.18140228453399" CI_START="0.7720375667293863" DF="0" EFFECT_SIZE="7.465035444180193" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-001.12.03" LOG_CI_END="1.85842531494321" LOG_CI_START="-0.11236156672860168" LOG_EFFECT_SIZE="0.8730318741073041" NO="3" P_CHI2="1.0" P_Z="0.0824798890478242" STUDIES="1" TAU2="0.0" TOTAL_1="197" TOTAL_2="197" WEIGHT="99.99999999999999" Z="1.736474954769633">
<NAME>Class II antiarrhythmics</NAME>
<DICH_DATA CI_END="72.18140228453399" CI_START="0.7720375667293863" EFFECT_SIZE="7.465035444180193" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.85842531494321" LOG_CI_START="-0.11236156672860168" LOG_EFFECT_SIZE="0.8730318741073041" ORDER="334" O_E="1.5" SE="1.157649969846422" STUDY_ID="STD-Kuhlkamp-2000" TOTAL_1="197" TOTAL_2="197" VAR="0.7461832061068703" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.5846246260685595" CI_END="3.746525393843679" CI_START="1.0338416411904605" DF="4" EFFECT_SIZE="1.9680736678115192" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="8" I2="12.751853723079856" ID="CMP-001.12.04" LOG_CI_END="0.5736286805798716" LOG_CI_START="0.014454020746187925" LOG_EFFECT_SIZE="0.2940413506630298" MODIFIED="2010-12-28 10:39:52 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.33263093385577336" P_Z="0.039275419183990724" STUDIES="7" TAU2="0.0" TOTAL_1="1605" TOTAL_2="938" WEIGHT="99.99999999999999" Z="2.061289606494201">
<NAME>Class III: Sotalol</NAME>
<DICH_DATA CI_END="53.766620926152854" CI_START="1.0528118484471085" EFFECT_SIZE="7.523704909286246" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.7305127432050487" LOG_CI_START="0.022350763889791982" LOG_EFFECT_SIZE="0.8764317535474203" ORDER="867" O_E="2.004474272930649" SE="1.0033828021879485" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="223" TOTAL_2="224" VAR="0.9932685714857689" WEIGHT="10.716102584681549"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="335" O_E="0.0" SE="0.0" STUDY_ID="STD-Benditt-1999" TOTAL_1="184" TOTAL_2="69" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-28 10:39:52 +0000" MODIFIED_BY="[Empty name]" ORDER="976" O_E="0.0" SE="0.0" STUDY_ID="STD-EMERALD-2000" TOTAL_1="108" TOTAL_2="106" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.371323379499582" CI_START="0.3847619309837751" EFFECT_SIZE="1.4375954769804182" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="2" LOG_CI_END="0.7300812997790568" LOG_CI_START="-0.41480790436177406" LOG_EFFECT_SIZE="0.1576366977086414" ORDER="336" O_E="0.8025477707006363" SE="0.6725135858052854" STUDY_ID="STD-PAFAC-2004" TOTAL_1="383" TOTAL_2="88" VAR="2.2110464970742414" WEIGHT="23.854375102905227"/>
<DICH_DATA CI_END="6.007583308640837" CI_START="0.8129459997107931" EFFECT_SIZE="2.2099413609163703" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="3" LOG_CI_END="0.7786998019864907" LOG_CI_START="-0.08993830164641405" LOG_EFFECT_SIZE="0.34438075017003833" ORDER="337" O_E="3.0458015267175576" SE="0.510242321901928" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="261" TOTAL_2="132" VAR="3.841024201767415" WEIGHT="41.43975814599095"/>
<DICH_DATA CI_END="3.2294735891450452" CI_START="0.16326815408962927" EFFECT_SIZE="0.7261337284418906" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.5091317372038408" LOG_CI_START="-0.7870985173570041" LOG_EFFECT_SIZE="-0.13898339007658164" ORDER="338" O_E="-0.5519999999999996" SE="0.7614120679722834" STUDY_ID="STD-SAFIRE_x002d_D-2000" TOTAL_1="182" TOTAL_2="68" VAR="1.724886361445783" WEIGHT="18.609326547523747"/>
<DICH_DATA CI_END="113.29018050149466" CI_START="0.4400653449064914" EFFECT_SIZE="7.060813151253114" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0541922687440057" LOG_CI_START="-0.3564828307292117" LOG_EFFECT_SIZE="0.8488547190073971" ORDER="339" O_E="0.974757281553398" SE="1.4160424864647638" STUDY_ID="STD-SOPAT-2004" TOTAL_1="264" TOTAL_2="251" VAR="0.4987092597761316" WEIGHT="5.3804376188985215"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.5158554051116466" CI_END="4.986965364505152" CI_START="0.8540142182582977" DF="2" EFFECT_SIZE="2.063719779245495" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="5" I2="20.504175401477593" ID="CMP-001.12.05" LOG_CI_END="0.6978363519647987" LOG_CI_START="-0.06853489879610214" LOG_EFFECT_SIZE="0.31465072658434834" MODIFIED="2012-03-22 14:05:41 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.2842425506728078" P_Z="0.10752597050926346" STUDIES="4" TAU2="0.0" TOTAL_1="1557" TOTAL_2="1147" WEIGHT="100.0" Z="1.6094134303769367">
<NAME>Class III: Azimilide</NAME>
<DICH_DATA CI_END="18.87621100210338" CI_START="0.3693764966788743" EFFECT_SIZE="2.640535682494779" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.2759148233295785" LOG_CI_START="-0.4325307420506507" LOG_EFFECT_SIZE="0.42169204063946397" MODIFIED="2012-03-22 14:04:54 +0000" MODIFIED_BY="[Empty name]" ORDER="1018" O_E="0.9641255605381165" SE="1.003549382046287" STUDY_ID="STD-A_x002d_COMET_x002d_I-2006" TOTAL_1="227" TOTAL_2="219" VAR="0.9929388521742903" WEIGHT="20.12223039695063"/>
<DICH_DATA CI_END="53.766620926152854" CI_START="1.0528118484471085" EFFECT_SIZE="7.523704909286246" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.7305127432050487" LOG_CI_START="0.022350763889791982" LOG_EFFECT_SIZE="0.8764317535474203" MODIFIED="2012-03-22 14:05:41 +0000" MODIFIED_BY="[Empty name]" ORDER="1021" O_E="2.004474272930649" SE="1.0033828021879485" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="223" TOTAL_2="224" VAR="0.9932685714857689" WEIGHT="20.12891226657167"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-03-22 14:05:41 +0000" MODIFIED_BY="[Empty name]" ORDER="1022" O_E="0.0" SE="0.0" STUDY_ID="STD-A_x002d_STAR-2006" TOTAL_1="216" TOTAL_2="215" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.846545652652908" CI_START="0.3922949397872779" EFFECT_SIZE="1.2284056313760892" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.5850708912200382" LOG_CI_START="-0.4063872937991818" LOG_EFFECT_SIZE="0.08934179871042822" MODIFIED="2012-03-22 14:05:41 +0000" MODIFIED_BY="[Empty name]" ORDER="1023" O_E="0.6065217391304341" SE="0.5823874456774577" STUDY_ID="STD-ASAP-2003" TOTAL_1="891" TOTAL_2="489" VAR="2.948329317976507" WEIGHT="59.7488573364777"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="13.075456954547649" CI_END="1.1976249741512115" CI_START="0.8170308876473076" DF="11" EFFECT_SIZE="0.9891898683768188" ESTIMABLE="YES" EVENTS_1="270" EVENTS_2="236" I2="15.872921013485529" ID="CMP-001.12.06" LOG_CI_END="0.07832084380040424" LOG_CI_START="-0.08776152476352247" LOG_EFFECT_SIZE="-0.004720340481559131" MODIFIED="2012-03-22 14:05:30 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.2884222737131542" P_Z="0.9112904762518419" STUDIES="14" TAU2="0.0" TOTAL_1="7119" TOTAL_2="5175" WEIGHT="99.99999999999999" Z="0.1114109513083112">
<NAME>All class III antiarrhythmics</NAME>
<DICH_DATA CI_END="18.87621100210338" CI_START="0.3693764966788743" EFFECT_SIZE="2.640535682494779" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.2759148233295785" LOG_CI_START="-0.4325307420506507" LOG_EFFECT_SIZE="0.42169204063946397" MODIFIED="2012-03-22 14:05:02 +0000" MODIFIED_BY="[Empty name]" ORDER="1019" O_E="0.9641255605381165" SE="1.003549382046287" STUDY_ID="STD-A_x002d_COMET_x002d_I-2006" TOTAL_1="227" TOTAL_2="219" VAR="0.9929388521742903" WEIGHT="0.9450281996174736"/>
<DICH_DATA CI_END="53.766620926152854" CI_START="1.0528118484471085" EFFECT_SIZE="7.523704909286246" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.7305127432050487" LOG_CI_START="0.022350763889791982" LOG_EFFECT_SIZE="0.8764317535474203" ORDER="868" O_E="2.004474272930649" SE="1.0033828021879485" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="223" TOTAL_2="224" VAR="0.9932685714857689" WEIGHT="0.9453420095229108"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-11-20 10:08:25 +0000" MODIFIED_BY="[Empty name]" ORDER="888" O_E="0.0" SE="0.0" STUDY_ID="STD-A_x002d_STAR-2006" TOTAL_1="216" TOTAL_2="215" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.846545652652908" CI_START="0.3922949397872779" EFFECT_SIZE="1.2284056313760892" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.5850708912200382" LOG_CI_START="-0.4063872937991818" LOG_EFFECT_SIZE="0.08934179871042822" ORDER="340" O_E="0.6065217391304341" SE="0.5823874456774577" STUDY_ID="STD-ASAP-2003" TOTAL_1="891" TOTAL_2="489" VAR="2.948329317976507" WEIGHT="2.8060684111066307"/>
<DICH_DATA CI_END="1.0762908893354253" CI_START="0.6495373719681742" EFFECT_SIZE="0.8361167117886241" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="139" LOG_CI_END="0.03192966404398068" LOG_CI_START="-0.1873958561804416" LOG_EFFECT_SIZE="-0.07773309606823046" MODIFIED="2010-11-20 10:20:56 +0000" MODIFIED_BY="[Empty name]" ORDER="902" O_E="-10.783707865168537" SE="0.1288328962586604" STUDY_ID="STD-ATHENA-2009" TOTAL_1="2301" TOTAL_2="2327" VAR="60.24853064116481" WEIGHT="57.341456945451576"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="341" O_E="0.0" SE="0.0" STUDY_ID="STD-Benditt-1999" TOTAL_1="184" TOTAL_2="69" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.4431434722617116" CI_START="0.6798268094585525" EFFECT_SIZE="0.9904986735673179" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="80" LOG_CI_END="0.1593095092738014" LOG_CI_START="-0.16760171270039934" LOG_EFFECT_SIZE="-0.004146101713299011" ORDER="342" O_E="-0.2588932806324067" SE="0.19202927002429282" STUDY_ID="STD-DIAMOND-2001" TOTAL_1="249" TOTAL_2="257" VAR="27.11846716635919" WEIGHT="25.809964175026128"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-28 10:39:58 +0000" MODIFIED_BY="[Empty name]" ORDER="977" O_E="0.0" SE="0.0" STUDY_ID="STD-EMERALD-2000" TOTAL_1="108" TOTAL_2="106" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="353.27126735483773" CI_START="0.040485957738138234" EFFECT_SIZE="3.7818680040723907" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5481083163573324" LOG_CI_START="-1.3926955825711107" LOG_EFFECT_SIZE="0.5777063668931108" MODIFIED="2010-12-28 10:32:26 +0000" MODIFIED_BY="[Empty name]" ORDER="958" O_E="0.2482435597189696" SE="2.3148477175244766" STUDY_ID="STD-EMERALD-2000" TOTAL_1="321" TOTAL_2="106" VAR="0.18661869477702395" WEIGHT="0.1776140884747426"/>
<DICH_DATA CI_END="4.615162631249554" CI_START="0.37137711023519626" EFFECT_SIZE="1.309185151633994" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.6641870095027342" LOG_CI_START="-0.43018486743762996" LOG_EFFECT_SIZE="0.11700107103255217" ORDER="822" O_E="0.651929260450161" SE="0.6428394577429287" STUDY_ID="STD-EURIDIS-ADONIS-2007" TOTAL_1="831" TOTAL_2="413" VAR="2.4198862275884667" WEIGHT="2.3031234198655737"/>
<DICH_DATA CI_END="5.371323379499582" CI_START="0.3847619309837751" EFFECT_SIZE="1.4375954769804182" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="2" LOG_CI_END="0.7300812997790568" LOG_CI_START="-0.41480790436177406" LOG_EFFECT_SIZE="0.1576366977086414" ORDER="343" O_E="0.8025477707006363" SE="0.6725135858052854" STUDY_ID="STD-PAFAC-2004" TOTAL_1="383" TOTAL_2="88" VAR="2.2110464970742414" WEIGHT="2.1043604909054583"/>
<DICH_DATA CI_END="4.8390786517420095" CI_START="0.7986279044657819" EFFECT_SIZE="1.965864502753387" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="3" LOG_CI_END="0.6847626809513502" LOG_CI_START="-0.09765551940615741" LOG_EFFECT_SIZE="0.29355358077259636" ORDER="344" O_E="3.1999999999999993" SE="0.45959632392255517" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="528" TOTAL_2="132" VAR="4.734203338391503" WEIGHT="4.505771576674938"/>
<DICH_DATA CI_END="3.2294735891450452" CI_START="0.16326815408962927" EFFECT_SIZE="0.7261337284418906" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.5091317372038408" LOG_CI_START="-0.7870985173570041" LOG_EFFECT_SIZE="-0.13898339007658164" ORDER="345" O_E="-0.5519999999999996" SE="0.7614120679722834" STUDY_ID="STD-SAFIRE_x002d_D-2000" TOTAL_1="182" TOTAL_2="68" VAR="1.724886361445783" WEIGHT="1.6416582442437433"/>
<DICH_DATA CI_END="113.29018050149466" CI_START="0.4400653449064914" EFFECT_SIZE="7.060813151253114" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0541922687440057" LOG_CI_START="-0.3564828307292117" LOG_EFFECT_SIZE="0.8488547190073971" ORDER="346" O_E="0.974757281553398" SE="1.4160424864647638" STUDY_ID="STD-SOPAT-2004" TOTAL_1="264" TOTAL_2="251" VAR="0.4987092597761316" WEIGHT="0.4746458584703204"/>
<DICH_DATA CI_END="19.573210244619457" CI_START="0.3829665080229595" EFFECT_SIZE="2.7378612050615585" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.2916620610788163" LOG_CI_START="-0.416839205187577" LOG_EFFECT_SIZE="0.4374114279456196" MODIFIED="2010-12-28 10:20:48 +0000" MODIFIED_BY="[Empty name]" ORDER="944" O_E="1.0" SE="1.0035821010225436" STUDY_ID="STD-SVA_x002d_4-2008" TOTAL_1="211" TOTAL_2="211" VAR="0.992874109263658" WEIGHT="0.9449665806404955"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2014-09-24 16:45:31 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Withdrawals due to adverse effects</NAME>
<DICH_OUTCOME CHI2="94.18830579887039" CI_END="1.8862520258713853" CI_START="1.5201684707687013" CI_STUDY="95" CI_TOTAL="95" DF="43" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.6933460537212317" ESTIMABLE="YES" EVENTS_1="1190" EVENTS_2="494" I2="54.346774118835775" I2_Q="66.52537587970366" ID="CMP-002.01" LOG_CI_END="0.27559971922462234" LOG_CI_START="0.18189172075450816" LOG_EFFECT_SIZE="0.22874571998956525" METHOD="PETO" MODIFIED="2014-06-26 16:18:31 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0852642513214938E-5" P_Q="8.984596619463492E-4" P_Z="1.082245608179402E-21" Q="29.87337502002539" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="37" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="9661" TOTAL_2="6972" WEIGHT="99.99999999999999" Z="9.56873223453207">
<NAME>Individual antiarrhythmics</NAME>
<GROUP_LABEL_1>Antiarrhythmic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="25.510301183940303" CI_END="1.4890246263114961" CI_START="0.8573579678407545" DF="6" EFFECT_SIZE="1.1298792535838789" ESTIMABLE="YES" EVENTS_1="225" EVENTS_2="89" I2="76.48008952643325" ID="CMP-002.01.01" LOG_CI_END="0.172901880413527" LOG_CI_START="-0.06683781168411818" LOG_EFFECT_SIZE="0.053032034364704425" NO="1" P_CHI2="2.745995876444196E-4" P_Z="0.3858793050115553" STUDIES="7" TAU2="0.0" TOTAL_1="1128" TOTAL_2="548" WEIGHT="15.278243842388644" Z="0.8671144646283803">
<NAME>Class Ia: Quinidine</NAME>
<DICH_DATA CI_END="4.727279277530424" CI_START="0.5839521131312015" EFFECT_SIZE="1.6614766695548966" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.6746112602482437" LOG_CI_START="-0.23362276565400186" LOG_EFFECT_SIZE="0.22049424729712094" ORDER="347" O_E="1.7837837837837842" SE="0.5335011626459151" STUDY_ID="STD-Byrne_x002d_Quinn-1970" TOTAL_1="32" TOTAL_2="42" VAR="3.513413450473799" WEIGHT="1.06452971122782"/>
<DICH_DATA CI_END="82.64084546794376" CI_START="0.8505035136266731" EFFECT_SIZE="8.383694259666504" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.91719475164061" LOG_CI_START="-0.0703238878767813" LOG_EFFECT_SIZE="0.9234354318819143" ORDER="348" O_E="1.56" SE="1.1674782872284526" STUDY_ID="STD-Hillestad-1971" TOTAL_1="48" TOTAL_2="52" VAR="0.7336727272727273" WEIGHT="0.22229561863663955"/>
<DICH_DATA CI_END="56.32059641298373" CI_START="0.9865240347640378" EFFECT_SIZE="7.453966864271246" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.7506672451663057" LOG_CI_START="-0.005892329531666832" LOG_EFFECT_SIZE="0.8723874578173194" ORDER="349" O_E="1.8867924528301887" SE="1.0318117892877168" STUDY_ID="STD-Lloyd-1984" TOTAL_1="28" TOTAL_2="25" VAR="0.9392885505381054" WEIGHT="0.2845951902782993"/>
<DICH_DATA CI_END="1.9305216969464964" CI_START="0.6571482859917904" EFFECT_SIZE="1.1263387697395277" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="20" LOG_CI_END="0.2856746869811433" LOG_CI_START="-0.18233662051403673" LOG_EFFECT_SIZE="0.051669033233553305" ORDER="350" O_E="1.5741935483871003" SE="0.274912158716004" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="88" VAR="13.231592091571281" WEIGHT="4.0090422339634415"/>
<DICH_DATA CI_END="9.648936448053911" CI_START="1.8840217766644973" EFFECT_SIZE="4.263661148565321" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="3" LOG_CI_END="0.9844794459659073" LOG_CI_START="0.27508591832446344" LOG_EFFECT_SIZE="0.6297826821451853" ORDER="352" O_E="8.35135135135135" SE="0.41670126969117954" STUDY_ID="STD-Sodermark-1975" TOTAL_1="110" TOTAL_2="75" VAR="5.759043414742592" WEIGHT="1.7449334983383928"/>
<DICH_DATA CI_END="0.9980593375504293" CI_START="0.46107254610926246" EFFECT_SIZE="0.6783640320156282" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="57" LOG_CI_END="-8.436378662803859E-4" LOG_CI_START="-0.336230736440792" LOG_EFFECT_SIZE="-0.1685371871535362" ORDER="351" O_E="-9.998699609882962" SE="0.19700804189558133" STUDY_ID="STD-SOPAT-2004" TOTAL_1="518" TOTAL_2="251" VAR="25.765115344096074" WEIGHT="7.806576477158792"/>
<DICH_DATA CI_END="133.25952883863062" CI_START="0.4726304768834543" EFFECT_SIZE="7.936152384138449" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.1246982734139985" LOG_CI_START="-0.3254782769576691" LOG_EFFECT_SIZE="0.8996099982281646" ORDER="353" O_E="1.0" SE="1.439245834257849" STUDY_ID="STD-Steinbeck-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.48275862068965514" WEIGHT="0.14627111278525906"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.18208730279165064" CI_END="13.17768356834122" CI_START="1.1263452707917512" DF="1" EFFECT_SIZE="3.852612304293192" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="1.1198390747570282" LOG_CI_START="0.05167153990653221" LOG_EFFECT_SIZE="0.5857553073317802" NO="2" P_CHI2="0.6695855542610105" P_Z="0.03158792982784592" STUDIES="2" TAU2="0.0" TOTAL_1="75" TOTAL_2="71" WEIGHT="0.7696168635007972" Z="2.149586593238234">
<NAME>Class Ia: Disopyramide</NAME>
<DICH_DATA CI_END="13.281487866698253" CI_START="0.8607433866821024" EFFECT_SIZE="3.3811171003913936" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.1232467298589253" LOG_CI_START="-0.06512630540923559" LOG_EFFECT_SIZE="0.5290602122248449" ORDER="354" O_E="2.5" SE="0.6980562034579147" STUDY_ID="STD-Karlson-1998" TOTAL_1="46" TOTAL_2="46" VAR="2.0521978021978025" WEIGHT="0.6217957449503665"/>
<DICH_DATA CI_END="110.37897064952469" CI_START="0.4032640727410121" EFFECT_SIZE="6.671721910353277" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.042886339690145" LOG_CI_START="-0.39441046806268326" LOG_EFFECT_SIZE="0.824237935813731" ORDER="355" O_E="0.9259259259259258" SE="1.4316802096877885" STUDY_ID="STD-Lloyd-1984" TOTAL_1="29" TOTAL_2="25" VAR="0.48787431736418474" WEIGHT="0.14782111855043073"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="42.93727702849919" CI_START="1.9435224978817696" DF="0" EFFECT_SIZE="9.13507328392445" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" I2="0.0" ID="CMP-002.01.03" LOG_CI_END="1.6328344991362287" LOG_CI_START="0.2885895723145221" LOG_EFFECT_SIZE="0.9607120357253753" NO="3" P_CHI2="1.0" P_Z="0.005086331719727785" STUDIES="3" TAU2="0.0" TOTAL_1="71" TOTAL_2="78" WEIGHT="0.4859555106599022" Z="2.801514741793241">
<NAME>Class Ic: Flecainide</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="356" O_E="0.0" SE="0.0" STUDY_ID="STD-Carunchio-1995" TOTAL_1="20" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="357" O_E="0.0" SE="0.0" STUDY_ID="STD-Steinbeck-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="42.93727702849919" CI_START="1.9435224978817696" EFFECT_SIZE="9.13507328392445" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="1.6328344991362287" LOG_CI_START="0.2885895723145221" LOG_EFFECT_SIZE="0.9607120357253753" ORDER="358" O_E="3.547945205479452" SE="0.7896161241347744" STUDY_ID="STD-Van-Gelder-1989" TOTAL_1="36" TOTAL_2="37" VAR="1.6038656408331768" WEIGHT="0.4859555106599022"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.676064843196199" CI_END="2.617367672173846" CI_START="1.088025489421846" DF="4" EFFECT_SIZE="1.6875315530424508" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="23" I2="14.457986915641087" ID="CMP-002.01.04" LOG_CI_END="0.4178647340194836" LOG_CI_START="0.03663906979744132" LOG_EFFECT_SIZE="0.22725190190846242" NO="4" P_CHI2="0.3221782577918335" P_Z="0.01945464158616432" STUDIES="5" TAU2="0.0" TOTAL_1="720" TOTAL_2="378" WEIGHT="6.042116071785928" Z="2.336702824390082">
<NAME>Class Ic: Propafenone</NAME>
<DICH_DATA CI_END="8.335148300201272" CI_START="0.8080092547567259" EFFECT_SIZE="2.595164150170933" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.9209133312649376" LOG_CI_START="-0.09258366488536518" LOG_EFFECT_SIZE="0.41416483318978625" ORDER="359" O_E="2.6907216494845363" SE="0.5953331524297303" STUDY_ID="STD-Bellandi-2001" TOTAL_1="102" TOTAL_2="92" VAR="2.8214987634482913" WEIGHT="0.8548863679787576"/>
<DICH_DATA CI_END="18.627411270105846" CI_START="0.5205130096918074" EFFECT_SIZE="3.113809548281636" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.2701525033542727" LOG_CI_START="-0.28356841127015175" LOG_EFFECT_SIZE="0.4932920460420605" ORDER="360" O_E="1.3636363636363638" SE="0.9126633562929538" STUDY_ID="STD-Dogan-2004" TOTAL_1="58" TOTAL_2="52" VAR="1.2005459094700128" WEIGHT="0.3637535998365086"/>
<DICH_DATA CI_END="44.1512152552961" CI_START="1.269307449723108" EFFECT_SIZE="7.486084853772088" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.6449426619658098" LOG_CI_START="0.10356682898670365" LOG_EFFECT_SIZE="0.8742547454762567" ORDER="361" O_E="2.455621301775148" SE="0.9054117942253541" STUDY_ID="STD-Kochiadakis-2004b" TOTAL_1="86" TOTAL_2="83" VAR="1.2198535798899932" WEIGHT="0.3696036340287247"/>
<DICH_DATA CI_END="2.276425067064995" CI_START="0.7728315351048687" EFFECT_SIZE="1.3263834585560255" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="17" LOG_CI_END="0.3572533592364393" LOG_CI_START="-0.11191516500533927" LOG_EFFECT_SIZE="0.12266909711555002" ORDER="362" O_E="3.718929254302097" SE="0.2755919135612713" STUDY_ID="STD-RAFT-2003" TOTAL_1="397" TOTAL_2="126" VAR="13.166400435886457" WEIGHT="3.9892898036335382"/>
<DICH_DATA CI_END="5.568297143647477" CI_START="0.23491165107156406" EFFECT_SIZE="1.1437035785863847" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="0.7457224026806577" LOG_CI_START="-0.6290954426919367" LOG_EFFECT_SIZE="0.05831347999436041" ORDER="363" O_E="0.20588235294117663" SE="0.8075748078299536" STUDY_ID="STD-Stroobandt-1997" TOTAL_1="77" TOTAL_2="25" VAR="1.5333259104457158" WEIGHT="0.4645826663083996"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5784890744332236" CI_END="4.479214644636745" CI_START="0.17515273570414142" DF="1" EFFECT_SIZE="0.8857464077342789" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-002.01.05" LOG_CI_END="0.6512018743999767" LOG_CI_START="-0.7565830750637639" LOG_EFFECT_SIZE="-0.05269060033189358" NO="5" P_CHI2="0.44690529670120105" P_Z="0.8833568724620943" STUDIES="2" TAU2="0.0" TOTAL_1="99" TOTAL_2="57" WEIGHT="0.4430785112592037" Z="0.14671513431599664">
<NAME>Class I others: aprindine, pilsicainide</NAME>
<DICH_DATA CI_END="150.13826080578548" CI_START="0.07523056855345664" EFFECT_SIZE="3.3608014999470575" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.176491380713628" LOG_CI_START="-1.1236056559968985" LOG_EFFECT_SIZE="0.5264428623583648" ORDER="364" O_E="0.32258064516129026" SE="1.9384933351075546" STUDY_ID="STD-Okishige-2000" TOTAL_1="52" TOTAL_2="10" VAR="0.26611623820815067" WEIGHT="0.08063060217821894"/>
<DICH_DATA CI_END="3.9512376864641414" CI_START="0.10970241203804439" EFFECT_SIZE="0.6583770232478792" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5967331554255523" LOG_CI_START="-0.9597838234435514" LOG_EFFECT_SIZE="-0.18152533400899956" ORDER="365" O_E="-0.5" SE="0.9143057782710197" STUDY_ID="STD-SMART-2002" TOTAL_1="47" TOTAL_2="47" VAR="1.1962365591397852" WEIGHT="0.3624479090809848"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.36081507599797824" CI_END="7.2489020633928325" CI_START="1.5731868458628622" DF="1" EFFECT_SIZE="3.376962743809556" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="6" I2="0.0" ID="CMP-002.01.06" LOG_CI_END="0.8602722322373512" LOG_CI_START="0.1967803064174341" LOG_EFFECT_SIZE="0.5285262693273927" MODIFIED="2010-12-27 14:26:51 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.5480541534078749" P_Z="0.0017929330762439001" STUDIES="2" TAU2="0.0" TOTAL_1="280" TOTAL_2="282" WEIGHT="1.9947204456373644" Z="3.1225472758689303">
<NAME>Class II: Beta-blockers</NAME>
<DICH_DATA CI_END="6.990335182622399" CI_START="1.4270918714409915" EFFECT_SIZE="3.1584569836818113" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="6" LOG_CI_END="0.8444980004199777" LOG_CI_START="0.1544519324528029" LOG_EFFECT_SIZE="0.49947496643639033" ORDER="366" O_E="7.0" SE="0.405336476107044" STUDY_ID="STD-Kuhlkamp-2000" TOTAL_1="197" TOTAL_2="197" VAR="6.086513994910942" WEIGHT="1.8441538625386864"/>
<DICH_DATA CI_END="123.54811742880564" CI_START="0.4751849318665752" EFFECT_SIZE="7.662127887385501" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0918361322026024" LOG_CI_START="-0.3231373393041214" LOG_EFFECT_SIZE="0.8843493964492404" MODIFIED="2010-12-27 14:26:51 +0000" MODIFIED_BY="[Empty name]" ORDER="936" O_E="1.0119047619047619" SE="1.4185673714745302" STUDY_ID="STD-Nergardh-2007" TOTAL_1="83" TOTAL_2="85" VAR="0.4969355506673727" WEIGHT="0.15056658309867793"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8141427815015754" CI_END="13.629307840611121" CI_START="2.3358110512510444" DF="3" EFFECT_SIZE="5.642294557624758" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="1" I2="0.0" ID="CMP-002.01.07" LOG_CI_END="1.1344738009090671" LOG_CI_START="0.3684377088522092" LOG_EFFECT_SIZE="0.7514557548806382" MODIFIED="2014-06-26 16:17:21 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.8460814207125213" P_Z="1.2039616185194358E-4" STUDIES="4" TAU2="0.0" TOTAL_1="183" TOTAL_2="136" WEIGHT="1.4964246704291817" Z="3.845318075253539">
<NAME>Class III: Amiodarone</NAME>
<DICH_DATA CI_END="14.26040858186083" CI_START="0.8639985230624987" EFFECT_SIZE="3.5101242076307697" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.1541319688752796" LOG_CI_START="-0.06348699991272148" LOG_EFFECT_SIZE="0.545322484481279" ORDER="367" O_E="2.454545454545454" SE="0.7152354095771745" STUDY_ID="STD-Channer-2004" TOTAL_1="61" TOTAL_2="38" VAR="1.9547984483049416" WEIGHT="0.5922846989163846"/>
<DICH_DATA CI_END="300.5347791914292" CI_START="0.05793575076459642" EFFECT_SIZE="4.172733883598098" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.4778947376928846" LOG_CI_START="-1.2370533608264507" LOG_EFFECT_SIZE="0.6204206884332171" ORDER="368" O_E="0.30000000000000004" SE="2.182178902359924" STUDY_ID="STD-GEFACA-2001" TOTAL_1="35" TOTAL_2="15" VAR="0.20999999999999996" WEIGHT="0.06362793406158769"/>
<DICH_DATA CI_END="27.81029479016203" CI_START="2.358744519316664" EFFECT_SIZE="8.099220975925737" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="0" LOG_CI_END="1.4442055924262647" LOG_CI_START="0.3726809040650725" LOG_EFFECT_SIZE="0.9084432482456686" ORDER="369" O_E="5.28" SE="0.6294189060761156" STUDY_ID="STD-Kochiadakis-2000" TOTAL_1="65" TOTAL_2="60" VAR="2.52418064516129" WEIGHT="0.7648019030945641"/>
<DICH_DATA CI_END="390.0795749354538" CI_START="0.15328725017167474" EFFECT_SIZE="7.732672590378534" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.591153210693601" LOG_CI_START="-0.8144939665439346" LOG_EFFECT_SIZE="0.8883296220748332" MODIFIED="2014-06-26 16:17:21 +0100" MODIFIED_BY="[Empty name]" ORDER="1055" O_E="0.5111111111111111" SE="2.0004940101347417" STUDY_ID="STD-Vijayalaskshmi-2006" TOTAL_1="22" TOTAL_2="23" VAR="0.24987654320987654" WEIGHT="0.07571013435664521"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7907930489333529" CI_END="3.203025083083462" CI_START="1.7182678853785305" DF="4" EFFECT_SIZE="2.3459870281662285" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="46" I2="0.0" ID="CMP-002.01.08" LOG_CI_END="0.5055603396635354" LOG_CI_START="0.2350908731577171" LOG_EFFECT_SIZE="0.3703256064106263" MODIFIED="2010-12-28 10:21:42 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.9396781165610932" P_Z="7.99913410394182E-8" STUDIES="5" TAU2="0.0" TOTAL_1="1756" TOTAL_2="1358" WEIGHT="12.00374704031532" Z="5.367148170140448">
<NAME>Class III: Azimilide</NAME>
<DICH_DATA CI_END="4.178752748231418" CI_START="1.3283127632981735" EFFECT_SIZE="2.355990367158387" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="16" LOG_CI_END="0.6210466752222457" LOG_CI_START="0.12330034565091305" LOG_EFFECT_SIZE="0.3721735104365793" MODIFIED="2010-08-20 11:25:22 +0100" MODIFIED_BY="[Empty name]" ORDER="837" O_E="10.024663677130047" SE="0.2923786578742692" STUDY_ID="STD-A_x002d_COMET_x002d_I-2006" TOTAL_1="227" TOTAL_2="219" VAR="11.6979204479289" WEIGHT="3.544354813897707"/>
<DICH_DATA CI_END="4.649687285454289" CI_START="1.2293287983639984" EFFECT_SIZE="2.390814606655205" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="12" LOG_CI_END="0.6674237454128644" LOG_CI_START="0.08966805556123204" LOG_EFFECT_SIZE="0.3785459004870482" MODIFIED="2010-08-27 16:32:50 +0100" MODIFIED_BY="[Empty name]" ORDER="846" O_E="7.567816091954022" SE="0.33937655215563817" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="211" TOTAL_2="224" VAR="8.68233089980779" WEIGHT="2.6306608475897875"/>
<DICH_DATA CI_END="18.842830019191098" CI_START="0.9531768000049803" EFFECT_SIZE="4.237988723525625" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.2751461303791987" LOG_CI_START="-0.02082653677505163" LOG_EFFECT_SIZE="0.6271597968020736" MODIFIED="2010-11-20 10:09:29 +0000" MODIFIED_BY="[Empty name]" ORDER="889" O_E="2.491879350348028" SE="0.7612607598545715" STUDY_ID="STD-A_x002d_STAR-2006" TOTAL_1="216" TOTAL_2="215" VAR="1.7255721060933134" WEIGHT="0.5228313723096207"/>
<DICH_DATA CI_END="3.630175709349705" CI_START="1.1984801170102204" EFFECT_SIZE="2.0858315868998374" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="11" LOG_CI_END="0.559927646455997" LOG_CI_START="0.07863083340982842" LOG_EFFECT_SIZE="0.3192792399329127" ORDER="379" O_E="9.197826086956525" SE="0.28271613044096777" STUDY_ID="STD-ASAP-2003" TOTAL_1="891" TOTAL_2="489" VAR="12.51119589206721" WEIGHT="3.7907692726288538"/>
<DICH_DATA CI_END="5.908332362962058" CI_START="1.0236990932152656" EFFECT_SIZE="2.4593402534782918" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="6" LOG_CI_END="0.7714649178078945" LOG_CI_START="0.01017231859225797" LOG_EFFECT_SIZE="0.3908186182000763" MODIFIED="2010-12-28 10:21:42 +0000" MODIFIED_BY="[Empty name]" ORDER="945" O_E="4.5" SE="0.44718704123840797" STUDY_ID="STD-SVA_x002d_4-2008" TOTAL_1="211" TOTAL_2="211" VAR="5.000593824228028" WEIGHT="1.5151307338893507"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.005671290279828919" CI_END="3.586591506496854" CI_START="0.7850854782155658" DF="1" EFFECT_SIZE="1.67802887580696" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="6" I2="0.0" ID="CMP-002.01.09" LOG_CI_END="0.5546819156844003" LOG_CI_START="-0.10508305574346871" LOG_EFFECT_SIZE="0.22479942997046584" MODIFIED="2010-12-28 10:33:47 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.9399696808001443" P_Z="0.1816723786342684" STUDIES="2" TAU2="0.0" TOTAL_1="503" TOTAL_2="174" WEIGHT="2.0173200988802287" Z="1.3356234585588844">
<NAME>Class III: Dofetilide</NAME>
<DICH_DATA CI_END="4.2821937757911925" CI_START="0.6840436439670202" EFFECT_SIZE="1.711492750368841" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="4" LOG_CI_END="0.6316663158899293" LOG_CI_START="-0.16491618814923806" LOG_EFFECT_SIZE="0.23337506387034557" MODIFIED="2010-12-28 10:33:47 +0000" MODIFIED_BY="[Empty name]" ORDER="960" O_E="2.4543325526932094" SE="0.4679165060195961" STUDY_ID="STD-EMERALD-2000" TOTAL_1="321" TOTAL_2="106" VAR="4.5673392294489465" WEIGHT="1.383858853944192"/>
<DICH_DATA CI_END="6.233831862441262" CI_START="0.4143574308642299" EFFECT_SIZE="1.6071821785226275" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="0.7947550844023693" LOG_CI_START="-0.382624868345819" LOG_EFFECT_SIZE="0.20606510802827518" ORDER="370" O_E="0.9920000000000009" SE="0.6915988123690467" STUDY_ID="STD-SAFIRE_x002d_D-2000" TOTAL_1="182" TOTAL_2="68" VAR="2.0906990522088353" WEIGHT="0.6334612449360365"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.0842141269964785" CI_END="1.9400149116975973" CI_START="1.3803656413345848" DF="2" EFFECT_SIZE="1.6364381833066937" ESTIMABLE="YES" EVENTS_1="392" EVENTS_2="216" I2="51.03097100663536" ID="CMP-002.01.10" LOG_CI_END="0.2878050680967691" LOG_CI_START="0.13999414073499347" LOG_EFFECT_SIZE="0.21389960441588127" MODIFIED="2010-11-20 10:33:46 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.1297552821061323" P_Z="1.4065317392318092E-8" STUDIES="3" TAU2="0.0" TOTAL_1="3283" TOTAL_2="2788" WEIGHT="40.19205759492834" Z="5.672591714906025">
<NAME>Class III: Dronedarone</NAME>
<DICH_DATA CI_END="1.9806478159384728" CI_START="1.355855699905359" EFFECT_SIZE="1.6387411725911076" ESTIMABLE="YES" EVENTS_1="290" EVENTS_2="187" LOG_CI_END="0.29680725938908364" LOG_CI_START="0.13221347119066454" LOG_EFFECT_SIZE="0.21451036528987408" MODIFIED="2010-11-20 10:33:46 +0000" MODIFIED_BY="[Empty name]" ORDER="904" O_E="52.83988764044943" SE="0.09668320594014311" STUDY_ID="STD-ATHENA-2009" TOTAL_1="2301" TOTAL_2="2327" VAR="106.97884736536918" WEIGHT="32.41353831499221"/>
<DICH_DATA CI_END="12.271779417734178" CI_START="1.5545355138408892" EFFECT_SIZE="4.3677130083018785" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="0" LOG_CI_END="1.0889075403368307" LOG_CI_START="0.1916006480832641" LOG_EFFECT_SIZE="0.6402540942100473" ORDER="823" O_E="5.306532663316585" SE="0.5270825102504971" STUDY_ID="STD-DAFNE-2003" TOTAL_1="151" TOTAL_2="48" VAR="3.599505063003459" WEIGHT="1.0906146228720721"/>
<DICH_DATA CI_END="2.1017890397123096" CI_START="0.9125072421745916" EFFECT_SIZE="1.38488184342949" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="29" LOG_CI_END="0.32258912297354314" LOG_CI_START="-0.03976368005068673" LOG_EFFECT_SIZE="0.1414127214614282" MODIFIED="2010-08-20 10:04:13 +0100" MODIFIED_BY="[Empty name]" ORDER="824" O_E="7.187299035369776" SE="0.2128478301717356" STUDY_ID="STD-EURIDIS-ADONIS-2007" TOTAL_1="831" TOTAL_2="413" VAR="22.073009263887574" WEIGHT="6.6879046570640615"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="27.312352050774344" CI_END="2.0920191866965636" CI_START="1.2797743024035029" DF="10" EFFECT_SIZE="1.6362494905329497" ESTIMABLE="YES" EVENTS_1="255" EVENTS_2="102" I2="63.38652935708448" ID="CMP-002.01.11" LOG_CI_END="0.320565663291906" LOG_CI_START="0.10713338537956042" LOG_EFFECT_SIZE="0.21384952433573315" MODIFIED="2014-06-26 16:18:31 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.002323751483059633" P_Z="8.580089755814121E-5" STUDIES="12" TAU2="0.0" TOTAL_1="1563" TOTAL_2="1102" WEIGHT="19.276719350215064" Z="3.927591177012075">
<NAME>Class III: Sotalol</NAME>
<DICH_DATA CI_END="4.995946911229559" CI_START="1.4225449776921204" EFFECT_SIZE="2.6658880673025402" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="12" LOG_CI_END="0.6986178147536282" LOG_CI_START="0.1530660067048519" LOG_EFFECT_SIZE="0.4258419107292401" MODIFIED="2010-08-27 18:13:26 +0100" MODIFIED_BY="[Empty name]" ORDER="871" O_E="9.548098434004473" SE="0.32045983257285454" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="223" TOTAL_2="224" VAR="9.737619426552357" WEIGHT="2.950402889473851"/>
<DICH_DATA CI_END="7.139763235365658" CI_START="0.5607294808668443" EFFECT_SIZE="2.000868744440466" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.8536838101964677" LOG_CI_START="-0.25124660987045216" LOG_EFFECT_SIZE="0.3012186001630078" ORDER="371" O_E="1.6464646464646462" SE="0.6490415982410989" STUDY_ID="STD-Bellandi-2001" TOTAL_1="106" TOTAL_2="92" VAR="2.373859085134274" WEIGHT="0.7192559492401165"/>
<DICH_DATA CI_END="9.212172032313898" CI_START="1.4945210034743894" EFFECT_SIZE="3.7104965422315748" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="1" LOG_CI_END="0.9643620395817095" LOG_CI_START="0.17450202284062655" LOG_EFFECT_SIZE="0.569432031211168" ORDER="372" O_E="6.09090909090909" SE="0.4639676837038525" STUDY_ID="STD-Benditt-1999" TOTAL_1="184" TOTAL_2="69" VAR="4.645415190869737" WEIGHT="1.407515102158845"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="373" O_E="0.0" SE="0.0" STUDY_ID="STD-Carunchio-1995" TOTAL_1="20" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="13.631820050462816" CI_START="1.395188919697957" EFFECT_SIZE="4.361073754217207" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="1.134553844470245" LOG_CI_START="0.14463301852517244" LOG_EFFECT_SIZE="0.6395934314977088" MODIFIED="2010-12-27 14:15:51 +0000" MODIFIED_BY="[Empty name]" ORDER="924" O_E="4.355555555555555" SE="0.5814843933472533" STUDY_ID="STD-DAPHNE-2008" TOTAL_1="69" TOTAL_2="66" VAR="2.9574940114243597" WEIGHT="0.8960915902211888"/>
<DICH_DATA CI_END="9.16690381264253" CI_START="1.4602886681119756" EFFECT_SIZE="3.658732807854976" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="4" LOG_CI_END="0.9622226743676763" LOG_CI_START="0.16443871508314936" LOG_EFFECT_SIZE="0.5633306947254129" MODIFIED="2010-12-28 10:45:14 +0000" MODIFIED_BY="[Empty name]" ORDER="980" O_E="5.906542056074766" SE="0.46862224677801984" STUDY_ID="STD-EMERALD-2000" TOTAL_1="108" TOTAL_2="106" VAR="4.553592847151913" WEIGHT="1.3796938353423778"/>
<DICH_DATA CI_END="44.67987407523911" CI_START="1.2845683044903577" EFFECT_SIZE="7.57590589208133" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.6501119404394118" LOG_CI_START="0.1087572020041299" LOG_EFFECT_SIZE="0.8794345712217709" ORDER="374" O_E="2.4702380952380953" SE="0.9053994031858922" STUDY_ID="STD-Kochiadakis-2004b" TOTAL_1="85" TOTAL_2="83" VAR="1.2198869692587613" WEIGHT="0.36961375067898344"/>
<DICH_DATA CI_END="1.9403740263898828" CI_START="0.6626459972714737" EFFECT_SIZE="1.1339228729489448" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="20" LOG_CI_END="0.2878854525799555" LOG_CI_START="-0.17871842105314945" LOG_EFFECT_SIZE="0.05458351576340305" ORDER="375" O_E="1.6730360934182613" SE="0.27408542509851114" STUDY_ID="STD-PAFAC-2004" TOTAL_1="383" TOTAL_2="88" VAR="13.311534320104863" WEIGHT="4.033263942753304"/>
<DICH_DATA CI_END="6.158078173696388" CI_START="0.2958209602781121" EFFECT_SIZE="1.3496994475847384" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7894451977515701" LOG_CI_START="-0.5289710574837401" LOG_EFFECT_SIZE="0.13023707013391495" ORDER="376" O_E="0.5" SE="0.7744442345909389" STUDY_ID="STD-Plewan-2001" TOTAL_1="64" TOTAL_2="64" VAR="1.6673228346456692" WEIGHT="0.5051824161057815"/>
<DICH_DATA CI_END="58.58069836700783" CI_START="0.348444529528686" EFFECT_SIZE="4.517977853194271" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.7677545447974399" LOG_CI_START="-0.45786634937956794" LOG_EFFECT_SIZE="0.6549440977089361" ORDER="378" O_E="0.8823529411764706" SE="1.3073407302406808" STUDY_ID="STD-Singh-1991" TOTAL_1="24" TOTAL_2="10" VAR="0.5850896508335955" WEIGHT="0.17727640820646373"/>
<DICH_DATA CI_END="1.3030568154607938" CI_START="0.5612102699123185" EFFECT_SIZE="0.8551542943328054" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="57" LOG_CI_END="0.11496335209261067" LOG_CI_START="-0.25087439016427693" LOG_EFFECT_SIZE="-0.06795551903583308" ORDER="377" O_E="-3.38834951456311" SE="0.21489490072772618" STUDY_ID="STD-SOPAT-2004" TOTAL_1="264" TOTAL_2="251" VAR="21.654481016595188" WEIGHT="6.561094715532482"/>
<DICH_DATA CI_END="46.688986440711915" CI_START="0.7758743354774353" EFFECT_SIZE="6.018703043746413" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.6692144460450964" LOG_CI_START="-0.11020861357188443" LOG_EFFECT_SIZE="0.779502916236606" MODIFIED="2014-06-26 16:18:31 +0100" MODIFIED_BY="[Empty name]" ORDER="1058" O_E="1.6428571428571428" SE="1.0452419135052178" STUDY_ID="STD-Vijayalaskshmi-2006" TOTAL_1="33" TOTAL_2="23" VAR="0.9153061224489796" WEIGHT="0.2773287505016723"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="20.329806793151505" CI_END="4.017842505566195" CI_START="0.8980792317118056" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="OR" EFFECT_SIZE="1.8995633473348352" ESTIMABLE="YES" EVENTS_1="225" EVENTS_2="89" I2="70.48668459544231" I2_Q="90.30723747058687" ID="CMP-002.02" LOG_CI_END="0.6039929089418242" LOG_CI_START="-0.046685346654184244" LOG_EFFECT_SIZE="0.27865378114382" METHOD="MH" MODIFIED="2011-01-13 14:07:21 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.002418739694792893" P_Q="0.00131813551866522" P_Z="0.0932077801833177" Q="10.316976166138963" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.5179679122187778" TOTALS="YES" TOTAL_1="1128" TOTAL_2="548" WEIGHT="100.0" Z="1.6787140818084652">
<NAME>Quinidine: older and recent studies</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.100450190102716" CI_END="7.6536474085743205" CI_START="1.7144486519975988" DF="4" EFFECT_SIZE="3.622400513816102" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="12" I2="2.4497356496409455" ID="CMP-002.02.01" LOG_CI_END="0.8838684510897244" LOG_CI_START="0.23412448245881204" LOG_EFFECT_SIZE="0.5589964667742683" NO="1" P_CHI2="0.3925823286412061" P_Z="7.450392913632153E-4" STUDIES="5" TAU2="0.021672088087786104" TOTAL_1="233" TOTAL_2="209" WEIGHT="49.17730346296207" Z="3.3724451330307637">
<NAME>Older studies, higher dose</NAME>
<DICH_DATA CI_END="4.761604835048673" CI_START="0.5833700766874712" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.6777533505231068" LOG_CI_START="-0.23405585129039405" LOG_EFFECT_SIZE="0.2218487496163564" ORDER="382" O_E="0.0" SE="0.5356012386735927" STUDY_ID="STD-Byrne_x002d_Quinn-1970" TOTAL_1="32" TOTAL_2="42" VAR="0.28686868686868683" WEIGHT="18.15097983024176"/>
<DICH_DATA CI_END="160.560761558474" CI_START="0.4063052875267676" EFFECT_SIZE="8.076923076923077" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.2056394193938447" LOG_CI_START="-0.39114752586764184" LOG_EFFECT_SIZE="0.9072459467631013" ORDER="383" O_E="0.0" SE="1.5253655059492877" STUDY_ID="STD-Hillestad-1971" TOTAL_1="48" TOTAL_2="52" VAR="2.3267399267399265" WEIGHT="5.1353508703460955"/>
<DICH_DATA CI_END="183.299009835243" CI_START="0.47871065288491116" EFFECT_SIZE="9.36734693877551" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.263160118948842" LOG_CI_START="-0.31992690793134665" LOG_EFFECT_SIZE="0.9716166055087476" ORDER="384" O_E="0.0" SE="1.5173181060764234" STUDY_ID="STD-Lloyd-1984" TOTAL_1="28" TOTAL_2="25" VAR="2.3022542350273443" WEIGHT="5.179936938989667"/>
<DICH_DATA CI_END="24.344299755497175" CI_START="2.046762080643776" EFFECT_SIZE="7.0588235294117645" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="3" LOG_CI_END="1.3863972869247436" LOG_CI_START="0.3110673624139582" LOG_EFFECT_SIZE="0.8487323246693509" ORDER="385" O_E="0.0" SE="0.6316541206266093" STUDY_ID="STD-Sodermark-1975" TOTAL_1="110" TOTAL_2="75" VAR="0.39898692810457514" WEIGHT="15.931616513988201"/>
<DICH_DATA CI_END="130.37173033563494" CI_START="0.2527856627165786" EFFECT_SIZE="5.7407407407407405" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.1151834296608754" LOG_CI_START="-0.5972475616382668" LOG_EFFECT_SIZE="0.7589679340113041" ORDER="386" O_E="0.0" SE="1.5932953910390666" STUDY_ID="STD-Steinbeck-1988" TOTAL_1="15" TOTAL_2="15" VAR="2.538590203106332" WEIGHT="4.779419309396349"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.1423269528625646" CI_END="1.364192034956539" CI_START="0.5223024031297029" DF="1" EFFECT_SIZE="0.8441094586534379" ESTIMABLE="YES" EVENTS_1="181" EVENTS_2="77" I2="53.32178411592096" ID="CMP-002.02.02" LOG_CI_END="0.13487550950789748" LOG_CI_START="-0.28207797595590645" LOG_EFFECT_SIZE="-0.07360123322400448" NO="2" P_CHI2="0.14328447380939024" P_Z="0.4889678779108618" STUDIES="2" TAU2="0.06590694561638641" TOTAL_1="895" TOTAL_2="339" WEIGHT="50.82269653703793" Z="0.6919513632381161">
<NAME>More recent studies, lower dose</NAME>
<DICH_DATA CI_END="1.9583118156706645" CI_START="0.6512666297854758" EFFECT_SIZE="1.129328621908127" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="20" LOG_CI_END="0.29188184428189806" LOG_CI_START="-0.18624117404657106" LOG_EFFECT_SIZE="0.05282033511766351" ORDER="387" O_E="0.0" SE="0.2808518277132539" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="88" VAR="0.07887774912987525" WEIGHT="24.47629902120241"/>
<DICH_DATA CI_END="0.9991242524990693" CI_START="0.47240905382642406" EFFECT_SIZE="0.6870191720600806" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="57" LOG_CI_END="-3.80498942022319E-4" LOG_CI_START="-0.3256817876267346" LOG_EFFECT_SIZE="-0.16303114328437845" ORDER="388" O_E="0.0" SE="0.19108358724074903" STUDY_ID="STD-SOPAT-2004" TOTAL_1="518" TOTAL_2="251" VAR="0.03651293731279295" WEIGHT="26.34639751583552"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="40.279103543259424" CI_END="1.683766518954571" CI_START="1.073164472402449" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.3442315306385244" ESTIMABLE="YES" EVENTS_1="339" EVENTS_2="117" I2="62.7598464700434" I2_Q="54.18979571689432" ID="CMP-002.03" LOG_CI_END="0.22628186949162132" LOG_CI_START="0.030666286721697713" LOG_EFFECT_SIZE="0.1284740781066595" METHOD="PETO" MODIFIED="2011-01-13 14:10:43 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="4.11513926568019E-4" P_Q="0.1127120424775141" P_Z="0.010038981257810308" Q="4.365839513921528" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2093" TOTAL_2="1107" WEIGHT="100.00000000000001" Z="2.574483714134394">
<NAME>Class I antiarrhythmics</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="26.919765167371835" CI_END="1.5418736181501984" CI_START="0.8986896334767984" DF="7" EFFECT_SIZE="1.177143082536251" ESTIMABLE="YES" EVENTS_1="234" EVENTS_2="91" I2="73.9968013967508" ID="CMP-002.03.01" LOG_CI_END="0.18804877761288702" LOG_CI_START="-0.046390267934138835" LOG_EFFECT_SIZE="0.0708292548393741" NO="1" P_CHI2="3.445457008741659E-4" P_Z="0.23629533661724" STUDIES="8" TAU2="0.0" TOTAL_1="1203" TOTAL_2="594" WEIGHT="69.62208199585417" Z="1.184297506527224">
<NAME>Class Ia</NAME>
<DICH_DATA CI_END="4.727279277530424" CI_START="0.5839521131312015" EFFECT_SIZE="1.6614766695548966" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.6746112602482437" LOG_CI_START="-0.23362276565400186" LOG_EFFECT_SIZE="0.22049424729712094" ORDER="389" O_E="1.7837837837837842" SE="0.5335011626459151" STUDY_ID="STD-Byrne_x002d_Quinn-1970" TOTAL_1="32" TOTAL_2="42" VAR="3.513413450473799" WEIGHT="4.638860997966065"/>
<DICH_DATA CI_END="82.64084546794376" CI_START="0.8505035136266731" EFFECT_SIZE="8.383694259666504" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.91719475164061" LOG_CI_START="-0.0703238878767813" LOG_EFFECT_SIZE="0.9234354318819143" ORDER="390" O_E="1.56" SE="1.1674782872284526" STUDY_ID="STD-Hillestad-1971" TOTAL_1="48" TOTAL_2="52" VAR="0.7336727272727273" WEIGHT="0.9686892384834139"/>
<DICH_DATA CI_END="13.281487866698253" CI_START="0.8607433866821024" EFFECT_SIZE="3.3811171003913936" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.1232467298589253" LOG_CI_START="-0.06512630540923559" LOG_EFFECT_SIZE="0.5290602122248449" ORDER="391" O_E="2.5" SE="0.6980562034579147" STUDY_ID="STD-Karlson-1998" TOTAL_1="46" TOTAL_2="46" VAR="2.0521978021978025" WEIGHT="2.7095758808127943"/>
<DICH_DATA CI_END="27.871975962080842" CI_START="0.7701732851760609" EFFECT_SIZE="4.633168601622868" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="1.4451677587746075" LOG_CI_START="-0.11341154972502382" LOG_EFFECT_SIZE="0.6658781045247919" ORDER="392" O_E="1.8292682926829267" SE="0.9155172009046879" STUDY_ID="STD-Lloyd-1984" TOTAL_1="57" TOTAL_2="25" VAR="1.1930729063388195" WEIGHT="1.5752485299442394"/>
<DICH_DATA CI_END="1.9305216969464964" CI_START="0.6571482859917904" EFFECT_SIZE="1.1263387697395277" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="20" LOG_CI_END="0.2856746869811433" LOG_CI_START="-0.18233662051403673" LOG_EFFECT_SIZE="0.051669033233553305" ORDER="393" O_E="1.5741935483871003" SE="0.274912158716004" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="88" VAR="13.231592091571281" WEIGHT="17.4700522326255"/>
<DICH_DATA CI_END="9.648936448053911" CI_START="1.8840217766644973" EFFECT_SIZE="4.263661148565321" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="3" LOG_CI_END="0.9844794459659073" LOG_CI_START="0.27508591832446344" LOG_EFFECT_SIZE="0.6297826821451853" ORDER="395" O_E="8.35135135135135" SE="0.41670126969117954" STUDY_ID="STD-Sodermark-1975" TOTAL_1="110" TOTAL_2="75" VAR="5.759043414742592" WEIGHT="7.60383093502418"/>
<DICH_DATA CI_END="0.9980593375504293" CI_START="0.46107254610926246" EFFECT_SIZE="0.6783640320156282" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="57" LOG_CI_END="-8.436378662803859E-4" LOG_CI_START="-0.336230736440792" LOG_EFFECT_SIZE="-0.1685371871535362" ORDER="394" O_E="-9.998699609882962" SE="0.19700804189558133" STUDY_ID="STD-SOPAT-2004" TOTAL_1="518" TOTAL_2="251" VAR="25.765115344096074" WEIGHT="34.01842406611906"/>
<DICH_DATA CI_END="133.25952883863062" CI_START="0.4726304768834543" EFFECT_SIZE="7.936152384138449" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.1246982734139985" LOG_CI_START="-0.3254782769576691" LOG_EFFECT_SIZE="0.8996099982281646" ORDER="396" O_E="1.0" SE="1.439245834257849" STUDY_ID="STD-Steinbeck-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.48275862068965514" WEIGHT="0.6374001148789179"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.9512376864641414" CI_START="0.10970241203804439" DF="0" EFFECT_SIZE="0.6583770232478792" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="0.5967331554255523" LOG_CI_START="-0.9597838234435514" LOG_EFFECT_SIZE="-0.18152533400899956" NO="2" P_CHI2="1.0" P_Z="0.6475611588736021" STUDIES="1" TAU2="0.0" TOTAL_1="47" TOTAL_2="47" WEIGHT="1.5794255918802682" Z="0.4571528891355099">
<NAME>Class Ib</NAME>
<DICH_DATA CI_END="3.9512376864641414" CI_START="0.10970241203804439" EFFECT_SIZE="0.6583770232478792" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5967331554255523" LOG_CI_START="-0.9597838234435514" LOG_EFFECT_SIZE="-0.18152533400899956" ORDER="397" O_E="-0.5" SE="0.9143057782710197" STUDY_ID="STD-SMART-2002" TOTAL_1="47" TOTAL_2="47" VAR="1.1962365591397852" WEIGHT="1.5794255918802682"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.993498861966064" CI_END="2.931529998295167" CI_START="1.2664168630610244" DF="6" EFFECT_SIZE="1.926795013593884" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="23" I2="33.28514194431839" ID="CMP-002.03.03" LOG_CI_END="0.46709434267138716" LOG_CI_START="0.10257668477090734" LOG_EFFECT_SIZE="0.2848355137211473" NO="3" P_CHI2="0.17394408699961805" P_Z="0.002190956891526781" STUDIES="9" TAU2="0.0" TOTAL_1="843" TOTAL_2="466" WEIGHT="28.798492412265574" Z="3.0630469405892575">
<NAME>Class Ic</NAME>
<DICH_DATA CI_END="8.335148300201272" CI_START="0.8080092547567259" EFFECT_SIZE="2.595164150170933" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.9209133312649376" LOG_CI_START="-0.09258366488536518" LOG_EFFECT_SIZE="0.41416483318978625" ORDER="398" O_E="2.6907216494845363" SE="0.5953331524297303" STUDY_ID="STD-Bellandi-2001" TOTAL_1="102" TOTAL_2="92" VAR="2.8214987634482913" WEIGHT="3.7253061030448076"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="399" O_E="0.0" SE="0.0" STUDY_ID="STD-Carunchio-1995" TOTAL_1="20" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="18.627411270105846" CI_START="0.5205130096918074" EFFECT_SIZE="3.113809548281636" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.2701525033542727" LOG_CI_START="-0.28356841127015175" LOG_EFFECT_SIZE="0.4932920460420605" ORDER="400" O_E="1.3636363636363638" SE="0.9126633562929538" STUDY_ID="STD-Dogan-2004" TOTAL_1="58" TOTAL_2="52" VAR="1.2005459094700128" WEIGHT="1.585115351271031"/>
<DICH_DATA CI_END="44.1512152552961" CI_START="1.269307449723108" EFFECT_SIZE="7.486084853772088" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.6449426619658098" LOG_CI_START="0.10356682898670365" LOG_EFFECT_SIZE="0.8742547454762567" ORDER="401" O_E="2.455621301775148" SE="0.9054117942253541" STUDY_ID="STD-Kochiadakis-2004b" TOTAL_1="86" TOTAL_2="83" VAR="1.2198535798899932" WEIGHT="1.6106078247687776"/>
<DICH_DATA CI_END="150.13826080578548" CI_START="0.07523056855345664" EFFECT_SIZE="3.3608014999470575" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.176491380713628" LOG_CI_START="-1.1236056559968985" LOG_EFFECT_SIZE="0.5264428623583648" ORDER="402" O_E="0.32258064516129026" SE="1.9384933351075546" STUDY_ID="STD-Okishige-2000" TOTAL_1="52" TOTAL_2="10" VAR="0.26611623820815067" WEIGHT="0.3513609359532572"/>
<DICH_DATA CI_END="2.276425067064995" CI_START="0.7728315351048687" EFFECT_SIZE="1.3263834585560255" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="17" LOG_CI_END="0.3572533592364393" LOG_CI_START="-0.11191516500533927" LOG_EFFECT_SIZE="0.12266909711555002" ORDER="403" O_E="3.718929254302097" SE="0.2755919135612713" STUDY_ID="STD-RAFT-2003" TOTAL_1="397" TOTAL_2="126" VAR="13.166400435886457" WEIGHT="17.38397781149286"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="404" O_E="0.0" SE="0.0" STUDY_ID="STD-Steinbeck-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.568297143647477" CI_START="0.23491165107156406" EFFECT_SIZE="1.1437035785863847" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="0.7457224026806577" LOG_CI_START="-0.6290954426919367" LOG_EFFECT_SIZE="0.05831347999436041" ORDER="405" O_E="0.20588235294117663" SE="0.8075748078299536" STUDY_ID="STD-Stroobandt-1997" TOTAL_1="77" TOTAL_2="25" VAR="1.5333259104457158" WEIGHT="2.024494373748764"/>
<DICH_DATA CI_END="42.93727702849919" CI_START="1.9435224978817696" EFFECT_SIZE="9.13507328392445" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="1.6328344991362287" LOG_CI_START="0.2885895723145221" LOG_EFFECT_SIZE="0.9607120357253753" ORDER="406" O_E="3.547945205479452" SE="0.7896161241347744" STUDY_ID="STD-Van-Gelder-1989" TOTAL_1="36" TOTAL_2="37" VAR="1.6038656408331768" WEIGHT="2.1176300119860763"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="25.483558301418185" CI_END="4.042535062706997" CI_START="1.3384055985445273" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="OR" EFFECT_SIZE="2.326059234035023" ESTIMABLE="YES" EVENTS_1="255" EVENTS_2="102" I2="60.759012215953014" I2_Q="94.7912338002976" ID="CMP-002.04" LOG_CI_END="0.606653795424235" LOG_CI_START="0.12658774460997888" LOG_EFFECT_SIZE="0.36662077001710697" METHOD="MH" MODIFIED="2014-07-01 15:56:06 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.004500523627882003" P_Q="1.1781292092782891E-5" P_Z="0.0027570473133747163" Q="19.198404414026793" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.39417040667563763" TOTALS="YES" TOTAL_1="1563" TOTAL_2="1102" WEIGHT="100.0" Z="2.993602667795783">
<NAME>Sotalol: heterogeneity study</NAME>
<GROUP_LABEL_1>Antiarrhythmic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.6521608390630059" CI_END="1.3279210234126904" CI_START="0.6800872576174517" DF="1" EFFECT_SIZE="0.9503168772284835" ESTIMABLE="YES" EVENTS_1="149" EVENTS_2="77" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="0.123172246631398" LOG_CI_START="-0.16743536218994692" LOG_EFFECT_SIZE="-0.02213155777927445" NO="1" P_CHI2="0.4193414577794049" P_Z="0.7653012489248305" STUDIES="2" TAU2="0.0" TOTAL_1="647" TOTAL_2="339" WEIGHT="34.873015507395685" Z="0.2985266376546378">
<NAME>PAFAC and SOPAT trials</NAME>
<DICH_DATA CI_END="1.9702390414608757" CI_START="0.6564740842996861" EFFECT_SIZE="1.1372822299651568" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="20" LOG_CI_END="0.2945189206232433" LOG_CI_START="-0.1827824139275809" LOG_EFFECT_SIZE="0.05586825334783122" ORDER="407" O_E="0.0" SE="0.28036916659486494" STUDY_ID="STD-PAFAC-2004" TOTAL_1="383" TOTAL_2="88" VAR="0.07860686957709914" WEIGHT="16.819791162325295"/>
<DICH_DATA CI_END="1.3034321165695175" CI_START="0.5607278917288249" EFFECT_SIZE="0.8549097863141265" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="57" LOG_CI_END="0.11508841780817489" LOG_CI_START="-0.25124784068651285" LOG_EFFECT_SIZE="-0.068079711439169" ORDER="408" O_E="0.0" SE="0.21518773163350513" STUDY_ID="STD-SOPAT-2004" TOTAL_1="264" TOTAL_2="251" VAR="0.046305759845573426" WEIGHT="18.05322434507039"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.162325323910462" CI_END="5.314119932964976" CI_START="2.1333354477416306" DF="8" EFFECT_SIZE="3.367016546817755" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="25" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="0.7254313516619747" LOG_CI_START="0.32905914970581895" LOG_EFFECT_SIZE="0.5272452506838968" MODIFIED="2014-07-01 15:56:06 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7400941857690043" P_Z="1.8461353901085736E-7" STUDIES="10" TAU2="0.0" TOTAL_1="916" TOTAL_2="763" WEIGHT="65.12698449260432" Z="5.214198661058155">
<NAME>Rest of studies</NAME>
<DICH_DATA CI_END="5.711913718480748" CI_START="1.4244543029321317" EFFECT_SIZE="2.8524305555555554" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="12" LOG_CI_END="0.7567816385666624" LOG_CI_START="0.1536485214570369" LOG_EFFECT_SIZE="0.4552150800118496" ORDER="872" O_E="0.0" SE="0.35428337854727415" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="223" TOTAL_2="224" VAR="0.12551671231487116" WEIGHT="15.301543490842684"/>
<DICH_DATA CI_END="8.358568905926466" CI_START="0.5264186506819282" EFFECT_SIZE="2.0976430976430978" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9221319270249068" LOG_CI_START="-0.27866873234099215" LOG_EFFECT_SIZE="0.3217315973419573" ORDER="409" O_E="0.0" SE="0.7053562513706574" STUDY_ID="STD-Bellandi-2001" TOTAL_1="106" TOTAL_2="92" VAR="0.497527441347666" WEIGHT="8.917835868385083"/>
<DICH_DATA CI_END="80.50608710960842" CI_START="1.4199559610880519" EFFECT_SIZE="10.69182389937107" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="1" LOG_CI_END="1.9058287188544425" LOG_CI_START="0.1522748752612027" LOG_EFFECT_SIZE="1.0290517970578223" ORDER="410" O_E="0.0" SE="1.0300462079581876" STUDY_ID="STD-Benditt-1999" TOTAL_1="184" TOTAL_2="69" VAR="1.0609951905290418" WEIGHT="5.464680492817822"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="411" O_E="0.0" SE="0.0" STUDY_ID="STD-Carunchio-1995" TOTAL_1="20" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="28.535732863901256" CI_START="1.2907445771634332" EFFECT_SIZE="6.068965517241379" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="1.4553890307192576" LOG_CI_START="0.11084030911112974" LOG_EFFECT_SIZE="0.7831146699151937" MODIFIED="2011-01-12 15:50:26 +0000" MODIFIED_BY="[Empty name]" ORDER="1017" O_E="0.0" SE="0.7897945746961268" STUDY_ID="STD-DAPHNE-2008" TOTAL_1="69" TOTAL_2="66" VAR="0.6237754702194358" WEIGHT="7.811825003033707"/>
<DICH_DATA CI_END="13.74662004226963" CI_START="1.4307005450004608" EFFECT_SIZE="4.434782608695652" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="4" LOG_CI_END="1.1381959288981676" LOG_CI_START="0.15554874259048188" LOG_EFFECT_SIZE="0.6468723357443247" MODIFIED="2010-12-28 10:48:15 +0000" MODIFIED_BY="[Empty name]" ORDER="993" O_E="0.0" SE="0.5772118214191553" STUDY_ID="STD-EMERALD-2000" TOTAL_1="108" TOTAL_2="106" VAR="0.33317348678601877" WEIGHT="10.93295087007315"/>
<DICH_DATA CI_END="209.7015929718977" CI_START="0.6208187585394257" EFFECT_SIZE="11.409937888198758" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.3216017295415354" LOG_CI_START="-0.20703516899361815" LOG_EFFECT_SIZE="1.0572832802739587" ORDER="412" O_E="0.0" SE="1.4853338311540678" STUDY_ID="STD-Kochiadakis-2004b" TOTAL_1="85" TOTAL_2="83" VAR="2.2062165899708206" WEIGHT="3.05801215862069"/>
<DICH_DATA CI_END="6.315414361523031" CI_START="0.2909596677286572" EFFECT_SIZE="1.3555555555555556" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.8004018503813436" LOG_CI_START="-0.5361672079104969" LOG_EFFECT_SIZE="0.13211732123542339" ORDER="413" O_E="0.0" SE="0.7851072809641692" STUDY_ID="STD-Plewan-2001" TOTAL_1="64" TOTAL_2="64" VAR="0.6163934426229508" WEIGHT="7.868889292233576"/>
<DICH_DATA CI_END="72.45163703754694" CI_START="0.16130564109814846" EFFECT_SIZE="3.4186046511627906" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8600482027587635" LOG_CI_START="-0.7923504444215842" LOG_EFFECT_SIZE="0.5338488791685896" ORDER="414" O_E="0.0" SE="1.558032094938791" STUDY_ID="STD-Singh-1991" TOTAL_1="24" TOTAL_2="10" VAR="2.4274640088593578" WEIGHT="2.8182301041845874"/>
<DICH_DATA CI_END="139.96748529938446" CI_START="0.3672396387144972" EFFECT_SIZE="7.169491525423729" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.1460271599990035" LOG_CI_START="-0.4350504485332075" LOG_EFFECT_SIZE="0.8554883557328982" MODIFIED="2014-07-01 15:56:06 +0100" MODIFIED_BY="[Empty name]" ORDER="1074" O_E="0.0" SE="1.5161377637920406" STUDY_ID="STD-Vijayalaskshmi-2006" TOTAL_1="33" TOTAL_2="23" VAR="2.2986737187963295" WEIGHT="2.9530172124130214"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="44.01262143218497" CI_END="2.0139805670852406" CI_START="1.5697868722048027" CI_STUDY="95" CI_TOTAL="95" DF="24" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.7780664371968768" ESTIMABLE="YES" EVENTS_1="829" EVENTS_2="371" I2="45.47018737118531" I2_Q="63.65436507985776" ID="CMP-002.05" LOG_CI_END="0.30405527572685237" LOG_CI_START="0.1958406928496815" LOG_EFFECT_SIZE="0.24994798428826698" METHOD="PETO" MODIFIED="2014-06-26 16:19:11 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.007604214998844783" P_Q="0.026502875033861728" P_Z="1.3778677798119814E-19" Q="11.005448133699424" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="23" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="7288" TOTAL_2="5558" WEIGHT="100.00000000000001" Z="9.054030135096221">
<NAME>Class III antiarrhythmics</NAME>
<GROUP_LABEL_1>Antiarrhythmic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8141427815015754" CI_END="13.629307840611121" CI_START="2.3358110512510444" DF="3" EFFECT_SIZE="5.642294557624758" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="1" I2="0.0" ID="CMP-002.05.01" LOG_CI_END="1.1344738009090671" LOG_CI_START="0.3684377088522092" LOG_EFFECT_SIZE="0.7514557548806382" MODIFIED="2014-06-26 16:17:50 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8460814207125213" P_Z="1.2039616185194358E-4" STUDIES="4" TAU2="0.0" TOTAL_1="183" TOTAL_2="136" WEIGHT="1.9955982545591437" Z="3.845318075253539">
<NAME>Amiodarone</NAME>
<DICH_DATA CI_END="14.26040858186083" CI_START="0.8639985230624987" EFFECT_SIZE="3.5101242076307697" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.1541319688752796" LOG_CI_START="-0.06348699991272148" LOG_EFFECT_SIZE="0.545322484481279" ORDER="415" O_E="2.454545454545454" SE="0.7152354095771745" STUDY_ID="STD-Channer-2004" TOTAL_1="61" TOTAL_2="38" VAR="1.9547984483049416" WEIGHT="0.7898575415898702"/>
<DICH_DATA CI_END="300.5347791914292" CI_START="0.05793575076459642" EFFECT_SIZE="4.172733883598098" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.4778947376928846" LOG_CI_START="-1.2370533608264507" LOG_EFFECT_SIZE="0.6204206884332171" ORDER="416" O_E="0.30000000000000004" SE="2.182178902359924" STUDY_ID="STD-GEFACA-2001" TOTAL_1="35" TOTAL_2="15" VAR="0.20999999999999996" WEIGHT="0.08485278053995958"/>
<DICH_DATA CI_END="27.81029479016203" CI_START="2.358744519316664" EFFECT_SIZE="8.099220975925737" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="0" LOG_CI_END="1.4442055924262647" LOG_CI_START="0.3726809040650725" LOG_EFFECT_SIZE="0.9084432482456686" ORDER="417" O_E="5.28" SE="0.6294189060761156" STUDY_ID="STD-Kochiadakis-2000" TOTAL_1="65" TOTAL_2="60" VAR="2.52418064516129" WEIGHT="1.0199226015575455"/>
<DICH_DATA CI_END="390.0795749354538" CI_START="0.15328725017167474" EFFECT_SIZE="7.732672590378534" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.591153210693601" LOG_CI_START="-0.8144939665439346" LOG_EFFECT_SIZE="0.8883296220748332" MODIFIED="2014-06-26 16:17:50 +0100" MODIFIED_BY="[Empty name]" ORDER="1059" O_E="0.5111111111111111" SE="2.0004940101347417" STUDY_ID="STD-Vijayalaskshmi-2006" TOTAL_1="22" TOTAL_2="23" VAR="0.24987654320987654" WEIGHT="0.1009653308717685"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.790793048933361" CI_END="3.2030250830834612" CI_START="1.7182678853785305" DF="4" EFFECT_SIZE="2.345987028166228" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="46" I2="0.0" ID="CMP-002.05.02" LOG_CI_END="0.5055603396635353" LOG_CI_START="0.2350908731577171" LOG_EFFECT_SIZE="0.37032560641062623" MODIFIED="2010-12-28 10:21:59 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9396781165610922" P_Z="7.999134103941865E-8" STUDIES="5" TAU2="0.0" TOTAL_1="1756" TOTAL_2="1358" WEIGHT="16.00792683734119" Z="5.367148170140447">
<NAME>Azimilide</NAME>
<DICH_DATA CI_END="4.178752748231418" CI_START="1.3283127632981735" EFFECT_SIZE="2.355990367158387" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="16" LOG_CI_END="0.6210466752222457" LOG_CI_START="0.12330034565091305" LOG_EFFECT_SIZE="0.3721735104365793" ORDER="838" O_E="10.024663677130047" SE="0.2923786578742692" STUDY_ID="STD-A_x002d_COMET_x002d_I-2006" TOTAL_1="227" TOTAL_2="219" VAR="11.6979204479289" WEIGHT="4.726671793057222"/>
<DICH_DATA CI_END="4.649687285454289" CI_START="1.2293287983639984" EFFECT_SIZE="2.390814606655205" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="12" LOG_CI_END="0.6674237454128644" LOG_CI_START="0.08966805556123204" LOG_EFFECT_SIZE="0.3785459004870482" ORDER="847" O_E="7.567816091954022" SE="0.33937655215563817" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="211" TOTAL_2="224" VAR="8.68233089980779" WEIGHT="3.5081900876985723"/>
<DICH_DATA CI_END="18.842830019191098" CI_START="0.9531768000049803" EFFECT_SIZE="4.237988723525625" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.2751461303791987" LOG_CI_START="-0.02082653677505163" LOG_EFFECT_SIZE="0.6271597968020736" MODIFIED="2010-11-20 10:10:08 +0000" MODIFIED_BY="[Empty name]" ORDER="890" O_E="2.491879350348028" SE="0.7612607598545715" STUDY_ID="STD-A_x002d_STAR-2006" TOTAL_1="216" TOTAL_2="215" VAR="1.7255721060933134" WEIGHT="0.6972361486867228"/>
<DICH_DATA CI_END="3.630175709349705" CI_START="1.1984801170102204" EFFECT_SIZE="2.0858315868998374" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="11" LOG_CI_END="0.559927646455997" LOG_CI_START="0.07863083340982842" LOG_EFFECT_SIZE="0.3192792399329127" ORDER="418" O_E="9.197826086956525" SE="0.28271613044096777" STUDY_ID="STD-ASAP-2003" TOTAL_1="891" TOTAL_2="489" VAR="12.51119589206721" WEIGHT="5.0552845682001095"/>
<DICH_DATA CI_END="5.908332362962058" CI_START="1.0236990932152656" EFFECT_SIZE="2.4593402534782918" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="6" LOG_CI_END="0.7714649178078945" LOG_CI_START="0.01017231859225797" LOG_EFFECT_SIZE="0.3908186182000763" MODIFIED="2010-12-28 10:21:59 +0000" MODIFIED_BY="[Empty name]" ORDER="946" O_E="4.5" SE="0.44718704123840797" STUDY_ID="STD-SVA_x002d_4-2008" TOTAL_1="211" TOTAL_2="211" VAR="5.000593824228028" WEIGHT="2.0205442396985624"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.005671290279828919" CI_END="3.586591506496854" CI_START="0.7850854782155658" DF="1" EFFECT_SIZE="1.67802887580696" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="6" I2="0.0" ID="CMP-002.05.03" LOG_CI_END="0.5546819156844003" LOG_CI_START="-0.10508305574346871" LOG_EFFECT_SIZE="0.22479942997046584" MODIFIED="2010-12-28 10:34:09 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9399696808001443" P_Z="0.1816723786342684" STUDIES="2" TAU2="0.0" TOTAL_1="503" TOTAL_2="174" WEIGHT="2.690252672095988" Z="1.3356234585588844">
<NAME>Dofetilide</NAME>
<DICH_DATA CI_END="4.2821937757911925" CI_START="0.6840436439670202" EFFECT_SIZE="1.711492750368841" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="4" LOG_CI_END="0.6316663158899293" LOG_CI_START="-0.16491618814923806" LOG_EFFECT_SIZE="0.23337506387034557" MODIFIED="2010-12-28 10:34:09 +0000" MODIFIED_BY="[Empty name]" ORDER="961" O_E="2.4543325526932094" SE="0.4679165060195961" STUDY_ID="STD-EMERALD-2000" TOTAL_1="321" TOTAL_2="106" VAR="4.5673392294489465" WEIGHT="1.8454830156570456"/>
<DICH_DATA CI_END="6.233831862441262" CI_START="0.4143574308642299" EFFECT_SIZE="1.6071821785226275" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="0.7947550844023693" LOG_CI_START="-0.382624868345819" LOG_EFFECT_SIZE="0.20606510802827518" ORDER="419" O_E="0.9920000000000009" SE="0.6915988123690467" STUDY_ID="STD-SAFIRE_x002d_D-2000" TOTAL_1="182" TOTAL_2="68" VAR="2.0906990522088353" WEIGHT="0.844769656438942"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.0842141269964785" CI_END="1.9400149116975973" CI_START="1.3803656413345848" DF="2" EFFECT_SIZE="1.6364381833066937" ESTIMABLE="YES" EVENTS_1="392" EVENTS_2="216" I2="51.03097100663536" ID="CMP-002.05.04" LOG_CI_END="0.2878050680967691" LOG_CI_START="0.13999414073499347" LOG_EFFECT_SIZE="0.21389960441588127" MODIFIED="2010-11-20 10:34:07 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.1297552821061323" P_Z="1.4065317392318092E-8" STUDIES="3" TAU2="0.0" TOTAL_1="3283" TOTAL_2="2788" WEIGHT="53.5992232476198" Z="5.672591714906025">
<NAME>Dronedarone</NAME>
<DICH_DATA CI_END="1.9806478159384728" CI_START="1.355855699905359" EFFECT_SIZE="1.6387411725911076" ESTIMABLE="YES" EVENTS_1="290" EVENTS_2="187" LOG_CI_END="0.29680725938908364" LOG_CI_START="0.13221347119066454" LOG_EFFECT_SIZE="0.21451036528987408" MODIFIED="2010-11-20 10:34:07 +0000" MODIFIED_BY="[Empty name]" ORDER="905" O_E="52.83988764044943" SE="0.09668320594014311" STUDY_ID="STD-ATHENA-2009" TOTAL_1="2301" TOTAL_2="2327" VAR="106.97884736536918" WEIGHT="43.22596503767383"/>
<DICH_DATA CI_END="12.271779417734178" CI_START="1.5545355138408892" EFFECT_SIZE="4.3677130083018785" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="0" LOG_CI_END="1.0889075403368307" LOG_CI_START="0.1916006480832641" LOG_EFFECT_SIZE="0.6402540942100473" ORDER="420" O_E="5.306532663316585" SE="0.5270825102504971" STUDY_ID="STD-DAFNE-2003" TOTAL_1="151" TOTAL_2="48" VAR="3.599505063003459" WEIGHT="1.4544191103024091"/>
<DICH_DATA CI_END="2.1017890397123096" CI_START="0.9125072421745916" EFFECT_SIZE="1.38488184342949" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="29" LOG_CI_END="0.32258912297354314" LOG_CI_START="-0.03976368005068673" LOG_EFFECT_SIZE="0.1414127214614282" MODIFIED="2010-08-20 10:04:39 +0100" MODIFIED_BY="[Empty name]" ORDER="421" O_E="7.187299035369776" SE="0.2128478301717356" STUDY_ID="STD-EURIDIS-ADONIS-2007" TOTAL_1="831" TOTAL_2="413" VAR="22.073009263887574" WEIGHT="8.918839099643558"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="27.312352050774333" CI_END="2.0920191866965636" CI_START="1.2797743024035029" DF="10" EFFECT_SIZE="1.63624949053295" ESTIMABLE="YES" EVENTS_1="255" EVENTS_2="102" I2="63.38652935708446" ID="CMP-002.05.05" LOG_CI_END="0.320565663291906" LOG_CI_START="0.10713338537956042" LOG_EFFECT_SIZE="0.21384952433573326" MODIFIED="2014-06-26 16:19:11 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.002323751483059411" P_Z="8.58008975581409E-5" STUDIES="12" TAU2="0.0" TOTAL_1="1563" TOTAL_2="1102" WEIGHT="25.706998988383887" Z="3.9275911770120757">
<NAME>Sotalol</NAME>
<DICH_DATA CI_END="4.995946911229559" CI_START="1.4225449776921204" EFFECT_SIZE="2.6658880673025402" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="12" LOG_CI_END="0.6986178147536282" LOG_CI_START="0.1530660067048519" LOG_EFFECT_SIZE="0.4258419107292401" ORDER="873" O_E="9.548098434004473" SE="0.32045983257285454" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="223" TOTAL_2="224" VAR="9.737619426552357" WEIGHT="3.9345908770614013"/>
<DICH_DATA CI_END="7.139763235365658" CI_START="0.5607294808668443" EFFECT_SIZE="2.000868744440466" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.8536838101964677" LOG_CI_START="-0.25124660987045216" LOG_EFFECT_SIZE="0.3012186001630078" ORDER="422" O_E="1.6464646464646462" SE="0.6490415982410989" STUDY_ID="STD-Bellandi-2001" TOTAL_1="106" TOTAL_2="92" VAR="2.373859085134274" WEIGHT="0.9591835427794656"/>
<DICH_DATA CI_END="9.212172032313898" CI_START="1.4945210034743894" EFFECT_SIZE="3.7104965422315748" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="1" LOG_CI_END="0.9643620395817095" LOG_CI_START="0.17450202284062655" LOG_EFFECT_SIZE="0.569432031211168" ORDER="423" O_E="6.09090909090909" SE="0.4639676837038525" STUDY_ID="STD-Benditt-1999" TOTAL_1="184" TOTAL_2="69" VAR="4.645415190869737" WEIGHT="1.8770304557517346"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="424" O_E="0.0" SE="0.0" STUDY_ID="STD-Carunchio-1995" TOTAL_1="20" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="13.631820050462816" CI_START="1.395188919697957" EFFECT_SIZE="4.361073754217207" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="1.134553844470245" LOG_CI_START="0.14463301852517244" LOG_EFFECT_SIZE="0.6395934314977088" MODIFIED="2010-12-27 14:16:07 +0000" MODIFIED_BY="[Empty name]" ORDER="927" O_E="4.355555555555555" SE="0.5814843933472533" STUDY_ID="STD-DAPHNE-2008" TOTAL_1="69" TOTAL_2="66" VAR="2.9574940114243597" WEIGHT="1.1950075728554093"/>
<DICH_DATA CI_END="9.16690381264253" CI_START="1.4602886681119756" EFFECT_SIZE="3.658732807854976" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="4" LOG_CI_END="0.9622226743676763" LOG_CI_START="0.16443871508314936" LOG_EFFECT_SIZE="0.5633306947254129" MODIFIED="2010-12-28 10:45:35 +0000" MODIFIED_BY="[Empty name]" ORDER="981" O_E="5.906542056074766" SE="0.46862224677801984" STUDY_ID="STD-EMERALD-2000" TOTAL_1="108" TOTAL_2="106" VAR="4.553592847151913" WEIGHT="1.8399286406081479"/>
<DICH_DATA CI_END="44.67987407523911" CI_START="1.2845683044903577" EFFECT_SIZE="7.57590589208133" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.6501119404394118" LOG_CI_START="0.1087572020041299" LOG_EFFECT_SIZE="0.8794345712217709" ORDER="425" O_E="2.4702380952380953" SE="0.9053994031858922" STUDY_ID="STD-Kochiadakis-2004b" TOTAL_1="85" TOTAL_2="83" VAR="1.2198869692587613" WEIGHT="0.4929085775527148"/>
<DICH_DATA CI_END="1.9403740263898828" CI_START="0.6626459972714737" EFFECT_SIZE="1.1339228729489448" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="20" LOG_CI_END="0.2878854525799555" LOG_CI_START="-0.17871842105314945" LOG_EFFECT_SIZE="0.05458351576340305" ORDER="426" O_E="1.6730360934182613" SE="0.27408542509851114" STUDY_ID="STD-PAFAC-2004" TOTAL_1="383" TOTAL_2="88" VAR="13.311534320104863" WEIGHT="5.378670001495229"/>
<DICH_DATA CI_END="6.158078173696388" CI_START="0.2958209602781121" EFFECT_SIZE="1.3496994475847384" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7894451977515701" LOG_CI_START="-0.5289710574837401" LOG_EFFECT_SIZE="0.13023707013391495" ORDER="427" O_E="0.5" SE="0.7744442345909389" STUDY_ID="STD-Plewan-2001" TOTAL_1="64" TOTAL_2="64" VAR="1.6673228346456692" WEIGHT="0.6736998979878681"/>
<DICH_DATA CI_END="58.58069836700783" CI_START="0.348444529528686" EFFECT_SIZE="4.517977853194271" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.7677545447974399" LOG_CI_START="-0.45786634937956794" LOG_EFFECT_SIZE="0.6549440977089361" ORDER="429" O_E="0.8823529411764706" SE="1.3073407302406808" STUDY_ID="STD-Singh-1991" TOTAL_1="24" TOTAL_2="10" VAR="0.5850896508335955" WEIGHT="0.23641182732564126"/>
<DICH_DATA CI_END="1.3030568154607938" CI_START="0.5612102699123185" EFFECT_SIZE="0.8551542943328054" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="57" LOG_CI_END="0.11496335209261067" LOG_CI_START="-0.25087439016427693" LOG_EFFECT_SIZE="-0.06795551903583308" ORDER="428" O_E="-3.38834951456311" SE="0.21489490072772618" STUDY_ID="STD-SOPAT-2004" TOTAL_1="264" TOTAL_2="251" VAR="21.654481016595188" WEIGHT="8.749728216227965"/>
<DICH_DATA CI_END="46.688986440711915" CI_START="0.7758743354774353" EFFECT_SIZE="6.018703043746413" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.6692144460450964" LOG_CI_START="-0.11020861357188443" LOG_EFFECT_SIZE="0.779502916236606" MODIFIED="2014-06-26 16:19:11 +0100" MODIFIED_BY="[Empty name]" ORDER="1060" O_E="1.6428571428571428" SE="1.0452419135052178" STUDY_ID="STD-Vijayalaskshmi-2006" TOTAL_1="33" TOTAL_2="23" VAR="0.9153061224489796" WEIGHT="0.3698393787383078"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="200.56943326034866" CI_END="1.1002150793224998" CI_START="0.8784793091780818" CI_STUDY="95" CI_TOTAL="95" DF="44" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.9831155490737282" ESTIMABLE="YES" EVENTS_1="790" EVENTS_2="768" I2="78.06245982512904" I2_Q="82.37517655976488" ID="CMP-002.06" LOG_CI_END="0.04147759300574281" LOG_CI_START="-0.05626846298554091" LOG_EFFECT_SIZE="-0.007395434989899057" METHOD="PETO" MODIFIED="2014-06-26 16:23:18 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="7.771561172376096E-16" P_Q="3.2940944416637308E-9" P_Z="0.7667868137964298" Q="62.411972734367744" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="28" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="4659" TOTAL_2="4587" WEIGHT="1200.0" Z="0.29658048262329906">
<NAME>Comparing antiarrhythmic drugs</NAME>
<GROUP_LABEL_1>Antiarrhythmic 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiarrhythmic 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Drug 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Drug 2</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.1020818208704265" CI_END="1.0254483737776743" CI_START="0.13502010039034776" DF="1" EFFECT_SIZE="0.3720969529203114" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" I2="0.0" ID="CMP-002.06.01" LOG_CI_END="0.010913800688918913" LOG_CI_START="-0.8696015734397933" LOG_EFFECT_SIZE="-0.42934388637543713" NO="1" P_CHI2="0.7493455556329162" P_Z="0.05595611023139008" STUDIES="2" TAU2="0.0" TOTAL_1="60" TOTAL_2="53" WEIGHT="100.0" Z="1.9113773115227977">
<NAME>Disopyramide vs other Class I drugs</NAME>
<DICH_DATA CI_END="2.475353846287896" CI_START="0.08646932916052305" EFFECT_SIZE="0.4626469350632671" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.3936372891306425" LOG_CI_START="-1.0631379103202396" LOG_EFFECT_SIZE="-0.3347503105947986" ORDER="430" O_E="-1.0526315789473686" SE="0.8557169633109855" STUDY_ID="STD-Lloyd-1984" TOTAL_1="29" TOTAL_2="28" VAR="1.365650969529086" WEIGHT="36.533291996385536"/>
<DICH_DATA CI_END="1.1717491739682055" CI_START="0.0919551204536907" EFFECT_SIZE="0.3282504172636479" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.06883465603378679" LOG_CI_START="-1.036424082381677" LOG_EFFECT_SIZE="-0.483794713173945" ORDER="431" O_E="-2.6428571428571432" SE="0.6492344540642356" STUDY_ID="STD-PRODIS-1996" TOTAL_1="31" TOTAL_2="25" VAR="2.372448979591837" WEIGHT="63.46670800361446"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9320391430713223" CI_END="3.643269179108636" CI_START="1.1395418476050088" DF="1" EFFECT_SIZE="2.0375617025464137" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="22" I2="0.0" ID="CMP-002.06.02" LOG_CI_END="0.5614912598180318" LOG_CI_START="0.056730278485437935" LOG_EFFECT_SIZE="0.30911076915173497" NO="2" P_CHI2="0.33433376910869095" P_Z="0.016371519686275635" STUDIES="2" TAU2="0.0" TOTAL_1="132" TOTAL_2="137" WEIGHT="100.0" Z="2.400526178435631">
<NAME>Quinidine vs Flecainide</NAME>
<DICH_DATA CI_END="3.4741768721244437" CI_START="1.0593181732324986" EFFECT_SIZE="1.9184000358802804" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="22" LOG_CI_END="0.5408519248284892" LOG_CI_START="0.02502642292647854" LOG_EFFECT_SIZE="0.28293917387748385" ORDER="432" O_E="7.09623430962343" SE="0.3029984531946558" STUDY_ID="STD-Naccarelli-1996" TOTAL_1="117" TOTAL_2="122" VAR="10.892289536041654" WEIGHT="95.7559861370435"/>
<DICH_DATA CI_END="133.25952883863062" CI_START="0.4726304768834543" EFFECT_SIZE="7.936152384138449" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.1246982734139985" LOG_CI_START="-0.3254782769576691" LOG_EFFECT_SIZE="0.8996099982281646" ORDER="433" O_E="1.0" SE="1.439245834257849" STUDY_ID="STD-Steinbeck-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.48275862068965514" WEIGHT="4.244013862956505"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2603825606990064" CI_END="3.5068798605103817" CI_START="1.4487288600637724" DF="3" EFFECT_SIZE="2.254000457563797" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="34" I2="0.0" ID="CMP-002.06.03" LOG_CI_END="0.5449208879769925" LOG_CI_START="0.16098711176741728" LOG_EFFECT_SIZE="0.3529539998722049" NO="3" P_CHI2="0.7385615178905571" P_Z="3.138068856232518E-4" STUDIES="4" TAU2="0.0" TOTAL_1="258" TOTAL_2="268" WEIGHT="100.00000000000001" Z="3.6036273483334327">
<NAME>Quinidine vs other Class I drugs</NAME>
<DICH_DATA CI_END="11.564794242170933" CI_START="0.40398264736963796" EFFECT_SIZE="2.161475466952461" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0631379103202399" LOG_CI_START="-0.3936372891306425" LOG_EFFECT_SIZE="0.3347503105947986" ORDER="434" O_E="1.0526315789473686" SE="0.8557169633109855" STUDY_ID="STD-Lloyd-1984" TOTAL_1="28" TOTAL_2="29" VAR="1.365650969529086" WEIGHT="6.9458845790346695"/>
<DICH_DATA CI_END="3.4741768721244437" CI_START="1.0593181732324986" EFFECT_SIZE="1.9184000358802804" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="22" LOG_CI_END="0.5408519248284892" LOG_CI_START="0.02502642292647854" LOG_EFFECT_SIZE="0.28293917387748385" ORDER="435" O_E="7.09623430962343" SE="0.3029984531946558" STUDY_ID="STD-Naccarelli-1996" TOTAL_1="117" TOTAL_2="122" VAR="10.892289536041654" WEIGHT="55.39965013524714"/>
<DICH_DATA CI_END="5.6516263677517715" CI_START="1.2736345444992523" EFFECT_SIZE="2.6829287308036145" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="10" LOG_CI_END="0.7521734426692118" LOG_CI_START="0.10504482982351612" LOG_EFFECT_SIZE="0.42860913624636404" ORDER="436" O_E="6.829999999999998" SE="0.380126550523858" STUDY_ID="STD-Richiardi-1992" TOTAL_1="98" TOTAL_2="102" VAR="6.920597487437186" WEIGHT="35.19908998583421"/>
<DICH_DATA CI_END="133.25952883863062" CI_START="0.4726304768834543" EFFECT_SIZE="7.936152384138449" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.1246982734139985" LOG_CI_START="-0.3254782769576691" LOG_EFFECT_SIZE="0.8996099982281646" ORDER="437" O_E="1.0" SE="1.439245834257849" STUDY_ID="STD-Steinbeck-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.48275862068965514" WEIGHT="2.455375299883977"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="18.360642744682995" CI_END="1.3961698267498286" CI_START="0.8912310565462599" DF="5" EFFECT_SIZE="1.115486400550118" ESTIMABLE="YES" EVENTS_1="230" EVENTS_2="171" I2="72.76783787186353" ID="CMP-002.06.04" LOG_CI_END="0.14493824803962688" LOG_CI_START="-0.050009688135714825" LOG_EFFECT_SIZE="0.04746427995195599" NO="4" P_CHI2="0.0025267863563289694" P_Z="0.3398857648500665" STUDIES="6" TAU2="0.0" TOTAL_1="1109" TOTAL_2="869" WEIGHT="100.0" Z="0.9543910141658342">
<NAME>Quinidine vs Sotalol</NAME>
<DICH_DATA CI_END="29.392378210876284" CI_START="2.077473964795399" EFFECT_SIZE="7.814211444318296" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="1.4682347273476808" LOG_CI_START="0.31753558984890756" LOG_EFFECT_SIZE="0.8928851585982941" ORDER="438" O_E="4.5" SE="0.6759263694193747" STUDY_ID="STD-Hohnloser-1995" TOTAL_1="25" TOTAL_2="25" VAR="2.1887755102040813" WEIGHT="2.8702102338557944"/>
<DICH_DATA CI_END="5.696193306574743" CI_START="1.2620105084376525" EFFECT_SIZE="2.681166874886669" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="11" LOG_CI_END="0.7555847191390193" LOG_CI_START="0.1010629711818756" LOG_EFFECT_SIZE="0.4283238451604475" ORDER="439" O_E="6.672131147540984" SE="0.3844693146849316" STUDY_ID="STD-Juul_x002d_Moller-1990" TOTAL_1="85" TOTAL_2="98" VAR="6.765137576747359" WEIGHT="8.871337885360472"/>
<DICH_DATA CI_END="9.159428728572776" CI_START="0.6604830545316773" EFFECT_SIZE="2.4596031111569494" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9618683876672693" LOG_CI_START="-0.1801383202414162" LOG_EFFECT_SIZE="0.3908650337129266" ORDER="440" O_E="2.0" SE="0.6708203932499369" STUDY_ID="STD-Kalusche-1994" TOTAL_1="41" TOTAL_2="41" VAR="2.2222222222222223" WEIGHT="2.914069960299072"/>
<DICH_DATA CI_END="1.3787272657267786" CI_START="0.7152105553962949" EFFECT_SIZE="0.9930157569044231" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="96" LOG_CI_END="0.13947836428718646" LOG_CI_START="-0.14556608465322163" LOG_EFFECT_SIZE="-0.0030438601830175822" ORDER="441" O_E="-0.25" SE="0.16743652030037412" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="383" VAR="35.66971343873517" WEIGHT="46.77481819093242"/>
<DICH_DATA CI_END="3.798197264903876" CI_START="0.49179251467144985" EFFECT_SIZE="1.366720521586363" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.5795775167028583" LOG_CI_START="-0.30821808572667153" LOG_EFFECT_SIZE="0.13567971548809332" ORDER="442" O_E="1.1487603305785132" SE="0.521495531526214" STUDY_ID="STD-SOCESP-1999" TOTAL_1="63" TOTAL_2="58" VAR="3.6770439177651806" WEIGHT="4.821823450556965"/>
<DICH_DATA CI_END="1.1775614081891173" CI_START="0.5437551607691379" EFFECT_SIZE="0.8001906602962857" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="53" LOG_CI_END="0.07098356424448655" LOG_CI_START="-0.26459660813767794" LOG_EFFECT_SIZE="-0.09680652194659574" ORDER="443" O_E="-5.73657289002557" SE="0.19712145440592738" STUDY_ID="STD-SOPAT-2004" TOTAL_1="518" TOTAL_2="264" VAR="25.735476299296028" WEIGHT="33.74774027899527"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.9136775693049466" CI_END="1.434246385266833" CI_START="0.31827858545869125" DF="1" EFFECT_SIZE="0.6756403708349352" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" I2="74.4485849359942" ID="CMP-002.06.05" LOG_CI_END="0.1566237640028689" LOG_CI_START="-0.4971925807631824" LOG_EFFECT_SIZE="-0.1702844083801567" NO="5" P_CHI2="0.047894743748085666" P_Z="0.3072862459456259" STUDIES="2" TAU2="0.0" TOTAL_1="145" TOTAL_2="152" WEIGHT="100.0" Z="1.020932897213638">
<NAME>Flecainide vs Propafenone</NAME>
<DICH_DATA CI_END="0.8615207521156919" CI_START="0.07088853952740959" EFFECT_SIZE="0.24712739202693995" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="-0.06473425690337457" LOG_CI_START="-1.1494239710555116" LOG_EFFECT_SIZE="-0.6070791139794431" ORDER="444" O_E="-3.443298969072165" SE="0.6371521073936454" STUDY_ID="STD-Aliot-1996" TOTAL_1="48" TOTAL_2="49" VAR="2.4632798384525456" WEIGHT="36.33293675703071"/>
<DICH_DATA CI_END="3.080944420783533" CI_START="0.4669596196336601" EFFECT_SIZE="1.1994484711072526" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.4886838638590577" LOG_CI_START="-0.33072067345639783" LOG_EFFECT_SIZE="0.07898159520132994" ORDER="445" O_E="0.7850000000000001" SE="0.4813222813369745" STUDY_ID="STD-FAPIS-1996" TOTAL_1="97" TOTAL_2="103" VAR="4.316463442211056" WEIGHT="63.667063242969284"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="34.14390492835936" CI_END="0.839682241644587" CI_START="0.3590848281600045" DF="4" EFFECT_SIZE="0.5491057761943083" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="62" I2="88.28487834536563" ID="CMP-002.06.06" LOG_CI_END="-0.07588503156744048" LOG_CI_START="-0.4448029440401387" LOG_EFFECT_SIZE="-0.26034398780378964" MODIFIED="2010-12-28 12:13:18 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="6.96228827035128E-7" P_Z="0.005670009364869114" STUDIES="5" TAU2="0.0" TOTAL_1="359" TOTAL_2="293" WEIGHT="100.00000000000001" Z="2.7662784724486644">
<NAME>Amiodarone vs Class I drugs</NAME>
<DICH_DATA CI_END="0.42983778522723937" CI_START="0.14204037412290502" EFFECT_SIZE="0.24709172350736067" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="47" LOG_CI_END="-0.36669541016983576" LOG_CI_START="-0.8475881924722299" LOG_EFFECT_SIZE="-0.6071418013210328" ORDER="446" O_E="-17.520000000000003" SE="0.28247880078209026" STUDY_ID="STD-AFFIRM-Substudy-2003" TOTAL_1="154" TOTAL_2="121" VAR="12.532227737226277" WEIGHT="58.852235938498026"/>
<DICH_DATA CI_END="16.36854481255196" CI_START="2.394939554373508" EFFECT_SIZE="6.261124133821018" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="2" LOG_CI_END="1.2140100717167703" LOG_CI_START="0.3792945567763384" LOG_EFFECT_SIZE="0.7966523142465544" ORDER="447" O_E="7.63013698630137" SE="0.49031602538444724" STUDY_ID="STD-Kochiadakis-2004a" TOTAL_1="72" TOTAL_2="74" VAR="4.159564128613118" WEIGHT="19.5336100357711"/>
<DICH_DATA CI_END="5.828368683347939" CI_START="0.21213520066312022" EFFECT_SIZE="1.1119362212738015" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="0.7655470160010466" LOG_CI_START="-0.6733872608312922" LOG_EFFECT_SIZE="0.046079877584877124" MODIFIED="2010-12-28 12:13:18 +0000" MODIFIED_BY="[Empty name]" ORDER="1013" O_E="0.14851485148514865" SE="0.8452371170508618" STUDY_ID="STD-PITAGORA-2008" TOTAL_1="70" TOTAL_2="31" VAR="1.399725517106166" WEIGHT="6.573210933373965"/>
<DICH_DATA CI_END="1.0930752208287218" CI_START="0.1011772438640445" EFFECT_SIZE="0.33255727052574247" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.038650049293504775" LOG_CI_START="-0.9949171552391721" LOG_EFFECT_SIZE="-0.4781335529728337" ORDER="448" O_E="-2.9868421052631575" SE="0.6071224921826704" STUDY_ID="STD-Villani-1992" TOTAL_1="35" TOTAL_2="41" VAR="2.7129847645429366" WEIGHT="12.740370092873023"/>
<DICH_DATA CI_END="15.251101319354364" CI_START="0.0563678520121386" EFFECT_SIZE="0.927184891050053" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1833012062827064" LOG_CI_START="-1.2489685143557785" LOG_EFFECT_SIZE="-0.03283365403653597" ORDER="449" O_E="-0.03703703703703698" SE="1.4287272738323407" STUDY_ID="STD-Vitolo-1981" TOTAL_1="28" TOTAL_2="26" VAR="0.48989310764293287" WEIGHT="2.300572999483893"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3505416971911117" CI_START="0.891265788245877" DF="0" EFFECT_SIZE="1.447396766112125" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="32" I2="0.0" ID="CMP-002.06.07" LOG_CI_END="0.3711679597146094" LOG_CI_START="-0.04999276380225886" LOG_EFFECT_SIZE="0.16058759795617525" MODIFIED="2010-12-28 11:03:00 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.13500336615178443" STUDIES="1" TAU2="0.0" TOTAL_1="255" TOTAL_2="249" WEIGHT="100.0" Z="1.494659358211951">
<NAME>Amiodarone vs Dronedarone</NAME>
<DICH_DATA CI_END="2.3505416971911117" CI_START="0.891265788245877" EFFECT_SIZE="1.447396766112125" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="32" LOG_CI_END="0.3711679597146094" LOG_CI_START="-0.04999276380225886" LOG_EFFECT_SIZE="0.16058759795617525" MODIFIED="2010-12-28 11:03:00 +0000" MODIFIED_BY="[Empty name]" ORDER="1005" O_E="6.041666666666664" SE="0.24739189377301268" STUDY_ID="STD-DYONISOS-2010" TOTAL_1="255" TOTAL_2="249" VAR="16.339135326927323" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.829527753771291" CI_END="1.7882357891570844" CI_START="0.6894960520020278" DF="4" EFFECT_SIZE="1.1103970085841102" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="35" I2="54.697463878614464" ID="CMP-002.06.08" LOG_CI_END="0.25242478245675365" LOG_CI_START="-0.16146821621567706" LOG_EFFECT_SIZE="0.045478283120538344" MODIFIED="2014-06-26 16:23:18 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.06550466975865066" P_Z="0.6666726759039558" STUDIES="5" TAU2="0.0" TOTAL_1="362" TOTAL_2="311" WEIGHT="100.0" Z="0.43071903743661133">
<NAME>Amiodarone vs Sotalol</NAME>
<DICH_DATA CI_END="1.5697132974810901" CI_START="0.418366109661492" EFFECT_SIZE="0.810379445414971" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="21" LOG_CI_END="0.1958203373186767" LOG_CI_START="-0.3784435033547631" LOG_EFFECT_SIZE="-0.09131158301804324" ORDER="450" O_E="-1.8477508650519034" SE="0.3373254226634356" STUDY_ID="STD-AFFIRM-Substudy-2003" TOTAL_1="154" TOTAL_2="135" VAR="8.788238886028662" WEIGHT="51.94613234960592"/>
<DICH_DATA CI_END="10.106702163379868" CI_START="1.1035462217533523" EFFECT_SIZE="3.33964264357495" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" LOG_CI_END="1.004609467570129" LOG_CI_START="0.04279052819275749" LOG_EFFECT_SIZE="0.5236999978814432" ORDER="451" O_E="3.7777777777777777" SE="0.5649772060708035" STUDY_ID="STD-Kochiadakis-2000" TOTAL_1="65" TOTAL_2="61" VAR="3.1328395061728402" WEIGHT="18.517805185797457"/>
<DICH_DATA CI_END="2.2811305295117315" CI_START="0.20745946360830467" EFFECT_SIZE="0.6879259524636585" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.3581501369315143" LOG_CI_START="-0.6830667493183916" LOG_EFFECT_SIZE="-0.16245830619343868" MODIFIED="2010-12-28 12:02:58 +0000" MODIFIED_BY="[Empty name]" ORDER="1009" O_E="-1.0" SE="0.611615953089906" STUDY_ID="STD-Niu-2006" TOTAL_1="51" TOTAL_2="51" VAR="2.673267326732673" WEIGHT="15.801334051250977"/>
<DICH_DATA CI_END="27.078062727739017" CI_START="0.7701808499361227" EFFECT_SIZE="4.566728081052525" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="1.4326175899706837" LOG_CI_START="-0.11340728403900148" LOG_EFFECT_SIZE="0.6596051529658411" MODIFIED="2010-12-28 12:12:39 +0000" MODIFIED_BY="[Empty name]" ORDER="1016" O_E="1.8415841584158414" SE="0.9081426639398406" STUDY_ID="STD-PITAGORA-2008" TOTAL_1="70" TOTAL_2="31" VAR="1.2125281835114203" WEIGHT="7.16709574183804"/>
<DICH_DATA CI_END="2.6100910268487043" CI_START="0.06333069863128885" EFFECT_SIZE="0.40656965974059917" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.41665565360982987" LOG_CI_START="-1.1983857210356832" LOG_EFFECT_SIZE="-0.3908650337129266" MODIFIED="2014-06-26 16:23:18 +0100" MODIFIED_BY="[Empty name]" ORDER="1068" O_E="-1.0" SE="0.9486832980505138" STUDY_ID="STD-Vijayalaskshmi-2006" TOTAL_1="22" TOTAL_2="33" VAR="1.1111111111111112" WEIGHT="6.567632671507608"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.948367733879676" CI_END="0.7163366910881273" CI_START="0.2778863696974541" DF="2" EFFECT_SIZE="0.4461616327829706" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="56" I2="71.21626147896343" ID="CMP-002.06.09" LOG_CI_END="-0.14488280351259203" LOG_CI_START="-0.5561327548072162" LOG_EFFECT_SIZE="-0.35050777915990416" MODIFIED="2010-12-28 10:59:48 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.030987145239196878" P_Z="8.349246069150396E-4" STUDIES="4" TAU2="0.0" TOTAL_1="290" TOTAL_2="277" WEIGHT="100.0" Z="3.3409493243313184">
<NAME>Sotalol vs Class I drugs other than quinidine</NAME>
<DICH_DATA CI_END="0.530099132271171" CI_START="0.17488993975657552" EFFECT_SIZE="0.30448153524954197" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="47" LOG_CI_END="-0.2756429066774608" LOG_CI_START="-0.7572351718470306" LOG_EFFECT_SIZE="-0.5164390392622457" ORDER="452" O_E="-14.859375" SE="0.2828896804807652" STUDY_ID="STD-AFFIRM-Substudy-2003" TOTAL_1="135" TOTAL_2="121" VAR="12.495849609375" WEIGHT="72.92101630254963"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="453" O_E="0.0" SE="0.0" STUDY_ID="STD-Carunchio-1995" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.6187830392512392" CI_START="0.28324656170758444" EFFECT_SIZE="1.012426715092819" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.55856254616968" LOG_CI_START="-0.5478353532756376" LOG_EFFECT_SIZE="0.005363596447021193" ORDER="454" O_E="0.029239766081871288" SE="0.6499036028921098" STUDY_ID="STD-Kochiadakis-2004b" TOTAL_1="85" TOTAL_2="86" VAR="2.367566088711056" WEIGHT="13.816213442800686"/>
<DICH_DATA CI_END="5.697873459025356" CI_START="0.4231227182833231" EFFECT_SIZE="1.552707218511336" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7557128000004636" LOG_CI_START="-0.37353365592560206" LOG_EFFECT_SIZE="0.1910895720374308" ORDER="455" O_E="1.0" SE="0.6633249580710799" STUDY_ID="STD-Reimold-1993" TOTAL_1="50" TOTAL_2="50" VAR="2.272727272727273" WEIGHT="13.262770254649686"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.7562149498004604" CI_START="1.2428214114094918" DF="0" EFFECT_SIZE="2.6746863719485736" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="22" I2="0.0" ID="CMP-002.06.10" LOG_CI_END="0.7601370030841" LOG_CI_START="0.09440872670145223" LOG_EFFECT_SIZE="0.42727286489277605" MODIFIED="2010-12-28 10:59:44 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Z="0.011874248558977528" STUDIES="1" TAU2="0.0" TOTAL_1="108" TOTAL_2="321" WEIGHT="100.0" Z="2.515859567544479">
<NAME>Sotalol vs Dofetilide</NAME>
<DICH_DATA CI_END="5.7562149498004604" CI_START="1.2428214114094915" EFFECT_SIZE="2.6746863719485736" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="22" LOG_CI_END="0.7601370030841" LOG_CI_START="0.09440872670145216" LOG_EFFECT_SIZE="0.42727286489277605" MODIFIED="2010-12-28 10:55:11 +0000" MODIFIED_BY="[Empty name]" ORDER="1001" O_E="6.433566433566433" SE="0.3910520849552831" STUDY_ID="STD-EMERALD-2000" TOTAL_1="108" TOTAL_2="321" VAR="6.539292874957211" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.4666411971729236" CI_END="7.108378887807169" CI_START="1.1485596046166333" DF="1" EFFECT_SIZE="2.8573408695577474" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" I2="31.816997781898838" ID="CMP-002.06.11" LOG_CI_END="0.8517705683311365" LOG_CI_START="0.060153537871846824" LOG_EFFECT_SIZE="0.4559620531014916" MODIFIED="2010-12-28 10:59:41 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.22587669797823295" P_Z="0.023956124203100216" STUDIES="2" TAU2="0.0" TOTAL_1="133" TOTAL_2="130" WEIGHT="100.0" Z="2.2578321789700855">
<NAME>Sotalol vs Other Beta-blockers</NAME>
<DICH_DATA CI_END="13.631820050462816" CI_START="1.395188919697957" EFFECT_SIZE="4.361073754217207" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="1.134553844470245" LOG_CI_START="0.14463301852517244" LOG_EFFECT_SIZE="0.6395934314977088" MODIFIED="2010-12-27 14:14:31 +0000" MODIFIED_BY="[Empty name]" ORDER="919" O_E="4.355555555555555" SE="0.5814843933472533" STUDY_ID="STD-DAPHNE-2008" TOTAL_1="69" TOTAL_2="66" VAR="2.9574940114243597" WEIGHT="63.948348872183146"/>
<DICH_DATA CI_END="6.158078173696388" CI_START="0.2958209602781121" EFFECT_SIZE="1.3496994475847384" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7894451977515701" LOG_CI_START="-0.5289710574837401" LOG_EFFECT_SIZE="0.13023707013391495" MODIFIED="2010-12-27 14:12:10 +0000" MODIFIED_BY="[Empty name]" ORDER="918" O_E="0.5" SE="0.7744442345909389" STUDY_ID="STD-Plewan-2001" TOTAL_1="64" TOTAL_2="64" VAR="1.6673228346456692" WEIGHT="36.05165112781685"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="62.20019507416899" CI_END="0.9630260657318043" CI_START="0.6540766358638787" DF="11" EFFECT_SIZE="0.793657891867198" ESTIMABLE="YES" EVENTS_1="244" EVENTS_2="299" I2="82.31516800408208" ID="CMP-002.06.12" LOG_CI_END="-0.016361957890741793" LOG_CI_START="-0.18437136393425957" LOG_EFFECT_SIZE="-0.10036666091250067" MODIFIED="2010-12-28 10:59:39 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="3.608358611906226E-9" P_Z="0.019195386419710136" STUDIES="13" TAU2="0.0" TOTAL_1="1448" TOTAL_2="1527" WEIGHT="100.00000000000001" Z="2.3417146131222233">
<NAME>Class III vs Class I drugs</NAME>
<DICH_DATA CI_END="0.38951567057091196" CI_START="0.1387051180233776" EFFECT_SIZE="0.23243884584658697" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="47" LOG_CI_END="-0.4094750655765903" LOG_CI_START="-0.8579075137767307" LOG_EFFECT_SIZE="-0.6336912896766604" ORDER="456" O_E="-21.02926829268293" SE="0.2634114398491811" STUDY_ID="STD-AFFIRM-Substudy-2003" TOTAL_1="289" TOTAL_2="121" VAR="14.412215106562774" WEIGHT="14.036962266384537"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="457" O_E="0.0" SE="0.0" STUDY_ID="STD-Carunchio-1995" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.4813538060865593" CI_START="0.034022425569835736" EFFECT_SIZE="0.12797196583758924" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="10" LOG_CI_END="-0.31753558984890756" LOG_CI_START="-1.4682347273476808" LOG_EFFECT_SIZE="-0.8928851585982942" ORDER="458" O_E="-4.5" SE="0.6759263694193747" STUDY_ID="STD-Hohnloser-1995" TOTAL_1="25" TOTAL_2="25" VAR="2.1887755102040813" WEIGHT="2.1317860591971614"/>
<DICH_DATA CI_END="0.792386428887968" CI_START="0.17555583987042106" EFFECT_SIZE="0.3729719359755515" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="22" LOG_CI_END="-0.1010629711818755" LOG_CI_START="-0.7555847191390194" LOG_EFFECT_SIZE="-0.4283238451604474" ORDER="459" O_E="-6.672131147540984" SE="0.3844693146849316" STUDY_ID="STD-Juul_x002d_Moller-1990" TOTAL_1="98" TOTAL_2="85" VAR="6.76513757674736" WEIGHT="6.588992752991922"/>
<DICH_DATA CI_END="1.51404338557794" CI_START="0.1091771146032838" EFFECT_SIZE="0.40656965974059917" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.18013832024141618" LOG_CI_START="-0.9618683876672693" LOG_EFFECT_SIZE="-0.3908650337129266" ORDER="460" O_E="-2.0" SE="0.6708203932499369" STUDY_ID="STD-Kalusche-1994" TOTAL_1="41" TOTAL_2="41" VAR="2.2222222222222223" WEIGHT="2.164361914543609"/>
<DICH_DATA CI_END="16.36854481255196" CI_START="2.394939554373508" EFFECT_SIZE="6.261124133821018" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="2" LOG_CI_END="1.2140100717167703" LOG_CI_START="0.3792945567763384" LOG_EFFECT_SIZE="0.7966523142465544" ORDER="461" O_E="7.63013698630137" SE="0.49031602538444724" STUDY_ID="STD-Kochiadakis-2004a" TOTAL_1="72" TOTAL_2="74" VAR="4.159564128613118" WEIGHT="4.051260981482403"/>
<DICH_DATA CI_END="3.6187830392512392" CI_START="0.28324656170758444" EFFECT_SIZE="1.012426715092819" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.55856254616968" LOG_CI_START="-0.5478353532756376" LOG_EFFECT_SIZE="0.005363596447021193" ORDER="462" O_E="0.029239766081871288" SE="0.6499036028921098" STUDY_ID="STD-Kochiadakis-2004b" TOTAL_1="85" TOTAL_2="86" VAR="2.367566088711056" WEIGHT="2.305921442657033"/>
<DICH_DATA CI_END="1.3981896554167947" CI_START="0.7253066105665668" EFFECT_SIZE="1.00703336583233" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="94" LOG_CI_END="0.14556608465322157" LOG_CI_START="-0.13947836428718643" LOG_EFFECT_SIZE="0.003043860183017605" ORDER="463" O_E="0.25" SE="0.16743652030037412" STUDY_ID="STD-PAFAC-2004" TOTAL_1="383" TOTAL_2="377" VAR="35.66971343873517" WEIGHT="34.740976171267235"/>
<DICH_DATA CI_END="5.697873459025356" CI_START="0.4231227182833231" EFFECT_SIZE="1.552707218511336" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7557128000004636" LOG_CI_START="-0.37353365592560206" LOG_EFFECT_SIZE="0.1910895720374308" ORDER="464" O_E="1.0" SE="0.6633249580710799" STUDY_ID="STD-Reimold-1993" TOTAL_1="50" TOTAL_2="50" VAR="2.272727272727273" WEIGHT="2.2135519580559637"/>
<DICH_DATA CI_END="2.033377837537984" CI_START="0.2632827971417403" EFFECT_SIZE="0.7316784845224189" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.30821808572667153" LOG_CI_START="-0.5795775167028583" LOG_EFFECT_SIZE="-0.13567971548809335" ORDER="465" O_E="-1.1487603305785132" SE="0.521495531526214" STUDY_ID="STD-SOCESP-1999" TOTAL_1="58" TOTAL_2="63" VAR="3.6770439177651806" WEIGHT="3.5813042161718305"/>
<DICH_DATA CI_END="1.8390630050949903" CI_START="0.8492126126465241" EFFECT_SIZE="1.2497021642688648" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="87" LOG_CI_END="0.2645966081376781" LOG_CI_START="-0.0709835642444864" LOG_EFFECT_SIZE="0.09680652194659585" ORDER="466" O_E="5.7365728900255775" SE="0.19712145440592738" STUDY_ID="STD-SOPAT-2004" TOTAL_1="264" TOTAL_2="518" VAR="25.735476299296028" WEIGHT="25.06539813967621"/>
<DICH_DATA CI_END="1.0930752208287218" CI_START="0.1011772438640445" EFFECT_SIZE="0.33255727052574247" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.038650049293504775" LOG_CI_START="-0.9949171552391721" LOG_EFFECT_SIZE="-0.4781335529728337" ORDER="467" O_E="-2.9868421052631575" SE="0.6071224921826704" STUDY_ID="STD-Villani-1992" TOTAL_1="35" TOTAL_2="41" VAR="2.7129847645429366" WEIGHT="2.642346404601206"/>
<DICH_DATA CI_END="15.251101319354364" CI_START="0.0563678520121386" EFFECT_SIZE="0.927184891050053" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1833012062827064" LOG_CI_START="-1.2489685143557785" LOG_EFFECT_SIZE="-0.03283365403653597" ORDER="468" O_E="-0.03703703703703698" SE="1.4287272738323407" STUDY_ID="STD-Vitolo-1981" TOTAL_1="28" TOTAL_2="26" VAR="0.48989310764293287" WEIGHT="0.4771376929708994"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="48.79046917002173" CI_END="2.4768304746221825" CI_START="1.7702644909467298" CI_STUDY="95" CI_TOTAL="95" DF="34" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.093954402397145" ESTIMABLE="YES" EVENTS_1="696" EVENTS_2="158" I2="30.314258955946705" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="0.39389628254237824" LOG_CI_START="0.24803815810036772" LOG_EFFECT_SIZE="0.320967220321373" METHOD="PETO" MODIFIED="2014-09-24 16:45:31 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.04817219368687631" P_Q="0.6232444696860144" P_Z="6.354947707687935E-18" Q="3.500946982218019" RANDOM="NO" SCALE="46.444823954952135" SORT_BY="STUDY" STUDIES="19" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="4204" TOTAL_2="2320" WEIGHT="600.0" Z="8.625973965515117">
<NAME>Subgroup analysis: Persistent atrial fibrillation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.809460215899666" CI_END="2.788462162322947" CI_START="1.2564280447179632" DF="4" EFFECT_SIZE="1.8717644249150172" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="32" I2="62.9953770113665" ID="CMP-002.07.01" LOG_CI_END="0.4453647557646993" LOG_CI_START="0.09913762171749378" LOG_EFFECT_SIZE="0.2722511887410966" NO="1" P_CHI2="0.02879104375968855" P_Z="0.002053496064067586" STUDIES="5" TAU2="0.0" TOTAL_1="595" TOTAL_2="282" WEIGHT="100.0" Z="3.0823842050924477">
<NAME>Class Ia: Quinidine</NAME>
<DICH_DATA CI_END="4.727279277530424" CI_START="0.5839521131312015" EFFECT_SIZE="1.6614766695548966" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.6746112602482437" LOG_CI_START="-0.23362276565400186" LOG_EFFECT_SIZE="0.22049424729712094" ORDER="469" O_E="1.7837837837837842" SE="0.5335011626459151" STUDY_ID="STD-Byrne_x002d_Quinn-1970" TOTAL_1="32" TOTAL_2="42" VAR="3.513413450473799" WEIGHT="14.53204269833964"/>
<DICH_DATA CI_END="82.64084546794376" CI_START="0.8505035136266731" EFFECT_SIZE="8.383694259666504" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.91719475164061" LOG_CI_START="-0.0703238878767813" LOG_EFFECT_SIZE="0.9234354318819143" ORDER="470" O_E="1.56" SE="1.1674782872284526" STUDY_ID="STD-Hillestad-1971" TOTAL_1="48" TOTAL_2="52" VAR="0.7336727272727273" WEIGHT="3.034588314078658"/>
<DICH_DATA CI_END="56.32059641298373" CI_START="0.9865240347640378" EFFECT_SIZE="7.453966864271246" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.7506672451663057" LOG_CI_START="-0.005892329531666832" LOG_EFFECT_SIZE="0.8723874578173194" ORDER="471" O_E="1.8867924528301887" SE="1.0318117892877168" STUDY_ID="STD-Lloyd-1984" TOTAL_1="28" TOTAL_2="25" VAR="0.9392885505381054" WEIGHT="3.8850484051743375"/>
<DICH_DATA CI_END="1.9305216969464964" CI_START="0.6571482859917904" EFFECT_SIZE="1.1263387697395277" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="20" LOG_CI_END="0.2856746869811433" LOG_CI_START="-0.18233662051403673" LOG_EFFECT_SIZE="0.051669033233553305" ORDER="472" O_E="1.5741935483871003" SE="0.274912158716004" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="88" VAR="13.231592091571281" WEIGHT="54.727991439719936"/>
<DICH_DATA CI_END="9.648936448053911" CI_START="1.8840217766644973" EFFECT_SIZE="4.263661148565321" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="3" LOG_CI_END="0.9844794459659073" LOG_CI_START="0.27508591832446344" LOG_EFFECT_SIZE="0.6297826821451853" ORDER="473" O_E="8.35135135135135" SE="0.41670126969117954" STUDY_ID="STD-Sodermark-1975" TOTAL_1="110" TOTAL_2="75" VAR="5.759043414742592" WEIGHT="23.82032914268744"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="14.353590522768133" CI_END="3.081123802306995" CI_START="1.4756864678916783" DF="7" EFFECT_SIZE="2.132316276016151" ESTIMABLE="YES" EVENTS_1="154" EVENTS_2="34" I2="51.2317145393247" ID="CMP-002.07.02" LOG_CI_END="0.4887091490078086" LOG_CI_START="0.16899409479819255" LOG_EFFECT_SIZE="0.32885162190300055" NO="2" P_CHI2="0.045238162430551454" P_Z="5.531628321785467E-5" STUDIES="8" TAU2="0.0" TOTAL_1="758" TOTAL_2="375" WEIGHT="100.0" Z="4.031948616125432">
<NAME>All class I antiarrhythmics</NAME>
<DICH_DATA CI_END="4.727279277530424" CI_START="0.5839521131312015" EFFECT_SIZE="1.6614766695548966" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.6746112602482437" LOG_CI_START="-0.23362276565400186" LOG_EFFECT_SIZE="0.22049424729712094" ORDER="474" O_E="1.7837837837837842" SE="0.5335011626459151" STUDY_ID="STD-Byrne_x002d_Quinn-1970" TOTAL_1="32" TOTAL_2="42" VAR="3.513413450473799" WEIGHT="12.391692726178245"/>
<DICH_DATA CI_END="82.64084546794376" CI_START="0.8505035136266731" EFFECT_SIZE="8.383694259666504" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.91719475164061" LOG_CI_START="-0.0703238878767813" LOG_EFFECT_SIZE="0.9234354318819143" ORDER="475" O_E="1.56" SE="1.1674782872284526" STUDY_ID="STD-Hillestad-1971" TOTAL_1="48" TOTAL_2="52" VAR="0.7336727272727273" WEIGHT="2.5876393786546212"/>
<DICH_DATA CI_END="13.281487866698253" CI_START="0.8607433866821024" EFFECT_SIZE="3.3811171003913936" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.1232467298589253" LOG_CI_START="-0.06512630540923559" LOG_EFFECT_SIZE="0.5290602122248449" ORDER="476" O_E="2.5" SE="0.6980562034579147" STUDY_ID="STD-Karlson-1998" TOTAL_1="46" TOTAL_2="46" VAR="2.0521978021978025" WEIGHT="7.23803359230156"/>
<DICH_DATA CI_END="27.871975962080842" CI_START="0.7701732851760609" EFFECT_SIZE="4.633168601622868" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="1.4451677587746075" LOG_CI_START="-0.11341154972502382" LOG_EFFECT_SIZE="0.6658781045247919" ORDER="477" O_E="1.8292682926829267" SE="0.9155172009046879" STUDY_ID="STD-Lloyd-1984" TOTAL_1="57" TOTAL_2="25" VAR="1.1930729063388195" WEIGHT="4.20792857535323"/>
<DICH_DATA CI_END="150.13826080578548" CI_START="0.07523056855345664" EFFECT_SIZE="3.3608014999470575" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.176491380713628" LOG_CI_START="-1.1236056559968985" LOG_EFFECT_SIZE="0.5264428623583648" ORDER="478" O_E="0.32258064516129026" SE="1.9384933351075546" STUDY_ID="STD-Okishige-2000" TOTAL_1="52" TOTAL_2="10" VAR="0.26611623820815067" WEIGHT="0.9385831470751494"/>
<DICH_DATA CI_END="1.9305216969464964" CI_START="0.6571482859917904" EFFECT_SIZE="1.1263387697395277" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="20" LOG_CI_END="0.2856746869811433" LOG_CI_START="-0.18233662051403673" LOG_EFFECT_SIZE="0.051669033233553305" ORDER="479" O_E="1.5741935483871003" SE="0.274912158716004" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="88" VAR="13.231592091571281" WEIGHT="46.66738651403821"/>
<DICH_DATA CI_END="9.648936448053911" CI_START="1.8840217766644973" EFFECT_SIZE="4.263661148565321" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="3" LOG_CI_END="0.9844794459659073" LOG_CI_START="0.27508591832446344" LOG_EFFECT_SIZE="0.6297826821451853" ORDER="480" O_E="8.35135135135135" SE="0.41670126969117954" STUDY_ID="STD-Sodermark-1975" TOTAL_1="110" TOTAL_2="75" VAR="5.759043414742592" WEIGHT="20.3119551394063"/>
<DICH_DATA CI_END="42.93727702849919" CI_START="1.9435224978817696" EFFECT_SIZE="9.13507328392445" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="1.6328344991362287" LOG_CI_START="0.2885895723145221" LOG_EFFECT_SIZE="0.9607120357253753" ORDER="481" O_E="3.547945205479452" SE="0.7896161241347744" STUDY_ID="STD-Van-Gelder-1989" TOTAL_1="36" TOTAL_2="37" VAR="1.6038656408331768" WEIGHT="5.656780926992669"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.36081507599797824" CI_END="7.2489020633928325" CI_START="1.5731868458628622" DF="1" EFFECT_SIZE="3.376962743809556" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="6" I2="0.0" ID="CMP-002.07.03" LOG_CI_END="0.8602722322373512" LOG_CI_START="0.1967803064174341" LOG_EFFECT_SIZE="0.5285262693273927" MODIFIED="2010-12-27 14:27:03 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5480541534078749" P_Z="0.0017929330762439001" STUDIES="2" TAU2="0.0" TOTAL_1="280" TOTAL_2="282" WEIGHT="100.0" Z="3.1225472758689303">
<NAME>Class II antiarrhythmics</NAME>
<DICH_DATA CI_END="6.990335182622399" CI_START="1.4270918714409915" EFFECT_SIZE="3.1584569836818113" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="6" LOG_CI_END="0.8444980004199777" LOG_CI_START="0.1544519324528029" LOG_EFFECT_SIZE="0.49947496643639033" ORDER="482" O_E="7.0" SE="0.405336476107044" STUDY_ID="STD-Kuhlkamp-2000" TOTAL_1="197" TOTAL_2="197" VAR="6.086513994910942" WEIGHT="92.45174513411236"/>
<DICH_DATA CI_END="123.54811742880564" CI_START="0.4751849318665752" EFFECT_SIZE="7.662127887385501" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0918361322026024" LOG_CI_START="-0.3231373393041214" LOG_EFFECT_SIZE="0.8843493964492404" MODIFIED="2010-12-27 14:27:03 +0000" MODIFIED_BY="[Empty name]" ORDER="937" O_E="1.0119047619047619" SE="1.4185673714745302" STUDY_ID="STD-Nergardh-2007" TOTAL_1="83" TOTAL_2="85" VAR="0.4969355506673727" WEIGHT="7.548254865887637"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.464335117697102" CI_END="2.740863414829894" CI_START="1.3520366650499307" DF="5" EFFECT_SIZE="1.9250319038249661" ESTIMABLE="YES" EVENTS_1="154" EVENTS_2="39" I2="40.92861482355446" ID="CMP-002.07.04" LOG_CI_END="0.4378873939256126" LOG_CI_START="0.13098846912999051" LOG_EFFECT_SIZE="0.2844379315278015" MODIFIED="2014-06-26 16:19:19 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.1324340583493585" P_Z="2.8010110384438155E-4" STUDIES="6" TAU2="0.0" TOTAL_1="835" TOTAL_2="515" WEIGHT="100.0" Z="3.63304043507365">
<NAME>Class III: Sotalol</NAME>
<DICH_DATA CI_END="4.995946911229559" CI_START="1.4225449776921204" EFFECT_SIZE="2.6658880673025402" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="12" LOG_CI_END="0.6986178147536282" LOG_CI_START="0.1530660067048519" LOG_EFFECT_SIZE="0.4258419107292401" ORDER="874" O_E="9.548098434004473" SE="0.32045983257285454" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="223" TOTAL_2="224" VAR="9.737619426552357" WEIGHT="31.64599352889389"/>
<DICH_DATA CI_END="9.16690381264253" CI_START="1.4602886681119756" EFFECT_SIZE="3.658732807854976" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="4" LOG_CI_END="0.9622226743676763" LOG_CI_START="0.16443871508314936" LOG_EFFECT_SIZE="0.5633306947254129" MODIFIED="2010-12-28 10:45:43 +0000" MODIFIED_BY="[Empty name]" ORDER="982" O_E="5.906542056074766" SE="0.46862224677801984" STUDY_ID="STD-EMERALD-2000" TOTAL_1="108" TOTAL_2="106" VAR="4.553592847151913" WEIGHT="14.798583048054814"/>
<DICH_DATA CI_END="1.9403740263898828" CI_START="0.6626459972714737" EFFECT_SIZE="1.1339228729489448" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="20" LOG_CI_END="0.2878854525799555" LOG_CI_START="-0.17871842105314945" LOG_EFFECT_SIZE="0.05458351576340305" ORDER="483" O_E="1.6730360934182613" SE="0.27408542509851114" STUDY_ID="STD-PAFAC-2004" TOTAL_1="383" TOTAL_2="88" VAR="13.311534320104863" WEIGHT="43.26075095983034"/>
<DICH_DATA CI_END="6.158078173696388" CI_START="0.2958209602781121" EFFECT_SIZE="1.3496994475847384" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7894451977515701" LOG_CI_START="-0.5289710574837401" LOG_EFFECT_SIZE="0.13023707013391495" ORDER="484" O_E="0.5" SE="0.7744442345909389" STUDY_ID="STD-Plewan-2001" TOTAL_1="64" TOTAL_2="64" VAR="1.6673228346456692" WEIGHT="5.41858182420826"/>
<DICH_DATA CI_END="58.58069836700783" CI_START="0.348444529528686" EFFECT_SIZE="4.517977853194271" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.7677545447974399" LOG_CI_START="-0.45786634937956794" LOG_EFFECT_SIZE="0.6549440977089361" ORDER="485" O_E="0.8823529411764706" SE="1.3073407302406808" STUDY_ID="STD-Singh-1991" TOTAL_1="24" TOTAL_2="10" VAR="0.5850896508335955" WEIGHT="1.9014650802242663"/>
<DICH_DATA CI_END="46.688986440711915" CI_START="0.7758743354774353" EFFECT_SIZE="6.018703043746413" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.6692144460450964" LOG_CI_START="-0.11020861357188443" LOG_EFFECT_SIZE="0.779502916236606" MODIFIED="2014-06-26 16:19:19 +0100" MODIFIED_BY="[Empty name]" ORDER="1061" O_E="1.6428571428571428" SE="1.0452419135052178" STUDY_ID="STD-Vijayalaskshmi-2006" TOTAL_1="33" TOTAL_2="23" VAR="0.9153061224489796" WEIGHT="2.974625558788429"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.18126069640289122" CI_END="12.73626981067943" CI_START="1.3646602198494677" DF="2" EFFECT_SIZE="4.169014363120368" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="1" I2="0.0" ID="CMP-002.07.05" LOG_CI_END="1.1050422507742517" LOG_CI_START="0.1350245319528806" LOG_EFFECT_SIZE="0.6200333913635662" MODIFIED="2014-09-24 16:29:42 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.9133553191766222" P_Z="0.012224031995927802" STUDIES="3" TAU2="0.0" TOTAL_1="129" TOTAL_2="76" WEIGHT="100.0" Z="2.5056101403207567">
<NAME>Class III: Amiodarone</NAME>
<DICH_DATA CI_END="14.26040858186083" CI_START="0.8639985230624987" EFFECT_SIZE="3.5101242076307697" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.1541319688752796" LOG_CI_START="-0.06348699991272148" LOG_EFFECT_SIZE="0.545322484481279" MODIFIED="2014-09-24 15:24:20 +0100" MODIFIED_BY="[Empty name]" ORDER="1075" O_E="2.454545454545454" SE="0.7152354095771745" STUDY_ID="STD-Channer-2004" TOTAL_1="61" TOTAL_2="38" VAR="1.9547984483049416" WEIGHT="63.465327342002"/>
<DICH_DATA CI_END="300.5347791914292" CI_START="0.05793575076459642" EFFECT_SIZE="4.172733883598098" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.4778947376928846" LOG_CI_START="-1.2370533608264507" LOG_EFFECT_SIZE="0.6204206884332171" MODIFIED="2014-09-24 15:24:27 +0100" MODIFIED_BY="[Empty name]" ORDER="1076" O_E="0.30000000000000004" SE="2.182178902359924" STUDY_ID="STD-GEFACA-2001" TOTAL_1="35" TOTAL_2="15" VAR="0.20999999999999996" WEIGHT="6.817950338244457"/>
<DICH_DATA CI_END="46.688986440711915" CI_START="0.7758743354774353" EFFECT_SIZE="6.018703043746413" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.6692144460450964" LOG_CI_START="-0.11020861357188443" LOG_EFFECT_SIZE="0.779502916236606" MODIFIED="2014-09-24 16:29:42 +0100" MODIFIED_BY="[Empty name]" ORDER="1078" O_E="1.6428571428571428" SE="1.0452419135052178" STUDY_ID="STD-Vijayalaskshmi-2006" TOTAL_1="33" TOTAL_2="23" VAR="0.9153061224489796" WEIGHT="29.716722319753544"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="11.120060559037952" CI_END="2.7895908670105354" CI_START="1.5371530412814685" DF="10" EFFECT_SIZE="2.0707554382775992" ESTIMABLE="YES" EVENTS_1="217" EVENTS_2="46" I2="10.072432187679148" ID="CMP-002.07.06" LOG_CI_END="0.4455405125105138" LOG_CI_START="0.18671710866777258" LOG_EFFECT_SIZE="0.31612881058914316" MODIFIED="2014-09-24 16:45:31 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.3482411506377099" P_Z="1.685953109304011E-6" STUDIES="10" TAU2="0.0" TOTAL_1="1607" TOTAL_2="790" WEIGHT="99.99999999999999" Z="4.787828875063164">
<NAME>All class III antiarrhythmics</NAME>
<DICH_DATA CI_END="4.995946911229559" CI_START="1.4225449776921204" EFFECT_SIZE="2.6658880673025402" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="12" LOG_CI_END="0.6986178147536282" LOG_CI_START="0.1530660067048519" LOG_EFFECT_SIZE="0.4258419107292401" ORDER="875" O_E="9.548098434004473" SE="0.32045983257285454" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="223" TOTAL_2="224" VAR="9.737619426552357" WEIGHT="22.507905855255032"/>
<DICH_DATA CI_END="14.26040858186083" CI_START="0.8639985230624987" EFFECT_SIZE="3.5101242076307697" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.1541319688752796" LOG_CI_START="-0.06348699991272148" LOG_EFFECT_SIZE="0.545322484481279" ORDER="486" O_E="2.454545454545454" SE="0.7152354095771745" STUDY_ID="STD-Channer-2004" TOTAL_1="61" TOTAL_2="38" VAR="1.9547984483049416" WEIGHT="4.518395874095489"/>
<DICH_DATA CI_END="12.271779417734178" CI_START="1.5545355138408892" EFFECT_SIZE="4.3677130083018785" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="0" LOG_CI_END="1.0889075403368307" LOG_CI_START="0.1916006480832641" LOG_EFFECT_SIZE="0.6402540942100473" ORDER="487" O_E="5.306532663316585" SE="0.5270825102504971" STUDY_ID="STD-DAFNE-2003" TOTAL_1="151" TOTAL_2="48" VAR="3.599505063003459" WEIGHT="8.32003362779605"/>
<DICH_DATA CI_END="9.16690381264253" CI_START="1.4602886681119756" EFFECT_SIZE="3.658732807854976" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="4" LOG_CI_END="0.9622226743676763" LOG_CI_START="0.16443871508314936" LOG_EFFECT_SIZE="0.5633306947254129" MODIFIED="2010-12-28 10:45:45 +0000" MODIFIED_BY="[Empty name]" ORDER="983" O_E="5.906542056074766" SE="0.46862224677801984" STUDY_ID="STD-EMERALD-2000" TOTAL_1="108" TOTAL_2="106" VAR="4.553592847151913" WEIGHT="10.525348611117947"/>
<DICH_DATA CI_END="4.2821937757911925" CI_START="0.6840436439670202" EFFECT_SIZE="1.711492750368841" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="4" LOG_CI_END="0.6316663158899293" LOG_CI_START="-0.16491618814923806" LOG_EFFECT_SIZE="0.23337506387034557" MODIFIED="2010-12-28 10:34:16 +0000" MODIFIED_BY="[Empty name]" ORDER="962" O_E="2.4543325526932094" SE="0.4679165060195961" STUDY_ID="STD-EMERALD-2000" TOTAL_1="321" TOTAL_2="106" VAR="4.5673392294489465" WEIGHT="10.557122524744956"/>
<DICH_DATA CI_END="300.5347791914292" CI_START="0.05793575076459642" EFFECT_SIZE="4.172733883598098" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.4778947376928846" LOG_CI_START="-1.2370533608264507" LOG_EFFECT_SIZE="0.6204206884332171" ORDER="488" O_E="0.30000000000000004" SE="2.182178902359924" STUDY_ID="STD-GEFACA-2001" TOTAL_1="35" TOTAL_2="15" VAR="0.20999999999999996" WEIGHT="0.4854020292387879"/>
<DICH_DATA CI_END="1.9403740263898828" CI_START="0.6626459972714737" EFFECT_SIZE="1.1339228729489448" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="20" LOG_CI_END="0.2878854525799555" LOG_CI_START="-0.17871842105314945" LOG_EFFECT_SIZE="0.05458351576340305" ORDER="489" O_E="1.6730360934182613" SE="0.27408542509851114" STUDY_ID="STD-PAFAC-2004" TOTAL_1="383" TOTAL_2="88" VAR="13.311534320104863" WEIGHT="30.768789386955575"/>
<DICH_DATA CI_END="6.158078173696388" CI_START="0.2958209602781121" EFFECT_SIZE="1.3496994475847384" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7894451977515701" LOG_CI_START="-0.5289710574837401" LOG_EFFECT_SIZE="0.13023707013391495" ORDER="490" O_E="0.5" SE="0.7744442345909389" STUDY_ID="STD-Plewan-2001" TOTAL_1="64" TOTAL_2="64" VAR="1.6673228346456692" WEIGHT="3.8539137492056"/>
<DICH_DATA CI_END="6.233831862441262" CI_START="0.4143574308642299" EFFECT_SIZE="1.6071821785226275" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="0.7947550844023693" LOG_CI_START="-0.382624868345819" LOG_EFFECT_SIZE="0.20606510802827518" ORDER="491" O_E="0.9920000000000009" SE="0.6915988123690467" STUDY_ID="STD-SAFIRE_x002d_D-2000" TOTAL_1="182" TOTAL_2="68" VAR="2.0906990522088353" WEIGHT="4.8325217260465685"/>
<DICH_DATA CI_END="58.58069836700783" CI_START="0.348444529528686" EFFECT_SIZE="4.517977853194271" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.7677545447974399" LOG_CI_START="-0.45786634937956794" LOG_EFFECT_SIZE="0.6549440977089361" ORDER="492" O_E="0.8823529411764706" SE="1.3073407302406808" STUDY_ID="STD-Singh-1991" TOTAL_1="24" TOTAL_2="10" VAR="0.5850896508335955" WEIGHT="1.35239858952972"/>
<DICH_DATA CI_END="32.1404098269527" CI_START="0.619815584455133" EFFECT_SIZE="4.463308963260351" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.5070514102135524" LOG_CI_START="-0.20773750819067308" LOG_EFFECT_SIZE="0.6496569510114397" MODIFIED="2014-09-24 16:45:21 +0100" MODIFIED_BY="[Empty name]" ORDER="1057" O_E="1.4743589743589745" SE="1.0072754990126864" STUDY_ID="STD-Vijayalaskshmi-2006" TOTAL_1="55" TOTAL_2="23" VAR="0.9856062740678125" WEIGHT="2.2781680260142725"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="72.61699601163905" CI_END="1.4654138932650917" CI_START="1.1676852780686384" CI_STUDY="95" CI_TOTAL="95" DF="18" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.3081063524969576" ESTIMABLE="YES" EVENTS_1="1118" EVENTS_2="533" I2="75.2124144640809" I2_Q="83.6366582726344" ID="CMP-002.08" LOG_CI_END="0.16596030467245748" LOG_CI_START="0.06732580474883915" LOG_EFFECT_SIZE="0.11664305471064833" METHOD="PETO" MODIFIED="2010-12-27 14:27:15 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.6221207155275863E-8" P_Q="6.503904967580798E-5" P_Z="3.558637577563033E-6" Q="24.44488458803323" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="6700" TOTAL_2="4698" WEIGHT="500.0" Z="4.635623163429512">
<NAME>Sensitivity analysis: Best quality studies</NAME>
<GROUP_LABEL_1>Antiarrhythmic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.2475367281593117" CI_END="1.1027724842535782" CI_START="0.5886697917944278" DF="1" EFFECT_SIZE="0.8057101517929247" ESTIMABLE="YES" EVENTS_1="181" EVENTS_2="77" I2="55.50684500631141" ID="CMP-002.08.01" LOG_CI_END="0.04248592130214453" LOG_CI_START="-0.2301282498912396" LOG_EFFECT_SIZE="-0.09382116429454754" NO="1" P_CHI2="0.1338273862182524" P_Z="0.17731848161905436" STUDIES="2" TAU2="0.0" TOTAL_1="895" TOTAL_2="339" WEIGHT="100.0" Z="1.3490575504564308">
<NAME>Class Ia: Quinidine</NAME>
<DICH_DATA CI_END="1.9305216969464964" CI_START="0.6571482859917904" EFFECT_SIZE="1.1263387697395277" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="20" LOG_CI_END="0.2856746869811433" LOG_CI_START="-0.18233662051403673" LOG_EFFECT_SIZE="0.051669033233553305" ORDER="493" O_E="1.5741935483871003" SE="0.274912158716004" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="88" VAR="13.231592091571281" WEIGHT="33.930023742130956"/>
<DICH_DATA CI_END="0.9980593375504293" CI_START="0.46107254610926246" EFFECT_SIZE="0.6783640320156282" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="57" LOG_CI_END="-8.436378662803859E-4" LOG_CI_START="-0.336230736440792" LOG_EFFECT_SIZE="-0.1685371871535362" ORDER="494" O_E="-9.998699609882962" SE="0.19700804189558133" STUDY_ID="STD-SOPAT-2004" TOTAL_1="518" TOTAL_2="251" VAR="25.765115344096074" WEIGHT="66.06997625786904"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="14.402854979034748" CI_END="1.2615447240245752" CI_START="0.701831154627144" DF="4" EFFECT_SIZE="0.9409523847017708" ESTIMABLE="YES" EVENTS_1="207" EVENTS_2="82" I2="72.22772842035467" ID="CMP-002.08.02" LOG_CI_END="0.10090265164533364" LOG_CI_START="-0.15376735714890843" LOG_EFFECT_SIZE="-0.026432352751787406" NO="2" P_CHI2="0.006114347968143474" P_Z="0.684116934042371" STUDIES="5" TAU2="0.0" TOTAL_1="1055" TOTAL_2="448" WEIGHT="100.0" Z="0.40685167181988785">
<NAME>All class I antiarrhythmics</NAME>
<DICH_DATA CI_END="1.9305216969464964" CI_START="0.6571482859917904" EFFECT_SIZE="1.1263387697395277" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="20" LOG_CI_END="0.2856746869811433" LOG_CI_START="-0.18233662051403673" LOG_EFFECT_SIZE="0.051669033233553305" ORDER="495" O_E="1.5741935483871003" SE="0.274912158716004" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="88" VAR="13.231592091571281" WEIGHT="29.61030729103227"/>
<DICH_DATA CI_END="3.9512376864641414" CI_START="0.10970241203804439" EFFECT_SIZE="0.6583770232478792" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5967331554255523" LOG_CI_START="-0.9597838234435514" LOG_EFFECT_SIZE="-0.18152533400899956" ORDER="496" O_E="-0.5" SE="0.9143057782710197" STUDY_ID="STD-SMART-2002" TOTAL_1="47" TOTAL_2="47" VAR="1.1962365591397852" WEIGHT="2.676996982960183"/>
<DICH_DATA CI_END="0.9980593375504293" CI_START="0.46107254610926246" EFFECT_SIZE="0.6783640320156282" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="57" LOG_CI_END="-8.436378662803859E-4" LOG_CI_START="-0.336230736440792" LOG_EFFECT_SIZE="-0.1685371871535362" ORDER="497" O_E="-9.998699609882962" SE="0.19700804189558133" STUDY_ID="STD-SOPAT-2004" TOTAL_1="518" TOTAL_2="251" VAR="25.765115344096074" WEIGHT="57.65844181469002"/>
<DICH_DATA CI_END="7.946971669032155" CI_START="0.7917843372528375" EFFECT_SIZE="2.508443281426092" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="2" LOG_CI_END="0.9002016647590686" LOG_CI_START="-0.10139309353095141" LOG_EFFECT_SIZE="0.3994042856140586" ORDER="498" O_E="2.6568627450980387" SE="0.5883417189935725" STUDY_ID="STD-Stroobandt-1997" TOTAL_1="77" TOTAL_2="25" VAR="2.888954552894736" WEIGHT="6.46504452895974"/>
<DICH_DATA CI_END="42.93727702849919" CI_START="1.9435224978817696" EFFECT_SIZE="9.13507328392445" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="1.6328344991362287" LOG_CI_START="0.2885895723145221" LOG_EFFECT_SIZE="0.9607120357253753" ORDER="499" O_E="3.547945205479452" SE="0.7896161241347744" STUDY_ID="STD-Van-Gelder-1989" TOTAL_1="36" TOTAL_2="37" VAR="1.6038656408331768" WEIGHT="3.589209382357789"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.36081507599797824" CI_END="7.2489020633928325" CI_START="1.5731868458628622" DF="1" EFFECT_SIZE="3.376962743809556" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="6" I2="0.0" ID="CMP-002.08.03" LOG_CI_END="0.8602722322373512" LOG_CI_START="0.1967803064174341" LOG_EFFECT_SIZE="0.5285262693273927" MODIFIED="2010-12-27 14:27:15 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5480541534078749" P_Z="0.0017929330762439001" STUDIES="2" TAU2="0.0" TOTAL_1="280" TOTAL_2="282" WEIGHT="100.0" Z="3.1225472758689303">
<NAME>Class II antiarrhythmics</NAME>
<DICH_DATA CI_END="6.990335182622399" CI_START="1.4270918714409915" EFFECT_SIZE="3.1584569836818113" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="6" LOG_CI_END="0.8444980004199777" LOG_CI_START="0.1544519324528029" LOG_EFFECT_SIZE="0.49947496643639033" ORDER="500" O_E="7.0" SE="0.405336476107044" STUDY_ID="STD-Kuhlkamp-2000" TOTAL_1="197" TOTAL_2="197" VAR="6.086513994910942" WEIGHT="92.45174513411236"/>
<DICH_DATA CI_END="123.54811742880564" CI_START="0.4751849318665752" EFFECT_SIZE="7.662127887385501" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0918361322026024" LOG_CI_START="-0.3231373393041214" LOG_EFFECT_SIZE="0.8843493964492404" MODIFIED="2010-12-27 14:27:15 +0000" MODIFIED_BY="[Empty name]" ORDER="938" O_E="1.0119047619047619" SE="1.4185673714745302" STUDY_ID="STD-Nergardh-2007" TOTAL_1="83" TOTAL_2="85" VAR="0.4969355506673727" WEIGHT="7.548254865887637"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="14.160385434388498" CI_END="1.7526870025662697" CI_START="1.0031492203227628" DF="3" EFFECT_SIZE="1.3259738308481785" ESTIMABLE="YES" EVENTS_1="205" EVENTS_2="90" I2="78.81413600003782" ID="CMP-002.08.04" LOG_CI_END="0.24370436606803358" LOG_CI_START="0.0013655399422031105" LOG_EFFECT_SIZE="0.1225349530051184" MODIFIED="2010-08-27 18:14:40 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0026947778424777358" P_Z="0.04747340508777437" STUDIES="4" TAU2="0.0" TOTAL_1="1054" TOTAL_2="632" WEIGHT="100.0" Z="1.9820521422567166">
<NAME>Class III: Sotalol</NAME>
<DICH_DATA CI_END="4.995946911229559" CI_START="1.4225449776921204" EFFECT_SIZE="2.6658880673025402" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="12" LOG_CI_END="0.6986178147536282" LOG_CI_START="0.1530660067048519" LOG_EFFECT_SIZE="0.4258419107292401" ORDER="876" O_E="9.548098434004473" SE="0.32045983257285454" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="223" TOTAL_2="224" VAR="9.737619426552357" WEIGHT="19.73213149109261"/>
<DICH_DATA CI_END="9.212172032313898" CI_START="1.4945210034743894" EFFECT_SIZE="3.7104965422315748" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="1" LOG_CI_END="0.9643620395817095" LOG_CI_START="0.17450202284062655" LOG_EFFECT_SIZE="0.569432031211168" ORDER="501" O_E="6.09090909090909" SE="0.4639676837038525" STUDY_ID="STD-Benditt-1999" TOTAL_1="184" TOTAL_2="69" VAR="4.645415190869737" WEIGHT="9.413383226603948"/>
<DICH_DATA CI_END="1.9403740263898828" CI_START="0.6626459972714737" EFFECT_SIZE="1.1339228729489448" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="20" LOG_CI_END="0.2878854525799555" LOG_CI_START="-0.17871842105314945" LOG_EFFECT_SIZE="0.05458351576340305" ORDER="502" O_E="1.6730360934182613" SE="0.27408542509851114" STUDY_ID="STD-PAFAC-2004" TOTAL_1="383" TOTAL_2="88" VAR="13.311534320104863" WEIGHT="26.974246378562647"/>
<DICH_DATA CI_END="1.3030568154607938" CI_START="0.5612102699123185" EFFECT_SIZE="0.8551542943328054" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="57" LOG_CI_END="0.11496335209261067" LOG_CI_START="-0.25087439016427693" LOG_EFFECT_SIZE="-0.06795551903583308" ORDER="503" O_E="-3.38834951456311" SE="0.21489490072772618" STUDY_ID="STD-SOPAT-2004" TOTAL_1="264" TOTAL_2="251" VAR="21.654481016595188" WEIGHT="43.88023890374081"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="17.000519206025274" CI_END="1.8095786598828854" CI_START="1.325142393465252" DF="5" EFFECT_SIZE="1.5485313676257415" ESTIMABLE="YES" EVENTS_1="503" EVENTS_2="278" I2="70.58913354700417" ID="CMP-002.08.05" LOG_CI_END="0.25757746603531834" LOG_CI_START="0.12226254798871061" LOG_EFFECT_SIZE="0.18992000701201442" MODIFIED="2010-11-20 10:34:21 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.004498827645129544" P_Z="3.759784837292145E-8" STUDIES="6" TAU2="0.0" TOTAL_1="3416" TOTAL_2="2997" WEIGHT="100.00000000000001" Z="5.501778799569318">
<NAME>All class III antiarrhythmics</NAME>
<DICH_DATA CI_END="4.995946911229559" CI_START="1.4225449776921204" EFFECT_SIZE="2.6658880673025402" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="12" LOG_CI_END="0.6986178147536282" LOG_CI_START="0.1530660067048519" LOG_EFFECT_SIZE="0.4258419107292401" ORDER="877" O_E="9.548098434004473" SE="0.32045983257285454" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="223" TOTAL_2="224" VAR="9.737619426552357" WEIGHT="6.1520429503157"/>
<DICH_DATA CI_END="1.9806478159384728" CI_START="1.355855699905359" EFFECT_SIZE="1.6387411725911076" ESTIMABLE="YES" EVENTS_1="290" EVENTS_2="187" LOG_CI_END="0.29680725938908364" LOG_CI_START="0.13221347119066454" LOG_EFFECT_SIZE="0.21451036528987408" MODIFIED="2010-11-20 10:34:21 +0000" MODIFIED_BY="[Empty name]" ORDER="906" O_E="52.83988764044943" SE="0.09668320594014311" STUDY_ID="STD-ATHENA-2009" TOTAL_1="2301" TOTAL_2="2327" VAR="106.97884736536918" WEIGHT="67.58720329246174"/>
<DICH_DATA CI_END="9.212172032313898" CI_START="1.4945210034743894" EFFECT_SIZE="3.7104965422315748" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="1" LOG_CI_END="0.9643620395817095" LOG_CI_START="0.17450202284062655" LOG_EFFECT_SIZE="0.569432031211168" ORDER="504" O_E="6.09090909090909" SE="0.4639676837038525" STUDY_ID="STD-Benditt-1999" TOTAL_1="184" TOTAL_2="69" VAR="4.645415190869737" WEIGHT="2.934885060136106"/>
<DICH_DATA CI_END="14.26040858186083" CI_START="0.8639985230624987" EFFECT_SIZE="3.5101242076307697" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.1541319688752796" LOG_CI_START="-0.06348699991272148" LOG_EFFECT_SIZE="0.545322484481279" ORDER="505" O_E="2.454545454545454" SE="0.7152354095771745" STUDY_ID="STD-Channer-2004" TOTAL_1="61" TOTAL_2="38" VAR="1.9547984483049416" WEIGHT="1.2350045207548577"/>
<DICH_DATA CI_END="1.9403740263898828" CI_START="0.6626459972714737" EFFECT_SIZE="1.1339228729489448" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="20" LOG_CI_END="0.2878854525799555" LOG_CI_START="-0.17871842105314945" LOG_EFFECT_SIZE="0.05458351576340305" ORDER="506" O_E="1.6730360934182613" SE="0.27408542509851114" STUDY_ID="STD-PAFAC-2004" TOTAL_1="383" TOTAL_2="88" VAR="13.311534320104863" WEIGHT="8.409974479859212"/>
<DICH_DATA CI_END="1.3030568154607938" CI_START="0.5612102699123185" EFFECT_SIZE="0.8551542943328054" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="57" LOG_CI_END="0.11496335209261067" LOG_CI_START="-0.25087439016427693" LOG_EFFECT_SIZE="-0.06795551903583308" ORDER="507" O_E="-3.38834951456311" SE="0.21489490072772618" STUDY_ID="STD-SOPAT-2004" TOTAL_1="264" TOTAL_2="251" VAR="21.654481016595188" WEIGHT="13.680889696472397"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="81.11934431979438" CI_END="1.5421275153228005" CI_START="1.2584002744337437" CI_STUDY="95" CI_TOTAL="95" DF="23" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.3930591116295243" ESTIMABLE="YES" EVENTS_1="1398" EVENTS_2="621" I2="71.64671362563314" I2_Q="87.14942323504718" ID="CMP-002.09" LOG_CI_END="0.18812028610883677" LOG_CI_START="0.09981880432680668" LOG_EFFECT_SIZE="0.14396954521782174" METHOD="PETO" MODIFIED="2010-12-28 10:45:59 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="2.0898139330149945E-8" P_Q="2.8840980229594138E-6" P_Z="1.6461555700382484E-10" Q="31.127007551202986" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="9888" TOTAL_2="6525" WEIGHT="500.0" Z="6.391175273685292">
<NAME>Sensitivity analysis: Studies &gt; 200 patients</NAME>
<GROUP_LABEL_1>Antiarrhythmic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.2475367281593117" CI_END="1.1027724842535782" CI_START="0.5886697917944278" DF="1" EFFECT_SIZE="0.8057101517929247" ESTIMABLE="YES" EVENTS_1="181" EVENTS_2="77" I2="55.50684500631141" ID="CMP-002.09.01" LOG_CI_END="0.04248592130214453" LOG_CI_START="-0.2301282498912396" LOG_EFFECT_SIZE="-0.09382116429454754" NO="1" P_CHI2="0.1338273862182524" P_Z="0.17731848161905436" STUDIES="2" TAU2="0.0" TOTAL_1="895" TOTAL_2="339" WEIGHT="100.0" Z="1.3490575504564308">
<NAME>Class Ia: Quinidine</NAME>
<DICH_DATA CI_END="1.9305216969464964" CI_START="0.6571482859917904" EFFECT_SIZE="1.1263387697395277" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="20" LOG_CI_END="0.2856746869811433" LOG_CI_START="-0.18233662051403673" LOG_EFFECT_SIZE="0.051669033233553305" ORDER="508" O_E="1.5741935483871003" SE="0.274912158716004" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="88" VAR="13.231592091571281" WEIGHT="33.930023742130956"/>
<DICH_DATA CI_END="0.9980593375504293" CI_START="0.46107254610926246" EFFECT_SIZE="0.6783640320156282" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="57" LOG_CI_END="-8.436378662803859E-4" LOG_CI_START="-0.336230736440792" LOG_EFFECT_SIZE="-0.1685371871535362" ORDER="509" O_E="-9.998699609882962" SE="0.19700804189558133" STUDY_ID="STD-SOPAT-2004" TOTAL_1="518" TOTAL_2="251" VAR="25.765115344096074" WEIGHT="66.06997625786904"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.693442083961027" CI_END="1.1986116448973636" CI_START="0.6965736606538901" DF="2" EFFECT_SIZE="0.9137402810364317" ESTIMABLE="YES" EVENTS_1="250" EVENTS_2="94" I2="57.38735102677347" ID="CMP-002.09.02" LOG_CI_END="0.07867849269143602" LOG_CI_START="-0.15703295142377766" LOG_EFFECT_SIZE="-0.03917722936617084" NO="2" P_CHI2="0.09568258641105054" P_Z="0.5147075976795166" STUDIES="3" TAU2="0.0" TOTAL_1="1292" TOTAL_2="465" WEIGHT="100.0" Z="0.65152507855518">
<NAME>All class I antiarrhythmics</NAME>
<DICH_DATA CI_END="1.9305216969464964" CI_START="0.6571482859917904" EFFECT_SIZE="1.1263387697395277" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="20" LOG_CI_END="0.2856746869811433" LOG_CI_START="-0.18233662051403673" LOG_EFFECT_SIZE="0.051669033233553305" ORDER="510" O_E="1.5741935483871003" SE="0.274912158716004" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="88" VAR="13.231592091571281" WEIGHT="25.365804744902643"/>
<DICH_DATA CI_END="2.276425067064995" CI_START="0.7728315351048687" EFFECT_SIZE="1.3263834585560255" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="17" LOG_CI_END="0.3572533592364393" LOG_CI_START="-0.11191516500533927" LOG_EFFECT_SIZE="0.12266909711555002" ORDER="511" O_E="3.718929254302097" SE="0.2755919135612713" STUDY_ID="STD-RAFT-2003" TOTAL_1="397" TOTAL_2="126" VAR="13.166400435886457" WEIGHT="25.24082818897091"/>
<DICH_DATA CI_END="0.9980593375504293" CI_START="0.46107254610926246" EFFECT_SIZE="0.6783640320156282" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="57" LOG_CI_END="-8.436378662803859E-4" LOG_CI_START="-0.336230736440792" LOG_EFFECT_SIZE="-0.1685371871535362" ORDER="512" O_E="-9.998699609882962" SE="0.19700804189558133" STUDY_ID="STD-SOPAT-2004" TOTAL_1="518" TOTAL_2="251" VAR="25.765115344096074" WEIGHT="49.39336706612645"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.990335182622399" CI_START="1.4270918714409917" DF="0" EFFECT_SIZE="3.1584569836818113" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="6" I2="0.0" ID="CMP-002.09.03" LOG_CI_END="0.8444980004199777" LOG_CI_START="0.15445193245280298" LOG_EFFECT_SIZE="0.49947496643639033" NO="3" P_CHI2="1.0" P_Z="0.0045488955888745766" STUDIES="1" TAU2="0.0" TOTAL_1="197" TOTAL_2="197" WEIGHT="100.0" Z="2.837355332749308">
<NAME>Class II antiarrhythmics</NAME>
<DICH_DATA CI_END="6.990335182622399" CI_START="1.4270918714409915" EFFECT_SIZE="3.1584569836818113" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="6" LOG_CI_END="0.8444980004199777" LOG_CI_START="0.1544519324528029" LOG_EFFECT_SIZE="0.49947496643639033" ORDER="513" O_E="7.0" SE="0.405336476107044" STUDY_ID="STD-Kuhlkamp-2000" TOTAL_1="197" TOTAL_2="197" VAR="6.086513994910942" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="18.455048446131414" CI_END="1.886735228404783" CI_START="1.106201189100703" DF="4" EFFECT_SIZE="1.44468292478992" ESTIMABLE="YES" EVENTS_1="221" EVENTS_2="94" I2="78.3257139005859" ID="CMP-002.09.04" LOG_CI_END="0.27571095850580774" LOG_CI_START="0.043834120974220916" LOG_EFFECT_SIZE="0.15977253974001432" MODIFIED="2010-12-28 10:45:54 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0010053316792277833" P_Z="0.006913357145714904" STUDIES="5" TAU2="0.0" TOTAL_1="1162" TOTAL_2="738" WEIGHT="100.0" Z="2.700989257422185">
<NAME>Class III: Sotalol</NAME>
<DICH_DATA CI_END="4.995946911229559" CI_START="1.4225449776921204" EFFECT_SIZE="2.6658880673025402" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="12" LOG_CI_END="0.6986178147536282" LOG_CI_START="0.1530660067048519" LOG_EFFECT_SIZE="0.4258419107292401" ORDER="878" O_E="9.548098434004473" SE="0.32045983257285454" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="223" TOTAL_2="224" VAR="9.737619426552357" WEIGHT="18.065198514389344"/>
<DICH_DATA CI_END="9.212172032313898" CI_START="1.4945210034743894" EFFECT_SIZE="3.7104965422315748" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="1" LOG_CI_END="0.9643620395817095" LOG_CI_START="0.17450202284062655" LOG_EFFECT_SIZE="0.569432031211168" ORDER="514" O_E="6.09090909090909" SE="0.4639676837038525" STUDY_ID="STD-Benditt-1999" TOTAL_1="184" TOTAL_2="69" VAR="4.645415190869737" WEIGHT="8.618158497341685"/>
<DICH_DATA CI_END="9.16690381264253" CI_START="1.4602886681119756" EFFECT_SIZE="3.658732807854976" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="4" LOG_CI_END="0.9622226743676763" LOG_CI_START="0.16443871508314936" LOG_EFFECT_SIZE="0.5633306947254129" MODIFIED="2010-12-28 10:45:54 +0000" MODIFIED_BY="[Empty name]" ORDER="984" O_E="5.906542056074766" SE="0.46862224677801984" STUDY_ID="STD-EMERALD-2000" TOTAL_1="108" TOTAL_2="106" VAR="4.553592847151913" WEIGHT="8.447809996886244"/>
<DICH_DATA CI_END="1.9403740263898828" CI_START="0.6626459972714737" EFFECT_SIZE="1.1339228729489448" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="20" LOG_CI_END="0.2878854525799555" LOG_CI_START="-0.17871842105314945" LOG_EFFECT_SIZE="0.05458351576340305" ORDER="515" O_E="1.6730360934182613" SE="0.27408542509851114" STUDY_ID="STD-PAFAC-2004" TOTAL_1="383" TOTAL_2="88" VAR="13.311534320104863" WEIGHT="24.695513296409704"/>
<DICH_DATA CI_END="1.3030568154607938" CI_START="0.5612102699123185" EFFECT_SIZE="0.8551542943328054" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="57" LOG_CI_END="0.11496335209261067" LOG_CI_START="-0.25087439016427693" LOG_EFFECT_SIZE="-0.06795551903583308" ORDER="516" O_E="-3.38834951456311" SE="0.21489490072772618" STUDY_ID="STD-SOPAT-2004" TOTAL_1="264" TOTAL_2="251" VAR="21.654481016595188" WEIGHT="40.17331969497302"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="24.596309510339648" CI_END="1.874889407222521" CI_START="1.439933042620202" DF="12" EFFECT_SIZE="1.6430810110029" ESTIMABLE="YES" EVENTS_1="726" EVENTS_2="350" I2="51.21219305296385" ID="CMP-002.09.05" LOG_CI_END="0.2729756553973267" LOG_CI_START="0.1583422977225723" LOG_EFFECT_SIZE="0.21565897655994953" MODIFIED="2010-12-28 10:45:59 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.01685606680379781" P_Z="1.6492023642583701E-13" STUDIES="12" TAU2="0.0" TOTAL_1="6342" TOTAL_2="4786" WEIGHT="100.0" Z="7.374534525971684">
<NAME>All class III antiarrhythmics</NAME>
<DICH_DATA CI_END="4.178752748231418" CI_START="1.3283127632981735" EFFECT_SIZE="2.355990367158387" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="16" LOG_CI_END="0.6210466752222457" LOG_CI_START="0.12330034565091305" LOG_EFFECT_SIZE="0.3721735104365793" ORDER="839" O_E="10.024663677130047" SE="0.2923786578742692" STUDY_ID="STD-A_x002d_COMET_x002d_I-2006" TOTAL_1="227" TOTAL_2="219" VAR="11.6979204479289" WEIGHT="5.304029053135408"/>
<DICH_DATA CI_END="4.995946911229559" CI_START="1.4225449776921204" EFFECT_SIZE="2.6658880673025402" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="12" LOG_CI_END="0.6986178147536282" LOG_CI_START="0.1530660067048519" LOG_EFFECT_SIZE="0.4258419107292401" ORDER="879" O_E="9.548098434004473" SE="0.32045983257285454" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="223" TOTAL_2="224" VAR="9.737619426552357" WEIGHT="4.415196408345705"/>
<DICH_DATA CI_END="18.842830019191098" CI_START="0.9531768000049803" EFFECT_SIZE="4.237988723525625" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.2751461303791987" LOG_CI_START="-0.02082653677505163" LOG_EFFECT_SIZE="0.6271597968020736" MODIFIED="2010-11-20 10:10:20 +0000" MODIFIED_BY="[Empty name]" ORDER="891" O_E="2.491879350348028" SE="0.7612607598545715" STUDY_ID="STD-A_x002d_STAR-2006" TOTAL_1="216" TOTAL_2="215" VAR="1.7255721060933134" WEIGHT="0.782402703518079"/>
<DICH_DATA CI_END="3.630175709349705" CI_START="1.1984801170102204" EFFECT_SIZE="2.0858315868998374" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="11" LOG_CI_END="0.559927646455997" LOG_CI_START="0.07863083340982842" LOG_EFFECT_SIZE="0.3192792399329127" ORDER="517" O_E="9.197826086956525" SE="0.28271613044096777" STUDY_ID="STD-ASAP-2003" TOTAL_1="891" TOTAL_2="489" VAR="12.51119589206721" WEIGHT="5.672781482519121"/>
<DICH_DATA CI_END="1.9806478159384728" CI_START="1.355855699905359" EFFECT_SIZE="1.6387411725911076" ESTIMABLE="YES" EVENTS_1="290" EVENTS_2="187" LOG_CI_END="0.29680725938908364" LOG_CI_START="0.13221347119066454" LOG_EFFECT_SIZE="0.21451036528987408" MODIFIED="2010-11-20 10:34:29 +0000" MODIFIED_BY="[Empty name]" ORDER="907" O_E="52.83988764044943" SE="0.09668320594014311" STUDY_ID="STD-ATHENA-2009" TOTAL_1="2301" TOTAL_2="2327" VAR="106.97884736536918" WEIGHT="48.50596454494757"/>
<DICH_DATA CI_END="9.212172032313898" CI_START="1.4945210034743894" EFFECT_SIZE="3.7104965422315748" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="1" LOG_CI_END="0.9643620395817095" LOG_CI_START="0.17450202284062655" LOG_EFFECT_SIZE="0.569432031211168" ORDER="518" O_E="6.09090909090909" SE="0.4639676837038525" STUDY_ID="STD-Benditt-1999" TOTAL_1="184" TOTAL_2="69" VAR="4.645415190869737" WEIGHT="2.106307462589389"/>
<DICH_DATA CI_END="4.2821937757911925" CI_START="0.6840436439670202" EFFECT_SIZE="1.711492750368841" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="4" LOG_CI_END="0.6316663158899293" LOG_CI_START="-0.16491618814923806" LOG_EFFECT_SIZE="0.23337506387034557" MODIFIED="2010-12-28 10:34:33 +0000" MODIFIED_BY="[Empty name]" ORDER="963" O_E="2.4543325526932094" SE="0.4679165060195961" STUDY_ID="STD-EMERALD-2000" TOTAL_1="321" TOTAL_2="106" VAR="4.5673392294489465" WEIGHT="2.07090654072719"/>
<DICH_DATA CI_END="9.16690381264253" CI_START="1.4602886681119756" EFFECT_SIZE="3.658732807854976" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="4" LOG_CI_END="0.9622226743676763" LOG_CI_START="0.16443871508314936" LOG_EFFECT_SIZE="0.5633306947254129" MODIFIED="2010-12-28 10:45:59 +0000" MODIFIED_BY="[Empty name]" ORDER="985" O_E="5.906542056074766" SE="0.46862224677801984" STUDY_ID="STD-EMERALD-2000" TOTAL_1="108" TOTAL_2="106" VAR="4.553592847151913" WEIGHT="2.0646737054635618"/>
<DICH_DATA CI_END="2.1017890397123096" CI_START="0.9125072421745916" EFFECT_SIZE="1.38488184342949" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="29" LOG_CI_END="0.32258912297354314" LOG_CI_START="-0.03976368005068673" LOG_EFFECT_SIZE="0.1414127214614282" ORDER="825" O_E="7.187299035369776" SE="0.2128478301717356" STUDY_ID="STD-EURIDIS-ADONIS-2007" TOTAL_1="831" TOTAL_2="413" VAR="22.073009263887574" WEIGHT="10.00826454128561"/>
<DICH_DATA CI_END="1.9403740263898828" CI_START="0.6626459972714737" EFFECT_SIZE="1.1339228729489448" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="20" LOG_CI_END="0.2878854525799555" LOG_CI_START="-0.17871842105314945" LOG_EFFECT_SIZE="0.05458351576340305" ORDER="519" O_E="1.6730360934182613" SE="0.27408542509851114" STUDY_ID="STD-PAFAC-2004" TOTAL_1="383" TOTAL_2="88" VAR="13.311534320104863" WEIGHT="6.035668056551518"/>
<DICH_DATA CI_END="6.233831862441262" CI_START="0.4143574308642299" EFFECT_SIZE="1.6071821785226275" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="0.7947550844023693" LOG_CI_START="-0.382624868345819" LOG_EFFECT_SIZE="0.20606510802827518" ORDER="520" O_E="0.9920000000000009" SE="0.6915988123690467" STUDY_ID="STD-SAFIRE_x002d_D-2000" TOTAL_1="182" TOTAL_2="68" VAR="2.0906990522088353" WEIGHT="0.9479572513456131"/>
<DICH_DATA CI_END="1.3030568154607938" CI_START="0.5612102699123185" EFFECT_SIZE="0.8551542943328054" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="57" LOG_CI_END="0.11496335209261067" LOG_CI_START="-0.25087439016427693" LOG_EFFECT_SIZE="-0.06795551903583308" ORDER="521" O_E="-3.38834951456311" SE="0.21489490072772618" STUDY_ID="STD-SOPAT-2004" TOTAL_1="264" TOTAL_2="251" VAR="21.654481016595188" WEIGHT="9.818496967375525"/>
<DICH_DATA CI_END="5.908332362962058" CI_START="1.0236990932152656" EFFECT_SIZE="2.4593402534782918" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="6" LOG_CI_END="0.7714649178078945" LOG_CI_START="0.01017231859225797" LOG_EFFECT_SIZE="0.3908186182000763" MODIFIED="2010-12-28 10:22:23 +0000" MODIFIED_BY="[Empty name]" ORDER="947" O_E="4.5" SE="0.44718704123840797" STUDY_ID="STD-SVA_x002d_4-2008" TOTAL_1="211" TOTAL_2="211" VAR="5.000593824228028" WEIGHT="2.267351282195706"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2014-09-25 09:12:59 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Pro-arrhythmia</NAME>
<DICH_OUTCOME CHI2="48.10831991183234" CI_END="3.901876160809956" CI_START="2.68178985220145" CI_STUDY="95" CI_TOTAL="95" DF="40" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.2348124972874226" ESTIMABLE="YES" EVENTS_1="407" EVENTS_2="81" I2="16.854298646663153" I2_Q="50.46754091169935" ID="CMP-003.01" LOG_CI_END="0.5912734814781924" LOG_CI_START="0.428424743088641" LOG_EFFECT_SIZE="0.5098491122834167" METHOD="PETO" MODIFIED="2014-09-25 09:12:59 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1774611547898003" P_Q="0.04026882043253688" P_Z="1.2715948016367518E-34" Q="16.151025301890503" RANDOM="NO" SCALE="124.56" SORT_BY="STUDY" STUDIES="39" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="10650" TOTAL_2="7508" WEIGHT="99.99999999999999" Z="12.272565418773066">
<NAME>Individual antiarrhythmics</NAME>
<GROUP_LABEL_1>Antiarrhythmic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.7093405731502793" CI_END="4.333926801358292" CI_START="1.0204920279551604" DF="6" EFFECT_SIZE="2.103030610934454" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="6" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.636881571950427" LOG_CI_START="0.008809616373395876" LOG_EFFECT_SIZE="0.3228455941619114" NO="1" P_CHI2="0.8443428116575826" P_Z="0.043910240760906875" STUDIES="7" TAU2="0.0" TOTAL_1="1128" TOTAL_2="548" WEIGHT="6.722796928443246" Z="2.014946636308376">
<NAME>Class Ia: Quinidine</NAME>
<DICH_DATA CI_END="527.8001204153296" CI_START="0.19326023079046073" EFFECT_SIZE="10.099642225480048" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.7224694849664623" LOG_CI_START="-0.713857506163923" LOG_EFFECT_SIZE="1.0043059894012696" ORDER="522" O_E="0.5675675675675675" SE="2.0185154846829296" STUDY_ID="STD-Byrne_x002d_Quinn-1970" TOTAL_1="32" TOTAL_2="42" VAR="0.2454346238130022" WEIGHT="0.22458452611363514"/>
<DICH_DATA CI_END="406.0194289218663" CI_START="0.15885962215189478" EFFECT_SIZE="8.031194996067258" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.6085468160197243" LOG_CI_START="-0.7989864747561749" LOG_EFFECT_SIZE="0.9047801706317746" ORDER="523" O_E="0.52" SE="2.001601922563589" STUDY_ID="STD-Hillestad-1971" TOTAL_1="48" TOTAL_2="52" VAR="0.2496" WEIGHT="0.2283960463568208"/>
<DICH_DATA CI_END="336.66216233879743" CI_START="0.13089423396819694" EFFECT_SIZE="6.638308206569926" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.527194308514986" LOG_CI_START="-0.8830794841669609" LOG_EFFECT_SIZE="0.8220574121740125" ORDER="524" O_E="0.4716981132075472" SE="2.0032117069489046" STUDY_ID="STD-Lloyd-1984" TOTAL_1="28" TOTAL_2="25" VAR="0.24919900320398714" WEIGHT="0.228029114935302"/>
<DICH_DATA CI_END="5.699142310829643" CI_START="0.5480449523248215" EFFECT_SIZE="1.767310435670826" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="2" LOG_CI_END="0.7558095016898109" LOG_CI_START="-0.2611838178916394" LOG_EFFECT_SIZE="0.24731284189908576" ORDER="525" O_E="1.5956989247311828" SE="0.5973869101202663" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="88" VAR="2.802132038385941" WEIGHT="2.564086053434007"/>
<DICH_DATA CI_END="55.574438326015326" CI_START="0.5394938182710082" EFFECT_SIZE="5.47558818126132" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.7448750821106622" LOG_CI_START="-0.26801352726683664" LOG_EFFECT_SIZE="0.7384307774219127" ORDER="527" O_E="1.2162162162162162" SE="1.182380733107656" STUDY_ID="STD-Sodermark-1975" TOTAL_1="110" TOTAL_2="75" VAR="0.7152952011941437" WEIGHT="0.6545296311328089"/>
<DICH_DATA CI_END="4.553625992405196" CI_START="0.36014000476185415" EFFECT_SIZE="1.2806025482516072" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.6583573573935461" LOG_CI_START="-0.44352863402351056" LOG_EFFECT_SIZE="0.10741436168501778" ORDER="526" O_E="0.5903771131339406" SE="0.6472532857820044" STUDY_ID="STD-SOPAT-2004" TOTAL_1="518" TOTAL_2="251" VAR="2.386994797100812" WEIGHT="2.184215442035766"/>
<DICH_DATA CI_END="21.36052798587458" CI_START="0.196038155693089" EFFECT_SIZE="2.0463329423584677" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3296119833058593" LOG_CI_START="-0.7076593919382393" LOG_EFFECT_SIZE="0.3109762956838099" ORDER="528" O_E="0.5" SE="1.1967032904743342" STUDY_ID="STD-Steinbeck-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.6982758620689655" WEIGHT="0.6389561144349057"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="75" TOTAL_2="71" WEIGHT="0.0" Z="0.0">
<NAME>Class Ia: Disopyramide</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="529" O_E="0.0" SE="0.0" STUDY_ID="STD-Karlson-1998" TOTAL_1="46" TOTAL_2="46" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="530" O_E="0.0" SE="0.0" STUDY_ID="STD-Lloyd-1984" TOTAL_1="29" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.113004857186956" CI_END="15.626266488768293" CI_START="1.762314442936603" DF="3" EFFECT_SIZE="5.247703795216781" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="1" I2="0.0" ID="CMP-003.01.03" LOG_CI_END="1.193855226450883" LOG_CI_START="0.24608340047132166" LOG_EFFECT_SIZE="0.7199693134611024" MODIFIED="2014-06-26 15:45:43 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5492863332556983" P_Z="0.0029037243270054183" STUDIES="4" TAU2="0.0" TOTAL_1="352" TOTAL_2="159" WEIGHT="2.9523049033647784" Z="2.9777503101009466">
<NAME>Class Ic: Flecainide</NAME>
<DICH_DATA CI_END="114.67836914532768" CI_START="1.074464145901942" EFFECT_SIZE="11.100351163686767" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.059481508165089" LOG_CI_START="0.03119192797382057" LOG_EFFECT_SIZE="1.0453367180694548" ORDER="531" O_E="1.6956521739130435" SE="1.1914273395996993" STUDY_ID="STD-Carunchio-1995" TOTAL_1="20" TOTAL_2="26" VAR="0.704473850031506" WEIGHT="0.6446275725519386"/>
<DICH_DATA CI_END="30.496684243496865" CI_START="0.4438640212231169" EFFECT_SIZE="3.679182096919122" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.4842526231817788" LOG_CI_START="-0.35275005663611314" LOG_EFFECT_SIZE="0.5657512832728328" MODIFIED="2014-06-26 15:45:43 +0100" MODIFIED_BY="[Empty name]" ORDER="1030" O_E="1.1187845303867405" SE="1.0790644674349497" STUDY_ID="STD-Flec_x002d_SL-2012" TOTAL_1="281" TOTAL_2="81" VAR="0.8588260642996483" WEIGHT="0.7858672980537998"/>
<DICH_DATA CI_END="16.79145288401582" CI_START="0.05955410808744988" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2250882751858339" LOG_CI_START="-1.2250882751858336" LOG_EFFECT_SIZE="0.0" ORDER="532" O_E="0.0" SE="1.439245834257849" STUDY_ID="STD-Steinbeck-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.48275862068965514" WEIGHT="0.44174743714018166"/>
<DICH_DATA CI_END="51.9923506145551" CI_START="1.409198415185668" EFFECT_SIZE="8.559645909020338" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.7159394526682996" LOG_CI_START="0.14897214609272302" LOG_EFFECT_SIZE="0.9324557993805113" ORDER="533" O_E="2.5342465753424657" SE="0.9204443524957582" STUDY_ID="STD-Van-Gelder-1989" TOTAL_1="36" TOTAL_2="37" VAR="1.1803340213923812" WEIGHT="1.0800625956188583"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.23022811612688" CI_END="7.023647158800229" CI_START="0.3273551576349466" DF="2" EFFECT_SIZE="1.5163202573471388" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="38.08486806194829" ID="CMP-003.01.04" LOG_CI_END="0.8465626861504658" LOG_CI_START="-0.4849808121736287" LOG_EFFECT_SIZE="0.18079093698841847" NO="4" P_CHI2="0.19886813581952079" P_Z="0.5945666813357022" STUDIES="5" TAU2="0.0" TOTAL_1="720" TOTAL_2="378" WEIGHT="1.4957467918853624" Z="0.5322300408128374">
<NAME>Class Ic: Propafenone</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="534" O_E="0.0" SE="0.0" STUDY_ID="STD-Bellandi-2001" TOTAL_1="102" TOTAL_2="92" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="337.75609931856343" CI_START="0.13143792565309734" EFFECT_SIZE="6.662879337877396" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5286032004075483" LOG_CI_START="-0.8812793035331449" LOG_EFFECT_SIZE="0.8236619484372019" ORDER="535" O_E="0.4727272727272728" SE="2.002981862005382" STUDY_ID="STD-Dogan-2004" TOTAL_1="58" TOTAL_2="52" VAR="0.24925619834710744" WEIGHT="0.2280814512516461"/>
<DICH_DATA CI_END="116.44460406423609" CI_START="0.4476924519516362" EFFECT_SIZE="7.2202056972121875" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0661193685304484" LOG_CI_START="-0.34902022771480684" LOG_EFFECT_SIZE="0.858549570407821" ORDER="536" O_E="0.9822485207100591" SE="1.4186649539682745" STUDY_ID="STD-Kochiadakis-2004b" TOTAL_1="86" TOTAL_2="83" VAR="0.4968671898576314" WEIGHT="0.45465745884578074"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="537" O_E="0.0" SE="0.0" STUDY_ID="STD-RAFT-2003" TOTAL_1="397" TOTAL_2="126" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.345473764788088" CI_START="0.05228504360725626" EFFECT_SIZE="0.41823228196646534" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.5244576284906134" LOG_CI_START="-1.2816225254306413" LOG_EFFECT_SIZE="-0.3785824484700139" ORDER="538" O_E="-0.7745098039215685" SE="1.060900422654293" STUDY_ID="STD-Stroobandt-1997" TOTAL_1="77" TOTAL_2="25" VAR="0.8884863399834791" WEIGHT="0.8130078817879357"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.01.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="99" TOTAL_2="57" WEIGHT="0.0" Z="0.0">
<NAME>Class I others: aprindine, pilsicainide</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="539" O_E="0.0" SE="0.0" STUDY_ID="STD-Okishige-2000" TOTAL_1="52" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="540" O_E="0.0" SE="0.0" STUDY_ID="STD-SMART-2002" TOTAL_1="47" TOTAL_2="47" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.173075441872206E-4" CI_END="20.816021044336882" CI_START="3.013047601532521" DF="1" EFFECT_SIZE="7.919574627534595" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="0" I2="0.0" ID="CMP-003.01.06" LOG_CI_END="1.318397718275676" LOG_CI_START="0.4790059929145127" LOG_EFFECT_SIZE="0.8987018555950943" MODIFIED="2010-12-27 14:27:24 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.9801780597650667" P_Z="2.705884906541976E-5" STUDIES="2" TAU2="0.0" TOTAL_1="280" TOTAL_2="282" WEIGHT="3.763911725486443" Z="4.196904059419498">
<NAME>Class II: Beta-blockers</NAME>
<DICH_DATA CI_END="22.29859542925435" CI_START="2.8383802776061007" EFFECT_SIZE="7.955620245129419" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="0" LOG_CI_END="1.3482775080465688" LOG_CI_START="0.453070580480903" LOG_EFFECT_SIZE="0.9006740442637359" ORDER="541" O_E="7.5" SE="0.5258489805978313" STUDY_ID="STD-Kuhlkamp-2000" TOTAL_1="197" TOTAL_2="197" VAR="3.616412213740458" WEIGHT="3.3091917132004753"/>
<DICH_DATA CI_END="123.54811742880564" CI_START="0.4751849318665752" EFFECT_SIZE="7.662127887385501" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0918361322026024" LOG_CI_START="-0.3231373393041214" LOG_EFFECT_SIZE="0.8843493964492404" MODIFIED="2010-12-27 14:27:24 +0000" MODIFIED_BY="[Empty name]" ORDER="939" O_E="1.0119047619047619" SE="1.4185673714745302" STUDY_ID="STD-Nergardh-2007" TOTAL_1="83" TOTAL_2="85" VAR="0.4969355506673727" WEIGHT="0.4547200122859677"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.459536083218477" CI_END="8.004037170546473" CI_START="0.8762017078333243" DF="3" EFFECT_SIZE="2.648235457506418" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="2" I2="0.0" ID="CMP-003.01.07" LOG_CI_END="0.9033090968214625" LOG_CI_START="-0.05739590465948012" LOG_EFFECT_SIZE="0.4229565960809912" MODIFIED="2014-06-26 16:20:50 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.6916403895139578" P_Z="0.08438813950145257" STUDIES="5" TAU2="0.0" TOTAL_1="450" TOTAL_2="268" WEIGHT="2.873351079841304" Z="1.725773664266371">
<NAME>Class III: Amiodarone</NAME>
<DICH_DATA CI_END="55.02084639341907" CI_START="0.49948008648183356" EFFECT_SIZE="5.242310284110303" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.7405272669181524" LOG_CI_START="-0.3014818217592214" LOG_EFFECT_SIZE="0.7195227225794656" ORDER="542" O_E="1.1515151515151516" SE="1.1994862467970997" STUDY_ID="STD-Channer-2004" TOTAL_1="61" TOTAL_2="38" VAR="0.6950394482862015" WEIGHT="0.635994639625779"/>
<DICH_DATA CI_END="300.5347791914292" CI_START="0.05793575076459642" EFFECT_SIZE="4.172733883598098" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.4778947376928846" LOG_CI_START="-1.2370533608264507" LOG_EFFECT_SIZE="0.6204206884332171" ORDER="543" O_E="0.30000000000000004" SE="2.182178902359924" STUDY_ID="STD-GEFACA-2001" TOTAL_1="35" TOTAL_2="15" VAR="0.20999999999999996" WEIGHT="0.19216013515597902"/>
<DICH_DATA CI_END="112.61705421551551" CI_START="0.4288835796392666" EFFECT_SIZE="6.949791747986384" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.051604163080656" LOG_CI_START="-0.36766058096673376" LOG_EFFECT_SIZE="0.841971791056961" ORDER="544" O_E="0.96" SE="1.421088086207059" STUDY_ID="STD-Kochiadakis-2000" TOTAL_1="65" TOTAL_2="60" VAR="0.4951741935483871" WEIGHT="0.45310828551433807"/>
<DICH_DATA CI_END="6.407894452568711" CI_START="0.32816178719016115" EFFECT_SIZE="1.4501124424267475" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="0.8067153496672391" LOG_CI_START="-0.4839119917736381" LOG_EFFECT_SIZE="0.1614016789468005" ORDER="545" O_E="0.6466165413533833" SE="0.7581208890707473" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="267" TOTAL_2="132" VAR="1.7398951339886728" WEIGHT="1.5920880195452078"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-06-26 16:20:50 +0100" MODIFIED_BY="[Empty name]" ORDER="1062" O_E="0.0" SE="0.0" STUDY_ID="STD-Vijayalaskshmi-2006" TOTAL_1="22" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.026331649746288" CI_END="9.192690232507655" CI_START="3.690191318265988" DF="4" EFFECT_SIZE="5.82432705876896" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="5" I2="0.0" ID="CMP-003.01.08" LOG_CI_END="0.9634426258755222" LOG_CI_START="0.567048882775132" LOG_EFFECT_SIZE="0.765245754325327" MODIFIED="2010-12-28 10:23:08 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.7309157105517305" P_Z="3.804856293877676E-14" STUDIES="5" TAU2="0.0" TOTAL_1="1756" TOTAL_2="1358" WEIGHT="16.87777586922029" Z="7.56749642952854">
<NAME>Class III: Azimilide</NAME>
<DICH_DATA CI_END="15.477705818968246" CI_START="2.578995508050132" EFFECT_SIZE="6.317984946329052" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="1" LOG_CI_END="1.1897065878713655" LOG_CI_START="0.4114505857088024" LOG_EFFECT_SIZE="0.800578586790084" MODIFIED="2010-08-20 11:26:53 +0100" MODIFIED_BY="[Empty name]" ORDER="840" O_E="8.820627802690582" SE="0.45715142809963144" STUDY_ID="STD-A_x002d_COMET_x002d_I-2006" TOTAL_1="227" TOTAL_2="219" VAR="4.784976821563888" WEIGHT="4.378484727380685"/>
<DICH_DATA CI_END="16.595752168415142" CI_START="3.681372063541693" EFFECT_SIZE="7.816337915306949" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="1" LOG_CI_END="1.2199969406969813" LOG_CI_START="0.5660097123060456" LOG_EFFECT_SIZE="0.8930033265015135" MODIFIED="2010-08-27 16:34:43 +0100" MODIFIED_BY="[Empty name]" ORDER="851" O_E="13.933333333333334" SE="0.3841553352458266" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="211" TOTAL_2="224" VAR="6.776200716845878" WEIGHT="6.200550693300695"/>
<DICH_DATA CI_END="43.61351559948655" CI_START="1.2876841747226375" EFFECT_SIZE="7.49402654395337" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.6396210957062067" LOG_CI_START="0.10980935836981624" LOG_EFFECT_SIZE="0.8747152270380114" MODIFIED="2010-11-20 10:11:00 +0000" MODIFIED_BY="[Empty name]" ORDER="892" O_E="2.4941995359628772" SE="0.8986189872016263" STUDY_ID="STD-A_x002d_STAR-2006" TOTAL_1="216" TOTAL_2="215" VAR="1.2383654265427082" WEIGHT="1.1331641320806594"/>
<DICH_DATA CI_END="10.823694468006494" CI_START="1.0064920955599788" EFFECT_SIZE="3.3006003888390976" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="1" LOG_CI_END="1.0343755244680208" LOG_CI_START="0.002810368526050755" LOG_EFFECT_SIZE="0.5185929464970358" ORDER="557" O_E="3.252173913043478" SE="0.6059464789301889" STUDY_ID="STD-ASAP-2003" TOTAL_1="891" TOTAL_2="489" VAR="2.723525636368372" WEIGHT="2.4921574018348585"/>
<DICH_DATA CI_END="12.376144156998786" CI_START="1.2491216456066434" EFFECT_SIZE="3.93183284940438" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.0925853593713757" LOG_CI_START="0.09660473416533341" LOG_EFFECT_SIZE="0.5945950467683545" MODIFIED="2010-12-28 10:23:08 +0000" MODIFIED_BY="[Empty name]" ORDER="948" O_E="4.0" SE="0.585043949429637" STUDY_ID="STD-SVA_x002d_4-2008" TOTAL_1="211" TOTAL_2="211" VAR="2.9216152019002375" WEIGHT="2.6734189146233933"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7206420422783719" CI_END="9.332741285028215" CI_START="1.5395720038021643" DF="2" EFFECT_SIZE="3.7905708278777848" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="1" I2="0.0" ID="CMP-003.01.09" LOG_CI_END="0.9700092268224755" LOG_CI_START="0.18740000510845745" LOG_EFFECT_SIZE="0.5787046159654664" MODIFIED="2010-12-28 10:35:01 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.6974525074082558" P_Z="0.0037481852174163616" STUDIES="3" TAU2="0.0" TOTAL_1="752" TOTAL_2="431" WEIGHT="4.329910053579333" Z="2.898611908751244">
<NAME>Class III: Dofetilide</NAME>
<DICH_DATA CI_END="55.165081595336" CI_START="1.0813553882341789" EFFECT_SIZE="7.723539229232589" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.741664264885331" LOG_CI_START="0.033968448609891524" LOG_EFFECT_SIZE="0.8878163567476114" ORDER="546" O_E="2.0316205533596836" SE="1.0031089757108158" STUDY_ID="STD-DIAMOND-2001" TOTAL_1="249" TOTAL_2="257" VAR="0.9938109260315962" WEIGHT="0.9093849612653343"/>
<DICH_DATA CI_END="21.677139410855276" CI_START="0.6853566945547612" EFFECT_SIZE="3.854422474771871" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="1.3360019706685393" LOG_CI_START="-0.16408334068537192" LOG_EFFECT_SIZE="0.5859593149915837" MODIFIED="2010-12-28 10:35:01 +0000" MODIFIED_BY="[Empty name]" ORDER="964" O_E="1.7377049180327866" SE="0.8811575374313362" STUDY_ID="STD-EMERALD-2000" TOTAL_1="321" TOTAL_2="106" VAR="1.2879318371935455" WEIGHT="1.1785197900323814"/>
<DICH_DATA CI_END="9.847085725410356" CI_START="0.8048510735042969" EFFECT_SIZE="2.8152153588998052" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" LOG_CI_END="0.9933077187573561" LOG_CI_START="-0.09428447235114018" LOG_EFFECT_SIZE="0.44951162320310784" ORDER="547" O_E="2.5359999999999996" SE="0.6388570367253034" STUDY_ID="STD-SAFIRE_x002d_D-2000" TOTAL_1="182" TOTAL_2="68" VAR="2.45014978313253" WEIGHT="2.2420053022816178"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.103848929839883" CI_END="3.321933905424974" CI_START="1.8543279611962027" DF="1" EFFECT_SIZE="2.481925648780646" ESTIMABLE="YES" EVENTS_1="140" EVENTS_2="50" I2="75.6326312908644" ID="CMP-003.01.10" LOG_CI_END="0.5213909872981649" LOG_CI_START="0.268186547036971" LOG_EFFECT_SIZE="0.39478876716756794" MODIFIED="2010-11-20 10:36:13 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.04278581271067505" P_Z="9.849255016023961E-10" STUDIES="3" TAU2="0.0" TOTAL_1="3283" TOTAL_2="2788" WEIGHT="41.36434599157258" Z="6.111834092255374">
<NAME>Class III: Dronedarone</NAME>
<DICH_DATA CI_END="3.798287102460783" CI_START="2.0365838541950883" EFFECT_SIZE="2.781282111988835" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="42" LOG_CI_END="0.579587788811204" LOG_CI_START="0.3089022964080104" LOG_EFFECT_SIZE="0.44424504260960723" MODIFIED="2010-11-20 10:36:13 +0000" MODIFIED_BY="[Empty name]" ORDER="910" O_E="40.46067415730337" SE="0.15900199815243318" STUDY_ID="STD-ATHENA-2009" TOTAL_1="2301" TOTAL_2="2327" VAR="39.554403167632216" WEIGHT="36.19418789860139"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="826" O_E="0.0" SE="0.0" STUDY_ID="STD-DAFNE-2003" TOTAL_1="151" TOTAL_2="48" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.550726275274827" CI_START="0.4903056225850418" EFFECT_SIZE="1.1183181275659664" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="8" LOG_CI_END="0.4066638558987064" LOG_CI_START="-0.309533126448587" LOG_EFFECT_SIZE="0.048565364725059776" MODIFIED="2010-08-20 10:08:18 +0100" MODIFIED_BY="[Empty name]" ORDER="827" O_E="0.6318327974276521" SE="0.42069765266303955" STUDY_ID="STD-EURIDIS-ADONIS-2007" TOTAL_1="831" TOTAL_2="413" VAR="5.650147980186652" WEIGHT="5.170158092971186"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="15.5937450508505" CI_END="4.977717694048243" CI_START="2.1349054355476094" DF="10" EFFECT_SIZE="3.259901311641981" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="14" I2="35.871723133920355" ID="CMP-003.01.11" LOG_CI_END="0.6970302624225009" LOG_CI_START="0.3293786429538275" LOG_EFFECT_SIZE="0.5132044526881643" MODIFIED="2014-06-26 16:21:07 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.111867593340638" P_Z="4.454302788805277E-8" STUDIES="12" TAU2="0.0" TOTAL_1="1755" TOTAL_2="1168" WEIGHT="19.619856656606657" Z="5.471822729507106">
<NAME>Class III: Sotalol</NAME>
<DICH_DATA CI_END="15.578352286875832" CI_START="3.378033836655343" EFFECT_SIZE="7.254254003300663" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="1" LOG_CI_END="1.1925215206946869" LOG_CI_START="0.5286639954419476" LOG_EFFECT_SIZE="0.8605927580683173" MODIFIED="2010-08-27 18:15:45 +0100" MODIFIED_BY="[Empty name]" ORDER="880" O_E="13.031319910514542" SE="0.3899531964812073" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="223" TOTAL_2="224" VAR="6.576200271259052" WEIGHT="6.01754063303774"/>
<DICH_DATA CI_END="48.27075560233522" CI_START="0.9201615882961537" EFFECT_SIZE="6.664600148793642" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.6836840970651457" LOG_CI_START="-0.03613590010752667" LOG_EFFECT_SIZE="0.8237740984788096" ORDER="548" O_E="1.8585858585858586" SE="1.0102307795855137" STUDY_ID="STD-Bellandi-2001" TOTAL_1="106" TOTAL_2="92" VAR="0.9798482181192534" WEIGHT="0.8966084096482904"/>
<DICH_DATA CI_END="4.564946046551029" CI_START="0.4077635597784828" EFFECT_SIZE="1.3643381729389379" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" LOG_CI_END="0.6594356489407147" LOG_CI_START="-0.38959158800919635" LOG_EFFECT_SIZE="0.1349220304657592" ORDER="549" O_E="0.8181818181818183" SE="0.6162037917529486" STUDY_ID="STD-Benditt-1999" TOTAL_1="184" TOTAL_2="69" VAR="2.633608815426997" WEIGHT="2.409879171049665"/>
<DICH_DATA CI_END="79.58177795923497" CI_START="1.9581405838909638" EFFECT_SIZE="12.483281185656974" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.9008136376158387" LOG_CI_START="0.2918438685786284" LOG_EFFECT_SIZE="1.0963287530972334" ORDER="550" O_E="2.8260869565217392" SE="0.9451168068612643" STUDY_ID="STD-Carunchio-1995" TOTAL_1="20" TOTAL_2="26" VAR="1.1195127074144087" WEIGHT="1.0244081579313753"/>
<DICH_DATA CI_END="117.83515727191389" CI_START="0.4549214596741123" EFFECT_SIZE="7.32159420803063" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0712748857922962" LOG_CI_START="-0.3420635760339083" LOG_EFFECT_SIZE="0.864605654879194" MODIFIED="2010-12-28 10:46:39 +0000" MODIFIED_BY="[Empty name]" ORDER="986" O_E="0.9906542056074767" SE="1.4176069586947648" STUDY_ID="STD-EMERALD-2000" TOTAL_1="108" TOTAL_2="106" VAR="0.49760911525577606" WEIGHT="0.4553363563923671"/>
<DICH_DATA CI_END="72.05541749986715" CI_START="0.7583730261316065" EFFECT_SIZE="7.3922178687150835" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8576666388883607" LOG_CI_START="-0.12011712241383157" LOG_EFFECT_SIZE="0.8687747582372646" ORDER="551" O_E="1.4821428571428572" SE="1.1617599715764204" STUDY_ID="STD-Kochiadakis-2004b" TOTAL_1="85" TOTAL_2="83" VAR="0.7409129445191249" WEIGHT="0.677971102655283"/>
<DICH_DATA CI_END="5.799474586854827" CI_START="0.6466761115173374" EFFECT_SIZE="1.936590218572555" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="2" LOG_CI_END="0.7633886497067798" LOG_CI_START="-0.1893131817741152" LOG_EFFECT_SIZE="0.28703773396633225" ORDER="552" O_E="2.1104033970276" SE="0.5596217717620015" STUDY_ID="STD-PAFAC-2004" TOTAL_1="383" TOTAL_2="88" VAR="3.193087324283532" WEIGHT="2.9218290085674616"/>
<DICH_DATA CI_END="6.158078173696388" CI_START="0.2958209602781121" EFFECT_SIZE="1.3496994475847384" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7894451977515701" LOG_CI_START="-0.5289710574837401" LOG_EFFECT_SIZE="0.13023707013391495" ORDER="553" O_E="0.5" SE="0.7744442345909389" STUDY_ID="STD-Plewan-2001" TOTAL_1="64" TOTAL_2="64" VAR="1.6673228346456692" WEIGHT="1.5256808631150567"/>
<DICH_DATA CI_END="7.215517186548279" CI_START="0.5719127499801987" EFFECT_SIZE="2.031414846034215" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="0.8582674654661188" LOG_CI_START="-0.2426702213684847" LOG_EFFECT_SIZE="0.307798622048817" ORDER="554" O_E="1.6946564885496187" SE="0.6466962469760881" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="261" TOTAL_2="132" VAR="2.3911086956780263" WEIGHT="2.1879798577815537"/>
<DICH_DATA CI_END="94.60661613296952" CI_START="0.1963508023594428" EFFECT_SIZE="4.309998258261872" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9759215090187774" LOG_CI_START="-0.7069673197077135" LOG_EFFECT_SIZE="0.6344770946555318" ORDER="556" O_E="0.588235294117647" SE="1.5759421785078283" STUDY_ID="STD-Singh-1991" TOTAL_1="24" TOTAL_2="10" VAR="0.40264234035860336" WEIGHT="0.36843717401347115"/>
<DICH_DATA CI_END="3.6919662362261247" CI_START="0.10917802752131842" EFFECT_SIZE="0.6348870697584525" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5672577206616394" LOG_CI_START="-0.961864756195521" LOG_EFFECT_SIZE="-0.19730351776694086" ORDER="555" O_E="-0.563106796116505" SE="0.8982141121842323" STUDY_ID="STD-SOPAT-2004" TOTAL_1="264" TOTAL_2="251" VAR="1.2394820783909704" WEIGHT="1.1341859224143938"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-06-26 16:21:07 +0100" MODIFIED_BY="[Empty name]" ORDER="1063" O_E="0.0" SE="0.0" STUDY_ID="STD-Vijayalaskshmi-2006" TOTAL_1="33" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.7093405731502798" CI_END="4.333926801358292" CI_START="1.0204920279551604" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.103030610934454" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="6" I2="0.0" I2_Q="45.44529180392953" ID="CMP-003.02" LOG_CI_END="0.636881571950427" LOG_CI_START="0.008809616373395876" LOG_EFFECT_SIZE="0.3228455941619114" METHOD="PETO" NO="2" P_CHI2="0.8443428116575826" P_Q="0.17577114483247802" P_Z="0.043910240760906875" Q="1.8330223606109015" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1128" TOTAL_2="548" WEIGHT="100.0" Z="2.014946636308376">
<NAME>Quinidine: older and recent studies</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7425653293441719" CI_END="17.32645242023981" CI_START="1.201661041521082" DF="4" EFFECT_SIZE="4.562951113169069" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="1.2387096503058805" LOG_CI_START="0.07978198134654385" LOG_EFFECT_SIZE="0.6592458158262122" NO="1" P_CHI2="0.9459778690471757" P_Z="0.02575962333228922" STUDIES="5" TAU2="0.0" TOTAL_1="233" TOTAL_2="209" WEIGHT="29.370148377078728" Z="2.229816563337979">
<NAME>Older studies, higher dose</NAME>
<DICH_DATA CI_END="527.8001204153296" CI_START="0.19326023079046073" EFFECT_SIZE="10.099642225480048" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.7224694849664623" LOG_CI_START="-0.713857506163923" LOG_EFFECT_SIZE="1.0043059894012696" ORDER="559" O_E="0.5675675675675675" SE="2.0185154846829296" STUDY_ID="STD-Byrne_x002d_Quinn-1970" TOTAL_1="32" TOTAL_2="42" VAR="0.2454346238130022" WEIGHT="3.340641231679159"/>
<DICH_DATA CI_END="406.0194289218663" CI_START="0.15885962215189478" EFFECT_SIZE="8.031194996067258" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.6085468160197243" LOG_CI_START="-0.7989864747561749" LOG_EFFECT_SIZE="0.9047801706317746" ORDER="560" O_E="0.52" SE="2.001601922563589" STUDY_ID="STD-Hillestad-1971" TOTAL_1="48" TOTAL_2="52" VAR="0.2496" WEIGHT="3.397336685725371"/>
<DICH_DATA CI_END="336.66216233879743" CI_START="0.13089423396819694" EFFECT_SIZE="6.638308206569926" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.527194308514986" LOG_CI_START="-0.8830794841669609" LOG_EFFECT_SIZE="0.8220574121740125" ORDER="561" O_E="0.4716981132075472" SE="2.0032117069489046" STUDY_ID="STD-Lloyd-1984" TOTAL_1="28" TOTAL_2="25" VAR="0.24919900320398714" WEIGHT="3.391878668393829"/>
<DICH_DATA CI_END="55.574438326015326" CI_START="0.5394938182710082" EFFECT_SIZE="5.47558818126132" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.7448750821106622" LOG_CI_START="-0.26801352726683664" LOG_EFFECT_SIZE="0.7384307774219127" ORDER="562" O_E="1.2162162162162162" SE="1.182380733107656" STUDY_ID="STD-Sodermark-1975" TOTAL_1="110" TOTAL_2="75" VAR="0.7152952011941437" WEIGHT="9.73597206786929"/>
<DICH_DATA CI_END="21.36052798587458" CI_START="0.196038155693089" EFFECT_SIZE="2.0463329423584677" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3296119833058593" LOG_CI_START="-0.7076593919382393" LOG_EFFECT_SIZE="0.3109762956838099" ORDER="563" O_E="0.5" SE="1.1967032904743342" STUDY_ID="STD-Steinbeck-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.6982758620689655" WEIGHT="9.50431972341108"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.13375288319520534" CI_END="3.6026915329458746" CI_START="0.6446028100183465" DF="1" EFFECT_SIZE="1.5239111147853128" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="5" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="0.5566270788657153" LOG_CI_START="-0.1907078055987356" LOG_EFFECT_SIZE="0.1829596366334898" NO="2" P_CHI2="0.7145723136565407" P_Z="0.33722556349164146" STUDIES="2" TAU2="0.0" TOTAL_1="895" TOTAL_2="339" WEIGHT="70.62985162292127" Z="0.9596616078831866">
<NAME>More recent studies, lower dose</NAME>
<DICH_DATA CI_END="5.699142310829643" CI_START="0.5480449523248215" EFFECT_SIZE="1.767310435670826" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="2" LOG_CI_END="0.7558095016898109" LOG_CI_START="-0.2611838178916394" LOG_EFFECT_SIZE="0.24731284189908576" ORDER="564" O_E="1.5956989247311828" SE="0.5973869101202663" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="88" VAR="2.802132038385941" WEIGHT="38.1401681580728"/>
<DICH_DATA CI_END="4.553625992405196" CI_START="0.36014000476185415" EFFECT_SIZE="1.2806025482516072" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.6583573573935461" LOG_CI_START="-0.44352863402351056" LOG_EFFECT_SIZE="0.10741436168501778" ORDER="565" O_E="0.5903771131339406" SE="0.6472532857820044" STUDY_ID="STD-SOPAT-2004" TOTAL_1="518" TOTAL_2="251" VAR="2.386994797100812" WEIGHT="32.48968346484847"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.272562054639453" CI_END="4.447031804533995" CI_START="1.4457278951283552" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.53558630899005" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.6480702354719211" LOG_CI_START="0.16008656075625177" LOG_EFFECT_SIZE="0.40407839811408647" METHOD="PETO" MODIFIED="2014-06-26 15:46:07 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6715085986580327" P_Q="0.3779927438534534" P_Z="0.0011706984117597398" Q="0.7772200381363903" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="18" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2374" TOTAL_2="1188" WEIGHT="100.0" Z="3.245924600636303">
<NAME>Class I antiarrhythmics</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.479856859096257" CI_END="4.260062238207354" CI_START="0.9994124866643532" DF="6" EFFECT_SIZE="2.063385420814958" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="6" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="0.6294159440587209" LOG_CI_START="-2.552287822162041E-4" LOG_EFFECT_SIZE="0.31458035763825226" NO="1" P_CHI2="0.8707152435088285" P_Z="0.050186015027682794" STUDIES="8" TAU2="0.0" TOTAL_1="1203" TOTAL_2="594" WEIGHT="60.059673071088355" Z="1.9583750942031986">
<NAME>Class Ia</NAME>
<DICH_DATA CI_END="527.8001204153296" CI_START="0.19326023079046073" EFFECT_SIZE="10.099642225480048" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.7224694849664623" LOG_CI_START="-0.713857506163923" LOG_EFFECT_SIZE="1.0043059894012696" ORDER="566" O_E="0.5675675675675675" SE="2.0185154846829296" STUDY_ID="STD-Byrne_x002d_Quinn-1970" TOTAL_1="32" TOTAL_2="42" VAR="0.2454346238130022" WEIGHT="2.0166086211929346"/>
<DICH_DATA CI_END="406.0194289218663" CI_START="0.15885962215189478" EFFECT_SIZE="8.031194996067258" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.6085468160197243" LOG_CI_START="-0.7989864747561749" LOG_EFFECT_SIZE="0.9047801706317746" ORDER="567" O_E="0.52" SE="2.001601922563589" STUDY_ID="STD-Hillestad-1971" TOTAL_1="48" TOTAL_2="52" VAR="0.2496" WEIGHT="2.0508333503640377"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="568" O_E="0.0" SE="0.0" STUDY_ID="STD-Karlson-1998" TOTAL_1="46" TOTAL_2="46" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="297.7026191115947" CI_START="0.059671421004225504" EFFECT_SIZE="4.214776188490744" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.473782655475443" LOG_CI_START="-1.2242336198239818" LOG_EFFECT_SIZE="0.6247745178257308" ORDER="569" O_E="0.30487804878048785" SE="2.172233065586672" STUDY_ID="STD-Lloyd-1984" TOTAL_1="57" TOTAL_2="25" VAR="0.2119274241522903" WEIGHT="1.741297393061947"/>
<DICH_DATA CI_END="5.699142310829643" CI_START="0.5480449523248215" EFFECT_SIZE="1.767310435670826" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="2" LOG_CI_END="0.7558095016898109" LOG_CI_START="-0.2611838178916394" LOG_EFFECT_SIZE="0.24731284189908576" ORDER="570" O_E="1.5956989247311828" SE="0.5973869101202663" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="88" VAR="2.802132038385941" WEIGHT="23.02366120370773"/>
<DICH_DATA CI_END="55.574438326015326" CI_START="0.5394938182710082" EFFECT_SIZE="5.47558818126132" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.7448750821106622" LOG_CI_START="-0.26801352726683664" LOG_EFFECT_SIZE="0.7384307774219127" ORDER="572" O_E="1.2162162162162162" SE="1.182380733107656" STUDY_ID="STD-Sodermark-1975" TOTAL_1="110" TOTAL_2="75" VAR="0.7152952011941437" WEIGHT="5.8772085495364745"/>
<DICH_DATA CI_END="4.553625992405196" CI_START="0.36014000476185415" EFFECT_SIZE="1.2806025482516072" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.6583573573935461" LOG_CI_START="-0.44352863402351056" LOG_EFFECT_SIZE="0.10741436168501778" ORDER="571" O_E="0.5903771131339406" SE="0.6472532857820044" STUDY_ID="STD-SOPAT-2004" TOTAL_1="518" TOTAL_2="251" VAR="2.386994797100812" WEIGHT="19.61269445929401"/>
<DICH_DATA CI_END="21.36052798587458" CI_START="0.196038155693089" EFFECT_SIZE="2.0463329423584677" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3296119833058593" LOG_CI_START="-0.7076593919382393" LOG_EFFECT_SIZE="0.3109762956838099" ORDER="573" O_E="0.5" SE="1.1967032904743342" STUDY_ID="STD-Steinbeck-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.6982758620689655" WEIGHT="5.737369493931222"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="47" TOTAL_2="47" WEIGHT="0.0" Z="0.0">
<NAME>Class Ib</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="574" O_E="0.0" SE="0.0" STUDY_ID="STD-SMART-2002" TOTAL_1="47" TOTAL_2="47" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.015485157406806" CI_END="8.408776304713756" CI_START="1.4209758390393148" DF="6" EFFECT_SIZE="3.4566845336079686" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="3" I2="14.47490992600387" ID="CMP-003.03.03" LOG_CI_END="0.9247327992725936" LOG_CI_START="0.15258669364801236" LOG_EFFECT_SIZE="0.538659746460303" MODIFIED="2014-06-26 15:46:07 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.31941770737307207" P_Z="0.006245694042192134" STUDIES="10" TAU2="0.0" TOTAL_1="1124" TOTAL_2="547" WEIGHT="39.94032692891165" Z="2.734595681550921">
<NAME>Class Ic</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="575" O_E="0.0" SE="0.0" STUDY_ID="STD-Bellandi-2001" TOTAL_1="102" TOTAL_2="92" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="114.67836914532768" CI_START="1.074464145901942" EFFECT_SIZE="11.100351163686767" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.059481508165089" LOG_CI_START="0.03119192797382057" LOG_EFFECT_SIZE="1.0453367180694548" ORDER="576" O_E="1.6956521739130435" SE="1.1914273395996993" STUDY_ID="STD-Carunchio-1995" TOTAL_1="20" TOTAL_2="26" VAR="0.704473850031506" WEIGHT="5.7882951366344795"/>
<DICH_DATA CI_END="337.75609931856343" CI_START="0.13143792565309734" EFFECT_SIZE="6.662879337877396" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5286032004075483" LOG_CI_START="-0.8812793035331449" LOG_EFFECT_SIZE="0.8236619484372019" ORDER="577" O_E="0.4727272727272728" SE="2.002981862005382" STUDY_ID="STD-Dogan-2004" TOTAL_1="58" TOTAL_2="52" VAR="0.24925619834710744" WEIGHT="2.0480085110384674"/>
<DICH_DATA CI_END="30.496684243496865" CI_START="0.4438640212231169" EFFECT_SIZE="3.679182096919122" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.4842526231817788" LOG_CI_START="-0.35275005663611314" LOG_EFFECT_SIZE="0.5657512832728328" MODIFIED="2014-06-26 15:46:07 +0100" MODIFIED_BY="[Empty name]" ORDER="1031" O_E="1.1187845303867405" SE="1.0790644674349497" STUDY_ID="STD-Flec_x002d_SL-2012" TOTAL_1="281" TOTAL_2="81" VAR="0.8588260642996483" WEIGHT="7.056526982482404"/>
<DICH_DATA CI_END="116.44460406423609" CI_START="0.4476924519516362" EFFECT_SIZE="7.2202056972121875" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0661193685304484" LOG_CI_START="-0.34902022771480684" LOG_EFFECT_SIZE="0.858549570407821" ORDER="578" O_E="0.9822485207100591" SE="1.4186649539682745" STUDY_ID="STD-Kochiadakis-2004b" TOTAL_1="86" TOTAL_2="83" VAR="0.4968671898576314" WEIGHT="4.082499213388183"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="579" O_E="0.0" SE="0.0" STUDY_ID="STD-Okishige-2000" TOTAL_1="52" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="580" O_E="0.0" SE="0.0" STUDY_ID="STD-RAFT-2003" TOTAL_1="397" TOTAL_2="126" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="16.79145288401582" CI_START="0.05955410808744988" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2250882751858339" LOG_CI_START="-1.2250882751858336" LOG_EFFECT_SIZE="0.0" ORDER="581" O_E="0.0" SE="1.439245834257849" STUDY_ID="STD-Steinbeck-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.48275862068965514" WEIGHT="3.9665764402487462"/>
<DICH_DATA CI_END="3.345473764788088" CI_START="0.05228504360725626" EFFECT_SIZE="0.41823228196646534" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.5244576284906134" LOG_CI_START="-1.2816225254306413" LOG_EFFECT_SIZE="-0.3785824484700139" ORDER="582" O_E="-0.7745098039215685" SE="1.060900422654293" STUDY_ID="STD-Stroobandt-1997" TOTAL_1="77" TOTAL_2="25" VAR="0.8884863399834791" WEIGHT="7.300230037584134"/>
<DICH_DATA CI_END="51.9923506145551" CI_START="1.409198415185668" EFFECT_SIZE="8.559645909020338" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.7159394526682996" LOG_CI_START="0.14897214609272302" LOG_EFFECT_SIZE="0.9324557993805113" ORDER="583" O_E="2.5342465753424657" SE="0.9204443524957582" STUDY_ID="STD-Van-Gelder-1989" TOTAL_1="36" TOTAL_2="37" VAR="1.1803340213923812" WEIGHT="9.698190607535235"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.593745050850485" CI_END="4.977717694048245" CI_START="2.1349054355476103" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.2599013116419817" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="14" I2="35.87172313392029" I2_Q="74.1851773816147" ID="CMP-003.04" LOG_CI_END="0.6970302624225011" LOG_CI_START="0.3293786429538277" LOG_EFFECT_SIZE="0.5132044526881644" METHOD="PETO" MODIFIED="2011-01-13 15:40:56 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.11186759334063856" P_Q="0.04904706511587675" P_Z="4.454302788805253E-8" Q="3.8737434488037152" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1722" TOTAL_2="1145" WEIGHT="100.0" Z="5.471822729507107">
<NAME>Sotalol: heterogeneity study</NAME>
<GROUP_LABEL_1>Antiarrhythmic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.1105287345624342" CI_END="3.5966810156503555" CI_START="0.558856449974368" DF="1" EFFECT_SIZE="1.4177546981394777" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="5" I2="9.952802761648869" ID="CMP-003.04.01" LOG_CI_END="0.5559019225875317" LOG_CI_START="-0.25269973234640924" LOG_EFFECT_SIZE="0.15160109512056122" NO="1" P_CHI2="0.29196707665893307" P_Z="0.46238231409325214" STUDIES="2" TAU2="0.0" TOTAL_1="647" TOTAL_2="339" WEIGHT="20.67301001210965" Z="0.7349297015163921">
<NAME>PAFAC and SOPAT trials</NAME>
<DICH_DATA CI_END="5.799474586854827" CI_START="0.6466761115173374" EFFECT_SIZE="1.936590218572555" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="2" LOG_CI_END="0.7633886497067798" LOG_CI_START="-0.1893131817741152" LOG_EFFECT_SIZE="0.28703773396633225" ORDER="584" O_E="2.1104033970276" SE="0.5596217717620015" STUDY_ID="STD-PAFAC-2004" TOTAL_1="383" TOTAL_2="88" VAR="3.193087324283532" WEIGHT="14.892203647082125"/>
<DICH_DATA CI_END="3.6919662362261247" CI_START="0.10917802752131842" EFFECT_SIZE="0.6348870697584525" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5672577206616394" LOG_CI_START="-0.961864756195521" LOG_EFFECT_SIZE="-0.19730351776694086" ORDER="585" O_E="-0.563106796116505" SE="0.8982141121842323" STUDY_ID="STD-SOPAT-2004" TOTAL_1="264" TOTAL_2="251" VAR="1.2394820783909704" WEIGHT="5.780806365027523"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="10.609472867484337" CI_END="6.513787510679866" CI_START="2.5179471034372165" DF="8" EFFECT_SIZE="4.049860787103908" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="9" I2="24.59568821257641" ID="CMP-003.04.02" LOG_CI_END="0.813833587135765" LOG_CI_START="0.4010466022902593" LOG_EFFECT_SIZE="0.6074400947130122" MODIFIED="2010-12-28 10:46:54 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2248237454167178" P_Z="8.002655731198915E-9" STUDIES="9" TAU2="0.0" TOTAL_1="1075" TOTAL_2="806" WEIGHT="79.32698998789036" Z="5.7684023581736525">
<NAME>Rest of studies</NAME>
<DICH_DATA CI_END="15.578352286875832" CI_START="3.378033836655343" EFFECT_SIZE="7.254254003300663" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="1" LOG_CI_END="1.1925215206946869" LOG_CI_START="0.5286639954419476" LOG_EFFECT_SIZE="0.8605927580683173" ORDER="881" O_E="13.031319910514542" SE="0.3899531964812073" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="223" TOTAL_2="224" VAR="6.576200271259052" WEIGHT="30.670665634101024"/>
<DICH_DATA CI_END="48.27075560233522" CI_START="0.9201615882961537" EFFECT_SIZE="6.664600148793642" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.6836840970651457" LOG_CI_START="-0.03613590010752667" LOG_EFFECT_SIZE="0.8237740984788096" ORDER="586" O_E="1.8585858585858586" SE="1.0102307795855137" STUDY_ID="STD-Bellandi-2001" TOTAL_1="106" TOTAL_2="92" VAR="0.9798482181192534" WEIGHT="4.569902957707759"/>
<DICH_DATA CI_END="4.564946046551029" CI_START="0.4077635597784828" EFFECT_SIZE="1.3643381729389379" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" LOG_CI_END="0.6594356489407147" LOG_CI_START="-0.38959158800919635" LOG_EFFECT_SIZE="0.1349220304657592" ORDER="587" O_E="0.8181818181818183" SE="0.6162037917529486" STUDY_ID="STD-Benditt-1999" TOTAL_1="184" TOTAL_2="69" VAR="2.633608815426997" WEIGHT="12.282858194268094"/>
<DICH_DATA CI_END="79.58177795923497" CI_START="1.9581405838909638" EFFECT_SIZE="12.483281185656974" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.9008136376158387" LOG_CI_START="0.2918438685786284" LOG_EFFECT_SIZE="1.0963287530972334" ORDER="588" O_E="2.8260869565217392" SE="0.9451168068612643" STUDY_ID="STD-Carunchio-1995" TOTAL_1="20" TOTAL_2="26" VAR="1.1195127074144087" WEIGHT="5.221282580504598"/>
<DICH_DATA CI_END="117.83515727191389" CI_START="0.4549214596741123" EFFECT_SIZE="7.32159420803063" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0712748857922962" LOG_CI_START="-0.3420635760339083" LOG_EFFECT_SIZE="0.864605654879194" MODIFIED="2010-12-28 10:46:54 +0000" MODIFIED_BY="[Empty name]" ORDER="987" O_E="0.9906542056074767" SE="1.4176069586947648" STUDY_ID="STD-EMERALD-2000" TOTAL_1="108" TOTAL_2="106" VAR="0.49760911525577606" WEIGHT="2.320793491827272"/>
<DICH_DATA CI_END="72.05541749986715" CI_START="0.7583730261316065" EFFECT_SIZE="7.3922178687150835" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8576666388883607" LOG_CI_START="-0.12011712241383157" LOG_EFFECT_SIZE="0.8687747582372646" ORDER="589" O_E="1.4821428571428572" SE="1.1617599715764204" STUDY_ID="STD-Kochiadakis-2004b" TOTAL_1="85" TOTAL_2="83" VAR="0.7409129445191249" WEIGHT="3.4555354532979616"/>
<DICH_DATA CI_END="6.158078173696388" CI_START="0.2958209602781121" EFFECT_SIZE="1.3496994475847384" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7894451977515701" LOG_CI_START="-0.5289710574837401" LOG_EFFECT_SIZE="0.13023707013391495" ORDER="590" O_E="0.5" SE="0.7744442345909389" STUDY_ID="STD-Plewan-2001" TOTAL_1="64" TOTAL_2="64" VAR="1.6673228346456692" WEIGHT="7.7762080009963235"/>
<DICH_DATA CI_END="7.215517186548279" CI_START="0.5719127499801987" EFFECT_SIZE="2.031414846034215" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="0.8582674654661188" LOG_CI_START="-0.2426702213684847" LOG_EFFECT_SIZE="0.307798622048817" ORDER="591" O_E="1.6946564885496187" SE="0.6466962469760881" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="261" TOTAL_2="132" VAR="2.3911086956780263" WEIGHT="11.151864644458493"/>
<DICH_DATA CI_END="94.60661613296952" CI_START="0.1963508023594428" EFFECT_SIZE="4.309998258261872" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9759215090187774" LOG_CI_START="-0.7069673197077135" LOG_EFFECT_SIZE="0.6344770946555318" ORDER="592" O_E="0.588235294117647" SE="1.5759421785078283" STUDY_ID="STD-Singh-1991" TOTAL_1="24" TOTAL_2="10" VAR="0.40264234035860336" WEIGHT="1.8778790307288311"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="33.69407848904216" CI_END="3.928251147290837" CI_START="2.6159698590560105" CI_STUDY="95" CI_TOTAL="95" DF="24" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.2056491698429856" ESTIMABLE="YES" EVENTS_1="337" EVENTS_2="72" I2="28.770866940892383" I2_Q="59.1418761636589" ID="CMP-003.05" LOG_CI_END="0.5941992460181201" LOG_CI_START="0.4176327357833211" LOG_EFFECT_SIZE="0.5059159909007206" METHOD="PETO" MODIFIED="2014-07-25 10:43:29 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.09025470871777519" P_Q="0.04411816502065946" P_Z="2.8472051127312123E-29" Q="9.789974733108561" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="24" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="7996" TOTAL_2="6013" WEIGHT="99.99999999999999" Z="11.231768924352663">
<NAME>Class III antiarrhythmics</NAME>
<GROUP_LABEL_1>Antiarrhythmic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.459536083218477" CI_END="8.004037170546473" CI_START="0.8762017078333243" DF="3" EFFECT_SIZE="2.648235457506418" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="2" I2="0.0" ID="CMP-003.05.01" LOG_CI_END="0.9033090968214625" LOG_CI_START="-0.05739590465948012" LOG_EFFECT_SIZE="0.4229565960809912" MODIFIED="2014-06-26 16:21:30 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6916403895139578" P_Z="0.08438813950145257" STUDIES="5" TAU2="0.0" TOTAL_1="450" TOTAL_2="268" WEIGHT="3.37782047242325" Z="1.725773664266371">
<NAME>Amiodarone</NAME>
<DICH_DATA CI_END="55.02084639341907" CI_START="0.49948008648183356" EFFECT_SIZE="5.242310284110303" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.7405272669181524" LOG_CI_START="-0.3014818217592214" LOG_EFFECT_SIZE="0.7195227225794656" ORDER="593" O_E="1.1515151515151516" SE="1.1994862467970997" STUDY_ID="STD-Channer-2004" TOTAL_1="61" TOTAL_2="38" VAR="0.6950394482862015" WEIGHT="0.7476551435538651"/>
<DICH_DATA CI_END="300.5347791914292" CI_START="0.05793575076459642" EFFECT_SIZE="4.172733883598098" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.4778947376928846" LOG_CI_START="-1.2370533608264507" LOG_EFFECT_SIZE="0.6204206884332171" ORDER="594" O_E="0.30000000000000004" SE="2.182178902359924" STUDY_ID="STD-GEFACA-2001" TOTAL_1="35" TOTAL_2="15" VAR="0.20999999999999996" WEIGHT="0.22589736529840748"/>
<DICH_DATA CI_END="112.61705421551551" CI_START="0.4288835796392666" EFFECT_SIZE="6.949791747986384" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.051604163080656" LOG_CI_START="-0.36766058096673376" LOG_EFFECT_SIZE="0.841971791056961" ORDER="595" O_E="0.96" SE="1.421088086207059" STUDY_ID="STD-Kochiadakis-2000" TOTAL_1="65" TOTAL_2="60" VAR="0.4951741935483871" WEIGHT="0.5326597413635445"/>
<DICH_DATA CI_END="6.407894452568711" CI_START="0.32816178719016115" EFFECT_SIZE="1.4501124424267475" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="0.8067153496672391" LOG_CI_START="-0.4839119917736381" LOG_EFFECT_SIZE="0.1614016789468005" ORDER="596" O_E="0.6466165413533833" SE="0.7581208890707473" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="267" TOTAL_2="132" VAR="1.7398951339886728" WEIGHT="1.8716082222074328"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-06-26 16:21:30 +0100" MODIFIED_BY="[Empty name]" ORDER="1064" O_E="0.0" SE="0.0" STUDY_ID="STD-Vijayalaskshmi-2006" TOTAL_1="22" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.0263316497462887" CI_END="9.192690232507655" CI_START="3.690191318265988" DF="4" EFFECT_SIZE="5.82432705876896" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="5" I2="0.0" ID="CMP-003.05.02" LOG_CI_END="0.9634426258755222" LOG_CI_START="0.567048882775132" LOG_EFFECT_SIZE="0.765245754325327" MODIFIED="2010-12-28 10:23:56 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7309157105517304" P_Z="3.804856293877676E-14" STUDIES="5" TAU2="0.0" TOTAL_1="1756" TOTAL_2="1358" WEIGHT="19.840978451951685" Z="7.56749642952854">
<NAME>Azimilide</NAME>
<DICH_DATA CI_END="15.477705818968246" CI_START="2.578995508050132" EFFECT_SIZE="6.317984946329052" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="1" LOG_CI_END="1.1897065878713655" LOG_CI_START="0.4114505857088024" LOG_EFFECT_SIZE="0.800578586790084" ORDER="841" O_E="8.820627802690582" SE="0.45715142809963144" STUDY_ID="STD-A_x002d_COMET_x002d_I-2006" TOTAL_1="227" TOTAL_2="219" VAR="4.784976821563888" WEIGHT="5.1472078905010985"/>
<DICH_DATA CI_END="16.595752168415142" CI_START="3.681372063541693" EFFECT_SIZE="7.816337915306949" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="1" LOG_CI_END="1.2199969406969813" LOG_CI_START="0.5660097123060456" LOG_EFFECT_SIZE="0.8930033265015135" ORDER="852" O_E="13.933333333333334" SE="0.3841553352458266" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="211" TOTAL_2="224" VAR="6.776200716845878" WEIGHT="7.289170898422211"/>
<DICH_DATA CI_END="43.61351559948655" CI_START="1.2876841747226375" EFFECT_SIZE="7.49402654395337" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.6396210957062067" LOG_CI_START="0.10980935836981624" LOG_EFFECT_SIZE="0.8747152270380114" MODIFIED="2010-11-20 10:11:17 +0000" MODIFIED_BY="[Empty name]" ORDER="893" O_E="2.4941995359628772" SE="0.8986189872016263" STUDY_ID="STD-A_x002d_STAR-2006" TOTAL_1="216" TOTAL_2="215" VAR="1.2383654265427082" WEIGHT="1.3321118434887447"/>
<DICH_DATA CI_END="10.823694468006494" CI_START="1.0064920955599788" EFFECT_SIZE="3.3006003888390976" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="1" LOG_CI_END="1.0343755244680208" LOG_CI_START="0.002810368526050755" LOG_EFFECT_SIZE="0.5185929464970358" ORDER="597" O_E="3.252173913043478" SE="0.6059464789301889" STUDY_ID="STD-ASAP-2003" TOTAL_1="891" TOTAL_2="489" VAR="2.723525636368372" WEIGHT="2.9297012646584952"/>
<DICH_DATA CI_END="12.376144156998786" CI_START="1.2491216456066434" EFFECT_SIZE="3.93183284940438" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.0925853593713757" LOG_CI_START="0.09660473416533341" LOG_EFFECT_SIZE="0.5945950467683545" MODIFIED="2010-12-28 10:23:56 +0000" MODIFIED_BY="[Empty name]" ORDER="949" O_E="4.0" SE="0.585043949429637" STUDY_ID="STD-SVA_x002d_4-2008" TOTAL_1="211" TOTAL_2="211" VAR="2.9216152019002375" WEIGHT="3.1427865548811362"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7206420422783721" CI_END="9.332741285028215" CI_START="1.5395720038021643" DF="2" EFFECT_SIZE="3.7905708278777848" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="1" I2="0.0" ID="CMP-003.05.03" LOG_CI_END="0.9700092268224755" LOG_CI_START="0.18740000510845745" LOG_EFFECT_SIZE="0.5787046159654664" MODIFIED="2010-12-28 10:35:17 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6974525074082558" P_Z="0.0037481852174163616" STUDIES="3" TAU2="0.0" TOTAL_1="752" TOTAL_2="431" WEIGHT="5.090105043320813" Z="2.898611908751244">
<NAME>Dofetilide</NAME>
<DICH_DATA CI_END="55.165081595336" CI_START="1.0813553882341789" EFFECT_SIZE="7.723539229232589" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.741664264885331" LOG_CI_START="0.033968448609891524" LOG_EFFECT_SIZE="0.8878163567476114" ORDER="598" O_E="2.0316205533596836" SE="1.0031089757108158" STUDY_ID="STD-DIAMOND-2001" TOTAL_1="249" TOTAL_2="257" VAR="0.9938109260315962" WEIGHT="1.0690441418824197"/>
<DICH_DATA CI_END="21.677139410855276" CI_START="0.6853566945547612" EFFECT_SIZE="3.854422474771871" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="1.3360019706685393" LOG_CI_START="-0.16408334068537192" LOG_EFFECT_SIZE="0.5859593149915837" MODIFIED="2010-12-28 10:35:17 +0000" MODIFIED_BY="[Empty name]" ORDER="965" O_E="1.7377049180327866" SE="0.8811575374313362" STUDY_ID="STD-EMERALD-2000" TOTAL_1="321" TOTAL_2="106" VAR="1.2879318371935455" WEIGHT="1.385430517647426"/>
<DICH_DATA CI_END="9.847085725410356" CI_START="0.8048510735042969" EFFECT_SIZE="2.8152153588998052" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" LOG_CI_END="0.9933077187573561" LOG_CI_START="-0.09428447235114018" LOG_EFFECT_SIZE="0.44951162320310784" ORDER="599" O_E="2.5359999999999996" SE="0.6388570367253034" STUDY_ID="STD-SAFIRE_x002d_D-2000" TOTAL_1="182" TOTAL_2="68" VAR="2.45014978313253" WEIGHT="2.6356303837909674"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.103848929839883" CI_END="3.321933905424974" CI_START="1.8543279611962027" DF="1" EFFECT_SIZE="2.481925648780646" ESTIMABLE="YES" EVENTS_1="140" EVENTS_2="50" I2="75.6326312908644" ID="CMP-003.05.04" LOG_CI_END="0.5213909872981649" LOG_CI_START="0.268186547036971" LOG_EFFECT_SIZE="0.39478876716756794" MODIFIED="2010-11-20 11:16:47 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.04278581271067505" P_Z="9.849255016023961E-10" STUDIES="3" TAU2="0.0" TOTAL_1="3283" TOTAL_2="2788" WEIGHT="48.62661430375898" Z="6.111834092255374">
<NAME>Dronedarone</NAME>
<DICH_DATA CI_END="3.798287102460783" CI_START="2.0365838541950883" EFFECT_SIZE="2.781282111988835" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="42" LOG_CI_END="0.579587788811204" LOG_CI_START="0.3089022964080104" LOG_EFFECT_SIZE="0.44424504260960723" MODIFIED="2010-11-20 11:16:47 +0000" MODIFIED_BY="[Empty name]" ORDER="911" O_E="40.46067415730337" SE="0.15900199815243318" STUDY_ID="STD-ATHENA-2009" TOTAL_1="2301" TOTAL_2="2327" VAR="39.554403167632216" WEIGHT="42.548740292948104"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="600" O_E="0.0" SE="0.0" STUDY_ID="STD-DAFNE-2003" TOTAL_1="151" TOTAL_2="48" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.550726275274827" CI_START="0.4903056225850418" EFFECT_SIZE="1.1183181275659664" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="8" LOG_CI_END="0.4066638558987064" LOG_CI_START="-0.309533126448587" LOG_EFFECT_SIZE="0.048565364725059776" ORDER="828" O_E="0.6318327974276521" SE="0.42069765266303955" STUDY_ID="STD-EURIDIS-ADONIS-2007" TOTAL_1="831" TOTAL_2="413" VAR="5.650147980186652" WEIGHT="6.077874010810874"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="15.593745050850515" CI_END="4.977717694048242" CI_START="2.134905435547609" DF="10" EFFECT_SIZE="3.2599013116419804" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="14" I2="35.87172313392042" ID="CMP-003.05.05" LOG_CI_END="0.6970302624225008" LOG_CI_START="0.32937864295382746" LOG_EFFECT_SIZE="0.5132044526881642" MODIFIED="2014-07-01 15:52:23 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.11186759334063756" P_Z="4.454302788805302E-8" STUDIES="12" TAU2="0.0" TOTAL_1="1755" TOTAL_2="1168" WEIGHT="23.06448172854526" Z="5.471822729507105">
<NAME>Sotalol</NAME>
<DICH_DATA CI_END="15.578352286875832" CI_START="3.378033836655343" EFFECT_SIZE="7.254254003300663" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="1" LOG_CI_END="1.1925215206946869" LOG_CI_START="0.5286639954419476" LOG_EFFECT_SIZE="0.8605927580683173" ORDER="882" O_E="13.031319910514542" SE="0.3899531964812073" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="223" TOTAL_2="224" VAR="6.576200271259052" WEIGHT="7.074030071200441"/>
<DICH_DATA CI_END="48.27075560233522" CI_START="0.9201615882961537" EFFECT_SIZE="6.664600148793642" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.6836840970651457" LOG_CI_START="-0.03613590010752667" LOG_EFFECT_SIZE="0.8237740984788096" ORDER="601" O_E="1.8585858585858586" SE="1.0102307795855137" STUDY_ID="STD-Bellandi-2001" TOTAL_1="106" TOTAL_2="92" VAR="0.9798482181192534" WEIGHT="1.0540244326927555"/>
<DICH_DATA CI_END="4.564946046551029" CI_START="0.4077635597784828" EFFECT_SIZE="1.3643381729389379" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" LOG_CI_END="0.6594356489407147" LOG_CI_START="-0.38959158800919635" LOG_EFFECT_SIZE="0.1349220304657592" ORDER="602" O_E="0.8181818181818183" SE="0.6162037917529486" STUDY_ID="STD-Benditt-1999" TOTAL_1="184" TOTAL_2="69" VAR="2.633608815426997" WEIGHT="2.832977583960089"/>
<DICH_DATA CI_END="79.58177795923497" CI_START="1.9581405838909638" EFFECT_SIZE="12.483281185656974" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.9008136376158387" LOG_CI_START="0.2918438685786284" LOG_EFFECT_SIZE="1.0963287530972334" ORDER="603" O_E="2.8260869565217392" SE="0.9451168068612643" STUDY_ID="STD-Carunchio-1995" TOTAL_1="20" TOTAL_2="26" VAR="1.1195127074144087" WEIGHT="1.2042617667761994"/>
<DICH_DATA CI_END="117.83515727191389" CI_START="0.4549214596741123" EFFECT_SIZE="7.32159420803063" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0712748857922962" LOG_CI_START="-0.3420635760339083" LOG_EFFECT_SIZE="0.864605654879194" MODIFIED="2010-12-28 10:47:01 +0000" MODIFIED_BY="[Empty name]" ORDER="988" O_E="0.9906542056074767" SE="1.4176069586947648" STUDY_ID="STD-EMERALD-2000" TOTAL_1="108" TOTAL_2="106" VAR="0.49760911525577606" WEIGHT="0.5352789908797686"/>
<DICH_DATA CI_END="72.05541749986715" CI_START="0.7583730261316065" EFFECT_SIZE="7.3922178687150835" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8576666388883607" LOG_CI_START="-0.12011712241383157" LOG_EFFECT_SIZE="0.8687747582372646" ORDER="604" O_E="1.4821428571428572" SE="1.1617599715764204" STUDY_ID="STD-Kochiadakis-2004b" TOTAL_1="85" TOTAL_2="83" VAR="0.7409129445191249" WEIGHT="0.7970013432493119"/>
<DICH_DATA CI_END="5.799474586854827" CI_START="0.6466761115173374" EFFECT_SIZE="1.936590218572555" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="2" LOG_CI_END="0.7633886497067798" LOG_CI_START="-0.1893131817741152" LOG_EFFECT_SIZE="0.28703773396633225" ORDER="605" O_E="2.1104033970276" SE="0.5596217717620015" STUDY_ID="STD-PAFAC-2004" TOTAL_1="383" TOTAL_2="88" VAR="3.193087324283532" WEIGHT="3.434809589159008"/>
<DICH_DATA CI_END="6.158078173696388" CI_START="0.2958209602781121" EFFECT_SIZE="1.3496994475847384" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7894451977515701" LOG_CI_START="-0.5289710574837401" LOG_EFFECT_SIZE="0.13023707013391495" ORDER="606" O_E="0.5" SE="0.7744442345909389" STUDY_ID="STD-Plewan-2001" TOTAL_1="64" TOTAL_2="64" VAR="1.6673228346456692" WEIGHT="1.7935420735634717"/>
<DICH_DATA CI_END="7.215517186548279" CI_START="0.5719127499801987" EFFECT_SIZE="2.031414846034215" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="0.8582674654661188" LOG_CI_START="-0.2426702213684847" LOG_EFFECT_SIZE="0.307798622048817" ORDER="607" O_E="1.6946564885496187" SE="0.6466962469760881" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="261" TOTAL_2="132" VAR="2.3911086956780263" WEIGHT="2.572119783313228"/>
<DICH_DATA CI_END="94.60661613296952" CI_START="0.1963508023594428" EFFECT_SIZE="4.309998258261872" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9759215090187774" LOG_CI_START="-0.7069673197077135" LOG_EFFECT_SIZE="0.6344770946555318" ORDER="609" O_E="0.588235294117647" SE="1.5759421785078283" STUDY_ID="STD-Singh-1991" TOTAL_1="24" TOTAL_2="10" VAR="0.40264234035860336" WEIGHT="0.4331230659266341"/>
<DICH_DATA CI_END="3.6919662362261247" CI_START="0.10917802752131842" EFFECT_SIZE="0.6348870697584525" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5672577206616394" LOG_CI_START="-0.961864756195521" LOG_EFFECT_SIZE="-0.19730351776694086" ORDER="608" O_E="-0.563106796116505" SE="0.8982141121842323" STUDY_ID="STD-SOPAT-2004" TOTAL_1="264" TOTAL_2="251" VAR="1.2394820783909704" WEIGHT="1.3333130278243543"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-06-26 16:22:02 +0100" MODIFIED_BY="[Empty name]" ORDER="1066" O_E="0.0" SE="0.0" STUDY_ID="STD-Vijayalaskshmi-2006" TOTAL_1="33" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="52.24927256718431" CI_END="0.9898851733470745" CI_START="0.6521193734151358" CI_STUDY="95" CI_TOTAL="95" DF="40" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8034446458817355" ESTIMABLE="YES" EVENTS_1="182" EVENTS_2="206" I2="23.443910250489484" I2_Q="34.21572537576268" ID="CMP-003.06" LOG_CI_END="-0.004415180628718968" LOG_CI_START="-0.18567289741206483" LOG_EFFECT_SIZE="-0.0950440390203919" METHOD="PETO" MODIFIED="2014-06-26 16:24:20 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.09287551657507787" P_Q="0.11639348336814892" P_Z="0.03983576643165911" Q="16.721321414323537" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="25" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="4596" TOTAL_2="4587" WEIGHT="1200.0" Z="2.0554478643008434">
<NAME>Comparing antiarrhythmic drugs</NAME>
<GROUP_LABEL_1>Antiarrhythmic 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiarrhythmic 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Drug 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Drug 2</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5433844497665555" CI_END="4.254968947462905" CI_START="0.04399859175924873" DF="1" EFFECT_SIZE="0.43268076184145354" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-003.06.01" LOG_CI_END="0.6288963949741392" LOG_CI_START="-1.3565612235359674" LOG_EFFECT_SIZE="-0.36383241428091406" NO="1" P_CHI2="0.46103356398963613" P_Z="0.472559093566155" STUDIES="2" TAU2="0.0" TOTAL_1="60" TOTAL_2="53" WEIGHT="100.0" Z="0.718321480902684">
<NAME>Disopyramide vs other Class I drugs</NAME>
<DICH_DATA CI_END="6.585149737479151" CI_START="0.0025896160809743343" EFFECT_SIZE="0.13058717263115827" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8185656546845261" LOG_CI_START="-2.586764616719195" LOG_EFFECT_SIZE="-0.8840994810173343" ORDER="610" O_E="-0.5087719298245614" SE="2.0003078580792497" STUDY_ID="STD-Lloyd-1984" TOTAL_1="29" TOTAL_2="28" VAR="0.24992305324715297" WEIGHT="33.994038666385954"/>
<DICH_DATA CI_END="13.366640572557277" CI_START="0.048106443305011064" EFFECT_SIZE="0.80188623687041" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1260222700796636" LOG_CI_START="-1.3177967509774438" LOG_EFFECT_SIZE="-0.09588724044889006" ORDER="611" O_E="-0.1071428571428572" SE="1.4355113900681986" STUDY_ID="STD-PRODIS-1996" TOTAL_1="31" TOTAL_2="25" VAR="0.4852736549165121" WEIGHT="66.00596133361405"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.05083630617904067" CI_END="3.9555381499947293" CI_START="0.6436540489515468" DF="1" EFFECT_SIZE="1.5956184211854718" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" I2="0.0" ID="CMP-003.06.02" LOG_CI_END="0.5972055775110539" LOG_CI_START="-0.19134749444274537" LOG_EFFECT_SIZE="0.2029290415341542" NO="2" P_CHI2="0.8216143776965538" P_Z="0.3130858516849997" STUDIES="2" TAU2="0.0" TOTAL_1="132" TOTAL_2="137" WEIGHT="100.0" Z="1.0087681526335568">
<NAME>Quinidine vs Flecainide</NAME>
<DICH_DATA CI_END="4.087862360813518" CI_START="0.5705344944925421" EFFECT_SIZE="1.5271759838282655" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.6114962645861706" LOG_CI_START="-0.24371809302510106" LOG_EFFECT_SIZE="0.18388908578053478" ORDER="612" O_E="1.6778242677824267" SE="0.5023571470402062" STUDY_ID="STD-Naccarelli-1996" TOTAL_1="117" TOTAL_2="122" VAR="3.96255067563343" WEIGHT="85.01819674213432"/>
<DICH_DATA CI_END="21.36052798587458" CI_START="0.196038155693089" EFFECT_SIZE="2.0463329423584677" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3296119833058593" LOG_CI_START="-0.7076593919382393" LOG_EFFECT_SIZE="0.3109762956838099" ORDER="613" O_E="0.5" SE="1.1967032904743342" STUDY_ID="STD-Steinbeck-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.6982758620689655" WEIGHT="14.981803257865677"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8447247243222531" CI_END="3.559899361588102" CI_START="0.7084169769563012" DF="3" EFFECT_SIZE="1.5880469590049628" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" I2="0.0" ID="CMP-003.06.03" LOG_CI_END="0.5514377206344641" LOG_CI_START="-0.14971103964727225" LOG_EFFECT_SIZE="0.20086334049359592" NO="3" P_CHI2="0.8387423078131245" P_Z="0.2614497677552734" STUDIES="4" TAU2="0.0" TOTAL_1="258" TOTAL_2="268" WEIGHT="100.00000000000003" Z="1.1229711453063482">
<NAME>Quinidine vs other Class I drugs</NAME>
<DICH_DATA CI_END="386.1576267412401" CI_START="0.15185683543512074" EFFECT_SIZE="7.657719972423989" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.586764616719195" LOG_CI_START="-0.8185656546845261" LOG_EFFECT_SIZE="0.8840994810173343" ORDER="614" O_E="0.5087719298245614" SE="2.0003078580792497" STUDY_ID="STD-Lloyd-1984" TOTAL_1="28" TOTAL_2="29" VAR="0.24992305324715297" WEIGHT="4.23937527808561"/>
<DICH_DATA CI_END="4.087862360813518" CI_START="0.5705344944925421" EFFECT_SIZE="1.5271759838282655" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.6114962645861706" LOG_CI_START="-0.24371809302510106" LOG_EFFECT_SIZE="0.18388908578053478" ORDER="615" O_E="1.6778242677824267" SE="0.5023571470402062" STUDY_ID="STD-Naccarelli-1996" TOTAL_1="117" TOTAL_2="122" VAR="3.96255067563343" WEIGHT="67.2156455924426"/>
<DICH_DATA CI_END="7.507708879693368" CI_START="0.14447145261595498" EFFECT_SIZE="1.0414651255164546" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8755074239927314" LOG_CI_START="-0.8402179604935573" LOG_EFFECT_SIZE="0.017644731749586973" ORDER="616" O_E="0.040000000000000036" SE="1.0078255838248722" STUDY_ID="STD-Richiardi-1992" TOTAL_1="98" TOTAL_2="102" VAR="0.9845306532663316" WEIGHT="16.70031978941626"/>
<DICH_DATA CI_END="21.36052798587458" CI_START="0.196038155693089" EFFECT_SIZE="2.0463329423584677" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3296119833058593" LOG_CI_START="-0.7076593919382393" LOG_EFFECT_SIZE="0.3109762956838099" ORDER="617" O_E="0.5" SE="1.1967032904743342" STUDY_ID="STD-Steinbeck-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.6982758620689655" WEIGHT="11.844659340055545"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.783476966205546" CI_END="1.67517637088175" CI_START="0.5961019191027406" DF="5" EFFECT_SIZE="0.9992876710528232" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="29" I2="0.0" ID="CMP-003.06.04" LOG_CI_END="0.22406053845842822" LOG_CI_START="-0.22467947999171212" LOG_EFFECT_SIZE="-3.094707666419558E-4" NO="4" P_CHI2="0.7333244601461872" P_Z="0.997843038225905" STUDIES="6" TAU2="0.0" TOTAL_1="1109" TOTAL_2="869" WEIGHT="100.0" Z="0.002703353977571126">
<NAME>Quinidine vs Sotalol</NAME>
<DICH_DATA CI_END="21.935007102604498" CI_START="0.3837940970466317" EFFECT_SIZE="2.901469669780394" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.341137779366514" LOG_CI_START="-0.41590170922480363" LOG_EFFECT_SIZE="0.46261803507085525" ORDER="618" O_E="1.0" SE="1.03209369308428" STUDY_ID="STD-Hohnloser-1995" TOTAL_1="25" TOTAL_2="25" VAR="0.9387755102040816" WEIGHT="6.52268729735822"/>
<DICH_DATA CI_END="18.729126942179235" CI_START="0.07115406692873341" EFFECT_SIZE="1.1544061468827016" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2725175332198093" LOG_CI_START="-1.147800272048707" LOG_EFFECT_SIZE="0.06235863058555117" ORDER="619" O_E="0.07103825136612019" SE="1.4217066595810859" STUDY_ID="STD-Juul_x002d_Moller-1990" TOTAL_1="85" TOTAL_2="98" VAR="0.49474339450152405" WEIGHT="3.4375166583387373"/>
<DICH_DATA CI_END="4.993294184089879" CI_START="0.0510380188321881" EFFECT_SIZE="0.504824566163568" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6983871536303563" LOG_CI_START="-1.2921061921816375" LOG_EFFECT_SIZE="-0.29685951927564047" ORDER="620" O_E="-0.5" SE="1.1692256444309357" STUDY_ID="STD-Kalusche-1994" TOTAL_1="41" TOTAL_2="41" VAR="0.7314814814814814" WEIGHT="5.0823918132193375"/>
<DICH_DATA CI_END="1.6596907559000866" CI_START="0.4430944353787565" EFFECT_SIZE="0.8575545104475227" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="20" LOG_CI_END="0.2200271750777237" LOG_CI_START="-0.3535037040407756" LOG_EFFECT_SIZE="-0.06673826448152594" ORDER="621" O_E="-1.3539473684210535" SE="0.3368948774178453" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="383" VAR="8.810715643578991" WEIGHT="61.21755668350857"/>
<DICH_DATA CI_END="3.61248719968925" CI_START="0.10180667372745458" EFFECT_SIZE="0.6064448084396218" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5578063169094695" LOG_CI_START="-0.9922237517830808" LOG_EFFECT_SIZE="-0.2172087174368056" ORDER="622" O_E="-0.6033057851239669" SE="0.9104953351225888" STUDY_ID="STD-SOCESP-1999" TOTAL_1="63" TOTAL_2="58" VAR="1.2062700635202515" WEIGHT="8.381260839235757"/>
<DICH_DATA CI_END="6.963919339518101" CI_START="0.4986750549678543" EFFECT_SIZE="1.8635269945525053" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="0.8428537322033253" LOG_CI_START="-0.3021823557855813" LOG_EFFECT_SIZE="0.270335688208872" ORDER="623" O_E="1.3759590792838878" SE="0.6725998661047319" STUDY_ID="STD-SOPAT-2004" TOTAL_1="518" TOTAL_2="264" VAR="2.210479272703219" WEIGHT="15.358586708339375"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.2423037462757587" CI_END="1.9348414957275726" CI_START="0.09659465717079614" DF="1" EFFECT_SIZE="0.4323139495316284" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="69.15773233310912" ID="CMP-003.06.05" LOG_CI_END="0.28664539294644537" LOG_CI_START="-1.0150468945514999" LOG_EFFECT_SIZE="-0.36420075080252723" NO="5" P_CHI2="0.07175972429998678" P_Z="0.27274745384508203" STUDIES="2" TAU2="0.0" TOTAL_1="145" TOTAL_2="152" WEIGHT="100.0" Z="1.096757446550558">
<NAME>Flecainide vs Propafenone</NAME>
<DICH_DATA CI_END="0.9493113902217121" CI_START="0.017687787200593868" EFFECT_SIZE="0.12958093168881585" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="-0.022591308254595734" LOG_CI_START="-1.7523264953368372" LOG_EFFECT_SIZE="-0.8874589017957165" ORDER="624" O_E="-1.9793814432989691" SE="1.0160550112193762" STUDY_ID="STD-Aliot-1996" TOTAL_1="48" TOTAL_2="49" VAR="0.9686470400680202" WEIGHT="56.631416301803824"/>
<DICH_DATA CI_END="20.294707557725822" CI_START="0.21417760361095523" EFFECT_SIZE="2.084867341271108" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3073827976103867" LOG_CI_START="-0.669225944973407" LOG_EFFECT_SIZE="0.3190784263184898" ORDER="625" O_E="0.5449999999999999" SE="1.1610697597647965" STUDY_ID="STD-FAPIS-1996" TOTAL_1="97" TOTAL_2="103" VAR="0.741794095477387" WEIGHT="43.36858369819617"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.9653510738909716" CI_END="0.5858202498159384" CI_START="0.13439682989990434" DF="2" EFFECT_SIZE="0.280592915923464" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="23" I2="32.55436033832887" ID="CMP-003.06.06" LOG_CI_END="-0.23223562031006392" LOG_CI_START="-0.8716109751305247" LOG_EFFECT_SIZE="-0.5519232977202942" MODIFIED="2010-12-28 12:11:06 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.2270295096948518" P_Z="7.149769584598412E-4" STUDIES="3" TAU2="0.0" TOTAL_1="254" TOTAL_2="221" WEIGHT="100.0" Z="3.383770668058091">
<NAME>Amiodarone vs Class I drugs</NAME>
<DICH_DATA CI_END="0.46090192345747055" CI_START="0.08821066573345926" EFFECT_SIZE="0.20163448491271369" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="20" LOG_CI_END="-0.33639147945364717" LOG_CI_START="-1.0544789002520918" LOG_EFFECT_SIZE="-0.6954351898528695" ORDER="626" O_E="-9.0" SE="0.421808105567067" STUDY_ID="STD-AFFIRM-Substudy-2003" TOTAL_1="154" TOTAL_2="121" VAR="5.62043795620438" WEIGHT="79.27881429949711"/>
<DICH_DATA CI_END="7.453821092652186" CI_START="0.14188134823865767" EFFECT_SIZE="1.028376480747803" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8723789645639997" LOG_CI_START="-0.8480746932630546" LOG_EFFECT_SIZE="0.012152135650472512" ORDER="627" O_E="0.027397260273972712" SE="1.0106029949905684" STUDY_ID="STD-Kochiadakis-2004a" TOTAL_1="72" TOTAL_2="74" VAR="0.9791265748248036" WEIGHT="13.811022291519016"/>
<DICH_DATA CI_END="15.251101319354364" CI_START="0.0563678520121386" EFFECT_SIZE="0.927184891050053" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1833012062827064" LOG_CI_START="-1.2489685143557785" LOG_EFFECT_SIZE="-0.03283365403653597" ORDER="628" O_E="-0.03703703703703698" SE="1.4287272738323407" STUDY_ID="STD-Vitolo-1981" TOTAL_1="28" TOTAL_2="26" VAR="0.48989310764293287" WEIGHT="6.910163408983876"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.562364505421954" CI_START="0.38326527915404984" DF="0" EFFECT_SIZE="1.914398678839735" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-003.06.07" LOG_CI_END="0.9805652944398991" LOG_CI_START="-0.41650052265748116" LOG_EFFECT_SIZE="0.282032385891209" MODIFIED="2010-12-28 11:04:01 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.42874872048955004" STUDIES="1" TAU2="0.0" TOTAL_1="255" TOTAL_2="249" WEIGHT="100.00000000000001" Z="0.7913346845306745">
<NAME>Amiodarone vs Dronedarone</NAME>
<DICH_DATA CI_END="9.562364505421954" CI_START="0.38326527915404984" EFFECT_SIZE="1.914398678839735" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9805652944398991" LOG_CI_START="-0.41650052265748116" LOG_EFFECT_SIZE="0.282032385891209" MODIFIED="2010-12-28 11:04:01 +0000" MODIFIED_BY="[Empty name]" ORDER="1006" O_E="0.9642857142857144" SE="0.8206433765503289" STUDY_ID="STD-DYONISOS-2010" TOTAL_1="255" TOTAL_2="249" VAR="1.4848789913579745" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.3885448457517055" CI_END="1.1952250566905211" CI_START="0.29768996383654545" DF="2" EFFECT_SIZE="0.5964951834698535" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="20" I2="0.0" ID="CMP-003.06.08" LOG_CI_END="0.0774496891135277" LOG_CI_START="-0.526235806683069" LOG_EFFECT_SIZE="-0.22439305878477064" MODIFIED="2014-06-26 16:24:20 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.8234336148072249" P_Z="0.14510044105835068" STUDIES="4" TAU2="0.0" TOTAL_1="508" TOTAL_2="490" WEIGHT="100.0" Z="1.4570577450054054">
<NAME>Amiodarone vs Sotalol</NAME>
<DICH_DATA CI_END="1.3980872756654292" CI_START="0.16303558246641436" EFFECT_SIZE="0.4774285007485369" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.1455342831098177" LOG_CI_START="-0.787717600612251" LOG_EFFECT_SIZE="-0.3210916587512167" ORDER="629" O_E="-2.460207612456747" SE="0.5481967761696728" STUDY_ID="STD-AFFIRM-Substudy-2003" TOTAL_1="154" TOTAL_2="135" VAR="3.3275688150285547" WEIGHT="41.843088480695485"/>
<DICH_DATA CI_END="6.819574253899657" CI_START="0.12873039968979844" EFFECT_SIZE="0.9369559858492618" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8337572624931975" LOG_CI_START="-0.8903188823222445" LOG_EFFECT_SIZE="-0.028280809914523534" ORDER="630" O_E="-0.06349206349206371" SE="1.012730861779147" STUDY_ID="STD-Kochiadakis-2000" TOTAL_1="65" TOTAL_2="61" VAR="0.9750163769211391" WEIGHT="12.260511742200668"/>
<DICH_DATA CI_END="1.8068503194402998" CI_START="0.2321840917933008" EFFECT_SIZE="0.6477051029794975" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.2569221768367501" LOG_CI_START="-0.6341675394771286" LOG_EFFECT_SIZE="-0.18862268132018925" ORDER="631" O_E="-1.5852272727272725" SE="0.5234305103280072" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="267" TOTAL_2="261" VAR="3.649908124990199" WEIGHT="45.89639977710384"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-06-26 16:24:20 +0100" MODIFIED_BY="[Empty name]" ORDER="1069" O_E="0.0" SE="0.0" STUDY_ID="STD-Vijayalaskshmi-2006" TOTAL_1="22" TOTAL_2="33" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.820899992913081" CI_END="1.3392028875555828" CI_START="0.4422214504723288" DF="3" EFFECT_SIZE="0.7695610719179868" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="31" I2="56.01753429727746" ID="CMP-003.06.09" LOG_CI_END="0.1268463770650329" LOG_CI_START="-0.3543601952809921" LOG_EFFECT_SIZE="-0.11375690910797959" MODIFIED="2010-12-28 11:03:32 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0778308211877976" P_Z="0.35409877763992603" STUDIES="4" TAU2="0.0" TOTAL_1="290" TOTAL_2="277" WEIGHT="100.0" Z="0.9266683277297851">
<NAME>Sotalol vs Class I drugs other than quinidine</NAME>
<DICH_DATA CI_END="0.8143791056752536" CI_START="0.17366225045661018" EFFECT_SIZE="0.376067691003104" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="20" LOG_CI_END="-0.08917337745126032" LOG_CI_START="-0.7602945753359422" LOG_EFFECT_SIZE="-0.4247339763936013" ORDER="632" O_E="-6.29296875" SE="0.39421991374096993" STUDY_ID="STD-AFFIRM-Substudy-2003" TOTAL_1="135" TOTAL_2="121" VAR="6.434619679170496" WEIGHT="51.41160800339886"/>
<DICH_DATA CI_END="8.494096519204948" CI_START="0.39827148025027564" EFFECT_SIZE="1.839281488541781" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.9291171916110944" LOG_CI_START="-0.39982079179150626" LOG_EFFECT_SIZE="0.2646481999097941" ORDER="633" O_E="1.0" SE="0.7806247497997998" STUDY_ID="STD-Carunchio-1995" TOTAL_1="20" TOTAL_2="20" VAR="1.641025641025641" WEIGHT="13.11153901652392"/>
<DICH_DATA CI_END="8.986302071334348" CI_START="0.2586084833964725" EFFECT_SIZE="1.5244454565547287" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9535810131562618" LOG_CI_START="-0.5873572326194091" LOG_EFFECT_SIZE="0.18311189026842628" ORDER="634" O_E="0.5146198830409356" SE="0.9051547533359646" STUDY_ID="STD-Kochiadakis-2004b" TOTAL_1="85" TOTAL_2="86" VAR="1.2205464929379979" WEIGHT="9.751976180966905"/>
<DICH_DATA CI_END="4.750163210320437" CI_START="0.534504958513047" EFFECT_SIZE="1.5934195272000804" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.6767085317562013" LOG_CI_START="-0.272048261559289" LOG_EFFECT_SIZE="0.20233013509845613" ORDER="635" O_E="1.5" SE="0.5573044368153888" STUDY_ID="STD-Reimold-1993" TOTAL_1="50" TOTAL_2="50" VAR="3.2196969696969697" WEIGHT="25.72487679911032"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.895520695150721" CI_START="0.18650700224847944" DF="0" EFFECT_SIZE="0.8523742646569485" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" I2="0.0" ID="CMP-003.06.10" LOG_CI_END="0.5905655159025135" LOG_CI_START="-0.7293048583282791" LOG_EFFECT_SIZE="-0.06936967121288276" MODIFIED="2010-12-28 11:03:28 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Z="0.8367726730017188" STUDIES="1" TAU2="0.0" TOTAL_1="108" TOTAL_2="321" WEIGHT="100.0" Z="0.20602334873357933">
<NAME>Sotalol vs Dofetilide</NAME>
<DICH_DATA CI_END="3.895520695150721" CI_START="0.18650700224847944" EFFECT_SIZE="0.8523742646569485" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.5905655159025135" LOG_CI_START="-0.7293048583282791" LOG_EFFECT_SIZE="-0.06936967121288276" MODIFIED="2010-12-28 10:56:02 +0000" MODIFIED_BY="[Empty name]" ORDER="1002" O_E="-0.26573426573426584" SE="0.7752983912868903" STUDY_ID="STD-EMERALD-2000" TOTAL_1="108" TOTAL_2="321" VAR="1.6636510342804047" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.158078173696388" CI_START="0.2958209602781121" DF="0" EFFECT_SIZE="1.3496994475847384" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-003.06.11" LOG_CI_END="0.7894451977515701" LOG_CI_START="-0.5289710574837401" LOG_EFFECT_SIZE="0.13023707013391495" MODIFIED="2010-12-28 11:03:26 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Z="0.6985917785369835" STUDIES="1" TAU2="0.0" TOTAL_1="64" TOTAL_2="64" WEIGHT="100.0" Z="0.38722211729546946">
<NAME>Sotalol vs Other Beta-blockers</NAME>
<DICH_DATA CI_END="6.158078173696388" CI_START="0.2958209602781121" EFFECT_SIZE="1.3496994475847384" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7894451977515701" LOG_CI_START="-0.5289710574837401" LOG_EFFECT_SIZE="0.13023707013391495" MODIFIED="2010-12-27 14:17:54 +0000" MODIFIED_BY="[Empty name]" ORDER="920" O_E="0.5" SE="0.7744442345909389" STUDY_ID="STD-Plewan-2001" TOTAL_1="64" TOTAL_2="64" VAR="1.6673228346456692" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="17.88842904755587" CI_END="1.1310389498110394" CI_START="0.5423501032454678" DF="11" EFFECT_SIZE="0.7832107578453341" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="66" I2="38.50773608595356" ID="CMP-003.06.12" LOG_CI_END="0.053477561067575355" LOG_CI_START="-0.2657202728319098" LOG_EFFECT_SIZE="-0.10612135588216726" MODIFIED="2010-12-28 11:03:23 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.08420586578899347" P_Z="0.19249638145357417" STUDIES="12" TAU2="0.0" TOTAL_1="1413" TOTAL_2="1486" WEIGHT="99.99999999999999" Z="1.3032296176865825">
<NAME>Class III vs Class I drugs</NAME>
<DICH_DATA CI_END="0.46577058943281086" CI_START="0.10012592802471443" EFFECT_SIZE="0.21595303311965414" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="20" LOG_CI_END="-0.33182793797887145" LOG_CI_START="-0.9994534455978956" LOG_EFFECT_SIZE="-0.6656406917883836" ORDER="636" O_E="-9.965853658536584" SE="0.39216652797497664" STUDY_ID="STD-AFFIRM-Substudy-2003" TOTAL_1="289" TOTAL_2="121" VAR="6.502179486247125" WEIGHT="22.858831625036135"/>
<DICH_DATA CI_END="8.494096519204948" CI_START="0.39827148025027564" EFFECT_SIZE="1.839281488541781" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.9291171916110944" LOG_CI_START="-0.39982079179150626" LOG_EFFECT_SIZE="0.2646481999097941" ORDER="637" O_E="1.0" SE="0.7806247497997998" STUDY_ID="STD-Carunchio-1995" TOTAL_1="20" TOTAL_2="20" VAR="1.641025641025641" WEIGHT="5.769131550415405"/>
<DICH_DATA CI_END="2.6055637845792563" CI_START="0.0455892261772399" EFFECT_SIZE="0.3446529220743803" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4159017092248037" LOG_CI_START="-1.341137779366514" LOG_EFFECT_SIZE="-0.4626180350708552" ORDER="638" O_E="-1.0" SE="1.03209369308428" STUDY_ID="STD-Hohnloser-1995" TOTAL_1="25" TOTAL_2="25" VAR="0.9387755102040816" WEIGHT="3.300325893317996"/>
<DICH_DATA CI_END="14.054010447520609" CI_START="0.053392771755309834" EFFECT_SIZE="0.8662462537126538" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.147800272048707" LOG_CI_START="-1.2725175332198093" LOG_EFFECT_SIZE="-0.062358630585551224" ORDER="639" O_E="-0.0710382513661203" SE="1.4217066595810859" STUDY_ID="STD-Juul_x002d_Moller-1990" TOTAL_1="98" TOTAL_2="85" VAR="0.4947433945015241" WEIGHT="1.7393023333836868"/>
<DICH_DATA CI_END="19.593237019798483" CI_START="0.20026859286326398" EFFECT_SIZE="1.9808861672472384" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2921061921816375" LOG_CI_START="-0.6983871536303564" LOG_EFFECT_SIZE="0.2968595192756405" ORDER="640" O_E="0.5" SE="1.1692256444309357" STUDY_ID="STD-Kalusche-1994" TOTAL_1="41" TOTAL_2="41" VAR="0.7314814814814814" WEIGHT="2.571570356890894"/>
<DICH_DATA CI_END="7.453821092652186" CI_START="0.14188134823865767" EFFECT_SIZE="1.028376480747803" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8723789645639997" LOG_CI_START="-0.8480746932630546" LOG_EFFECT_SIZE="0.012152135650472512" ORDER="641" O_E="0.027397260273972712" SE="1.0106029949905684" STUDY_ID="STD-Kochiadakis-2004a" TOTAL_1="72" TOTAL_2="74" VAR="0.9791265748248036" WEIGHT="3.4421826651907157"/>
<DICH_DATA CI_END="8.986302071334348" CI_START="0.2586084833964725" EFFECT_SIZE="1.5244454565547287" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9535810131562618" LOG_CI_START="-0.5873572326194091" LOG_EFFECT_SIZE="0.18311189026842628" ORDER="642" O_E="0.5146198830409356" SE="0.9051547533359646" STUDY_ID="STD-Kochiadakis-2004b" TOTAL_1="85" TOTAL_2="86" VAR="1.2205464929379979" WEIGHT="4.290909968205337"/>
<DICH_DATA CI_END="2.2568552438380354" CI_START="0.6025218833358376" EFFECT_SIZE="1.1661066297443188" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="17" LOG_CI_END="0.3535037040407756" LOG_CI_START="-0.22002717507772368" LOG_EFFECT_SIZE="0.06673826448152591" ORDER="643" O_E="1.3539473684210535" SE="0.3368948774178453" STUDY_ID="STD-PAFAC-2004" TOTAL_1="383" TOTAL_2="377" VAR="8.810715643578991" WEIGHT="30.974639475676483"/>
<DICH_DATA CI_END="4.750163210320437" CI_START="0.534504958513047" EFFECT_SIZE="1.5934195272000804" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.6767085317562013" LOG_CI_START="-0.272048261559289" LOG_EFFECT_SIZE="0.20233013509845613" ORDER="644" O_E="1.5" SE="0.5573044368153888" STUDY_ID="STD-Reimold-1993" TOTAL_1="50" TOTAL_2="50" VAR="3.2196969696969697" WEIGHT="11.319052491493292"/>
<DICH_DATA CI_END="9.822538772625927" CI_START="0.2768175898549955" EFFECT_SIZE="1.648954671692207" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9922237517830808" LOG_CI_START="-0.5578063169094695" LOG_EFFECT_SIZE="0.21720871743680553" ORDER="645" O_E="0.6033057851239669" SE="0.9104953351225888" STUDY_ID="STD-SOCESP-1999" TOTAL_1="58" TOTAL_2="63" VAR="1.2062700635202515" WEIGHT="4.240720259207419"/>
<DICH_DATA CI_END="2.005313861276784" CI_START="0.14359729790741654" EFFECT_SIZE="0.5366168576700084" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.30218235578558145" LOG_CI_START="-0.8428537322033252" LOG_EFFECT_SIZE="-0.2703356882088719" ORDER="646" O_E="-1.3759590792838874" SE="0.6725998661047319" STUDY_ID="STD-SOPAT-2004" TOTAL_1="264" TOTAL_2="518" VAR="2.210479272703219" WEIGHT="7.77108254428072"/>
<DICH_DATA CI_END="15.251101319354364" CI_START="0.0563678520121386" EFFECT_SIZE="0.927184891050053" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1833012062827064" LOG_CI_START="-1.2489685143557785" LOG_EFFECT_SIZE="-0.03283365403653597" ORDER="647" O_E="-0.03703703703703698" SE="1.4287272738323407" STUDY_ID="STD-Vitolo-1981" TOTAL_1="28" TOTAL_2="26" VAR="0.48989310764293287" WEIGHT="1.7222508369019043"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="24.7800317030658" CI_END="4.7800463609968595" CI_START="2.7847682845158706" CI_STUDY="95" CI_TOTAL="95" DF="33" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.6484683779114153" ESTIMABLE="YES" EVENTS_1="244" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="0.6794321087935983" LOG_CI_START="0.4447890641622623" LOG_EFFECT_SIZE="0.5621105864779303" METHOD="PETO" MODIFIED="2014-09-25 09:10:46 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.8477015591818191" P_Q="0.6296511231023081" P_Z="5.967382774941142E-21" Q="3.4586659984423043" RANDOM="NO" SCALE="169.53677000201333" SORT_BY="STUDY" STUDIES="22" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="5779" TOTAL_2="3054" WEIGHT="600.0" Z="9.390574577281114">
<NAME>Subgroup analysis: Persistent atrial fibrillation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.781792121429671" CI_END="7.2074807818365665" CI_START="1.0792628874448345" DF="4" EFFECT_SIZE="2.7890440153945377" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="2" I2="0.0" ID="CMP-003.07.01" LOG_CI_END="0.8577834930507471" LOG_CI_START="0.0331272432562745" LOG_EFFECT_SIZE="0.44545536815351083" NO="1" P_CHI2="0.7758118978339124" P_Z="0.034223259956905866" STUDIES="5" TAU2="0.0" TOTAL_1="595" TOTAL_2="282" WEIGHT="100.0" Z="2.1174313018751922">
<NAME>Class Ia: Quinidine</NAME>
<DICH_DATA CI_END="527.8001204153296" CI_START="0.19326023079046073" EFFECT_SIZE="10.099642225480048" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.7224694849664623" LOG_CI_START="-0.713857506163923" LOG_EFFECT_SIZE="1.0043059894012696" ORDER="648" O_E="0.5675675675675675" SE="2.0185154846829296" STUDY_ID="STD-Byrne_x002d_Quinn-1970" TOTAL_1="32" TOTAL_2="42" VAR="0.2454346238130022" WEIGHT="5.759130805942829"/>
<DICH_DATA CI_END="406.0194289218663" CI_START="0.15885962215189478" EFFECT_SIZE="8.031194996067258" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.6085468160197243" LOG_CI_START="-0.7989864747561749" LOG_EFFECT_SIZE="0.9047801706317746" ORDER="649" O_E="0.52" SE="2.001601922563589" STUDY_ID="STD-Hillestad-1971" TOTAL_1="48" TOTAL_2="52" VAR="0.2496" WEIGHT="5.8568714830494"/>
<DICH_DATA CI_END="336.66216233879743" CI_START="0.13089423396819694" EFFECT_SIZE="6.638308206569926" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.527194308514986" LOG_CI_START="-0.8830794841669609" LOG_EFFECT_SIZE="0.8220574121740125" ORDER="650" O_E="0.4716981132075472" SE="2.0032117069489046" STUDY_ID="STD-Lloyd-1984" TOTAL_1="28" TOTAL_2="25" VAR="0.24919900320398714" WEIGHT="5.847462081209009"/>
<DICH_DATA CI_END="5.699142310829643" CI_START="0.5480449523248215" EFFECT_SIZE="1.767310435670826" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="2" LOG_CI_END="0.7558095016898109" LOG_CI_START="-0.2611838178916394" LOG_EFFECT_SIZE="0.24731284189908576" ORDER="651" O_E="1.5956989247311828" SE="0.5973869101202663" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="88" VAR="2.802132038385941" WEIGHT="65.7521122891094"/>
<DICH_DATA CI_END="55.574438326015326" CI_START="0.5394938182710082" EFFECT_SIZE="5.47558818126132" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.7448750821106622" LOG_CI_START="-0.26801352726683664" LOG_EFFECT_SIZE="0.7384307774219127" ORDER="652" O_E="1.2162162162162162" SE="1.182380733107656" STUDY_ID="STD-Sodermark-1975" TOTAL_1="110" TOTAL_2="75" VAR="0.7152952011941437" WEIGHT="16.784423340689358"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.8528446757893615" CI_END="7.672176321171792" CI_START="1.6021171540101034" DF="6" EFFECT_SIZE="3.5059556889298324" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="2" I2="0.0" ID="CMP-003.07.02" LOG_CI_END="0.8849185751886789" LOG_CI_START="0.20469427047469346" LOG_EFFECT_SIZE="0.5448064228316862" MODIFIED="2014-06-26 15:46:19 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8270768902104128" P_Z="0.0016920437897512556" STUDIES="9" TAU2="0.0" TOTAL_1="1039" TOTAL_2="456" WEIGHT="100.0" Z="3.139555466913769">
<NAME>All class I antiarrhythmics</NAME>
<DICH_DATA CI_END="527.8001204153296" CI_START="0.19326023079046073" EFFECT_SIZE="10.099642225480048" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.7224694849664623" LOG_CI_START="-0.713857506163923" LOG_EFFECT_SIZE="1.0043059894012696" ORDER="653" O_E="0.5675675675675675" SE="2.0185154846829296" STUDY_ID="STD-Byrne_x002d_Quinn-1970" TOTAL_1="32" TOTAL_2="42" VAR="0.2454346238130022" WEIGHT="3.918459154512033"/>
<DICH_DATA CI_END="30.496684243496865" CI_START="0.4438640212231169" EFFECT_SIZE="3.679182096919122" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.4842526231817788" LOG_CI_START="-0.35275005663611314" LOG_EFFECT_SIZE="0.5657512832728328" MODIFIED="2014-06-26 15:46:19 +0100" MODIFIED_BY="[Empty name]" ORDER="1032" O_E="1.1187845303867405" SE="1.0790644674349497" STUDY_ID="STD-Flec_x002d_SL-2012" TOTAL_1="281" TOTAL_2="81" VAR="0.8588260642996483" WEIGHT="13.7114918893942"/>
<DICH_DATA CI_END="406.0194289218663" CI_START="0.15885962215189478" EFFECT_SIZE="8.031194996067258" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.6085468160197243" LOG_CI_START="-0.7989864747561749" LOG_EFFECT_SIZE="0.9047801706317746" ORDER="654" O_E="0.52" SE="2.001601922563589" STUDY_ID="STD-Hillestad-1971" TOTAL_1="48" TOTAL_2="52" VAR="0.2496" WEIGHT="3.984961004162894"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="655" O_E="0.0" SE="0.0" STUDY_ID="STD-Karlson-1998" TOTAL_1="46" TOTAL_2="46" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="297.7026191115947" CI_START="0.059671421004225504" EFFECT_SIZE="4.214776188490744" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.473782655475443" LOG_CI_START="-1.2242336198239818" LOG_EFFECT_SIZE="0.6247745178257308" ORDER="656" O_E="0.30487804878048785" SE="2.172233065586672" STUDY_ID="STD-Lloyd-1984" TOTAL_1="57" TOTAL_2="25" VAR="0.2119274241522903" WEIGHT="3.3835036897418522"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="657" O_E="0.0" SE="0.0" STUDY_ID="STD-Okishige-2000" TOTAL_1="52" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.699142310829643" CI_START="0.5480449523248215" EFFECT_SIZE="1.767310435670826" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="2" LOG_CI_END="0.7558095016898109" LOG_CI_START="-0.2611838178916394" LOG_EFFECT_SIZE="0.24731284189908576" ORDER="658" O_E="1.5956989247311828" SE="0.5973869101202663" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="88" VAR="2.802132038385941" WEIGHT="44.73712700914846"/>
<DICH_DATA CI_END="55.574438326015326" CI_START="0.5394938182710082" EFFECT_SIZE="5.47558818126132" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.7448750821106622" LOG_CI_START="-0.26801352726683664" LOG_EFFECT_SIZE="0.7384307774219127" ORDER="659" O_E="1.2162162162162162" SE="1.182380733107656" STUDY_ID="STD-Sodermark-1975" TOTAL_1="110" TOTAL_2="75" VAR="0.7152952011941437" WEIGHT="11.419965878299335"/>
<DICH_DATA CI_END="51.9923506145551" CI_START="1.409198415185668" EFFECT_SIZE="8.559645909020338" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.7159394526682996" LOG_CI_START="0.14897214609272302" LOG_EFFECT_SIZE="0.9324557993805113" ORDER="660" O_E="2.5342465753424657" SE="0.9204443524957582" STUDY_ID="STD-Van-Gelder-1989" TOTAL_1="36" TOTAL_2="37" VAR="1.1803340213923812" WEIGHT="18.844491374741228"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.173075441872206E-4" CI_END="20.816021044336882" CI_START="3.013047601532521" DF="1" EFFECT_SIZE="7.919574627534595" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="0" I2="0.0" ID="CMP-003.07.03" LOG_CI_END="1.318397718275676" LOG_CI_START="0.4790059929145127" LOG_EFFECT_SIZE="0.8987018555950943" MODIFIED="2010-12-27 14:28:10 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9801780597650667" P_Z="2.705884906541976E-5" STUDIES="2" TAU2="0.0" TOTAL_1="280" TOTAL_2="282" WEIGHT="100.00000000000001" Z="4.196904059419498">
<NAME>Class II antiarrhythmics</NAME>
<DICH_DATA CI_END="22.29859542925435" CI_START="2.8383802776061007" EFFECT_SIZE="7.955620245129419" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="0" LOG_CI_END="1.3482775080465688" LOG_CI_START="0.453070580480903" LOG_EFFECT_SIZE="0.9006740442637359" ORDER="661" O_E="7.5" SE="0.5258489805978313" STUDY_ID="STD-Kuhlkamp-2000" TOTAL_1="197" TOTAL_2="197" VAR="3.616412213740458" WEIGHT="87.91895120156677"/>
<DICH_DATA CI_END="123.54811742880564" CI_START="0.4751849318665752" EFFECT_SIZE="7.662127887385501" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0918361322026024" LOG_CI_START="-0.3231373393041214" LOG_EFFECT_SIZE="0.8843493964492404" MODIFIED="2010-12-27 14:28:10 +0000" MODIFIED_BY="[Empty name]" ORDER="940" O_E="1.0119047619047619" SE="1.4185673714745302" STUDY_ID="STD-Nergardh-2007" TOTAL_1="83" TOTAL_2="85" VAR="0.4969355506673727" WEIGHT="12.081048798433239"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.1070747455572985" CI_END="6.019606886017625" CI_START="2.16754806440799" DF="5" EFFECT_SIZE="3.612172096437891" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="8" I2="29.647566980696965" ID="CMP-003.07.04" LOG_CI_END="0.7795681303262789" LOG_CI_START="0.33596873654074033" LOG_EFFECT_SIZE="0.5577684334335096" MODIFIED="2014-06-26 16:22:16 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.2127981540573466" P_Z="8.273679783866067E-7" STUDIES="7" TAU2="0.0" TOTAL_1="1096" TOTAL_2="647" WEIGHT="99.99999999999999" Z="4.928798625777762">
<NAME>Class III: Sotalol</NAME>
<DICH_DATA CI_END="15.578352286875832" CI_START="3.378033836655343" EFFECT_SIZE="7.254254003300663" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="1" LOG_CI_END="1.1925215206946869" LOG_CI_START="0.5286639954419476" LOG_EFFECT_SIZE="0.8605927580683173" ORDER="883" O_E="13.031319910514542" SE="0.3899531964812073" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="223" TOTAL_2="224" VAR="6.576200271259052" WEIGHT="44.65109591900014"/>
<DICH_DATA CI_END="117.83515727191389" CI_START="0.4549214596741123" EFFECT_SIZE="7.32159420803063" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0712748857922962" LOG_CI_START="-0.3420635760339083" LOG_EFFECT_SIZE="0.864605654879194" MODIFIED="2010-12-28 10:47:08 +0000" MODIFIED_BY="[Empty name]" ORDER="989" O_E="0.9906542056074767" SE="1.4176069586947648" STUDY_ID="STD-EMERALD-2000" TOTAL_1="108" TOTAL_2="106" VAR="0.49760911525577606" WEIGHT="3.378667227116022"/>
<DICH_DATA CI_END="5.799474586854827" CI_START="0.6466761115173374" EFFECT_SIZE="1.936590218572555" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="2" LOG_CI_END="0.7633886497067798" LOG_CI_START="-0.1893131817741152" LOG_EFFECT_SIZE="0.28703773396633225" ORDER="662" O_E="2.1104033970276" SE="0.5596217717620015" STUDY_ID="STD-PAFAC-2004" TOTAL_1="383" TOTAL_2="88" VAR="3.193087324283532" WEIGHT="21.68042980951228"/>
<DICH_DATA CI_END="6.158078173696388" CI_START="0.2958209602781121" EFFECT_SIZE="1.3496994475847384" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7894451977515701" LOG_CI_START="-0.5289710574837401" LOG_EFFECT_SIZE="0.13023707013391495" ORDER="663" O_E="0.5" SE="0.7744442345909389" STUDY_ID="STD-Plewan-2001" TOTAL_1="64" TOTAL_2="64" VAR="1.6673228346456692" WEIGHT="11.320791452029415"/>
<DICH_DATA CI_END="7.215517186548279" CI_START="0.5719127499801987" EFFECT_SIZE="2.031414846034215" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="0.8582674654661188" LOG_CI_START="-0.2426702213684847" LOG_EFFECT_SIZE="0.307798622048817" ORDER="664" O_E="1.6946564885496187" SE="0.6466962469760881" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="261" TOTAL_2="132" VAR="2.3911086956780263" WEIGHT="16.235153936854477"/>
<DICH_DATA CI_END="94.60661613296952" CI_START="0.1963508023594428" EFFECT_SIZE="4.309998258261872" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9759215090187774" LOG_CI_START="-0.7069673197077135" LOG_EFFECT_SIZE="0.6344770946555318" ORDER="665" O_E="0.588235294117647" SE="1.5759421785078283" STUDY_ID="STD-Singh-1991" TOTAL_1="24" TOTAL_2="10" VAR="0.40264234035860336" WEIGHT="2.7338616554876647"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-06-26 16:22:16 +0100" MODIFIED_BY="[Empty name]" ORDER="1067" O_E="0.0" SE="0.0" STUDY_ID="STD-Vijayalaskshmi-2006" TOTAL_1="33" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9122950142132715" CI_END="7.377337339964743" CI_START="0.6624007472720782" DF="2" EFFECT_SIZE="2.210600318210158" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" I2="0.0" ID="CMP-003.07.05" LOG_CI_END="0.8678996426878202" LOG_CI_START="-0.17887918628362767" LOG_EFFECT_SIZE="0.34451022820209626" MODIFIED="2014-09-24 16:41:26 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.6337203829715509" P_Z="0.19701397923500066" STUDIES="4" TAU2="0.0" TOTAL_1="385" TOTAL_2="208" WEIGHT="99.99999999999999" Z="1.2901056477140531">
<NAME>Class III: Amiodarone</NAME>
<DICH_DATA CI_END="55.02084639341907" CI_START="0.49948008648183356" EFFECT_SIZE="5.242310284110303" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.7405272669181524" LOG_CI_START="-0.3014818217592214" LOG_EFFECT_SIZE="0.7195227225794656" MODIFIED="2014-09-24 16:38:53 +0100" MODIFIED_BY="[Empty name]" ORDER="1084" O_E="1.1515151515151516" SE="1.1994862467970997" STUDY_ID="STD-Channer-2004" TOTAL_1="61" TOTAL_2="38" VAR="0.6950394482862015" WEIGHT="26.278133793706417"/>
<DICH_DATA CI_END="300.5347791914292" CI_START="0.05793575076459642" EFFECT_SIZE="4.172733883598098" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.4778947376928846" LOG_CI_START="-1.2370533608264507" LOG_EFFECT_SIZE="0.6204206884332171" MODIFIED="2014-09-24 16:39:00 +0100" MODIFIED_BY="[Empty name]" ORDER="1085" O_E="0.30000000000000004" SE="2.182178902359924" STUDY_ID="STD-GEFACA-2001" TOTAL_1="35" TOTAL_2="15" VAR="0.20999999999999996" WEIGHT="7.939704876155449"/>
<DICH_DATA CI_END="6.407894452568711" CI_START="0.32816178719016115" EFFECT_SIZE="1.4501124424267475" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="0.8067153496672391" LOG_CI_START="-0.4839119917736381" LOG_EFFECT_SIZE="0.1614016789468005" MODIFIED="2014-09-24 16:41:26 +0100" MODIFIED_BY="[Empty name]" ORDER="1088" O_E="0.6466165413533833" SE="0.7581208890707473" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="267" TOTAL_2="132" VAR="1.7398951339886728" WEIGHT="65.78216133013812"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-09-24 16:39:26 +0100" MODIFIED_BY="[Empty name]" ORDER="1086" O_E="0.0" SE="0.0" STUDY_ID="STD-Vijayalaskshmi-2006" TOTAL_1="22" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.666741840089722" CI_END="5.5304938271725455" CI_START="2.33309336038371" DF="10" EFFECT_SIZE="3.5920966618145673" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="9" I2="0.0" ID="CMP-003.07.06" LOG_CI_END="0.7427639119268918" LOG_CI_START="0.36793211774284235" LOG_EFFECT_SIZE="0.5553480148348671" MODIFIED="2014-09-24 16:44:57 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.5639959693900922" P_Z="6.3323146926719915E-9" STUDIES="12" TAU2="0.0" TOTAL_1="2384" TOTAL_2="1179" WEIGHT="100.0" Z="5.807736295858082">
<NAME>All class III antiarrhythmics</NAME>
<DICH_DATA CI_END="15.578352286875832" CI_START="3.378033836655343" EFFECT_SIZE="7.254254003300663" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="1" LOG_CI_END="1.1925215206946869" LOG_CI_START="0.5286639954419476" LOG_EFFECT_SIZE="0.8605927580683173" ORDER="884" O_E="13.031319910514542" SE="0.3899531964812073" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="223" TOTAL_2="224" VAR="6.576200271259052" WEIGHT="31.880349820035825"/>
<DICH_DATA CI_END="55.02084639341907" CI_START="0.49948008648183356" EFFECT_SIZE="5.242310284110303" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.7405272669181524" LOG_CI_START="-0.3014818217592214" LOG_EFFECT_SIZE="0.7195227225794656" ORDER="666" O_E="1.1515151515151516" SE="1.1994862467970997" STUDY_ID="STD-Channer-2004" TOTAL_1="61" TOTAL_2="38" VAR="0.6950394482862015" WEIGHT="3.3694382525011672"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="667" O_E="0.0" SE="0.0" STUDY_ID="STD-DAFNE-2003" TOTAL_1="151" TOTAL_2="48" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="55.165081595336" CI_START="1.0813553882341789" EFFECT_SIZE="7.723539229232589" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.741664264885331" LOG_CI_START="0.033968448609891524" LOG_EFFECT_SIZE="0.8878163567476114" ORDER="668" O_E="2.0316205533596836" SE="1.0031089757108158" STUDY_ID="STD-DIAMOND-2001" TOTAL_1="249" TOTAL_2="257" VAR="0.9938109260315962" WEIGHT="4.817833805234026"/>
<DICH_DATA CI_END="21.677139410855276" CI_START="0.6853566945547612" EFFECT_SIZE="3.854422474771871" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="1.3360019706685393" LOG_CI_START="-0.16408334068537192" LOG_EFFECT_SIZE="0.5859593149915837" MODIFIED="2010-12-28 10:35:23 +0000" MODIFIED_BY="[Empty name]" ORDER="966" O_E="1.7377049180327866" SE="0.8811575374313362" STUDY_ID="STD-EMERALD-2000" TOTAL_1="321" TOTAL_2="106" VAR="1.2879318371935455" WEIGHT="6.2436841672144725"/>
<DICH_DATA CI_END="117.83515727191389" CI_START="0.4549214596741123" EFFECT_SIZE="7.32159420803063" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0712748857922962" LOG_CI_START="-0.3420635760339083" LOG_EFFECT_SIZE="0.864605654879194" MODIFIED="2010-12-28 10:47:12 +0000" MODIFIED_BY="[Empty name]" ORDER="990" O_E="0.9906542056074767" SE="1.4176069586947648" STUDY_ID="STD-EMERALD-2000" TOTAL_1="108" TOTAL_2="106" VAR="0.49760911525577606" WEIGHT="2.4123280942834517"/>
<DICH_DATA CI_END="300.5347791914292" CI_START="0.05793575076459642" EFFECT_SIZE="4.172733883598098" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.4778947376928846" LOG_CI_START="-1.2370533608264507" LOG_EFFECT_SIZE="0.6204206884332171" ORDER="669" O_E="0.30000000000000004" SE="2.182178902359924" STUDY_ID="STD-GEFACA-2001" TOTAL_1="35" TOTAL_2="15" VAR="0.20999999999999996" WEIGHT="1.0180458602313445"/>
<DICH_DATA CI_END="5.799474586854827" CI_START="0.6466761115173374" EFFECT_SIZE="1.936590218572555" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="2" LOG_CI_END="0.7633886497067798" LOG_CI_START="-0.1893131817741152" LOG_EFFECT_SIZE="0.28703773396633225" ORDER="670" O_E="2.1104033970276" SE="0.5596217717620015" STUDY_ID="STD-PAFAC-2004" TOTAL_1="383" TOTAL_2="88" VAR="3.193087324283532" WEIGHT="15.479568246876337"/>
<DICH_DATA CI_END="6.158078173696388" CI_START="0.2958209602781121" EFFECT_SIZE="1.3496994475847384" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7894451977515701" LOG_CI_START="-0.5289710574837401" LOG_EFFECT_SIZE="0.13023707013391495" ORDER="671" O_E="0.5" SE="0.7744442345909389" STUDY_ID="STD-Plewan-2001" TOTAL_1="64" TOTAL_2="64" VAR="1.6673228346456692" WEIGHT="8.082910045143878"/>
<DICH_DATA CI_END="5.644101920661696" CI_START="0.5088591068434735" EFFECT_SIZE="1.6947131504421165" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="2" LOG_CI_END="0.7515948476020321" LOG_CI_START="-0.2934024486861732" LOG_EFFECT_SIZE="0.22909619945792942" ORDER="672" O_E="1.4000000000000004" SE="0.6138365846597347" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="528" TOTAL_2="132" VAR="2.6539605462822458" WEIGHT="12.865969273142658"/>
<DICH_DATA CI_END="9.847085725410356" CI_START="0.8048510735042969" EFFECT_SIZE="2.8152153588998052" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" LOG_CI_END="0.9933077187573561" LOG_CI_START="-0.09428447235114018" LOG_EFFECT_SIZE="0.44951162320310784" ORDER="673" O_E="2.5359999999999996" SE="0.6388570367253034" STUDY_ID="STD-SAFIRE_x002d_D-2000" TOTAL_1="182" TOTAL_2="68" VAR="2.45014978313253" WEIGHT="11.877927826975235"/>
<DICH_DATA CI_END="94.60661613296952" CI_START="0.1963508023594428" EFFECT_SIZE="4.309998258261872" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9759215090187774" LOG_CI_START="-0.7069673197077135" LOG_EFFECT_SIZE="0.6344770946555318" ORDER="674" O_E="0.588235294117647" SE="1.5759421785078283" STUDY_ID="STD-Singh-1991" TOTAL_1="24" TOTAL_2="10" VAR="0.40264234035860336" WEIGHT="1.951944608361601"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-09-24 16:44:54 +0100" MODIFIED_BY="[Empty name]" ORDER="1087" O_E="0.0" SE="0.0" STUDY_ID="STD-Vijayalaskshmi-2006" TOTAL_1="55" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="34.298247435750525" CI_END="3.4216650387313012" CI_START="2.275841807493775" CI_STUDY="95" CI_TOTAL="95" DF="19" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.7905498286869026" ESTIMABLE="YES" EVENTS_1="363" EVENTS_2="78" I2="44.60358350498256" I2_Q="42.68950480626388" ID="CMP-003.08" LOG_CI_END="0.5342374923614691" LOG_CI_START="0.3571420712027347" LOG_EFFECT_SIZE="0.4456897817821019" METHOD="PETO" MODIFIED="2014-06-26 15:46:29 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.016943461563259765" P_Q="0.13697441030264368" P_Z="5.894977046368278E-23" Q="6.9795244073151705" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="7230" TOTAL_2="5036" WEIGHT="500.0" Z="9.865144054599432">
<NAME>Sensitivity analysis: Best quality studies</NAME>
<GROUP_LABEL_1>Antiarrhythmic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.13375288319520534" CI_END="3.6026915329458746" CI_START="0.6446028100183465" DF="1" EFFECT_SIZE="1.5239111147853128" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="5" I2="0.0" ID="CMP-003.08.01" LOG_CI_END="0.5566270788657153" LOG_CI_START="-0.1907078055987356" LOG_EFFECT_SIZE="0.1829596366334898" NO="1" P_CHI2="0.7145723136565407" P_Z="0.33722556349164146" STUDIES="2" TAU2="0.0" TOTAL_1="895" TOTAL_2="339" WEIGHT="99.99999999999999" Z="0.9596616078831866">
<NAME>Class Ia: Quinidine</NAME>
<DICH_DATA CI_END="5.699142310829643" CI_START="0.5480449523248215" EFFECT_SIZE="1.767310435670826" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="2" LOG_CI_END="0.7558095016898109" LOG_CI_START="-0.2611838178916394" LOG_EFFECT_SIZE="0.24731284189908576" ORDER="675" O_E="1.5956989247311828" SE="0.5973869101202663" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="88" VAR="2.802132038385941" WEIGHT="54.00006835876644"/>
<DICH_DATA CI_END="4.553625992405196" CI_START="0.36014000476185415" EFFECT_SIZE="1.2806025482516072" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.6583573573935461" LOG_CI_START="-0.44352863402351056" LOG_EFFECT_SIZE="0.10741436168501778" ORDER="676" O_E="0.5903771131339406" SE="0.6472532857820044" STUDY_ID="STD-SOPAT-2004" TOTAL_1="518" TOTAL_2="251" VAR="2.386994797100812" WEIGHT="45.999931641233545"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.2567990462274707" CI_END="4.109419928777807" CI_START="1.161111597287511" DF="4" EFFECT_SIZE="2.1843752281667017" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="7" I2="0.0" ID="CMP-003.08.02" LOG_CI_END="0.6137805227251533" LOG_CI_START="0.06487396285398253" LOG_EFFECT_SIZE="0.339327242789568" MODIFIED="2014-06-26 15:46:29 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5158062372185469" P_Z="0.015382295994133523" STUDIES="6" TAU2="0.0" TOTAL_1="1336" TOTAL_2="529" WEIGHT="99.99999999999999" Z="2.4232509627756125">
<NAME>All class I antiarrhythmics</NAME>
<DICH_DATA CI_END="30.496684243496865" CI_START="0.4438640212231169" EFFECT_SIZE="3.679182096919122" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.4842526231817788" LOG_CI_START="-0.35275005663611314" LOG_EFFECT_SIZE="0.5657512832728328" MODIFIED="2014-06-26 15:46:29 +0100" MODIFIED_BY="[Empty name]" ORDER="1033" O_E="1.1187845303867405" SE="1.0790644674349497" STUDY_ID="STD-Flec_x002d_SL-2012" TOTAL_1="281" TOTAL_2="81" VAR="0.8588260642996483" WEIGHT="8.928474492669425"/>
<DICH_DATA CI_END="5.699142310829643" CI_START="0.5480449523248215" EFFECT_SIZE="1.767310435670826" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="2" LOG_CI_END="0.7558095016898109" LOG_CI_START="-0.2611838178916394" LOG_EFFECT_SIZE="0.24731284189908576" ORDER="677" O_E="1.5956989247311828" SE="0.5973869101202663" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="88" VAR="2.802132038385941" WEIGHT="29.131352051154675"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="678" O_E="0.0" SE="0.0" STUDY_ID="STD-SMART-2002" TOTAL_1="47" TOTAL_2="47" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.553625992405196" CI_START="0.36014000476185415" EFFECT_SIZE="1.2806025482516072" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.6583573573935461" LOG_CI_START="-0.44352863402351056" LOG_EFFECT_SIZE="0.10741436168501778" ORDER="679" O_E="0.5903771131339406" SE="0.6472532857820044" STUDY_ID="STD-SOPAT-2004" TOTAL_1="518" TOTAL_2="251" VAR="2.386994797100812" WEIGHT="24.815527900202735"/>
<DICH_DATA CI_END="7.162603296803337" CI_START="0.5675865193660641" EFFECT_SIZE="2.0162829848095485" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="2" LOG_CI_END="0.8550708982785108" LOG_CI_START="-0.24596792793347777" LOG_EFFECT_SIZE="0.3045514851725165" ORDER="680" O_E="1.6764705882352935" SE="0.646755656747012" STUDY_ID="STD-Stroobandt-1997" TOTAL_1="77" TOTAL_2="25" VAR="2.390669430264826" WEIGHT="24.853729894574634"/>
<DICH_DATA CI_END="51.9923506145551" CI_START="1.409198415185668" EFFECT_SIZE="8.559645909020338" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.7159394526682996" LOG_CI_START="0.14897214609272302" LOG_EFFECT_SIZE="0.9324557993805113" ORDER="681" O_E="2.5342465753424657" SE="0.9204443524957582" STUDY_ID="STD-Van-Gelder-1989" TOTAL_1="36" TOTAL_2="37" VAR="1.1803340213923812" WEIGHT="12.270915661398517"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.173075441872206E-4" CI_END="20.816021044336882" CI_START="3.013047601532521" DF="1" EFFECT_SIZE="7.919574627534595" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="0" I2="0.0" ID="CMP-003.08.03" LOG_CI_END="1.318397718275676" LOG_CI_START="0.4790059929145127" LOG_EFFECT_SIZE="0.8987018555950943" MODIFIED="2010-12-27 14:28:17 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9801780597650667" P_Z="2.705884906541976E-5" STUDIES="2" TAU2="0.0" TOTAL_1="280" TOTAL_2="282" WEIGHT="100.00000000000001" Z="4.196904059419498">
<NAME>Class II antiarrhythmics</NAME>
<DICH_DATA CI_END="22.29859542925435" CI_START="2.8383802776061007" EFFECT_SIZE="7.955620245129419" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="0" LOG_CI_END="1.3482775080465688" LOG_CI_START="0.453070580480903" LOG_EFFECT_SIZE="0.9006740442637359" ORDER="682" O_E="7.5" SE="0.5258489805978313" STUDY_ID="STD-Kuhlkamp-2000" TOTAL_1="197" TOTAL_2="197" VAR="3.616412213740458" WEIGHT="87.91895120156677"/>
<DICH_DATA CI_END="123.54811742880564" CI_START="0.4751849318665752" EFFECT_SIZE="7.662127887385501" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0918361322026024" LOG_CI_START="-0.3231373393041214" LOG_EFFECT_SIZE="0.8843493964492404" MODIFIED="2010-12-27 14:28:17 +0000" MODIFIED_BY="[Empty name]" ORDER="941" O_E="1.0119047619047619" SE="1.4185673714745302" STUDY_ID="STD-Nergardh-2007" TOTAL_1="83" TOTAL_2="85" VAR="0.4969355506673727" WEIGHT="12.081048798433239"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="11.324175464427377" CI_END="4.530532497564155" CI_START="1.7067037536382275" DF="3" EFFECT_SIZE="2.7806971822858952" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="12" I2="73.50800498081387" ID="CMP-003.08.04" LOG_CI_END="0.6561492499515855" LOG_CI_START="0.23215814365388185" LOG_EFFECT_SIZE="0.4441536968027337" MODIFIED="2010-08-27 18:16:49 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.01009609932998301" P_Z="4.019823530047144E-5" STUDIES="4" TAU2="0.0" TOTAL_1="1054" TOTAL_2="632" WEIGHT="99.99999999999999" Z="4.106337309455">
<NAME>Class III: Sotalol</NAME>
<DICH_DATA CI_END="15.578352286875832" CI_START="3.378033836655343" EFFECT_SIZE="7.254254003300663" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="1" LOG_CI_END="1.1925215206946869" LOG_CI_START="0.5286639954419476" LOG_EFFECT_SIZE="0.8605927580683173" ORDER="885" O_E="13.031319910514542" SE="0.3899531964812073" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="223" TOTAL_2="224" VAR="6.576200271259052" WEIGHT="40.7909414096288"/>
<DICH_DATA CI_END="3.4562033102117318" CI_START="0.6105449035678854" EFFECT_SIZE="1.452641496290199" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="6" LOG_CI_END="0.538599281812067" LOG_CI_START="-0.2142823896149186" LOG_EFFECT_SIZE="0.16215844609857416" ORDER="683" O_E="1.90909090909091" SE="0.44224642062059033" STUDY_ID="STD-Benditt-1999" TOTAL_1="184" TOTAL_2="69" VAR="5.112947658402205" WEIGHT="31.714658885297716"/>
<DICH_DATA CI_END="5.799474586854827" CI_START="0.6466761115173374" EFFECT_SIZE="1.936590218572555" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="2" LOG_CI_END="0.7633886497067798" LOG_CI_START="-0.1893131817741152" LOG_EFFECT_SIZE="0.28703773396633225" ORDER="684" O_E="2.1104033970276" SE="0.5596217717620015" STUDY_ID="STD-PAFAC-2004" TOTAL_1="383" TOTAL_2="88" VAR="3.193087324283532" WEIGHT="19.80612399076785"/>
<DICH_DATA CI_END="3.6919662362261247" CI_START="0.10917802752131842" EFFECT_SIZE="0.6348870697584525" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5672577206616394" LOG_CI_START="-0.961864756195521" LOG_EFFECT_SIZE="-0.19730351776694086" ORDER="685" O_E="-0.563106796116505" SE="0.8982141121842323" STUDY_ID="STD-SOPAT-2004" TOTAL_1="264" TOTAL_2="251" VAR="1.2394820783909704" WEIGHT="7.688275714305622"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.603378327041119" CI_END="3.695084877355326" CI_START="2.2021863949017932" DF="6" EFFECT_SIZE="2.8525892878084047" ESTIMABLE="YES" EVENTS_1="201" EVENTS_2="54" I2="52.39371663447785" ID="CMP-003.08.05" LOG_CI_END="0.5676244187372559" LOG_CI_START="0.3428540752403458" LOG_EFFECT_SIZE="0.45523924698880086" MODIFIED="2010-11-20 11:17:01 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.04978503355446362" P_Z="2.0342852987997724E-15" STUDIES="7" TAU2="0.0" TOTAL_1="3665" TOTAL_2="3254" WEIGHT="100.00000000000001" Z="7.939237130359679">
<NAME>All class III antiarrhythmics</NAME>
<DICH_DATA CI_END="15.578352286875832" CI_START="3.378033836655343" EFFECT_SIZE="7.254254003300663" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="1" LOG_CI_END="1.1925215206946869" LOG_CI_START="0.5286639954419476" LOG_EFFECT_SIZE="0.8605927580683173" ORDER="886" O_E="13.031319910514542" SE="0.3899531964812073" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="223" TOTAL_2="224" VAR="6.576200271259052" WEIGHT="11.463790830942227"/>
<DICH_DATA CI_END="3.798287102460783" CI_START="2.0365838541950883" EFFECT_SIZE="2.781282111988835" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="42" LOG_CI_END="0.579587788811204" LOG_CI_START="0.3089022964080104" LOG_EFFECT_SIZE="0.44424504260960723" MODIFIED="2010-11-20 11:17:01 +0000" MODIFIED_BY="[Empty name]" ORDER="912" O_E="40.46067415730337" SE="0.15900199815243318" STUDY_ID="STD-ATHENA-2009" TOTAL_1="2301" TOTAL_2="2327" VAR="39.554403167632216" WEIGHT="68.9521890533422"/>
<DICH_DATA CI_END="3.4562033102117318" CI_START="0.6105449035678854" EFFECT_SIZE="1.452641496290199" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="6" LOG_CI_END="0.538599281812067" LOG_CI_START="-0.2142823896149186" LOG_EFFECT_SIZE="0.16215844609857416" ORDER="686" O_E="1.90909090909091" SE="0.44224642062059033" STUDY_ID="STD-Benditt-1999" TOTAL_1="184" TOTAL_2="69" VAR="5.112947658402205" WEIGHT="8.913013604778307"/>
<DICH_DATA CI_END="55.02084639341907" CI_START="0.49948008648183356" EFFECT_SIZE="5.242310284110303" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.7405272669181524" LOG_CI_START="-0.3014818217592214" LOG_EFFECT_SIZE="0.7195227225794656" ORDER="687" O_E="1.1515151515151516" SE="1.1994862467970997" STUDY_ID="STD-Channer-2004" TOTAL_1="61" TOTAL_2="38" VAR="0.6950394482862015" WEIGHT="1.2116095200490329"/>
<DICH_DATA CI_END="55.165081595336" CI_START="1.0813553882341789" EFFECT_SIZE="7.723539229232589" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.741664264885331" LOG_CI_START="0.033968448609891524" LOG_EFFECT_SIZE="0.8878163567476114" ORDER="688" O_E="2.0316205533596836" SE="1.0031089757108158" STUDY_ID="STD-DIAMOND-2001" TOTAL_1="249" TOTAL_2="257" VAR="0.9938109260315962" WEIGHT="1.7324351618856628"/>
<DICH_DATA CI_END="5.799474586854827" CI_START="0.6466761115173374" EFFECT_SIZE="1.936590218572555" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="2" LOG_CI_END="0.7633886497067798" LOG_CI_START="-0.1893131817741152" LOG_EFFECT_SIZE="0.28703773396633225" ORDER="689" O_E="2.1104033970276" SE="0.5596217717620015" STUDY_ID="STD-PAFAC-2004" TOTAL_1="383" TOTAL_2="88" VAR="3.193087324283532" WEIGHT="5.566266792466644"/>
<DICH_DATA CI_END="3.6919662362261247" CI_START="0.10917802752131842" EFFECT_SIZE="0.6348870697584525" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5672577206616394" LOG_CI_START="-0.961864756195521" LOG_EFFECT_SIZE="-0.19730351776694086" ORDER="690" O_E="-0.563106796116505" SE="0.8982141121842323" STUDY_ID="STD-SOPAT-2004" TOTAL_1="264" TOTAL_2="251" VAR="1.2394820783909704" WEIGHT="2.1606950365359223"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="43.284787212753955" CI_END="3.329136059290817" CI_START="2.308890622264728" CI_STUDY="95" CI_TOTAL="95" DF="26" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.7724738100728596" ESTIMABLE="YES" EVENTS_1="450" EVENTS_2="93" I2="39.93270690646009" I2_Q="45.23275118141934" ID="CMP-003.09" LOG_CI_END="0.5223315448087308" LOG_CI_START="0.3634033598240626" LOG_EFFECT_SIZE="0.4428674523163967" METHOD="PETO" MODIFIED="2014-06-26 15:46:38 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.018021410147857186" P_Q="0.12068650333508979" P_Z="8.92674980425345E-28" Q="7.303635085359511" RANDOM="NO" SCALE="177.97322933533022" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="11207" TOTAL_2="7127" WEIGHT="500.0" Z="10.923226192369633">
<NAME>Sensitivity analysis: Studies &gt; 200 patients</NAME>
<GROUP_LABEL_1>Antiarrhythmic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.13375288319520534" CI_END="3.6026915329458746" CI_START="0.6446028100183465" DF="1" EFFECT_SIZE="1.5239111147853128" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="5" I2="0.0" ID="CMP-003.09.01" LOG_CI_END="0.5566270788657153" LOG_CI_START="-0.1907078055987356" LOG_EFFECT_SIZE="0.1829596366334898" NO="1" P_CHI2="0.7145723136565407" P_Z="0.33722556349164146" STUDIES="2" TAU2="0.0" TOTAL_1="895" TOTAL_2="339" WEIGHT="99.99999999999999" Z="0.9596616078831866">
<NAME>Class Ia: Quinidine</NAME>
<DICH_DATA CI_END="5.699142310829643" CI_START="0.5480449523248215" EFFECT_SIZE="1.767310435670826" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="2" LOG_CI_END="0.7558095016898109" LOG_CI_START="-0.2611838178916394" LOG_EFFECT_SIZE="0.24731284189908576" ORDER="691" O_E="1.5956989247311828" SE="0.5973869101202663" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="88" VAR="2.802132038385941" WEIGHT="54.00006835876644"/>
<DICH_DATA CI_END="4.553625992405196" CI_START="0.36014000476185415" EFFECT_SIZE="1.2806025482516072" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.6583573573935461" LOG_CI_START="-0.44352863402351056" LOG_EFFECT_SIZE="0.10741436168501778" ORDER="692" O_E="0.5903771131339406" SE="0.6472532857820044" STUDY_ID="STD-SOPAT-2004" TOTAL_1="518" TOTAL_2="251" VAR="2.386994797100812" WEIGHT="45.999931641233545"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7062158319937056" CI_END="3.8321130440011033" CI_START="0.7783876014167839" DF="2" EFFECT_SIZE="1.7270985150471265" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="5" I2="0.0" ID="CMP-003.09.02" LOG_CI_END="0.5834383119048793" LOG_CI_START="-0.10880409036452295" LOG_EFFECT_SIZE="0.23731711077017822" MODIFIED="2014-06-26 15:46:38 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7025014779367076" P_Z="0.17899875318625422" STUDIES="4" TAU2="0.0" TOTAL_1="1573" TOTAL_2="546" WEIGHT="100.0" Z="1.343844261778216">
<NAME>All class I antiarrhythmics</NAME>
<DICH_DATA CI_END="30.496684243496865" CI_START="0.4438640212231169" EFFECT_SIZE="3.679182096919122" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.4842526231817788" LOG_CI_START="-0.35275005663611314" LOG_EFFECT_SIZE="0.5657512832728328" MODIFIED="2014-06-26 15:46:38 +0100" MODIFIED_BY="[Empty name]" ORDER="1034" O_E="1.1187845303867405" SE="1.0790644674349497" STUDY_ID="STD-Flec_x002d_SL-2012" TOTAL_1="281" TOTAL_2="81" VAR="0.8588260642996483" WEIGHT="14.200276995047034"/>
<DICH_DATA CI_END="5.699142310829643" CI_START="0.5480449523248215" EFFECT_SIZE="1.767310435670826" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="2" LOG_CI_END="0.7558095016898109" LOG_CI_START="-0.2611838178916394" LOG_EFFECT_SIZE="0.24731284189908576" ORDER="693" O_E="1.5956989247311828" SE="0.5973869101202663" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="88" VAR="2.802132038385941" WEIGHT="46.33190907430687"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="694" O_E="0.0" SE="0.0" STUDY_ID="STD-RAFT-2003" TOTAL_1="397" TOTAL_2="126" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.553625992405196" CI_START="0.36014000476185415" EFFECT_SIZE="1.2806025482516072" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.6583573573935461" LOG_CI_START="-0.44352863402351056" LOG_EFFECT_SIZE="0.10741436168501778" ORDER="695" O_E="0.5903771131339406" SE="0.6472532857820044" STUDY_ID="STD-SOPAT-2004" TOTAL_1="518" TOTAL_2="251" VAR="2.386994797100812" WEIGHT="39.4678139306461"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="22.29859542925435" CI_START="2.8383802776061007" DF="0" EFFECT_SIZE="7.955620245129419" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="0" I2="0.0" ID="CMP-003.09.03" LOG_CI_END="1.3482775080465688" LOG_CI_START="0.453070580480903" LOG_EFFECT_SIZE="0.9006740442637359" NO="3" P_CHI2="1.0" P_Z="8.017801767255479E-5" STUDIES="1" TAU2="0.0" TOTAL_1="197" TOTAL_2="197" WEIGHT="100.0" Z="3.943867354483735">
<NAME>Class II antiarrhythmics</NAME>
<DICH_DATA CI_END="22.29859542925435" CI_START="2.8383802776061007" EFFECT_SIZE="7.955620245129419" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="0" LOG_CI_END="1.3482775080465688" LOG_CI_START="0.453070580480903" LOG_EFFECT_SIZE="0.9006740442637359" ORDER="696" O_E="7.5" SE="0.5258489805978313" STUDY_ID="STD-Kuhlkamp-2000" TOTAL_1="197" TOTAL_2="197" VAR="3.616412213740458" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.02247040260336" CI_END="4.297680468026667" CI_START="1.748973687682068" DF="5" EFFECT_SIZE="2.741629088086825" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="14" I2="58.41120973841371" ID="CMP-003.09.04" LOG_CI_END="0.6332341226185506" LOG_CI_START="0.24278327581347237" LOG_EFFECT_SIZE="0.4380086992160115" MODIFIED="2010-12-28 10:47:19 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.03448122985126234" P_Z="1.0956309048177178E-5" STUDIES="6" TAU2="0.0" TOTAL_1="1423" TOTAL_2="870" WEIGHT="100.0" Z="4.397384625508026">
<NAME>Class III: Sotalol</NAME>
<DICH_DATA CI_END="15.578352286875832" CI_START="3.378033836655343" EFFECT_SIZE="7.254254003300663" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="1" LOG_CI_END="1.1925215206946869" LOG_CI_START="0.5286639954419476" LOG_EFFECT_SIZE="0.8605927580683173" ORDER="887" O_E="13.031319910514542" SE="0.3899531964812073" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="223" TOTAL_2="224" VAR="6.576200271259052" WEIGHT="34.59258150430757"/>
<DICH_DATA CI_END="3.4562033102117318" CI_START="0.6105449035678854" EFFECT_SIZE="1.452641496290199" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="6" LOG_CI_END="0.538599281812067" LOG_CI_START="-0.2142823896149186" LOG_EFFECT_SIZE="0.16215844609857416" ORDER="697" O_E="1.90909090909091" SE="0.44224642062059033" STUDY_ID="STD-Benditt-1999" TOTAL_1="184" TOTAL_2="69" VAR="5.112947658402205" WEIGHT="26.895479350520752"/>
<DICH_DATA CI_END="117.83515727191389" CI_START="0.4549214596741123" EFFECT_SIZE="7.32159420803063" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0712748857922962" LOG_CI_START="-0.3420635760339083" LOG_EFFECT_SIZE="0.864605654879194" MODIFIED="2010-12-28 10:47:19 +0000" MODIFIED_BY="[Empty name]" ORDER="991" O_E="0.9906542056074767" SE="1.4176069586947648" STUDY_ID="STD-EMERALD-2000" TOTAL_1="108" TOTAL_2="106" VAR="0.49760911525577606" WEIGHT="2.6175577334532987"/>
<DICH_DATA CI_END="5.799474586854827" CI_START="0.6466761115173374" EFFECT_SIZE="1.936590218572555" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="2" LOG_CI_END="0.7633886497067798" LOG_CI_START="-0.1893131817741152" LOG_EFFECT_SIZE="0.28703773396633225" ORDER="698" O_E="2.1104033970276" SE="0.5596217717620015" STUDY_ID="STD-PAFAC-2004" TOTAL_1="383" TOTAL_2="88" VAR="3.193087324283532" WEIGHT="16.79649781932535"/>
<DICH_DATA CI_END="7.215517186548279" CI_START="0.5719127499801987" EFFECT_SIZE="2.031414846034215" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="0.8582674654661188" LOG_CI_START="-0.2426702213684847" LOG_EFFECT_SIZE="0.307798622048817" ORDER="699" O_E="1.6946564885496187" SE="0.6466962469760881" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="261" TOTAL_2="132" VAR="2.3911086956780263" WEIGHT="12.577874612852154"/>
<DICH_DATA CI_END="3.6919662362261247" CI_START="0.10917802752131842" EFFECT_SIZE="0.6348870697584525" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5672577206616394" LOG_CI_START="-0.961864756195521" LOG_EFFECT_SIZE="-0.19730351776694086" ORDER="700" O_E="-0.563106796116505" SE="0.8982141121842323" STUDY_ID="STD-SOPAT-2004" TOTAL_1="264" TOTAL_2="251" VAR="1.2394820783909704" WEIGHT="6.520008979540878"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="23.118713009602143" CI_END="3.5500503079495993" CI_START="2.295811607550263" DF="14" EFFECT_SIZE="2.8548636927843116" ESTIMABLE="YES" EVENTS_1="297" EVENTS_2="69" I2="39.442995835515454" ID="CMP-003.09.05" LOG_CI_END="0.5502345075086429" LOG_CI_START="0.3609362473329862" LOG_EFFECT_SIZE="0.45558537742081456" MODIFIED="2010-12-28 10:47:23 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.05836531480200069" P_Z="3.943026450542944E-21" STUDIES="14" TAU2="0.0" TOTAL_1="7119" TOTAL_2="5175" WEIGHT="100.00000000000001" Z="9.434116624202472">
<NAME>All class III antiarrhythmics</NAME>
<DICH_DATA CI_END="15.477705818968246" CI_START="2.578995508050132" EFFECT_SIZE="6.317984946329052" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="1" LOG_CI_END="1.1897065878713655" LOG_CI_START="0.4114505857088024" LOG_EFFECT_SIZE="0.800578586790084" ORDER="842" O_E="8.820627802690582" SE="0.45715142809963144" STUDY_ID="STD-A_x002d_COMET_x002d_I-2006" TOTAL_1="227" TOTAL_2="219" VAR="4.784976821563888" WEIGHT="5.916274109254555"/>
<DICH_DATA CI_END="15.578352286875832" CI_START="3.378033836655343" EFFECT_SIZE="7.254254003300663" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="1" LOG_CI_END="1.1925215206946869" LOG_CI_START="0.5286639954419476" LOG_EFFECT_SIZE="0.8605927580683173" ORDER="888" O_E="13.031319910514542" SE="0.3899531964812073" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="223" TOTAL_2="224" VAR="6.576200271259052" WEIGHT="8.130990985533499"/>
<DICH_DATA CI_END="43.61351559948655" CI_START="1.2876841747226375" EFFECT_SIZE="7.49402654395337" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.6396210957062067" LOG_CI_START="0.10980935836981624" LOG_EFFECT_SIZE="0.8747152270380114" MODIFIED="2010-11-20 10:11:29 +0000" MODIFIED_BY="[Empty name]" ORDER="894" O_E="2.4941995359628772" SE="0.8986189872016263" STUDY_ID="STD-A_x002d_STAR-2006" TOTAL_1="216" TOTAL_2="215" VAR="1.2383654265427082" WEIGHT="1.5311483386571667"/>
<DICH_DATA CI_END="10.823694468006494" CI_START="1.0064920955599788" EFFECT_SIZE="3.3006003888390976" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="1" LOG_CI_END="1.0343755244680208" LOG_CI_START="0.002810368526050755" LOG_EFFECT_SIZE="0.5185929464970358" ORDER="701" O_E="3.252173913043478" SE="0.6059464789301889" STUDY_ID="STD-ASAP-2003" TOTAL_1="891" TOTAL_2="489" VAR="2.723525636368372" WEIGHT="3.367440388785611"/>
<DICH_DATA CI_END="3.798287102460783" CI_START="2.0365838541950883" EFFECT_SIZE="2.781282111988835" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="42" LOG_CI_END="0.579587788811204" LOG_CI_START="0.3089022964080104" LOG_EFFECT_SIZE="0.44424504260960723" MODIFIED="2010-11-20 11:17:12 +0000" MODIFIED_BY="[Empty name]" ORDER="913" O_E="40.46067415730337" SE="0.15900199815243318" STUDY_ID="STD-ATHENA-2009" TOTAL_1="2301" TOTAL_2="2327" VAR="39.554403167632216" WEIGHT="48.906128513114744"/>
<DICH_DATA CI_END="3.4562033102117318" CI_START="0.6105449035678854" EFFECT_SIZE="1.452641496290199" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="6" LOG_CI_END="0.538599281812067" LOG_CI_START="-0.2142823896149186" LOG_EFFECT_SIZE="0.16215844609857416" ORDER="702" O_E="1.90909090909091" SE="0.44224642062059033" STUDY_ID="STD-Benditt-1999" TOTAL_1="184" TOTAL_2="69" VAR="5.112947658402205" WEIGHT="6.321786077846057"/>
<DICH_DATA CI_END="55.165081595336" CI_START="1.0813553882341789" EFFECT_SIZE="7.723539229232589" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.741664264885331" LOG_CI_START="0.033968448609891524" LOG_EFFECT_SIZE="0.8878163567476114" ORDER="703" O_E="2.0316205533596836" SE="1.0031089757108158" STUDY_ID="STD-DIAMOND-2001" TOTAL_1="249" TOTAL_2="257" VAR="0.9938109260315962" WEIGHT="1.2287745730925734"/>
<DICH_DATA CI_END="117.83515727191389" CI_START="0.4549214596741123" EFFECT_SIZE="7.32159420803063" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0712748857922962" LOG_CI_START="-0.3420635760339083" LOG_EFFECT_SIZE="0.864605654879194" MODIFIED="2010-12-28 10:47:23 +0000" MODIFIED_BY="[Empty name]" ORDER="992" O_E="0.9906542056074767" SE="1.4176069586947648" STUDY_ID="STD-EMERALD-2000" TOTAL_1="108" TOTAL_2="106" VAR="0.49760911525577606" WEIGHT="0.6152573011115694"/>
<DICH_DATA CI_END="21.677139410855276" CI_START="0.6853566945547612" EFFECT_SIZE="3.854422474771871" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="1.3360019706685393" LOG_CI_START="-0.16408334068537192" LOG_EFFECT_SIZE="0.5859593149915837" MODIFIED="2010-12-28 10:35:31 +0000" MODIFIED_BY="[Empty name]" ORDER="967" O_E="1.7377049180327866" SE="0.8811575374313362" STUDY_ID="STD-EMERALD-2000" TOTAL_1="321" TOTAL_2="106" VAR="1.2879318371935455" WEIGHT="1.5924335826526403"/>
<DICH_DATA CI_END="2.550726275274827" CI_START="0.4903056225850418" EFFECT_SIZE="1.1183181275659664" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="8" LOG_CI_END="0.4066638558987064" LOG_CI_START="-0.309533126448587" LOG_EFFECT_SIZE="0.048565364725059776" ORDER="829" O_E="0.6318327974276521" SE="0.42069765266303955" STUDY_ID="STD-EURIDIS-ADONIS-2007" TOTAL_1="831" TOTAL_2="413" VAR="5.650147980186652" WEIGHT="6.985995012136734"/>
<DICH_DATA CI_END="5.799474586854827" CI_START="0.6466761115173374" EFFECT_SIZE="1.936590218572555" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="2" LOG_CI_END="0.7633886497067798" LOG_CI_START="-0.1893131817741152" LOG_EFFECT_SIZE="0.28703773396633225" ORDER="704" O_E="2.1104033970276" SE="0.5596217717620015" STUDY_ID="STD-PAFAC-2004" TOTAL_1="383" TOTAL_2="88" VAR="3.193087324283532" WEIGHT="3.9480190959573553"/>
<DICH_DATA CI_END="5.644101920661696" CI_START="0.5088591068434735" EFFECT_SIZE="1.6947131504421165" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="2" LOG_CI_END="0.7515948476020321" LOG_CI_START="-0.2934024486861732" LOG_EFFECT_SIZE="0.22909619945792942" ORDER="705" O_E="1.4000000000000004" SE="0.6138365846597347" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="528" TOTAL_2="132" VAR="2.6539605462822458" WEIGHT="3.281428239357895"/>
<DICH_DATA CI_END="9.847085725410356" CI_START="0.8048510735042969" EFFECT_SIZE="2.8152153588998052" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" LOG_CI_END="0.9933077187573561" LOG_CI_START="-0.09428447235114018" LOG_EFFECT_SIZE="0.44951162320310784" ORDER="706" O_E="2.5359999999999996" SE="0.6388570367253034" STUDY_ID="STD-SAFIRE_x002d_D-2000" TOTAL_1="182" TOTAL_2="68" VAR="2.45014978313253" WEIGHT="3.0294311271094014"/>
<DICH_DATA CI_END="3.6919662362261247" CI_START="0.10917802752131842" EFFECT_SIZE="0.6348870697584525" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5672577206616394" LOG_CI_START="-0.961864756195521" LOG_EFFECT_SIZE="-0.19730351776694086" ORDER="707" O_E="-0.563106796116505" SE="0.8982141121842323" STUDY_ID="STD-SOPAT-2004" TOTAL_1="264" TOTAL_2="251" VAR="1.2394820783909704" WEIGHT="1.5325289970522404"/>
<DICH_DATA CI_END="12.376144156998786" CI_START="1.2491216456066434" EFFECT_SIZE="3.93183284940438" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.0925853593713757" LOG_CI_START="0.09660473416533341" LOG_EFFECT_SIZE="0.5945950467683545" MODIFIED="2010-12-28 10:24:15 +0000" MODIFIED_BY="[Empty name]" ORDER="950" O_E="4.0" SE="0.585043949429637" STUDY_ID="STD-SVA_x002d_4-2008" TOTAL_1="211" TOTAL_2="211" VAR="2.9216152019002375" WEIGHT="3.612363658337965"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2015-04-14 15:47:03 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Stroke</NAME>
<DICH_OUTCOME CHI2="9.633237548642681" CI_END="1.0321200141711098" CI_START="0.5420223954435697" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.7479519787167328" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="83" I2="0.0" I2_Q="14.348562007668543" ID="CMP-004.01" LOG_CI_END="0.013730199676677948" LOG_CI_START="-0.2659827687814951" LOG_EFFECT_SIZE="-0.12612628455240862" METHOD="PETO" MODIFIED="2015-04-14 15:47:03 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6481014122127389" P_Q="0.3223421173822645" P_Z="0.07713658601005002" Q="5.83761360836424" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5208" TOTAL_2="3931" WEIGHT="100.0" Z="1.7675474726052036">
<NAME>Individual antiarrhythmics</NAME>
<GROUP_LABEL_1>Antiarrhythmic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.009340417441311" CI_END="7.045950887631192" CI_START="0.19653040436678526" DF="3" EFFECT_SIZE="1.176751280897823" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.3103808856976334" ID="CMP-004.01.01" LOG_CI_END="0.8479396116943435" LOG_CI_START="-0.706570252274476" LOG_EFFECT_SIZE="0.07068467970993368" MODIFIED="2014-09-25 11:55:19 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3901875106365249" P_Z="0.8585329742350443" STUDIES="4" TAU2="0.0" TOTAL_1="704" TOTAL_2="403" WEIGHT="3.2377121882123814" Z="0.17824193940656524">
<NAME>Class Ia: Quinidine</NAME>
<DICH_DATA CI_END="406.0194289218663" CI_START="0.15885962215189478" EFFECT_SIZE="8.031194996067258" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.6085468160197243" LOG_CI_START="-0.7989864747561749" LOG_EFFECT_SIZE="0.9047801706317746" MODIFIED="2014-09-25 11:53:48 +0100" MODIFIED_BY="[Empty name]" ORDER="1095" O_E="0.52" SE="2.001601922563589" STUDY_ID="STD-Hillestad-1971" TOTAL_1="48" TOTAL_2="52" VAR="0.2496" WEIGHT="0.6738216944923525"/>
<DICH_DATA CI_END="14.695576631735326" CI_START="0.053979918686759505" EFFECT_SIZE="0.8906548330504451" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1671866317878403" LOG_CI_START="-1.267767773983249" LOG_EFFECT_SIZE="-0.050290571097704274" MODIFIED="2014-09-25 11:55:02 +0100" MODIFIED_BY="[Empty name]" ORDER="1096" O_E="-0.05660377358490565" SE="1.4303042711686382" STUDY_ID="STD-Lloyd-1984" TOTAL_1="28" TOTAL_2="25" VAR="0.4888134293616671" WEIGHT="1.3196037390348414"/>
<DICH_DATA CI_END="4.596773250210648" CI_START="0.0015668501898466933" EFFECT_SIZE="0.08486727897001742" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.6624530813854921" LOG_CI_START="-2.8049725254415345" LOG_EFFECT_SIZE="-1.071259722028021" MODIFIED="2014-09-25 11:55:11 +0100" MODIFIED_BY="[Empty name]" ORDER="1094" O_E="-0.5945945945945946" SE="2.0367829654837672" STUDY_ID="STD-Sodermark-1975" TOTAL_1="110" TOTAL_2="75" VAR="0.2410518626734843" WEIGHT="0.6507450904134017"/>
<DICH_DATA CI_END="288.4499007343767" CI_START="0.06751473237868977" EFFECT_SIZE="4.413005535090691" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.4600703938383806" LOG_CI_START="-1.1706014495001542" LOG_EFFECT_SIZE="0.6447344721691133" MODIFIED="2014-09-25 11:55:19 +0100" MODIFIED_BY="[Empty name]" ORDER="1091" O_E="0.32639791937581275" SE="2.1326746128925302" STUDY_ID="STD-SOPAT-2004" TOTAL_1="518" TOTAL_2="251" VAR="0.21986231760295316" WEIGHT="0.5935416642717857"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.003191196698760862" CI_END="2.0053884405047024" CI_START="0.007786236829967081" DF="1" EFFECT_SIZE="0.12495771018167692" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="0.30219850724471065" LOG_CI_START="-2.10867239070473" LOG_EFFECT_SIZE="-0.9032369417300095" MODIFIED="2014-09-25 11:55:46 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9549509521272506" P_Z="0.14193920418747555" STUDIES="2" TAU2="0.0" TOTAL_1="75" TOTAL_2="71" WEIGHT="1.346099910462887" Z="1.4686077772166533">
<NAME>Class Ia: Disopyramide</NAME>
<DICH_DATA CI_END="6.820467167072353" CI_START="0.0026853936013588454" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8338141226232082" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" MODIFIED="2014-09-25 11:55:36 +0100" MODIFIED_BY="[Empty name]" ORDER="1098" O_E="-0.5" SE="2.0" STUDY_ID="STD-Karlson-1998" TOTAL_1="46" TOTAL_2="46" VAR="0.25" WEIGHT="0.6749015369514749"/>
<DICH_DATA CI_END="5.875121197500809" CI_START="0.0022637632646797757" EFFECT_SIZE="0.11532512103806256" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7690168300693758" LOG_CI_START="-2.645168991891423" LOG_EFFECT_SIZE="-0.9380760809110238" MODIFIED="2014-09-25 11:55:46 +0100" MODIFIED_BY="[Empty name]" ORDER="1097" O_E="-0.5370370370370371" SE="2.00550965231216" STUDY_ID="STD-Lloyd-1984" TOTAL_1="29" TOTAL_2="25" VAR="0.24862825788751722" WEIGHT="0.6711983735114122"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="55.59963936657034" CI_START="0.2399534267520752" DF="0" EFFECT_SIZE="3.652577718842973" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-004.01.03" LOG_CI_END="1.7450719746465102" LOG_CI_START="-0.6198730435690655" LOG_EFFECT_SIZE="0.5625994655387223" MODIFIED="2014-09-25 11:56:10 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.3510698648018292" STUDIES="2" TAU2="0.0" TOTAL_1="301" TOTAL_2="107" WEIGHT="1.398888524681445" Z="0.9325161318205879">
<NAME>Class Ic: Flecainide</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-09-25 11:56:01 +0100" MODIFIED_BY="[Empty name]" ORDER="1102" O_E="0.0" SE="0.0" STUDY_ID="STD-Carunchio-1995" TOTAL_1="20" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="55.599639366570386" CI_START="0.2399534267520751" EFFECT_SIZE="3.652577718842973" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.7450719746465104" LOG_CI_START="-0.6198730435690657" LOG_EFFECT_SIZE="0.5625994655387223" MODIFIED="2014-09-25 11:56:10 +0100" MODIFIED_BY="[Empty name]" ORDER="1101" O_E="0.6712707182320443" SE="1.3891804103664722" STUDY_ID="STD-Flec_x002d_SL-2012" TOTAL_1="281" TOTAL_2="81" VAR="0.5181824488799558" WEIGHT="1.398888524681445"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.370612493660778" CI_START="0.3042330434643272" DF="0" EFFECT_SIZE="1.153119569146943" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" I2="0.0" ID="CMP-004.01.04" LOG_CI_END="0.6405423028691687" LOG_CI_START="-0.5167936179790552" LOG_EFFECT_SIZE="0.061874342445056754" MODIFIED="2014-11-27 10:54:25 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.8340032446747074" STUDIES="1" TAU2="0.0" TOTAL_1="267" TOTAL_2="132" WEIGHT="5.841257328959619" Z="0.20957006617495832">
<NAME>Class III: Amiodarone</NAME>
<DICH_DATA CI_END="4.370612493660778" CI_START="0.3042330434643272" EFFECT_SIZE="1.153119569146943" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.6405423028691687" LOG_CI_START="-0.5167936179790552" LOG_EFFECT_SIZE="0.061874342445056754" MODIFIED="2014-09-25 11:56:30 +0100" MODIFIED_BY="[Empty name]" ORDER="1116" O_E="0.3082706766917296" SE="0.6798248488114494" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="267" TOTAL_2="132" VAR="2.16374426829154" WEIGHT="5.841257328959619"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.981301812655031E-4" CI_END="0.946281207083016" CI_START="0.46162119676636826" DF="1" EFFECT_SIZE="0.6609262162232524" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="73" I2="0.0" ID="CMP-004.01.05" LOG_CI_END="-0.023979784807097497" LOG_CI_START="-0.3357142574188068" LOG_EFFECT_SIZE="-0.17984702111295214" MODIFIED="2014-11-27 10:54:25 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.9760919211961384" P_Z="0.023728340789382463" STUDIES="2" TAU2="0.0" TOTAL_1="3132" TOTAL_2="2740" WEIGHT="80.51105974894165" Z="2.2614995457833795">
<NAME>Class III: Dronedarone</NAME>
<DICH_DATA CI_END="0.9567057573993081" CI_START="0.45776406034261763" EFFECT_SIZE="0.6617745175361972" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="70" LOG_CI_END="-0.01922161247071594" LOG_CI_START="-0.3393583073530102" LOG_EFFECT_SIZE="-0.17928995991186308" MODIFIED="2014-09-25 11:56:44 +0100" MODIFIED_BY="[Empty name]" ORDER="1278" O_E="-11.674157303370784" SE="0.18804987927605707" STUDY_ID="STD-ATHENA-2009" TOTAL_1="2301" TOTAL_2="2327" VAR="28.278338063195754" WEIGHT="76.34037528513683"/>
<DICH_DATA CI_END="3.1244994823370806" CI_START="0.13339285250240057" EFFECT_SIZE="0.6455895744133553" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.4947804570501008" LOG_CI_START="-0.8748674402989923" LOG_EFFECT_SIZE="-0.1900434916244457" MODIFIED="2014-09-25 11:56:55 +0100" MODIFIED_BY="[Empty name]" ORDER="1126" O_E="-0.67604501607717" SE="0.8045379547692935" STUDY_ID="STD-EURIDIS-ADONIS-2007" TOTAL_1="831" TOTAL_2="413" VAR="1.5449233093481185" WEIGHT="4.170684463804816"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7821941959571039" CI_END="5.341657123331112" CI_START="0.5216275111145374" DF="2" EFFECT_SIZE="1.6692379430358177" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" I2="0.0" ID="CMP-004.01.06" LOG_CI_END="0.7276760075669793" LOG_CI_START="-0.2826395115818172" LOG_EFFECT_SIZE="0.22251824799258108" MODIFIED="2014-11-27 10:54:25 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.6763146814845973" P_Z="0.38794528751870194" STUDIES="4" TAU2="0.0" TOTAL_1="729" TOTAL_2="478" WEIGHT="7.664982298742015" Z="0.863349604558889">
<NAME>Class III: Sotalol</NAME>
<DICH_DATA CI_END="322.41376441811474" CI_START="0.048517258288955645" EFFECT_SIZE="3.9550767229205763" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.50841357433414" LOG_CI_START="-1.3141037491001972" LOG_EFFECT_SIZE="0.5971549126169712" MODIFIED="2014-09-25 11:58:12 +0100" MODIFIED_BY="[Empty name]" ORDER="1129" O_E="0.2727272727272727" SE="2.2453655975512468" STUDY_ID="STD-Benditt-1999" TOTAL_1="184" TOTAL_2="69" VAR="0.19834710743801653" WEIGHT="0.5354590706391867"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-09-25 11:58:21 +0100" MODIFIED_BY="[Empty name]" ORDER="1132" O_E="0.0" SE="0.0" STUDY_ID="STD-Carunchio-1995" TOTAL_1="20" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.7493978231250935" CI_START="0.37644441826530006" EFFECT_SIZE="1.3371179082776539" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.6766385488517268" LOG_CI_START="-0.42429913798287666" LOG_EFFECT_SIZE="0.12616970543442504" MODIFIED="2014-09-25 11:58:31 +0100" MODIFIED_BY="[Empty name]" ORDER="1139" O_E="0.6946564885496187" SE="0.6466962469760881" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="261" TOTAL_2="132" VAR="2.3911086956780263" WEIGHT="6.455051734924546"/>
<DICH_DATA CI_END="354.93512309034577" CI_START="0.1393983148391029" EFFECT_SIZE="7.034014361373153" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5501489776783086" LOG_CI_START="-0.8557424763133491" LOG_EFFECT_SIZE="0.8472032506824799" MODIFIED="2014-09-25 11:58:42 +0100" MODIFIED_BY="[Empty name]" ORDER="1137" O_E="0.487378640776699" SE="2.0006374995093026" STUDY_ID="STD-SOPAT-2004" TOTAL_1="264" TOTAL_2="251" VAR="0.24984070129135638" WEIGHT="0.674471493178283"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.783732059576305" CI_END="2.7410297002283084" CI_START="0.13534570274572877" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6090866859686843" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" I2_Q="43.541116276441095" ID="CMP-004.02" LOG_CI_END="0.4379137413313204" LOG_CI_START="-0.8685555286148956" LOG_EFFECT_SIZE="-0.2153208936417876" METHOD="PETO" MODIFIED="2014-11-27 10:54:44 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4428400551298779" P_Q="0.1832337094661446" P_Z="0.5182480090958842" Q="1.7712004454362327" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="779" TOTAL_2="474" WEIGHT="100.0" Z="0.6460484090441052">
<NAME>Class I antiarrhythmics</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.009340417441311" CI_END="7.045950887631192" CI_START="0.19653040436678526" DF="3" EFFECT_SIZE="1.176751280897823" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.3103808856976334" ID="CMP-004.02.01" LOG_CI_END="0.8479396116943435" LOG_CI_START="-0.706570252274476" LOG_EFFECT_SIZE="0.07068467970993368" MODIFIED="2014-09-25 11:59:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3901875106365249" P_Z="0.8585329742350443" STUDIES="4" TAU2="0.0" TOTAL_1="704" TOTAL_2="403" WEIGHT="70.6336149587826" Z="0.17824193940656524">
<NAME>Class Ia</NAME>
<DICH_DATA CI_END="406.0194289218663" CI_START="0.15885962215189478" EFFECT_SIZE="8.031194996067258" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.6085468160197243" LOG_CI_START="-0.7989864747561749" LOG_EFFECT_SIZE="0.9047801706317746" MODIFIED="2014-09-25 11:59:53 +0100" MODIFIED_BY="[Empty name]" ORDER="1279" O_E="0.52" SE="2.001601922563589" STUDY_ID="STD-Hillestad-1971" TOTAL_1="48" TOTAL_2="52" VAR="0.2496" WEIGHT="14.700028709446629"/>
<DICH_DATA CI_END="14.695576631735326" CI_START="0.053979918686759505" EFFECT_SIZE="0.8906548330504451" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1671866317878403" LOG_CI_START="-1.267767773983249" LOG_EFFECT_SIZE="-0.050290571097704274" MODIFIED="2014-09-25 11:59:53 +0100" MODIFIED_BY="[Empty name]" ORDER="1280" O_E="-0.05660377358490565" SE="1.4303042711686382" STUDY_ID="STD-Lloyd-1984" TOTAL_1="28" TOTAL_2="25" VAR="0.4888134293616671" WEIGHT="28.788347136136093"/>
<DICH_DATA CI_END="4.596773250210648" CI_START="0.0015668501898466933" EFFECT_SIZE="0.08486727897001742" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.6624530813854921" LOG_CI_START="-2.8049725254415345" LOG_EFFECT_SIZE="-1.071259722028021" MODIFIED="2014-09-25 11:59:53 +0100" MODIFIED_BY="[Empty name]" ORDER="1281" O_E="-0.5945945945945946" SE="2.0367829654837672" STUDY_ID="STD-Sodermark-1975" TOTAL_1="110" TOTAL_2="75" VAR="0.2410518626734843" WEIGHT="14.196591753869415"/>
<DICH_DATA CI_END="288.4499007343767" CI_START="0.06751473237868977" EFFECT_SIZE="4.413005535090691" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.4600703938383806" LOG_CI_START="-1.1706014495001542" LOG_EFFECT_SIZE="0.6447344721691133" MODIFIED="2014-09-25 11:59:53 +0100" MODIFIED_BY="[Empty name]" ORDER="1282" O_E="0.32639791937581275" SE="2.1326746128925302" STUDY_ID="STD-SOPAT-2004" TOTAL_1="518" TOTAL_2="251" VAR="0.21986231760295316" WEIGHT="12.948647359330467"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.003191196698760862" CI_END="2.0053884405047024" CI_START="0.007786236829967081" DF="1" EFFECT_SIZE="0.12495771018167692" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-004.02.02" LOG_CI_END="0.30219850724471065" LOG_CI_START="-2.10867239070473" LOG_EFFECT_SIZE="-0.9032369417300095" MODIFIED="2014-11-27 10:54:44 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9549509521272506" P_Z="0.14193920418747555" STUDIES="2" TAU2="0.0" TOTAL_1="75" TOTAL_2="71" WEIGHT="29.36638504121739" Z="1.4686077772166533">
<NAME>Class Ic</NAME>
<DICH_DATA CI_END="6.820467167072353" CI_START="0.0026853936013588454" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8338141226232082" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" MODIFIED="2014-09-25 12:00:02 +0100" MODIFIED_BY="[Empty name]" ORDER="1283" O_E="-0.5" SE="2.0" STUDY_ID="STD-Karlson-1998" TOTAL_1="46" TOTAL_2="46" VAR="0.25" WEIGHT="14.72358644776305"/>
<DICH_DATA CI_END="5.875121197500809" CI_START="0.0022637632646797757" EFFECT_SIZE="0.11532512103806256" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7690168300693758" LOG_CI_START="-2.645168991891423" LOG_EFFECT_SIZE="-0.9380760809110238" MODIFIED="2014-09-25 12:00:02 +0100" MODIFIED_BY="[Empty name]" ORDER="1284" O_E="-0.5370370370370371" SE="2.00550965231216" STUDY_ID="STD-Lloyd-1984" TOTAL_1="29" TOTAL_2="25" VAR="0.24862825788751722" WEIGHT="14.64279859345434"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.4682733147325924" CI_END="1.0285193975606115" CI_START="0.5293429482840555" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.7378614302645685" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="79" I2="0.0" I2_Q="25.51712497238171" ID="CMP-004.03" LOG_CI_END="0.012212486768804109" LOG_CI_START="-0.2762628680603512" LOG_EFFECT_SIZE="-0.13202519064577353" METHOD="PETO" MODIFIED="2014-11-27 10:55:01 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6281937395101693" P_Q="0.2611684246917986" P_Z="0.07281070622175224" Q="2.6851809885942224" RANDOM="NO" SCALE="13.012562164634678" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4128" TOTAL_2="3350" WEIGHT="100.00000000000003" Z="1.7940154289505916">
<NAME>Class III antiarrhythmics</NAME>
<GROUP_LABEL_1>Antiarrhythmic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.370612493660778" CI_START="0.3042330434643272" DF="0" EFFECT_SIZE="1.153119569146943" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" I2="0.0" ID="CMP-004.03.01" LOG_CI_END="0.6405423028691687" LOG_CI_START="-0.5167936179790552" LOG_EFFECT_SIZE="0.061874342445056754" MODIFIED="2014-09-25 12:00:34 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.8340032446747074" STUDIES="1" TAU2="0.0" TOTAL_1="267" TOTAL_2="132" WEIGHT="6.212960133601501" Z="0.20957006617495832">
<NAME>Amiodarone</NAME>
<DICH_DATA CI_END="4.370612493660778" CI_START="0.3042330434643272" EFFECT_SIZE="1.153119569146943" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.6405423028691687" LOG_CI_START="-0.5167936179790552" LOG_EFFECT_SIZE="0.061874342445056754" MODIFIED="2014-09-25 12:00:34 +0100" MODIFIED_BY="[Empty name]" ORDER="1285" O_E="0.3082706766917296" SE="0.6798248488114494" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="267" TOTAL_2="132" VAR="2.16374426829154" WEIGHT="6.212960133601501"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.981301812655031E-4" CI_END="0.946281207083016" CI_START="0.46162119676636826" DF="1" EFFECT_SIZE="0.6609262162232524" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="73" I2="0.0" ID="CMP-004.03.02" LOG_CI_END="-0.023979784807097497" LOG_CI_START="-0.3357142574188068" LOG_EFFECT_SIZE="-0.17984702111295214" MODIFIED="2014-11-27 10:55:01 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9760919211961384" P_Z="0.023728340789382463" STUDIES="2" TAU2="0.0" TOTAL_1="3132" TOTAL_2="2740" WEIGHT="85.63430377467643" Z="2.2614995457833795">
<NAME>Dronedarone</NAME>
<DICH_DATA CI_END="0.9567057573993081" CI_START="0.45776406034261763" EFFECT_SIZE="0.6617745175361972" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="70" LOG_CI_END="-0.01922161247071594" LOG_CI_START="-0.3393583073530102" LOG_EFFECT_SIZE="-0.17928995991186308" MODIFIED="2014-09-25 12:00:43 +0100" MODIFIED_BY="[Empty name]" ORDER="1286" O_E="-11.674157303370784" SE="0.18804987927605707" STUDY_ID="STD-ATHENA-2009" TOTAL_1="2301" TOTAL_2="2327" VAR="28.278338063195754" WEIGHT="81.19822180736037"/>
<DICH_DATA CI_END="3.1244994823370806" CI_START="0.13339285250240057" EFFECT_SIZE="0.6455895744133553" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.4947804570501008" LOG_CI_START="-0.8748674402989923" LOG_EFFECT_SIZE="-0.1900434916244457" MODIFIED="2014-09-25 12:00:43 +0100" MODIFIED_BY="[Empty name]" ORDER="1287" O_E="-0.67604501607717" SE="0.8045379547692935" STUDY_ID="STD-EURIDIS-ADONIS-2007" TOTAL_1="831" TOTAL_2="413" VAR="1.5449233093481185" WEIGHT="4.436081967316049"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7821941959571042" CI_END="5.341657123331112" CI_START="0.5216275111145374" DF="2" EFFECT_SIZE="1.6692379430358177" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" I2="0.0" ID="CMP-004.03.03" LOG_CI_END="0.7276760075669793" LOG_CI_START="-0.2826395115818172" LOG_EFFECT_SIZE="0.22251824799258108" MODIFIED="2014-11-27 10:55:01 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6763146814845973" P_Z="0.38794528751870194" STUDIES="4" TAU2="0.0" TOTAL_1="729" TOTAL_2="478" WEIGHT="8.152736091722103" Z="0.863349604558889">
<NAME>Sotalol</NAME>
<DICH_DATA CI_END="322.41376441811474" CI_START="0.048517258288955645" EFFECT_SIZE="3.9550767229205763" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.50841357433414" LOG_CI_START="-1.3141037491001972" LOG_EFFECT_SIZE="0.5971549126169712" MODIFIED="2014-09-25 12:00:50 +0100" MODIFIED_BY="[Empty name]" ORDER="1288" O_E="0.2727272727272727" SE="2.2453655975512468" STUDY_ID="STD-Benditt-1999" TOTAL_1="184" TOTAL_2="69" VAR="0.19834710743801653" WEIGHT="0.5695324947529932"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-09-25 12:00:50 +0100" MODIFIED_BY="[Empty name]" ORDER="1289" O_E="0.0" SE="0.0" STUDY_ID="STD-Carunchio-1995" TOTAL_1="20" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.7493978231250935" CI_START="0.37644441826530006" EFFECT_SIZE="1.3371179082776539" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.6766385488517268" LOG_CI_START="-0.42429913798287666" LOG_EFFECT_SIZE="0.12616970543442504" MODIFIED="2014-09-25 12:00:50 +0100" MODIFIED_BY="[Empty name]" ORDER="1290" O_E="0.6946564885496187" SE="0.6466962469760881" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="261" TOTAL_2="132" VAR="2.3911086956780263" WEIGHT="6.865812757570204"/>
<DICH_DATA CI_END="354.93512309034577" CI_START="0.1393983148391029" EFFECT_SIZE="7.034014361373153" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5501489776783086" LOG_CI_START="-0.8557424763133491" LOG_EFFECT_SIZE="0.8472032506824799" MODIFIED="2014-09-25 12:00:50 +0100" MODIFIED_BY="[Empty name]" ORDER="1291" O_E="0.487378640776699" SE="2.0006374995093026" STUDY_ID="STD-SOPAT-2004" TOTAL_1="264" TOTAL_2="251" VAR="0.24984070129135638" WEIGHT="0.7173908393989055"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.477101985937413" CI_END="1.9695105410563454" CI_START="0.6377599747226403" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.120747515223687" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.29435830954747255" LOG_CI_START="-0.1953427401926929" LOG_EFFECT_SIZE="0.04950778467738982" METHOD="PETO" MODIFIED="2014-11-27 10:55:07 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.7468242937107648" P_Q="0.9781102712405239" P_Z="0.6918861023291617" Q="0.4508020632509111" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1784" TOTAL_2="984" WEIGHT="500.0" Z="0.3962967813670556">
<NAME>Subgroup analysis: Persistent atrial fibrillation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.538980735409948" CI_END="6.337307431183863" CI_START="0.12071149428504002" DF="2" EFFECT_SIZE="0.8746346950366722" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="21.228232569591487" ID="CMP-004.04.01" LOG_CI_END="0.8019047758372726" LOG_CI_START="-0.9182513739217779" LOG_EFFECT_SIZE="-0.05817329904225259" MODIFIED="2014-09-25 12:02:56 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.28097488764667855" P_Z="0.8945361992962545" STUDIES="3" TAU2="0.0" TOTAL_1="186" TOTAL_2="152" WEIGHT="100.0" Z="0.13256653589345882">
<NAME>Class Ia: Quinidine</NAME>
<DICH_DATA CI_END="406.0194289218663" CI_START="0.15885962215189478" EFFECT_SIZE="8.031194996067258" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.6085468160197243" LOG_CI_START="-0.7989864747561749" LOG_EFFECT_SIZE="0.9047801706317746" MODIFIED="2014-09-25 12:02:56 +0100" MODIFIED_BY="[Empty name]" ORDER="1292" O_E="0.52" SE="2.001601922563589" STUDY_ID="STD-Hillestad-1971" TOTAL_1="48" TOTAL_2="52" VAR="0.2496" WEIGHT="25.483291958347642"/>
<DICH_DATA CI_END="14.695576631735326" CI_START="0.053979918686759505" EFFECT_SIZE="0.8906548330504451" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1671866317878403" LOG_CI_START="-1.267767773983249" LOG_EFFECT_SIZE="-0.050290571097704274" MODIFIED="2014-09-25 12:02:56 +0100" MODIFIED_BY="[Empty name]" ORDER="1293" O_E="-0.05660377358490565" SE="1.4303042711686382" STUDY_ID="STD-Lloyd-1984" TOTAL_1="28" TOTAL_2="25" VAR="0.4888134293616671" WEIGHT="49.90615117621997"/>
<DICH_DATA CI_END="4.596773250210648" CI_START="0.0015668501898466933" EFFECT_SIZE="0.08486727897001742" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.6624530813854921" LOG_CI_START="-2.8049725254415345" LOG_EFFECT_SIZE="-1.071259722028021" MODIFIED="2014-09-25 12:02:56 +0100" MODIFIED_BY="[Empty name]" ORDER="1294" O_E="-0.5945945945945946" SE="2.0367829654837672" STUDY_ID="STD-Sodermark-1975" TOTAL_1="110" TOTAL_2="75" VAR="0.2410518626734843" WEIGHT="24.610556865432383"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.462423646191003" CI_END="3.121301383733889" CI_START="0.1947299042901246" DF="5" EFFECT_SIZE="0.7796221647151481" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="8.465539770307917" ID="CMP-004.04.02" LOG_CI_END="0.49433570489513606" LOG_CI_START="-0.7105673496051834" LOG_EFFECT_SIZE="-0.10811582235502372" MODIFIED="2014-09-25 12:04:34 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.36208394741887373" P_Z="0.725037221822252" STUDIES="5" TAU2="0.0" TOTAL_1="542" TOTAL_2="304" WEIGHT="100.0" Z="0.35173471788177096">
<NAME>All class I antiarrhythmics</NAME>
<DICH_DATA CI_END="55.599639366570386" CI_START="0.2399534267520751" EFFECT_SIZE="3.652577718842973" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.7450719746465104" LOG_CI_START="-0.6198730435690657" LOG_EFFECT_SIZE="0.5625994655387223" MODIFIED="2014-09-25 12:04:34 +0100" MODIFIED_BY="[Empty name]" ORDER="1300" O_E="0.6712707182320443" SE="1.3891804103664722" STUDY_ID="STD-Flec_x002d_SL-2012" TOTAL_1="281" TOTAL_2="81" VAR="0.5181824488799558" WEIGHT="25.957455241197312"/>
<DICH_DATA CI_END="406.0194289218663" CI_START="0.15885962215189478" EFFECT_SIZE="8.031194996067258" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.6085468160197243" LOG_CI_START="-0.7989864747561749" LOG_EFFECT_SIZE="0.9047801706317746" MODIFIED="2014-09-25 12:03:31 +0100" MODIFIED_BY="[Empty name]" ORDER="1295" O_E="0.52" SE="2.001601922563589" STUDY_ID="STD-Hillestad-1971" TOTAL_1="48" TOTAL_2="52" VAR="0.2496" WEIGHT="12.503281116925276"/>
<DICH_DATA CI_END="6.820467167072353" CI_START="0.0026853936013588454" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8338141226232082" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" MODIFIED="2014-09-25 12:03:59 +0100" MODIFIED_BY="[Empty name]" ORDER="1299" O_E="-0.5" SE="2.0" STUDY_ID="STD-Karlson-1998" TOTAL_1="46" TOTAL_2="46" VAR="0.25" WEIGHT="12.52331842640753"/>
<DICH_DATA CI_END="14.695576631735326" CI_START="0.053979918686759505" EFFECT_SIZE="0.8906548330504451" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1671866317878403" LOG_CI_START="-1.267767773983249" LOG_EFFECT_SIZE="-0.050290571097704274" MODIFIED="2014-09-25 12:03:31 +0100" MODIFIED_BY="[Empty name]" ORDER="1296" O_E="-0.05660377358490565" SE="1.4303042711686382" STUDY_ID="STD-Lloyd-1984" TOTAL_1="28" TOTAL_2="25" VAR="0.4888134293616671" WEIGHT="24.486264908001683"/>
<DICH_DATA CI_END="5.875121197500809" CI_START="0.0022637632646797757" EFFECT_SIZE="0.11532512103806256" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7690168300693758" LOG_CI_START="-2.645168991891423" LOG_EFFECT_SIZE="-0.9380760809110238" MODIFIED="2014-09-25 12:03:31 +0100" MODIFIED_BY="[Empty name]" ORDER="1298" O_E="-0.5370370370370371" SE="2.00550965231216" STUDY_ID="STD-Lloyd-1984" TOTAL_1="29" TOTAL_2="25" VAR="0.24862825788751722" WEIGHT="12.45460337331339"/>
<DICH_DATA CI_END="4.596773250210648" CI_START="0.0015668501898466933" EFFECT_SIZE="0.08486727897001742" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.6624530813854921" LOG_CI_START="-2.8049725254415345" LOG_EFFECT_SIZE="-1.071259722028021" MODIFIED="2014-09-25 12:03:31 +0100" MODIFIED_BY="[Empty name]" ORDER="1297" O_E="-0.5945945945945946" SE="2.0367829654837672" STUDY_ID="STD-Sodermark-1975" TOTAL_1="110" TOTAL_2="75" VAR="0.2410518626734843" WEIGHT="12.075076934154813"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.7493978231250935" CI_START="0.37644441826530006" DF="0" EFFECT_SIZE="1.3371179082776539" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" I2="0.0" ID="CMP-004.04.03" LOG_CI_END="0.6766385488517268" LOG_CI_START="-0.42429913798287666" LOG_EFFECT_SIZE="0.12616970543442504" MODIFIED="2014-11-27 10:55:07 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.6532644915967729" STUDIES="1" TAU2="0.0" TOTAL_1="261" TOTAL_2="132" WEIGHT="100.0" Z="0.4492317440826264">
<NAME>Class III: Sotalol</NAME>
<DICH_DATA CI_END="4.7493978231250935" CI_START="0.37644441826530006" EFFECT_SIZE="1.3371179082776539" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.6766385488517268" LOG_CI_START="-0.42429913798287666" LOG_EFFECT_SIZE="0.12616970543442504" MODIFIED="2014-09-25 12:06:34 +0100" MODIFIED_BY="[Empty name]" ORDER="1303" O_E="0.6946564885496187" SE="0.6466962469760881" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="261" TOTAL_2="132" VAR="2.3911086956780263" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.370612493660778" CI_START="0.3042330434643272" DF="0" EFFECT_SIZE="1.153119569146943" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" I2="0.0" ID="CMP-004.04.04" LOG_CI_END="0.6405423028691687" LOG_CI_START="-0.5167936179790552" LOG_EFFECT_SIZE="0.061874342445056754" MODIFIED="2014-11-27 10:55:07 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.8340032446747074" STUDIES="1" TAU2="0.0" TOTAL_1="267" TOTAL_2="132" WEIGHT="100.0" Z="0.20957006617495832">
<NAME>Class III: Amiodarone</NAME>
<DICH_DATA CI_END="4.370612493660778" CI_START="0.3042330434643272" EFFECT_SIZE="1.153119569146943" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.6405423028691687" LOG_CI_START="-0.5167936179790552" LOG_EFFECT_SIZE="0.061874342445056754" MODIFIED="2014-09-25 12:05:04 +0100" MODIFIED_BY="[Empty name]" ORDER="1301" O_E="0.3082706766917296" SE="0.6798248488114494" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="267" TOTAL_2="132" VAR="2.16374426829154" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.024895541085551115" CI_END="3.1222202557260768" CI_START="0.49749639745117297" DF="1" EFFECT_SIZE="1.2463118908494788" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="6" I2="0.0" ID="CMP-004.04.05" LOG_CI_END="0.4944635369302304" LOG_CI_START="-0.3032100597880872" LOG_EFFECT_SIZE="0.09562673857107158" MODIFIED="2014-11-27 10:55:07 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.8746276484007387" P_Z="0.6384057715054792" STUDIES="1" TAU2="0.0" TOTAL_1="528" TOTAL_2="264" WEIGHT="100.00000000000001" Z="0.46992896425155956">
<NAME>All class III antiarrhythmics</NAME>
<DICH_DATA CI_END="4.7493978231250935" CI_START="0.37644441826530006" EFFECT_SIZE="1.3371179082776539" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.6766385488517268" LOG_CI_START="-0.42429913798287666" LOG_EFFECT_SIZE="0.12616970543442504" MODIFIED="2014-09-25 12:06:40 +0100" MODIFIED_BY="[Empty name]" ORDER="1304" O_E="0.6946564885496187" SE="0.6466962469760881" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="261" TOTAL_2="132" VAR="2.3911086956780263" WEIGHT="52.4958481556377"/>
<DICH_DATA CI_END="4.370612493660778" CI_START="0.3042330434643272" EFFECT_SIZE="1.153119569146943" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.6405423028691687" LOG_CI_START="-0.5167936179790552" LOG_EFFECT_SIZE="0.061874342445056754" MODIFIED="2014-09-25 12:05:06 +0100" MODIFIED_BY="[Empty name]" ORDER="1302" O_E="0.3082706766917296" SE="0.6798248488114494" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="267" TOTAL_2="132" VAR="2.16374426829154" WEIGHT="47.50415184436231"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.12738381975071" CI_END="19.55490172781579" CI_START="1.099183581338204" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="4.636208247468742" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="1.2912556377683557" LOG_CI_START="0.04107023264535798" LOG_EFFECT_SIZE="0.6661629352068568" METHOD="PETO" MODIFIED="2014-11-27 10:55:15 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.9999589428382604" P_Q="0.9971953704990063" P_Z="0.03673124510983458" Q="0.04855675206067777" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2213" TOTAL_2="1223" WEIGHT="400.0" Z="2.0887387670510744">
<NAME>Sensitivity analysis: Best quality studies</NAME>
<GROUP_LABEL_1>Antiarrhythmic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="288.4499007343767" CI_START="0.06751473237868977" DF="0" EFFECT_SIZE="4.413005535090691" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-004.05.01" LOG_CI_END="2.4600703938383806" LOG_CI_START="-1.1706014495001542" LOG_EFFECT_SIZE="0.6447344721691133" MODIFIED="2014-09-25 12:07:41 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4863658629944161" STUDIES="1" TAU2="0.0" TOTAL_1="518" TOTAL_2="251" WEIGHT="100.0" Z="0.6961005563537388">
<NAME>Class Ia: Quinidine</NAME>
<DICH_DATA CI_END="288.4499007343767" CI_START="0.06751473237868977" EFFECT_SIZE="4.413005535090691" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.4600703938383806" LOG_CI_START="-1.1706014495001542" LOG_EFFECT_SIZE="0.6447344721691133" MODIFIED="2014-09-25 12:07:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1305" O_E="0.32639791937581275" SE="2.1326746128925302" STUDY_ID="STD-SOPAT-2004" TOTAL_1="518" TOTAL_2="251" VAR="0.21986231760295316" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.005521267213137157" CI_END="37.833705064877584" CI_START="0.39468972718096734" DF="1" EFFECT_SIZE="3.8642689774783685" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-004.05.02" LOG_CI_END="1.5778788739504122" LOG_CI_START="-0.4037441770923972" LOG_EFFECT_SIZE="0.5870673484290075" MODIFIED="2014-09-25 12:08:17 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9407675156533366" P_Z="0.2455193508359652" STUDIES="2" TAU2="0.0" TOTAL_1="799" TOTAL_2="332" WEIGHT="100.0" Z="1.1613014481384578">
<NAME>All class I antiarrhythmics</NAME>
<DICH_DATA CI_END="55.599639366570386" CI_START="0.2399534267520751" EFFECT_SIZE="3.652577718842973" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.7450719746465104" LOG_CI_START="-0.6198730435690657" LOG_EFFECT_SIZE="0.5625994655387223" MODIFIED="2014-09-25 12:08:09 +0100" MODIFIED_BY="[Empty name]" ORDER="1306" O_E="0.6712707182320443" SE="1.3891804103664722" STUDY_ID="STD-Flec_x002d_SL-2012" TOTAL_1="281" TOTAL_2="81" VAR="0.5181824488799558" WEIGHT="70.21016507566489"/>
<DICH_DATA CI_END="288.4499007343767" CI_START="0.06751473237868977" EFFECT_SIZE="4.413005535090691" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.4600703938383806" LOG_CI_START="-1.1706014495001542" LOG_EFFECT_SIZE="0.6447344721691133" MODIFIED="2014-09-25 12:08:17 +0100" MODIFIED_BY="[Empty name]" ORDER="1307" O_E="0.32639791937581275" SE="2.1326746128925302" STUDY_ID="STD-SOPAT-2004" TOTAL_1="518" TOTAL_2="251" VAR="0.21986231760295316" WEIGHT="29.789834924335118"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.03665290023844739" CI_END="101.85973360719548" CI_START="0.29179940645026725" DF="1" EFFECT_SIZE="5.451844624323218" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-004.05.03" LOG_CI_END="2.0080025360353653" LOG_CI_START="-0.534915595840908" LOG_EFFECT_SIZE="0.7365434700972286" MODIFIED="2014-11-27 10:55:15 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8481735345548232" P_Z="0.25621303198182865" STUDIES="2" TAU2="0.0" TOTAL_1="448" TOTAL_2="320" WEIGHT="100.0" Z="1.1353874561219743">
<NAME>Class III: Sotalol</NAME>
<DICH_DATA CI_END="322.41376441811474" CI_START="0.048517258288955645" EFFECT_SIZE="3.9550767229205763" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.50841357433414" LOG_CI_START="-1.3141037491001972" LOG_EFFECT_SIZE="0.5971549126169712" MODIFIED="2014-09-25 12:09:12 +0100" MODIFIED_BY="[Empty name]" ORDER="1308" O_E="0.2727272727272727" SE="2.2453655975512468" STUDY_ID="STD-Benditt-1999" TOTAL_1="184" TOTAL_2="69" VAR="0.19834710743801653" WEIGHT="44.25535536103426"/>
<DICH_DATA CI_END="354.93512309034577" CI_START="0.1393983148391029" EFFECT_SIZE="7.034014361373153" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5501489776783086" LOG_CI_START="-0.8557424763133491" LOG_EFFECT_SIZE="0.8472032506824799" MODIFIED="2014-09-25 12:09:12 +0100" MODIFIED_BY="[Empty name]" ORDER="1309" O_E="0.487378640776699" SE="2.0006374995093026" STUDY_ID="STD-SOPAT-2004" TOTAL_1="264" TOTAL_2="251" VAR="0.24984070129135638" WEIGHT="55.74464463896574"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.03665290023844739" CI_END="101.85973360719548" CI_START="0.29179940645026725" DF="1" EFFECT_SIZE="5.451844624323218" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-004.05.04" LOG_CI_END="2.0080025360353653" LOG_CI_START="-0.534915595840908" LOG_EFFECT_SIZE="0.7365434700972286" MODIFIED="2014-11-27 10:55:15 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.8481735345548232" P_Z="0.25621303198182865" STUDIES="2" TAU2="0.0" TOTAL_1="448" TOTAL_2="320" WEIGHT="100.0" Z="1.1353874561219743">
<NAME>All class III antiarrhythmics</NAME>
<DICH_DATA CI_END="322.41376441811474" CI_START="0.048517258288955645" EFFECT_SIZE="3.9550767229205763" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.50841357433414" LOG_CI_START="-1.3141037491001972" LOG_EFFECT_SIZE="0.5971549126169712" MODIFIED="2014-09-25 12:09:30 +0100" MODIFIED_BY="[Empty name]" ORDER="1310" O_E="0.2727272727272727" SE="2.2453655975512468" STUDY_ID="STD-Benditt-1999" TOTAL_1="184" TOTAL_2="69" VAR="0.19834710743801653" WEIGHT="44.25535536103426"/>
<DICH_DATA CI_END="354.93512309034577" CI_START="0.1393983148391029" EFFECT_SIZE="7.034014361373153" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5501489776783086" LOG_CI_START="-0.8557424763133491" LOG_EFFECT_SIZE="0.8472032506824799" MODIFIED="2014-09-25 12:09:30 +0100" MODIFIED_BY="[Empty name]" ORDER="1311" O_E="0.487378640776699" SE="2.0006374995093026" STUDY_ID="STD-SOPAT-2004" TOTAL_1="264" TOTAL_2="251" VAR="0.24984070129135638" WEIGHT="55.74464463896574"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.804663892049463" CI_END="0.9342232459470537" CI_START="0.57722774414481" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.7343429558358001" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="152" I2="0.0" I2_Q="20.122383247403977" ID="CMP-004.06" LOG_CI_END="-0.029549330517591076" LOG_CI_START="-0.2386528029433667" LOG_EFFECT_SIZE="-0.1341010667304789" METHOD="PETO" MODIFIED="2014-11-27 10:55:23 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.7195180410954036" P_Q="0.28651243570602214" P_Z="0.011940217626968055" Q="5.007660672186993" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="8999" TOTAL_2="6967" WEIGHT="500.0" Z="2.513906230547536">
<NAME>Sensitivity analysis: Studies &gt; 200 patients</NAME>
<GROUP_LABEL_1>Antiarrhythmic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="288.4499007343767" CI_START="0.06751473237868977" DF="0" EFFECT_SIZE="4.413005535090691" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-004.06.01" LOG_CI_END="2.4600703938383806" LOG_CI_START="-1.1706014495001542" LOG_EFFECT_SIZE="0.6447344721691133" MODIFIED="2014-09-25 12:11:15 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4863658629944161" STUDIES="1" TAU2="0.0" TOTAL_1="518" TOTAL_2="251" WEIGHT="100.0" Z="0.6961005563537388">
<NAME>Class Ia: Quinidine</NAME>
<DICH_DATA CI_END="288.4499007343767" CI_START="0.06751473237868977" EFFECT_SIZE="4.413005535090691" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.4600703938383806" LOG_CI_START="-1.1706014495001542" LOG_EFFECT_SIZE="0.6447344721691133" MODIFIED="2014-09-25 12:11:15 +0100" MODIFIED_BY="[Empty name]" ORDER="1312" O_E="0.32639791937581275" SE="2.1326746128925302" STUDY_ID="STD-SOPAT-2004" TOTAL_1="518" TOTAL_2="251" VAR="0.21986231760295316" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.005521267213137157" CI_END="37.833705064877584" CI_START="0.39468972718096734" DF="1" EFFECT_SIZE="3.8642689774783685" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-004.06.02" LOG_CI_END="1.5778788739504122" LOG_CI_START="-0.4037441770923972" LOG_EFFECT_SIZE="0.5870673484290075" MODIFIED="2014-09-25 12:11:50 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9407675156533366" P_Z="0.2455193508359652" STUDIES="2" TAU2="0.0" TOTAL_1="799" TOTAL_2="332" WEIGHT="100.0" Z="1.1613014481384578">
<NAME>All class I antiarrhythmics</NAME>
<DICH_DATA CI_END="55.599639366570386" CI_START="0.2399534267520751" EFFECT_SIZE="3.652577718842973" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.7450719746465104" LOG_CI_START="-0.6198730435690657" LOG_EFFECT_SIZE="0.5625994655387223" MODIFIED="2014-09-25 12:11:50 +0100" MODIFIED_BY="[Empty name]" ORDER="1314" O_E="0.6712707182320443" SE="1.3891804103664722" STUDY_ID="STD-Flec_x002d_SL-2012" TOTAL_1="281" TOTAL_2="81" VAR="0.5181824488799558" WEIGHT="70.21016507566489"/>
<DICH_DATA CI_END="288.4499007343767" CI_START="0.06751473237868977" EFFECT_SIZE="4.413005535090691" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.4600703938383806" LOG_CI_START="-1.1706014495001542" LOG_EFFECT_SIZE="0.6447344721691133" MODIFIED="2014-09-25 12:11:37 +0100" MODIFIED_BY="[Empty name]" ORDER="1313" O_E="0.32639791937581275" SE="2.1326746128925302" STUDY_ID="STD-SOPAT-2004" TOTAL_1="518" TOTAL_2="251" VAR="0.21986231760295316" WEIGHT="29.789834924335118"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.981301812655031E-4" CI_END="0.946281207083016" CI_START="0.46162119676636826" DF="1" EFFECT_SIZE="0.6609262162232524" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="73" I2="0.0" ID="CMP-004.06.03" LOG_CI_END="-0.023979784807097497" LOG_CI_START="-0.3357142574188068" LOG_EFFECT_SIZE="-0.17984702111295214" MODIFIED="2014-11-27 10:55:23 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9760919211961384" P_Z="0.023728340789382463" STUDIES="2" TAU2="0.0" TOTAL_1="3132" TOTAL_2="2740" WEIGHT="100.0" Z="2.2614995457833795">
<NAME>Class III: Dronedarone</NAME>
<DICH_DATA CI_END="0.9567057573993081" CI_START="0.45776406034261763" EFFECT_SIZE="0.6617745175361972" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="70" LOG_CI_END="-0.01922161247071594" LOG_CI_START="-0.3393583073530102" LOG_EFFECT_SIZE="-0.17928995991186308" MODIFIED="2014-09-25 12:14:10 +0100" MODIFIED_BY="[Empty name]" ORDER="1321" O_E="-11.674157303370784" SE="0.18804987927605707" STUDY_ID="STD-ATHENA-2009" TOTAL_1="2301" TOTAL_2="2327" VAR="28.278338063195754" WEIGHT="94.81973721770612"/>
<DICH_DATA CI_END="3.1244994823370806" CI_START="0.13339285250240057" EFFECT_SIZE="0.6455895744133553" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.4947804570501008" LOG_CI_START="-0.8748674402989923" LOG_EFFECT_SIZE="-0.1900434916244457" MODIFIED="2014-09-25 12:14:10 +0100" MODIFIED_BY="[Empty name]" ORDER="1322" O_E="-0.67604501607717" SE="0.8045379547692935" STUDY_ID="STD-EURIDIS-ADONIS-2007" TOTAL_1="831" TOTAL_2="413" VAR="1.5449233093481185" WEIGHT="5.180262782293885"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7821941959571042" CI_END="5.341657123331112" CI_START="0.5216275111145374" DF="2" EFFECT_SIZE="1.6692379430358177" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" I2="0.0" ID="CMP-004.06.04" LOG_CI_END="0.7276760075669793" LOG_CI_START="-0.2826395115818172" LOG_EFFECT_SIZE="0.22251824799258108" MODIFIED="2014-11-27 10:55:23 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.6763146814845973" P_Z="0.38794528751870194" STUDIES="3" TAU2="0.0" TOTAL_1="709" TOTAL_2="452" WEIGHT="99.99999999999999" Z="0.863349604558889">
<NAME>Class III: Sotalol</NAME>
<DICH_DATA CI_END="322.41376441811474" CI_START="0.048517258288955645" EFFECT_SIZE="3.9550767229205763" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.50841357433414" LOG_CI_START="-1.3141037491001972" LOG_EFFECT_SIZE="0.5971549126169712" MODIFIED="2014-09-25 12:12:38 +0100" MODIFIED_BY="[Empty name]" ORDER="1315" O_E="0.2727272727272727" SE="2.2453655975512468" STUDY_ID="STD-Benditt-1999" TOTAL_1="184" TOTAL_2="69" VAR="0.19834710743801653" WEIGHT="6.985783525254412"/>
<DICH_DATA CI_END="4.7493978231250935" CI_START="0.37644441826530006" EFFECT_SIZE="1.3371179082776539" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.6766385488517268" LOG_CI_START="-0.42429913798287666" LOG_EFFECT_SIZE="0.12616970543442504" MODIFIED="2014-09-25 12:12:38 +0100" MODIFIED_BY="[Empty name]" ORDER="1316" O_E="0.6946564885496187" SE="0.6466962469760881" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="261" TOTAL_2="132" VAR="2.3911086956780263" WEIGHT="84.21482898902394"/>
<DICH_DATA CI_END="354.93512309034577" CI_START="0.1393983148391029" EFFECT_SIZE="7.034014361373153" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5501489776783086" LOG_CI_START="-0.8557424763133491" LOG_EFFECT_SIZE="0.8472032506824799" MODIFIED="2014-09-25 12:12:38 +0100" MODIFIED_BY="[Empty name]" ORDER="1317" O_E="0.487378640776699" SE="2.0006374995093026" STUDY_ID="STD-SOPAT-2004" TOTAL_1="264" TOTAL_2="251" VAR="0.24984070129135638" WEIGHT="8.79938748572163"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.008389626510963" CI_END="1.009412015984585" CI_START="0.5083832621353984" DF="4" EFFECT_SIZE="0.7163575737890346" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="76" I2="0.0" ID="CMP-004.06.05" LOG_CI_END="0.004068470245833833" LOG_CI_START="-0.2938087564695202" LOG_EFFECT_SIZE="-0.14487014311184318" MODIFIED="2014-11-27 10:55:23 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.5564224695817466" P_Z="0.056595116496470116" STUDIES="5" TAU2="0.0" TOTAL_1="3841" TOTAL_2="3192" WEIGHT="99.99999999999997" Z="1.9064247781902726">
<NAME>All class III antiarrhythmics</NAME>
<DICH_DATA CI_END="0.9567057573993081" CI_START="0.45776406034261763" EFFECT_SIZE="0.6617745175361972" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="70" LOG_CI_END="-0.01922161247071594" LOG_CI_START="-0.3393583073530102" LOG_EFFECT_SIZE="-0.17928995991186308" MODIFIED="2014-09-25 12:14:24 +0100" MODIFIED_BY="[Empty name]" ORDER="1323" O_E="-11.674157303370784" SE="0.18804987927605707" STUDY_ID="STD-ATHENA-2009" TOTAL_1="2301" TOTAL_2="2327" VAR="28.278338063195754" WEIGHT="86.57723063125653"/>
<DICH_DATA CI_END="322.41376441811474" CI_START="0.048517258288955645" EFFECT_SIZE="3.9550767229205763" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.50841357433414" LOG_CI_START="-1.3141037491001972" LOG_EFFECT_SIZE="0.5971549126169712" MODIFIED="2014-09-25 12:13:57 +0100" MODIFIED_BY="[Empty name]" ORDER="1318" O_E="0.2727272727272727" SE="2.2453655975512468" STUDY_ID="STD-Benditt-1999" TOTAL_1="184" TOTAL_2="69" VAR="0.19834710743801653" WEIGHT="0.607261403669743"/>
<DICH_DATA CI_END="3.1244994823370806" CI_START="0.13339285250240057" EFFECT_SIZE="0.6455895744133553" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.4947804570501008" LOG_CI_START="-0.8748674402989923" LOG_EFFECT_SIZE="-0.1900434916244457" MODIFIED="2014-09-25 12:14:24 +0100" MODIFIED_BY="[Empty name]" ORDER="1324" O_E="-0.67604501607717" SE="0.8045379547692935" STUDY_ID="STD-EURIDIS-ADONIS-2007" TOTAL_1="831" TOTAL_2="413" VAR="1.5449233093481185" WEIGHT="4.72995199937575"/>
<DICH_DATA CI_END="4.7493978231250935" CI_START="0.37644441826530006" EFFECT_SIZE="1.3371179082776539" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.6766385488517268" LOG_CI_START="-0.42429913798287666" LOG_EFFECT_SIZE="0.12616970543442504" MODIFIED="2014-09-25 12:13:57 +0100" MODIFIED_BY="[Empty name]" ORDER="1319" O_E="0.6946564885496187" SE="0.6466962469760881" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="261" TOTAL_2="132" VAR="2.3911086956780263" WEIGHT="7.320641281941182"/>
<DICH_DATA CI_END="354.93512309034577" CI_START="0.1393983148391029" EFFECT_SIZE="7.034014361373153" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5501489776783086" LOG_CI_START="-0.8557424763133491" LOG_EFFECT_SIZE="0.8472032506824799" MODIFIED="2014-09-25 12:13:57 +0100" MODIFIED_BY="[Empty name]" ORDER="1320" O_E="0.487378640776699" SE="2.0006374995093026" STUDY_ID="STD-SOPAT-2004" TOTAL_1="264" TOTAL_2="251" VAR="0.24984070129135638" WEIGHT="0.7649146837567778"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2014-09-25 11:16:19 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Atrial fibrillation recurrence</NAME>
<DICH_OUTCOME CHI2="132.7797686664622" CI_END="0.5156498910918866" CI_START="0.4394427307877597" CI_STUDY="95" CI_TOTAL="95" DF="50" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.47602373498789907" ESTIMABLE="YES" EVENTS_1="5299" EVENTS_2="4118" I2="62.34366085875769" I2_Q="87.8960699773486" ID="CMP-005.01" LOG_CI_END="-0.2876450696396864" LOG_CI_START="-0.3570977151828327" LOG_EFFECT_SIZE="-0.3223713924112595" METHOD="PETO" MODIFIED="2014-06-26 16:26:46 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.9698479514218548E-9" P_Q="1.5420997812043424E-13" P_Z="5.681089138108311E-74" Q="82.6177942311788" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="40" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="8220" TOTAL_2="5202" WEIGHT="99.99999999999999" Z="18.19473725819645">
<NAME>Individual antiarrhythmics</NAME>
<GROUP_LABEL_1>Antiarrhythmic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.543851280405191" CI_END="0.6459312097151338" CI_START="0.40052340416128573" DF="6" EFFECT_SIZE="0.508635986702792" ESTIMABLE="YES" EVENTS_1="741" EVENTS_2="417" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="-0.18981373097069598" LOG_CI_START="-0.397372101299783" LOG_EFFECT_SIZE="-0.2935929161352395" NO="1" P_CHI2="0.6034971255314154" P_Z="2.9434358473499708E-8" STUDIES="7" TAU2="0.0" TOTAL_1="1106" TOTAL_2="518" WEIGHT="11.196881507264175" Z="5.544768354355474">
<NAME>Class Ia: Quinidine</NAME>
<DICH_DATA CI_END="0.6892971723618935" CI_START="0.047626751891230494" EFFECT_SIZE="0.18118770766088588" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="40" LOG_CI_END="-0.16159350306702794" LOG_CI_START="-1.3221490360365151" LOG_EFFECT_SIZE="-0.7418712695517715" ORDER="708" O_E="-3.675675675675677" SE="0.6817160649088166" STUDY_ID="STD-Byrne_x002d_Quinn-1970" TOTAL_1="32" TOTAL_2="42" VAR="2.1517556060318004" WEIGHT="0.35813414863937976"/>
<DICH_DATA CI_END="1.450174726390495" CI_START="0.14237278316171528" EFFECT_SIZE="0.45438465188317456" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" LOG_CI_END="0.16142033198368702" LOG_CI_START="-0.8465730251121738" LOG_EFFECT_SIZE="-0.3425763465642434" ORDER="709" O_E="-2.25" SE="0.5921002876056983" STUDY_ID="STD-Hillestad-1971" TOTAL_1="26" TOTAL_2="22" VAR="2.8523936170212765" WEIGHT="0.47474701901681426"/>
<DICH_DATA CI_END="1.9130341172951466" CI_START="0.21109933897239028" EFFECT_SIZE="0.6354842544018188" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="17" LOG_CI_END="0.2817227153597031" LOG_CI_START="-0.6755131266217267" LOG_EFFECT_SIZE="-0.1968952056310118" ORDER="710" O_E="-1.4339622641509422" SE="0.5622850719737296" STUDY_ID="STD-Lloyd-1984" TOTAL_1="28" TOTAL_2="25" VAR="3.1629104252813756" WEIGHT="0.5264288514947749"/>
<DICH_DATA CI_END="0.7111269963597585" CI_START="0.2628634293081412" EFFECT_SIZE="0.4323531900387971" ESTIMABLE="YES" EVENTS_1="244" EVENTS_2="73" LOG_CI_END="-0.14805283401965802" LOG_CI_START="-0.5802698306088895" LOG_EFFECT_SIZE="-0.3641613323142738" ORDER="711" O_E="-13.008602150537627" SE="0.2538864033051532" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="88" VAR="15.513904497629785" WEIGHT="2.5821050326331414"/>
<DICH_DATA CI_END="0.8158429372023623" CI_START="0.24628398598538406" EFFECT_SIZE="0.4482511020758579" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="54" LOG_CI_END="-0.08839344182433408" LOG_CI_START="-0.6085638261807316" LOG_EFFECT_SIZE="-0.3484786340025328" ORDER="713" O_E="-8.594594594594597" SE="0.3055506586558776" STUDY_ID="STD-Sodermark-1975" TOTAL_1="110" TOTAL_2="75" VAR="10.711087115317433" WEIGHT="1.7827331571918985"/>
<DICH_DATA CI_END="0.8802646280406021" CI_START="0.43778209399267676" EFFECT_SIZE="0.6207770067675666" ESTIMABLE="YES" EVENTS_1="375" EVENTS_2="204" LOG_CI_END="-0.055386749189298846" LOG_CI_START="-0.3587420057630772" LOG_EFFECT_SIZE="-0.20706437747618803" ORDER="712" O_E="-15.015604681404398" SE="0.17819237934417545" STUDY_ID="STD-SOPAT-2004" TOTAL_1="518" TOTAL_2="251" VAR="31.493559322266766" WEIGHT="5.241728672106976"/>
<DICH_DATA CI_END="1.791248784970214" CI_START="0.06428662330481592" EFFECT_SIZE="0.3393425052724598" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.25315590881731415" LOG_CI_START="-1.191879385229312" LOG_EFFECT_SIZE="-0.46936173820599886" ORDER="714" O_E="-1.5" SE="0.8488208847630564" STUDY_ID="STD-Steinbeck-1988" TOTAL_1="15" TOTAL_2="15" VAR="1.3879310344827587" WEIGHT="0.2310046261811902"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.07587821844744558" CI_END="1.0101158575891338" CI_START="0.26924339717318235" DF="1" EFFECT_SIZE="0.5215045781542104" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="49" I2="0.0" ID="CMP-005.01.02" LOG_CI_END="0.004371189055874122" LOG_CI_START="-0.5698549383787764" LOG_EFFECT_SIZE="-0.2827418746614511" NO="2" P_CHI2="0.7829628507960363" P_Z="0.05359144248924878" STUDIES="2" TAU2="0.0" TOTAL_1="75" TOTAL_2="71" WEIGHT="1.4628900574798447" Z="1.930124265621643">
<NAME>Class Ia: Disopyramide</NAME>
<DICH_DATA CI_END="1.116950638570605" CI_START="0.21117950502052535" EFFECT_SIZE="0.4856717852477124" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="32" LOG_CI_END="0.04803398075205501" LOG_CI_START="-0.6753482323900853" LOG_EFFECT_SIZE="-0.31365712581901517" ORDER="715" O_E="-4.0" SE="0.42491829279939874" STUDY_ID="STD-Karlson-1998" TOTAL_1="46" TOTAL_2="46" VAR="5.538461538461538" WEIGHT="0.9218111026590063"/>
<DICH_DATA CI_END="1.7459065688335207" CI_START="0.19853313879477597" EFFECT_SIZE="0.5887446909764338" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="17" LOG_CI_END="0.24202099897680296" LOG_CI_START="-0.7021669911955852" LOG_EFFECT_SIZE="-0.23007299610939108" ORDER="716" O_E="-1.7222222222222214" SE="0.5546206992331904" STUDY_ID="STD-Lloyd-1984" TOTAL_1="29" TOTAL_2="25" VAR="3.250931749359423" WEIGHT="0.5410789548208385"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.4737681118171535" CI_END="0.565867367995156" CI_START="0.2579491571973784" DF="3" EFFECT_SIZE="0.382053675103184" ESTIMABLE="YES" EVENTS_1="162" EVENTS_2="111" I2="32.942434095417134" ID="CMP-005.01.03" LOG_CI_END="-0.24728534990325907" LOG_CI_START="-0.5884658867677067" LOG_EFFECT_SIZE="-0.41787561833548287" MODIFIED="2014-06-26 15:47:26 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.2146423670048072" P_Z="1.5779540576354164E-6" STUDIES="4" TAU2="0.0" TOTAL_1="352" TOTAL_2="159" WEIGHT="4.143898315453298" Z="4.801101314172282">
<NAME>Class Ic: Flecainide</NAME>
<DICH_DATA CI_END="0.582203481068571" CI_START="0.057498995068715926" EFFECT_SIZE="0.18296479193263115" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="19" LOG_CI_END="-0.23492520218756896" LOG_CI_START="-1.2403397455699385" LOG_EFFECT_SIZE="-0.7376324738787537" ORDER="717" O_E="-4.869565217391305" SE="0.5905854796650598" STUDY_ID="STD-Carunchio-1995" TOTAL_1="20" TOTAL_2="26" VAR="2.8670447385003155" WEIGHT="0.47718552406952525"/>
<DICH_DATA CI_END="0.7006689495158462" CI_START="0.2609477556210965" EFFECT_SIZE="0.42759559142904113" ESTIMABLE="YES" EVENTS_1="131" EVENTS_2="55" LOG_CI_END="-0.1544871280504838" LOG_CI_START="-0.5834464341048028" LOG_EFFECT_SIZE="-0.3689667810776433" MODIFIED="2014-06-26 15:47:26 +0100" MODIFIED_BY="[Empty name]" ORDER="1035" O_E="-13.381215469613267" SE="0.2519728197591174" STUDY_ID="STD-Flec_x002d_SL-2012" TOTAL_1="281" TOTAL_2="81" VAR="15.750436997710523" WEIGHT="2.6214730562620794"/>
<DICH_DATA CI_END="0.6172926973181766" CI_START="0.03328143701494946" EFFECT_SIZE="0.143333136523217" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="13" LOG_CI_END="-0.20950886078305847" LOG_CI_START="-1.4777979301520636" LOG_EFFECT_SIZE="-0.8436533954675609" ORDER="718" O_E="-3.5" SE="0.7449992774794993" STUDY_ID="STD-Steinbeck-1988" TOTAL_1="15" TOTAL_2="15" VAR="1.8017241379310345" WEIGHT="0.29987557063272513"/>
<DICH_DATA CI_END="1.5429411864747646" CI_START="0.24204115473887347" EFFECT_SIZE="0.6111098644830727" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="24" LOG_CI_END="0.1883493720279735" LOG_CI_START="-0.6161107837865255" LOG_EFFECT_SIZE="-0.21388070587927605" ORDER="719" O_E="-2.205479452054796" SE="0.47254387766743117" STUDY_ID="STD-Van-Gelder-1989" TOTAL_1="36" TOTAL_2="37" VAR="4.478326139988741" WEIGHT="0.7453641644889687"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.796335292248326" CI_END="0.4780482934121942" CI_START="0.2832667234462467" DF="4" EFFECT_SIZE="0.3679880075816904" ESTIMABLE="YES" EVENTS_1="376" EVENTS_2="276" I2="0.0" ID="CMP-005.01.04" LOG_CI_END="-0.32052822785859963" LOG_CI_START="-0.5478044409137222" LOG_EFFECT_SIZE="-0.43416633438616087" NO="4" P_CHI2="0.9389387045854906" P_Z="6.979878996627229E-14" STUDIES="5" TAU2="0.0" TOTAL_1="720" TOTAL_2="378" WEIGHT="9.338338612955056" Z="7.488248481949706">
<NAME>Class Ic: Propafenone</NAME>
<DICH_DATA CI_END="0.6900980952016661" CI_START="0.22284661466907307" EFFECT_SIZE="0.39215561235977103" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="62" LOG_CI_END="-0.1610891713254131" LOG_CI_START="-0.6519939590276962" LOG_EFFECT_SIZE="-0.4065415651765546" ORDER="720" O_E="-11.25773195876289" SE="0.288359902314211" STUDY_ID="STD-Bellandi-2001" TOTAL_1="102" TOTAL_2="92" VAR="12.02625091068688" WEIGHT="2.0016265412061665"/>
<DICH_DATA CI_END="0.9185838914096333" CI_START="0.20442554208424146" EFFECT_SIZE="0.4333382165829207" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="35" LOG_CI_END="-0.03688117478272425" LOG_CI_START="-0.689464841936465" LOG_EFFECT_SIZE="-0.3631730083595946" ORDER="721" O_E="-5.690909090909088" SE="0.38333087642735797" STUDY_ID="STD-Dogan-2004" TOTAL_1="58" TOTAL_2="52" VAR="6.805380241110017" WEIGHT="1.132674664346232"/>
<DICH_DATA CI_END="0.5667774028207857" CI_START="0.16920102099928358" EFFECT_SIZE="0.30967614573389274" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="58" LOG_CI_END="-0.24658747321969615" LOG_CI_START="-0.7715970206526864" LOG_EFFECT_SIZE="-0.5090922469361913" ORDER="722" O_E="-12.325443786982248" SE="0.30839320700131184" STUDY_ID="STD-Kochiadakis-2004b" TOTAL_1="86" TOTAL_2="83" VAR="10.514542808124967" WEIGHT="1.7500206930398474"/>
<DICH_DATA CI_END="0.532878617235521" CI_START="0.23108792617207216" EFFECT_SIZE="0.3509156801261494" ESTIMABLE="YES" EVENTS_1="232" EVENTS_2="104" LOG_CI_END="-0.2733717062986568" LOG_CI_START="-0.6362227448446693" LOG_EFFECT_SIZE="-0.454797225571663" ORDER="723" O_E="-23.051625239005745" SE="0.21314049618353628" STUDY_ID="STD-RAFT-2003" TOTAL_1="397" TOTAL_2="126" VAR="22.012433403959818" WEIGHT="3.663707939000804"/>
<DICH_DATA CI_END="1.1124951063594568" CI_START="0.18409731745925123" EFFECT_SIZE="0.45255647688141687" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="17" LOG_CI_END="0.04629810928374793" LOG_CI_START="-0.7349525396933374" LOG_EFFECT_SIZE="-0.3443272152047947" ORDER="724" O_E="-3.764705882352942" SE="0.4589104984622226" STUDY_ID="STD-Stroobandt-1997" TOTAL_1="77" TOTAL_2="25" VAR="4.748364109767378" WEIGHT="0.7903087753620074"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.250300398012959" CI_END="1.0704679382985778" CI_START="0.604619194219078" DF="2" EFFECT_SIZE="0.8045032394536666" ESTIMABLE="YES" EVENTS_1="675" EVENTS_2="463" I2="38.467225945556244" ID="CMP-005.01.05" LOG_CI_END="0.02957366422407794" LOG_CI_START="-0.21851806984243538" LOG_EFFECT_SIZE="-0.09447220280917874" NO="5" P_CHI2="0.1968822607009465" P_Z="0.1355181626493374" STUDIES="3" TAU2="0.0" TOTAL_1="833" TOTAL_2="550" WEIGHT="7.837056849919954" Z="1.4926907237990623">
<NAME>Class I others: aprindine, bidisomide, pilsicainide</NAME>
<DICH_DATA CI_END="1.1686176791098624" CI_START="0.6316381748011966" EFFECT_SIZE="0.8591528024009256" ESTIMABLE="YES" EVENTS_1="607" EVENTS_2="418" LOG_CI_END="0.06767245212809186" LOG_CI_START="-0.19953163008157862" LOG_EFFECT_SIZE="-0.06592958897674335" ORDER="725" O_E="-6.162184189079085" SE="0.15695700057149928" STUDY_ID="STD-AFIB-1997" TOTAL_1="734" TOTAL_2="493" VAR="40.59182881805225" WEIGHT="6.756027503642874"/>
<DICH_DATA CI_END="0.9541191042383869" CI_START="0.04436783141814796" EFFECT_SIZE="0.20574789323267223" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="10" LOG_CI_END="-0.020397408225854084" LOG_CI_START="-1.3529317979264008" LOG_EFFECT_SIZE="-0.6866646030761274" ORDER="726" O_E="-2.5806451612903203" SE="0.7827372966617115" STUDY_ID="STD-Okishige-2000" TOTAL_1="52" TOTAL_2="10" VAR="1.6321795943433242" WEIGHT="0.2716568962609575"/>
<DICH_DATA CI_END="1.7866360970621007" CI_START="0.3020236361415423" EFFECT_SIZE="0.7345790158290866" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="35" LOG_CI_END="0.2520361041946625" LOG_CI_START="-0.5199590681548776" LOG_EFFECT_SIZE="-0.13396148198010746" ORDER="727" O_E="-1.5" SE="0.45347378567585434" STUDY_ID="STD-SMART-2002" TOTAL_1="47" TOTAL_2="47" VAR="4.862903225806452" WEIGHT="0.8093724500161236"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.1004191827591354" CI_END="0.8828241914186497" CI_START="0.437961266483147" DF="1" EFFECT_SIZE="0.6218060798638688" ESTIMABLE="YES" EVENTS_1="172" EVENTS_2="203" I2="52.39045576195947" ID="CMP-005.01.06" LOG_CI_END="-0.054125774677033466" LOG_CI_START="-0.3585642970220973" LOG_EFFECT_SIZE="-0.20634503584956537" MODIFIED="2010-12-27 14:29:08 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.14725881631486049" P_Z="0.007886669926371428" STUDIES="2" TAU2="0.0" TOTAL_1="280" TOTAL_2="282" WEIGHT="5.204492365531085" Z="2.6568834688757113">
<NAME>Class II: Beta-blockers</NAME>
<DICH_DATA CI_END="1.1282506841858055" CI_START="0.4851291071466984" EFFECT_SIZE="0.7398292012733152" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="140" LOG_CI_END="0.05240560555405347" LOG_CI_START="-0.3141426674601803" LOG_EFFECT_SIZE="-0.1308685309530634" ORDER="728" O_E="-6.5" SE="0.2153122700117753" STUDY_ID="STD-Kuhlkamp-2000" TOTAL_1="197" TOTAL_2="197" VAR="21.570610687022903" WEIGHT="3.590171798494798"/>
<DICH_DATA CI_END="0.7927095699183808" CI_START="0.22515601151004294" EFFECT_SIZE="0.4224728690089627" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="63" LOG_CI_END="-0.10088589879202069" LOG_CI_START="-0.6475164531834537" LOG_EFFECT_SIZE="-0.3742011759877372" MODIFIED="2010-12-27 14:29:08 +0000" MODIFIED_BY="[Empty name]" ORDER="942" O_E="-8.357142857142854" SE="0.3210934935144117" STUDY_ID="STD-Nergardh-2007" TOTAL_1="83" TOTAL_2="85" VAR="9.699224000977637" WEIGHT="1.6143205670362866"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.726438565528581" CI_END="0.2558867829479044" CI_START="0.14255002260136418" DF="5" EFFECT_SIZE="0.1909886559265082" ESTIMABLE="YES" EVENTS_1="217" EVENTS_2="254" I2="0.0" ID="CMP-005.01.07" LOG_CI_END="-0.5919521456916855" LOG_CI_START="-0.8460327094969486" LOG_EFFECT_SIZE="-0.7189924275943171" MODIFIED="2014-06-26 16:25:22 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.7420719753262387" P_Z="1.363617547036013E-28" STUDIES="6" TAU2="0.0" TOTAL_1="499" TOTAL_2="313" WEIGHT="7.471962740461766" Z="11.092538855683179">
<NAME>Class III: Amiodarone</NAME>
<DICH_DATA CI_END="0.3244281554847841" CI_START="0.057903549941752716" EFFECT_SIZE="0.1370603586148231" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="36" LOG_CI_END="-0.4888814625956894" LOG_CI_START="-1.2372948097984093" LOG_EFFECT_SIZE="-0.8630881361970493" ORDER="729" O_E="-10.282828282828284" SE="0.43962170485269497" STUDY_ID="STD-Channer-2004" TOTAL_1="61" TOTAL_2="38" VAR="5.174182559463945" WEIGHT="0.8611811957844439"/>
<DICH_DATA CI_END="0.3788098949306661" CI_START="0.033470350366971914" EFFECT_SIZE="0.11260062124964149" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="-0.421578685271559" LOG_CI_START="-1.4753397414322997" LOG_EFFECT_SIZE="-0.9484592133519294" ORDER="730" O_E="-5.699999999999999" SE="0.618984460590173" STUDY_ID="STD-GEFACA-2001" TOTAL_1="35" TOTAL_2="15" VAR="2.6099999999999994" WEIGHT="0.43440348212805663"/>
<DICH_DATA CI_END="0.4492953039628822" CI_START="0.1083605330200395" EFFECT_SIZE="0.2206487675488322" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="47" LOG_CI_END="-0.34746812063169147" LOG_CI_START="-0.9651288673607911" LOG_EFFECT_SIZE="-0.6562984939962413" ORDER="731" O_E="-11.479999999999997" SE="0.3628169800986797" STUDY_ID="STD-Kochiadakis-2000" TOTAL_1="65" TOTAL_2="60" VAR="7.596696774193548" WEIGHT="1.26437989708071"/>
<DICH_DATA CI_END="0.32722060914935297" CI_START="0.13877406944543474" EFFECT_SIZE="0.2130956018740644" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="114" LOG_CI_END="-0.48515935121717374" LOG_CI_START="-0.8576916761637672" LOG_EFFECT_SIZE="-0.6714255136904705" ORDER="732" O_E="-32.28571428571428" SE="0.21882733173837812" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="267" TOTAL_2="132" VAR="20.883191467541792" WEIGHT="3.4757590388686124"/>
<DICH_DATA CI_END="0.5324482652481015" CI_START="0.10391473449562894" EFFECT_SIZE="0.23522164040732876" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="27" LOG_CI_END="-0.27372258358646745" LOG_CI_START="-0.98332286768396" LOG_EFFECT_SIZE="-0.6285227256352137" MODIFIED="2014-06-26 15:58:55 +0100" MODIFIED_BY="[Empty name]" ORDER="1041" O_E="-8.329787234042552" SE="0.4168227194569235" STUDY_ID="STD-Santas-2012" TOTAL_1="49" TOTAL_2="45" VAR="5.755687875114999" WEIGHT="0.9579658448245945"/>
<DICH_DATA CI_END="0.3617345675912048" CI_START="0.035819494172640895" EFFECT_SIZE="0.11382947437230805" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="18" LOG_CI_END="-0.4416099877913599" LOG_CI_START="-1.445880551361972" LOG_EFFECT_SIZE="-0.9437452695766658" MODIFIED="2014-06-26 16:25:22 +0100" MODIFIED_BY="[Empty name]" ORDER="1070" O_E="-6.244444444444444" SE="0.5899135002608419" STUDY_ID="STD-Vijayalaskshmi-2006" TOTAL_1="22" TOTAL_2="23" VAR="2.8735802469135803" WEIGHT="0.4782732817753488"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.604527198500624" CI_END="0.8989863615560058" CI_START="0.5506558919581765" DF="3" EFFECT_SIZE="0.7035852022185076" ESTIMABLE="YES" EVENTS_1="604" EVENTS_2="656" I2="0.0" ID="CMP-005.01.08" LOG_CI_END="-0.046246896860650706" LOG_CI_START="-0.25911970951173136" LOG_EFFECT_SIZE="-0.15268330318619097" MODIFIED="2010-12-28 10:24:51 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.45669646943708675" P_Z="0.004929983165129782" STUDIES="4" TAU2="0.0" TOTAL_1="797" TOTAL_2="805" WEIGHT="10.644792241727918" Z="2.8115734607786695">
<NAME>Class III: Azimilide</NAME>
<DICH_DATA CI_END="1.0933935106921964" CI_START="0.4116181895531199" EFFECT_SIZE="0.6708656030385308" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="117" LOG_CI_END="0.03877649201855855" LOG_CI_START="-0.385505441859065" LOG_EFFECT_SIZE="-0.17336447492025328" MODIFIED="2010-08-20 11:28:32 +0100" MODIFIED_BY="[Empty name]" ORDER="843" O_E="-6.426751592356695" SE="0.2492253081891608" STUDY_ID="STD-A_x002d_COMET_x002d_I-2006" TOTAL_1="159" TOTAL_2="155" VAR="16.09962337674626" WEIGHT="2.6795909792371027"/>
<DICH_DATA CI_END="1.2621415786610972" CI_START="0.4644468951831723" EFFECT_SIZE="0.7656355121666799" ESTIMABLE="YES" EVENTS_1="171" EVENTS_2="190" LOG_CI_END="0.10110807391171979" LOG_CI_START="-0.33306393602422224" LOG_EFFECT_SIZE="-0.11597793105625122" MODIFIED="2010-08-27 16:36:46 +0100" MODIFIED_BY="[Empty name]" ORDER="856" O_E="-4.105747126436768" SE="0.2550347878224832" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="211" TOTAL_2="224" VAR="15.374505346511022" WEIGHT="2.5589037005826873"/>
<DICH_DATA CI_END="0.8531478467524782" CI_START="0.23587293279811006" EFFECT_SIZE="0.4485916681391882" ESTIMABLE="YES" EVENTS_1="188" EVENTS_2="202" LOG_CI_END="-0.06897570099557579" LOG_CI_START="-0.6273218929883597" LOG_EFFECT_SIZE="-0.34814879699196777" MODIFIED="2010-11-20 10:12:33 +0000" MODIFIED_BY="[Empty name]" ORDER="895" O_E="-7.452436194895597" SE="0.32797531703478655" STUDY_ID="STD-A_x002d_STAR-2006" TOTAL_1="216" TOTAL_2="215" VAR="9.296461582355823" WEIGHT="1.547285548982787"/>
<DICH_DATA CI_END="1.237329742066832" CI_START="0.5481955992032969" EFFECT_SIZE="0.8235889262031075" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="147" LOG_CI_END="0.09248545231841637" LOG_CI_START="-0.2610644552054873" LOG_EFFECT_SIZE="-0.08428950144353549" MODIFIED="2010-12-28 10:24:51 +0000" MODIFIED_BY="[Empty name]" ORDER="951" O_E="-4.5" SE="0.2076769657798085" STUDY_ID="STD-SVA_x002d_4-2008" TOTAL_1="211" TOTAL_2="211" VAR="23.18586698337292" WEIGHT="3.859012012925341"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.310953185635555" CI_END="0.3933898295256139" CI_START="0.2319428543965176" DF="2" EFFECT_SIZE="0.30206615161373235" ESTIMABLE="YES" EVENTS_1="448" EVENTS_2="363" I2="75.93537160747397" ID="CMP-005.01.09" LOG_CI_END="-0.40517687227128496" LOG_CI_START="-0.6346190025113105" LOG_EFFECT_SIZE="-0.5198979373912977" MODIFIED="2010-12-28 10:35:53 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.015678336064250398" P_Z="6.552110982759506E-19" STUDIES="3" TAU2="0.0" TOTAL_1="752" TOTAL_2="431" WEIGHT="9.162864285322257" Z="8.882250455551642">
<NAME>Class III: Dofetilide</NAME>
<DICH_DATA CI_END="0.3068852264243933" CI_START="0.1437806924281964" EFFECT_SIZE="0.21005754057229914" ESTIMABLE="YES" EVENTS_1="132" EVENTS_2="221" LOG_CI_END="-0.5130240181722759" LOG_CI_START="-0.8422994292164805" LOG_EFFECT_SIZE="-0.6776617236943783" ORDER="733" O_E="-41.709486166007906" SE="0.19341800638693776" STUDY_ID="STD-DIAMOND-2001" TOTAL_1="249" TOTAL_2="257" VAR="26.730445370538085" WEIGHT="4.448964960841202"/>
<DICH_DATA CI_END="0.5689602712639514" CI_START="0.22426628708284518" EFFECT_SIZE="0.3572094729063254" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="89" LOG_CI_END="-0.2449180579866873" LOG_CI_START="-0.6492360069980228" LOG_EFFECT_SIZE="-0.44707703249235503" MODIFIED="2010-12-28 10:35:53 +0000" MODIFIED_BY="[Empty name]" ORDER="968" O_E="-18.25058548009369" SE="0.2374983646553843" STUDY_ID="STD-EMERALD-2000" TOTAL_1="321" TOTAL_2="106" VAR="17.728776003817273" WEIGHT="2.950744072768796"/>
<DICH_DATA CI_END="1.0419385867045163" CI_START="0.3124580724793979" EFFECT_SIZE="0.5705805135505428" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="53" LOG_CI_END="0.01784212180289649" LOG_CI_START="-0.5052082506798179" LOG_EFFECT_SIZE="-0.2436830644384607" ORDER="734" O_E="-5.944000000000003" SE="0.3072423779374474" STUDY_ID="STD-SAFIRE_x002d_D-2000" TOTAL_1="182" TOTAL_2="68" VAR="10.59345837751004" WEIGHT="1.7631552517122588"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.4389966325286585" CI_END="0.7489899004418588" CI_START="0.462757084495342" DF="1" EFFECT_SIZE="0.5887277661576112" ESTIMABLE="YES" EVENTS_1="648" EVENTS_2="353" I2="0.0" ID="CMP-005.01.10" LOG_CI_END="-0.12552403839124437" LOG_CI_START="-0.33464692377185473" LOG_EFFECT_SIZE="-0.23008548108154958" MODIFIED="2010-08-20 10:15:23 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.5076071592155167" P_Z="1.6115343537307838E-5" STUDIES="2" TAU2="0.0" TOTAL_1="982" TOTAL_2="461" WEIGHT="11.02997330969628" Z="4.312863754386794">
<NAME>Class III: Dronedarone</NAME>
<DICH_DATA CI_END="1.0178504787267657" CI_START="0.20209961227942247" EFFECT_SIZE="0.45354954206691017" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="43" LOG_CI_END="0.007683985237284965" LOG_CI_START="-0.694434519661682" LOG_EFFECT_SIZE="-0.34337526721219847" ORDER="744" O_E="-4.64824120603015" SE="0.4124278853203052" STUDY_ID="STD-DAFNE-2003" TOTAL_1="151" TOTAL_2="48" VAR="5.879006728480226" WEIGHT="0.9784908024161246"/>
<DICH_DATA CI_END="0.7770978877586998" CI_START="0.4692565646378449" EFFECT_SIZE="0.6038694272746162" ESTIMABLE="YES" EVENTS_1="532" EVENTS_2="310" LOG_CI_END="-0.10952427150050074" LOG_CI_START="-0.3285896431263289" LOG_EFFECT_SIZE="-0.21905695731341482" MODIFIED="2010-08-20 10:15:23 +0100" MODIFIED_BY="[Empty name]" ORDER="745" O_E="-30.46141479099674" SE="0.12868008368408979" STUDY_ID="STD-EURIDIS-ADONIS-2007" TOTAL_1="831" TOTAL_2="413" VAR="60.3917105256252" WEIGHT="10.051482507280154"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="20.840506369399808" CI_END="0.6002380044873934" CI_START="0.42847623465049256" DF="12" EFFECT_SIZE="0.5071367863376545" ESTIMABLE="YES" EVENTS_1="1216" EVENTS_2="973" I2="42.41982518419205" ID="CMP-005.01.11" LOG_CI_END="-0.22167651038295177" LOG_CI_START="-0.36807326113022726" LOG_EFFECT_SIZE="-0.2948748857565895" MODIFIED="2014-06-26 16:26:46 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.0527653986702068" P_Z="2.889515550824982E-15" STUDIES="13" TAU2="0.0" TOTAL_1="1824" TOTAL_2="1234" WEIGHT="22.506849714188355" Z="7.895587205019084">
<NAME>Class III: Sotalol</NAME>
<DICH_DATA CI_END="0.5897313461816622" CI_START="0.24755086325099263" EFFECT_SIZE="0.38208441977322294" ESTIMABLE="YES" EVENTS_1="150" EVENTS_2="190" LOG_CI_END="-0.2293457874131082" LOG_CI_START="-0.6063355548728367" LOG_EFFECT_SIZE="-0.4178406711429725" MODIFIED="2010-08-27 18:17:59 +0100" MODIFIED_BY="[Empty name]" ORDER="889" O_E="-19.61968680089487" SE="0.22144565553529005" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="223" TOTAL_2="224" VAR="20.39227462226426" WEIGHT="3.394051764146819"/>
<DICH_DATA CI_END="0.5560177432550629" CI_START="0.18229195178371482" EFFECT_SIZE="0.31836702034655195" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="62" LOG_CI_END="-0.25491134929058196" LOG_CI_START="-0.7392325050865465" LOG_EFFECT_SIZE="-0.49707192718856424" ORDER="735" O_E="-14.141414141414138" SE="0.284492644342936" STUDY_ID="STD-Bellandi-2001" TOTAL_1="106" TOTAL_2="92" VAR="12.355431461722802" WEIGHT="2.0564147318647246"/>
<DICH_DATA CI_END="1.7236564330023032" CI_START="0.47734476653030977" EFFECT_SIZE="0.9070713189104542" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="53" LOG_CI_END="0.23645070457407255" LOG_CI_START="-0.32116783455182196" LOG_EFFECT_SIZE="-0.0423585649888747" ORDER="736" O_E="-0.9090909090909065" SE="0.32754789013883595" STUDY_ID="STD-Benditt-1999" TOTAL_1="184" TOTAL_2="69" VAR="9.320739866194414" WEIGHT="1.5513263807987168"/>
<DICH_DATA CI_END="0.8489996279350025" CI_START="0.08162095968684081" EFFECT_SIZE="0.2632416464122379" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="19" LOG_CI_END="-0.07109250008091274" LOG_CI_START="-1.0881983031642053" LOG_EFFECT_SIZE="-0.579645401622559" ORDER="737" O_E="-3.7391304347826093" SE="0.5974529834860508" STUDY_ID="STD-Carunchio-1995" TOTAL_1="20" TOTAL_2="26" VAR="2.8015122873345932" WEIGHT="0.4662784263765074"/>
<DICH_DATA CI_END="2.5422464443091535" CI_START="0.43793368144435946" EFFECT_SIZE="1.0551470724477894" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="54" LOG_CI_END="0.4052176485845123" LOG_CI_START="-0.35859165196953896" LOG_EFFECT_SIZE="0.02331299830748672" MODIFIED="2010-12-27 14:19:19 +0000" MODIFIED_BY="[Empty name]" ORDER="928" O_E="0.2666666666666657" SE="0.4486653640624653" STUDY_ID="STD-DAPHNE-2008" TOTAL_1="69" TOTAL_2="66" VAR="4.967694859038143" WEIGHT="0.8268137719983967"/>
<DICH_DATA CI_END="0.8030625020136358" CI_START="0.22893753763389477" EFFECT_SIZE="0.428778674582956" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="89" LOG_CI_END="-0.09525065245072305" LOG_CI_START="-0.6402829925998801" LOG_EFFECT_SIZE="-0.3677668225253015" MODIFIED="2010-12-28 10:48:52 +0000" MODIFIED_BY="[Empty name]" ORDER="994" O_E="-8.26168224299066" SE="0.3201546945572106" STUDY_ID="STD-EMERALD-2000" TOTAL_1="108" TOTAL_2="106" VAR="9.756190035663364" WEIGHT="1.6238018865115769"/>
<DICH_DATA CI_END="0.8319561758631644" CI_START="0.24276565553742369" EFFECT_SIZE="0.4494111551929138" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="58" LOG_CI_END="-0.07989955000984499" LOG_CI_START="-0.6148127536165463" LOG_EFFECT_SIZE="-0.3473561518131956" ORDER="738" O_E="-8.101190476190474" SE="0.31421066366163836" STUDY_ID="STD-Kochiadakis-2004b" TOTAL_1="85" TOTAL_2="83" VAR="10.128803829415997" WEIGHT="1.6858190242491589"/>
<DICH_DATA CI_END="0.7637732483695356" CI_START="0.27909880868501896" EFFECT_SIZE="0.46170142270240455" ESTIMABLE="YES" EVENTS_1="255" EVENTS_2="73" LOG_CI_END="-0.11703555712917849" LOG_CI_START="-0.5542420172649579" LOG_EFFECT_SIZE="-0.33563878719706824" ORDER="739" O_E="-11.717622080679405" SE="0.2568172388906384" STUDY_ID="STD-PAFAC-2004" TOTAL_1="383" TOTAL_2="88" VAR="15.161831125551203" WEIGHT="2.5235066039758607"/>
<DICH_DATA CI_END="2.2616658695023157" CI_START="0.5671780267892732" EFFECT_SIZE="1.1325931242599743" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="29" LOG_CI_END="0.354428444201308" LOG_CI_START="-0.24628060262932172" LOG_EFFECT_SIZE="0.054073920785993164" ORDER="740" O_E="1.0" SE="0.35285946766605064" STUDY_ID="STD-Plewan-2001" TOTAL_1="64" TOTAL_2="64" VAR="8.031496062992126" WEIGHT="1.33674707144121"/>
<DICH_DATA CI_END="0.6761368115640589" CI_START="0.255498542602637" EFFECT_SIZE="0.4156344186356693" ESTIMABLE="YES" EVENTS_1="183" EVENTS_2="114" LOG_CI_END="-0.1699654187097426" LOG_CI_START="-0.5926115727951702" LOG_EFFECT_SIZE="-0.38128849575245644" ORDER="741" O_E="-14.244274809160316" SE="0.2482644430419843" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="261" TOTAL_2="132" VAR="16.22448622826556" WEIGHT="2.700372916972131"/>
<DICH_DATA CI_END="1.5527248534647287" CI_START="0.025625962313727435" EFFECT_SIZE="0.1994744810206937" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="10" LOG_CI_END="0.19109450453169866" LOG_CI_START="-1.5913198168749398" LOG_EFFECT_SIZE="-0.7001126561716206" ORDER="743" O_E="-1.470588235294116" SE="1.0469989954874475" STUDY_ID="STD-Singh-1991" TOTAL_1="24" TOTAL_2="10" VAR="0.9122365523749608" WEIGHT="0.15183093290274957"/>
<DICH_DATA CI_END="1.0527959222624643" CI_START="0.4571419235743097" EFFECT_SIZE="0.6937414165481635" ESTIMABLE="YES" EVENTS_1="198" EVENTS_2="204" LOG_CI_END="0.022344194143797416" LOG_CI_START="-0.33994894860328156" LOG_EFFECT_SIZE="-0.15880237722974205" ORDER="742" O_E="-8.073786407766988" SE="0.21281278542961407" STUDY_ID="STD-SOPAT-2004" TOTAL_1="264" TOTAL_2="251" VAR="22.08027956587773" WEIGHT="3.6750001263518253"/>
<DICH_DATA CI_END="1.2313142649754805" CI_START="0.13257536390003036" EFFECT_SIZE="0.40403209866843837" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.0903689108728789" LOG_CI_START="-0.877537172132777" LOG_EFFECT_SIZE="-0.39358413062994907" MODIFIED="2014-06-26 16:26:46 +0100" MODIFIED_BY="[Empty name]" ORDER="1073" O_E="-2.803571428571427" SE="0.568552824369905" STUDY_ID="STD-Vijayalaskshmi-2006" TOTAL_1="33" TOTAL_2="23" VAR="3.0935586734693876" WEIGHT="0.5148860765986797"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.543851280405189" CI_END="0.6459312097151338" CI_START="0.40052340416128573" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.508635986702792" ESTIMABLE="YES" EVENTS_1="741" EVENTS_2="417" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-0.18981373097069598" LOG_CI_START="-0.397372101299783" LOG_EFFECT_SIZE="-0.2935929161352395" METHOD="PETO" NO="2" P_CHI2="0.6034971255314157" P_Q="0.3184951582989721" P_Z="2.9434358473499708E-8" Q="0.9951171207477418" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1106" TOTAL_2="518" WEIGHT="100.0" Z="5.544768354355474">
<NAME>Quinidine: old and recent studies</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.188721501937242" CI_END="0.653195469728113" CI_START="0.27345222463696994" DF="4" EFFECT_SIZE="0.42263193717458586" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="140" I2="0.0" ID="CMP-005.02.01" LOG_CI_END="-0.1849568359973792" LOG_CI_START="-0.5631185391255821" LOG_EFFECT_SIZE="-0.3740376875614806" NO="1" P_CHI2="0.7010946781608969" P_Z="1.0567440740907178E-4" STUDIES="5" TAU2="0.0" TOTAL_1="211" TOTAL_2="179" WEIGHT="30.124886115261052" Z="3.8771794733144334">
<NAME>Older studies, higher dose</NAME>
<DICH_DATA CI_END="0.6892971723618935" CI_START="0.047626751891230494" EFFECT_SIZE="0.18118770766088588" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="40" LOG_CI_END="-0.16159350306702794" LOG_CI_START="-1.3221490360365151" LOG_EFFECT_SIZE="-0.7418712695517715" ORDER="746" O_E="-3.675675675675677" SE="0.6817160649088166" STUDY_ID="STD-Byrne_x002d_Quinn-1970" TOTAL_1="32" TOTAL_2="42" VAR="2.1517556060318004" WEIGHT="3.19851691211552"/>
<DICH_DATA CI_END="1.450174726390495" CI_START="0.14237278316171528" EFFECT_SIZE="0.45438465188317456" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" LOG_CI_END="0.16142033198368702" LOG_CI_START="-0.8465730251121738" LOG_EFFECT_SIZE="-0.3425763465642434" ORDER="747" O_E="-2.25" SE="0.5921002876056983" STUDY_ID="STD-Hillestad-1971" TOTAL_1="26" TOTAL_2="22" VAR="2.8523936170212765" WEIGHT="4.239993240160787"/>
<DICH_DATA CI_END="1.9130341172951466" CI_START="0.21109933897239028" EFFECT_SIZE="0.6354842544018188" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="17" LOG_CI_END="0.2817227153597031" LOG_CI_START="-0.6755131266217267" LOG_EFFECT_SIZE="-0.1968952056310118" ORDER="748" O_E="-1.4339622641509422" SE="0.5622850719737296" STUDY_ID="STD-Lloyd-1984" TOTAL_1="28" TOTAL_2="25" VAR="3.1629104252813756" WEIGHT="4.701566692058364"/>
<DICH_DATA CI_END="0.8158429372023623" CI_START="0.24628398598538406" EFFECT_SIZE="0.4482511020758579" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="54" LOG_CI_END="-0.08839344182433408" LOG_CI_START="-0.6085638261807316" LOG_EFFECT_SIZE="-0.3484786340025328" ORDER="749" O_E="-8.594594594594597" SE="0.3055506586558776" STUDY_ID="STD-Sodermark-1975" TOTAL_1="110" TOTAL_2="75" VAR="10.711087115317433" WEIGHT="15.921693518282918"/>
<DICH_DATA CI_END="1.791248784970214" CI_START="0.06428662330481592" EFFECT_SIZE="0.3393425052724598" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.25315590881731415" LOG_CI_START="-1.191879385229312" LOG_EFFECT_SIZE="-0.46936173820599886" ORDER="750" O_E="-1.5" SE="0.8488208847630564" STUDY_ID="STD-Steinbeck-1988" TOTAL_1="15" TOTAL_2="15" VAR="1.3879310344827587" WEIGHT="2.0631157526434647"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3600126577202136" CI_END="0.7332287048183275" CI_START="0.413940730549578" DF="1" EFFECT_SIZE="0.5509203442716736" ESTIMABLE="YES" EVENTS_1="619" EVENTS_2="277" I2="26.47127257798483" ID="CMP-005.02.02" LOG_CI_END="-0.13476054139097068" LOG_CI_START="-0.3830618381978806" LOG_EFFECT_SIZE="-0.2589111897944256" NO="2" P_CHI2="0.24353546027023276" P_Z="4.3618545329885505E-5" STUDIES="2" TAU2="0.0" TOTAL_1="895" TOTAL_2="339" WEIGHT="69.87511388473895" Z="4.087426152962137">
<NAME>More recent studies, lower dose</NAME>
<DICH_DATA CI_END="0.7111269963597585" CI_START="0.2628634293081412" EFFECT_SIZE="0.4323531900387971" ESTIMABLE="YES" EVENTS_1="244" EVENTS_2="73" LOG_CI_END="-0.14805283401965802" LOG_CI_START="-0.5802698306088895" LOG_EFFECT_SIZE="-0.3641613323142738" ORDER="751" O_E="-13.008602150537627" SE="0.2538864033051532" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="88" VAR="15.513904497629785" WEIGHT="23.060930232743427"/>
<DICH_DATA CI_END="0.8802646280406021" CI_START="0.43778209399267676" EFFECT_SIZE="0.6207770067675666" ESTIMABLE="YES" EVENTS_1="375" EVENTS_2="204" LOG_CI_END="-0.055386749189298846" LOG_CI_START="-0.3587420057630772" LOG_EFFECT_SIZE="-0.20706437747618803" ORDER="752" O_E="-15.015604681404398" SE="0.17819237934417545" STUDY_ID="STD-SOPAT-2004" TOTAL_1="518" TOTAL_2="251" VAR="31.493559322266766" WEIGHT="46.81418365199553"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="33.977748781192716" CI_END="0.5599126329179133" CI_START="0.42658175862758296" CI_STUDY="95" CI_TOTAL="95" DF="20" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.48872130670549213" ESTIMABLE="YES" EVENTS_1="2006" EVENTS_2="1326" I2="41.137948459168214" I2_Q="91.06668234709424" ID="CMP-005.03" LOG_CI_END="-0.2518797337112198" LOG_CI_START="-0.36999771967131245" LOG_EFFECT_SIZE="-0.31093872669126615" METHOD="PETO" MODIFIED="2014-06-26 15:59:25 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.02627563531626309" P_Q="1.3755882886101745E-5" P_Z="5.783286583386466E-25" Q="22.388098998690097" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="20" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3135" TOTAL_2="1696" WEIGHT="100.00000000000001" Z="10.318982342274724">
<NAME>Class I antiarrhythmics</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.549444752806703" CI_END="0.6375159780675497" CI_START="0.4040450598075623" DF="7" EFFECT_SIZE="0.5075285031272427" ESTIMABLE="YES" EVENTS_1="781" EVENTS_2="449" I2="0.0" ID="CMP-005.03.01" LOG_CI_END="-0.19550892603187525" LOG_CI_START="-0.39357019891280515" LOG_EFFECT_SIZE="-0.2945395624723402" NO="1" P_CHI2="0.7147554562620011" P_Z="5.5634618629676475E-9" STUDIES="8" TAU2="0.0" TOTAL_1="1181" TOTAL_2="564" WEIGHT="35.56582888897683" Z="5.829377203033776">
<NAME>Class Ia</NAME>
<DICH_DATA CI_END="0.6892971723618935" CI_START="0.047626751891230494" EFFECT_SIZE="0.18118770766088588" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="40" LOG_CI_END="-0.16159350306702794" LOG_CI_START="-1.3221490360365151" LOG_EFFECT_SIZE="-0.7418712695517715" ORDER="753" O_E="-3.675675675675677" SE="0.6817160649088166" STUDY_ID="STD-Byrne_x002d_Quinn-1970" TOTAL_1="32" TOTAL_2="42" VAR="2.1517556060318004" WEIGHT="1.0358579737584637"/>
<DICH_DATA CI_END="1.450174726390495" CI_START="0.14237278316171528" EFFECT_SIZE="0.45438465188317456" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" LOG_CI_END="0.16142033198368702" LOG_CI_START="-0.8465730251121738" LOG_EFFECT_SIZE="-0.3425763465642434" ORDER="754" O_E="-2.25" SE="0.5921002876056983" STUDY_ID="STD-Hillestad-1971" TOTAL_1="26" TOTAL_2="22" VAR="2.8523936170212765" WEIGHT="1.3731460321082432"/>
<DICH_DATA CI_END="1.116950638570605" CI_START="0.21117950502052535" EFFECT_SIZE="0.4856717852477124" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="32" LOG_CI_END="0.04803398075205501" LOG_CI_START="-0.6753482323900853" LOG_EFFECT_SIZE="-0.31365712581901517" ORDER="755" O_E="-4.0" SE="0.42491829279939874" STUDY_ID="STD-Karlson-1998" TOTAL_1="46" TOTAL_2="46" VAR="5.538461538461538" WEIGHT="2.6662226559967266"/>
<DICH_DATA CI_END="1.593193665050236" CI_START="0.23691921165982616" EFFECT_SIZE="0.6143762586112285" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="17" LOG_CI_END="0.20226857087362268" LOG_CI_START="-0.6253997211279917" LOG_EFFECT_SIZE="-0.2115655751271845" ORDER="756" O_E="-2.060975609756099" SE="0.48617645174586965" STUDY_ID="STD-Lloyd-1984" TOTAL_1="57" TOTAL_2="25" VAR="4.2306993191883135" WEIGHT="2.036664206692882"/>
<DICH_DATA CI_END="0.7111269963597585" CI_START="0.2628634293081412" EFFECT_SIZE="0.4323531900387971" ESTIMABLE="YES" EVENTS_1="244" EVENTS_2="73" LOG_CI_END="-0.14805283401965802" LOG_CI_START="-0.5802698306088895" LOG_EFFECT_SIZE="-0.3641613323142738" ORDER="757" O_E="-13.008602150537627" SE="0.2538864033051532" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="88" VAR="15.513904497629785" WEIGHT="7.468413993182647"/>
<DICH_DATA CI_END="0.8158429372023623" CI_START="0.24628398598538406" EFFECT_SIZE="0.4482511020758579" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="54" LOG_CI_END="-0.08839344182433408" LOG_CI_START="-0.6085638261807316" LOG_EFFECT_SIZE="-0.3484786340025328" ORDER="759" O_E="-8.594594594594597" SE="0.3055506586558776" STUDY_ID="STD-Sodermark-1975" TOTAL_1="110" TOTAL_2="75" VAR="10.711087115317433" WEIGHT="5.156331399774743"/>
<DICH_DATA CI_END="0.8802646280406021" CI_START="0.43778209399267676" EFFECT_SIZE="0.6207770067675666" ESTIMABLE="YES" EVENTS_1="375" EVENTS_2="204" LOG_CI_END="-0.055386749189298846" LOG_CI_START="-0.3587420057630772" LOG_EFFECT_SIZE="-0.20706437747618803" ORDER="758" O_E="-15.015604681404398" SE="0.17819237934417545" STUDY_ID="STD-SOPAT-2004" TOTAL_1="518" TOTAL_2="251" VAR="31.493559322266766" WEIGHT="15.161040805264713"/>
<DICH_DATA CI_END="1.791248784970214" CI_START="0.06428662330481592" EFFECT_SIZE="0.3393425052724598" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.25315590881731415" LOG_CI_START="-1.191879385229312" LOG_EFFECT_SIZE="-0.46936173820599886" ORDER="760" O_E="-1.5" SE="0.8488208847630564" STUDY_ID="STD-Steinbeck-1988" TOTAL_1="15" TOTAL_2="15" VAR="1.3879310344827587" WEIGHT="0.6681518221984134"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.106564274306779" CI_END="1.1299141787903577" CI_START="0.6317406062339174" DF="1" EFFECT_SIZE="0.8448743505997324" ESTIMABLE="YES" EVENTS_1="639" EVENTS_2="453" I2="0.0" ID="CMP-005.03.02" LOG_CI_END="0.0530454584451863" LOG_CI_START="-0.19946120716998733" LOG_EFFECT_SIZE="-0.07320787436240052" NO="2" P_CHI2="0.7440901207261327" P_Z="0.25575439354448104" STUDIES="2" TAU2="0.0" TOTAL_1="781" TOTAL_2="540" WEIGHT="21.88196768289936" Z="1.1364832432084195">
<NAME>Class Ib</NAME>
<DICH_DATA CI_END="1.1686176791098624" CI_START="0.6316381748011966" EFFECT_SIZE="0.8591528024009256" ESTIMABLE="YES" EVENTS_1="607" EVENTS_2="418" LOG_CI_END="0.06767245212809186" LOG_CI_START="-0.19953163008157862" LOG_EFFECT_SIZE="-0.06592958897674335" ORDER="761" O_E="-6.162184189079085" SE="0.15695700057149928" STUDY_ID="STD-AFIB-1997" TOTAL_1="734" TOTAL_2="493" VAR="40.59182881805225" WEIGHT="19.540959685547396"/>
<DICH_DATA CI_END="1.7866360970621007" CI_START="0.3020236361415423" EFFECT_SIZE="0.7345790158290866" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="35" LOG_CI_END="0.2520361041946625" LOG_CI_START="-0.5199590681548776" LOG_EFFECT_SIZE="-0.13396148198010746" ORDER="762" O_E="-1.5" SE="0.45347378567585434" STUDY_ID="STD-SMART-2002" TOTAL_1="47" TOTAL_2="47" VAR="4.862903225806452" WEIGHT="2.341007997351965"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.933640755389125" CI_END="0.4401909150615397" CI_START="0.2901132265234084" DF="10" EFFECT_SIZE="0.35735865269333394" ESTIMABLE="YES" EVENTS_1="586" EVENTS_2="424" I2="0.0" ID="CMP-005.03.03" LOG_CI_END="-0.35635892493432175" LOG_CI_START="-0.5374324708692171" LOG_EFFECT_SIZE="-0.4468956979017694" MODIFIED="2014-06-26 15:59:25 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7316945052107529" P_Z="3.8691747572893506E-22" STUDIES="11" TAU2="0.0" TOTAL_1="1173" TOTAL_2="592" WEIGHT="42.552203428123825" Z="9.674516155422156">
<NAME>Class Ic</NAME>
<DICH_DATA CI_END="0.6900980952016661" CI_START="0.22284661466907307" EFFECT_SIZE="0.39215561235977103" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="62" LOG_CI_END="-0.1610891713254131" LOG_CI_START="-0.6519939590276962" LOG_EFFECT_SIZE="-0.4065415651765546" ORDER="763" O_E="-11.25773195876289" SE="0.288359902314211" STUDY_ID="STD-Bellandi-2001" TOTAL_1="102" TOTAL_2="92" VAR="12.02625091068688" WEIGHT="5.789452977528752"/>
<DICH_DATA CI_END="0.582203481068571" CI_START="0.057498995068715926" EFFECT_SIZE="0.18296479193263115" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="19" LOG_CI_END="-0.23492520218756896" LOG_CI_START="-1.2403397455699385" LOG_EFFECT_SIZE="-0.7376324738787537" ORDER="764" O_E="-4.869565217391305" SE="0.5905854796650598" STUDY_ID="STD-Carunchio-1995" TOTAL_1="20" TOTAL_2="26" VAR="2.8670447385003155" WEIGHT="1.3801991012235384"/>
<DICH_DATA CI_END="0.9185838914096333" CI_START="0.20442554208424146" EFFECT_SIZE="0.4333382165829207" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="35" LOG_CI_END="-0.03688117478272425" LOG_CI_START="-0.689464841936465" LOG_EFFECT_SIZE="-0.3631730083595946" ORDER="765" O_E="-5.690909090909088" SE="0.38333087642735797" STUDY_ID="STD-Dogan-2004" TOTAL_1="58" TOTAL_2="52" VAR="6.805380241110017" WEIGHT="3.276118982774443"/>
<DICH_DATA CI_END="0.7006689495158462" CI_START="0.2609477556210965" EFFECT_SIZE="0.42759559142904113" ESTIMABLE="YES" EVENTS_1="131" EVENTS_2="55" LOG_CI_END="-0.1544871280504838" LOG_CI_START="-0.5834464341048028" LOG_EFFECT_SIZE="-0.3689667810776433" MODIFIED="2014-06-26 15:47:49 +0100" MODIFIED_BY="[Empty name]" ORDER="1036" O_E="-13.381215469613267" SE="0.2519728197591174" STUDY_ID="STD-Flec_x002d_SL-2012" TOTAL_1="281" TOTAL_2="81" VAR="15.750436997710523" WEIGHT="7.582281049262266"/>
<DICH_DATA CI_END="0.5667774028207857" CI_START="0.16920102099928358" EFFECT_SIZE="0.30967614573389274" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="58" LOG_CI_END="-0.24658747321969615" LOG_CI_START="-0.7715970206526864" LOG_EFFECT_SIZE="-0.5090922469361913" ORDER="766" O_E="-12.325443786982248" SE="0.30839320700131184" STUDY_ID="STD-Kochiadakis-2004b" TOTAL_1="86" TOTAL_2="83" VAR="10.514542808124967" WEIGHT="5.061714712251569"/>
<DICH_DATA CI_END="0.9541191042383869" CI_START="0.04436783141814796" EFFECT_SIZE="0.20574789323267223" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="10" LOG_CI_END="-0.020397408225854084" LOG_CI_START="-1.3529317979264008" LOG_EFFECT_SIZE="-0.6866646030761274" ORDER="767" O_E="-2.5806451612903203" SE="0.7827372966617115" STUDY_ID="STD-Okishige-2000" TOTAL_1="52" TOTAL_2="10" VAR="1.6321795943433242" WEIGHT="0.7857333995863657"/>
<DICH_DATA CI_END="0.532878617235521" CI_START="0.23108792617207216" EFFECT_SIZE="0.3509156801261494" ESTIMABLE="YES" EVENTS_1="232" EVENTS_2="104" LOG_CI_END="-0.2733717062986568" LOG_CI_START="-0.6362227448446693" LOG_EFFECT_SIZE="-0.454797225571663" ORDER="768" O_E="-23.051625239005745" SE="0.21314049618353628" STUDY_ID="STD-RAFT-2003" TOTAL_1="397" TOTAL_2="126" VAR="22.012433403959818" WEIGHT="10.59681434053248"/>
<DICH_DATA CI_END="0.5324482652481015" CI_START="0.10391473449562894" EFFECT_SIZE="0.23522164040732876" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="27" LOG_CI_END="-0.27372258358646745" LOG_CI_START="-0.98332286768396" LOG_EFFECT_SIZE="-0.6285227256352137" MODIFIED="2014-06-26 15:59:25 +0100" MODIFIED_BY="[Empty name]" ORDER="1042" O_E="-8.329787234042552" SE="0.4168227194569235" STUDY_ID="STD-Santas-2012" TOTAL_1="49" TOTAL_2="45" VAR="5.755687875114999" WEIGHT="2.770795699655618"/>
<DICH_DATA CI_END="0.6172926973181766" CI_START="0.03328143701494946" EFFECT_SIZE="0.143333136523217" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="13" LOG_CI_END="-0.20950886078305847" LOG_CI_START="-1.4777979301520636" LOG_EFFECT_SIZE="-0.8436533954675609" ORDER="769" O_E="-3.5" SE="0.7449992774794993" STUDY_ID="STD-Steinbeck-1988" TOTAL_1="15" TOTAL_2="15" VAR="1.8017241379310345" WEIGHT="0.8673523654625367"/>
<DICH_DATA CI_END="1.1124951063594568" CI_START="0.18409731745925123" EFFECT_SIZE="0.45255647688141687" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="17" LOG_CI_END="0.04629810928374793" LOG_CI_START="-0.7349525396933374" LOG_EFFECT_SIZE="-0.3443272152047947" ORDER="770" O_E="-3.764705882352942" SE="0.4589104984622226" STUDY_ID="STD-Stroobandt-1997" TOTAL_1="77" TOTAL_2="25" VAR="4.748364109767378" WEIGHT="2.2858687165136895"/>
<DICH_DATA CI_END="1.5429411864747646" CI_START="0.24204115473887347" EFFECT_SIZE="0.6111098644830727" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="24" LOG_CI_END="0.1883493720279735" LOG_CI_START="-0.6161107837865255" LOG_EFFECT_SIZE="-0.21388070587927605" ORDER="771" O_E="-2.205479452054796" SE="0.47254387766743117" STUDY_ID="STD-Van-Gelder-1989" TOTAL_1="36" TOTAL_2="37" VAR="4.478326139988741" WEIGHT="2.155872083332563"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="93.61792599920769" CI_END="0.5072093130567011" CI_START="0.4124946372036252" CI_STUDY="95" CI_TOTAL="95" DF="26" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.45740695400881687" ESTIMABLE="YES" EVENTS_1="3121" EVENTS_2="2572" I2="72.22754112260503" I2_Q="93.21838523073492" ID="CMP-005.04" LOG_CI_END="-0.2948127808124388" LOG_CI_START="-0.3845816932910569" LOG_EFFECT_SIZE="-0.3396972370517478" METHOD="PETO" MODIFIED="2014-06-26 16:27:03 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.4434061723633818E-9" P_Q="4.744871162642994E-12" P_Z="8.894780160944177E-50" Q="58.983002368822" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="23" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4805" TOTAL_2="3199" WEIGHT="100.0" Z="14.833517124935094">
<NAME>Class III antiarrhythmics</NAME>
<GROUP_LABEL_1>Antiarrhythmic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.4399402443211073" CI_END="0.2533753043061929" CI_START="0.13540709713310584" DF="4" EFFECT_SIZE="0.18522638700066174" ESTIMABLE="YES" EVENTS_1="205" EVENTS_2="227" I2="0.0" ID="CMP-005.04.01" LOG_CI_END="-0.5962357167067454" LOG_CI_START="-0.8683585722463808" LOG_EFFECT_SIZE="-0.732297144476563" MODIFIED="2014-06-26 16:25:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6554218053080898" P_Z="5.1485252218918987E-26" STUDIES="5" TAU2="0.0" TOTAL_1="450" TOTAL_2="268" WEIGHT="10.882329926073854" Z="10.54873561656078">
<NAME>Amiodarone</NAME>
<DICH_DATA CI_END="0.3244281554847841" CI_START="0.057903549941752716" EFFECT_SIZE="0.1370603586148231" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="36" LOG_CI_END="-0.4888814625956894" LOG_CI_START="-1.2372948097984093" LOG_EFFECT_SIZE="-0.8630881361970493" ORDER="772" O_E="-10.282828282828284" SE="0.43962170485269497" STUDY_ID="STD-Channer-2004" TOTAL_1="61" TOTAL_2="38" VAR="5.174182559463945" WEIGHT="1.4386954812542054"/>
<DICH_DATA CI_END="0.3788098949306661" CI_START="0.033470350366971914" EFFECT_SIZE="0.11260062124964149" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="-0.421578685271559" LOG_CI_START="-1.4753397414322997" LOG_EFFECT_SIZE="-0.9484592133519294" ORDER="773" O_E="-5.699999999999999" SE="0.618984460590173" STUDY_ID="STD-GEFACA-2001" TOTAL_1="35" TOTAL_2="15" VAR="2.6099999999999994" WEIGHT="0.7257175723738863"/>
<DICH_DATA CI_END="0.4492953039628822" CI_START="0.1083605330200395" EFFECT_SIZE="0.2206487675488322" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="47" LOG_CI_END="-0.34746812063169147" LOG_CI_START="-0.9651288673607911" LOG_EFFECT_SIZE="-0.6562984939962413" ORDER="774" O_E="-11.479999999999997" SE="0.3628169800986797" STUDY_ID="STD-Kochiadakis-2000" TOTAL_1="65" TOTAL_2="60" VAR="7.596696774193548" WEIGHT="2.1122821229993396"/>
<DICH_DATA CI_END="0.32722060914935297" CI_START="0.13877406944543474" EFFECT_SIZE="0.2130956018740644" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="114" LOG_CI_END="-0.48515935121717374" LOG_CI_START="-0.8576916761637672" LOG_EFFECT_SIZE="-0.6714255136904705" ORDER="775" O_E="-32.28571428571428" SE="0.21882733173837812" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="267" TOTAL_2="132" VAR="20.883191467541792" WEIGHT="5.806627975189076"/>
<DICH_DATA CI_END="0.3617345675912048" CI_START="0.035819494172640895" EFFECT_SIZE="0.11382947437230805" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="18" LOG_CI_END="-0.4416099877913599" LOG_CI_START="-1.445880551361972" LOG_EFFECT_SIZE="-0.9437452695766658" MODIFIED="2014-06-26 16:25:39 +0100" MODIFIED_BY="[Empty name]" ORDER="1071" O_E="-6.244444444444444" SE="0.5899135002608419" STUDY_ID="STD-Vijayalaskshmi-2006" TOTAL_1="22" TOTAL_2="23" VAR="2.8735802469135803" WEIGHT="0.7990067742573473"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.604527198500624" CI_END="0.8989863615560058" CI_START="0.5506558919581765" DF="3" EFFECT_SIZE="0.7035852022185076" ESTIMABLE="YES" EVENTS_1="604" EVENTS_2="656" I2="0.0" ID="CMP-005.04.02" LOG_CI_END="-0.046246896860650706" LOG_CI_START="-0.25911970951173136" LOG_EFFECT_SIZE="-0.15268330318619097" MODIFIED="2011-02-25 20:41:32 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.45669646943708675" P_Z="0.004929983165129782" STUDIES="4" TAU2="0.0" TOTAL_1="797" TOTAL_2="805" WEIGHT="17.783266253408847" Z="2.8115734607786695">
<NAME>Azimilide</NAME>
<DICH_DATA CI_END="1.0933935106921964" CI_START="0.4116181895531199" EFFECT_SIZE="0.6708656030385308" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="117" LOG_CI_END="0.03877649201855855" LOG_CI_START="-0.385505441859065" LOG_EFFECT_SIZE="-0.17336447492025328" ORDER="844" O_E="-6.426751592356695" SE="0.2492253081891608" STUDY_ID="STD-A_x002d_COMET_x002d_I-2006" TOTAL_1="159" TOTAL_2="155" VAR="16.09962337674626" WEIGHT="4.476543905404662"/>
<DICH_DATA CI_END="1.2621415786610972" CI_START="0.4644468951831723" EFFECT_SIZE="0.7656355121666799" ESTIMABLE="YES" EVENTS_1="171" EVENTS_2="190" LOG_CI_END="0.10110807391171979" LOG_CI_START="-0.33306393602422224" LOG_EFFECT_SIZE="-0.11597793105625122" ORDER="857" O_E="-4.105747126436768" SE="0.2550347878224832" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="211" TOTAL_2="224" VAR="15.374505346511022" WEIGHT="4.274922872229623"/>
<DICH_DATA CI_END="0.8531478467524782" CI_START="0.23587293279811006" EFFECT_SIZE="0.4485916681391882" ESTIMABLE="YES" EVENTS_1="188" EVENTS_2="202" LOG_CI_END="-0.06897570099557579" LOG_CI_START="-0.6273218929883597" LOG_EFFECT_SIZE="-0.34814879699196777" MODIFIED="2010-11-20 10:13:21 +0000" MODIFIED_BY="[Empty name]" ORDER="896" O_E="-7.452436194895597" SE="0.32797531703478655" STUDY_ID="STD-A_x002d_STAR-2006" TOTAL_1="216" TOTAL_2="215" VAR="9.296461582355823" WEIGHT="2.584906333798608"/>
<DICH_DATA CI_END="1.237329742066832" CI_START="0.5481955992032969" EFFECT_SIZE="0.8235889262031075" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="147" LOG_CI_END="0.09248545231841637" LOG_CI_START="-0.2610644552054873" LOG_EFFECT_SIZE="-0.08428950144353549" MODIFIED="2010-12-28 10:25:38 +0000" MODIFIED_BY="[Empty name]" ORDER="952" O_E="-4.5" SE="0.2076769657798085" STUDY_ID="STD-SVA_x002d_4-2008" TOTAL_1="211" TOTAL_2="211" VAR="23.18586698337292" WEIGHT="6.446893141975955"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.310953185635555" CI_END="0.3933898295256139" CI_START="0.2319428543965176" DF="2" EFFECT_SIZE="0.30206615161373235" ESTIMABLE="YES" EVENTS_1="448" EVENTS_2="363" I2="75.93537160747397" ID="CMP-005.04.03" LOG_CI_END="-0.40517687227128496" LOG_CI_START="-0.6346190025113105" LOG_EFFECT_SIZE="-0.5198979373912977" MODIFIED="2011-02-25 20:41:32 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.015678336064250398" P_Z="6.552110982759506E-19" STUDIES="3" TAU2="0.0" TOTAL_1="752" TOTAL_2="431" WEIGHT="15.307546782452404" Z="8.882250455551642">
<NAME>Dofetilide</NAME>
<DICH_DATA CI_END="0.3068852264243933" CI_START="0.1437806924281964" EFFECT_SIZE="0.21005754057229914" ESTIMABLE="YES" EVENTS_1="132" EVENTS_2="221" LOG_CI_END="-0.5130240181722759" LOG_CI_START="-0.8422994292164805" LOG_EFFECT_SIZE="-0.6776617236943783" ORDER="776" O_E="-41.709486166007906" SE="0.19341800638693776" STUDY_ID="STD-DIAMOND-2001" TOTAL_1="249" TOTAL_2="257" VAR="26.730445370538085" WEIGHT="7.432472767348541"/>
<DICH_DATA CI_END="0.5689602712639514" CI_START="0.22426628708284518" EFFECT_SIZE="0.3572094729063254" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="89" LOG_CI_END="-0.2449180579866873" LOG_CI_START="-0.6492360069980228" LOG_EFFECT_SIZE="-0.44707703249235503" MODIFIED="2010-12-28 10:36:20 +0000" MODIFIED_BY="[Empty name]" ORDER="969" O_E="-18.25058548009369" SE="0.2374983646553843" STUDY_ID="STD-EMERALD-2000" TOTAL_1="321" TOTAL_2="106" VAR="17.728776003817273" WEIGHT="4.929534207912139"/>
<DICH_DATA CI_END="1.0419385867045163" CI_START="0.3124580724793979" EFFECT_SIZE="0.5705805135505428" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="53" LOG_CI_END="0.01784212180289649" LOG_CI_START="-0.5052082506798179" LOG_EFFECT_SIZE="-0.2436830644384607" ORDER="777" O_E="-5.944000000000003" SE="0.3072423779374474" STUDY_ID="STD-SAFIRE_x002d_D-2000" TOTAL_1="182" TOTAL_2="68" VAR="10.59345837751004" WEIGHT="2.9455398071917225"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.4389966325286585" CI_END="0.7489899004418588" CI_START="0.462757084495342" DF="1" EFFECT_SIZE="0.5887277661576112" ESTIMABLE="YES" EVENTS_1="648" EVENTS_2="353" I2="0.0" ID="CMP-005.04.04" LOG_CI_END="-0.12552403839124437" LOG_CI_START="-0.33464692377185473" LOG_EFFECT_SIZE="-0.23008548108154958" MODIFIED="2011-02-25 20:41:32 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5076071592155167" P_Z="1.6115343537307838E-5" STUDIES="2" TAU2="0.0" TOTAL_1="982" TOTAL_2="461" WEIGHT="18.426752507710965" Z="4.312863754386794">
<NAME>Dronedarone</NAME>
<DICH_DATA CI_END="1.0178504787267657" CI_START="0.20209961227942247" EFFECT_SIZE="0.45354954206691017" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="43" LOG_CI_END="0.007683985237284965" LOG_CI_START="-0.694434519661682" LOG_EFFECT_SIZE="-0.34337526721219847" ORDER="778" O_E="-4.64824120603015" SE="0.4124278853203052" STUDY_ID="STD-DAFNE-2003" TOTAL_1="151" TOTAL_2="48" VAR="5.879006728480226" WEIGHT="1.6346737513265952"/>
<DICH_DATA CI_END="0.7770978877586998" CI_START="0.4692565646378449" EFFECT_SIZE="0.6038694272746162" ESTIMABLE="YES" EVENTS_1="532" EVENTS_2="310" LOG_CI_END="-0.10952427150050074" LOG_CI_START="-0.3285896431263289" LOG_EFFECT_SIZE="-0.21905695731341482" ORDER="830" O_E="-30.46141479099674" SE="0.12868008368408979" STUDY_ID="STD-EURIDIS-ADONIS-2007" TOTAL_1="831" TOTAL_2="413" VAR="60.3917105256252" WEIGHT="16.79207875638437"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="20.84050636939978" CI_END="0.6002380044873934" CI_START="0.4284762346504925" DF="12" EFFECT_SIZE="0.5071367863376544" ESTIMABLE="YES" EVENTS_1="1216" EVENTS_2="973" I2="42.41982518419197" ID="CMP-005.04.05" LOG_CI_END="-0.22167651038295177" LOG_CI_START="-0.3680732611302273" LOG_EFFECT_SIZE="-0.2948748857565896" MODIFIED="2014-06-26 16:27:03 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.05276539867020713" P_Z="2.889515550824941E-15" STUDIES="13" TAU2="0.0" TOTAL_1="1824" TOTAL_2="1234" WEIGHT="37.60010453035394" Z="7.895587205019086">
<NAME>Sotalol</NAME>
<DICH_DATA CI_END="0.5897313461816622" CI_START="0.24755086325099263" EFFECT_SIZE="0.38208441977322294" ESTIMABLE="YES" EVENTS_1="150" EVENTS_2="190" LOG_CI_END="-0.2293457874131082" LOG_CI_START="-0.6063355548728367" LOG_EFFECT_SIZE="-0.4178406711429725" ORDER="890" O_E="-19.61968680089487" SE="0.22144565553529005" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="223" TOTAL_2="224" VAR="20.39227462226426" WEIGHT="5.670127216111583"/>
<DICH_DATA CI_END="0.5560177432550629" CI_START="0.18229195178371482" EFFECT_SIZE="0.31836702034655195" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="62" LOG_CI_END="-0.25491134929058196" LOG_CI_START="-0.7392325050865465" LOG_EFFECT_SIZE="-0.49707192718856424" ORDER="780" O_E="-14.141414141414138" SE="0.284492644342936" STUDY_ID="STD-Bellandi-2001" TOTAL_1="106" TOTAL_2="92" VAR="12.355431461722802" WEIGHT="3.4354611977139506"/>
<DICH_DATA CI_END="1.7236564330023032" CI_START="0.47734476653030977" EFFECT_SIZE="0.9070713189104542" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="53" LOG_CI_END="0.23645070457407255" LOG_CI_START="-0.32116783455182196" LOG_EFFECT_SIZE="-0.0423585649888747" ORDER="781" O_E="-0.9090909090909065" SE="0.32754789013883595" STUDY_ID="STD-Benditt-1999" TOTAL_1="184" TOTAL_2="69" VAR="9.320739866194414" WEIGHT="2.591656976407323"/>
<DICH_DATA CI_END="0.8489996279350025" CI_START="0.08162095968684081" EFFECT_SIZE="0.2632416464122379" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="19" LOG_CI_END="-0.07109250008091274" LOG_CI_START="-1.0881983031642053" LOG_EFFECT_SIZE="-0.579645401622559" ORDER="782" O_E="-3.7391304347826093" SE="0.5974529834860508" STUDY_ID="STD-Carunchio-1995" TOTAL_1="20" TOTAL_2="26" VAR="2.8015122873345932" WEIGHT="0.7789680828122892"/>
<DICH_DATA CI_END="2.5422464443091535" CI_START="0.43793368144435946" EFFECT_SIZE="1.0551470724477894" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="54" LOG_CI_END="0.4052176485845123" LOG_CI_START="-0.35859165196953896" LOG_EFFECT_SIZE="0.02331299830748672" MODIFIED="2010-12-27 14:19:38 +0000" MODIFIED_BY="[Empty name]" ORDER="929" O_E="0.2666666666666657" SE="0.4486653640624653" STUDY_ID="STD-DAPHNE-2008" TOTAL_1="69" TOTAL_2="66" VAR="4.967694859038143" WEIGHT="1.381281016626589"/>
<DICH_DATA CI_END="0.8030625020136358" CI_START="0.22893753763389477" EFFECT_SIZE="0.428778674582956" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="89" LOG_CI_END="-0.09525065245072305" LOG_CI_START="-0.6402829925998801" LOG_EFFECT_SIZE="-0.3677668225253015" MODIFIED="2010-12-28 10:49:04 +0000" MODIFIED_BY="[Empty name]" ORDER="995" O_E="-8.26168224299066" SE="0.3201546945572106" STUDY_ID="STD-EMERALD-2000" TOTAL_1="108" TOTAL_2="106" VAR="9.756190035663364" WEIGHT="2.7127350759769797"/>
<DICH_DATA CI_END="0.8319561758631644" CI_START="0.24276565553742369" EFFECT_SIZE="0.4494111551929138" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="58" LOG_CI_END="-0.07989955000984499" LOG_CI_START="-0.6148127536165463" LOG_EFFECT_SIZE="-0.3473561518131956" ORDER="783" O_E="-8.101190476190474" SE="0.31421066366163836" STUDY_ID="STD-Kochiadakis-2004b" TOTAL_1="85" TOTAL_2="83" VAR="10.128803829415997" WEIGHT="2.816341351009618"/>
<DICH_DATA CI_END="0.7637732483695356" CI_START="0.27909880868501896" EFFECT_SIZE="0.46170142270240455" ESTIMABLE="YES" EVENTS_1="255" EVENTS_2="73" LOG_CI_END="-0.11703555712917849" LOG_CI_START="-0.5542420172649579" LOG_EFFECT_SIZE="-0.33563878719706824" ORDER="784" O_E="-11.717622080679405" SE="0.2568172388906384" STUDY_ID="STD-PAFAC-2004" TOTAL_1="383" TOTAL_2="88" VAR="15.161831125551203" WEIGHT="4.215788228803774"/>
<DICH_DATA CI_END="2.2616658695023157" CI_START="0.5671780267892732" EFFECT_SIZE="1.1325931242599743" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="29" LOG_CI_END="0.354428444201308" LOG_CI_START="-0.24628060262932172" LOG_EFFECT_SIZE="0.054073920785993164" ORDER="785" O_E="1.0" SE="0.35285946766605064" STUDY_ID="STD-Plewan-2001" TOTAL_1="64" TOTAL_2="64" VAR="8.031496062992126" WEIGHT="2.2331792434348934"/>
<DICH_DATA CI_END="0.6761368115640589" CI_START="0.255498542602637" EFFECT_SIZE="0.4156344186356693" ESTIMABLE="YES" EVENTS_1="183" EVENTS_2="114" LOG_CI_END="-0.1699654187097426" LOG_CI_START="-0.5926115727951702" LOG_EFFECT_SIZE="-0.38128849575245644" ORDER="786" O_E="-14.244274809160316" SE="0.2482644430419843" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="261" TOTAL_2="132" VAR="16.22448622826556" WEIGHT="4.511262359613194"/>
<DICH_DATA CI_END="1.5527248534647287" CI_START="0.025625962313727435" EFFECT_SIZE="0.1994744810206937" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="10" LOG_CI_END="0.19109450453169866" LOG_CI_START="-1.5913198168749398" LOG_EFFECT_SIZE="-0.7001126561716206" ORDER="788" O_E="-1.470588235294116" SE="1.0469989954874475" STUDY_ID="STD-Singh-1991" TOTAL_1="24" TOTAL_2="10" VAR="0.9122365523749608" WEIGHT="0.2536498452951266"/>
<DICH_DATA CI_END="1.0527959222624643" CI_START="0.4571419235743097" EFFECT_SIZE="0.6937414165481635" ESTIMABLE="YES" EVENTS_1="198" EVENTS_2="204" LOG_CI_END="0.022344194143797416" LOG_CI_START="-0.33994894860328156" LOG_EFFECT_SIZE="-0.15880237722974205" ORDER="787" O_E="-8.073786407766988" SE="0.21281278542961407" STUDY_ID="STD-SOPAT-2004" TOTAL_1="264" TOTAL_2="251" VAR="22.08027956587773" WEIGHT="6.139481564707095"/>
<DICH_DATA CI_END="1.2313142649754805" CI_START="0.13257536390003036" EFFECT_SIZE="0.40403209866843837" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.0903689108728789" LOG_CI_START="-0.877537172132777" LOG_EFFECT_SIZE="-0.39358413062994907" MODIFIED="2014-06-26 16:27:03 +0100" MODIFIED_BY="[Empty name]" ORDER="1074" O_E="-2.803571428571427" SE="0.568552824369905" STUDY_ID="STD-Vijayalaskshmi-2006" TOTAL_1="33" TOTAL_2="23" VAR="3.0935586734693876" WEIGHT="0.8601723718415266"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="144.16945801450566" CI_END="0.8371319316258515" CI_START="0.7043925307371259" CI_STUDY="95" CI_TOTAL="95" DF="47" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.7678993943732423" ESTIMABLE="YES" EVENTS_1="2734" EVENTS_2="3082" I2="67.39947514037885" I2_Q="86.95143393036928" ID="CMP-005.05" LOG_CI_END="-0.07720609199257797" LOG_CI_START="-0.15218525786780543" LOG_EFFECT_SIZE="-0.11469567493019169" METHOD="PETO" MODIFIED="2014-06-26 16:28:27 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="8.413603147516824E-12" P_Q="2.1582735598713043E-13" P_Z="2.0184387209507267E-9" Q="84.30045064952722" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="29" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="4713" TOTAL_2="4846" WEIGHT="1200.0" Z="5.99631616120609">
<NAME>Comparing antiarrhythmic drugs</NAME>
<GROUP_LABEL_1>Antiarrhythmic 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiarrhythmic 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Drug 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Drug 2</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.29322923541576235" CI_END="1.600534507246191" CI_START="0.35883445881403286" DF="1" EFFECT_SIZE="0.7578436076928219" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="27" I2="0.0" ID="CMP-005.05.01" LOG_CI_END="0.20426504189474293" LOG_CI_START="-0.4451058583977112" LOG_EFFECT_SIZE="-0.12042040825148415" NO="1" P_CHI2="0.5881586327107254" P_Z="0.4672762610958975" STUDIES="2" TAU2="0.0" TOTAL_1="60" TOTAL_2="53" WEIGHT="100.00000000000001" Z="0.7269178925948909">
<NAME>Disopyramide vs other Class I drugs</NAME>
<DICH_DATA CI_END="2.608184561164641" CI_START="0.3276216677922056" EFFECT_SIZE="0.924390488829608" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" LOG_CI_END="0.4163383198280471" LOG_CI_START="-0.4846273831893862" LOG_EFFECT_SIZE="-0.034144531680669554" ORDER="789" O_E="-0.2807017543859658" SE="0.5292317138045978" STUDY_ID="STD-Lloyd-1984" TOTAL_1="29" TOTAL_2="28" VAR="3.5703293321021854" WEIGHT="51.94803542547626"/>
<DICH_DATA CI_END="1.797620640522116" CI_START="0.20793080028029431" EFFECT_SIZE="0.611376069521975" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.25469804606738927" LOG_CI_START="-0.682081174925299" LOG_EFFECT_SIZE="-0.21369156442895487" ORDER="790" O_E="-1.625" SE="0.5502687515430357" STUDY_ID="STD-PRODIS-1996" TOTAL_1="31" TOTAL_2="25" VAR="3.3025568181818183" WEIGHT="48.05196457452375"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.1695705451732152" CI_END="2.4121854660754862" CI_START="0.7881971540622019" DF="1" EFFECT_SIZE="1.3788682748656247" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="99" I2="14.498530753277612" ID="CMP-005.05.02" LOG_CI_END="0.38241069641860037" LOG_CI_START="-0.10336513757154858" LOG_EFFECT_SIZE="0.13952277942352584" NO="2" P_CHI2="0.27948955151212274" P_Z="0.26022160727011523" STUDIES="2" TAU2="0.0" TOTAL_1="132" TOTAL_2="137" WEIGHT="100.0" Z="1.1258675444879473">
<NAME>Quinidine vs Flecainide</NAME>
<DICH_DATA CI_END="2.219278922704744" CI_START="0.6562337611531096" EFFECT_SIZE="1.206799798845838" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="93" LOG_CI_END="0.346211888522693" LOG_CI_START="-0.18294143029662202" LOG_EFFECT_SIZE="0.0816352291130355" ORDER="791" O_E="1.9456066945606665" SE="0.31082727882563815" STUDY_ID="STD-Naccarelli-1996" TOTAL_1="117" TOTAL_2="122" VAR="10.350509952409737" WEIGHT="84.27694095842638"/>
<DICH_DATA CI_END="11.543809113054088" CI_START="0.687481255659712" EFFECT_SIZE="2.817117744102729" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="1.0623491367069993" LOG_CI_START="-0.1627391384788346" LOG_EFFECT_SIZE="0.4498049991140823" ORDER="792" O_E="2.0" SE="0.7196229171289245" STUDY_ID="STD-Steinbeck-1988" TOTAL_1="15" TOTAL_2="15" VAR="1.9310344827586206" WEIGHT="15.723059041573624"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3345061620757925" CI_END="1.8730336182705847" CI_START="0.8962752458786568" DF="3" EFFECT_SIZE="1.2956672669919769" ESTIMABLE="YES" EVENTS_1="176" EVENTS_2="168" I2="0.0" ID="CMP-005.05.03" LOG_CI_END="0.2725455724090754" LOG_CI_START="-0.047558598139905324" LOG_EFFECT_SIZE="0.11249348713458507" NO="3" P_CHI2="0.7209561574908455" P_Z="0.16833564053702546" STUDIES="4" TAU2="0.0" TOTAL_1="258" TOTAL_2="268" WEIGHT="100.0" Z="1.3775714505748333">
<NAME>Quinidine vs other Class I drugs</NAME>
<DICH_DATA CI_END="3.052301170245709" CI_START="0.38340845003448176" EFFECT_SIZE="1.0817939086176915" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" LOG_CI_END="0.4846273831893862" LOG_CI_START="-0.41633831982804703" LOG_EFFECT_SIZE="0.0341445316806696" ORDER="793" O_E="0.2807017543859658" SE="0.5292317138045978" STUDY_ID="STD-Lloyd-1984" TOTAL_1="28" TOTAL_2="29" VAR="3.5703293321021854" WEIGHT="12.623103609334619"/>
<DICH_DATA CI_END="2.219278922704744" CI_START="0.6562337611531096" EFFECT_SIZE="1.206799798845838" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="93" LOG_CI_END="0.346211888522693" LOG_CI_START="-0.18294143029662202" LOG_EFFECT_SIZE="0.0816352291130355" ORDER="794" O_E="1.9456066945606665" SE="0.31082727882563815" STUDY_ID="STD-Naccarelli-1996" TOTAL_1="117" TOTAL_2="122" VAR="10.350509952409737" WEIGHT="36.59482008114589"/>
<DICH_DATA CI_END="2.2371956083189932" CI_START="0.7360048367381704" EFFECT_SIZE="1.2831939792767781" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="53" LOG_CI_END="0.34970395812416183" LOG_CI_START="-0.13311933163832215" LOG_EFFECT_SIZE="0.10829231324291985" ORDER="795" O_E="3.1000000000000014" SE="0.28361279042031307" STUDY_ID="STD-Richiardi-1992" TOTAL_1="98" TOTAL_2="102" VAR="12.43221105527638" WEIGHT="43.954793422787105"/>
<DICH_DATA CI_END="11.543809113054088" CI_START="0.687481255659712" EFFECT_SIZE="2.817117744102729" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="1.0623491367069993" LOG_CI_START="-0.1627391384788346" LOG_EFFECT_SIZE="0.4498049991140823" ORDER="796" O_E="2.0" SE="0.7196229171289245" STUDY_ID="STD-Steinbeck-1988" TOTAL_1="15" TOTAL_2="15" VAR="1.9310344827586206" WEIGHT="6.8272828867323945"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.103458131762299" CI_END="1.1114447093506925" CI_START="0.7564441076197306" DF="5" EFFECT_SIZE="0.9169219167047189" ESTIMABLE="YES" EVENTS_1="715" EVENTS_2="556" I2="2.027216234388369" ID="CMP-005.05.04" LOG_CI_END="0.04588786287742597" LOG_CI_START="-0.12122315574268831" LOG_EFFECT_SIZE="-0.037667646432631166" NO="4" P_CHI2="0.4033852683950303" P_Z="0.3769278137213199" STUDIES="6" TAU2="0.0" TOTAL_1="1109" TOTAL_2="869" WEIGHT="100.0" Z="0.8835710655103327">
<NAME>Quinidine vs Sotalol</NAME>
<DICH_DATA CI_END="1.3481135178072958" CI_START="0.1405006403099894" EFFECT_SIZE="0.4352135251373484" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.12972646347644484" LOG_CI_START="-0.8523216965243002" LOG_EFFECT_SIZE="-0.36129761652392767" ORDER="797" O_E="-2.5" SE="0.5768599504012304" STUDY_ID="STD-Hohnloser-1995" TOTAL_1="25" TOTAL_2="25" VAR="3.0051020408163263" WEIGHT="2.8956402204902356"/>
<DICH_DATA CI_END="2.332111485493442" CI_START="0.7290793809662697" EFFECT_SIZE="1.303953372704671" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="50" LOG_CI_END="0.36774930782681653" LOG_CI_START="-0.1372251838373399" LOG_EFFECT_SIZE="0.11526206199473837" ORDER="798" O_E="3.016393442622949" SE="0.2966245160675733" STUDY_ID="STD-Juul_x002d_Moller-1990" TOTAL_1="85" TOTAL_2="98" VAR="11.365431128935562" WEIGHT="10.951441599373313"/>
<DICH_DATA CI_END="1.323111619271554" CI_START="0.23365741067199092" EFFECT_SIZE="0.5560169376817727" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="21" LOG_CI_END="0.12159648333256624" LOG_CI_START="-0.6314204403494271" LOG_EFFECT_SIZE="-0.25491197850843045" ORDER="799" O_E="-3.0" SE="0.4423258684646914" STUDY_ID="STD-Kalusche-1994" TOTAL_1="41" TOTAL_2="41" VAR="5.111111111111111" WEIGHT="4.924937224663264"/>
<DICH_DATA CI_END="1.2422898538800218" CI_START="0.6827992074600425" EFFECT_SIZE="0.9209964862391881" ESTIMABLE="YES" EVENTS_1="244" EVENTS_2="255" LOG_CI_END="0.09422293823507007" LOG_CI_START="-0.16570699165210478" LOG_EFFECT_SIZE="-0.03574202670851735" ORDER="800" O_E="-3.530263157894723" SE="0.15268412748963064" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="383" VAR="42.8955476320169" WEIGHT="41.33306334232882"/>
<DICH_DATA CI_END="2.6003865768095644" CI_START="0.5980177469774943" EFFECT_SIZE="1.2470273942196195" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="20" LOG_CI_END="0.41503791554596076" LOG_CI_START="-0.22328592754999854" LOG_EFFECT_SIZE="0.09587599399798105" ORDER="801" O_E="1.5702479338842963" SE="0.3749545851885497" STUDY_ID="STD-SOCESP-1999" TOTAL_1="63" TOTAL_2="58" VAR="7.11283382282631" WEIGHT="6.853746534824584"/>
<DICH_DATA CI_END="1.2235967499369926" CI_START="0.6264936415218522" EFFECT_SIZE="0.8755430221424472" ESTIMABLE="YES" EVENTS_1="375" EVENTS_2="198" LOG_CI_END="0.08763831476057789" LOG_CI_START="-0.2030833324367686" LOG_EFFECT_SIZE="-0.05772250883809532" ORDER="802" O_E="-4.55754475703327" SE="0.17077133465908437" STUDY_ID="STD-SOPAT-2004" TOTAL_1="518" TOTAL_2="264" VAR="34.29020288356469" WEIGHT="33.041171078319785"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.492573400350918" CI_END="1.4024025935258095" CI_START="0.5364030879686501" DF="1" EFFECT_SIZE="0.8673252456503777" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="56" I2="33.00161990258631" ID="CMP-005.05.05" LOG_CI_END="0.14687270624668136" LOG_CI_START="-0.27050873066405384" LOG_EFFECT_SIZE="-0.06181801220868619" NO="5" P_CHI2="0.22181796943177134" P_Z="0.561525430655859" STUDIES="2" TAU2="0.0" TOTAL_1="145" TOTAL_2="152" WEIGHT="100.0" Z="0.580577221745465">
<NAME>Flecainide vs Propafenone</NAME>
<DICH_DATA CI_END="1.2939044066227001" CI_START="0.2643804220918021" EFFECT_SIZE="0.5848786140468398" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="26" LOG_CI_END="0.11190219193560688" LOG_CI_START="-0.5777707083857406" LOG_EFFECT_SIZE="-0.23293425822506686" ORDER="803" O_E="-3.268041237113401" SE="0.40511727558467536" STUDY_ID="STD-Aliot-1996" TOTAL_1="48" TOTAL_2="49" VAR="6.093102348814965" WEIGHT="36.62519427071049"/>
<DICH_DATA CI_END="1.991679407180627" CI_START="0.5955600087544141" EFFECT_SIZE="1.0891118423635289" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="30" LOG_CI_END="0.29921943303467796" LOG_CI_START="-0.2250744723711548" LOG_EFFECT_SIZE="0.03707248033176153" ORDER="804" O_E="0.8999999999999986" SE="0.3079728353320743" STUDY_ID="STD-FAPIS-1996" TOTAL_1="97" TOTAL_2="103" VAR="10.543266331658293" WEIGHT="63.37480572928951"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.536369815161305" CI_END="0.49951351059112603" CI_START="0.2593328084823857" DF="4" EFFECT_SIZE="0.3599169926198159" ESTIMABLE="YES" EVENTS_1="142" EVENTS_2="229" I2="27.750491142299936" ID="CMP-005.05.06" LOG_CI_END="-0.30145276069961857" LOG_CI_START="-0.5861425366763785" LOG_EFFECT_SIZE="-0.4437976486879986" MODIFIED="2010-12-28 12:12:17 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.23655124172094377" P_Z="9.919289214894374E-10" STUDIES="5" TAU2="0.0" TOTAL_1="311" TOTAL_2="332" WEIGHT="100.0" Z="6.110703518366206">
<NAME>Amiodarone vs Class I drugs</NAME>
<DICH_DATA CI_END="0.4382944177934455" CI_START="0.13662209525258018" EFFECT_SIZE="0.24470533646908948" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="99" LOG_CI_END="-0.3582340605733776" LOG_CI_START="-0.8644790585587006" LOG_EFFECT_SIZE="-0.6113565595660391" ORDER="805" O_E="-15.91891891891892" SE="0.29737081776973423" STUDY_ID="STD-AFFIRM-Substudy-2003" TOTAL_1="106" TOTAL_2="116" VAR="11.308455820379509" WEIGHT="31.624396834323964"/>
<DICH_DATA CI_END="1.0054104711061784" CI_START="0.2605347415469299" EFFECT_SIZE="0.5118049992313726" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="32" LOG_CI_END="0.002343403987294025" LOG_CI_START="-0.5841343566020567" LOG_EFFECT_SIZE="-0.2908954763073813" ORDER="806" O_E="-5.643835616438356" SE="0.34449993968192033" STUDY_ID="STD-Kochiadakis-2004a" TOTAL_1="72" TOTAL_2="74" VAR="8.426004749548662" WEIGHT="23.56354591290987"/>
<DICH_DATA CI_END="1.1660238978832378" CI_START="0.29555341242014294" EFFECT_SIZE="0.5870454343428857" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="54" LOG_CI_END="0.06670745146284236" LOG_CI_START="-0.5293640219801842" LOG_EFFECT_SIZE="-0.23132828525867086" MODIFIED="2010-12-28 12:12:17 +0000" MODIFIED_BY="[Empty name]" ORDER="1015" O_E="-4.344827586206897" SE="0.350135334101814" STUDY_ID="STD-PITAGORA-2008" TOTAL_1="70" TOTAL_2="75" VAR="8.156956004756243" WEIGHT="22.81114395739631"/>
<DICH_DATA CI_END="0.6470635494657259" CI_START="0.10535837127534922" EFFECT_SIZE="0.26110067346400173" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="30" LOG_CI_END="-0.18905306426644408" LOG_CI_START="-0.9773309517098616" LOG_EFFECT_SIZE="-0.5831920079881528" ORDER="807" O_E="-6.2631578947368425" SE="0.46303833312273757" STUDY_ID="STD-Villani-1992" TOTAL_1="35" TOTAL_2="41" VAR="4.6640812557710065" WEIGHT="13.043227019043556"/>
<DICH_DATA CI_END="0.7639262252278789" CI_START="0.08547651538752872" EFFECT_SIZE="0.25553424769613076" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="14" LOG_CI_END="-0.11694858059117788" LOG_CI_START="-1.0681531909863804" LOG_EFFECT_SIZE="-0.5925508857887792" ORDER="808" O_E="-4.37037037037037" SE="0.5587422966849018" STUDY_ID="STD-Vitolo-1981" TOTAL_1="28" TOTAL_2="26" VAR="3.2031472422807146" WEIGHT="8.957686276326298"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6340504731219738" CI_START="0.314285717454891" DF="0" EFFECT_SIZE="0.44640005359290963" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="163" I2="0.0" ID="CMP-005.05.07" LOG_CI_END="-0.1978761690490814" LOG_CI_START="-0.5026753548127363" LOG_EFFECT_SIZE="-0.3502757619309088" MODIFIED="2010-12-28 11:04:49 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="6.643919384851809E-6" STUDIES="1" TAU2="0.0" TOTAL_1="255" TOTAL_2="249" WEIGHT="100.0" Z="4.504788136634001">
<NAME>Amiodarone vs Dronedarone</NAME>
<DICH_DATA CI_END="0.6340504731219738" CI_START="0.314285717454891" EFFECT_SIZE="0.44640005359290963" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="163" LOG_CI_END="-0.1978761690490814" LOG_CI_START="-0.5026753548127363" LOG_EFFECT_SIZE="-0.3502757619309088" MODIFIED="2010-12-28 11:04:49 +0000" MODIFIED_BY="[Empty name]" ORDER="1007" O_E="-25.160714285714278" SE="0.1790405504978737" STUDY_ID="STD-DYONISOS-2010" TOTAL_1="255" TOTAL_2="249" VAR="31.195876399764675" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.066727062360349" CI_END="0.5268809746159294" CI_START="0.3298789506291318" DF="5" EFFECT_SIZE="0.41690159871695986" ESTIMABLE="YES" EVENTS_1="289" EVENTS_2="382" I2="0.0" ID="CMP-005.05.08" LOG_CI_END="-0.278287483280496" LOG_CI_START="-0.48164539563158887" LOG_EFFECT_SIZE="-0.3799664394560424" MODIFIED="2014-06-26 16:28:27 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.9570062658847006" P_Z="2.4026591462899695E-13" STUDIES="6" TAU2="0.0" TOTAL_1="606" TOTAL_2="562" WEIGHT="100.00000000000001" Z="7.324234676268892">
<NAME>Amiodarone vs Sotalol</NAME>
<DICH_DATA CI_END="0.7168408887212581" CI_START="0.26850950322397116" EFFECT_SIZE="0.43872382078156524" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="81" LOG_CI_END="-0.14457723041128773" LOG_CI_START="-0.5710403389227341" LOG_EFFECT_SIZE="-0.35780878466701094" ORDER="809" O_E="-13.12890625" SE="0.2505065409660569" STUDY_ID="STD-AFFIRM-Substudy-2003" TOTAL_1="131" TOTAL_2="125" VAR="15.935359281652115" WEIGHT="22.738363937049865"/>
<DICH_DATA CI_END="0.8236953708003709" CI_START="0.20442733876997177" EFFECT_SIZE="0.41034845267146425" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="39" LOG_CI_END="-0.08423337476113059" LOG_CI_START="-0.6894610249610446" LOG_EFFECT_SIZE="-0.38684719986108757" ORDER="810" O_E="-7.047619047619051" SE="0.35551371765261564" STUDY_ID="STD-Kochiadakis-2000" TOTAL_1="65" TOTAL_2="61" VAR="7.912018140589572" WEIGHT="11.289757876021623"/>
<DICH_DATA CI_END="0.8376610041351344" CI_START="0.17435397035506778" EFFECT_SIZE="0.3821642603417718" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="36" LOG_CI_END="-0.07693170191838379" LOG_CI_START="-0.7585681585050151" LOG_EFFECT_SIZE="-0.4177499302116994" MODIFIED="2010-12-28 12:04:52 +0000" MODIFIED_BY="[Empty name]" ORDER="1010" O_E="-6.0" SE="0.40039662875386495" STUDY_ID="STD-Niu-2006" TOTAL_1="51" TOTAL_2="51" VAR="6.237623762376237" WEIGHT="8.900543546238538"/>
<DICH_DATA CI_END="1.1303644654465252" CI_START="0.1928599388209546" EFFECT_SIZE="0.46690686614291493" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="24" LOG_CI_END="0.05321849641387561" LOG_CI_START="-0.7147579753414938" LOG_EFFECT_SIZE="-0.3307697394638091" MODIFIED="2010-12-28 12:14:41 +0000" MODIFIED_BY="[Empty name]" ORDER="1017" O_E="-3.742574257425744" SE="0.45111318105394976" STUDY_ID="STD-PITAGORA-2008" TOTAL_1="70" TOTAL_2="31" VAR="4.9139300068620715" WEIGHT="7.011748331640723"/>
<DICH_DATA CI_END="0.6092233439944984" CI_START="0.30392850904499696" EFFECT_SIZE="0.43030261748640947" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="183" LOG_CI_END="-0.21522346388202512" LOG_CI_START="-0.5172285603997768" LOG_EFFECT_SIZE="-0.36622601214090095" ORDER="811" O_E="-26.795454545454533" SE="0.17739928864386534" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="267" TOTAL_2="261" VAR="31.775782340395505" WEIGHT="45.341262187436925"/>
<DICH_DATA CI_END="0.7310360220228111" CI_START="0.08467240546867648" EFFECT_SIZE="0.24879424926819305" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="19" LOG_CI_END="-0.13606122252190422" LOG_CI_START="-1.0722581021282722" LOG_EFFECT_SIZE="-0.6041596623250882" MODIFIED="2014-06-26 16:28:27 +0100" MODIFIED_BY="[Empty name]" ORDER="1076" O_E="-4.6" SE="0.5499266813300748" STUDY_ID="STD-Vijayalaskshmi-2006" TOTAL_1="22" TOTAL_2="33" VAR="3.3066666666666666" WEIGHT="4.718324121612337"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.94652788634623" CI_END="1.44704151624807" CI_START="0.6677238448508256" DF="3" EFFECT_SIZE="0.982967000915051" ESTIMABLE="YES" EVENTS_1="150" EVENTS_2="157" I2="39.35139821447645" ID="CMP-005.05.09" LOG_CI_END="0.16048099139463903" LOG_CI_START="-0.17540311455245566" LOG_EFFECT_SIZE="-0.0074610615789083064" MODIFIED="2010-12-28 11:04:30 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.17575492177200813" P_Z="0.9306125704215824" STUDIES="4" TAU2="0.0" TOTAL_1="243" TOTAL_2="251" WEIGHT="99.99999999999999" Z="0.08707415279363769">
<NAME>Sotalol vs Class I drugs other than quinidine</NAME>
<DICH_DATA CI_END="1.1600645773403921" CI_START="0.26656635452230726" EFFECT_SIZE="0.5560882892060302" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="81" LOG_CI_END="0.06448216578033812" LOG_CI_START="-0.5741946672530519" LOG_EFFECT_SIZE="-0.2548562507363569" ORDER="812" O_E="-4.169398907103826" SE="0.3751619332251248" STUDY_ID="STD-AFFIRM-Substudy-2003" TOTAL_1="88" TOTAL_2="95" VAR="7.104973619351474" WEIGHT="27.65773306359876"/>
<DICH_DATA CI_END="5.538197271267038" CI_START="0.42548474295220534" EFFECT_SIZE="1.5350630092552098" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.7433684213078653" LOG_CI_START="-0.3711160082479351" LOG_EFFECT_SIZE="0.18612620652996503" ORDER="813" O_E="1.0" SE="0.6546536707079771" STUDY_ID="STD-Carunchio-1995" TOTAL_1="20" TOTAL_2="20" VAR="2.3333333333333335" WEIGHT="9.083033089096961"/>
<DICH_DATA CI_END="2.7086635250204534" CI_START="0.8156761001364641" EFFECT_SIZE="1.4864024019997313" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="35" LOG_CI_END="0.4327550595541149" LOG_CI_START="-0.08848226262959699" LOG_EFFECT_SIZE="0.17213639846225892" ORDER="814" O_E="4.228070175438596" SE="0.30617738321706955" STUDY_ID="STD-Kochiadakis-2004b" TOTAL_1="85" TOTAL_2="86" VAR="10.667282240689442" WEIGHT="41.52483324125082"/>
<DICH_DATA CI_END="1.7520989790741084" CI_START="0.3334948291115494" EFFECT_SIZE="0.7644056185120828" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="35" LOG_CI_END="0.24355863656465784" LOG_CI_START="-0.47691089549774834" LOG_EFFECT_SIZE="-0.11667612946654528" ORDER="815" O_E="-1.5" SE="0.42320736951515897" STUDY_ID="STD-Reimold-1993" TOTAL_1="50" TOTAL_2="50" VAR="5.583333333333334" WEIGHT="21.734400606053445"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1596332922439196" CI_START="0.876458326527338" DF="0" EFFECT_SIZE="1.3758010689168807" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="196" I2="0.0" ID="CMP-005.05.10" LOG_CI_END="0.33438001380123256" LOG_CI_START="-0.057268728731034384" LOG_EFFECT_SIZE="0.1385556425350991" MODIFIED="2010-12-28 11:04:23 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Z="0.16551080821022163" STUDIES="1" TAU2="0.0" TOTAL_1="108" TOTAL_2="321" WEIGHT="100.00000000000001" Z="1.3867736046732064">
<NAME>Sotalol vs Dofetilide</NAME>
<DICH_DATA CI_END="2.1596332922439196" CI_START="0.876458326527338" EFFECT_SIZE="1.3758010689168807" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="196" LOG_CI_END="0.33438001380123256" LOG_CI_START="-0.057268728731034384" LOG_EFFECT_SIZE="0.1385556425350991" MODIFIED="2010-12-28 10:56:31 +0000" MODIFIED_BY="[Empty name]" ORDER="1003" O_E="6.027972027972027" SE="0.23005641005599597" STUDY_ID="STD-EMERALD-2000" TOTAL_1="108" TOTAL_2="321" VAR="18.89432246075603" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.015398028804267432" CI_END="1.8984828779859422" CI_START="0.6400742087838105" DF="1" EFFECT_SIZE="1.1023474615639406" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="83" I2="0.0" ID="CMP-005.05.11" LOG_CI_END="0.2784066846837401" LOG_CI_START="-0.1937696719583049" LOG_EFFECT_SIZE="0.0423185063627176" MODIFIED="2010-12-28 11:04:21 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.901244974071871" P_Z="0.7253475000001965" STUDIES="2" TAU2="0.0" TOTAL_1="133" TOTAL_2="130" WEIGHT="100.0" Z="0.3513210569894509">
<NAME>Sotalol vs Other Beta-blockers</NAME>
<DICH_DATA CI_END="2.5422464443091535" CI_START="0.43793368144435946" EFFECT_SIZE="1.0551470724477894" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="54" LOG_CI_END="0.4052176485845123" LOG_CI_START="-0.35859165196953896" LOG_EFFECT_SIZE="0.02331299830748672" MODIFIED="2010-12-27 14:19:52 +0000" MODIFIED_BY="[Empty name]" ORDER="930" O_E="0.2666666666666657" SE="0.4486653640624653" STUDY_ID="STD-DAPHNE-2008" TOTAL_1="69" TOTAL_2="66" VAR="4.967694859038143" WEIGHT="38.21541578114053"/>
<DICH_DATA CI_END="2.2616658695023157" CI_START="0.5671780267892732" EFFECT_SIZE="1.1325931242599743" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="29" LOG_CI_END="0.354428444201308" LOG_CI_START="-0.24628060262932172" LOG_EFFECT_SIZE="0.054073920785993164" MODIFIED="2010-12-27 14:21:00 +0000" MODIFIED_BY="[Empty name]" ORDER="931" O_E="1.0" SE="0.35285946766605064" STUDY_ID="STD-Plewan-2001" TOTAL_1="64" TOTAL_2="64" VAR="8.031496062992126" WEIGHT="61.784584218859464"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="38.91064709752834" CI_END="1.041795753594373" CI_START="0.758876932274048" DF="12" EFFECT_SIZE="0.8891539605399212" ESTIMABLE="YES" EVENTS_1="806" EVENTS_2="966" I2="69.16011196132932" ID="CMP-005.05.12" LOG_CI_END="0.01778258289674532" LOG_CI_START="-0.11982864830461391" LOG_EFFECT_SIZE="-0.05102303270393427" MODIFIED="2010-12-28 11:04:19 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0886122205600035E-4" P_Z="0.14610778714894923" STUDIES="13" TAU2="0.0" TOTAL_1="1353" TOTAL_2="1522" WEIGHT="100.00000000000001" Z="1.4534178004030929">
<NAME>Class III vs Class I drugs</NAME>
<DICH_DATA CI_END="0.6148206960673104" CI_START="0.21873628030595837" EFFECT_SIZE="0.3667200459654253" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="99" LOG_CI_END="-0.21125152172442602" LOG_CI_START="-0.6600791775023319" LOG_EFFECT_SIZE="-0.43566534961337894" ORDER="816" O_E="-14.432258064516134" SE="0.26364358673666966" STUDY_ID="STD-AFFIRM-Substudy-2003" TOTAL_1="194" TOTAL_2="116" VAR="14.386845417900046" WEIGHT="9.400447802392012"/>
<DICH_DATA CI_END="5.538197271267038" CI_START="0.42548474295220534" EFFECT_SIZE="1.5350630092552098" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.7433684213078653" LOG_CI_START="-0.3711160082479351" LOG_EFFECT_SIZE="0.18612620652996503" ORDER="817" O_E="1.0" SE="0.6546536707079771" STUDY_ID="STD-Carunchio-1995" TOTAL_1="20" TOTAL_2="20" VAR="2.3333333333333335" WEIGHT="1.524613462398832"/>
<DICH_DATA CI_END="7.117405285795707" CI_START="0.7417772960444" EFFECT_SIZE="2.2977227090642725" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.8523216965243002" LOG_CI_START="-0.12972646347644484" LOG_EFFECT_SIZE="0.3612976165239277" ORDER="818" O_E="2.5" SE="0.5768599504012304" STUDY_ID="STD-Hohnloser-1995" TOTAL_1="25" TOTAL_2="25" VAR="3.0051020408163263" WEIGHT="1.9635510117046182"/>
<DICH_DATA CI_END="1.3715927594532593" CI_START="0.42879596718268126" EFFECT_SIZE="0.7668985877353818" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="49" LOG_CI_END="0.13722518383733984" LOG_CI_START="-0.36774930782681653" LOG_EFFECT_SIZE="-0.1152620619947383" ORDER="819" O_E="-3.016393442622949" SE="0.29662451606757323" STUDY_ID="STD-Juul_x002d_Moller-1990" TOTAL_1="98" TOTAL_2="85" VAR="11.365431128935565" WEIGHT="7.426238273632252"/>
<DICH_DATA CI_END="4.279770100695858" CI_START="0.7557941336427498" EFFECT_SIZE="1.7985063623589355" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="15" LOG_CI_END="0.6314204403494271" LOG_CI_START="-0.12159648333256626" LOG_EFFECT_SIZE="0.25491197850843045" ORDER="820" O_E="3.0" SE="0.4423258684646914" STUDY_ID="STD-Kalusche-1994" TOTAL_1="41" TOTAL_2="41" VAR="5.111111111111111" WEIGHT="3.3396294890641083"/>
<DICH_DATA CI_END="1.0054104711061784" CI_START="0.2605347415469299" EFFECT_SIZE="0.5118049992313726" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="32" LOG_CI_END="0.002343403987294025" LOG_CI_START="-0.5841343566020567" LOG_EFFECT_SIZE="-0.2908954763073813" ORDER="821" O_E="-5.643835616438356" SE="0.34449993968192033" STUDY_ID="STD-Kochiadakis-2004a" TOTAL_1="72" TOTAL_2="74" VAR="8.426004749548662" WEIGHT="5.505600118027881"/>
<DICH_DATA CI_END="2.7086635250204534" CI_START="0.8156761001364641" EFFECT_SIZE="1.4864024019997313" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="35" LOG_CI_END="0.4327550595541149" LOG_CI_START="-0.08848226262959699" LOG_EFFECT_SIZE="0.17213639846225892" ORDER="822" O_E="4.228070175438596" SE="0.30617738321706955" STUDY_ID="STD-Kochiadakis-2004b" TOTAL_1="85" TOTAL_2="86" VAR="10.667282240689442" WEIGHT="6.970063762012758"/>
<DICH_DATA CI_END="1.4645594035176441" CI_START="0.8049651189508775" EFFECT_SIZE="1.0857804725004068" ESTIMABLE="YES" EVENTS_1="255" EVENTS_2="244" LOG_CI_END="0.1657069916521048" LOG_CI_START="-0.09422293823507008" LOG_EFFECT_SIZE="0.03574202670851735" ORDER="823" O_E="3.530263157894723" SE="0.15268412748963064" STUDY_ID="STD-PAFAC-2004" TOTAL_1="383" TOTAL_2="377" VAR="42.8955476320169" WEIGHT="28.02819831288999"/>
<DICH_DATA CI_END="1.7520989790741084" CI_START="0.3334948291115494" EFFECT_SIZE="0.7644056185120828" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="35" LOG_CI_END="0.24355863656465784" LOG_CI_START="-0.47691089549774834" LOG_EFFECT_SIZE="-0.11667612946654528" ORDER="824" O_E="-1.5" SE="0.42320736951515897" STUDY_ID="STD-Reimold-1993" TOTAL_1="50" TOTAL_2="50" VAR="5.583333333333334" WEIGHT="3.648182213597206"/>
<DICH_DATA CI_END="1.6721911766903363" CI_START="0.38455820719814215" EFFECT_SIZE="0.8019070027132744" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="25" LOG_CI_END="0.22328592754999857" LOG_CI_START="-0.4150379155459607" LOG_EFFECT_SIZE="-0.09587599399798108" ORDER="825" O_E="-1.5702479338842963" SE="0.3749545851885497" STUDY_ID="STD-SOCESP-1999" TOTAL_1="58" TOTAL_2="63" VAR="7.11283382282631" WEIGHT="4.647566658037175"/>
<DICH_DATA CI_END="1.5961853939504334" CI_START="0.8172627134319316" EFFECT_SIZE="1.1421483293339565" ESTIMABLE="YES" EVENTS_1="198" EVENTS_2="375" LOG_CI_END="0.20308333243676824" LOG_CI_START="-0.08763831476057822" LOG_EFFECT_SIZE="0.05772250883809502" ORDER="826" O_E="4.5575447570332415" SE="0.17077133465908437" STUDY_ID="STD-SOPAT-2004" TOTAL_1="264" TOTAL_2="518" VAR="34.29020288356469" WEIGHT="22.405416404858563"/>
<DICH_DATA CI_END="0.6470635494657259" CI_START="0.10535837127534922" EFFECT_SIZE="0.26110067346400173" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="30" LOG_CI_END="-0.18905306426644408" LOG_CI_START="-0.9773309517098616" LOG_EFFECT_SIZE="-0.5831920079881528" ORDER="827" O_E="-6.2631578947368425" SE="0.46303833312273757" STUDY_ID="STD-Villani-1992" TOTAL_1="35" TOTAL_2="41" VAR="4.6640812557710065" WEIGHT="3.0475376024016545"/>
<DICH_DATA CI_END="0.7639262252278789" CI_START="0.08547651538752872" EFFECT_SIZE="0.25553424769613076" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="14" LOG_CI_END="-0.11694858059117788" LOG_CI_START="-1.0681531909863804" LOG_EFFECT_SIZE="-0.5925508857887792" ORDER="828" O_E="-4.37037037037037" SE="0.5587422966849018" STUDY_ID="STD-Vitolo-1981" TOTAL_1="28" TOTAL_2="26" VAR="3.2031472422807146" WEIGHT="2.092954888982945"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="84.12653160172617" CI_END="0.4185593870068301" CI_START="0.3437406003329996" CI_STUDY="95" CI_TOTAL="95" DF="41" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.37930970850314405" ESTIMABLE="YES" EVENTS_1="3516" EVENTS_2="2458" I2="51.263888788256274" I2_Q="84.32272357751964" ID="CMP-005.06" LOG_CI_END="-0.3782429137290829" LOG_CI_START="-0.4637691688833513" LOG_EFFECT_SIZE="-0.42100604130621705" METHOD="PETO" MODIFIED="2014-09-24 16:44:24 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="8.348332709828821E-5" P_Q="6.237463879510408E-6" P_Z="0.0" Q="31.893294889093593" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="23" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="5833" TOTAL_2="3084" WEIGHT="600.0" Z="19.29598523273556">
<NAME>Subgroup analysis: Persistent atrial fibrillation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.117311057273768" CI_END="0.6017412404678152" CI_START="0.30840323111442036" DF="4" EFFECT_SIZE="0.4307887450422464" ESTIMABLE="YES" EVENTS_1="356" EVENTS_2="200" I2="0.0" ID="CMP-005.06.01" LOG_CI_END="-0.22059022302082726" LOG_CI_START="-0.5108810805308983" LOG_EFFECT_SIZE="-0.3657356517758628" NO="1" P_CHI2="0.714192922727495" P_Z="7.864793621042646E-7" STUDIES="5" TAU2="0.0" TOTAL_1="573" TOTAL_2="252" WEIGHT="100.00000000000003" Z="4.938692947421569">
<NAME>Class Ia: Quinidine</NAME>
<DICH_DATA CI_END="0.6892971723618935" CI_START="0.047626751891230494" EFFECT_SIZE="0.18118770766088588" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="40" LOG_CI_END="-0.16159350306702794" LOG_CI_START="-1.3221490360365151" LOG_EFFECT_SIZE="-0.7418712695517715" ORDER="829" O_E="-3.675675675675677" SE="0.6817160649088166" STUDY_ID="STD-Byrne_x002d_Quinn-1970" TOTAL_1="32" TOTAL_2="42" VAR="2.1517556060318004" WEIGHT="6.256549194127982"/>
<DICH_DATA CI_END="1.450174726390495" CI_START="0.14237278316171528" EFFECT_SIZE="0.45438465188317456" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" LOG_CI_END="0.16142033198368702" LOG_CI_START="-0.8465730251121738" LOG_EFFECT_SIZE="-0.3425763465642434" ORDER="830" O_E="-2.25" SE="0.5921002876056983" STUDY_ID="STD-Hillestad-1971" TOTAL_1="26" TOTAL_2="22" VAR="2.8523936170212765" WEIGHT="8.293758331979697"/>
<DICH_DATA CI_END="1.9130341172951466" CI_START="0.21109933897239028" EFFECT_SIZE="0.6354842544018188" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="17" LOG_CI_END="0.2817227153597031" LOG_CI_START="-0.6755131266217267" LOG_EFFECT_SIZE="-0.1968952056310118" ORDER="831" O_E="-1.4339622641509422" SE="0.5622850719737296" STUDY_ID="STD-Lloyd-1984" TOTAL_1="28" TOTAL_2="25" VAR="3.1629104252813756" WEIGHT="9.196632097493291"/>
<DICH_DATA CI_END="0.7111269963597585" CI_START="0.2628634293081412" EFFECT_SIZE="0.4323531900387971" ESTIMABLE="YES" EVENTS_1="244" EVENTS_2="73" LOG_CI_END="-0.14805283401965802" LOG_CI_START="-0.5802698306088895" LOG_EFFECT_SIZE="-0.3641613323142738" ORDER="832" O_E="-13.008602150537627" SE="0.2538864033051532" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="88" VAR="15.513904497629785" WEIGHT="45.108982827945574"/>
<DICH_DATA CI_END="0.8158429372023623" CI_START="0.24628398598538406" EFFECT_SIZE="0.4482511020758579" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="54" LOG_CI_END="-0.08839344182433408" LOG_CI_START="-0.6085638261807316" LOG_EFFECT_SIZE="-0.3484786340025328" ORDER="833" O_E="-8.594594594594597" SE="0.3055506586558776" STUDY_ID="STD-Sodermark-1975" TOTAL_1="110" TOTAL_2="75" VAR="10.711087115317433" WEIGHT="31.144077548453474"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.7217315358497025" CI_END="0.5277673485025524" CI_START="0.32879332902201786" DF="9" EFFECT_SIZE="0.4165649810813166" ESTIMABLE="YES" EVENTS_1="594" EVENTS_2="348" I2="0.0" ID="CMP-005.06.02" LOG_CI_END="-0.2775574818761211" LOG_CI_START="-0.48307700256239194" LOG_EFFECT_SIZE="-0.3803172422192565" MODIFIED="2014-06-26 15:59:46 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7674131219927878" P_Z="4.049661535120826E-13" STUDIES="10" TAU2="0.0" TOTAL_1="1066" TOTAL_2="471" WEIGHT="100.00000000000001" Z="7.253890968218222">
<NAME>All class I antiarrhythmics</NAME>
<DICH_DATA CI_END="0.6892971723618935" CI_START="0.047626751891230494" EFFECT_SIZE="0.18118770766088588" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="40" LOG_CI_END="-0.16159350306702794" LOG_CI_START="-1.3221490360365151" LOG_EFFECT_SIZE="-0.7418712695517715" ORDER="834" O_E="-3.675675675675677" SE="0.6817160649088166" STUDY_ID="STD-Byrne_x002d_Quinn-1970" TOTAL_1="32" TOTAL_2="42" VAR="2.1517556060318004" WEIGHT="3.1359873629234354"/>
<DICH_DATA CI_END="0.7006689495158462" CI_START="0.2609477556210965" EFFECT_SIZE="0.42759559142904113" ESTIMABLE="YES" EVENTS_1="131" EVENTS_2="55" LOG_CI_END="-0.1544871280504838" LOG_CI_START="-0.5834464341048028" LOG_EFFECT_SIZE="-0.3689667810776433" MODIFIED="2014-06-26 15:48:00 +0100" MODIFIED_BY="[Empty name]" ORDER="1037" O_E="-13.381215469613267" SE="0.2519728197591174" STUDY_ID="STD-Flec_x002d_SL-2012" TOTAL_1="281" TOTAL_2="81" VAR="15.750436997710523" WEIGHT="22.954824073367355"/>
<DICH_DATA CI_END="1.450174726390495" CI_START="0.14237278316171528" EFFECT_SIZE="0.45438465188317456" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" LOG_CI_END="0.16142033198368702" LOG_CI_START="-0.8465730251121738" LOG_EFFECT_SIZE="-0.3425763465642434" ORDER="835" O_E="-2.25" SE="0.5921002876056983" STUDY_ID="STD-Hillestad-1971" TOTAL_1="26" TOTAL_2="22" VAR="2.8523936170212765" WEIGHT="4.157103302990068"/>
<DICH_DATA CI_END="1.116950638570605" CI_START="0.21117950502052535" EFFECT_SIZE="0.4856717852477124" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="32" LOG_CI_END="0.04803398075205501" LOG_CI_START="-0.6753482323900853" LOG_EFFECT_SIZE="-0.31365712581901517" ORDER="836" O_E="-4.0" SE="0.42491829279939874" STUDY_ID="STD-Karlson-1998" TOTAL_1="46" TOTAL_2="46" VAR="5.538461538461538" WEIGHT="8.071802088473882"/>
<DICH_DATA CI_END="1.593193665050236" CI_START="0.23691921165982616" EFFECT_SIZE="0.6143762586112285" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="17" LOG_CI_END="0.20226857087362268" LOG_CI_START="-0.6253997211279917" LOG_EFFECT_SIZE="-0.2115655751271845" ORDER="837" O_E="-2.060975609756099" SE="0.48617645174586965" STUDY_ID="STD-Lloyd-1984" TOTAL_1="57" TOTAL_2="25" VAR="4.2306993191883135" WEIGHT="6.16585803894834"/>
<DICH_DATA CI_END="0.9541191042383869" CI_START="0.04436783141814796" EFFECT_SIZE="0.20574789323267223" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="10" LOG_CI_END="-0.020397408225854084" LOG_CI_START="-1.3529317979264008" LOG_EFFECT_SIZE="-0.6866646030761274" ORDER="838" O_E="-2.5806451612903203" SE="0.7827372966617115" STUDY_ID="STD-Okishige-2000" TOTAL_1="52" TOTAL_2="10" VAR="1.6321795943433242" WEIGHT="2.37875275776394"/>
<DICH_DATA CI_END="0.7111269963597585" CI_START="0.2628634293081412" EFFECT_SIZE="0.4323531900387971" ESTIMABLE="YES" EVENTS_1="244" EVENTS_2="73" LOG_CI_END="-0.14805283401965802" LOG_CI_START="-0.5802698306088895" LOG_EFFECT_SIZE="-0.3641613323142738" ORDER="839" O_E="-13.008602150537627" SE="0.2538864033051532" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="88" VAR="15.513904497629785" WEIGHT="22.610099547452528"/>
<DICH_DATA CI_END="0.5324482652481015" CI_START="0.10391473449562894" EFFECT_SIZE="0.23522164040732876" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="27" LOG_CI_END="-0.27372258358646745" LOG_CI_START="-0.98332286768396" LOG_EFFECT_SIZE="-0.6285227256352137" MODIFIED="2014-06-26 15:59:46 +0100" MODIFIED_BY="[Empty name]" ORDER="1043" O_E="-8.329787234042552" SE="0.4168227194569235" STUDY_ID="STD-Santas-2012" TOTAL_1="49" TOTAL_2="45" VAR="5.755687875114999" WEIGHT="8.388389643645024"/>
<DICH_DATA CI_END="0.8158429372023623" CI_START="0.24628398598538406" EFFECT_SIZE="0.4482511020758579" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="54" LOG_CI_END="-0.08839344182433408" LOG_CI_START="-0.6085638261807316" LOG_EFFECT_SIZE="-0.3484786340025328" ORDER="840" O_E="-8.594594594594597" SE="0.3055506586558776" STUDY_ID="STD-Sodermark-1975" TOTAL_1="110" TOTAL_2="75" VAR="10.711087115317433" WEIGHT="15.610431659919227"/>
<DICH_DATA CI_END="1.5429411864747646" CI_START="0.24204115473887347" EFFECT_SIZE="0.6111098644830727" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="24" LOG_CI_END="0.1883493720279735" LOG_CI_START="-0.6161107837865255" LOG_EFFECT_SIZE="-0.21388070587927605" ORDER="841" O_E="-2.205479452054796" SE="0.47254387766743117" STUDY_ID="STD-Van-Gelder-1989" TOTAL_1="36" TOTAL_2="37" VAR="4.478326139988741" WEIGHT="6.526751524516221"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.1004191827591354" CI_END="0.8828241914186497" CI_START="0.437961266483147" DF="1" EFFECT_SIZE="0.6218060798638688" ESTIMABLE="YES" EVENTS_1="172" EVENTS_2="203" I2="52.39045576195947" ID="CMP-005.06.03" LOG_CI_END="-0.054125774677033466" LOG_CI_START="-0.3585642970220973" LOG_EFFECT_SIZE="-0.20634503584956537" MODIFIED="2010-12-27 14:29:26 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.14725881631486049" P_Z="0.007886669926371428" STUDIES="2" TAU2="0.0" TOTAL_1="280" TOTAL_2="282" WEIGHT="100.0" Z="2.6568834688757113">
<NAME>Class II antiarrhythmics</NAME>
<DICH_DATA CI_END="1.1282506841858055" CI_START="0.4851291071466984" EFFECT_SIZE="0.7398292012733152" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="140" LOG_CI_END="0.05240560555405347" LOG_CI_START="-0.3141426674601803" LOG_EFFECT_SIZE="-0.1308685309530634" ORDER="842" O_E="-6.5" SE="0.2153122700117753" STUDY_ID="STD-Kuhlkamp-2000" TOTAL_1="197" TOTAL_2="197" VAR="21.570610687022903" WEIGHT="68.98217052391514"/>
<DICH_DATA CI_END="0.7927095699183808" CI_START="0.22515601151004294" EFFECT_SIZE="0.4224728690089627" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="63" LOG_CI_END="-0.10088589879202069" LOG_CI_START="-0.6475164531834537" LOG_EFFECT_SIZE="-0.3742011759877372" MODIFIED="2010-12-27 14:29:26 +0000" MODIFIED_BY="[Empty name]" ORDER="943" O_E="-8.357142857142854" SE="0.3210934935144117" STUDY_ID="STD-Nergardh-2007" TOTAL_1="83" TOTAL_2="85" VAR="9.699224000977637" WEIGHT="31.01782947608485"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.127091325591387" CI_END="0.5781952186597971" CI_START="0.3660997690270398" DF="6" EFFECT_SIZE="0.46008383584287166" ESTIMABLE="YES" EVENTS_1="731" EVENTS_2="523" I2="26.172848813614188" ID="CMP-005.06.04" LOG_CI_END="-0.23792550401481094" LOG_CI_START="-0.4364005451155018" LOG_EFFECT_SIZE="-0.33716302456515634" MODIFIED="2014-06-26 16:27:11 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.22893945936496118" P_Z="2.7560744532894462E-11" STUDIES="7" TAU2="0.0" TOTAL_1="1096" TOTAL_2="647" WEIGHT="99.99999999999999" Z="6.659047721078917">
<NAME>Class III: Sotalol</NAME>
<DICH_DATA CI_END="0.5897313461816622" CI_START="0.24755086325099263" EFFECT_SIZE="0.38208441977322294" ESTIMABLE="YES" EVENTS_1="150" EVENTS_2="190" LOG_CI_END="-0.2293457874131082" LOG_CI_START="-0.6063355548728367" LOG_EFFECT_SIZE="-0.4178406711429725" ORDER="891" O_E="-19.61968680089487" SE="0.22144565553529005" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="223" TOTAL_2="224" VAR="20.39227462226426" WEIGHT="27.717411930136894"/>
<DICH_DATA CI_END="0.8030625020136358" CI_START="0.22893753763389477" EFFECT_SIZE="0.428778674582956" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="89" LOG_CI_END="-0.09525065245072305" LOG_CI_START="-0.6402829925998801" LOG_EFFECT_SIZE="-0.3677668225253015" MODIFIED="2010-12-28 10:49:15 +0000" MODIFIED_BY="[Empty name]" ORDER="996" O_E="-8.26168224299066" SE="0.3201546945572106" STUDY_ID="STD-EMERALD-2000" TOTAL_1="108" TOTAL_2="106" VAR="9.756190035663364" WEIGHT="13.260724617347895"/>
<DICH_DATA CI_END="0.7637732483695356" CI_START="0.27909880868501896" EFFECT_SIZE="0.46170142270240455" ESTIMABLE="YES" EVENTS_1="255" EVENTS_2="73" LOG_CI_END="-0.11703555712917849" LOG_CI_START="-0.5542420172649579" LOG_EFFECT_SIZE="-0.33563878719706824" ORDER="843" O_E="-11.717622080679405" SE="0.2568172388906384" STUDY_ID="STD-PAFAC-2004" TOTAL_1="383" TOTAL_2="88" VAR="15.161831125551203" WEIGHT="20.608133555795142"/>
<DICH_DATA CI_END="2.2616658695023157" CI_START="0.5671780267892732" EFFECT_SIZE="1.1325931242599743" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="29" LOG_CI_END="0.354428444201308" LOG_CI_START="-0.24628060262932172" LOG_EFFECT_SIZE="0.054073920785993164" ORDER="844" O_E="1.0" SE="0.35285946766605064" STUDY_ID="STD-Plewan-2001" TOTAL_1="64" TOTAL_2="64" VAR="8.031496062992126" WEIGHT="10.916500925805385"/>
<DICH_DATA CI_END="0.6761368115640589" CI_START="0.255498542602637" EFFECT_SIZE="0.4156344186356693" ESTIMABLE="YES" EVENTS_1="183" EVENTS_2="114" LOG_CI_END="-0.1699654187097426" LOG_CI_START="-0.5926115727951702" LOG_EFFECT_SIZE="-0.38128849575245644" ORDER="845" O_E="-14.244274809160316" SE="0.2482644430419843" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="261" TOTAL_2="132" VAR="16.22448622826556" WEIGHT="22.05250647481409"/>
<DICH_DATA CI_END="1.5527248534647287" CI_START="0.025625962313727435" EFFECT_SIZE="0.1994744810206937" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="10" LOG_CI_END="0.19109450453169866" LOG_CI_START="-1.5913198168749398" LOG_EFFECT_SIZE="-0.7001126561716206" ORDER="846" O_E="-1.470588235294116" SE="1.0469989954874475" STUDY_ID="STD-Singh-1991" TOTAL_1="24" TOTAL_2="10" VAR="0.9122365523749608" WEIGHT="1.2399223121631924"/>
<DICH_DATA CI_END="1.2313142649754805" CI_START="0.13257536390003036" EFFECT_SIZE="0.40403209866843837" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.0903689108728789" LOG_CI_START="-0.877537172132777" LOG_EFFECT_SIZE="-0.39358413062994907" MODIFIED="2014-06-26 16:27:11 +0100" MODIFIED_BY="[Empty name]" ORDER="1075" O_E="-2.803571428571427" SE="0.568552824369905" STUDY_ID="STD-Vijayalaskshmi-2006" TOTAL_1="33" TOTAL_2="23" VAR="3.0935586734693876" WEIGHT="4.204800183937406"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.5358839898613965" CI_END="0.2556330120445519" CI_START="0.13454228971361348" DF="4" EFFECT_SIZE="0.1854547135202062" ESTIMABLE="YES" EVENTS_1="190" EVENTS_2="207" I2="0.0" ID="CMP-005.06.05" LOG_CI_END="-0.5923830627866425" LOG_CI_START="-0.8711411855314259" LOG_EFFECT_SIZE="-0.7317621241590342" MODIFIED="2014-09-24 16:44:08 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.6382220491285638" P_Z="7.807818227147262E-25" STUDIES="5" TAU2="0.0" TOTAL_1="434" TOTAL_2="253" WEIGHT="100.0" Z="10.290121015884006">
<NAME>Class III: Amiodarone</NAME>
<DICH_DATA CI_END="0.3244281554847841" CI_START="0.057903549941752716" EFFECT_SIZE="0.1370603586148231" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="36" LOG_CI_END="-0.4888814625956894" LOG_CI_START="-1.2372948097984093" LOG_EFFECT_SIZE="-0.8630881361970493" MODIFIED="2014-09-24 16:42:12 +0100" MODIFIED_BY="[Empty name]" ORDER="1089" O_E="-10.282828282828284" SE="0.43962170485269497" STUDY_ID="STD-Channer-2004" TOTAL_1="61" TOTAL_2="38" VAR="5.174182559463945" WEIGHT="13.8730519996635"/>
<DICH_DATA CI_END="0.3788098949306661" CI_START="0.033470350366971914" EFFECT_SIZE="0.11260062124964149" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="-0.421578685271559" LOG_CI_START="-1.4753397414322997" LOG_EFFECT_SIZE="-0.9484592133519294" MODIFIED="2014-09-24 16:42:18 +0100" MODIFIED_BY="[Empty name]" ORDER="1090" O_E="-5.699999999999999" SE="0.618984460590173" STUDY_ID="STD-GEFACA-2001" TOTAL_1="35" TOTAL_2="15" VAR="2.6099999999999994" WEIGHT="6.997949009915301"/>
<DICH_DATA CI_END="0.32722060914935297" CI_START="0.13877406944543474" EFFECT_SIZE="0.2130956018740644" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="114" LOG_CI_END="-0.48515935121717374" LOG_CI_START="-0.8576916761637672" LOG_EFFECT_SIZE="-0.6714255136904705" MODIFIED="2014-09-24 16:44:08 +0100" MODIFIED_BY="[Empty name]" ORDER="1091" O_E="-32.28571428571428" SE="0.21882733173837812" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="267" TOTAL_2="132" VAR="20.883191467541792" WEIGHT="55.99214906289493"/>
<DICH_DATA CI_END="0.5324482652481015" CI_START="0.10391473449562894" EFFECT_SIZE="0.23522164040732876" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="27" LOG_CI_END="-0.27372258358646745" LOG_CI_START="-0.98332286768396" LOG_EFFECT_SIZE="-0.6285227256352137" MODIFIED="2014-09-24 16:43:30 +0100" MODIFIED_BY="[Empty name]" ORDER="1094" O_E="-8.329787234042552" SE="0.4168227194569235" STUDY_ID="STD-Santas-2012" TOTAL_1="49" TOTAL_2="45" VAR="5.755687875114999" WEIGHT="15.432187841778743"/>
<DICH_DATA CI_END="0.3617345675912048" CI_START="0.035819494172640895" EFFECT_SIZE="0.11382947437230805" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="18" LOG_CI_END="-0.4416099877913599" LOG_CI_START="-1.445880551361972" LOG_EFFECT_SIZE="-0.9437452695766658" MODIFIED="2014-09-24 16:42:47 +0100" MODIFIED_BY="[Empty name]" ORDER="1092" O_E="-6.244444444444444" SE="0.5899135002608419" STUDY_ID="STD-Vijayalaskshmi-2006" TOTAL_1="22" TOTAL_2="23" VAR="2.8735802469135803" WEIGHT="7.7046620857475325"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="31.630799621297164" CI_END="0.40610673673655956" CI_START="0.29520951259362666" DF="12" EFFECT_SIZE="0.3462464033213746" ESTIMABLE="YES" EVENTS_1="1473" EVENTS_2="977" I2="62.062293259509175" ID="CMP-005.06.06" LOG_CI_END="-0.39135980611881094" LOG_CI_START="-0.5298696522678354" LOG_EFFECT_SIZE="-0.4606147291933232" MODIFIED="2014-09-24 16:44:24 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0015773154797134037" P_Z="7.663293613237882E-39" STUDIES="12" TAU2="0.0" TOTAL_1="2384" TOTAL_2="1179" WEIGHT="100.0" Z="13.03572713518521">
<NAME>All class III antiarrhythmics</NAME>
<DICH_DATA CI_END="0.5897313461816622" CI_START="0.24755086325099263" EFFECT_SIZE="0.38208441977322294" ESTIMABLE="YES" EVENTS_1="150" EVENTS_2="190" LOG_CI_END="-0.2293457874131082" LOG_CI_START="-0.6063355548728367" LOG_EFFECT_SIZE="-0.4178406711429725" ORDER="892" O_E="-19.61968680089487" SE="0.22144565553529005" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="223" TOTAL_2="224" VAR="20.39227462226426" WEIGHT="13.49901776596183"/>
<DICH_DATA CI_END="0.3244281554847841" CI_START="0.057903549941752716" EFFECT_SIZE="0.1370603586148231" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="36" LOG_CI_END="-0.4888814625956894" LOG_CI_START="-1.2372948097984093" LOG_EFFECT_SIZE="-0.8630881361970493" ORDER="847" O_E="-10.282828282828284" SE="0.43962170485269497" STUDY_ID="STD-Channer-2004" TOTAL_1="61" TOTAL_2="38" VAR="5.174182559463945" WEIGHT="3.425139352442588"/>
<DICH_DATA CI_END="1.0178504787267657" CI_START="0.20209961227942247" EFFECT_SIZE="0.45354954206691017" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="43" LOG_CI_END="0.007683985237284965" LOG_CI_START="-0.694434519661682" LOG_EFFECT_SIZE="-0.34337526721219847" ORDER="848" O_E="-4.64824120603015" SE="0.4124278853203052" STUDY_ID="STD-DAFNE-2003" TOTAL_1="151" TOTAL_2="48" VAR="5.879006728480226" WEIGHT="3.891709862877075"/>
<DICH_DATA CI_END="0.3068852264243933" CI_START="0.1437806924281964" EFFECT_SIZE="0.21005754057229914" ESTIMABLE="YES" EVENTS_1="132" EVENTS_2="221" LOG_CI_END="-0.5130240181722759" LOG_CI_START="-0.8422994292164805" LOG_EFFECT_SIZE="-0.6776617236943783" ORDER="849" O_E="-41.709486166007906" SE="0.19341800638693776" STUDY_ID="STD-DIAMOND-2001" TOTAL_1="249" TOTAL_2="257" VAR="26.730445370538085" WEIGHT="17.694679168110397"/>
<DICH_DATA CI_END="0.8030625020136358" CI_START="0.22893753763389477" EFFECT_SIZE="0.428778674582956" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="89" LOG_CI_END="-0.09525065245072305" LOG_CI_START="-0.6402829925998801" LOG_EFFECT_SIZE="-0.3677668225253015" MODIFIED="2010-12-28 10:49:20 +0000" MODIFIED_BY="[Empty name]" ORDER="997" O_E="-8.26168224299066" SE="0.3201546945572106" STUDY_ID="STD-EMERALD-2000" TOTAL_1="108" TOTAL_2="106" VAR="9.756190035663364" WEIGHT="6.4582781989278795"/>
<DICH_DATA CI_END="0.5689602712639514" CI_START="0.22426628708284518" EFFECT_SIZE="0.3572094729063254" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="89" LOG_CI_END="-0.2449180579866873" LOG_CI_START="-0.6492360069980228" LOG_EFFECT_SIZE="-0.44707703249235503" MODIFIED="2010-12-28 10:36:30 +0000" MODIFIED_BY="[Empty name]" ORDER="970" O_E="-18.25058548009369" SE="0.2374983646553843" STUDY_ID="STD-EMERALD-2000" TOTAL_1="321" TOTAL_2="106" VAR="17.728776003817273" WEIGHT="11.735868934552142"/>
<DICH_DATA CI_END="0.3788098949306661" CI_START="0.033470350366971914" EFFECT_SIZE="0.11260062124964149" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="-0.421578685271559" LOG_CI_START="-1.4753397414322997" LOG_EFFECT_SIZE="-0.9484592133519294" ORDER="850" O_E="-5.699999999999999" SE="0.618984460590173" STUDY_ID="STD-GEFACA-2001" TOTAL_1="35" TOTAL_2="15" VAR="2.6099999999999994" WEIGHT="1.727734498568082"/>
<DICH_DATA CI_END="0.7637732483695356" CI_START="0.27909880868501896" EFFECT_SIZE="0.46170142270240455" ESTIMABLE="YES" EVENTS_1="255" EVENTS_2="73" LOG_CI_END="-0.11703555712917849" LOG_CI_START="-0.5542420172649579" LOG_EFFECT_SIZE="-0.33563878719706824" ORDER="851" O_E="-11.717622080679405" SE="0.2568172388906384" STUDY_ID="STD-PAFAC-2004" TOTAL_1="383" TOTAL_2="88" VAR="15.161831125551203" WEIGHT="10.036635516121898"/>
<DICH_DATA CI_END="2.2616658695023157" CI_START="0.5671780267892732" EFFECT_SIZE="1.1325931242599743" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="29" LOG_CI_END="0.354428444201308" LOG_CI_START="-0.24628060262932172" LOG_EFFECT_SIZE="0.054073920785993164" ORDER="852" O_E="1.0" SE="0.35285946766605064" STUDY_ID="STD-Plewan-2001" TOTAL_1="64" TOTAL_2="64" VAR="8.031496062992126" WEIGHT="5.31658728856139"/>
<DICH_DATA CI_END="0.4648214077640007" CI_START="0.20886823631154172" EFFECT_SIZE="0.31158695036781436" ESTIMABLE="YES" EVENTS_1="316" EVENTS_2="114" LOG_CI_END="-0.33271387833787414" LOG_CI_START="-0.6801276004385165" LOG_EFFECT_SIZE="-0.5064207393881952" ORDER="853" O_E="-28.0" SE="0.20407254008757708" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="528" TOTAL_2="132" VAR="24.012139605462824" WEIGHT="15.895249801069388"/>
<DICH_DATA CI_END="1.0419385867045163" CI_START="0.3124580724793979" EFFECT_SIZE="0.5705805135505428" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="53" LOG_CI_END="0.01784212180289649" LOG_CI_START="-0.5052082506798179" LOG_EFFECT_SIZE="-0.2436830644384607" ORDER="854" O_E="-5.944000000000003" SE="0.3072423779374474" STUDY_ID="STD-SAFIRE_x002d_D-2000" TOTAL_1="182" TOTAL_2="68" VAR="10.59345837751004" WEIGHT="7.012522413015004"/>
<DICH_DATA CI_END="1.5527248534647287" CI_START="0.025625962313727435" EFFECT_SIZE="0.1994744810206937" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="10" LOG_CI_END="0.19109450453169866" LOG_CI_START="-1.5913198168749398" LOG_EFFECT_SIZE="-0.7001126561716206" ORDER="855" O_E="-1.470588235294116" SE="1.0469989954874475" STUDY_ID="STD-Singh-1991" TOTAL_1="24" TOTAL_2="10" VAR="0.9122365523749608" WEIGHT="0.6038707135605476"/>
<DICH_DATA CI_END="0.6667279944190264" CI_START="0.09581351613331533" EFFECT_SIZE="0.2527480038492893" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="18" LOG_CI_END="-0.1760513094365123" LOG_CI_START="-1.0185732219437373" LOG_EFFECT_SIZE="-0.5973122656901247" MODIFIED="2014-09-24 16:44:18 +0100" MODIFIED_BY="[Empty name]" ORDER="1072" O_E="-5.615384615384617" SE="0.49490154195747266" STUDY_ID="STD-Vijayalaskshmi-2006" TOTAL_1="55" TOTAL_2="23" VAR="4.0828402366863905" WEIGHT="2.7027064862317824"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="51.7742811427638" CI_END="0.5544604736922849" CI_START="0.4454949516502616" CI_STUDY="95" CI_TOTAL="95" DF="19" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.4970003439833071" ESTIMABLE="YES" EVENTS_1="3274" EVENTS_2="2185" I2="63.30224277260579" I2_Q="52.63819089718154" ID="CMP-005.07" LOG_CI_END="-0.2561294083411187" LOG_CI_START="-0.35115721302521324" LOG_EFFECT_SIZE="-0.30364331068316597" METHOD="PETO" MODIFIED="2014-06-26 15:48:12 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="7.150900090568957E-5" P_Q="0.07655282569055477" P_Z="5.4227088715159375E-36" Q="8.445623331905121" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="4929" TOTAL_2="2709" WEIGHT="500.0" Z="12.525385702930434">
<NAME>Sensitivity analysis: Best quality studies</NAME>
<GROUP_LABEL_1>Antiarrhythmic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.3600126577202136" CI_END="0.7332287048183275" CI_START="0.413940730549578" DF="1" EFFECT_SIZE="0.5509203442716736" ESTIMABLE="YES" EVENTS_1="619" EVENTS_2="277" I2="26.47127257798483" ID="CMP-005.07.01" LOG_CI_END="-0.13476054139097068" LOG_CI_START="-0.3830618381978806" LOG_EFFECT_SIZE="-0.2589111897944256" NO="1" P_CHI2="0.24353546027023276" P_Z="4.3618545329885505E-5" STUDIES="2" TAU2="0.0" TOTAL_1="895" TOTAL_2="339" WEIGHT="100.0" Z="4.087426152962137">
<NAME>Class Ia: Quinidine</NAME>
<DICH_DATA CI_END="0.7111269963597585" CI_START="0.2628634293081412" EFFECT_SIZE="0.4323531900387971" ESTIMABLE="YES" EVENTS_1="244" EVENTS_2="73" LOG_CI_END="-0.14805283401965802" LOG_CI_START="-0.5802698306088895" LOG_EFFECT_SIZE="-0.3641613323142738" ORDER="856" O_E="-13.008602150537627" SE="0.2538864033051532" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="88" VAR="15.513904497629785" WEIGHT="33.00306640041132"/>
<DICH_DATA CI_END="0.8802646280406021" CI_START="0.43778209399267676" EFFECT_SIZE="0.6207770067675666" ESTIMABLE="YES" EVENTS_1="375" EVENTS_2="204" LOG_CI_END="-0.055386749189298846" LOG_CI_START="-0.3587420057630772" LOG_EFFECT_SIZE="-0.20706437747618803" ORDER="857" O_E="-15.015604681404398" SE="0.17819237934417545" STUDY_ID="STD-SOPAT-2004" TOTAL_1="518" TOTAL_2="251" VAR="31.493559322266766" WEIGHT="66.99693359958869"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.883832187377255" CI_END="0.6620410749758295" CI_START="0.4233364736729216" DF="5" EFFECT_SIZE="0.5294016755799872" ESTIMABLE="YES" EVENTS_1="838" EVENTS_2="408" I2="0.0" ID="CMP-005.07.02" LOG_CI_END="-0.17911506481716574" LOG_CI_START="-0.3733143121248962" LOG_EFFECT_SIZE="-0.2762146884710309" MODIFIED="2014-06-26 15:48:12 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7178899140164137" P_Z="2.4693836871030224E-8" STUDIES="6" TAU2="0.0" TOTAL_1="1336" TOTAL_2="529" WEIGHT="100.0" Z="5.575416474671593">
<NAME>All class I antiarrhythmics</NAME>
<DICH_DATA CI_END="0.7006689495158462" CI_START="0.2609477556210965" EFFECT_SIZE="0.42759559142904113" ESTIMABLE="YES" EVENTS_1="131" EVENTS_2="55" LOG_CI_END="-0.1544871280504838" LOG_CI_START="-0.5834464341048028" LOG_EFFECT_SIZE="-0.3689667810776433" MODIFIED="2014-06-26 15:48:12 +0100" MODIFIED_BY="[Empty name]" ORDER="1038" O_E="-13.381215469613267" SE="0.2519728197591174" STUDY_ID="STD-Flec_x002d_SL-2012" TOTAL_1="281" TOTAL_2="81" VAR="15.750436997710523" WEIGHT="20.495706649358446"/>
<DICH_DATA CI_END="0.7111269963597585" CI_START="0.2628634293081412" EFFECT_SIZE="0.4323531900387971" ESTIMABLE="YES" EVENTS_1="244" EVENTS_2="73" LOG_CI_END="-0.14805283401965802" LOG_CI_START="-0.5802698306088895" LOG_EFFECT_SIZE="-0.3641613323142738" ORDER="858" O_E="-13.008602150537627" SE="0.2538864033051532" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="88" VAR="15.513904497629785" WEIGHT="20.187911968144277"/>
<DICH_DATA CI_END="1.7866360970621007" CI_START="0.3020236361415423" EFFECT_SIZE="0.7345790158290866" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="35" LOG_CI_END="0.2520361041946625" LOG_CI_START="-0.5199590681548776" LOG_EFFECT_SIZE="-0.13396148198010746" ORDER="859" O_E="-1.5" SE="0.45347378567585434" STUDY_ID="STD-SMART-2002" TOTAL_1="47" TOTAL_2="47" VAR="4.862903225806452" WEIGHT="6.3279919150710375"/>
<DICH_DATA CI_END="0.8802646280406021" CI_START="0.43778209399267676" EFFECT_SIZE="0.6207770067675666" ESTIMABLE="YES" EVENTS_1="375" EVENTS_2="204" LOG_CI_END="-0.055386749189298846" LOG_CI_START="-0.3587420057630772" LOG_EFFECT_SIZE="-0.20706437747618803" ORDER="860" O_E="-15.015604681404398" SE="0.17819237934417545" STUDY_ID="STD-SOPAT-2004" TOTAL_1="518" TOTAL_2="251" VAR="31.493559322266766" WEIGHT="40.98189487105499"/>
<DICH_DATA CI_END="1.1124951063594568" CI_START="0.18409731745925123" EFFECT_SIZE="0.45255647688141687" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="17" LOG_CI_END="0.04629810928374793" LOG_CI_START="-0.7349525396933374" LOG_EFFECT_SIZE="-0.3443272152047947" ORDER="861" O_E="-3.764705882352942" SE="0.4589104984622226" STUDY_ID="STD-Stroobandt-1997" TOTAL_1="77" TOTAL_2="25" VAR="4.748364109767378" WEIGHT="6.1789446141894855"/>
<DICH_DATA CI_END="1.5429411864747646" CI_START="0.24204115473887347" EFFECT_SIZE="0.6111098644830727" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="24" LOG_CI_END="0.1883493720279735" LOG_CI_START="-0.6161107837865255" LOG_EFFECT_SIZE="-0.21388070587927605" ORDER="862" O_E="-2.205479452054796" SE="0.47254387766743117" STUDY_ID="STD-Van-Gelder-1989" TOTAL_1="36" TOTAL_2="37" VAR="4.478326139988741" WEIGHT="5.827549982181765"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.1004191827591354" CI_END="0.8828241914186497" CI_START="0.437961266483147" DF="1" EFFECT_SIZE="0.6218060798638688" ESTIMABLE="YES" EVENTS_1="172" EVENTS_2="203" I2="52.39045576195947" ID="CMP-005.07.03" LOG_CI_END="-0.054125774677033466" LOG_CI_START="-0.3585642970220973" LOG_EFFECT_SIZE="-0.20634503584956537" MODIFIED="2010-12-27 14:29:34 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.14725881631486049" P_Z="0.007886669926371428" STUDIES="2" TAU2="0.0" TOTAL_1="280" TOTAL_2="282" WEIGHT="100.0" Z="2.6568834688757113">
<NAME>Class II antiarrhythmics</NAME>
<DICH_DATA CI_END="1.1282506841858055" CI_START="0.4851291071466984" EFFECT_SIZE="0.7398292012733152" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="140" LOG_CI_END="0.05240560555405347" LOG_CI_START="-0.3141426674601803" LOG_EFFECT_SIZE="-0.1308685309530634" ORDER="863" O_E="-6.5" SE="0.2153122700117753" STUDY_ID="STD-Kuhlkamp-2000" TOTAL_1="197" TOTAL_2="197" VAR="21.570610687022903" WEIGHT="68.98217052391514"/>
<DICH_DATA CI_END="0.7927095699183808" CI_START="0.22515601151004294" EFFECT_SIZE="0.4224728690089627" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="63" LOG_CI_END="-0.10088589879202069" LOG_CI_START="-0.6475164531834537" LOG_EFFECT_SIZE="-0.3742011759877372" MODIFIED="2010-12-27 14:29:34 +0000" MODIFIED_BY="[Empty name]" ORDER="944" O_E="-8.357142857142854" SE="0.3210934935144117" STUDY_ID="STD-Nergardh-2007" TOTAL_1="83" TOTAL_2="85" VAR="9.699224000977637" WEIGHT="31.01782947608485"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.692374011606357" CI_END="0.695816557355054" CI_START="0.4309664222060605" DF="3" EFFECT_SIZE="0.5476071331119106" ESTIMABLE="YES" EVENTS_1="741" EVENTS_2="520" I2="55.17285802023016" ID="CMP-005.07.04" LOG_CI_END="-0.15750524117857076" LOG_CI_START="-0.36555656561350297" LOG_EFFECT_SIZE="-0.26153090339603685" MODIFIED="2010-08-27 18:18:49 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0823768363349704" P_Z="8.32691685696271E-7" STUDIES="4" TAU2="0.0" TOTAL_1="1054" TOTAL_2="632" WEIGHT="100.0" Z="4.927545190040535">
<NAME>Class III: Sotalol</NAME>
<DICH_DATA CI_END="0.5897313461816622" CI_START="0.24755086325099263" EFFECT_SIZE="0.38208441977322294" ESTIMABLE="YES" EVENTS_1="150" EVENTS_2="190" LOG_CI_END="-0.2293457874131082" LOG_CI_START="-0.6063355548728367" LOG_EFFECT_SIZE="-0.4178406711429725" ORDER="893" O_E="-19.61968680089487" SE="0.22144565553529005" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="223" TOTAL_2="224" VAR="20.39227462226426" WEIGHT="30.45662982105785"/>
<DICH_DATA CI_END="1.7236564330023032" CI_START="0.47734476653030977" EFFECT_SIZE="0.9070713189104542" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="53" LOG_CI_END="0.23645070457407255" LOG_CI_START="-0.32116783455182196" LOG_EFFECT_SIZE="-0.0423585649888747" ORDER="864" O_E="-0.9090909090909065" SE="0.32754789013883595" STUDY_ID="STD-Benditt-1999" TOTAL_1="184" TOTAL_2="69" VAR="9.320739866194414" WEIGHT="13.920875871940323"/>
<DICH_DATA CI_END="0.7637732483695356" CI_START="0.27909880868501896" EFFECT_SIZE="0.46170142270240455" ESTIMABLE="YES" EVENTS_1="255" EVENTS_2="73" LOG_CI_END="-0.11703555712917849" LOG_CI_START="-0.5542420172649579" LOG_EFFECT_SIZE="-0.33563878719706824" ORDER="865" O_E="-11.717622080679405" SE="0.2568172388906384" STUDY_ID="STD-PAFAC-2004" TOTAL_1="383" TOTAL_2="88" VAR="15.161831125551203" WEIGHT="22.64476555725357"/>
<DICH_DATA CI_END="1.0527959222624643" CI_START="0.4571419235743097" EFFECT_SIZE="0.6937414165481635" ESTIMABLE="YES" EVENTS_1="198" EVENTS_2="204" LOG_CI_END="0.022344194143797416" LOG_CI_START="-0.33994894860328156" LOG_EFFECT_SIZE="-0.15880237722974205" ORDER="866" O_E="-8.073786407766988" SE="0.21281278542961407" STUDY_ID="STD-SOPAT-2004" TOTAL_1="264" TOTAL_2="251" VAR="22.08027956587773" WEIGHT="32.97772874974826"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="30.292019771395758" CI_END="0.4787154785008624" CI_START="0.3227440180046448" DF="5" EFFECT_SIZE="0.3930681327866512" ESTIMABLE="YES" EVENTS_1="904" EVENTS_2="777" I2="83.49400258637948" ID="CMP-005.07.05" LOG_CI_END="-0.31992253007218713" LOG_CI_START="-0.49114179854767565" LOG_EFFECT_SIZE="-0.4055321643099314" MODIFIED="2010-08-27 18:18:57 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.2919577654701975E-5" P_Z="1.627216426335837E-20" STUDIES="6" TAU2="0.0" TOTAL_1="1364" TOTAL_2="927" WEIGHT="100.0" Z="9.284333985270257">
<NAME>All class III antiarrhythmics</NAME>
<DICH_DATA CI_END="0.5897313461816622" CI_START="0.24755086325099263" EFFECT_SIZE="0.38208441977322294" ESTIMABLE="YES" EVENTS_1="150" EVENTS_2="190" LOG_CI_END="-0.2293457874131082" LOG_CI_START="-0.6063355548728367" LOG_EFFECT_SIZE="-0.4178406711429725" ORDER="894" O_E="-19.61968680089487" SE="0.22144565553529005" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="223" TOTAL_2="224" VAR="20.39227462226426" WEIGHT="20.627478807879278"/>
<DICH_DATA CI_END="1.7236564330023032" CI_START="0.47734476653030977" EFFECT_SIZE="0.9070713189104542" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="53" LOG_CI_END="0.23645070457407255" LOG_CI_START="-0.32116783455182196" LOG_EFFECT_SIZE="-0.0423585649888747" ORDER="867" O_E="-0.9090909090909065" SE="0.32754789013883595" STUDY_ID="STD-Benditt-1999" TOTAL_1="184" TOTAL_2="69" VAR="9.320739866194414" WEIGHT="9.42824513817443"/>
<DICH_DATA CI_END="0.3244281554847841" CI_START="0.057903549941752716" EFFECT_SIZE="0.1370603586148231" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="36" LOG_CI_END="-0.4888814625956894" LOG_CI_START="-1.2372948097984093" LOG_EFFECT_SIZE="-0.8630881361970493" ORDER="868" O_E="-10.282828282828284" SE="0.43962170485269497" STUDY_ID="STD-Channer-2004" TOTAL_1="61" TOTAL_2="38" VAR="5.174182559463945" WEIGHT="5.233861502478641"/>
<DICH_DATA CI_END="0.3068852264243933" CI_START="0.1437806924281964" EFFECT_SIZE="0.21005754057229914" ESTIMABLE="YES" EVENTS_1="132" EVENTS_2="221" LOG_CI_END="-0.5130240181722759" LOG_CI_START="-0.8422994292164805" LOG_EFFECT_SIZE="-0.6776617236943783" ORDER="869" O_E="-41.709486166007906" SE="0.19341800638693776" STUDY_ID="STD-DIAMOND-2001" TOTAL_1="249" TOTAL_2="257" VAR="26.730445370538085" WEIGHT="27.038753921249732"/>
<DICH_DATA CI_END="0.7637732483695356" CI_START="0.27909880868501896" EFFECT_SIZE="0.46170142270240455" ESTIMABLE="YES" EVENTS_1="255" EVENTS_2="73" LOG_CI_END="-0.11703555712917849" LOG_CI_START="-0.5542420172649579" LOG_EFFECT_SIZE="-0.33563878719706824" ORDER="870" O_E="-11.717622080679405" SE="0.2568172388906384" STUDY_ID="STD-PAFAC-2004" TOTAL_1="383" TOTAL_2="88" VAR="15.161831125551203" WEIGHT="15.336707455356228"/>
<DICH_DATA CI_END="1.0527959222624643" CI_START="0.4571419235743097" EFFECT_SIZE="0.6937414165481635" ESTIMABLE="YES" EVENTS_1="198" EVENTS_2="204" LOG_CI_END="0.022344194143797416" LOG_CI_START="-0.33994894860328156" LOG_EFFECT_SIZE="-0.15880237722974205" ORDER="871" O_E="-8.073786407766988" SE="0.21281278542961407" STUDY_ID="STD-SOPAT-2004" TOTAL_1="264" TOTAL_2="251" VAR="22.08027956587773" WEIGHT="22.3349531748617"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="73.58979737908301" CI_END="0.5667197407213855" CI_START="0.47960608378393393" CI_STUDY="95" CI_TOTAL="95" DF="26" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.5213465598336965" ESTIMABLE="YES" EVENTS_1="5877" EVENTS_2="3856" I2="64.66901537170128" I2_Q="22.486259869430903" ID="CMP-005.08" LOG_CI_END="-0.24663165918301988" LOG_CI_START="-0.31911531653016617" LOG_EFFECT_SIZE="-0.28287348785659305" METHOD="PETO" MODIFIED="2014-06-26 15:48:27 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.9640464974379768E-6" P_Q="0.27123434195817575" P_Z="7.903137284694294E-53" Q="5.160375429262147" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="8681" TOTAL_2="4740" WEIGHT="500.0" Z="15.297844194722563">
<NAME>Sensitivity analysis: Studies &gt; 200 patients</NAME>
<GROUP_LABEL_1>Antiarrhythmic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.3600126577202136" CI_END="0.7332287048183275" CI_START="0.413940730549578" DF="1" EFFECT_SIZE="0.5509203442716736" ESTIMABLE="YES" EVENTS_1="619" EVENTS_2="277" I2="26.47127257798483" ID="CMP-005.08.01" LOG_CI_END="-0.13476054139097068" LOG_CI_START="-0.3830618381978806" LOG_EFFECT_SIZE="-0.2589111897944256" NO="1" P_CHI2="0.24353546027023276" P_Z="4.3618545329885505E-5" STUDIES="2" TAU2="0.0" TOTAL_1="895" TOTAL_2="339" WEIGHT="100.0" Z="4.087426152962137">
<NAME>Class Ia: Quinidine</NAME>
<DICH_DATA CI_END="0.7111269963597585" CI_START="0.2628634293081412" EFFECT_SIZE="0.4323531900387971" ESTIMABLE="YES" EVENTS_1="244" EVENTS_2="73" LOG_CI_END="-0.14805283401965802" LOG_CI_START="-0.5802698306088895" LOG_EFFECT_SIZE="-0.3641613323142738" ORDER="872" O_E="-13.008602150537627" SE="0.2538864033051532" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="88" VAR="15.513904497629785" WEIGHT="33.00306640041132"/>
<DICH_DATA CI_END="0.8802646280406021" CI_START="0.43778209399267676" EFFECT_SIZE="0.6207770067675666" ESTIMABLE="YES" EVENTS_1="375" EVENTS_2="204" LOG_CI_END="-0.055386749189298846" LOG_CI_START="-0.3587420057630772" LOG_EFFECT_SIZE="-0.20706437747618803" ORDER="873" O_E="-15.015604681404398" SE="0.17819237934417545" STUDY_ID="STD-SOPAT-2004" TOTAL_1="518" TOTAL_2="251" VAR="31.493559322266766" WEIGHT="66.99693359958869"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="14.729443620592418" CI_END="0.6782287653318793" CI_START="0.4778908868668035" DF="4" EFFECT_SIZE="0.5693148040961423" ESTIMABLE="YES" EVENTS_1="1589" EVENTS_2="854" I2="72.84350921165941" ID="CMP-005.08.02" LOG_CI_END="-0.16862379468181893" LOG_CI_START="-0.3206712511724396" LOG_EFFECT_SIZE="-0.24464752292712927" MODIFIED="2014-06-26 15:48:27 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.005296575014144822" P_Z="2.840447132107368E-10" STUDIES="5" TAU2="0.0" TOTAL_1="2307" TOTAL_2="1039" WEIGHT="100.00000000000001" Z="6.307245710140364">
<NAME>All class I antiarrhythmics</NAME>
<DICH_DATA CI_END="1.1686176791098624" CI_START="0.6316381748011966" EFFECT_SIZE="0.8591528024009256" ESTIMABLE="YES" EVENTS_1="607" EVENTS_2="418" LOG_CI_END="0.06767245212809186" LOG_CI_START="-0.19953163008157862" LOG_EFFECT_SIZE="-0.06592958897674335" ORDER="874" O_E="-6.162184189079085" SE="0.15695700057149928" STUDY_ID="STD-AFIB-1997" TOTAL_1="734" TOTAL_2="493" VAR="40.59182881805225" WEIGHT="32.379649356579556"/>
<DICH_DATA CI_END="0.7006689495158462" CI_START="0.2609477556210965" EFFECT_SIZE="0.42759559142904113" ESTIMABLE="YES" EVENTS_1="131" EVENTS_2="55" LOG_CI_END="-0.1544871280504838" LOG_CI_START="-0.5834464341048028" LOG_EFFECT_SIZE="-0.3689667810776433" MODIFIED="2014-06-26 15:48:27 +0100" MODIFIED_BY="[Empty name]" ORDER="1039" O_E="-13.381215469613267" SE="0.2519728197591174" STUDY_ID="STD-Flec_x002d_SL-2012" TOTAL_1="281" TOTAL_2="81" VAR="15.750436997710523" WEIGHT="12.563948017339806"/>
<DICH_DATA CI_END="0.7111269963597585" CI_START="0.2628634293081412" EFFECT_SIZE="0.4323531900387971" ESTIMABLE="YES" EVENTS_1="244" EVENTS_2="73" LOG_CI_END="-0.14805283401965802" LOG_CI_START="-0.5802698306088895" LOG_EFFECT_SIZE="-0.3641613323142738" ORDER="875" O_E="-13.008602150537627" SE="0.2538864033051532" STUDY_ID="STD-PAFAC-2004" TOTAL_1="377" TOTAL_2="88" VAR="15.513904497629785" WEIGHT="12.375268678737466"/>
<DICH_DATA CI_END="0.532878617235521" CI_START="0.23108792617207216" EFFECT_SIZE="0.3509156801261494" ESTIMABLE="YES" EVENTS_1="232" EVENTS_2="104" LOG_CI_END="-0.2733717062986568" LOG_CI_START="-0.6362227448446693" LOG_EFFECT_SIZE="-0.454797225571663" ORDER="876" O_E="-23.051625239005745" SE="0.21314049618353628" STUDY_ID="STD-RAFT-2003" TOTAL_1="397" TOTAL_2="126" VAR="22.012433403959818" WEIGHT="17.559072745899467"/>
<DICH_DATA CI_END="0.8802646280406021" CI_START="0.43778209399267676" EFFECT_SIZE="0.6207770067675666" ESTIMABLE="YES" EVENTS_1="375" EVENTS_2="204" LOG_CI_END="-0.055386749189298846" LOG_CI_START="-0.3587420057630772" LOG_EFFECT_SIZE="-0.20706437747618803" ORDER="877" O_E="-15.015604681404398" SE="0.17819237934417545" STUDY_ID="STD-SOPAT-2004" TOTAL_1="518" TOTAL_2="251" VAR="31.493559322266766" WEIGHT="25.12206120144371"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1282506841858055" CI_START="0.4851291071466984" DF="0" EFFECT_SIZE="0.7398292012733152" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="140" I2="0.0" ID="CMP-005.08.03" LOG_CI_END="0.05240560555405347" LOG_CI_START="-0.3141426674601803" LOG_EFFECT_SIZE="-0.1308685309530634" NO="3" P_CHI2="1.0" P_Z="0.16165418199047818" STUDIES="1" TAU2="0.0" TOTAL_1="197" TOTAL_2="197" WEIGHT="100.0" Z="1.3995297550765393">
<NAME>Class II antiarrhythmics</NAME>
<DICH_DATA CI_END="1.1282506841858055" CI_START="0.4851291071466984" EFFECT_SIZE="0.7398292012733152" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="140" LOG_CI_END="0.05240560555405347" LOG_CI_START="-0.3141426674601803" LOG_EFFECT_SIZE="-0.1308685309530634" ORDER="878" O_E="-6.5" SE="0.2153122700117753" STUDY_ID="STD-Kuhlkamp-2000" TOTAL_1="197" TOTAL_2="197" VAR="21.570610687022903" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.00342199527985" CI_END="0.623312298570285" CI_START="0.41506274852758607" DF="5" EFFECT_SIZE="0.5086390820961656" ESTIMABLE="YES" EVENTS_1="998" EVENTS_2="723" I2="37.52672290741595" ID="CMP-005.08.04" LOG_CI_END="-0.20529430396229925" LOG_CI_START="-0.38188624237401025" LOG_EFFECT_SIZE="-0.2935902731681547" MODIFIED="2010-12-28 10:49:28 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.15604725011566167" P_Z="7.171914223331263E-11" STUDIES="6" TAU2="0.0" TOTAL_1="1423" TOTAL_2="870" WEIGHT="100.0" Z="6.51701733155333">
<NAME>Class III: Sotalol</NAME>
<DICH_DATA CI_END="0.5897313461816622" CI_START="0.24755086325099263" EFFECT_SIZE="0.38208441977322294" ESTIMABLE="YES" EVENTS_1="150" EVENTS_2="190" LOG_CI_END="-0.2293457874131082" LOG_CI_START="-0.6063355548728367" LOG_EFFECT_SIZE="-0.4178406711429725" ORDER="895" O_E="-19.61968680089487" SE="0.22144565553529005" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="223" TOTAL_2="224" VAR="20.39227462226426" WEIGHT="21.942323954232233"/>
<DICH_DATA CI_END="1.7236564330023032" CI_START="0.47734476653030977" EFFECT_SIZE="0.9070713189104542" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="53" LOG_CI_END="0.23645070457407255" LOG_CI_START="-0.32116783455182196" LOG_EFFECT_SIZE="-0.0423585649888747" ORDER="879" O_E="-0.9090909090909065" SE="0.32754789013883595" STUDY_ID="STD-Benditt-1999" TOTAL_1="184" TOTAL_2="69" VAR="9.320739866194414" WEIGHT="10.029224175603822"/>
<DICH_DATA CI_END="0.8030625020136358" CI_START="0.22893753763389477" EFFECT_SIZE="0.428778674582956" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="89" LOG_CI_END="-0.09525065245072305" LOG_CI_START="-0.6402829925998801" LOG_EFFECT_SIZE="-0.3677668225253015" MODIFIED="2010-12-28 10:49:28 +0000" MODIFIED_BY="[Empty name]" ORDER="998" O_E="-8.26168224299066" SE="0.3201546945572106" STUDY_ID="STD-EMERALD-2000" TOTAL_1="108" TOTAL_2="106" VAR="9.756190035663364" WEIGHT="10.497773607258745"/>
<DICH_DATA CI_END="0.7637732483695356" CI_START="0.27909880868501896" EFFECT_SIZE="0.46170142270240455" ESTIMABLE="YES" EVENTS_1="255" EVENTS_2="73" LOG_CI_END="-0.11703555712917849" LOG_CI_START="-0.5542420172649579" LOG_EFFECT_SIZE="-0.33563878719706824" ORDER="880" O_E="-11.717622080679405" SE="0.2568172388906384" STUDY_ID="STD-PAFAC-2004" TOTAL_1="383" TOTAL_2="88" VAR="15.161831125551203" WEIGHT="16.314306101634198"/>
<DICH_DATA CI_END="0.6761368115640589" CI_START="0.255498542602637" EFFECT_SIZE="0.4156344186356693" ESTIMABLE="YES" EVENTS_1="183" EVENTS_2="114" LOG_CI_END="-0.1699654187097426" LOG_CI_START="-0.5926115727951702" LOG_EFFECT_SIZE="-0.38128849575245644" ORDER="881" O_E="-14.244274809160316" SE="0.2482644430419843" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="261" TOTAL_2="132" VAR="16.22448622826556" WEIGHT="17.457735314279205"/>
<DICH_DATA CI_END="1.0527959222624643" CI_START="0.4571419235743097" EFFECT_SIZE="0.6937414165481635" ESTIMABLE="YES" EVENTS_1="198" EVENTS_2="204" LOG_CI_END="0.022344194143797416" LOG_CI_START="-0.33994894860328156" LOG_EFFECT_SIZE="-0.15880237722974205" ORDER="882" O_E="-8.073786407766988" SE="0.21281278542961407" STUDY_ID="STD-SOPAT-2004" TOTAL_1="264" TOTAL_2="251" VAR="22.08027956587773" WEIGHT="23.7586368469918"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="44.3365436762284" CI_END="0.5475985895601853" CI_START="0.43036319832078856" DF="12" EFFECT_SIZE="0.48545471508584004" ESTIMABLE="YES" EVENTS_1="2544" EVENTS_2="1862" I2="72.93429075655722" ID="CMP-005.08.05" LOG_CI_END="-0.2615376791410744" LOG_CI_START="-0.3661648736092196" LOG_EFFECT_SIZE="-0.313851276375147" MODIFIED="2010-12-28 10:49:33 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.338136744644114E-5" P_Z="6.374655202730312E-32" STUDIES="12" TAU2="0.0" TOTAL_1="3859" TOTAL_2="2295" WEIGHT="99.99999999999999" Z="11.758648434074171">
<NAME>All class III antiarrhythmics</NAME>
<DICH_DATA CI_END="1.0933935106921964" CI_START="0.4116181895531199" EFFECT_SIZE="0.6708656030385308" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="117" LOG_CI_END="0.03877649201855855" LOG_CI_START="-0.385505441859065" LOG_EFFECT_SIZE="-0.17336447492025328" ORDER="845" O_E="-6.426751592356695" SE="0.2492253081891608" STUDY_ID="STD-A_x002d_COMET_x002d_I-2006" TOTAL_1="159" TOTAL_2="155" VAR="16.09962337674626" WEIGHT="6.0810710930419605"/>
<DICH_DATA CI_END="0.5897313461816622" CI_START="0.24755086325099263" EFFECT_SIZE="0.38208441977322294" ESTIMABLE="YES" EVENTS_1="150" EVENTS_2="190" LOG_CI_END="-0.2293457874131082" LOG_CI_START="-0.6063355548728367" LOG_EFFECT_SIZE="-0.4178406711429725" ORDER="896" O_E="-19.61968680089487" SE="0.22144565553529005" STUDY_ID="STD-A_x002d_COMET_x002d_II-2006" TOTAL_1="223" TOTAL_2="224" VAR="20.39227462226426" WEIGHT="7.7024703513211135"/>
<DICH_DATA CI_END="0.8531478467524782" CI_START="0.23587293279811006" EFFECT_SIZE="0.4485916681391882" ESTIMABLE="YES" EVENTS_1="188" EVENTS_2="202" LOG_CI_END="-0.06897570099557579" LOG_CI_START="-0.6273218929883597" LOG_EFFECT_SIZE="-0.34814879699196777" MODIFIED="2010-11-20 10:13:32 +0000" MODIFIED_BY="[Empty name]" ORDER="897" O_E="-7.452436194895597" SE="0.32797531703478655" STUDY_ID="STD-A_x002d_STAR-2006" TOTAL_1="216" TOTAL_2="215" VAR="9.296461582355823" WEIGHT="3.511414054423946"/>
<DICH_DATA CI_END="1.7236564330023032" CI_START="0.47734476653030977" EFFECT_SIZE="0.9070713189104542" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="53" LOG_CI_END="0.23645070457407255" LOG_CI_START="-0.32116783455182196" LOG_EFFECT_SIZE="-0.0423585649888747" ORDER="883" O_E="-0.9090909090909065" SE="0.32754789013883595" STUDY_ID="STD-Benditt-1999" TOTAL_1="184" TOTAL_2="69" VAR="9.320739866194414" WEIGHT="3.520584329192781"/>
<DICH_DATA CI_END="0.3068852264243933" CI_START="0.1437806924281964" EFFECT_SIZE="0.21005754057229914" ESTIMABLE="YES" EVENTS_1="132" EVENTS_2="221" LOG_CI_END="-0.5130240181722759" LOG_CI_START="-0.8422994292164805" LOG_EFFECT_SIZE="-0.6776617236943783" ORDER="884" O_E="-41.709486166007906" SE="0.19341800638693776" STUDY_ID="STD-DIAMOND-2001" TOTAL_1="249" TOTAL_2="257" VAR="26.730445370538085" WEIGHT="10.096493243543678"/>
<DICH_DATA CI_END="0.8030625020136358" CI_START="0.22893753763389477" EFFECT_SIZE="0.428778674582956" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="89" LOG_CI_END="-0.09525065245072305" LOG_CI_START="-0.6402829925998801" LOG_EFFECT_SIZE="-0.3677668225253015" MODIFIED="2010-12-28 10:49:33 +0000" MODIFIED_BY="[Empty name]" ORDER="999" O_E="-8.26168224299066" SE="0.3201546945572106" STUDY_ID="STD-EMERALD-2000" TOTAL_1="108" TOTAL_2="106" VAR="9.756190035663364" WEIGHT="3.685060439972027"/>
<DICH_DATA CI_END="0.5689602712639514" CI_START="0.22426628708284518" EFFECT_SIZE="0.3572094729063254" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="89" LOG_CI_END="-0.2449180579866873" LOG_CI_START="-0.6492360069980228" LOG_EFFECT_SIZE="-0.44707703249235503" MODIFIED="2010-12-28 10:36:38 +0000" MODIFIED_BY="[Empty name]" ORDER="971" O_E="-18.25058548009369" SE="0.2374983646553843" STUDY_ID="STD-EMERALD-2000" TOTAL_1="321" TOTAL_2="106" VAR="17.728776003817273" WEIGHT="6.696426664709819"/>
<DICH_DATA CI_END="0.7770978877586998" CI_START="0.4692565646378449" EFFECT_SIZE="0.6038694272746162" ESTIMABLE="YES" EVENTS_1="532" EVENTS_2="310" LOG_CI_END="-0.10952427150050074" LOG_CI_START="-0.3285896431263289" LOG_EFFECT_SIZE="-0.21905695731341482" ORDER="831" O_E="-30.46141479099674" SE="0.12868008368408979" STUDY_ID="STD-EURIDIS-ADONIS-2007" TOTAL_1="831" TOTAL_2="413" VAR="60.3917105256252" WEIGHT="22.810861878121646"/>
<DICH_DATA CI_END="0.7637732483695356" CI_START="0.27909880868501896" EFFECT_SIZE="0.46170142270240455" ESTIMABLE="YES" EVENTS_1="255" EVENTS_2="73" LOG_CI_END="-0.11703555712917849" LOG_CI_START="-0.5542420172649579" LOG_EFFECT_SIZE="-0.33563878719706824" ORDER="885" O_E="-11.717622080679405" SE="0.2568172388906384" STUDY_ID="STD-PAFAC-2004" TOTAL_1="383" TOTAL_2="88" VAR="15.161831125551203" WEIGHT="5.726852785161672"/>
<DICH_DATA CI_END="0.4648214077640007" CI_START="0.20886823631154172" EFFECT_SIZE="0.31158695036781436" ESTIMABLE="YES" EVENTS_1="316" EVENTS_2="114" LOG_CI_END="-0.33271387833787414" LOG_CI_START="-0.6801276004385165" LOG_EFFECT_SIZE="-0.5064207393881952" ORDER="886" O_E="-28.0" SE="0.20407254008757708" STUDY_ID="STD-SAFE_x002d_T-2005" TOTAL_1="528" TOTAL_2="132" VAR="24.012139605462824" WEIGHT="9.069748069248226"/>
<DICH_DATA CI_END="1.0419385867045163" CI_START="0.3124580724793979" EFFECT_SIZE="0.5705805135505428" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="53" LOG_CI_END="0.01784212180289649" LOG_CI_START="-0.5052082506798179" LOG_EFFECT_SIZE="-0.2436830644384607" ORDER="887" O_E="-5.944000000000003" SE="0.3072423779374474" STUDY_ID="STD-SAFIRE_x002d_D-2000" TOTAL_1="182" TOTAL_2="68" VAR="10.59345837751004" WEIGHT="4.001309347886044"/>
<DICH_DATA CI_END="1.0527959222624643" CI_START="0.4571419235743097" EFFECT_SIZE="0.6937414165481635" ESTIMABLE="YES" EVENTS_1="198" EVENTS_2="204" LOG_CI_END="0.022344194143797416" LOG_CI_START="-0.33994894860328156" LOG_EFFECT_SIZE="-0.15880237722974205" ORDER="888" O_E="-8.073786407766988" SE="0.21281278542961407" STUDY_ID="STD-SOPAT-2004" TOTAL_1="264" TOTAL_2="251" VAR="22.08027956587773" WEIGHT="8.340055332491918"/>
<DICH_DATA CI_END="1.237329742066832" CI_START="0.5481955992032969" EFFECT_SIZE="0.8235889262031075" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="147" LOG_CI_END="0.09248545231841637" LOG_CI_START="-0.2610644552054873" LOG_EFFECT_SIZE="-0.08428950144353549" MODIFIED="2010-12-28 10:25:53 +0000" MODIFIED_BY="[Empty name]" ORDER="953" O_E="-4.5" SE="0.2076769657798085" STUDY_ID="STD-SVA_x002d_4-2008" TOTAL_1="211" TOTAL_2="211" VAR="23.18586698337292" WEIGHT="8.757652410885168"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-04-14 15:59:10 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Figure PRISMA flow diagram 2014.jpg" FILE_TYPE="JPG" ID="FIG-01" MODIFIED="2015-03-16 06:26:40 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>PRISMA flow diagram: selection of studies for inclusion (results of all searches combined).</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Figure Number of studies assessing outcomes.jpg" FILE_TYPE="JPG" ID="FIG-02" MODIFIED="2015-03-19 16:05:46 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Number of studies assessing each primary outcome.</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2015-03-16 06:39:07 +0000" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.01" SETTINGS="SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;SHOW_STUDY_NAMES:NO;SHOW_EFFECT_ESTIMATE:YES;SHOW_CI_LINES:YES;DISTINGUISH_SUBGROUPS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: all-cause mortality, by individual antiarrhythmics, compared with control.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAH8CAMAAAA63SGLAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAAAw40lEQVR42u19CWAUZbbuaXpPQpKuJEIUI5HAePWpIBJ2xtfICDJX
XBJxLqKo80Dv6OCdGR3Qdy9ujLTCKINbYCQRJ6MYRhC3KCQqaQfSgqCoIySQTEQSJkl19l4qy621
l6Q7vae7qs4HSdfyV3Xl76/Pf/5TX52jMAACEX2Mwi5AILEQSCyEvKEKtqGV/jFwL+wCWA1Ww5A2
Bquwm99iGHwSA7hPwrRHH0/exLIa+F8G35QBgXAGf/v47ew+A7dmQGbhUOiPcFYr98KbIe8d7Fa+
icApK3Y6WqyhBmnQGMfbIOa/L+Nk4PbBMGYJTZa8iWWwgod/ZPDTwO2LBXbYAAmFxAK372QIop2L
O8M0QkOFxAIIgwcBCYjMQuc92HBEgE3saIl8krPFsg6xOIN9LN7gGLiWBuvg2Z5BCFkZDO6TGTzP
y58BiSZNKAx+xr1AH/jQ6KghdJKEcwxCeuEGvz6SFYaPjPofPpFX6GMN450baLAvIZ7CINqYA4nU
iWAotAY7xZMdnPannsFeCNtisYaIt0YIN6jVq6FzMYUdMRLhBsnDLgDMk/LWw8s3jK/ETomB8y4/
6HiCwaXbriIAVlGTsU/8Q6n3sVFvtduF4c+ux05i0ct+B8knK0q2v/Dk0Re0oDSBefQ7G7FngicW
6PWuzUgsT2JRX11/X/Y5dWe+Q8lsu/f4w6Ns2DXoY0UaY1g9vnA9lKuBKO9lXff8za/qV1uwY5BY
EeLZ+oI8yGcYZRvDRbKM9ZCH/eIDikChBAyNCz7B4Tn0UDim/ArWie/4/vLj+cIu83Q19g9arPBQ
9W9H6bHwPKXApnzVda7o+7eTirCDgnLePb+o6LzTsCRteLGgt3d9V8ep59nZoaN7+0euMfC9Zuq6
l7ZhLyGxQoZK+e6bKgYdV54zscTaUevhWykPL9Eexl7CoTDEySDA+s28F0WU65lZoAXKCc8mhGY9
3phG5z00VGzY6UkiMu+cmvkZ2nBBwSokFA6FwXpXqr3rfuK5wfTZno7t5dt9ND0xafSb6GmhxQoK
Jdv3dxGDh8Zv/g/hu/XW0rtWIKfQxwoCC/+gGUIiguZVh8/WK3cvxC5DixXQaS+dnu9vX0eq37Gz
ehmBvEKL5R/mpXunhHFY3inVVuw8tFh+zVXZX5cV+Dc9/i0W45dN2Sj7ezw4K/SDWyofuMnkf7dD
639f2S/tL8p+dohDoU9zRUH+5jnDtRjGYMHOtfn5QFmQWIjB3tVNA2HRkffeC48VWKD4EicSC+HF
D+cj6zXhHLcgC2AqwMl7Jpb1w0r9alk/x4M+1hB8ef3vZwZs1KElVz9JUc2b3JtMZQef3lOrsU0t
vKTq2Q6T8mPbydMmnBXirFAAFcyMroNqV6QqBtq1etfMsTWDmtGQ0/CrnLsB/jJxOmPDCOY/DoUI
2LoAILhIQbsuN4PISDc4XHw80aJuyDmwcO0ltK81aTLjcNGketxJIrFkD2p16bqgTf35zG+izSY4
7epJ13XnHJj353uupMmZV8a7/8tWL6WQWHI3V5Ng95xgG4/j+UXPApO5yELmR1+Z5014+v3kIzTh
Jn7I7c9/uWD8FiSWvHHpjs1Be0SqTu6he8P5dhv0c9syR8154fWFF2cxyxMLhTjWqvopcuxMdN4F
c1UQkpvdo1aDXUePnj9cuH72vG72WGrGHxtOPZaVc4jx0qprbvdo7lTI7R4PWizOu1p8NLQD2n7g
PKtmxc6Fc8tqmEVyxnOqW9e+fubv/a87HI6Tha3u1mTR9RVILBnCOX7hXcMbrMFzuxSt7iyQ1Nn0
5sJRwhzwo/6vkxeO267tXq7VapdrM9ytiQeObbhPXvd4cChk7NWNluYALXpV3mNZR2pr+/n9TYrU
DydOt+vYsFWLdk1xq+2bKa/e4Yuj5K5HWpBYciIWWZsfmHmHbvrBzSxKpWpRjutgfazqmusJuy7r
uesJ6ovisjZ674G+m9r8vdVo+Xhash8KqaWBvSuq99IWVa/gM2UlJX06ALfpmeGPnLyIMU8noAbU
X5SyhJr3vd3feSbZimQTLpX5vUJy3MmVAZ/Zog5t3whKeBKUHMuSu4pNju1bX+lSwRWFk0zQqzL9
vuZt2N/G2SNLtz9tRM84cteO7WixZICl5UcC86p3BsMYtYpLXaRSt9O/U/NTbgV7ff/YJDtjoCbS
c8BmPlPWCf++VPO+gkctSCwZYN3rAaNX1CHeu1KrDjHMUiVz29Xbdbpzo67V0aCnfcc+hPN4216b
OczZVu3OR2JJHIQTYE5AXpG9eYLHrc7rpV2klkZu7WQztE4ucDAxK/pn8gCpT+e8sGm6Yd8VwLlF
Bp6WbGeFltK9rxqD8u5dkQbqEDMmqj6Zy4YbKF3foJZJqT2ak7XTND0B5n5NG45K/7lWuRKrpPTS
YJ+k4fjkek3vaSIYYqVSQ7KPGmxT38vU1WYHfvfiyZuRWJL8u4suC1rHwNssgV+QbE9+/zLVuJ6/
R+AtWZxzkFjS+6Mr5ofWnurtyWB+BDepYHuzckxHpMHOoilS9uNlGMei7t97QhlaJ8GT2fu3uzK6
24706x1KZaTXkVf42rvCDEF62nj5zQpL5m/eGaqxUat+mOF9TGrkF/L812X8czytya1ILNHzqtpH
/pjAzLKFykWy7nRPT8/Z4ZrM2bmwmF0ohz09p8/Kwsdye1aS8rFIGKnnZlr1jYo0u2OsVR/o7Uii
+mRe7WK7HdKl9ESPbx/LCpIseWJembQHouPOdGiHZ8u/1uhznvnjuvt7pvYEuqaafO3iW+Df1tlh
k9SHQomGGJxXLLthhN7KpmWf4iF02uoALec8+2vTf8GiySShs0vex5Ikr8gFi79eOVKDjWMs591n
jQ08Odx8g8acUVYTTFsRYdh6hVbhlxSYRmS27BuxNxvL31DstI5NCtC05q3Fmy6FiSdJsE6Qy6xQ
OqV7zRUAI6kMbsrm4xHOpkCGdHKOQ03AsadqIBvkQizJjIIPP/5DlE8ZII6la+Ke4rGNVgQ40cmy
iTa6aeHC245YpdTnfiLvdinNCs33Ew8uHtm33PTg2KcO/uHRe3uznhp+Fkrm/O35B+2/3/DINS3P
nP3YhMQSE17pqRzxzI2bmx+esNrwW8VTAaYLN68qhs2/1D39K8OWyZlSujEt+ZvQ5th8Wh2pUTmN
5cqn1wLwP90ElCwci8QSA6jffbeTSGBicXjrVmGpaMMaidTjkbbzXjkJdorgPskp19Kqk7sk8sS0
pIlV9HTX5kTn1Vtdb3VNoH/e4lbV+yZXS6LvJT0UWvJiRquoDoWMj+U9gov/iWnJWixqMQX5sTNX
0eQVDI64k5PE/xyPRBWk5MVfrXhDNFGhqwblODJ9/9yOUpE/MS3NoZB8tGGPiEYT96zQhZLtd6/A
oTDxMOX1GPOqI5onG8orWLHxBnF/AhK0WFm7RyCCHUXn3a+k1Vy2TLzP8UjOYpFbUr4V1yzjTxT4
ztg9XXHJViRWgsD8aO0RccWud65962y3zycp1M9/XbpYrNNDqc0KR1+9dkQmgw5tdOzrixe9uOTJ
8x6d0PS8r93bj/ZdJlLFg6R8LNHFFalrvtw2saXJcVtHett4vz7jCTE+vSOhodCy+nqx+YO67z4t
HDv7ontyx7en1/trtV6UNaalMxSa14x9QWTDxvmf/LP6txf1XPnG+QefJ0eTfp7+everD8d8pxQb
sSQzFDoXjGjOqfDCDZTB1pKV3C6s5pRqvmlcfhGUfvMQAf9M8z8aOm9+D4fCOKFr94qEv8aspL5P
B9KXJgkzva8uO9lZeBHAosdqAC46l+63TpjmvaElDHAoHAHvKmnLNtPIDoPhzAq5fMs9LxcV8Y+m
jp6oui6Dng8+9Zukt+GfX7wwbJmwL79vNyGxRhQlpr9sHOk+D4dYo3RdzMu21FuPcBtevPPvf2hK
Jze9sHHHwA/pWy8c9ujD1MudPehjjeCU/XpnHDJ6huNjKQ3co42ZKv5hw9Jvnun9/MK0bY92v+U4
S/taAVBxx7qV6GONGI4WxMO7Csd3d+Vb/gcfbSh4rMQ5bey7v+7s7192e0Bewfzjk9FijVSMYbqI
YqJcvmXaxg7Kt/zPtM87Z4wP0j4/tEYcz/GI22I5rygV0dUmz+dmdhka7+0Xtc2eFySvoHPCzCK0
WDFG5dOwLl7PeIYVx0q2J2s+mJIxNN9yKPeizMsX3pWPxIolFhQUxu0uWngBUibfcpY6wnzLZIoY
6gCLllhkfO/MRvUpHSn6liKNY5GOjw/H9QKiJJsJF3suMO1I7HCpOJ1381LHXSBnkAd3LU3sJ6ZF
ORRu+eOaQgJkjq1H1xNIrOgihk84i8xwEUisaIEa6EJWCVicty5RO0NsPlbF+IcS4jo6EuIqXoeb
StBiRWMMLC7/LjFmqXEON7hQUrxPgxYrYjg3n5RcMbLIsGK3IjEvTERxLKrdtF2ZKNrvOMex3DAp
gRy3N/Ek8eKxWM7xx9BA+cYqW+I9xyMWH4v2rk6qkUJ+YH5ck2jZdURisSwPbT6CvPKLOTt3J1qC
SbFYrHBDgaR8gl7kd4mUJ14Ezjtpr1KGW2XQnP1FbDLjdWgTjlj/foUigXz4xB8KzUshxBm1xxN4
ZfQ/cujmBAM1MNuqTIt4PPx+9YKsBCeW1ZowBYOcVxRuDs27siS77vubd725q2kBBW9NBchakKjM
ytLrT6R8amOeY7WkqKw54cZe818uSKESmlhWg8GQKMy6oDfUR5766X88nl6z8gbi0Iys6w9AVs5L
CepuUW3l9hb13KYpEyBrVn/nwAmHPtyvwCp6hpMgXx+fPpbew7eKp49lebHd1BOqd0W9Mo54mzuo
5L83bLu/1L4+55GO3pwHfh7NS4tigDQNWDfQ1G4/+GJKp9qk/nHjy+FW8aX/bvuMdzaijzUsSh56
OIyjdh5tzqvhnKrSN/NhxS1lzYf+eqC+YUVUry2Ktwqv5Au/nugzatqYhbFJMyM43TpIsiUwsdgo
g5Xxtaxxcriafl581/Ohj17VhaNg0mSS89wL6N//b2v3jAPzIKd7aoJ+fw7O4F61zfZWfumjCE5H
bP760tUJbrHiWrq3fMKzYRgZsuZYPuSXMSaL3LCG4eW1KWUvwYF5DclHEpRYikPc6+jMZt7UnGiN
bHp4pDBBfSzPsGh8fCyLybSnOpzqlTdbrqf9jN/X/NkET854gHG1TDX2XWs7GnKe3hPNC4xiHCv1
1YPsX2pQXPxf3Pz3ljcGIjqjiXbaHj4Z3wwiowLwKl7eVW14B5I1ixgrNXGgBizXLuMG0r49969y
NB/akjgxHm+0q2emNpJUak9HG58ha5ou8rNOSCmK6/zQp8Wygt0ex1kh9duKJ8J0X28mZ7BWak3N
20ndz3Jc+2z6d88ealT25nwbxQemoimboQy3/ub+VIV5u0NzXud5Z27ZqhkdubV5r5k69tK2BCOW
nkHchkJq0uInfhKmwcr5/3nswjOTs/d848j90eHI/XX9N70bHwTo+Taacayo6rFsR7r0A700C3rV
cPmyN5LqnojGJ3t6ZfKOOHqOCXgTuinsfCrVtcuGLMUGiSJNDgRzvG5MJ1gci3QWAYTNK3Jyv8Ph
eJ35mVwQWw9DJLyirlgdp+daE8timR+H9eKtS5SQzLqxKw75DhPNYm25omCnZHkVnzma+v27is2y
J5ZWv4oAShQ0Cfm5QktenMakFbvj4mYlzFBI7uUsdpamXgwa5FCdd1KvGnMubn/Y1m9H/InpRLFY
5qVHuYVl/3gIpAdLnkpd3hs3Y1ygGPF6PIlBLHLL8jWbOYI98fUTFsnxiry8Vg35tjHxioUTz39d
unpk3zwxhkLnQ2v5GMN9mzULbnhAYkOh5Qph6eu4zU3IY0a5Ecszs2vFHfXqimm90nq0htQr+Jt/
9vPPxdOBrBg9cryO/1BYOck9HSZ/WaeG+bfskhav8nJcy+fGxPPO8KlLHh6x94r341+WpN0NL7jW
JjQdNQGsKT1qkhCxTD9u7lRxi739/4qnMX63uyL1xAg9IhZni2W+RLuz2c2y29gMkAUNiW+yQolj
EeXAzUcscDy+gzyxueBRmfhYFs9Rf8venWzHF+3aJynnnfetyLyzukS4dstIeFpxtFikcyuA599I
bVjLfaEL/1YisXhD+RgKLPpzCXEtlkucI+Doxc/HIh/N3Og93vfdyccZTIqLqxOcKaHpsXqLf9ye
ssG2sVeVAJe+7avRvx1lkyyxnP9z5Kj382/mLeSPF3P/mpprNkqKWL3rOzsU63shEYgF26qf+eLt
16TqY22ZMgdkhYTKe0N1ElIkVmIl3JEpKjfFNFdbPJx3800o5os/Jt8wqUJSPhbpuO2JD0T/sSRg
fqwQYXrvvfXXHVRKh1gOx6s3iP/77tCK/2/Yfvr+12J2i2OEfSzag5VG8kaxPKUTECV5sfF3R9bH
2rqUBKyEk1C4cHlsnpgeyaGwqfeBnT+RyOchhaGQxY7mUW/uiEGe1hEcCjNH37AOzVUijoadD4ia
WBanHKNXgkuZ4K4lpRYpsbbeJc/8/2R3Ugbz2tqTnNDMWnBplEeTkXHeqQWl1dIiTLB6LOKspprl
VVJiW6zXFaoS0VkssmzDb5ZJzLsKPtxAcyqD+Ul4T6v4P1aJzWL9Y8cD8vXaM85qDoqAV7Di2agm
mIy5xSJrJXljMJQAabNdlyWOv4r63bJofVqxtljmpaVyn8232n/UicTDVD97yVZREIssWl6wTpJs
Cd5g0f7VDOf5reL4szTfly2ITiKA2Ebe7Yc+/8AEsgbrtz9z29iuZ0RxudsOw2NRyVwaWx+LlH2k
XSxxLG9XCyIPOsZuKNy6QMo3nIOOYyVz88EMEfEKSm3OpkS1WOTje/88X8KWSDKyGZ+wFNcebUlI
YpUUa14fC0gs0aJo7/sJSaysZ2+QtnsldWKxdiuSmFYsZoVF/7OtZ4/EJ4OS0WMNA9XYAxsTiFiW
pM9+p5R8p8uAV/Dx1w//LezaFr6HQiuAIcyhcGvpvi6U80kElfec0ESTWAyZBEKFSCzy0T+p8QOR
DMK/0+vXeQ+HWDJ6UkIOzjv/od7x53Dm98NmqbAKv4Ijl2Xp+xr8kksO103dEoYm3o/FsobhYznt
bxagxZIgzI/nLZsTJWKFMRQuzrlLRikZ5ESssJ5YiB6xKFk57fIiFoT+jJXv0r16d/wqqDhWyUXV
oJRVP2tlxivY/f6dH4YS9PapbjBYrSFNBp03X4Y+rsTRcvLU0pJILRa4S0IHYbEyzdd/honUJA/l
yR1bDgdvs6JwE7okxyi/bpadjyWMTsQIEct8qTzv38iVWKshyOd4IlOQkg8+XouDhJywLtjneCKy
WBUbblgm0xvOcrVYTLj00s0xJpb58XWyddrlS6wgI5bhD4UkzNkp38mgjHnFPMKzOmAV3HCFftRC
eA9k/sigjFH1vKLdFAtiFf1jZSHSSr5QfqXd2tkT/aFwwa5XV8lbJtohc2bl3/X+7hg473KNXqHz
7u1mD1O6JvSh0PyKErbLfhh0aJFX8O+P3lSljNZQWLS8GHsUwWLO7oHrs6Jjsczazw99gD2KFouD
qXpb+Xvbo2GxHNM/xodwGKCLxWH+kTlARuq8m1Ecg/AB52IfeTqCHwpJ+67DGLpCDEU73DX0iemg
LVZJ8WQsWILhBt8wP573cpjEMj++bAV2IBLLL7XmhGuxMOsjEisUBONjWVTPb8cbzhhuCAlBhBu2
PrT5UuwoRGgIPBTeCuhdIUKGKmCLtZPRu0LEwGIZsJMQMfGxEL5mhdgFSCwEEguBxEIgkFgIJJY4
gHd0kFgIJBYCiSVzYBwLiYVAYiGQWAgEEguBxBIJMI6FxEIgsRBILJkD41hhEsuKXYOIAbGQVwgc
ChEJCN9P6VgNrqq9IZTuRSACEIuHAfApHT/AOFY4QyGSCREbH8tqRfcdEf2h0IBGKxAw2wzOChGJ
RCw0WAi0WAgkFgKJhRgG6LsjsRBILAQSS+ZAPRYSC4HEQiCxEAgkFgKJJRJgHAuJhUBiIZBYMgfG
sZBYCCQWAomFQCCxEEgskQDjWEgsBBILgcSSOTCOhcRCILEQSCwEAomFQGKJBBjHQmIhkFgIJJbM
gXEsJBYiHlBhFyD8gM0W6k6UNijJo5VPfgzerZBYiIAYLmu2VcgnagCfrXAoRAQ2XVYrY5qs/JKL
SQYrDoXRhpziWJxxMtAv1uDTHiOxEMM6WYZgGqGPhQjVx3JxZ5hGvowYEis8yCrPeyCrZfDBLHTe
EUGHHry4BMO7W2ixEAENlhCyMghLHhv9mSxFIDOHtU9wKAwH/oo0WcVepMmK545rf6vCc9dkDzRY
4VgsHP4QkULlz64htxCRwKfzLkTusRgmIvi5YxAWy+DxKtZhMZbXLdZzj6TzjgFSxAg679gviFg4
7wZ03hGxcN4RiFhYLLe9cuuaDeJxLD3MbYwuOFb9wJ1XRMOF1wV7v6j8BxtcS+KKPnioHK0xY24M
zxuCSjMxZoLeLBEuf1T8v6dim7nH1l5JpX9DIJbovDGDqE4rsf7FOBYiJkBiIZBYCCQWQubwEW7g
4+60z88viSsQ7758cUJ0tz28WSJcPkbeETgUIpBYCCQWAoHEQiCxEEgsBAKJhUBiIZBYCAQSC4HE
QiCxhgGVqtGuTGkUVo1G7DlENIiVfnWlY3n+3dhfiCCh1AfX7qKNjuK6WjDm1jE/udA2oO1RUqmj
Umfl1hlz/6XqhdQBVbJDaGDMbRtQ25RZA0qlrmETdjNaLD/QwFRdlueGvuQZGaCankyxa9rPIO3q
5KSrPdKR9elnGaBjZlfa9AnYy0gsf2g7CLMu51nEor4WboNVUNvArtXmw1I4dQqcHg1OA9M89Y1d
PdjLMsQQod+QpzG5BmTZ6llQ3W2ESqB/2BezUzvbtQbsstnp3cDQMxs+TyZ9nxghJQzmkSpgCw4E
kF/+gYKquUAWsEQDzxfgl0eBeQ5QwpoCrKQ+a7Z5uPMipAFrYIvlkwCLHO/rsy6v7l7kOO64mjFI
h1WTD3ekXn2sdT5vsdKmHoUphzt0s76mprINlFMqFPqZXzdep/0Q+136xDKE52PttaRpbqpog+q/
36RlN5wrONgKdYd6DPA516LuSGHP4Q6w5nWr2fW3ew5ZoWNJ568ObcduRx8rtKdb5h85Pfq6Q76c
c9aIIWRssSIiFmHvVSjb1b7CEwoHdrasiRVRLR12uueLV55xB4Qs4dfHqtLPts7WZ2EPIaJKrIFC
9UnDc0qSwC5CRJFYKbofOpohvyulg8Q+QkSNWFUpXZzr1K4ez2/K1GtTKXa+5xdDdlXptPoqX/uN
rhfU30gUQ9QNdmbDm/29/Oon/UfYVwqs1gdfSrFDbp3fcw3eRWlPdaZTDa5whHt3neuAOvwIJAG7
PiiL5WwVlma8yr2mv6IniE+5uzVVizTadACbWquj7ZFNo17kMkuZOq3WINihl2a2QMtMG7fKWSdj
2iINt8GSpEkHz21UsjqFwk9I2kPhgCuGoG7hXnuX0L/yu9jln73tTKKZkJri2HctQNoH1NsLhOZd
+xxt3cBHRx9mjlkyiCylFZy2Zpquqd9rW0YtpcnAD0TizruLDVQmTzWP6aFND9bZAFqq6jIHgGq+
zWZ3WcS5oJ/joidzDNHvdeI6Yu5cdkFfS9R7bXNkA4lRVYkTS5cuLJ13D9+OpRo3RSTTUu6nX6wD
r2dnAZxJTh/rCndR6Zvdg62CaU56v4OLn3cQrmXudbbRaBzAD0TaxGq3p3ELZOdM3sn/C/3LfD67
fIGi+TlmlOzekNRJ06KnsahDODC1P9W1DKo8SE97hxtVh0QtTpHgPUiaKysrMWAvcWKp07p1xY1A
Gc7T3cVtSbo3E6hrOWvUr7Yxd4J0VcTePnpMI4jbXJamr3WJ209q6876B3WfleZMFTl+8Ft8MQEy
va1kFhiS8QORuI9F/ktz73SrrmdbF7+heX+XNkXHybmSu8Yyo9foBRoj7aV/PF2TliIcVzE6exQI
s0L1/s7x3Sn0qNpuzFYOfod6h877vVttGrsePxCpICJ1Q1DIbMFelj7CFfpFAOQVDoWDx0PsHkQM
hkKbQ4s+DyLModC/0K/x08yWa7KxyxBhwS+xqvRaPfODXYSIpo/VeIbm1FztHhT6IaJJLJv+V4yt
0o87bROiBqHrsYw0NFUQlujK6PuUCHEPhY2fjuNuFc89fobzs6jONhuM04b2nHwlPaK+btOH8ygY
Pj0mRYtVpb9xLr84d5yetVnh6LHY45ensauEVqOzMSosbRJJb7BpkinQWYDSgTFdS5tDjY45LF2r
Kbbp1FXsIVQScyrUaUmHWOQZndtnn/v5HiaeFY4eizueU9F0JzmTaH/NqHXocujVrCZ1Bmivg8+0
ALsaoZt0JjFC0/7Giv/MPtsxnz3EoGvsA9RpSYhYxI27bW5vq+NGxoEPR4/lNeRSRC190t5TUMuY
n0ritB3UTrixCeAqgjkjSZ8RWom5M08T/Bl6awlGyIo6LekMhfpr9giDW9Wea1jrFY4eyxM/9Het
oVvNIoBgpBD5jAirZRlJ2Vg5Fn1GHdOKkdi4GNxPsOuo05LQrDD7xjOczao6M46LkYajx2JRzGUx
Inqayug9n5NAzmUZalEAvDlezdHoAtAcGHIRCk6xhTotKYUbaJvFMMt25le8Fx+OHosdNldVcCe0
ETST4Bk95FUz/hNcR3tX55x7eOP0fe21Q67Bzim2UKclJWLRNotmlm3PjcKN6HD0WEwgK62CY+bH
hLq7DWBmhsbOePaEhnkQyDaLT1qadHf20Av5wqljuIg6LVHC/01o5l7hr2IkcDBy08aqn9nwE5AG
QkljZHMcnxujy9BwTpO2DU2RVIk1jB5L3x8rXglZjhzIKxkOhQhEbCwWAhH1WWH7lVe2s/+ubMc+
QkRvKGxPc1EsDTsJEcOhMHQ9FiPH8p8By1eyLIR0EGxy23D0WJXB7UTplYx8rCEIUo9F6eYTQ42P
JVmTZAHIYvNgZerVOk6yZUzXabjWVDKzILRDyIhYQeqx0vVf9Qy1QdM+cbZOoyl4sJvmYzdJJfFJ
/vrPpnSzCxnvNLW62yFkRKwg9Vi9p1rsnk4Wt6DLB72etkun1Q5waa9o1BP8kuMqwupuh5ARsYLU
Y832fKqnspI3XYykqk/YKWivwEN6BVyyLL4dQkbEClKPpfB511pBU4wmppnd6VN7RYLF3Q4hI2IF
qcc6NCFLN/Tg/RYg6EM1F1NaVns1xI/SfgnXutshJEwsPvDefuU8bj1IPdYnto6kobNC6zVaG23U
rPaU/fTRd2cPuR3ZeqNW6W6HkADwJjQiGggp8t6E/YWIgcWibBOasYMQUbdYN8F/YIchoj4rNP/1
7Scxpx8iTPgu0sSGAOavufl4NfYQIhgEWaSJRlX5s7BmL4YrEVG2WGdWfATFvzjkys+eOaBM7qLX
jP4LwQ3aZczNPaNL6/H/3rZkPT7iLDeLVeJYRv+evkDwsqhOsrE+LbQYV2Ulpe0eZv9NKV34icjM
eSeL9zPB9RUNZfyGMPVY1j62HqF3XizI0mu0BBidk4FM0iaTbGIsLZs9i9Vj8Totfh9CSsQqa+CM
yZoN/Ecbnh6L3M/cVFSWeufFgq5kZ1s33aoSctod5YwZ7G9sS2NqGDp1DCk5nZawDyEdYpEb1nCS
lsKcXdyW8PRYY5Yw6TxqCe+8WGBrAT0nxOpVw1xmdK5nk2LparlWnE5L2IeQjvN+cdM6E7tmerTs
NLugtjFuPGli6jiTr6hXNtdBt25gOdED517QbiRYF53e9dN73WfKrazrp+gdufS2efeCSdkHuY+w
L61FauWFdUz7ebm5uf/sY5twR5vuOSKs8fsQ0nHeLb8oFAxUwXfcuBaRHmtwXqzboZnXQ3zulfyK
Ppo85T4GE2NJbSis/sVKYZFYs4l9jUiPNTgvVkWLjU/+qKag2M316m+5Vq59Nh1+QhIiFrVhrXtl
+htsSr6I9FiD82K1jxbSYVWmae5zK7Aafqa1N7ijFekaQyd+QiKFL3XDg46XPTY4H9octXcz4jOE
EkUw6gbzE3s7LnD/s++Kni7LjJ+AnC0WAhELi4VAxGhWCNDqYwmBiJRYpEao5NxyAm/XIaJGLMKh
5ZjVop0UZsVC5CMSywcyHdqzLK8cmcKWEPNjXRBGxivj4LXhc2sZA7Xz0djHXqOf98ccXjEgFs2s
0S2evApZjzUzjIupDLjBz97KUE7qf29lWG+ACIVYkOnU/njSKfAqWD0WsPUFkyn6u01/u4u1Hroq
pi4h35b74meu4mobchotY5rOI2eWhatVaGS3M/ULqRS2lfAeela35dmuSqPRZbKZttizpc/XErb5
TD4utpUmHQadw0jM11uES3FfV9YiLQGu+omDcngVA+bwiphYkGFPneiuixOkHos57h2mviAjtoLV
jZ66ql2NQlvu+991O1vbkNdogfIsu5XTYhm5WoUs2PqFGVanR9XCjB+TuPwP7nbzU5z76MvLUDvf
YW5k9peN7skuq+BKqkx7sakf2HNoPf6iMp0rh4T7b7Ad7OoGV/1E8M7htZo51w/O1muRNxEQq0XX
oTvrWgtSj0XjtqvgFL/urau6ivBd25DTaDGqLY9juFqFDOpYqZZDDVZ31cJWooW7Pe1up3ZUXUaf
xnEartKxp2mZdZqYy5VA0C8h6oE9B+l5jlOuW9zu6xo2hxdzEh0BqNSPhFi0f3UB42cJ7YLLj8UR
hC30BUL+q1lGo7GfWzuTkr5mSG3DfK494XkMX6vQvcG7aiG9785B7RpgfnYjm4OLEI5yfRfucKff
+r8e5yDuFJbd1+U/h9cA5vCKBrFaGP+K9rMEmxWkHgvYLFikV+FKD10V0d04013bcICrbcjlxvIG
X6vQ46xe4qwsIHcMapfR3aS/3ce7MzjlrnxY7vbThHN4XZf/HF4KzOEVBWK1aCcx3kiGy2YFqcdi
NufBBJ3wCbGmwa2rYtq6Gva1cLUNDfAz7eD352sVepyVAkOSa60HJmkGtdNXEe/S/rcjD74cUuh3
P1/5kIL97nNkwgSNsOy+Ls0EPofXED8Kc3hFgVjUST7OkOnQcl/PIPVYjO/iYDVXmrGuqbpbV8W0
TRamYkWjs9khk9BQQ+4b8bUKPc6arp7hOhKSFtnqB7VLXqCd3047XQ71kt7BZ7M6dKO4c2xyn0Oh
ddYLDfjrYihmY3J4+aqfiDm8QoIfdUOra/bUGusK8iFptAYUkb8hdw6UhkUVodQrHCFoQpljpUWh
tA93Dq0D2RBLYsVfNhPS3D0aJaO4cyCv4hXHQiCQWAgxEQtTdiAS3WKhOguJ5QfB6bFce41Go1bv
jnGOG9wQYDj5E0I2xApZj1VZ2ai72bU2A3saieUTweuxXHaHsL4maKAYdRZfp5CjqZ7XNPF5s6hF
rNaJfptURs+VwuuzeI0VQjrEequL/gdvPc38ZhG8Hssd0TboBR0Vo87yqFPooafi8mYZfpt2H3vE
4x2QUUtpeH0Wr7FCSIdYt6bQ/+DWtcxvFsHrsdxO1hTw1FF5aJw89FRc3iznVc3MKQy25fQR2Zxq
qpYAtSPzMjt+RpIeCoPXY7l8rMrjt3rqqDiNE1cc06WnmkUAQe+ew9H2MRhwH0EwGqsORmOFkDCx
gtdjudH8mqeOitM4ccUxXXoqPm8Wr7FZrSO8lFe8xgohYWIFr8dyw6B06aiqSK86hS49FZ83S/Ml
xQ6NbXoKdFlg4CQszDu8W4WfkaSJFbweSwhS0X55u0tHpR3rVafQpafi82bpN6XsY9dT0qHVphHy
DqZwGiuECIHZZhDRAGabQSTWUIhAILEQCUss0scSAhEpscgFTMiTff59ATILEb1ZYVa9Rg1Tj3Cv
CES0ZoXNmhlZcACycsYLvApaj+VuYDAahjTwu4aQh/OubsipnpeV0yDUsQ+nXiG1ZNCz6PgoHxIL
mhv+80DOAwKvQtBjuWwR6ZzpZPJiFWnmE1VsPUKjK38Vn9dKyEOVrsNahfIgVvfU7hzHvANb6Fdu
Q/B6LJdlmqDJ10ygX1c2vef4OVuPEFz5q/i8VkIequfOMrUKtVirUPLESj6S3KA9MK+BfuU2hKzH
oq2OGlSM1fmC0E/nklyBK38Vn9dK0GgtIZhahaewVqF04LfYOO1fXfGSuVfQfAZZr5D7z/GqTZub
/bN9ptxHQKhAyJckVPXBqD+AkjvTKKZwIb0baxWKGkEXG8+i/asD0xtyBAlf6HosfWllZWVp3qCt
fP4qPq+VRx4qplbha65mWKtQokNhVv2hFTCP9uDr+Yld6HqsMYzi6p3BCYr4/FV8XiuPPFRMrUJ3
yMy7jiFCKsQic5i46AE2nsVNzoLXY/GzQtLB1Eq9Sj9obsfnr+LzWnnkoRpUq9CrjiFCfPATeSdd
vjpJYCchAiIB82MhJEkslM0gRtJ5RyBiRKzGup5TPT9itUJEdIlVb1OoJ9idenxeFBHNWeGPjjQ2
W/JZezrOChFRc94bHRdyWbjPVwi3ASPTYxn9N0RZloyGQrtWCIKn8sSKUI/lrcSq9LENIQdijXHd
TknlX8PWYxkZsAbKS5cFgjqLGWmxBqD04Fvd0HCBa//TnO0atc0EsM3JSg/e/HJUqq0PklK6Prm2
D5I/KDlexlYZcakbOH3DVsWL+hfsdXV11rMOZvufWu7UvvnDf6f1uRsa9mxad3EdbP38lY5iBX4Y
IkaQ6oZs1xgmLESgx6IoLv+Cly6Lg+Mqgrn9qMsHPd5ylsNQaD0jLLU38e1CzY8F5KopxqtWkXTr
H7gN+eBR/Y8H1gCUF7HOG+DrFJJJF/JDYth6LEPSMAELrAEoL2Kp9fbTra3Q2qiz8tPDsPVYhvQW
/++ONQBlRizITte1t/fobWrBiw9bj2WbymWH9AmsAShZoGwGEQ2gbAYR16EQ3HNABCK6xLLkIbMQ
0ScWefk5ZBYi6sSy6I+ry/V4Bw8RXWKRl9vyId+2MCZxSzSEsiWWJU/FhKqI8jECCULXYzGyBkbL
IKBKI0glLkBJlkyJRV5ey0Xc82t5PyscPVZlZWWbhwB1foUQBJ2Jkix5Eov2rwQ+ELyfFYYei4E+
uVvIiWWcs45ZSuGqF7okWZYkTToIdQ0RkiYWuVCV71rJV13H2Kww8mNx55oNoGJzYjE1CzPahOqF
LkzTNfWDUNcQIWliEbVj3LNBcsxHjPUKQ4/lgo7LiQVs9ULS4b1TX0vUg2ddQ4R0h0Ki9nLBZyfz
alnrFboey43ZhKDDclcvdOEOtyRrAD8OqTvvxPE8zmZReeUcJ8KpV8ie6XNXTizwmfbqFJcpy4wJ
sWQRbsjnbBY55hzvbYVTr5DhVXebKycWDW0jW4vQ7BHI+oLLlMXXNURInFhA2GibReaVC4+BhazH
AjaQ1d2mZ3Ni3cg+bQGtE9lahJox7rb1Dh1zDXxdQ4RU4F+PRepVY2rxMWhEUBiix/Kb3BZMR/eU
52GPIYLCkMe/hlOQYjI/RNgWC6XJiJgQC6XJiJhA5WfIdC/qsJMQUSOWm0527CNEGAh6KIxcj+X3
IISMLNZgUJ1tNhintYZy7koAWzpWh0OLNRwi0WMx5Qj5OoXGtEUaG/C6LEGLxZ+P3sfUMUxiahym
s3m0MG+W9IkViR4LFGeFOoUApRWpwOuyYNqLrBaLPx8oS8Godehy6MV+tr7htE+crdPwM5I0sSLR
Y8EpQqhTCHXE3LkuXZZ+CavF4s8HtQT0noJarmohk0cL82aJF35u6fS6fC9+KfR6hfxCrrscoapP
KEf409zc3IY+uPtWMLnPx+ybRzdTejWr78cPSQQIul7hEAJGoMdi4NZkMeB1WbwWiz8fu4NuNtfV
DPNmSX8ojESPxcCtyWLA67L281ULufMxeEYPedWuZpg3S3rEsgvg1yPRY7EjKlenkAevy7JyWiz+
fAxmZmjsbtcf82aJF3gTGhENhHQTGkObiFj4WK3JWPsLEQNildP/EIhoE4vqP9aPgyEi6sTaOWr6
qBrsIESUidVauAgWTo6iyULrh8Ri8OExAjLK3CYrdD2WJVmj+Z2bTud7thuyhJAJsaoHJtK/J54U
iBFGfqyfapqato13rc7CzkZiAVkzigmGT1cIJisMPVbfKYJot9OcZDVWTEqsLL1Gy8XYed0VQm7E
qoFF7OvEGv7jD0OPpc41UOAEMLAaKyYpVleys62box6vu0LIi1jkhxM5yzKxkDdZYeixPulzJi3K
BFZjxd0mtLWAfjbHU153hZAXsWryJnILxDGeWGHkx8rv6j53kDZQswggOFFVa1oKf0+a2YbpsGRH
LMvkSYKBmljLkSYMPdZ8Eoi2Pk+N1e3QzOsgvHVXCOnBp4L0nmsXCaumDflvs8773ww91E69nRF2
KpOanr24DnSfXLKvpB/0qY+9qWXrow5SkJ4uavz9ywoK9I+otzU44axd2dDevel8tsUfZ7DbXG0R
IkdQClJyylL3yqRC9jmZMPRYX7Rlj+lvo135DI2NbqdKgfbR2fz7eeuuENKDLz1W6YQZHhtKB27H
bkIEQDB6LEtBucPheEz4KSjEgBMiKhYLgYiFxUIgYhRuQCCQWAgkFgKJhUBEhKH5sazYKYjIocDo
AgKHQgQSC4HEQiCQWAgkFgKJhUAgsRBILAQSC4FAYiGQWAgkFgKBxEIgsRBILAQiKvhfs+BmJkjn
ycsAAAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2015-03-17 12:24:31 +0000" MODIFIED_BY="[Empty name]" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. Only one item, allocation concealment, was assessed in all included trials. The remaining items were assessed only in trials included in the last update.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADnCAMAAAD7EqYIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2015-03-17 12:24:31 +0000" MODIFIED_BY="[Empty name]" NO="5" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. Only one item, allocation concealment, was assessed in all included trials. The remaining items were assessed only in trials included in the last update.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAU0AAAgECAIAAAC2XbTkAABlsElEQVR42u3dv27b1v//cQEBggwe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</FILE>
</FIGURE>
<FIGURE FILENAME="Figure Mortality.jpg" FILE_TYPE="JPG" ID="FIG-06" MODIFIED="2015-04-14 15:58:51 +0100" MODIFIED_BY="[Empty name]" NO="6" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Overall mortality.</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Figure Withdrawals Proarrhythmia.jpg" FILE_TYPE="JPG" ID="FIG-07" MODIFIED="2015-04-14 15:59:10 +0100" MODIFIED_BY="[Empty name]" NO="7" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Withdrawals due to adverse events and pro-arrhythmia.</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Figure AF recurrence.jpg" FILE_TYPE="JPG" ID="FIG-08" MODIFIED="2015-03-19 16:06:53 +0000" MODIFIED_BY="[Empty name]" NO="8" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Recurrence of atrial fibrillation.</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2015-03-16 06:33:01 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2015-03-16 06:32:07 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-02-18 15:30:33 +0000" MODIFIED_BY="[Empty name]">Search strategies 2005</TITLE>
<APPENDIX_BODY MODIFIED="2015-03-16 06:32:07 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">CENTRAL</HEADING>
<P>1 ATRIAL FIBRILLATION<BR/>2 (atrial near fibrillat*)<BR/>3 (auricular* near fibrillat*)<BR/>4 (atrium near fibrillat*)<BR/>5 (atrial next arrhythmi*)<BR/>6 (#1 or #2 or #3 or #4 or #5)<BR/>7 ANTI-ARRHYTHMIA AGENTS<BR/>8 antiarrhythmi*<BR/>9 anti-arrhythmi*<BR/>10 (anti next arrhythmi*)<BR/>11 procainamide<BR/>12 disopyramide<BR/>13 quinidine<BR/>14 mexiletine<BR/>15 flecainide<BR/>16 propafenone<BR/>17 bisoprolol<BR/>18 esmolol<BR/>19 amiodarone<BR/>20 dofetilide<BR/>21 sotalol<BR/>22 azimilide<BR/>23 ibutilide<BR/>24 cibenzoline<BR/>25 moricizine<BR/>26 (#7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17)<BR/>27 (#18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26)<BR/>28 (#26 or #27)<BR/>29 (#6 and #28)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Search strategy for MEDLINE in PubMed</HEADING>
<P>("Atrial Fibrillation" [mh] OR ((atrial OR atrium OR auricular) AND fibrillat*))<BR/>AND<BR/>("Anti-Arrhythmia Agents" [mh] OR antiarrhythmi* [tw] OR anti-arrhythmi* [tw] OR procainamide [tw] OR disopyramide [tw] OR quinidine [tw] OR mexiletine [tw] OR flecainide [tw] propafenone [tw] OR bisoprolol [tw] OR esmolol [tw] OR amiodarone [tw] OR dofetilide [tw] OR sotalol [tw] OR ibutilide [tw] OR azimilide [tw] OR moricizine [tw] OR cibenzoline [tw])<BR/>AND<BR/>("randomized controlled trial" [pt] OR "controlled clinical trial" [pt] OR "randomized controlled trials" [mh] OR "random allocation" [mh] OR "double-blind method" [mh] OR "single-blind method" [mh] OR "clinical trial" [pt] OR "clinical trials" [mh] OR ("clinical trial" [tw]) OR ((singl* [tw] OR doubl* [tw] OR trebl* [tw] OR tripl* [tw]) AND (mask* [tw] OR blind* [tw])) OR ( placebos [mh] OR placebo* [tw] OR random* [tw] OR "research design" [mh:noexp] OR "comparative study" [mh] OR "evaluation studies" [mh] OR "follow-up studies" [mh] OR "prospective studies" [mh] OR control* [tw] OR prospectiv* [tw] OR volunteer* [tw]) NOT (animal [mh] NOT human [mh]))<BR/>
<BR/>Notes: The strategy to locate randomized controlled trials is the Cochrane highly sensitive search strategy (all phases), as contained in the Cochrane Reviewer's Handbook (ref: CR Handbook 2003).<BR/>The "related articles" feature of PubMed MEDLINE was also used.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Search strategy for EMBASE.com</HEADING>
<P>
<BR/># 1 (atrial OR 'atrium'/exp OR auricular) AND fibrillat*<BR/>
<BR/># 2 'anti-arrhythmic' OR antiarrhythmi* OR 'procainamide'/exp OR 'disopyramide'/exp OR 'quinidine'/exp OR 'mexiletine'/exp OR 'flecainide'/exp OR 'propafenone'/exp OR 'bisoprolol'/exp OR 'esmolol'/exp OR 'amiodarone'/exp OR 'dofetilide'/exp OR 'sotalol'/exp OR 'ibutilide'/exp OR 'azimilide'/exp OR 'dronedarone'/exp OR 'moricizine'/exp OR 'cibenzoline'/exp<BR/>
<BR/># 3 'randomized controlled trial'/exp OR 'controlled clinical trial'/exp OR 'randomized controlled trials'/exp OR 'random allocation'/exp OR 'double-blind method'/exp OR 'single-blind method'/exp OR 'clinical trial'/exp OR 'clinical trials'/exp OR ((singl* OR doubl* OR trebl* OR tripl*) AND (mask* OR blind*)) OR ('placebos'/exp OR placebo* OR random* OR 'comparative study'/exp OR 'evaluation studies'/exp OR 'follow-up studies'/exp OR 'prospective studies'/exp OR control* OR prospectiv* OR volunteer*)<BR/>
<BR/># 4 #1 AND #2 AND #3<BR/>
<BR/>Note: The "related articles" feature was also used.<BR/>
</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2015-03-16 06:31:09 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2010-02-18 15:30:48 +0000" MODIFIED_BY="[Empty name]">Search strategies 2010</TITLE>
<APPENDIX_BODY MODIFIED="2015-03-16 06:31:09 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">CENTRAL in The Cochrane Library</HEADING>
<P>#1 MeSH descriptor Atrial Fibrillation this term only<BR/>#2 (atrial in All Text near/3 fibrillat* in All Text)<BR/>#3 (auricular* in All Text near/3 fibrillat* in All Text)<BR/>#4 (atrium in All Text near/3 fibrillat* in All Text)<BR/>#5 atrial next arrhythmi* in All Text<BR/>#6 (#1 or #2 or #3 or #4 or #5)<BR/>#7 MeSH descriptor Anti-Arrhythmia Agents explode all trees<BR/>#8 antiarrhythmi* in All Text<BR/>#9 anti-arrhythmi* in All Text<BR/>#10 dronedarone in All Text<BR/>#11 amiodarone in All Text<BR/>#12 bisoprolol in All Text<BR/>#13 disopyramide in All Text<BR/>#14 dofetilide in All Text<BR/>#15 azimilide in All Text<BR/>#16 ibutilide in All Text<BR/>#17 flecainide in All Text<BR/>#18 propafenone in All Text<BR/>#19 quinidine in All Text<BR/>#20 cibenzoline in All Text<BR/>#21 moricizine in All Text<BR/>#22 mexiletine in All Text<BR/>#23 procainamide in All Text<BR/>#24 sotalol in All Text<BR/>#25 esmolol in All Text<BR/>#26 (#7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16)<BR/>#27 (#17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25)<BR/>#28 (#26 or #27)<BR/>#29 (#6 and #28)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">MEDLINE on Ovid</HEADING>
<P>1 Atrial Fibrillation/<BR/>2 atrial fibrillation.tw.<BR/>3 atrium fibrillation.tw.<BR/>4 auricular fibrillation.tw.<BR/>5 or/1-4<BR/>6 exp Anti-Arrhythmia Agents/<BR/>7 antiarrhythmi$.tw.<BR/>8 anti-arrhythmi$.tw.<BR/>9 dronedarone.tw.<BR/>10 amiodarone.tw.<BR/>11 bisoprolol.tw.<BR/>12 disopyramide.tw.<BR/>13 dofetilide.tw.<BR/>14 azimilide.tw.<BR/>15 ibutilide.tw.<BR/>16 flecainide.tw.<BR/>17 propafenone.tw.<BR/>18 quinidine.tw.<BR/>19 cibenzoline.tw.<BR/>20 moricizine.tw.<BR/>21 mexiletine.tw.<BR/>22 procainamide.tw.<BR/>23 sotalol.tw.<BR/>24 esmolol.tw.<BR/>25 or/6-24<BR/>26 5 and 25<BR/>27 randomized controlled trial.pt.<BR/>28 controlled clinical trial.pt.<BR/>29 Randomized controlled trials/<BR/>30 random allocation/<BR/>31 double blind method/<BR/>32 single-blind method/<BR/>33 or/27-32<BR/>34 exp animal/ not humans/<BR/>35 33 not 34<BR/>36 clinical trial.pt.<BR/>37 exp Clinical Trials as Topic/<BR/>38 (clin$ adj25 trial$).ti,ab.<BR/>39 ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$ or mask$)).ti,ab.<BR/>40 placebos/<BR/>41 placebo$.ti,ab.<BR/>42 random$.ti,ab.<BR/>43 research design/<BR/>44 or/36-43<BR/>45 44 not 34<BR/>46 35 or 45<BR/>47 26 and 46<BR/>48 limit 47 to yr="2005 - 2010"</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">EMBASE on Ovid to 2010 Week 06</HEADING>
<P>1 heart atrium fibrillation/<BR/>2 atrial fibrillation.tw.<BR/>3 atrium fibrillation.tw.<BR/>4 auricular fibrillation.tw.<BR/>5 or/1-4<BR/>6 exp antiarrhythmic agent/<BR/>7 antiarrhythmi$.tw.<BR/>8 anti-arrhythmi$.tw.<BR/>9 dronedarone.tw.<BR/>10 amiodarone.tw.<BR/>11 bisoprolol.tw.<BR/>12 disopyramide.tw.<BR/>13 dofetilide.tw.<BR/>14 azimilide.tw.<BR/>15 ibutilide.tw.<BR/>16 flecainide.tw.<BR/>17 propafenone.tw.<BR/>18 quinidine.tw.<BR/>19 cibenzoline.tw.<BR/>20 moricizine.tw.<BR/>21 mexiletine.tw.<BR/>22 procainamide.tw.<BR/>23 sotalol.tw.<BR/>24 esmolol.tw.<BR/>25 or/6-24<BR/>26 5 and 25<BR/>27 random$.tw.<BR/>28 factorial$.tw.<BR/>29 (crossover$ or cross-over$).tw.<BR/>30 placebo$.tw.<BR/>31 (doubl$ adj blind$).tw.<BR/>32 (singl$ adj blind$).tw.<BR/>33 assign$.tw.<BR/>34 allocat$.tw.<BR/>35 volunteer$.tw.<BR/>36 Crossover Procedure/<BR/>37 Double-blind Procedure/<BR/>38 Randomized Controlled Trial/<BR/>39 Single-blind Procedure/<BR/>40 or/27-39<BR/>41 (animal/ or nonhuman/) not human/<BR/>42 40 not 41<BR/>43 26 and 42<BR/>44 limit 43 to yr="2005 - 2010"<BR/>
<BR/>
</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2015-03-16 06:33:01 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2014-07-17 10:27:01 +0100" MODIFIED_BY="[Empty name]">Search strategies 2014</TITLE>
<APPENDIX_BODY MODIFIED="2015-03-16 06:33:01 +0000" MODIFIED_BY="[Empty name]">
<P>Note: The RCT filter for MEDLINE was updated. The RCT filter for MEDLINE is now the Cochrane sensitivity-maximising RCT filter, and for EMBASE, terms as recommended in the Cochrane Handbook have been applied. (Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.)</P>
<SUBSECTION>
<HEADING LEVEL="3">CENTRAL</HEADING>
<P>#1 MeSH descriptor Atrial Fibrillation this term only<BR/>#2 (atrial in All Text near/3 fibrillat* in All Text)<BR/>#3 (auricular* in All Text near/3 fibrillat* in All Text)<BR/>#4 (atrium in All Text near/3 fibrillat* in All Text)<BR/>#5 atrial next arrhythmi* in All Text<BR/>#6 (#1 or #2 or #3 or #4 or #5)<BR/>#7 MeSH descriptor Anti-Arrhythmia Agents explode all trees<BR/>#8 antiarrhythmi* in All Text<BR/>#9 anti-arrhythmi* in All Text<BR/>#10 dronedarone in All Text<BR/>#11 amiodarone in All Text<BR/>#12 bisoprolol in All; Text<BR/>#13 disopyramide in All Text<BR/>#14 dofetilide in All Text<BR/>#15 azimilide in All Text<BR/>#16 ibutilide in All Text<BR/>#17 flecainide in All Text<BR/>#18 propafenone in All Text<BR/>#19 quinidine in All Text<BR/>#20 cibenzoline in All Text<BR/>#21 moricizine in All Text<BR/>#22 mexiletine in All Text<BR/>#23 procainamide in All Text<BR/>#24 sotalol in All Text<BR/>#25 esmolol in All Text<BR/>#26 (#7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16)<BR/>#27 (#17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25)<BR/>#28 (#26 or #27)<BR/>#29 (#6 and #28)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">MEDLINE Ovid (up to October 2013)</HEADING>
<P>1 Atrial Fibrillation/<BR/>2 atrial fibrillation.tw.<BR/>3 atrium fibrillation.tw.<BR/>4 auricular fibrillation.tw.<BR/>5 or/1-4<BR/>6 exp Anti-Arrhythmia Agents/<BR/>7 antiarrhythmi$.tw.<BR/>8 anti-arrhythmi$.tw.<BR/>9 dronedarone.tw.<BR/>10 amiodarone.tw.<BR/>11 bisoprolol.tw.<BR/>12 disopyramide.tw.<BR/>13 dofetilide.tw.<BR/>14 azimilide.tw.<BR/>15 ibutilide.tw.<BR/>16 flecainide.tw.<BR/>17 propafenone.tw.<BR/>18 quinidine.tw.<BR/>19 cibenzoline.tw.<BR/>20 moricizine.tw.<BR/>21 mexiletine.tw.<BR/>22 procainamide.tw.<BR/>23 sotalol.tw.<BR/>24 esmolol.tw.<BR/>25 or/6-24<BR/>26 5 and 25<BR/>27 randomized controlled trial.pt.<BR/>28 controlled clinical trial.pt.<BR/>29 randomized.ab.<BR/>30 placebo.ab.<BR/>31 drug therapy.fs.<BR/>32 randomly.ab.<BR/>33 trial.ab.<BR/>34 groups.ab.<BR/>35 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34<BR/>36 exp animals/ not humans.sh.<BR/>37 35 not 36<BR/>38 26 and 37(6063)<BR/>39 (201002* or 201003* or 201004* or 201005* or 201006* or 201007* or 201008* or 201009* or 201010* or 201011* or 201012* or 2011* or 2012* or 2013*).ed.<BR/>40 38 and 39</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">MEDLINE PubMed (October 2013 to January 2014)</HEADING>
<P>("Atrial Fibrillation" [mh] OR ((atrial OR atrium OR auricular) AND fibrillat*))<BR/>AND<BR/>("Anti-Arrhythmia Agents" [mh] OR antiarrhythmi* [tw] OR anti-arrhythmi* [tw] OR procainamide [tw] OR disopyramide [tw] OR quinidine [tw] OR mexiletine [tw] OR flecainide [tw] propafenone [tw] OR bisoprolol [tw] OR esmolol [tw] OR amiodarone [tw] OR dofetilide [tw] OR sotalol [tw] OR ibutilide [tw] OR azimilide [tw] OR moricizine [tw] OR cibenzoline [tw])<BR/>AND<BR/>("randomized controlled trial" [pt] OR "controlled clinical trial" [pt] OR randomized [tiab] OR placebo [tiab] OR "drug therapy" [sh] OR randomly [tiab] OR trial [tiab] OR groups [tiab]) NOT (animal [mh] NOT human [mh]))<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">EMBASE Ovid (up to October 2013)</HEADING>
<P>1 exp heart atrium fibrillation/<BR/>2 atrial fibrillation.tw.<BR/>3 atrium fibrillation.tw.<BR/>4 auricular fibrillation.tw.<BR/>5 or/1-4<BR/>6 exp antiarrhythmic agent/<BR/>7 antiarrhythmi$.tw.<BR/>8 anti-arrhythmi$.tw.<BR/>9 dronedarone.tw.<BR/>10 amiodarone.tw.<BR/>11 bisoprolol.tw.<BR/>12 disopyramide.tw.<BR/>13 dofetilide.tw.<BR/>14 azimilide.tw.<BR/>15 ibutilide.tw.<BR/>16 flecainide.tw.<BR/>17 propafenone.tw.<BR/>18 quinidine.tw.<BR/>19 cibenzoline.tw.<BR/>20 moricizine.tw.<BR/>21 mexiletine.tw.<BR/>22 procainamide.tw.<BR/>23 sotalol.tw.<BR/>24 esmolol.tw.<BR/>25 or/6-24<BR/>26 5 and 25<BR/>27 random$.tw.<BR/>28 factorial$.tw.<BR/>29 crossover$.tw.<BR/>30 cross over$.tw.<BR/>31 cross-over$.tw.<BR/>32 placebo$.tw.<BR/>33 (doubl$ adj blind$).tw.<BR/>34 (singl$ adj blind$).tw.<BR/>35 assign$.tw.<BR/>36 allocat$.tw.<BR/>37 volunteer$.tw.<BR/>38 crossover procedure/<BR/>39 double blind procedure/<BR/>40 randomized controlled trial/<BR/>41 single blind procedure/<BR/>42 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41<BR/>43 (animal/ or nonhuman/) not human/<BR/>44 42 not 43<BR/>45 26 and 44<BR/>46 (2010* or 2011* or 2012* or 2013*).em.<BR/>47 (2010* or 2011* or 2012* or 2013*).dd.<BR/>48 46 or 47<BR/>49 45 and 48</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">EMBASE.com (October 2013 to January 2014)</HEADING>
<P>("Atrial Fibrillation" [mh] OR ((atrial OR atrium OR auricular) AND fibrillat*))<BR/># 1 (atrial OR 'atrium'/exp OR auricular) AND fibrillat*<BR/># 2 'anti-arrhythmic' OR antiarrhythmi* OR 'procainamide'/exp OR 'disopyramide'/exp OR 'quinidine'/exp OR 'mexiletine'/exp OR 'flecainide'/exp OR 'propafenone'/exp OR 'bisoprolol'/exp OR 'esmolol'/exp OR 'amiodarone'/exp OR 'dofetilide'/exp OR 'sotalol'/exp OR 'ibutilide'/exp OR 'azimilide'/exp OR 'dronedarone'/exp OR 'moricizine'/exp OR 'cibenzoline'/exp<BR/># 3 'randomized controlled trial'/exp OR 'randomized controlled trial' OR 'controlled clinical trial'/exp OR 'controlled clinical trial' OR randomized OR 'placebo'/exp OR placebo OR 'drug therapy'/exp OR 'drug therapy' OR randomly OR trial OR groups NOT ('animal'/exp OR animal NOT ('human'/exp OR human))<BR/># 4 #1 AND #2 AND #3<BR/>
</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>